TRIAZOLE-ISOXAZOLE COMPOUND AND MEDICAL USE THEREOF

Abstract
A compound represented by Formula [I]:
Description
TECHNICAL FIELD

The present invention relates to triazole compounds and medicinal use thereof. The present invention relates to isoxazole compounds and medicinal use thereof.


In particular, the present invention relates to compounds which can inhibit retinoid-related orphan receptor gamma (RORγ), thereby the differentiation and activation of T helper 17 (Th17) cells can be inhibited, and the production of interleukin-17 (IL-17) can be inhibited.


Specifically, the present invention relates to compounds for preventing or treating a disease related to Th17 cells, for example, autoimmune disease such as rheumatoid arthritis, psoriasis, inflammatory bowel disease such as Crohn's disease and ulcerative colitis, multiple sclerosis, systemic lupus erythematosus (SLE), ankylosing spondylitis, uveitis, polymyalgia rheumatica, and type I diabetes; allergic disease such as asthma; dry eye; fibrosis such as pulmonary fibrosis and primary biliary cirrhosis; and metabolic disease such as diabetes and medicinal use thereof.


BACKGROUND ART

RORγ is a nuclear receptor which is important for the differentiation and activation of Th17 cells. RORγt is also known as a splice variant of RORγ. RORγ and RORγt differ only in their N-terminal domains, and share the same ligand-binding domain and DNA-binding domain. It is reported that RORγ is expressed in other tissues besides Th17 cells. By inhibiting RORγ, the differentiation and activation of Th17 cells can be inhibited. IL-17 produced in Th17 cells is involved in the induction of a variety of chemokines, cytokines, metalloproteases and other inflammatory mediators, and the migration of neutrophil, hence, the inhibition of IL-17 may lead to the inhibition of such induction and migration. RORγ in adipose tissues is related to the regulation of adipogenesis, and by inhibiting RORγ, insulin resistance can be improved.


It is known that Th17 cells are involved in autoimmune disease such as rheumatoid arthritis, psoriasis, inflammatory bowel disease such as Crohn's disease and ulcerative colitis, multiple sclerosis, systemic lupus erythematosus, ankylosing spondylitis, uveitis, polymyalgia rheumatica, and type I diabetes; allergic disease; dry eye; and fibrosis such as pulmonary fibrosis and primary biliary cirrhosis.


As for rheumatoid arthritis, for example, it is reported that the administration of anti-IL-17 antibody can improve swelling and joint destruction associated with collagen-induced arthritis. Moreover, it is reported that swelling and joint destruction associated with collagen-induced arthritis can be improved in IL-17-deficient mice.


As for psoriasis, it is reported that in a clinical trial, the administration of anti-IL-17 antibody is effective in treating psoriasis.


As for inflammatory bowel disease such as Crohn's disease and ulcerative colitis, in a colitis model induced by the adaptive transfer of naive T-cells, the adaptive transfer of naive T-cells derived from RORγ-KO mice does not increase IL-17 in the mucosa, thereby the onset of colitis can be suppressed.


As for multiple sclerosis, the disease state of mouse experimental autoimmune encephalomyelitis model which is an animal model of multiple sclerosis can be suppressed in RORγt-KO mice.


As for systemic lupus erythematosus, it is reported that the onset of GBM nephritis model which is an animal model of glomerulonephritis can be inhibited in RORγt-KO mice. Nephritis associated with SLE may also be suppressed.


As for ankylosing spondylitis, it is reported that the administration of anti-IL-17 antibody is effective in treating ankylosing spondylitis.


As for uveitis, it is reported that the administration of anti-IL-17 antibody is effective in treating uveitis associated with Behcet's disease, sarcoidosis and Harada disease.


As for polymyalgia rheumatica, an efficacy of anti-IL-antibody in treatment of polymyalgia rheumatica is currently tested in a clinical trial.


As for type I diabetes, the disease state of NOD mice which is a type I diabetes model can be suppressed by the administration of anti-IL-17 antibody.


As for allergic disease such as asthma; in OVA-sensitized model, the attenuated eosinophilic pulmonary inflammation, the reduced numbers of CD4+ lymphocytes, and the decrease of Th2 cytokines/chemokines level are exhibited in RORγ-KO mice, that is, the allergenic reaction can be inhibited in RORγ-KO mice.


As for dry eye, it is reported that the Th17 cells increases in an animal model of dry eye, and an efficacy of anti-IL-17 antibody in dry eye patient is currently tested in a clinical trial.


As for fibrosis, in a bleomycin-induced pulmonary fibrosis model which is an animal model of pulmonary fibrosis, the administration of anti-IL-17 antibody can inhibit inflammation and fibrosis in lung and can increase survival of the animal.


As for primary biliary cirrhosis, it is reported that Th17 cells in the lesion area of a patient with a primary biliary cirrhosis increase, and an efficacy of an antibody to IL-23 which activates Th17 cells is currently tested in a clinical trial.


As for metabolic disease, the insulin resistance which is induced by feeding a high-fat diet can be suppressed in RORγ KO mice.


On the basis of these findings, RORγ antagonists are thought to be useful for preventing or treating autoimmune disease such as rheumatoid arthritis, psoriasis, inflammatory bowel disease such as Crohn's disease and ulcerative colitis, multiple sclerosis, systemic lupus erythematosus, ankylosing spondylitis, uveitis, polymyalgia rheumatica, and type I diabetes; allergic disease such as asthma; dry eye; fibrosis such as pulmonary fibrosis and primary biliary cirrhosis; and metabolic disease such as diabetes.


SUMMARY OF INVENTION
Technical Problem

An object of the present invention is to provide novel RORγ antagonists. Another object of the present invention is to provide medicaments of preventing or treating autoimmune disease such as rheumatoid arthritis, psoriasis, inflammatory bowel disease such as Crohn's disease and ulcerative colitis, multiple sclerosis, systemic lupus erythematosus, ankylosing spondylitis, uveitis, polymyalgia rheumatica, and type I diabetes; allergic disease such as asthma; dry eye; fibrosis such as pulmonary fibrosis and primary biliary cirrhosis; and metabolic disease such as diabetes.


Solution to Problem

The present inventors have found triazole compounds which are RORγ antagonists, thereby have completed the present invention. The present inventors have found isoxazole compounds which are RORγ antagonists, thereby have completed the present invention.


That is, the present invention provides the following aspects.


[01] A compound represented by Formula [I]:




embedded image


or a pharmaceutically acceptable salt thereof, wherein




embedded image




embedded image


is monocyclic heteroaromatic group wherein the monocyclic heteroaromatic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom;


each Ra1 is the same or different and selected from


(1) C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(2) halogen atom, or


(3) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A;


Rb is

(1) C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 halogen atoms, or


(2) C3-7 cycloalkyl group;


Rc is

(1) hydrogen atom, or


(2) C1-6 alkyl group;


each Rd is the same or different and selected from


(1) halogen atom, or


(2) C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 halogen atoms;


Re is hydrogen atom;


na is an integer selected from 0 or 1 to 3;


nc is an integer selected from 0 or 1 to 3;


nd is an integer selected from 0 or 1 to 3;


m is an integer selected from 0 or 1 to 5;


Group A is

(a) C1-6 alkyl group,


(b) halogen atom,


(c) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from the group consisting of C1-6 alkyl group and halogen atom.


[02] The compound according to [01], or a pharmaceutically acceptable salt thereof, wherein




embedded image


is monocyclic heteroaromatic group selected from the following (1) to (7):




embedded image


[03] The compound according to [01], or a pharmaceutically acceptable salt thereof, wherein the compound is represented by Formula [II-A]:




embedded image


wherein each symbol is as defined in [01].


[04] The compound according to [01], or a pharmaceutically acceptable salt thereof, wherein the compound is represented by Formula [II-B]:




embedded image


wherein each symbol is as defined in [01].


[05] The compound according to [01], or a pharmaceutically acceptable salt thereof, wherein the compound is represented by Formula [II-C]:




embedded image


wherein each symbol is as defined in [01].


[06] The compound according to [01], or a pharmaceutically acceptable salt thereof, wherein the compound is represented by Formula [II-D]:




embedded image


wherein each symbol is as defined in [01].


[07] The compound according to [01], or a pharmaceutically acceptable salt thereof, wherein the compound is represented by Formula [II-E]:




embedded image


wherein each symbol is as defined in [01].


[08] The compound according to [01], or a pharmaceutically acceptable salt thereof, wherein the compound is represented by Formula [II-F]:




embedded image


wherein each symbol is as defined in [01].


[09] The compound according to [01], or a pharmaceutically acceptable salt thereof, wherein the compound is represented by Formula [II-G]:




embedded image


wherein each symbol is as defined in [01].


[10] The compound according to any one of [01] to [09], or a pharmaceutically acceptable salt thereof, wherein Rc is hydrogen atom.


[11] A pharmaceutical composition comprising the compound according to any one of [01] to [10] or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable carrier.


[12] A RORγ antagonist comprising the compound according to any one of [01] to [10] or a pharmaceutically acceptable salt thereof.


[13] A medicament for treating or preventing a disease selected from the group consisting of autoimmune disease, allergic disease, dry eye, fibrosis, and metabolic disease, comprising the compound according to any one of [01] to [10] or a pharmaceutically acceptable salt thereof.


[14] The medicament according to [13] wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, ankylosing spondylitis, uveitis, polymyalgia rheumatica and type I diabetes.


[15] The medicament according to [13] wherein the metabolic disease is diabetes.


[16] A method of inhibiting RORγ in a mammal, comprising administering to said mammal a therapeutically effective amount of the compound according to any one of [01] to [10] or a pharmaceutically acceptable salt thereof.


[17] A method of treating or preventing a disease in a mammal selected from the group consisting of autoimmune disease, allergic disease, dry eye, fibrosis, and metabolic disease, comprising administering to said mammal a therapeutically effective amount of the compound according to any one of [01] to [10] or a pharmaceutically acceptable salt thereof.


[18] The method according to [17] wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, ankylosing spondylitis, uveitis, polymyalgia rheumatica and type I diabetes.


[19] The method according to [17] wherein the metabolic disease is diabetes.


[20] A pharmaceutical composition for treating or preventing a disease selected from the group consisting of autoimmune disease, allergic disease, dry eye, fibrosis, and metabolic disease, which comprises:


(a) the compound according to any one of [01] to [10] or a pharmaceutically acceptable salt thereof, and


(b) at least one additional medicament for treating or preventing a disease selected from the group consisting of autoimmune disease, allergic disease, dry eye, fibrosis, and metabolic disease.


[21] A combination drug comprising:


(a) the compound according to any one of [01] to [10] or a pharmaceutically acceptable salt thereof, and


(b) at least one additional medicament for treating or preventing a disease selected from the group consisting of autoimmune disease, allergic disease, dry eye, fibrosis, and metabolic disease,


wherein the compound of (a) and the additional medicament of (b) may be administered simultaneously, separately or consecutively.


[22] Use of the compound according to any one of [01] to [10] or a pharmaceutically acceptable salt thereof in the manufacture of a RORγ antagonist.


[23] Use of the compound according to any one of [01] to [10] or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a disease selected from the group consisting of autoimmune disease, allergic disease, dry eye, fibrosis, and metabolic disease.


[24] The use according to [23] wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, psoriasis, inflammatory bowel disease such as Crohn's disease and ulcerative colitis, multiple sclerosis, systemic lupus erythematosus, ankylosing spondylitis, uveitis, polymyalgia rheumatica and type I diabetes.


[25] The use according to [24] wherein the metabolic disease is diabetes.


[26] The compound according to any one of [01] to [10] or a pharmaceutically acceptable salt thereof for use in treating or preventing a disease selected from the group consisting of autoimmune disease, allergic disease, dry eye, fibrosis, and metabolic disease.


[27] A commercial package comprising the medicament according to [13], and instructions which explain that the medicament can be used to treat and/or prevent a disease selected from the group consisting of autoimmune disease, allergic disease, dry eye, fibrosis, and metabolic disease.


[28] A commercial package comprising the combination drug according to [21], and instructions which explain that the combination drug can be used to treat and/or prevent a disease selected from the group consisting of autoimmune disease, allergic disease, dry eye, fibrosis, and metabolic disease.


[29] A medicament for treating or preventing a disease selected from the group consisting of autoimmune disease such as rheumatoid arthritis, psoriasis, inflammatory bowel disease such as Crohn's disease and ulcerative colitis, multiple sclerosis, systemic lupus erythematosus, ankylosing spondylitis, uveitis, polymyalgia rheumatica and type I diabetes; allergic disease such as asthma; dry eye; fibrosis such as pulmonary fibrosis and primary biliary cirrhosis; and metabolic disease such as diabetes, comprising the compound according to any one of [01] to [10] or a pharmaceutically acceptable salt thereof.


[30] A pharmaceutical composition for treating or preventing a disease selected from the group consisting of autoimmune disease such as rheumatoid arthritis, psoriasis, inflammatory bowel disease such as Crohn's disease and ulcerative colitis, multiple sclerosis, systemic lupus erythematosus, ankylosing spondylitis, uveitis, polymyalgia rheumatica and type I diabetes; allergic disease such as asthma; dry eye; fibrosis such as pulmonary fibrosis and primary biliary cirrhosis; and metabolic disease such as diabetes, comprising:


(a) the compound according to any one of [01] to [10] or a pharmaceutically acceptable salt thereof, and


(b) at least one additional medicament for treating or preventing a disease selected from the group consisting of autoimmune disease such as rheumatoid arthritis, psoriasis, inflammatory bowel disease such as Crohn's disease and ulcerative colitis, multiple sclerosis, systemic lupus erythematosus, ankylosing spondylitis, uveitis, polymyalgia rheumatica and type I diabetes; allergic disease such as asthma; dry eye; fibrosis such as pulmonary fibrosis and primary biliary cirrhosis; and metabolic disease such as diabetes.


[31] A combination drug comprising:


(a) the compound according to any one of [01] to [10] or a pharmaceutically acceptable salt thereof, and


(b) at least one an additional medicament for treating or preventing a disease selected from the group consisting of autoimmune disease such as rheumatoid arthritis, psoriasis, inflammatory bowel disease such as Crohn's disease and ulcerative colitis, multiple sclerosis, systemic lupus erythematosus, ankylosing spondylitis, uveitis, polymyalgia rheumatica and type I diabetes; allergic disease such as asthma; dry eye; fibrosis such as pulmonary fibrosis and primary biliary cirrhosis; and metabolic disease such as diabetes,


wherein the compound of (a) and the additional medicament of (b) may be administered simultaneously, separately or consecutively.


[101] A compound represented by the following formulas:




embedded image


or a pharmaceutically acceptable salt thereof, wherein




embedded image


is unsaturated heteromonocyclic group selected from the following (i) to (v):




embedded image


Ra is selected from the following (1) to (12):


(1) C1-12 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(2) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(3) C2-12 alkenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(4) C2-12 alkynyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(5) C5-11 spirocyclic cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(6) cross-linked C5-12 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(7) saturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered,


(8) phenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(9) C9-10 fused carbocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(10) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


(11) saturated fused heterocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the saturated fused heterocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered,


(12) unsaturated fused heterocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the unsaturated fused heterocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered;


Rb is selected from the following (1) to (6):


(1) C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 halogen atoms,


(2) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from the group consisting of halogen atom and C1-6 alkyl group,


(3) —CH═CH—C(═O)—ORbb1,


(4) —CH2—CH2—C(═O)—ORbb2,


(5) —CH2—O—CH2—C(═O)—ORbb3,


(6) hydrogen atom;

    • Rbb1, Rbb2 and Rbb3 are each independently hydrogen atom or C1-6 alkyl group;


      each Rd is the same or different and selected from the following (1) to (13):


(1) halogen atom,


(2) C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group B,


(3) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group B,


(4) C2-6 alkenyl group,


(5) cyano group,


(6) —C(═O)—ORdd1,


(7) —C(═O)—NRdd2Rdd3,


(8) —ORdd4,


(9) —NRdd5—C(═O)—Rdd6,


(10) —NRdd7—C(═O)—NRdd8Rdd9,


(11) —NRdd10—S(═O)2—Rdd11,


(12) —NRdd12—S(═O)2—NRdd13Rdd14,


(13) —NRdd15Rdd16;

    • Rdd1, Rdd2, Rdd3, Rdd4, Rdd5, Rdd6, Rdd7, Rdd8, Rdd9, Rdd10, Rdd11, Rdd12, Rdd13, Rdd14, Rdd15, and Rdd16 are each independently hydrogen atom or C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group B;


      Re is hydrogen atom or C1-6 alkyl group;


      each Rj is the same or different C1-12 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A;


      Q is selected from the following (1) to (9):


(1) phenyl group,


(2) C3-7 cycloalkyl group,


(3) C9-10 fused carbocyclic group,


(4) cross-linked C5-12 cycloalkyl group,


(5) C3-8 alkyl group,


(6) saturated heteromonocyclic group wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered,


(7) unsaturated fused heterocyclic group wherein the unsaturated fused heterocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered,


(8) unsaturated heteromonocyclic group wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


(9) saturated fused heterocyclic group wherein the saturated fused heterocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered;


Y is selected from the following (1) to (3):


(1) single bond,


(2) —S(═O)2—,


(3) C1-3 alkylene which may optionally be substituted with 1 to 3 hydroxyl groups;


m is each independently an integer selected from 0 or 1 to 5;


nj is each independently 0, 1 or 2;


Group A consists of the following (a) to (m):


(a) C1-7 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,


(b) halogen atom,


(c) phenyl group,


(d) saturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered,


(e) unsaturated fused heterocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA wherein the unsaturated fused heterocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered,


(f) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


(g) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,


(h) —C(═O)—NRA1RA2,


(i) —C(═O)—ORA3,


(j) —C(═O)—RA4,


(k) —ORA5,


(l) —NRA6RA7,


(m) —S(═O)2—,

    • RA1, RA2, RA3 and RA4 are each independently hydrogen atom or C1-6 alkyl group;
    • RA5, RA6, and RA7 are each independently:
      • hydrogen atom,
      • C1-6 alkyl group which may optionally be substituted with the same or different 1 to 6 halogen atoms,
      • C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,
      • benzyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,
      • phenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,
      • C1-6 alkylcarbonyl group,
      • C1-6 alkylsulfonyl group, or
      • C2-6 alkenyl group; and
    • RA8 is each independently C1-6 alkyl group;


      Group AA consists of the following (a) to (o):


(a) halogen atom,


(b) C1-3 alkyl group which may optionally be substituted with the same or different 1 to 6 halogen atoms,


(c) —ORAA1,


(d) —C(═O)—NRAA2RAA3,


(e) —C(═O)—ORAA4,


(f) —O—C(═O)—RAA5,


(g) —C(═O)—RAA6,


(h) ═O,


(i) C3-7 cycloalkyl group,


(j) phenyl group which may optionally be substituted with the same or different 1 to 5 C1-3 alkyl groups,


(k) —NRAA7RAA8,


(l) —NRAA9—C(═O)—RAA10,


(m) —NRAA11—C(═O)—NRAA12RAA13,


(n) —NRAA14—S(═O)2—RAA15,


(o) —NRAA16—S(═O)2—NRAA17RAA18;


RAA1, RAA2, RAA3, RAA4, RAA5, RAA6, RAA7, RAA8, RAA9, RAA10, RAA11, RAA12, RAA13, RAA14, RAA15, RAA16, RAA17, and RAA18 are each independently hydrogen atom or C1-6 alkyl group;


Group B consists of the following (a) to (k):


(a) halogen atom,


(b) C3-7 cycloalkyl group


(c) —ORB1,


(d) —C(═O)—NRB2RB3,


(e) —C(═O)—ORB4,


(f) C1-6 alkyl group,


(g) —NRB5RB6,


(h) —NRB7—C(═O)—RB8,


(i) —NRB9—C(═O)—NRB10RB11,


(j) —NRB12—S(═O)2—RB13,


(k) —NRB14—S(═O)2—NRB15RB16;


RB1, RB2, RB3, RB4, RB5, RB6, RB7, RB8, RB9, RB10, RB11, RB12, RB13, RB14, RB15, and RB16 are each independently, hydrogen atom or C1-6 alkyl group;


provided that when Ra is


(1) phenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(2) C9-10 fused carbocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A, or


(3) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


Q is selected from the following (1) to (6):


(1) phenyl group,


(2) C3-7 cycloalkyl group,


(3) C9-10 fused carbocyclic group,


(4) cross-linked C5-12 cycloalkyl group,


(5) C3-8 alkyl group,


(6) saturated heteromonocyclic group wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered; and further provided that when Rb is hydrogen atom,


Q is selected from the following (1) to (5):


(1) phenyl group,


(2) C3-7 cycloalkyl group,


(3) C9-10 fused carbocyclic group,


(4) cross-linked C5-12 cycloalkyl group,


(5) saturated heteromonocyclic group wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered.


[102] A compound represented by the following formulas:




embedded image


or a pharmaceutically acceptable salt thereof, wherein




embedded image


is unsaturated heteromonocyclic group selected from the following (i) to (v):




embedded image


Ra is selected from the following (1) to (12):


(1) C1-12 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(2) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(3) C2-12 alkenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(4) C2-12 alkynyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(5) C5-11 spirocyclic cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(6) cross-linked C5-12 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(7) saturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered,


(8) phenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(9) C9-10 fused carbocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(10) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


(11) saturated fused heterocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the saturated fused heterocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered,


(12) unsaturated fused heterocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the unsaturated fused heterocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered;


Rb is selected from the following (1) to (6):


(1) C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 halogen atoms,


(2) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from the group consisting of halogen atom and C1-6 alkyl group,


(3) —CH═CH—C(═O)—ORbb1,


(4) —CH2—CH2—C(═O)—ORbb2,


(5) —CH2—O—CH2—C(═O)—ORbb3,


(6) hydrogen atom;

    • Rbb1, Rbb2, and Rbb3 are each independently hydrogen atom or C1-6 alkyl group;


      each Rd is the same or different and selected from the following (1) to (13):


(1) halogen atom,


(2) C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group B,


(3) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group B,


(4) C2-6 alkenyl group,


(5) cyano group,


(6) —C(═O)—ORdd1,


(7) —C(═O)—NRdd2Rdd3,


(8) —ORdd4,


(9) —NRdd5—C(═O)—Rdd6,


(10) —NRdd7—C(═O)—NRdd8Rdd9,


(11) —NRdd10—S(═O)2—Rdd11,


(12) —NRdd12—S(═O)2—NRdd13Rdd14,


(13) —NRdd15Rdd16;

    • Rdd1, Rdd2, Rdd3, Rdd4, Rdd5, Rdd6, Rdd7, Rdd8, Rdd9, Rdd10, Rdd11, Rdd12, Rdd13, Rdd14, Rdd15, and Rdd16 are each independently hydrogen atom or C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group B;


      Re is hydrogen atom or C1-6 alkyl group;


      each Rj is the same or different C1-12 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A;


      each Rw is the same or different and selected from the following (1) to (17):


(1) C1-12 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from the group consisting of hydroxyl group and halogen atom,


(2) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 C1-6 alkyl groups wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 7-membered,


(3) —(CH2)wn1—C(═O)—ORww1,


(4) —(CH2)wn1—C(═O)—(CH2)wn1—NRww2Rww3,


(5) —(CH2)wn1—C(═O)—(CH2)wn1—C(═O)—ORww4,


(6) —NRww5Rww6,


(7) —ORww7,


(8) —C(═O)—Rww8,


(9) —S(═O)2—Rww9,


(10) ═O,


(11) methylene,


(12) —(CH2)wn2-ring P,


(13) halogen atom,


(14) —NRww10—C(═O)—Rww11,


(15) —NRww12—C(═O)—NRww13Rww14,


(16) —NRww15—S(═O)2—Rww16,


(17) —NRww17—S(═O)2—NRww18Rww19;

    • Rww1, Rww2, Rww3, Rww4, Rww5, Rww6 and Rww7 are each independently hydrogen atom or C1-6 alkyl group;
    • Rww8 is each independently
      • hydrogen atom,
      • C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from the group consisting of hydroxyl group and halogen atom, or
      • saturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 alkyl groups wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered;
    • Rww9 is each independently C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 halogen atoms;
    • Rww10, Rww11, Rww12, Rww13, Rww14, Rww15, Rww16, Rww17, Rww18, and Rww19 are each independently hydrogen atom or C1-6 alkyl group;
    • ring P is monocyclic heterocycle which is a carboxylic acid equivalent wherein the carboxylic acid equivalent may optionally be substituted;
    • wn1 is each independently an integer selected from 0 or 1 to 3; and
    • wn2 is each independently an integer selected from 1 to 3;


      Q is selected from the following (1) to (9):


(1) phenyl group,


(2) C3-7 cycloalkyl group,


(3) C9-10 fused carbocyclic group,


(4) cross-linked C5-12 cycloalkyl group,


(5) C3-8 alkyl group,


(6) saturated heteromonocyclic group wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered,


(7) unsaturated fused heterocyclic group wherein the unsaturated fused heterocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered,


(8) unsaturated heteromonocyclic group wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


(9) saturated fused heterocyclic group wherein the saturated fused heterocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered;


Y is selected from the following (1) to (3):


(1) single bond,


(2) —S(═O)2—,


(3) C1-3 alkylene which may optionally be substituted with 1 to 3 hydroxyl groups;


cyclic moiety W is selected from the following (1) to (3):


(1) pyrrolidinyl,


(2) piperidinyl,


(3) C3-7 cycloalkyl;


cn is each independently an integer selected from 0 or 1 to 3;


m is each independently an integer selected from 0 or 1 to 5;


nj is each independently 0, 1 or 2;


Group A consists of the following (a) to (m):


(a) alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,


(b) halogen atom,


(c) phenyl group,


(d) saturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered,


(e) unsaturated fused heterocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA wherein the unsaturated fused heterocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered,


(f) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


(g) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,


(h) —C(═O)—NRA1RA2,


(i) —C(═O)—ORA3,


(j) —C(═O) —RA4,


(k) —ORA5,


(l) —NRA6RA7,


(m) —S(═O)2—RA8;

    • RA1, RA2, RA3, and RA4 are each independently hydrogen atom or C1-6 alkyl group;
    • RA5, RA6, and RA7 are each independently:
      • hydrogen atom,
      • C1-6 alkyl group which may optionally be substituted with the same or different 1 to 6 halogen atoms,
      • C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,
      • benzyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,
      • phenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,
      • C1-6 alkylcarbonyl group,
      • C1-6 alkylsulfonyl group, or
      • C2-6 alkenyl group; and
    • RA8 is each independently C1-6 alkyl group;


      Group AA consists of the following (a) to (o):


(a) halogen atom,


(b) C1-3 alkyl group which may optionally be substituted with the same or different 1 to 6 halogen atoms,


(c) —ORAA1,


(d) —C(═O)—NRAA2RAA3,


(e) —C(═O)—ORAA4,


(f) —O—C(═O)—RAA5,


(g) —C(═O)—RAA6,


(h) ═O,


(i) C3-7 cycloalkyl group,


(j) phenyl group which may optionally be substituted with the same or different 1 to 5 C1-3 alkyl groups,


(k) —NRAA7RAA8,


(l) —NRAA9—C(═O)—RAA10,


(m) —NRAA11—C(═O)—NRAA12RAA13,


(n) —NRAA14—S(═O)2—RAA15,


(o) —NRAA16—S(═O)2—NRAA17RAA18,


RAA1, RAA2, RAA3, RAA4, RAA5, RAA6, RAA7, RAA8, RAA9, RAA10, RAA11, RAA12, RAA13, RAA14, RAA15, RAA16, RAA17, and RAA18 are each independently hydrogen atom or C1-6 alkyl group;


Group B consists of the following (a) to (k):


(a) halogen atom,


(b) C3-7 cycloalkyl group


(c) —ORB1,


(d) —C(═O)—NRB2RB3,


(e) —C(═O)—ORB4,


(f) C1-6 alkyl group,


(g) —NRB5RB6,


(h) —NRB7—C(═O)—RB8,


(i) —NRB8—C(═O)—NRB10RB11,


(j) —NRB12—S(═O)2—RB13,


(k) —NRB14—S(═O)2—NRB15RB16;


RB1, RB2, RB3, RB4, RB5, RB6, RB7, RB8, RB9, RB10, RB11, RB12, RB13, RB14, RB15, and RB16 are each independently, hydrogen atom or C1-6 alkyl group;


provided that when Rb is hydrogen atom,


Q is selected from the following (1) to (5):


(1) phenyl group,


(2) C3-7 cycloalkyl group,


(3) C9-15 fused carbocyclic group,


(4) cross-linked C5-12 cycloalkyl group,


(5) saturated heteromonocyclic group wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered;


and further provided that when




embedded image


is




embedded image


cyclic moiety W is selected from the following (1) or (2):


(1) pyrrolidinyl,


(2) piperidinyl.


[103] A compound represented by the following formulas:




embedded image


or a pharmaceutically acceptable salt thereof, wherein




embedded image


is unsaturated heteromonocyclic group selected from the following (i) to (v):




embedded image


Ra is selected from the following (1) to (12):


(1) C1-12 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(2) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(3) C2-12 alkenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(4) C2-12 alkynyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(5) C5-11 spirocyclic cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(6) cross-linked C5-12 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(7) saturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered,


(8) phenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(9) C9-10 fused carbocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(10) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


(11) saturated fused heterocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the saturated fused heterocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered,


(12) unsaturated fused heterocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the unsaturated fused heterocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered;


Rb is selected from the following (1) to (6):


(1) C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 halogen atoms,


(2) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from the group consisting of halogen atom and C1-6 alkyl group,


(3) —CH═CH—C(═O)—ORbb1,


(4) —CH2—CH2—C(═O)—ORbb2,


(5) —CH2—O—CH2—C(═O)—ORbb3,


(6) hydrogen atom;

    • Rbb1, Rbb2, and Rbb3 are each independently hydrogen atom or C1-6 alkyl group;


      Rc is selected from the following (1) to (17):


(1) —(CH2)n1—C(═O)—ORcc1,


(2) —O—(CH2)n2—C(═O)—ORcc2,


(3) —(CH2)n3-ring P,


(4) —(CH2)n4—C(═O)—NH—S(═O)2—CH3,


(5) C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group 0,


(6) C3-6 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group C,


(7) C2-12 alkenyl group,


(8) C2-12 alkynyl group,


(9) —NRcc3Rcc4,


(10) —ORcc5,


(11) —O—CH2CH2—OH,


(12) —O—CH2C(═O)NH—CH3,




embedded image


Rcc1 and Rcc2 are each independently hydrogen atom or C1-6 alkyl group;

    • Rcc3 and Rcc4 are each independently, hydrogen atom,
    • C1-6 alkyl group,
    • C1-6 alkylcarbonyl group,
    • benzyloxycarbonyl group, or
    • C1-6 alkyl group which is substituted with 1 to 3 hydroxyl groups;
    • Rcc5 is
      • hydrogen atom,
      • C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group C, or
      • benzyl group;
    • ring P is monocyclic heterocycle which is a carboxylic acid equivalent wherein the carboxylic acid equivalent may optionally be substituted;
    • n1 is an integer selected from 0 or 1 to 3;
    • n2 is an integer selected from 0 or 1 to 3;
    • n3 is an integer selected from 1 to 3; and
    • n4 is an integer selected from 1 to 3;


      each Rd is the same or different and selected from the following (1) to (13):


(1) halogen atom,


(2) C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group B,


(3) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group B,


(4) C2-6 alkenyl group,


(5) cyano group,


(6) —C(═O)—ORdd1,


(7) —C(═O)—NRdd2Rdd3,


(8) —ORdd4,


(9) —NRdd5—C(═O)—Rdd6,


(10) —NRdd7—C(═O)—NRdd8Rdd9,


(11) —NRdd10—S(═O)2—Rdd11,


(12) —NRdd12—S(═O)2—NRdd13Rdd14,


(13) —NRdd15Rdd16;

    • Rdd1, Rdd2, Rdd3, Rdd4, Rdd5, Rdd6, Rdd7, Rdd8, Rdd9, Rdd10, Rdd11, Rdd12, Rdd13, Rdd14, Rdd15, and Rdd16 are each independently hydrogen atom or C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group. B;


      Re is hydrogen atom or C1-6 alkyl group;


      each Rj is the same or different C1-12 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A;


      Q is selected from the following (1) to (9):


(1) phenyl group,


(2) C3-7 cycloalkyl group,


(3) C9-10 fused carbocyclic group,


(4) cross-linked C5-12 cycloalkyl group,


(5) C3-8 alkyl group,


(6) saturated heteromonocyclic group wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered,


(7) unsaturated fused heterocyclic group wherein the unsaturated fused heterocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered,


(8) unsaturated heteromonocyclic group wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


(9) saturated fused heterocyclic group wherein the saturated fused heterocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered;


Y is selected from the following (1) to (3):


(1) single bond,


(2) —S(═O)2—,


(3) C1-3 alkylene which may optionally be substituted with 1 to 3 hydroxyl groups;


m is each independently an integer selected from 0 or 1 to 5;


nj is each independently 0, 1 or


Group A consists of the following (a) to (m):


(a) C1-7 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,


(b) halogen atom,


(c) phenyl group,


(d) saturated heteromonocyclic group which may optionally substituted with the same or different 1 to 5 substituents selected from Group AA wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered,


(e) unsaturated fused heterocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA wherein the unsaturated fused heterocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered,


(f) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


(g) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,


(h) —C(═O)—NRA1RA2,


(i) —C(═O)—ORA3,


(j) —C(═O)—RA4,


(k) —ORA5,


(l) —NRA6RA7,


(m) —S(═O)2—RA8;

    • RA1, RA2, RA3, and RA4 are each independently hydrogen atom or C1-6 alkyl group;
    • RA5, RA6, and RA7 are each independently:
      • hydrogen atom,
      • C1-6 alkyl group which may optionally be substituted with the same or different 1 to 6 halogen atoms,
      • C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,
      • benzyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,
      • phenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,
      • C1-6 alkylcarbonyl group,
      • C1-6 alkylsulfonyl group, or
      • C2-6 alkenyl group; and
    • RA8 is each independently C1-6 alkyl group;


      Group AA consists of the following (a) to (o):


(a) halogen atom,


(b) C1-3 alkyl group which may optionally be substituted with the same or different 1 to 6 halogen atoms,


(c) —ORAA1,


(d) —C(═O)—NRAA2RAA3,


(e) —C(═O)—ORAA4,


(f) —O—C(═O)—RAA5,


(g) —C(═O)—RAA6,


(h) ═O,


(i) C3-7 cycloalkyl group,


(j) phenyl group which may optionally be substituted with the same or different 1 to 5 C1-3 alkyl groups,


(k) —NRAA7RAA8,


(l) —NRAA9—C(═O)—RAA10,


(m) —NRAA11—(═O)—NRAA12RAA13,


(n) —NRAA14—S(═O)2—RAA15,


(o) —NRAA16—S(═O)2—NRAA17RAA18;


RAA1, RAA2, RAA3, RAA4, RAA5, RAA6, RAA7, RAA8, RAA9, RAA10, RAA11, RAA12, RAA13, RAA14, RAA15, RAA16, RAA17, and RAA18 are each independently hydrogen atom or C1-6 alkyl group;


Group B consists of the following (a) to (k):


(a) halogen atom,


(b) C3-7 cycloalkyl group


(c) —ORB1,


(d) —C(═O)—NRB2RB3,


(e) —C(═O)—ORB4,


(f) C1-6 alkyl group,


(g) —NRB5RB6,


(h) —NRB7—C(═O)—RB8,


(i) —NRB9—C(═O)—NRB10RB11,


(j) —NRB12—S—(═O)2—RB13;


(k) —NRB14—S(═O)2—NRB15RB16;

    • RB1, RB2, RB3, RB4, RB5, RB6, RB7, RB8, RB9, RB10, RB11, RB12, RB13, RB14, RB15, and RB16 are each independently hydrogen atom or C1-6 alkyl group;


      Group C consists of the following (a) to (k):


(a) phenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group CC,


(b) cyano group,


(c) halogen atom,


(d) —ORCD1,


(e) —NRCD2RCD3,


(f) —C(═O)—NRCD4RCD5,




embedded image


(i) saturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group CC wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered, excluding ring P,


(j) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group CC wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered, excluding ring P,




embedded image




    • RCD1, RCD2, and RCD3 are each independently,
      • hydrogen atom,
      • C1-6 alkyl group,
      • C1-6 alkylcarbonyl group,
      • benzyl group,
      • —C(═O)—O—CH2-phenyl,
      • —C(═O)—N(CH3)2,
      • —C(═O)—C(OH) (CH3)2,
      • —C(═O)—CH2—O—CH3, or
      • —C(═O)—CH2—CN; and

    • RCD4 and RCD5 are each independently hydrogen atom or C1-6 alkyl group;


      Group CC consists of the following (a) to (c):





(a) halogen atom,


(b) C1-3 alkyl group which may optionally be substituted with the same or different 1 to 6 halogen atoms,


(c) —ORAA1,

    • RAA1 is each independently hydrogen atom or C1-6 alkyl group;


      provided that when Ra is


(1) phenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(2) C9-10 fused carbocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A, or


(3) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


Q is selected from the following (1) to (6):


(1) phenyl group,


(2) C3-7 cycloalkyl group,


(3) C9-10 fused carbocyclic group,


(4) cross-linked C5-12 cycloalkyl group,


(5) C3-8 alkyl group,


(6) saturated heteromonocyclic group wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered;


and further provided that when Rb is hydrogen atom,


Q is selected from the following (1) to (5):


(1) phenyl group,


(2) C3-7 cycloalkyl group,


(3) C9-10 fused carbocyclic group,


(4) cross-linked C5-12 cycloalkyl group,


(5) saturated heteromonocyclic group wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered.


[104] A compound represented by the following formulas:




embedded image


or a pharmaceutically acceptable salt thereof, wherein




embedded image


is unsaturated heteromonocyclic group selected from the following (i) to (v):




embedded image


Ra is selected from the following (1) to (12):


(1) C1-12 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(2) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(3) C2-12 alkenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(4) C2-12 alkynyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(5) C5-11 spirocyclic cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(6) cross-linked C5-12 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(7) saturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered,


(8) phenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(9) C9-10 fused carbocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(10) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


(11) saturated fused heterocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the saturated fused heterocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered,


(12) unsaturated fused heterocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the unsaturated fused heterocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered;


Rb is selected from the following (1) to (6):


(1) C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 halogen atoms,


(2) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from the group consisting of halogen atom and C1-6 alkyl group,


(3) —CH═CH—C(═O)—ORbb1,


(4) —CH2—CH2—C(═O)—ORbb2,


(5) —CH2—O—CH2—C(═O)—ORbb3,


(6) hydrogen atom;

    • Rbb1, Rbb2 and Rbb3 are each independently hydrogen atom or C1-6 alkyl group;


      Rc is selected from the following (1) to (17):


(1) —(CH2)n1—C(═O)—ORcc1,


(2) —O—(CH2)n2—C(═O)—ORcc2,


(3) —(CH2)n3-ring P,


(4) —(CH2)n4—C(═O)—NH—S(═O)2—CH3,


(5) C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group C,


(6) C3-6 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group C,


(7) C2-12 alkenyl group,


(8) C2-12 alkynyl group,


(9) —NRcc3Rcc4,


(10) —ORcc5,


(11) —O—CH2CH2—OH,


(12) —O—CH2O(═O)NH—CH3,




embedded image


Rcc1 and Rcc2 are each independently hydrogen atom or C1-6 alkyl group;

    • Rcc3 and Rcc4 are each independently,
    • hydrogen atom,
    • C1-6 alkyl group,
    • C1-6 alkylcarbonyl group,
    • benzyloxycarbonyl group, or
    • C1-6 alkyl group which is substituted with 1 to 3 hydroxyl groups;
    • Rcc5 is
      • hydrogen atom,
      • C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group C, or
      • benzyl group;
    • ring P is monocyclic heterocycle which is a carboxylic acid equivalent wherein the carboxylic acid equivalent may optionally be substituted;
    • n1 is an integer selected from 0 or 1 to 3;
    • n2 is an integer selected from 0 or 1 to 3;
    • n3 is an integer selected from 1 to 3; and
    • n4 is an integer selected from 1 to 3;


      each Rd is the same or different and selected from the following (1) to (13):


(1) halogen atom,


(2) C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group B,


(3) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group B,


(4) C2-6 alkenyl group,


(5) cyano group,


(6) —C(═O)—ORdd1,


(7) —C(═O)—NRdd2Rdd3,


(8) —ORdd4,


(9) —NRdd5—C(═O)—Rdd6,


(10) —NRdd7—C(═O)—NRdd8Rdd9,


(11) —NRdd10—S(═O)2—Rdd11,


(12) —NRdd12—S(═O)2—NRdd13—Rdd14,


(13) —NRdd15Rdd16;

    • Rdd1, Rdd2, Rdd3, Rdd4, Rdd5, Rdd6, Rdd7, Rdd8, Rdd9, Rdd10, Rdd11, Rdd12, Rdd13, Rdd14, Rdd15, and Rdd16 are each independently hydrogen atom or C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group B;


      Re is hydrogen atom or C1-6 alkyl group;


      Rf is hydrogen atom or C1-6 alkyl group;


      each Rj is the same or different C1-12 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A;


      Q is selected from the following (1) to (9):


(1) phenyl group,


(2) C3-7 cycloalkyl group,


(3) C9-10 fused carbocyclic group,


(4) cross-linked C5-12 cycloalkyl group,


(5) C3-8 alkyl group,


(6) saturated heteromonocyclic group wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered,


(7) unsaturated fused heterocyclic group wherein the unsaturated fused heterocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered,


(8) unsaturated heteromonocyclic group wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


(9) saturated fused heterocyclic group wherein the saturated fused heterocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered;


Y is selected from the following (1) to (3):


(1) single bond,


(2) —S(═O)2—,


(3) C1-3 alkylene which may optionally be substituted with 1 to 3 hydroxyl groups;


m is each independently an integer selected from 0 or 1 to 5;


nj is each independently 0, 1 or 2;


Group A consists of the following (a) to (m):


(a) alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,


(b) halogen atom,


(c) phenyl group,


(d) saturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered,


(e) unsaturated fused heterocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA wherein the unsaturated fused heterocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered,


(f) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


(g) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,


(h) —C(═O)—NRA2RA2,


(i) —C(═O)—ORA5,


(j) —C(═O)—RA4,


(k) —ORA5,


(l) —NRA6RA7,


(m) —S(═O)2—RA8;

    • RA1, RA2, RA3, and RA4 are each independently hydrogen atom or C1-6 alkyl group;
    • RA5, RA6, and RA7 are each independently:
      • hydrogen atom,
      • C1-6 alkyl group which may optionally be substituted with the same or different 1 to 6 halogen atoms,
      • C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,
      • benzyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,
      • phenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,
      • C1-6 alkylcarbonyl group,
      • C1-6 alkylsulfonyl group, or
      • C2-6 alkenyl group; and
    • RA8 is each independently C1-6 alkyl group;


      Group AA consists of the following (a) to (o):


(a) halogen atom,


(b) C1-3 alkyl group which may optionally be substituted with the same or different 1 to 6 halogen atoms,


(c) —ORAA1,


(d) —C(═O)—NRAA2RAA3,


(e) —C(═O)—ORAA4,


(f) —O—C(═O)—RAA5,


(g) —C(═O)—RAA6,


(h) ═O,


(i) C3-7 cycloalkyl group,


(j) phenyl group which may optionally be substituted with the same or different 1 to 5 C1-3 alkyl groups,


(k) —NRAA7RAA8,


(l) —NRAA9—C(═O)—RAA10,


(m) —NRAA11—C(═O)—NRAA12RAA13,


(n) —NRAA14—S(═O)2—RAA15,


(o) —NRAA16—S(═)2—NRAA17RAA18;


RAA1, RAA2, RAA3, RAA4, RAA5, RAA6, RAA7, RAA8, RAA9, RAA10, RAA11, RAA12, RAA13, RAA14, RAA15, RAA16, RAA17, and RAA18 are each independently hydrogen atom or C1-6 alkyl group;


Group B consists of the following (a) to (k):


(a) halogen atom,


(b) C3-7 cycloalkyl group


(c) —ORB1,


(d) —C(═O)—NRB2RB3,


(e) —C(═O)—ORB4,


(f) C1-6 alkyl group,


(g) —NRB5RB6,


(h) —NRB7—C(═O)—RB9,


(i) —NRB9—C(═O)—NRB10RB11,


(j) —NRB12—S(═O)2—RB13,


(k) —NRB14—S(═O)2—NRB15RB16;

    • RB1, RB2, RB3, RB4, RB5, RB6, RB7, RB8, RB9, RB10, RB11, RB12, RB13, RB14, RB15, and RB16 are each independently hydrogen atom or C1-6 alkyl group;


      Group C consists of the following (a) to (k):


(a) phenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group CC,


(b) cyano group,


(c) halogen atom,


(d) —ORCD1,


(e) —NRCD2RCD3,


(f) —C(═O)—NRCD4RCD5,




embedded image


(i) saturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group CC wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered, excluding ring P,


(j) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group CC wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered, excluding ring P,




embedded image




    • RCD1, RCD2, and RCD3 are each independently,
      • hydrogen atom,
      • C1-6 alkyl group,
      • C1-6 alkylcarbonyl group,
      • benzyl group,
      • —C(═O)—O—CH2-phenyl,
      • —C(═O)—N(CH3)2,
      • —C(═O)—C(OH) (CH3)2,
      • —C(═O)—CH2—O—CH3, or
      • —C(═O)—CH2—CN; and

    • RCD4 and RCD5 are each independently hydrogen atom or C1-6 alkyl group;


      Group CC consists of the following (a) to (c):





(a) halogen atom,


(b) C1-3 alkyl group which may optionally be substituted with the same or different 1 to 6 halogen atoms,


(c) —ORAA1,

    • RAA1 is each independently hydrogen atom or C1-6 alkyl group;


      provided that when Ra is


(1) phenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(2) C9-10 fused carbocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A, or


(3) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


Q is selected from the following (1) to (6):


(1) phenyl group,


(2) C3-7 cycloalkyl group,


(3) C9-10 fused carbocyclic group,


(4) cross-linked C5-12 cycloalkyl group,


(5) C3-8 alkyl group,


(6) saturated heteromonocyclic group wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered;


further provided that when Rb is hydrogen atom,


Q is selected from the following (1) to (5):


(1) phenyl group,


(2) C3-7 cycloalkyl group,


(3) C9-10 fused carbocyclic group,


(4) cross-linked C5-12 cycloalkyl group,


(5) saturated heteromonocyclic group wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered;


and further provided that when




embedded image


is




embedded image


Q is selected from the following (1) to (6):


(1) C3-7 cycloalkyl group,


(2) C9-10 fused carbocyclic group selected from the group consisting of indanyl group and 1,2,3,4-tetrahydronaphthyl group,


(3) cross-linked C5-12 cycloalkyl group,


(4) saturated heteromonocyclic group wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered,


(5) unsaturated fused heterocyclic group wherein the unsaturated fused heterocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered,


(6) unsaturated heteromonocyclic group wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered.


[105] A compound represented by the following formulas:




embedded image


or a pharmaceutically acceptable salt thereof, wherein




embedded image


is unsaturated heteromonocyclic group selected from the following (i) to (v):




embedded image


Ra is selected from the following (1) to (12):


(1) C1-12 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(2) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(3) C2-12 alkenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(4) C2-12 alkynyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(5) C5-11 spirocyclic cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(6) cross-linked C5-12 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(7) saturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered,


(8) phenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(9) C9-10 fused carbocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(10) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


(11) saturated fused heterocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the saturated fused heterocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered,


(12) unsaturated fused heterocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the unsaturated fused heterocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered;


Rb is selected from the following (1) to (6):


(1) C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 halogen atoms,


(2) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from the group consisting of halogen atom and C1-6 alkyl group,


(3) —CH═CH—C(═O)—ORbb1,


(4) —CH2—CH2—C(═O)—ORbb2,


(5) —CH2—O—CH2—C(═O)—ORbb3,


(6) hydrogen atom;

    • Rbb1, Rbb2, and Rbb3 are each independently hydrogen atom or C1-6 alkyl group;


      Rc is selected from the following (1) to (17):


(1) —(CH2)n1—C(═O)—ORcc1,


(2) —O—(CH2)n2—C(═O)—ORcc2,


(3) —(CH2)n3-ring P,


(4) —(CH2)n4—C(═O)—NH—S(═O)2—CH3,


(5) C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group C,


(6) C3-6 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group C,


(7) C2-12 alkenyl group,


(8) C2-12 alkynyl group,


(9) —NRcc3Rcc4,


(10) —ORcc5,


(11) —O—CH2CH2—OH,


(12) —O—CH2C(═O)NH—CH3,




embedded image


Rcc1 and Rcc2 are each independently hydrogen atom or C1-6 alkyl group;

    • Rcc3 and Rcc4 are each independently,
    • hydrogen atom,
    • C1-6 alkyl group,
    • C1-6 alkylcarbonyl group,
    • benzyloxycarbonyl group, or
    • C1-6 alkyl group which is substituted with 1 to 3 hydroxyl groups;
    • Rcc5 is
      • hydrogen atom,
      • C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group C, or
      • benzyl group;
    • ring P is monocyclic heterocycle which is a carboxylic acid equivalent wherein the carboxylic acid equivalent may optionally be substituted;
    • n1 is an integer selected from 0 or 1 to 3;
    • n2 is an integer selected from 0 or 1 to 3;
    • n3 is an integer selected from 1 to 3; and
    • n4 is an integer selected from 1 to 3;


      each Rd is the same or different and selected from the following (1) to (13)


(1) halogen atom,


(2) C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group B,


(3) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group B,


(4) C2-6 alkenyl group,


(5) cyano group,


(6) —C(═O)—ORdd1,


(7) —C(═O)—NRdd2Rdd3,


(8) —ORdd4,


(9) —NRdd5—C(═O)—Rdd6,


(10) —NRdd7—C(═O)—NRdd8Rdd9,


(11) —NRdd10—S(═O)2—Rdd11,


(12) —NRdd12—S(═O)2—NRdd13Rdd14,


(13) —NRdd15Rdd16;

    • Rdd1, Rdd2, Rdd3, Rdd4, Rdd5, Rdd6, Rdd7, Rdd8, Rdd9, Rdd10, Rdd11, Rdd12, Rdd13, Rdd14, Rdd15, and Rdd16 are each independently hydrogen atom or alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group B;


      Re is hydrogen atom or C1-6 alkyl group;


      Rf is hydrogen atom or C1-6 alkyl group;


      each Rj is the same or different C1-12 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A;


      Q is selected from the following (1) to (9):


(1) phenyl group,


(2) C3-7 cycloalkyl group,


(3) C9-10 fused carbocyclic group,


(4) cross-linked C5-12 cycloalkyl group,


(5) C3-9 alkyl group,


(6) saturated heteromonocyclic group wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered,


(7) unsaturated fused heterocyclic group wherein the unsaturated fused heterocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered, unsaturated heteromonocyclic group wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


(9) saturated fused heterocyclic group wherein the saturated fused heterocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered;


Y is selected from the following (1) to (3):


(1) single bond,


(2) —S(═O)2—,


(3) C1-3 alkylene which may optionally be substituted with 1 to 3 hydroxyl groups;


m is each independently an integer selected from 0 or 1 to 5;


nj is each independently 0, 1 or 2;


Group A consists of the following (a) to (m):


(a) C1-7 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,


(b) halogen atom,


(c) phenyl group,


(d) saturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered,


(e) unsaturated fused heterocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA wherein the unsaturated fused heterocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered,


(f) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


(g) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,


(h) —C(═O)—NRA1RA2,


(i) —C(═O)—ORA3,


(j) —C(═O)—RA4,


(k) —ORA5,


(l) —NRA6RA7,


(m) —S(═O)2RA8;

    • RA1, RA2, RA3, and RA4 are each independently hydrogen atom or C1-6 alkyl group;
    • RA5, RA6, and RA7 are each independently:
      • hydrogen atom,
      • C1-6 alkyl group which may optionally be substituted with the same or different 1 to 6 halogen atoms,
      • C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,
      • benzyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,
      • phenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,
        • C1-6 alkylcarbonyl group,
        • C1-6 alkylsulfonyl group, or
        • C2-6 alkenyl group; and
      • RA8 is each independently C1-6 alkyl group;


        Group AA consists of the following (a) to (o):


(a) halogen atom,


(b) C1-3 alkyl group which may optionally be substituted with the same or different 1 to 6 halogen atoms,


(c) —ORAA1,


(d) —C(═O)—NRAA2RAA3,


(e) —C(═O)—ORAA4,


(f) —O—C(═O)—RAA5,


(g) —C(═O)—RAA6,


(h) ═O,


(i) C3-7 cycloalkyl group,


(j) phenyl group which may optionally be substituted with the same or different 1 to 5 C1-3 alkyl groups,


(k) —NRAA7RAA8,


(l) —NRAA9—C(═O)—RAA10,


(m) —NRAA11—C(═O)—NRAA12RAA13,


(n) —NRAA14—S(═O)2—RAA15,


(o) —NRAA16—S(═O)2—NRAA17RAA18;


RAA1, RAA2, RAA3, RAA4, RAA5, RAA6, RAA7, RAA8, RAA9, RAA10, RAA11, RAA12, RAA13, RAA14, RAA15, RAA16, RAA17, and RAA18 are each independently hydrogen atom or C1-6 alkyl group;


Group B consists of the following (a) to (k):


(a) halogen atom,


(b) C3-7 cycloalkyl group


(c) —ORB1,


(d) —C(═O)—NRB2RB3,


(e) —C(═O)—ORB4,


(f) C1-6 alkyl group,


(g) —NRB5RB6,


(h) —NRB7—C(═O)—RB8,


(i) —NRB9—C(═O)—NRB10RB11,


(j) —NRB12—S(═O)2—RB13,


(k) —NRB14—S(═O)2—NRB15RB16;

    • RB1, RB2, RB3, RB4, RB5, RB6, RB7, RB8, RB9, RB10, RB11, RB12, RB13, RB14, RB15, and RB16 are each independently hydrogen atom or C1-6 alkyl group;


      Group C consists of the following (a) to (k):


(a) phenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group CC,


(b) cyano group,


(c) halogen atom,


(d) —ORCD1,


(e) —NRCD2RCD3,


(f) —C(═O)—NRCD4RCD5,




embedded image


(i) saturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group CC wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered, excluding ring P,


(j) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group CC wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered, excluding ring P,




embedded image




    • RCD1, RCD2, and RCD3 are each independently,
      • hydrogen atom,
      • C1-6 alkyl group,
      • C1-6 alkylcarbonyl group,
      • benzyl group,
      • —C(═O)—O—CH2-phenyl,
      • —C(═O)—N(CH2)2,
      • —C(═O)—C(OH) (CH3)2,
      • —C(═O)—CH2—O—CH3, or
      • —C(═O)—CH2—CN; and

    • RCD4 and RCD5 are each independently hydrogen atom or C1-6 alkyl group;


      Group CC consists of the following (a) to (c):





(a) halogen atom,


(b) C1-3 alkyl group which may optionally be substituted with the same or different 1 to 6 halogen atoms,


(c) —ORAA1,

    • RAA1 is each independently hydrogen atom or C1-6 alkyl group;


      provided that when Ra is


(1) phenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(2) C9-10 fused carbocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A, or


(3) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


Q is selected from the following (1) to (6):


(1) phenyl group,


(2) C3-7 cycloalkyl group,


(3) C9-10 fused carbocyclic group,


(4) cross-linked C5-12 cycloalkyl group,


(5) C3-8 alkyl group,


(6) saturated heteromonocyclic group wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered;


further provided that when Rb is hydrogen atom,


Q is selected from the following (1) to (5):


(1) phenyl group,


(2) C3-7 cycloalkyl group,


(3) C9-10 fused carbocyclic group,


(4) cross-linked C3-12 cycloalkyl group,


(5) saturated heteromonocyclic group wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered and further provided that when




embedded image


is




embedded image


Ra is selected from the following (1) or (2):


(1) saturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered,


(2) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered.


[106] A compound represented by the following formulas:




embedded image


or a pharmaceutically acceptable salt thereof, wherein




embedded image


is unsaturated heteromonocyclic group selected from the following (i) to (v):




embedded image


Ra is selected from the following (1) to (12):


(1) C1-12 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(2) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(3) C2-12 alkenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(4) C2-12 alkynyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(5) C5-11 spirocyclic cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(6) cross-linked C5-12 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(7) saturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered,


(8) phenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(9) C9-10 fused carbocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(10) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


(11) saturated fused heterocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the saturated fused heterocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered,


(12) unsaturated fused heterocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the unsaturated fused heterocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered;


Rb is selected from the following (1) to (6):


(1) C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 halogen atoms,


(2) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from the group consisting of halogen atom and C1-6 alkyl group,


(3) —CH═CH—C(═O)—ORbb1,


(4) —CH2—CH2—C(═O)—ORbb2,


(5) —CH2—O—CH2—C(═O)—ORbb3,


(6) hydrogen atom;

    • Rbb1, Rbb2, and Rbb3 are each independently hydrogen atom or C1-6 alkyl group;


      Rc is selected from the following (1) to (17):


(1) —(CH2)n1—C(═O)_ORcc1,


(2) —O—(CH2)n2—C(═O)—ORcc2,


(3) —(CH2)n3-ring P,


(4) —(CH2)n4—C(═O)—NH—S(═O)2—CH3,


(5) C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group C,


(6) C3-6 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group C,


(7) C2-12 alkenyl group,


(8) C2-12 alkynyl group,


(9) —NRcc3Rcc4,


(10) —ORcc5,


(11) —O—CH2CH2—OH,


(12) —O—CH2C(═O)NH—CH3,




embedded image


Rcc1 and Rcc2 are each independently hydrogen atom or C1-6 alkyl group;

    • Rcc3 and Rcc4 are each independently,
    • hydrogen atom,
    • C1-6 alkyl group,
    • C1-6 alkylcarbonyl group,
    • benzyloxycarbonyl group, or
    • C1-6 alkyl group which is substituted with 1 to 3 hydroxyl groups;
    • Rcc5 is
      • hydrogen atom,
      • C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group C, or
      • benzyl group;
    • ring P is monocyclic heterocycle which is a carboxylic acid equivalent wherein the carboxylic acid equivalent may optionally be substituted;
    • n1 is an integer selected from 0 or 1 to 3;
    • n2 is an integer selected from 0 or 1 to 3;
    • n3 is an integer selected from 1 to 3; and
    • n4 is an integer selected from 1 to 3;


      each Rd is the same or different and selected from the following (1) to (13):


(1) halogen atom,


(2) C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group B,


(3) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group B,


(4) C2-6 alkenyl group,


(5) cyano group,


(6) —C(═O)—ORdd1,


(7) —C(═O)—NRdd2Rdd3,


(8) —ORdd4,


(9) —NRdd5—C(═O)—Rdd6,


(10) —NRdd7—C(═O)—NRdd8Rdd9,


(11) —NRdd10—S(═O)2—Rdd11,


(12) —NRdd12—S(═O)2—NRdd13Rdd14,


(13) —NRdd15Rdd16,

    • Rdd1, Rdd2, Rdd3, Rdd4, Rdd5, Rdd6, Rdd7, Rdd8, Rdd9, Rdd10, Rdd11, Rdd12, Rdd13, Rdd14, Rdd15, and Rdd16 are each independently hydrogen atom or C1-8 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group B;


      Re is hydrogen atom or C1-6 alkyl group;


      Rf is hydrogen atom or C1-6 alkyl group;


      each Rj is the same or different C1-12 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A;


      Q is selected from the following (1) to (9):


(1) phenyl group,


(2) C3-7 cycloalkyl group,


(3) C9-10 fused carbocyclic group,


(4) cross-linked C5-12 cycloalkyl group,


(5) C3-8 alkyl group,


(6) saturated heteromonocyclic group wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered,


(7) unsaturated fused heterocyclic group wherein the unsaturated fused heterocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered,


(8) unsaturated heteromonocyclic group wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


(9) saturated fused heterocyclic group wherein the saturated fused heterocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered;


Y is selected from the following (1) to (3):


(1) single bond,


(2) —S(═O)2—,


(3) C1-3 alkylene which may optionally be substituted with 1 to 3 hydroxyl groups;


m is each independently an integer selected from 0 or 1 to 5;


nj is each independently 0, 1 or 2;


Group A consists of the following (a) to (m):


(a) alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,


(b) halogen atom,


(c) phenyl group,


(d) saturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered,


(e) unsaturated fused heterocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA wherein the unsaturated fused heterocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered,


(f) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


(g) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,


(h) —C(═O)—NRA1RA2,


(i) —C(═O)—ORA3,


(j) —C(═O)—RA4,


(k) —ORA5,


(l) —NRA6RA7,


(m) —S(═O)2—RA8;

    • RA1, RA2, RA3, and RA4 are each independently hydrogen atom or C1-6 alkyl group;
    • RA5, RA6, and RA7 are each independently:
      • hydrogen atom,
      • C1-6 alkyl group which may optionally be substituted with the same or different 1 to 6 halogen atoms,
      • C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,
      • benzyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,
      • phenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,
      • C1-6 alkylcarbonyl group,
      • C1-6 alkylsulfonyl group, or
      • C2-6 alkenyl group; and
    • RA8 is each independently C1-6 alkyl group;


      Group AA consists of the following (a) to (o):


(a) halogen atom,


(b) C1-3 alkyl group which may optionally be substituted with the same or different 1 to 6 halogen atoms,


(c) —ORAA1,


(d) —C(═O)—NRAA2RAA3,


(e) —C(═O)—ORAA4,


(f) —O—C(═O)—RAA5,


(g) —C(═O)—RAA6,


(h) ═O,


(i) C3-7 cycloalkyl group,


(j) phenyl group which may optionally be substituted with the same or different 1 to 5 C1-3 alkyl groups,


(k) —NRAA7RAA8,


(l) —NRAA9—C(═O)—RAA10,


(m) —NRAA11—C(═O)—NRAA12RAA13,


(n) —NRAA14—S(═O)2—RAA15,


(o) —NRAA16—S(═O)2—NRAA17RAA18;


RAA1, RAA2, RAA3, RAA4, RAA5, RAA6, RAA7, RAA8, RAA9, RAA10, RAA11, RAA12, RAA13, RAA14, RAA15, RAA16, RAA17, and RAA18 are each independently hydrogen atom or C1-6 alkyl group;


Group B consists of the following (a) to (k):


(a) halogen atom,


(b) C3-7 cycloalkyl group


(c) —ORB1,


(d) —C(═O)—NRB2RB3,


(e) —C(═O)—ORB4,


(f) C1-6 alkyl group,


(g) —NRB5RB6,


(h) —NRB7—C(═O)—RB8,


(i) —NRB9—C(═O)—NR10RB11,


(j) —NRB12—S(═O)2—RB13,


(k) —NRB14—S(═O)2—NRB15RB16;

    • RB1, RB2, RB3, RB4, RB5, RB6, RB7, RB8, RB9, RB10, RB11, RB12, RB13, RB14, RB15, and RB16 are each independently hydrogen atom or C1-6 alkyl group;


      Group C consists of the following (a) to (k):


(a) phenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group CC,


(b) cyano group,


(c) halogen atom,


(d) —ORCD1,


(e) —NRCD2RCD3,


(f) —C(═O)—NRCD4RCD5,




embedded image


(i) saturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group CC wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered, excluding ring P,


(j) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group CC wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered, excluding ring P,




embedded image




    • RCD1, RCD2, and RCD3 are each independently,
      • hydrogen atom,
      • C1-6 alkyl group,
      • C1-6 alkylcarbonyl group,
      • benzyl group,
      • —C(═O)—O—CH2-phenyl,
      • —C(═O)—N(CH3)2,
      • —C(═O)—C(OH) (CH3)2,
      • —C(═O)—CH2—O—CH3, or
      • —C(═O)—CH2—CN; and

    • RCD4 and RCD5 are each independently hydrogen atom or C1-6 alkyl group;


      Group CC consists of the following (a) to (c):





(a) halogen atom,


(b) C1-3 alkyl group which may optionally be substituted with the same or different 1 to 6 halogen atoms,


(c) —ORAA1,

    • RAA1 is each independently hydrogen atom or C1-6 alkyl group;


      provided that when Ra is


(1) phenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(2) C9-10 fused carbocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A, or


(3) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


Q is selected from the following (1) to (6):


(1) phenyl group,


(2) C3-7 cycloalkyl group,


(3) C9-10 fused carbocyclic group,


(4) cross-linked C5-12 cycloalkyl group,


(5) C3-8 alkyl group,


(6) saturated heteromonocyclic group wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered;


further provided that when Rb is hydrogen atom,


Q is selected from the following (1) to (5):


(1) phenyl group,


(2) C3-7 cycloalkyl group,


(3) C9-10 fused carbocyclic group,


(4) cross-linked C5-12 cycloalkyl group,


(5) saturated heteromonocyclic group wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered;


and further provided that when




embedded image


is




embedded image


Rc is selected from the following (1) to (15):


(1) —(CH2)n3-ring P,


(2) —(CH2)n4—C(═O)—NH—S(═O)2—CH3,


(3) C1-5 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group C,


(4) C3-6 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group C,


(5) C2-12 alkenyl group.


(6) C2-12 alkynyl group,


(7) —NRcc3Rcc4,


(8) —ORcc5,


(9) —O—CH2CH2—OH,


(10) —O—CH2C(═O)NH—CH3,




embedded image


[107] A compound represented by the following formula:




embedded image


or a pharmaceutically acceptable salt thereof, wherein




embedded image


is unsaturated heteromonocyclic group selected from the following (i) to (ii):




embedded image


Ra is selected from the following (1) to (12):


(1) C1-12 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(2) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(3) C2-12 alkenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(4) C2-12 alkynyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(5) C5-11 spirocyclic cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(6) cross-linked C5-12 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(7) saturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered,


(8) phenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(9) C9-10 fused carbocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(10) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


(11) saturated fused heterocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the saturated fused heterocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered,


(12) unsaturated fused heterocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the unsaturated fused heterocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered;


Rb is selected from the following (1) to (6):


(1) C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 halogen atoms,


(2) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from the group consisting of halogen atom and C1-6 alkyl group,


(3) —CH═CH—C(═O)—ORbb1,


(4) —CH2—CH2—C(═O)—ORbb2,


(5) —CH2—O—CH2—C(═O)—ORbb3,


(6) hydrogen atom;

    • Rbb1, Rbb2, and Rbb3 are each independently hydrogen atom or C1-6 alkyl group;


      Rc is selected from the following (1) to (15):


(1) —(CH2)n3-ring P,


(2) —(CH2)n4—C(═O)—NH—S(═O)2—CH3,


(3) C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group C,


(4) C3-6 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group C,


(5) C2-12 alkenyl group,


(6) C2-12 alkynyl group,


(7) —NRcc3Rcc4,


(8) —ORcc5,


(9) —O—CH2CH2—OH,


(10) —O—CH2C(═O)NH—CH3,




embedded image


Rcc3 and Rcc4 are each independently,

    • hydrogen atom,
    • C1-6 alkyl group,
    • C1-6 alkylcarbonyl group,
    • benzyloxycarbonyl group, or
    • C1-6 alkyl group which is substituted with 1 to 3 hydroxyl groups;
    • Rcc5 is
      • hydrogen atom,
      • C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group C, or
      • benzyl group;
    • ring P is monocyclic heterocycle which is a carboxylic acid equivalent wherein the carboxylic acid equivalent may optionally be substituted;
    • n3 is an integer selected from 1 to 3; and
    • n4 is an integer selected from 1 to 3;


      each Rd is the same or different and selected from the following (1) to (13):


(1) halogen atom,


(2) C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group B,


(3) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group B,


(4) C2-6 alkenyl group,


(5) cyano group,


(6) —C(═O)—ORdd1,


(7) —C(═O) —NRdd2Rdd3,


(8) —ORdd4,


(9) —NRdd5—C(═O)—Rdd6,


(10) —NRdd7—C(═O)—NRdd8Rdd9,


(11) —NRdd10—S(═O)2—Rdd11,


(12) —NRdd12—S(═O)2—NRdd13Rdd14,


(13) —NRdd15Rdd16;

    • Rdd1, Rdd2, Rdd3, Rdd4, Rdd5, Rdd6, Rdd7, Rdd8, Rdd9, Rdd10, Rdd11, Rdd12, Rdd13, Rdd14, Rdd15, and Rdd16 are each independently hydrogen atom or C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group B;


      Re is hydrogen atom or C1-6 alkyl group;


      Q is selected from the following (1) to (9):


(1) phenyl group,


(2) C3-7 cycloalkyl group,


(3) C9-10 fused carbocyclic group,


(4) cross-linked C5-12 cycloalkyl group,


(5) C3-8 alkyl group,


(6) saturated heteromonocyclic group wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered,


(7) unsaturated fused heterocyclic group wherein the unsaturated fused heterocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered,


(8) unsaturated heteromonocyclic group wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


(9) saturated fused heterocyclic group wherein the saturated fused heterocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered;


Y is selected from the following (1) to (3):


(1) single bond,


(2) —S(═O)2—,


(3) C1-3 alkylene which may optionally be substituted with 1 to 3 hydroxyl groups;


m is each independently an integer selected from 0 or 1 to 5;


Group A consists of the following (a) to (m):


(a) C1-7 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,


(b) halogen atom,


(c) phenyl group,


(d) saturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered,


(e) unsaturated fused heterocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA wherein the unsaturated fused heterocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered,


(f) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


(g) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,


(h) —C(═O)—NRA1RA2,


(i) —C(═O)—ORA3,


(j) —C(═O)—RA4,


(k) —ORA5,


(l) —NRA6RA7,


(m) —S(═O)2—RA8;

    • RA1, RA2, RA3, and RA4 are each independently hydrogen atom or C1-6 alkyl group;
    • RA5, RA6, and RA7 are each independently:
      • hydrogen atom,
      • C1-6 alkyl group which may optionally be substituted with the same or different 1 to 6 halogen atoms,
      • C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,
      • benzyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,
      • phenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,
      • C1-6 alkylcarbonyl group,
      • C1-6 alkylsulfonyl group, or
      • C2-6 alkenyl group; and
    • RA8 is each independently C1-6 alkyl group;


      Group AA consists of the following (a) to (o):


(a) halogen atom,


(b) C1-3 alkyl group which may optionally be substituted with the same or different 1 to 6 halogen atoms,


(c) —ORAA1,


(d) —C(═O)—NRAA2RAA3,


(e) —C(═O)—ORAA4,


(f) —O—C(═O)—RAA5,


(g) —C(═O)—RAA6,


(h) ═O,


(i) C3-7 cycloalkyl group,


(j) phenyl group which may optionally be substituted with the same or different 1 to 5 C1-3 alkyl groups,


(k) —NRAA7RAA8,


(l) —NRAA9—C(═O)—RAA10,


(m) —NRAA11—C(═O)—NRAA12RAA13,


(n) —NRAA14—S(═O)2—RAA15,


(o) —NRAA16—S(═O)2—NRAA17RAA18;


RAA1, RAA2, RAA3, RAA4, RAA5, RAA6, RAA7, RAA8, RAA9, RAA10, RAA11, RAA12, RAA13, RAA14, RAA15, RAA16, RAA17, and RAA18 are each independently hydrogen atom or C1-6 alkyl group;


Group B consists of the following (a) to (k):


(a) halogen atom,


(b) C3-7 cycloalkyl group


(c) —ORB1,


(d) —C(═O)—NRB2RB3,


(e) —C(═O)—ORB4,


(f) C1-6 alkyl group,


(g) —NRB5RB6,


(h) —NRB7—C(═O)—RB8,


(i) —NRB9—C(═O)—NRB10RB11,


(j) —NRB12—S(═O)2—RB13,


(k) —NRB14—S(═O)2—NRB15RB16;

    • RB1, RB2, RB3, RB4, RB5, RB6, RB7, RB8, RB9, RB10, RB11, RB12, RB13, RB14, RB15, and RB16 are each independently hydrogen atom or C1-6 alkyl group;


      Group C consists of the following (a) to (k):


(a) phenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group CC,


(b) cyano group,


(c) halogen atom,


(d) —ORCD1,


(e) —NRCD2RCD3,


(f) —C(═O)—NRCD4RCD5,




embedded image


(i) saturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group CC wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered, excluding ring P,


(j) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group CC wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered, excluding ring P,




embedded image




    • RCD1, RCD2, and RCD3 are each independently,
      • hydrogen atom,
      • C1-6 alkyl group,
      • C1-6 alkylcarbonyl group,
      • benzyl group,
      • —C(═O)—O—CH2-phenyl,
      • —C(═O)—N(CH3)2,
      • —C(═O)—C(OH) (CH3)2,
      • —C(═O)—CH2—O—CH3, or
      • —C(═O)—CH2—CN; and

    • RCD4 and RCD5 are each independently hydrogen atom or C1-6 alkyl group;


      Group CC consists of the following (a) to (c):





(a) halogen atom,


(b) C1-3 alkyl group which may optionally be substituted with the same or different 1 to 6 halogen atoms,


(c) ORAA1,

    • RAA1 is each independently hydrogen atom or C1-6 alkyl group;


      provided that when Ra is


(1) phenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(2) C9-10 fused carbocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A, or


(3) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


Q is selected from the following (1) to (6):


(1) phenyl group,


(2) C3-7 cycloalkyl group,


(3) C9-10 fused carbocyclic group,


(4) cross-linked C5-12 cycloalkyl group,


(5) C3-8 alkyl group,


(6) saturated heteromonocyclic group wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered;


and further provided that when Rb is hydrogen atom,


Q is selected from the following (1) to (5):


(1) phenyl group,


(2) C3-7 cycloalkyl group,


(3) C9-10 fused carbocyclic group,


(4) cross-linked C5-12 cycloalkyl group,


(5) saturated heteromonocyclic group wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered.


[108] A compound represented by the following formula:




embedded image


or a pharmaceutically acceptable salt thereof, wherein




embedded image


is unsaturated heteromonocyclic group selected from the following (i) to (ii):




embedded image


each Rau is the same or different and selected from the following (1) or (2):


(1) C7-12 alkyl group,


(2) C1-12 alkyl group which is substituted with the same or different 1 to 5 substituents selected from Group AU;


Rb is selected from the following (1) to (6):


(1) C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 halogen atoms,


(2) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from the group consisting of halogen atom and C1-6 alkyl group,


(3) —CH═CH—C(═O)—ORbb1,


(4) —CH2—CH2—C(═O)—ORbb2,


(5) —CH2—O—CH2—C(═O)—ORbb3,


(6) hydrogen atom;

    • Rbb1, Rbb2, and Rbb3 are each independently hydrogen atom or C1-6 alkyl group;


      Rc is selected from the following (1) or (2):


(1) —(CH2)n1—C(═O)—ORcc1,


(2) —O—(CH2)n2—C(═O)—ORcc2,


Rcc1 and Rcc2 are each independently hydrogen atom or C1-6 alkyl group;

    • n1 is an integer selected from 0 or 1 to 3; and
    • n2 is an integer selected from 0 or 1 to 3;


      each Rd is the same or different and selected from the following (1) to (13):


(1) halogen atom,


(2) C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group B,


(3) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group B,


(4) C2-6 alkenyl group,


(5) cyano group,


(6) —C(═O)—ORdd1,


(7) —C(═O)—Ndd2Rdd3,


(8) —ORdd4,


(9) —NRdd5—C(═O)—Rdd6,


(10) —NRdd7—C(═O)—NRdd8Rdd9,


(11) —NRdd10—S(═O)2—Rdd11,


(12) —NRdd12—S(═O)2—NRdd13Rdd14,


(13) —NRdd15Rdd16;

    • Rdd1, Rdd2, Rdd3, Rdd4, Rdd5, Rdd6, Rdd7, Rdd8, Rdd9, Rdd10, Rdd11, Rdd12, Rdd13, Rdd14, Rdd15, and Rdd16 are each independently hydrogen atom or C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group B;


      Re is hydrogen atom or C1-6 alkyl group;


      Q is selected from the following (1) to (9):


(1) phenyl group,


(2) C3-7 cycloalkyl group,


(3) C9-10 fused carbocyclic group,


(4) cross-linked C5-12 cycloalkyl group,


(5) C3-8 alkyl group,


(6) saturated heteromonocyclic group wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered,


(7) unsaturated fused heterocyclic group wherein the unsaturated fused heterocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered,


(8) unsaturated heteromonocyclic group wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


(9) saturated fused heterocyclic group wherein the saturated fused heterocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered;


cyclic moiety UU is selected from the following (1) or (2):


(1) C3-7 cycloalkyl group,


(2) phenyl group;


Y is selected from the following (1) to (3):


(1) single bond,


(2) —S(═O)2—,


(3) alkylene which may optionally be substituted with 1 to 3 hydroxyl groups;


m is each independently an integer selected from 0 or 1 to 5;


nu is an integer selected from 0 or 1 to 3;


Group B consists of the following (a) to (k):


(a) halogen atom,


(b) C3-7 cycloalkyl group


(c) —ORB1,


(d) —C(═O)—NRB2RB3,


(e) —C(═O)—ORB4,


(f) C1-6 alkyl group,


(g) —NRB5RB6,


(h) —NRB7—C(═O)—RB8,


(i) —NRB9—C(═O)—NRB10RB11,


(j) —NRB12—S(═O)2—RB13,


(k) —NRB14—S(═O)2—NRB15RB16;

    • RB1, RB2, RB3, RB4, RB5, RB6, RB7, RB8, RB9, RB10, RB11, RB12, RB13, RB14, RB15, and RB16 are each independently, hydrogen atom or C1-6 alkyl group;


      Group AU consists of the following (a) to (j)


(a) —ORAU1,


(b) —C(═O)—ORAU2,


(c) —C(═O)—NRAU3RAU4,


(d) phenyl group,


(e) C3-7 cycloalkyl group,


(f) —NRAU5RAU6,


(g) —NRAU7—C(═O)—RAU8,


(h) —NRAU9—C(═O)—NRAU10RAU12,


(i) —NRAU13—S(═O)2—RAU14,


(j) —NRAU15—S(═O)2—NRAU16RAU17,

    • RAU1, RAU2, RAU3, RAU4, RAU5, RAU6, RAU7, RAU8, RAU9, RAU10, RAU11, RAU12, RAU13, RAU14, RAU15, RAU16 and RAU17 are each independently hydrogen atom or C1-6 alkyl group;


      provided that when cyclic moiety UU is phenyl group,


      Q is selected from the following (1) to (6):


(1) phenyl group,


(2) C3-7 cycloalkyl group,


(3) C9-10 fused carbocyclic group,


(4) cross-linked C5-12 cycloalkyl group,


(5) C3-8 alkyl group,


(6) saturated heteromonocyclic group wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered;


and further provided that when Rb is hydrogen atom,


Q is selected from the following (1) to (5):


(1) phenyl group,


(2) C3-7 cycloalkyl group,


(3) C9-10 fused carbocyclic group,


(4) cross-linked C5-12 cycloalkyl group,


(5) saturated heteromonocyclic group wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered.


[109] A compound represented by the following formula:




embedded image


or a pharmaceutically acceptable salt thereof, wherein




embedded image


is unsaturated heteromonocyclic group selected from the following (i) to (ii):




embedded image


Ra is selected from the following (1) to (12):


(1) C1-12 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(2) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(3) C2-12 alkenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(4) C2-12 alkynyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(5) C5-11 spirocyclic cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(6) cross-linked C5-12 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(7) saturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered,


(8) phenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(9) C9-10 fused carbocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(10) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


(11) saturated fused heterocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the saturated fused heterocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered,


(12) unsaturated fused heterocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the unsaturated fused heterocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered;


Rc is selected from the following (1) or (2):


(1) —(CH2)n1—C(═O)—ORcc1,


(2) —O—(CH2)n2—C(═O)—ORcc2,


Rcc1 and Rcc2 are each independently hydrogen atom or C1-6 alkyl group;

    • n1 is an integer selected from 0 or 1 to 3; and
    • n2 is an integer selected from 0 or 1 to 3;


      each Rd is the same or different and selected from the following (1) to (13):


(1) halogen atom,


(2) C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group B,


(3) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group B,


(4) C2-6 alkenyl group,


(5) cyano group,


(6) —C(═O)—ORdd1,


(7) —C(═O)—NRdd2Rdd3,


(8) —ORdd4,


(9) —NRdd5—C(═O)—Rdd6,


(10) —NRdd7—C(═O)—NRdd8Rdd9,


(11) —NRdd10—S(═O)2—Rdd11,


(12) —NRdd12—S(═O)2—NRdd13Rdd14,


(13) —NRdd15Rdd16;

    • Rdd1, Rdd2, Rdd3, Rdd4, Rdd5, Rdd6, Rdd7, Rdd8, Rdd9, Rdd10, Rdd11, Rdd12, Rdd13, Rdd14, Rdd15, and Rdd16 are each independently hydrogen atom or C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group B;


      Re is hydrogen atom or C1-6 alkyl group;


      Q is selected from the following (1) to (9):


(1) phenyl group,


(2) C3-7 cycloalkyl group,


(3) C9-10 fused carbocyclic group,


(4) cross-linked C5-12 cycloalkyl group,


(5) C3-8 alkyl group,


(6) saturated heteromonocyclic group wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered,


(7) unsaturated fused heterocyclic group wherein the unsaturated fused heterocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered,


(8) unsaturated heteromonocyclic group wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


(9) saturated fused heterocyclic group wherein the saturated fused heterocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered;


Y is selected from the following (1) to (3):


(1) single bond,


(2) —S(═O)2—,


(3) C1-3 alkylene which may optionally be substituted with 1 to 3 hydroxyl groups;


m is each independently an integer selected from 0 or 1 to 5;


Group A consists of the following (a) to (m):


(a) C1-7 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,


(b) halogen atom,


(c) phenyl group,


(d) saturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered,


(e) unsaturated fused heterocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA wherein the unsaturated fused heterocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered,


(f) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


(g) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,


(h) —C(═O)—NRA1RA2,


(i) —C(═O)—ORA3,


(j) —C(═O)—RA4,


(k) —ORA5,


(l) —NRA6RA7,


(m) —S(═O)2—RA8;

    • RA1, RA2, RA3, and RA4 are each independently hydrogen atom or C1-6 alkyl group;
    • RA5, RA6, and RA7 are each independently:
      • hydrogen atom,
      • C1-6 alkyl group which may optionally be substituted with the same or different 1 to 6 halogen atoms,
      • C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,
      • benzyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,
      • phenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,
      • C1-6 alkylcarbonyl group,
      • C1-6 alkylsulfonyl group, or
      • C2-6 alkenyl group; and
    • RA8 is each independently C1-6 alkyl group;


      Group AA consists of the following (a) to (o):


(a) halogen atom,


(b) C1-3 alkyl group which may optionally be substituted with the same or different 1 to 6 halogen atoms,


(c) —ORAA1,


(d) —C(═O)—NRAA2RAA3,


(e) —C(═O)—ORAA4,


(f) —O—C(═O)—RAA5,


(g) —C(═O)—RAA6,


(h) ═O,


(i) C3-7 cycloalkyl group,


(j) phenyl group which may optionally be substituted with the same or different 1 to 5 C1-3 alkyl groups,


(k) —NRAA7RAA8,


(l) —NRAA9—C(═O)—RAA10,


(m) —NRAA11—C(═O)—NRAA12RAA13,


(n) —NRAA14—S(═O)2—RAA15,


(o) —NRAA16—S(═O)2—NRAA17RAA18;


RAA1, RAA2, RAA3, RAA4, RAA5, RAA6, RAA7, RAA8, RAA9, RAA10, RAA11, RAA12, RAA13, RAA14, RAA15, RAA16, RAA17, and RAA18 are each independently hydrogen atom or C1-6 alkyl group;


Group B consists of the following (a) to (k):


(a) halogen atom,


(c) —ORB1,


(d) —C(═O)—NRB2RB3,


(e) —C(═O)—ORB4,


(f) C1-6 alkyl group,


(g) —NRB5RB6,


(h) —NRB7—C(═O)—RB8,


(i) —NRB9—C(═O)—NRB10RB11,


(j) —NRB12—S(═O)2—RB13,


(k) —NRB14—S(═O)2—NRB15RB16;


RB1, RB2, RB3, RB4, RB5, RB6, RB7, RB8, RB9, RB10, RB11, RB12, RB13, RB14, RB15, and RB16 are each independently, hydrogen atom or C1-6 alkyl group;


provided that when Ra is


(1) phenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(2) C9-10 fused carbocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A, or


(3) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


Q is selected from the following (1) to (6):


(1) phenyl group,


(2) C3-7 cycloalkyl group,


(3) C9-10 fused carbocyclic group,


(4) cross-linked C5-12 cycloalkyl group,


(5) C3-8 alkyl group,


(6) saturated heteromonocyclic group wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered.


[110] A compound represented by the following formula:




embedded image


or a pharmaceutically acceptable salt thereof, wherein




embedded image


is unsaturated heteromonocyclic group selected from the following (i) to




embedded image


Ra is selected from the following (1) to (12):


(1) C1-12 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(2) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(3) C2-12 alkenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(4) C2-12 alkynyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(5) C5-11 spirocyclic cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(6) cross-linked C5-12 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(7) saturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered,


(8) phenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(9) C9-10 fused carbocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(10) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


(11) saturated fused heterocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the saturated fused heterocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered,


(12) unsaturated fused heterocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the unsaturated fused heterocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered;


Rb is selected from the following (1) to (6):


(1) C2-6 alkyl group which may optionally be substituted with the same or different 1 to 5 halogen atoms,


(2) C3-7 cycloalkyl group which may optionally substituted with the same or different 1 to 5 substituents selected from the group consisting of halogen atom and C1-6 alkyl group,


(3) —CH═CH—C(═O)—ORbb1,


(4) —CH2—CH2—C(═O)—ORbb2,


(5) —CH2—O—CH2—C(═O)—ORbb3,


(6) hydrogen atom;

    • Rbb1, Rbb2 and Rbb3 are each independently hydrogen atom or C1-6 alkyl group;


      Rb is selected from the following (1) or (2):


(1) —(CH2)n1—C(═O)_ORcc1,


(2) —O—(CH2)n2—C(═O)—ORcc2,


Rcc2 and Rcc2 are each independently hydrogen atom or C1-6 alkyl group;

    • n1 is an integer selected from 0 or 1 to 3; and
    • n2 is an integer selected from 0 or 1 to 3;


      each Rd is the same or different and selected from the following (1) to (13):


(1) halogen atom,


(2) C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group B,


(3) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group B,


(4) C2-6 alkenyl group,


(5) cyano group,


(6) —C(═O)—ORdd1,


(7) —C(═O)—NRdd2Rdd3,


(8) —ORdd4,


(9) —NRdd5—C(═O)—Rdd6,


(10) —NRdd7—C(═O)—NRdd8Rdd9,


(11) —NRdd10—S(═O)2—Rdd11,


(12) —NRdd12—S(═O)2—NRdd13Rdd14,


(13) —NRdd15Rdd16;

    • Rdd1, Rdd2, Rdd3, Rdd4, Rdd5, Rdd6, Rdd7, Rdd8, Rdd9, Rdd10, Rdd11, Rdd12, Rdd13, Rdd14, Rdd15, and Rdd16 are each independently hydrogen atom or C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group B;


      Re is hydrogen atom or C1-6 alkyl group;


      Q is selected from the following (1) to (9):


(1) phenyl group,


(2) C3-7 cycloalkyl group,


(3) C9-10 fused carbocyclic group,


(4) cross-linked C5-12 cycloalkyl group,


(5) C3-8 alkyl group,


(6) saturated heteromonocyclic group wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered,


(7) unsaturated fused heterocyclic group wherein the unsaturated fused heterocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered,


(8) unsaturated heteromonocyclic group wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


(9) saturated fused heterocyclic group wherein the saturated fused heterocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered;


m is each independently an integer selected from 0 or 1 to 5;


Group A consists of the following (a) to (m):


(a) C1-7 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,


(b) halogen atom,


(c) phenyl group,


(d) saturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered,


(e) unsaturated fused heterocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA wherein the unsaturated fused heterocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered,


(f) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


(g) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,


(h) —C(═O)—NRA1RA2,


(i) —C(═O)—ORA3,


(j) —C(═O)—RA4,


(k) —ORA5,


(l) —NRA6RA7,


(m) —S(═O)2—,

    • RA1, RA2, RA3 and RA4 are each independently hydrogen atom or C1-6 alkyl group;
    • RA5, RA6, and RA7 are each independently:
      • hydrogen atom,
      • C1-6 alkyl group which may optionally be substituted with the same or different 1 to 6 halogen atoms,
      • C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,
      • benzyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,
      • phenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,
      • C1-6 alkylcarbonyl group.
      • C1-6 alkylsulfonyl group, or
      • C2-6 alkenyl group; and
    • RA8 is each independently C1-6 alkyl group;


      Group AA consists of the following (a) to (o):


(a) halogen atom,


(b) C1-3 alkyl group which may optionally be substituted with the same or different 1 to 6 halogen atoms,


(c) —ORAA1,


(d) —C(═O)—NRAA2RAA3,


(e) —C(═O)—ORAA4,


(f) —O—C(═O)—RAA5,


(g) —C(═O)—RAA6,


(h) ═O,


(i) C3-7 cycloalkyl group,


(j) phenyl group which may optionally be substituted with the same or different 1 to 5 C1-3 alkyl groups,


(k) —NRAA7RAA8,


(l) —NRAA9—C(═O)—RAA10,


(m) —NRAA11—C(═O)—NRAA12RAA13,


(n) —NRAA14—S(═O)2—RAA15,


(o) —NRAA16—S(═O)2—NRAA17RAA18;


RAA1, RAA2, RAA3, RAA4, RAA5, RAA6, RAA7, RAA8, RAA9, RAA10, RAA11, RAA12, RAA13, RAA14, RAA15, RAA16, RAA17, and RAA18 are each independently hydrogen atom or C1-6 alkyl group;


Group B consists of the following (a) to (k):


(c) —ORB1,


(d) —C(═O)—NRB2RB3,


(e) —C(═O)—ORB4,


(f) C1-6 alkyl group,


(g) —NRB5RB6,


(h) —NRB7—C(═O)—RB8,


(i) —NRB9—C(═O)—NRB10RB11,


(j) —NRB12—S(═O)2—RB13,


(k) —NRB14—S(═O)2—NRB15RB16;


RB1, RB2, RB3, RB4, RB5, RB6, RB7, RB8, RB9, RB10, RB11, RB12, RB13, RB14, RB15, and RB16 are each independently, hydrogen atom or C1-6 alkyl group;


provided that when Ra is


(1) phenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(2) C9-10 fused carbocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A, or


(3) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


Q is selected from the following (1) to (6):


(1) phenyl group,


(2) C3-7 cycloalkyl group,


(3) C9-10 fused carbocyclic group,


(4) cross-linked C5-12 cycloalkyl group,


(5) C3-8 alkyl group,


(6) saturated heteromonocyclic group wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered;


and further provided that when Rb is hydrogen atom,


Q is selected from the following (1) to (5):


(1) phenyl group,


(2) C3-7 cycloalkyl group,


(3) C9-10 fused carbocyclic group,


(4) cross-linked C5-12 cycloalkyl group,


(5) saturated heteromonocyclic group wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered.


[111] A compound represented by the following formula:




embedded image


or a pharmaceutically acceptable salt thereof, wherein




embedded image


is unsaturated heteromonocyclic group selected from the following (i) to (ii):




embedded image


Ra is selected from the following (1) to (12):


(1) C1-12 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(2) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(3) C2-12 alkenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(4) C2-12 alkynyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(5) C5-11 spirocyclic cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(6) cross-linked C3-12 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(7) saturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered,


(8) phenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(9) C9-10 fused carbocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(10) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


(11) saturated fused heterocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the saturated fused heterocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered,


(12) unsaturated fused heterocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the unsaturated fused heterocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered;


Rb is selected from the following (1) to (6):


(1) C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 halogen atoms,


(2) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from the group consisting of halogen atom and C1-6 alkyl group,


(3) —CH═CH—C(═O)—ORbb1,


(4) —CH2—CH2—C(═O)—ORbb2,


(5) —CH2—O—CH2—C(═O)—ORbb3,


(6) hydrogen atom;

    • Rbb1, Rbb2 and Rbb3 are each independently hydrogen atom or C1-6 alkyl group;


      Rc is selected from the following (1) or (2):


(1) —(CH2)n1—C(═O)—ORcc1,


(2) —O—(CH2)n2—C(═O)—ORcc2,


Rcc1 and Rcc2 are each independently hydrogen atom or C1-6 alkyl group;

    • n1 is an integer selected from 0 or 1 to 3; and
    • n2 is an integer selected from 0 or 1 to 3;


      each Rd is the same or different and selected from the following (1) to (13):


(1) halogen atom,


(2) C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group B,


(3) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group B,


(4) C2-6 alkenyl group,


(5) cyano group,


(6) —C(═O)—ORdd1,


(7) —C(═O)—NRdd2Rdd3,


(8) —ORdd4,


(9) —NRdd5—C(═O)—Rdd6,


(10) —NRdd7—C(═O)—NRdd8Rdd9,


(11) —NRdd10—S(═O)2—Rdd11,


(12) —NRdd12—S(═O)2—NRdd13Rdd14,


(13) —NRdd15Rdd16;

    • Rdd1, Rdd2, Rdd3, Rdd4, Rdd5, Rdd6, Rdd7, Rdd8, Rdd9, Rdd10, Rdd11, Rdd12, Rdd13, Rdd14, Rdd15, and Rdd16 are each independently hydrogen atom or C2-6 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group B;


      Re is hydrogen atom or C1-6 alkyl group;


      Q is selected from the following (1) to (7):


(1) C3-7 cycloalkyl group,


(2) C9-10 fused carbocyclic group selected from the group consisting of indanyl group and 1,2,3,4-tetrahydronaphthyl group,


(3) cross-linked C5-12 cycloalkyl group,


(4) saturated heteromonocyclic group wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered,


(5) unsaturated fused heterocyclic group wherein the unsaturated fused heterocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered,


(6) unsaturated heteromonocyclic group wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


(7) saturated fused heterocyclic group wherein the saturated fused heterocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered;


Y is selected from the following (1) to (3):


(1) single bond,


(2) —S(═O)2—,


(3) C1-3 alkylene which may optionally be substituted with 1 to 3 hydroxyl groups;


m is each independently an integer selected from 0 or 1 to 5;


Group A consists of the following (a) to (m):


(a) alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,


(b) halogen atom,


(c) phenyl group,


(d) saturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered,


(e) unsaturated fused heterocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA wherein the unsaturated fused heterocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered,


(f) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


(g) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,


(h) —C(═O)—NRA1RA2,


(i) —C(═O)—ORA3,


(j) —C(═O)—RA4,


(k) —ORA5,


(l) —NRA6RA7,


(m) —S(═O)2—,

    • RA1, RA2, RA3 and RA4 are each independently hydrogen atom or C1-6 alkyl group;
    • RA5, RA6, and RA7 are each independently:
      • hydrogen atom,
      • C1-6 alkyl group which may optionally be substituted with the same or different 1 to 6 halogen atoms,
      • C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,
      • benzyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,
      • phenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AA,
      • C1-6 alkylcarbonyl group,
      • C1-6 alkylsulfonyl group, or
      • C2-6 alkenyl group; and
    • RA8 is each independently C1-6 alkyl group;


      Group AA consists of the following (a) to (o):


(a) halogen atom,


(b) C1-3 alkyl group which may optionally be substituted with the same or different 1 to 6 halogen atoms,


(c) —ORAA1,


(d) —C(═O)—NRAA2RAA3,


(e) —C(═O)—ORAA4,


(f) —O—C(═O)—RAA5,


(g) —C(═O)—RAA6,


(h) ═O,


(i) C3-7 cycloalkyl group,


(j) phenyl group which may optionally be substituted with the same or different 1 to 5 C1-3 alkyl groups,


(k) —NRAA7RAA8,


(l) —NRAA9—C(═O)—RAA10,


(m) —NRAA11—C(═O)—NRAA12RAA13,


(n) —NRAA14—S(═O)2—RAA15,


(o) —NRAA16—S(═O)2—NRAA17RAA18;


RAA1, RAA2, RAA3, RAA4, RAA5, RAA6, RAA7, RAA8, RAA9, RAA10, RAA11, RAA12, RAA13, RAA14, RAA15, RAA16, RAA17, and RAA18 are each independently hydrogen atom or C1-6 alkyl group;


Group B consists of the following (a) to (k):


(a) halogen atom,


(b) C3-7 cycloalkyl group


(c) —ORB1,


(d) —C(═O)—NRB2RB3,


(e) —C(═O)—ORB4,


(f) C1-6 alkyl group,


(g) —NRB5RB6,


(h) —NRB7—C(═O)—RB8,


(i) —NRB9—C(═O)—NRB10RB11,


(j) —NRB12—S(═O)2—RB13,


(k) —NRB14—S(═O)2—NRB15RB16;


RB1, RB2, RB3, RB4, RB5, RB6, RB7, RB8, RB9, RB10, RB11, RB12, RB13, RB14, RB15, and RB16 are each independently, hydrogen atom or C1-6 alkyl group;


provided that when Ra is


(1) phenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(2) C9-10 fused carbocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A, or


(3) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


Q is selected from the following (1) to (4):


(1) C3-7 cycloalkyl group,


(2) C9-10 fused carbocyclic group selected from the group consisting of indanyl group and 1,2,3,4-tetrahydronaphthyl group,


(3) cross-linked C5-12 cycloalkyl group,


(4) saturated heteromonocyclic group wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered;


and further provided that when Rb is hydrogen atom,


Q is selected from the following (1) to (4):


(1) C3-7 cycloalkyl group,


(2) C9-10 fused carbocyclic group selected from the group consisting of indanyl group and 1,2,3,4-tetrahydronaphthyl group,


(3) cross-linked C5-12 cycloalkyl group,


(4) saturated heteromonocyclic group wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered.


[112] The compound according to any one of [101] to and [109] to [111], or a pharmaceutically acceptable salt thereof, wherein

    • Ra is selected from the following (1) to (4)


(1) C1-12 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(2) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(3) phenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(4) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered.


[113] The compound according to any one of [101] to [107] and [109] to [111], or a pharmaceutically acceptable salt thereof, wherein


Ra is selected from the following (1) to (3)


(1) C1-12 alkyl group,


(2) cyclobutyl group substituted with C1-7 alkyl group,


(3) phenyl group substituted with C1-7 alkyl group.


[114] The compound according to any one of [101] to [108] and [110] to [111], or a pharmaceutically acceptable salt thereof, wherein

    • Rb is selected from the following (1) or (2)


(1) C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 halogen atoms,


(2) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from the group consisting of halogen atom and C1-6 alkyl group.


[115] The compound according to any one of [101] to [108] and [110] to [111], or a pharmaceutically acceptable salt thereof, wherein


Rb is selected from the following (1) or (2)


(1) C1-3 alkyl group which may optionally be substituted with the same or different 1 to 5 halogen atoms,


(2) cyclopropyl group.


[116] The compound according to any one of [101] to [109] and [111], or a pharmaceutically acceptable salt thereof, wherein Re is hydrogen atom, and Y is single bond.


[117] The compound according to any one of [101] to [111], or a pharmaceutically acceptable salt thereof, wherein Q is phenyl group or C9-10 fused carbocyclic group.


[118] A pharmaceutical composition comprising the compound according to any one of [101] to [117] or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable carrier.


[119] A RORγ antagonist comprising the compound according to any one of [101] to [117] or a pharmaceutically acceptable salt thereof.


[120] A medicament for treating or preventing a disease selected from the group consisting of autoimmune disease, allergic disease, dry eye, fibrosis, and metabolic disease, comprising the compound according to any one of [101] to [117] or a pharmaceutically acceptable salt thereof.


[121] The medicament according to [120] wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, ankylosing spondylitis, uveitis, polymyalgia rheumatica, and type I diabetes.


[122] The medicament according to [120] wherein the metabolic disease is diabetes.


[123] A method of inhibiting RORγ in a mammal, comprising administering to said mammal a therapeutically effective amount of the compound according to any one of [101] to [117] or a pharmaceutically acceptable salt thereof.


[124] A method of treating or preventing a disease in a mammal selected from the group consisting of autoimmune disease, allergic disease, dry eye, fibrosis, and metabolic disease, comprising administering to said mammal a therapeutically effective amount of the compound according to any one of [101] to [117] or a pharmaceutically acceptable salt thereof.


[125] The method according to [124] wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, ankylosing spondylitis, uveitis, polymyalgia rheumatica, and type I diabetes.


[126] The method according to [124] wherein the metabolic disease is diabetes.


[127] A pharmaceutical composition for treating or preventing a disease selected from the group consisting of autoimmune disease, allergic disease, dry eye, fibrosis, and metabolic disease, which comprises:


(a) the compound according to any one of [101] to [117] or a pharmaceutically acceptable salt thereof, and


(b) at least one additional medicament for treating or preventing a disease selected from the group consisting of autoimmune disease, allergic disease, dry eye, fibrosis, and metabolic disease.


[128] A combination drug comprising:


(a) the compound according to any one of [101] to [117] or a pharmaceutically acceptable salt thereof, and


(b) at least one additional medicament for treating or preventing a disease selected from the group consisting of autoimmune disease, allergic disease, dry eye, fibrosis, and metabolic disease,


wherein the compound of (a) and the additional medicament of (b) may be administered simultaneously, separately or consecutively.


[129] Use of the compound according to any one of [101] to [117] or a pharmaceutically acceptable salt thereof in the manufacture of a RORγ antagonist.


[130] Use of the compound according to any one of [101] to [117] or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a disease selected from the group consisting of autoimmune disease, allergic disease, dry eye, fibrosis, and metabolic disease.


[131] The use according to [130] wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, psoriasis, inflammatory bowel disease such as Crohn's disease and ulcerative colitis, multiple sclerosis, systemic lupus erythematosus, ankylosing spondylitis, uveitis, polymyalgia rheumatica, and type I diabetes.


[132] The use according to [130] wherein the metabolic disease is diabetes.


[133] The compound according to any one of [101] to [117] or a pharmaceutically acceptable salt thereof for use in treating or preventing a disease selected from the group consisting of autoimmune disease, allergic disease, dry eye, fibrosis, and metabolic disease.


[134] A commercial package comprising the medicament according to [120], and instructions which explain that the medicament can be used to treat and/or prevent a disease selected from the group consisting of autoimmune disease, allergic disease, dry eye, fibrosis, and metabolic disease.


[135] A commercial package comprising the combination drug according to [128], and instructions which explain that the combination drug can be used to treat and/or prevent a disease selected from the group consisting of autoimmune disease, allergic disease, dry eye, fibrosis, and metabolic disease.


[136] A medicament for treating or preventing a disease selected from the group consisting of autoimmune disease such as rheumatoid arthritis, psoriasis, inflammatory bowel disease such as Crohn's disease and ulcerative colitis, multiple sclerosis, systemic lupus erythematosus, ankylosing spondylitis, uveitis, polymyalgia rheumatica and type I diabetes; allergic disease such as asthma; dry eye; fibrosis such as pulmonary fibrosis and primary biliary cirrhosis; and metabolic disease such as diabetes, comprising the compound according to any one of [101] to [117] or a pharmaceutically acceptable salt thereof.


[137] A pharmaceutical composition for treating or preventing a disease selected from the group consisting of autoimmune disease such as rheumatoid arthritis, psoriasis, inflammatory bowel disease such as Crohn's disease and ulcerative colitis, multiple sclerosis, systemic lupus erythematosus, ankylosing spondylitis, uveitis, polymyalgia rheumatica and type I diabetes; allergic disease such as asthma; dry eye; fibrosis such as pulmonary fibrosis and primary biliary cirrhosis; and metabolic disease such as diabetes, comprising:


(a) the compound according to any one of [101] to [117] or a pharmaceutically acceptable salt thereof, and


(b) at least one additional medicament for treating or preventing a disease selected from the group consisting of autoimmune disease such as rheumatoid arthritis, psoriasis, inflammatory bowel disease such as Crohn's disease and ulcerative colitis, multiple sclerosis, systemic lupus erythematosus, ankylosing spondylitis, uveitis, polymyalgia rheumatica and type I diabetes; allergic disease such as asthma; dry eye; fibrosis such as pulmonary fibrosis and primary biliary cirrhosis; and metabolic disease such as diabetes.


[138] A combination drug comprising:


(a) the compound according to any one of [101] to [117] or a pharmaceutically acceptable salt thereof, and


(b) at least one an additional medicament for treating or preventing a disease selected from the group consisting of autoimmune disease such as rheumatoid arthritis, psoriasis, inflammatory bowel disease such as Crohn's disease and ulcerative colitis, multiple sclerosis, systemic lupus erythematosus, ankylosing spondylitis, uveitis, polymyalgia rheumatica and type I diabetes; allergic disease such as asthma; dry eye; fibrosis such as pulmonary fibrosis and primary biliary cirrhosis; and metabolic disease such as diabetes,


wherein the compound of (a) and the additional medicament of (b) may be administered simultaneously, separately or consecutively.


[139] A compound represented by the following formulas or a salt thereof:




embedded image


wherein each symbol is as defined in [101].


[140] A compound represented by the following formulas or a salt thereof:




embedded image


wherein each symbol is as defined in [102].


[141] A compound represented by the following formulas or a salt thereof:




embedded image


wherein each symbol is as defined in [103].


[142] A compound represented by the following formulas or a salt thereof:




embedded image


wherein each symbol is as defined in [104].


[143] The compound according to any one of [139] to [142] or a salt thereof, wherein


Ra is selected from the following (1) to (3)


(1) C1-12 alkyl group,


(2) cyclobutyl group substituted with C1-7 alkyl group,


(3) phenyl group substituted with C1-7 alkyl group.


[144] The compound according to any one of [139] to [142] or a salt thereof, wherein

    • Rb is selected from the following (1) or (2)


(1) C1-3 alkyl group which may optionally be substituted with the same or different 1 to 5 halogen atoms,


(2) cyclopropyl group.


[145] The compound according to any one of [139] to [144] or a salt thereof for the manufacture of a RORγ antagonist.


[146] The compound according to any one of [139] to [144] or a salt thereof in the manufacture of a medicament for treating or preventing a disease selected from the group consisting of autoimmune disease such as rheumatoid arthritis, psoriasis, inflammatory bowel disease such as Crohn's disease and ulcerative colitis, multiple sclerosis, systemic lupus erythematosus, ankylosing spondylitis, uveitis, polymyalgia rheumatica and type I diabetes; allergic disease such as asthma; dry eye; fibrosis such as pulmonary fibrosis and primary biliary cirrhosis; and metabolic disease such as diabetes.







DESCRIPTION OF EMBODIMENTS

The followings are definitions of terms that may be used in the specification.


The phrases “may be substituted” and “may optionally be substituted” mean to be substituted with the given number of given substituent(s) at any replaceable position(s) or not to be substituted (unsubstituted). The phrase “not substituted” herein means that all replaceable positions are occupied with hydrogen atoms.


For example, the phrase “C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A” includes both cases where C1-6 alkyl group may be substituted with the same or different 1 to 5 substituents selected from Group A at any replaceable position(s) thereof and where C1-6 alkyl group is not substituted (unsubstituted).


When a bond between a substituent and a ring is shown as a line crossing a bond connecting two atoms in the ring, such substituent may bind to any atom in the ring. When a substituent is shown without indicating the atom via which the substituent bind to the rest of the compound of a given formula, the substituent may be bonded via any atom in the substituent.


For example, the following aspects are included:




embedded image


The term “halogen atom” includes for example, fluorine atom, chlorine atom, bromine atom, or iodine atom and the like.


The term “alkyl group” refers to a straight- or branched-chain saturated hydrocarbon group, and includes for example, C1-12 alkyl group, C1-8 alkyl group, C1-6 alkyl group, C1-4 alkyl group, C1-3 alkyl group, C5-12 alkyl group, C5-8 alkyl group which have 1 to 12, 1 to 8, 1 to 6, 1 to 4, 1 to 3, 5 to 12, and 5 to 8 carbon atoms, respectively. Preferred examples of alkyl group include “C1-3 alkyl group”, “C1-6 alkyl group”. Examples of “C1-3 alkyl group” include methyl group, ethyl group, propyl group, and isopropyl group. Examples of “C1-6 alkyl group” include butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group, isopentyl group, neopenty group, tert-pentyl group, 1-ethylpropyl group, hexyl group, isohexyl group, 1,1-dimethylbutyl group, 2,2-dimethylbutyl group, 3,3-dimethylbutyl group, 2-ethylbutyl group, and 1,1-dimethyl-2-methylpropyl group, besides the above-mentioned examples of C1-3 alkyl group. Examples of “C1-12 alkyl group” include heptyl, octyl, nonyl, decyl, undecyl, and dodecyl, besides the above-mentioned examples, which may be a straight- or branched-chain.


The term “C1-6 alkyl group” refers to a straight- or branched-chain saturated hydrocarbon group having 1 to 6 carbon atoms. Examples of “C1-6 alkyl group” include methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group, isopentyl group, neopenty group, tert-pentyl group, 1-ethylpropyl group, hexyl group, isohexyl group, 1,1-dimethylbutyl group, 2,2-dimethylbutyl group, 3,3-dimethylbutyl group, 2-ethylbutyl group, and 1,1-dimethyl-2-methylpropyl.


The term “C3-7 cycloalkyl group” refers to a monocyclic saturated hydrocarbon group having 3 to 7 carbon atoms. Examples of “C3-7 cycloalkyl group” include cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, and cycloheptyl group.


The term “monocyclic heteroaromatic group” refers to a monocyclic heteroaromatic group which contains the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom or sulfur atom besides carbon atom and is preferably 5- to 7-membered. The monocyclic heteroaromatic group may be attached via any available nitrogen or carbon atom in the ring. Examples of “monocyclic heteroaromatic group” include a monocyclic heteroaromatic group which contains the same or different 1 to 3 hetero atoms selected from nitrogen atom, oxygen atom or sulfur atom besides carbon atom and is 5- to 6-membered.


Examples of “monocyclic heteroaromatic group” include furyl group, thienyl group, pyrrolyl group, oxazolyl group, isoxazolyl group, thiazolyl group, isothiazolyl group, imidazolyl group, pyrazolyl group, oxadiazolyl group (1,2,5-oxadiazolyl group, 1,3,4-oxadiazolyl group, 1,2,4-oxadiazolyl group), thiadiazolyl group (1,2,5-thiadiazolyl group, 1,3,4-thiadiazolyl group, 1,2,4-thiadiazolyl group), triazolyl group (1,2,3-triazolyl group, 1,2,4-triazolyl group), tetrazolyl group, pyridyl group, pyrimidinyl group, pyridazinyl group, pyrazinyl group, and triazinyl.


Preferred examples of “monocyclic heteroaromatic group” include:




embedded image


The more preferred examples of “monocyclic heteroaromatic group” include:




embedded image


When the monocyclic heteroaromatic group is substituted, the monocyclic heteroaromatic group may be substituted at the carbon atom, and further the monocyclic heteroaromatic group may be substituted at nitrogen atom if the monocyclic heteroaromatic group has nitrogen atom(s) as a ring member. When nitrogen atom is contained in the monocyclic heteroaromatic ring as a ring member, the nitrogen atom may be quaternized with a substituent or may be oxidized to form a N-oxide derivative thereof.


The term “C1-3 alkylene” refers to a bivalent group derived from a straight- or branched-chain C1-3 alkyl, and includes for example, methylene, ethylene, trimethylene, and methylmethylene.


The term “C1-6 alkylcarbonyl group” refers to a carbonyl with a C1-6 alkyl. Examples of “C1-6 alkylcarbonyl group” include acetyl group, propionyl group, butyryl group, isobutyryl group. The term “C1-6 alkylsulfonyl group” refers to sulfonyl with C1-6 alkyl. Examples of “C1-6 alkylsulfonyl group” include methylsulfonyl group, ethylsulfonyl group, propylsulfonyl group, isopropylsulfonyl group (i.e. propane-2-sulfonyl group), n-butylsulfonyl group, isobutylsulfonyl group (i.e. 2-methylpropane-1-sulfonyl group).


The term “alkenyl group” refers to a straight- or branched-chain unsaturated hydrocarbon group having one or more double bonds. Examples of “alkenyl group” include vinyl group, 1-propenyl group, isopropenyl group, allyl group, methylpropenyl group (such as 1-methyl-1-propenyl group and 2-methyl-1-propenyl group), 1-butenyl group, 2-butenyl group, 3-butenyl group, methylbutenyl group (such as 1-methyl-1-butenyl group, 2-methyl-1-butenyl group, and 3-methyl-1-butenyl group), pentenyl group, methylpentenyl group, hexenyl group.


The term “C2-12 alkenyl group” refers to alkenyl group having 2 to 12 carbon atoms, and the term “C2-6 alkenyl group” refers to alkenyl group having 2 to 6 carbon atoms.


The term “C2-12 alkynyl group” refers to a straight- or branched-chain unsaturated hydrocarbon group having 2 to 12 carbon atoms and one or more triple bonds. Examples of “C2-12 alkynyl group” include ethynyl group, propynyl group (1-propynyl group, 2-propynyl group), butynyl group, pentynyl group, and hexynyl group. Preferred examples of “C2-12 alkynyl group” include ethynyl group, and 1-propynyl group.


The term “C5-11 spirocyclic cycloalkyl group” refers to spirocyclic cycloalkyl group having 5 to 11 carbon atoms. Examples of “C5-11 spirocyclic cycloalkyl group” include:




embedded image


The term “cross-linked C5-12 cycloalkyl group” refers to cross-linked cycloalkyl group having 5 to 12 carbon atoms. Examples of “cross-linked C5-12 cycloalkyl group” include:




embedded image


Examples of “C9-10 fused carbocyclic group” include:




embedded image


Examples of “C9-10 fused carbocyclic group selected from the group consisting of indanyl group and 1,2,3,4-tetrahydronaphthyl group” include:




embedded image


The term “heteromonocyclic group” is “saturated heteromonocyclic group” or “unsaturated heteromonocyclic group”.


The term “saturated heteromonocyclic group” refers to monocyclic saturated heterocyclic group which contains the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom or sulfur atom besides carbon atom and is 4- to 6-membered.


Examples of “saturated heteromonocyclic group” include oxiranyl group, thiolanyl group, aziridinyl group, azetidinyl group, oxetanyl group, pyrrolidinyl group, pyrrolidino group (1-pyrrolidinyl group), tetrahydrofuranyl group, tetrahydrothienyl group, oxazolinyl group, oxazolidinyl group, isoxazolinyl group, isoxazolidinyl group, thiazolinyl group, thiazolidinyl group, isothiazolinyl group, isothiazolidinyl group, imidazolinyl group, imidazolidinyl group, pyrazolinyl group, pyrazolidinyl group, piperidinyl group, piperidino group (1-piperidinyl group), morpholinyl group, morpholino group (4-morpholinyl group), thiomorpholinyl group, thio morpholino group 4-thiomorpholinyl group)piperazinyl group, piperazino group (1-piperazinyl group), hexahydro-1,3-oxazinyl group, homomorpholine, and homopiperazine.


The term “unsaturated heteromonocyclic group” refers to monocyclic group which has an unsaturated bond, contains the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom or sulfur atom besides carbon atom, and is 5- to 6-membered.


Examples of “unsaturated heteromonocyclic group” include furyl group, thienyl group, pyrrolyl group, oxazolyl group, isoxazolyl group, thiazolyl group, isothiazolyl group, imidazolyl group, pyrazolyl group, oxadiazolyl group (1,2,5-oxadiazolyl group, 1,3,4-oxadiazolyl group, 1,2,4-oxadiazolyl group), thiadiazolyl group (1,2,5-thiadiazolyl group, 1,3,4-thiadiazolyl group, 1,2,4-thiadiazolyl group), triazolyl group (1,2,3-triazolyl group, 1,2,4-triazolyl group), tetrazolyl group, pyridyl group, pyrimidinyl group, pyridazinyl group, pyrazinyl group, and triazinyl group.


Preferred examples of “unsaturated heteromonocyclic group” include thienyl group, oxazolyl group, thiazolyl group, imidazolyl group, pyrazolyl group, oxadiazolyl group (1,3,4-oxadiazolyl group, 1,2,4-oxadiazolyl group), triazolyl group (1,2,4-triazolyl group), tetrazolyl group, pyridyl group, and pyrimidinyl group.


The term “unsaturated fused heterocyclic group” refers to unsaturated fused heterocyclic group which has an unsaturated bond, contains the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom or sulfur atom besides carbon atom, and is 8- to 10-membered.


Examples of “unsaturated fused heterocyclic group” include quinolyl group, benzofuranyl group, benzothienyl group, indolyl group, imidazole[1,2-a]pyridyl group, and [1,2,4]triazolo[4,3-a]pyridinyl group.


The term “saturated fused heterocyclic group” refers to saturated fused heterocyclic group which contains the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom or sulfur atom besides carbon atom, and is 8- to 10-membered.


Examples of “saturated fused heterocyclic group” include octahydroindolyl group.


The term “ring P” is “monocyclic heterocycle which is a carboxylic acid equivalent wherein the carboxylic acid equivalent may optionally be substituted”. The “ring P” includes the following:




embedded image


Examples of a compound wherein “cyclic moiety W is selected from the following (1) to (3):


(1) pyrrolidinyl,


(2) piperidinyl,


(3) C3-7 cycloalkyl”


include the following:




embedded image


wherein nw is an integer selected from 0 or 1 to 4.


The term “autoimmune disease” is a collective term for diseases which relate to conditions wherein own immune system excessively reacts to own healthy cells or tissues and attacks them, and includes for example, rheumatoid arthritis, psoriasis, inflammatory bowel disease such as Crohn's disease and ulcerative colitis, multiple sclerosis, systemic lupus erythematosus, Behcet's disease, sarcoidosis, Harada disease, ankylosing spondylitis, uveitis, polymyalgia rheumatica, type I diabetes.


The “allergic disease” refers to a disease due to an excessive immune response to a particular antigen, and includes for example, atopic dermatitis, allergic rhinitis such as pollinosis, allergic conjunctivitis, allergic gastroenteritis, bronchial asthma, childhood asthma, food allergy, drug allergy, hives and the like.


The term “metabolic disease” refers to a disease caused by abnormal metabolic turnover or a disease relating to metabolic abnormality, and includes for example, diabetes such as type I diabetes and type II diabetes.


The “RORγ antagonist” refers to a compound which can inhibit a function of retinoid-related orphan receptor y (RORγ) to make the activity thereof disappear or reduced.


Examples of each substituent in the compound represented by formula [I] are explained as follows.


In one aspect,




embedded image


is




embedded image


A compound represented by Formula [I] wherein




embedded image


is




embedded image


is a compound represented by the following formula:




embedded image


A compound represented by Formula [I] wherein




embedded image


is




embedded image


is a compound represented by the following formula:




embedded image


In one aspect,




embedded image


is monocyclic heteroaromatic group wherein the monocyclic heteroaromatic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and, for example is 5- to 7-membered.


Examples of




embedded image


include furyl group, thienyl group, pyrrolyl group, oxazolyl group, isoxazolyl group, thiazolyl group, isothiazolyl group, imidazolyl group, pyrazolyl group, oxadiazolyl group oxadiazolyl group, 1,3,4-oxadiazolyl group, 1,2,4-oxadiazolyl group), thiadiazolyl group (1,2,5-thiadiazolyl group, 1,3,4-thiadiazolyl group, 1,2,4-thiadiazolyl group), triazolyl group (1,2,3-triazolyl group, 1,2,4-triazolyl group), tetrazolyl group, pyridyl group, pyrimidinyl group, pyridazinyl group, and pyrazinyl group, and triazinyl, and preferred examples include:




embedded image


The more preferred examples of




embedded image


include:




embedded image


and the further preferred examples include:




embedded image


In one aspect, each Ra1 is the same or different and selected from:


(1) C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(2) halogen atom, or


(3) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A.


Examples of Ra1 which is C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A include C1-6 alkyl group (such as methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group, isopentyl group, neopenty group, tert-pentyl group, 1-ethylpropyl group, hexyl group, isohexyl group, 1,1-dimethylbutyl group, 2,2-dimethylbutyl group, 3,3-dimethylbutyl group, 2-ethylbutyl group, and 1,1-dimethyl-2-methylpropyl group), which may optionally be substituted with the same or different 1 to 5 substituents selected from the group consisting of halogen atom such as fluorine atom and C3-7 cycloalkyl group wherein said C3-7 cycloalkyl group may optionally be substituted with the same or different 1 to 5 substituents selected from the group consisting of C1-6 alkyl group such as CH3— and halogen atom.


Preferred examples of Ra1 include CH3—, (CH3)2CHCH2—, (CH3)3C—, (CH3)2CH(CH2)2—, (CH3)3CCH2—, (CH3)3C(CH2)2—, CF3—, CF3(CH2)2—, (CH3)2CHCF2—, CF3C(CH3)2—, (CH3)2CHCH2CF2—, (CH3)3CCF2—, (CH3)3CCH2CF2—,




embedded image


Examples of Ra1 which is halogen atom include fluorine atom, chlorine atom, bromine atom, and iodine atom, and the preferred examples include chlorine atom.


Examples of Ra1 which is C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A include cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, and cycloheptyl group, each of which may optionally be substituted with the same or different 1 substituents selected from the group consisting of C1-6 alkyl group such as (CH3)3CCH2—, (CH3)2CHCH2—, and CH3— and halogen atom such as fluorine atom;


Preferred examples of said Ra1 include




embedded image


In one aspect, Rb is:


(1) C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 halogen atoms, or


(2) C3-7 cycloalkyl group.


Examples of Rb which is C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 halogen atoms include C1-3 alkyl group which may optionally be substituted with the same or different 1 to 3 halogen atoms such as fluorine. Preferred examples of Rb include CF3—, CHF2—, and CH3CF2—.


Examples of Rb which is C3-7 cycloalkyl group include cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, and cycloheptyl group, and preferred examples include cyclopropyl group.


In one aspect, Rc is


(1) hydrogen atom, or


(2) C1-6 alkyl group.


In one preferred aspect, Rc is hydrogen atom.


Preferred examples of Rc which is C1-6 alkyl group include CH3—, CH3CH2—, and (CH3)3CCH2—.


In one aspect, each Rd is the same or different and selected from


(1) halogen atom, or


(2) C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 halogen atoms.


Preferred examples of Rd which is halogen atom include fluorine atom and chlorine atom.


Examples of Rd which is C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 halogen atoms include CH3— and CH3CH2—, and preferred examples include CH3—.


In one aspect, Re is hydrogen atom.


In one aspect, na is an integer selected from 0 or 1 to 3.


Preferred examples of na include 1 and 2.


In one aspect, nc is an integer selected from 0 or 1 to 3.


Preferred examples of nc include 1, 2, and 3.


In one aspect, nd is an integer selected from 0 or 1 to 3.


Preferred examples of nd include 1.


In one aspect, m is an integer selected from 0 or 1 to 5.


Preferred examples of m include 2 and 3.


In one aspect, Group A is


(a) C1-6 alkyl group,


(b) halogen atom,


(c) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from the group consisting of C1-6 alkyl group and halogen atom.


In Group A, preferred examples of C1-6 alkyl group include methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group, isopentyl group, neopenty group, tert-pentyl group, 1-ethylpropyl group, hexyl group, isohexyl group, 1,1-dimethylbutyl group, 2,2-dimethylbutyl group, 3,3-dimethylbutyl group, 2-ethylbutyl group, and 1,1-dimethyl-2-methylpropyl group; and the more preferred examples include (CH3)3CCH2—, (CH3)2CHCH2—, and CH3—.


In Group A, examples of halogen atom include fluorine atom, chlorine atom, bromine atom, and iodine atom, and preferred examples include fluorine atom.


In Group A, examples of C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from the group consisting of C1-6 alkyl group and halogen atom include cyclopropyl group, cyclobutyl group, cyclopentyl group, and cyclohexyl group, each of which may optionally be substituted with the same or different 1 to 5 C1-6 alkyl groups such as CH3—; and specific examples include




embedded image


The preferred aspects of a compound represented by Formula [I] include compounds of the following formulas.


Each symbol in each formula is as defined in [01].




embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


Other preferred aspects of a compound represented by Formula [I] include compounds of the following formulas:









TABLE 1









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image


















TABLE 2









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image


















TABLE 3









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image











Examples of each substituent in the compounds represented by the general formulas described in [101] to [117], [139] to [142] are explained as follows.




embedded image


is unsaturated heteromonocyclic group selected from the following (i) to (v):




embedded image


Examples of




embedded image


which is substituted with Ra and Rb include




embedded image


In one aspect, Ra is selected from the following (1) to (12):


(1) C1-12 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(2) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(3) C2-12 alkenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(4) C2-12 alkynyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(5) C5-11 spirocyclic cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(6) cross-linked C5-12 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(7) saturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered,


(8) phenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(9) C9-10 fused carbocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A,


(10) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


(11) saturated fused heterocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the saturated heteromonocyclic group has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered,


(12) unsaturated fused heterocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the unsaturated heteromonocyclic group has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered.


In one aspect, examples of “C1-12 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A” include:




embedded image


In one aspect, examples of “C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A” include cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, cycloheptyl group,




embedded image


In one aspect, examples of “C2-12 alkenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A” include




embedded image


In one aspect, examples of “C2-12 alkynyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A” include




embedded image


In one aspect, examples of “C5-11 spirocyclic cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A” include




embedded image


In one aspect, examples of “cross-linked C5-12 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A” include




embedded image


In one aspect, examples of “saturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered” include




embedded image


and the examples further include




embedded image


In one aspect, examples of “phenyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A” include




embedded image


In one aspect, examples of “C9-10 fused carbocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A” include




embedded image


In one aspect, examples of “unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered” include furyl group, thienyl group, pyrrolyl group, oxazolyl group, isoxazolyl group, thiazolyl group, isothiazolyl group, imidazolyl group, pyrazolyl group, oxadiazolyl group (1,2,5-oxadiazolyl group, 1,3,4-oxadiazolyl group, 1,2,4-oxadiazolyl group), thiadiazolyl group (1,2,5-thiadiazolyl group, 1,3,4-thiadiazolyl group, 1,2,4-thiadiazolyl group), triazolyl group (1,2,3-triazolyl group, 1,2,4-triazolyl group), tetrazolyl group, pyridyl group, pyrimidinyl group, pyridazinyl group, pyrazinyl group, and triazinyl group, and the examples further include




embedded image


and further the examples include




embedded image


In one aspect, examples of “saturated fused heterocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the saturated fused heterocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered” include




embedded image


In one aspect, examples of “unsaturated fused heterocyclic group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A wherein the unsaturated fused heterocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered” include quinolyl group, benzofuranyl group, benzothienyl group, indolyl group, imidazole[1,2-a]pyridyl group, and [1,2,4]triazolo[4,3-a]pyridinyl group, and the examples further include




embedded image


In a preferred aspect, Ra is selected from the following (1) to (3):


(1) C1-12 alkyl group,


(2) cyclobutyl group substituted with C1-7 alkyl group,


(3) phenyl group substituted with alkyl group.

    • Rb is selected from the following (1) to (6):


(1) C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 halogen atoms,


(2) C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from the group consisting of halogen atom and C1-6 alkyl group,


(3) —CH═CH—C(═O)—ORbb1,


(4) —CH2—CH2—C(═O)—ORbb2,


(5) —CH2—O—CH2—C(═O)—ORbb3,


(6) hydrogen atom.

    • Rbb1, Rbb2, and Rbb3 are each independently hydrogen atom or C1-6 alkyl group.


In one aspect, examples of “C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 halogen atoms” include




embedded image


In one aspect, examples of “C3-7 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from the group consisting of halogen atom and C1-6 alkyl group” include




embedded image


In one aspect, examples of “—CH═CH—C(═O)—ORbb1” include


—CH═CH—C(═O)—OH,
—CH═CH—C(═O)—OCH3.

In one aspect, examples of “—CH2—CH2—C(═O)—ORbb2” include


—CH2—CH2—C(═O)—OH,


—CH2—CH2—C(═O)—OCH3.


In one aspect, examples of “—CH2—O—CH2—C(═O)—ORbb3” include


—CH2—O—CH2—C(═O)—OH,


—CH2—O—CH2—C(═O)—OCH3.


In a preferred aspect, Rb is selected from the following (1) or (2):


(1) C1-3 alkyl group which may optionally be substituted with the same or different 1 to 5 halogen atoms,


(2) cyclopropyl group.

    • Re is hydrogen atom or C1-6 alkyl group, preferably “hydrogen atom”.


Each Rj is the same or different C1-12 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A, and examples of Rj include




embedded image


Q is selected from the following (1) to (9):


(1) phenyl group,


(2) C3-7 cycloalkyl group,


(3) C9-10 fused carbocyclic group,


(4) cross-linked C5-12 cycloalkyl group,


(5) C3-8 alkyl group,


(6) saturated heteromonocyclic group wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered,


(7) unsaturated fused heterocyclic group wherein the unsaturated fused heterocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered,


(8) unsaturated heteromonocyclic group wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered,


(9) saturated fused heterocyclic group wherein the saturated fused heterocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered.


In one aspect, examples of “C3-7 cycloalkyl group” include




embedded image


In one aspect, examples of “C9-10 fused carbocyclic group” include




embedded image


In one aspect, examples of “cross-linked C5-12 cycloalkyl group” include




embedded image


In one aspect, examples of “C3-8 alkyl group” include




embedded image


In one aspect, examples of “saturated heteromonocyclic group wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered” include




embedded image


In one aspect, examples of “unsaturated fused heterocyclic group wherein the unsaturated fused heterocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered” include quinolyl group, benzofuranyl group, benzothienyl group, indolyl group, imidazole[1,2-a]pyridyl group, and [1,2,4]triazolo[4,3-a]pyridinyl group, and the examples further include




embedded image


In one aspect, examples of “unsaturated heteromonocyclic group wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered” include




embedded image


and the examples further include




embedded image


In one aspect, examples of “saturated fused heterocyclic group wherein the saturated fused heterocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered” include




embedded image


Preferably, Q is phenyl group.


Examples of the moiety:




embedded image


include




embedded image


and the examples further include




embedded image


Y is selected from the following (1) to (3):


(1) single bond,


(2) —S(═O)2—,


(3) alkylene which may optionally be substituted with 1 to 3 hydroxyl groups.


Examples of said “C1-3 alkylene which may optionally be substituted with 1 to 3 hydroxyl groups” include




embedded image


Preferred examples of Y include “single bond”.


m is each independently an integer selected from 0 or 1 to 5, preferably “0, 1, 2, or 3”.


nj is each independently 0, 1 or 2, preferably “2”.


Examples of each substituent in the compounds represented by the general formulas described in [102] and [139] are explained as follows.


Each Rw is the same or different and selected from the following (1) to (17):


(1) C1-12 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from the group consisting of hydroxyl group and halogen atom,


(2) unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 C1-6 alkyl groups wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 7-membered,


(3) —(CH2)wn1—C(═O)—ORww1,


(4) —(CH2)wn1—C(═O)—(CH2)wn1—NRww2Rww3,


(5) —(CH2)wn1—C(═O)—(CH2)wn1—C(═O)—ORww4,


(6) —NRww5Rww6,


(7) —ORww7,


(8) —C(═O)—Rww8,


(9) —S(═O)2—Rww9,


(10) ═O,


(11) methylene,


(12) —(CH2)wn2-ring P,


(13) halogen atom,


(14) —NRww10—C(═O)—Rww11,


(15) —NRww12—C(═O)—NRww13Rww14,


(16) —NRww15—S(═O)2—Rww16,


(17) —NRww17—S(═O)2—NRww18Rww19;


In one aspect, examples of “C1-12 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from the group consisting of hydroxyl group and halogen atom” include




embedded image


In one aspect, examples of “unsaturated heteromonocyclic group which may optionally be substituted with the same or different 1 to 5 C1-6 alkyl groups wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 7-membered” include




embedded image


In one aspect, examples of “—(CH2)wn2-ring P” include




embedded image


Cyclic moiety W is selected from the following (1) to (3)


(1) pyrrolidinyl,


(2) piperidinyl,


(3) C3-7 cycloalkyl,


preferably, pyrrolidinyl, piperidinyl, or, C3-6 cycloalkyl.


cn is each independently an integer selected from 0 or 1 to 3, preferably 0, 1 or 2.


In Formula [III-X-C], examples of the moiety




embedded image


include




embedded image


wherein nw is an integer selected from 0 or 1 to 4, and the examples further include




embedded image


Examples of each substituent in the compounds represented by the general formulas described in [103] to [107], and [141] are explained as follows.


Rc is selected from the following (1) to (17):


(1) —(CH2)n1—C(═O)—ORcc1,


(2) —O—(CH2)n2—C(═O)—ORcc2,


(3) —(CH2)n3-ring P,


(4) —(CH2)n4—C(═O)—NH—S(═O)2—CH3,


(5) C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group C,


(6) C3-6 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group C,


(7) C2-12 alkenyl group,


(8) C2-12 alkynyl group,


(9) —NRcc3Rcc4,


(10) —ORcc5,


(11) —O—CH2CH2—OH,


(12) —O—CH2C(═O)NH—CH3,




embedded image


In one aspect, examples of “—(CH2)n1—C(═O)—ORcc1” include


—CH2—C(═O)—OH,

—CH2—C(═O)—OCH3,


—(CH2)2—C(═O)—OH,


—(CH2)2—C(═O)—OCH3,


—(CH2)3—C(═O)—OH,


—(CH2)3—C(═O)—OCH3.


In one aspect, examples of “—O—(CH2)n2—C(═O)—ORcc2” include


—O—CH2—C(═O)—OH,

—O—CH2—C(═O)—OCH3,


—O—(CH2)2—C(═O)—OH,


—O—(CH2)2—C(═O)—OCH3.


In one aspect, examples of “—(CH2)n3-ring P” include




embedded image


In one aspect, examples of “—(CH2)n4—C(═O)—NH—S(═O)2—CH3” include


—CH2—C(═O)—NH—S(═O)2—CH3,


—(CH2)2—C(═O)—NH—S(═O)2—CH3,


—(CH2)3—C(═O)—NH—S(═O)2—CH3.


In one aspect, examples of “C1-6 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group C” include


—(CH2)2—OH,


—(CH2)3—OH,


—(CH2)4—OH,




embedded image


In one aspect, examples of “C3-6 cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group C” include




embedded image


In one aspect, examples of “—NRcc3Rcc4” include


—NH2,

—N(CH3)2,


—NH(CH3),
—NH—C(═O)—CH3,

—N(CH3)—C(═O)—CH2.


In one aspect, examples of “—ORcc5” include


—OH,
—O—CH3,
—O—CH2-Ph.

Rf is hydrogen atom or C1-6 alkyl group, preferably hydrogen atom or methyl group.




embedded image


Examples of each substituent in the compounds represented by the general formula described in [108] are explained as follows.


Each Rau is the same or different and selected from the following (1) or (2):


(1) C7-12 alkyl group,


(2) C1-12 alkyl group which is substituted with the same or different 1 to 5 substituents selected from Group AU.


Examples of “C1-12 alkyl group which is substituted with the same or different 1 to 5 substituents selected from Group AU” include




embedded image


Cyclic moiety UU is selected from the following (1) or (2):


(1) C3-7 cycloalkyl group,


(2) phenyl group.


Examples of “C3-7 cycloalkyl group” include




embedded image


nu is an integer selected from 0 or 1 to 3, preferably “1”.


Preferred aspects of a compound described in [101] include compounds of the following formulas.


Each symbol in each formula is as defined in [101].









TABLE 4





Aspects









embedded image

  [III-X-B]








embedded image

  [III-F-B]








embedded image

  [III-H-B]








embedded image

  [III-G-B]








embedded image

  [III-J-B]








embedded image

  [III-K-B]








embedded image

  [III-L-B]










Other preferred aspects include the following compounds.









TABLE 5





Table 101-2









embedded image

  [III-X-B-QB]








embedded image

  [III-F-B-QB]








embedded image

  [III-H-B-QB]








embedded image

  [III-G-B-QB]








embedded image

  [III-J-B-QB]








embedded image

  [III-K-B-QB]








embedded image

  [III-L-B-QB]










Preferred examples of the combination of substituents in Tables 101-1 and 101-2 are shown below:









TABLE 6





Aspect 101-3


















Ra
selected from the following (1) to (3):




(1) C1-12 alkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group A,




(2) C3-7 cycloalkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group A,




(3) phenyl group which may optionally be substituted




with the same or different 1 to 5 substituents




selected from Group A,



Rb
selected from the following (1) or (2):




(1) C1-6 alkyl group which may optionally be




substituted with the same or different 1 to 5 halogen




atoms,




(2) C3-7 cycloalkyl group which may optionally be




substituted with the same or different 1 to 5 substituents




selected from the group consisting of halogen atom




and C1-6 alkyl group,



m
an integer selected from 0 or 1 to 4



Rd
selected from the following (1) to (3):




(1) halogen atom,




(2) C1-6 alkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group B,




(3) C3-7 cycloalkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group B,

















TABLE 7





Aspect 101-4


















Ra
selected from the following (1) to (3):




(1) C1-12 alkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group A,




(2) cyclobutyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group A,




(3) phenyl group which may optionally be substituted




with the same or different 1 to 5 substituents




selected from Group A,



Rb
selected from the following (1) or (2):




(1) C1-3 alkyl group which may optionally be




substituted with the same or different 1 to 5




halogen atoms,




(2) cyclopropyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from the group consisting




of halogen atom and C1-6 alkyl group,



m
an integer selected from 0 or 1 to 3



Rd
selected from the following (1) to (3):




(1) halogen atom,




(2) C1-3 alkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group B,




(3) cyclopropyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group B,

















TABLE 8





Aspect 101-5


















Ra
selected from the following (1) to (3):




(1) C1-12 alkyl group,




(2) cyclobutyl group substituted with C1-7 alkyl




group,




(3) phenyl group substituted with C1-7 alkyl group,



Rb
selected from the following (1) or (2):




(1) C1-3 alkyl group which may optionally be




substituted with the same or different 1 to 5 halogen




atoms,




(2) cyclopropyl group,



m
an integer selected from 0 or 1 to 3



Rd
selected from the following (1) to (3):




(1) halogen atom,




(2) C1-3 alkyl group,




(3) cyclopropyl group,










Other preferred examples of the combination of substituents in Tables 101-1 and 101-2 are shown below:









TABLE 9





Aspect 101-6


















Ra
selected from the following (1) to (3):




(1) C1-12 alkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group A,




(2) C3-7 cycloalkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group A,




(3) phenyl group which may optionally be substituted




with the same or different 1 to 5 substituents




selected from Group A,



Rb
selected from the following (1) to (3):




(1) —CH═CH—C(═O)—ORbb1,




(2) —CH2—CH2—C(═O)—ORbb2,




(3) —CH2—O—CH2—C(═O)—ORbb3



m
an integer selected from 0 or 1 to 4



Rd
selected from the following (1) to (3):




(1) halogen atom,




(2) C1-6 alkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group B,




(3) C3-7 cycloalkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group B,

















TABLE 10





Aspect 101-7
















Ra
selected from the following (1) to (3):



(1) C1-12 alkyl group which may optionally be



substituted with the same or different 1 to 5



substituents selected from Group A,



(2) cyclobutyl group which may optionally be



substituted with the same or different 1 to 5



substituents selected from Group A,



(3) phenyl group which may optionally be substituted



with the same or different 1 to 5 substituents selected



from Group A,


Rb
selected from the following (1) to (3):



(1) —CH═CH—C(═O)—ORbb1,



(2) —CH2—CH2—C(═O)—ORbb2,



(3) —CH2—O—CH2—C(═O)—ORbb3


m
an integer selected from 0 or 1 to 3


Rd
selected from the following (1) to (3):



(1) halogen atom,



(2) C1-3 alkyl group which may optionally be



substituted with the same or different 1 to 5



substituents selected from Group B,



(3) cyclopropyl group which may optionally be substituted



with the same or different 1 to 5 substituents



selected from Group B,
















TABLE 11





Aspect 101-8


















Ra
selected from the following (1) to (3):




(1) C1-12 alkyl group,




(2) cyclobutyl group substituted with C1-7 alkyl




group,




(3) phenyl group substituted with C1-7 alkyl group,



Rb
selected from the following (1) to (3):




(1) —CH═CH—C(═O)—ORbb1,




(2) —CH2—CH2—C(═O)—ORbb2,




(3) —CH2—O—CH2—C(═O)—ORbb3



m
an integer selected from 0 or 1 to 3



Rd
selected from the following (1) to (3):




(1) halogen atom,




(2) C1-3 alkyl group,




(3) cyclopropyl group,










Preferred aspects of [101] include the following compounds:









TABLE 12









embedded image









embedded image









embedded image









embedded image











Preferred aspects of a compound described in [102] includes compounds of the following formulas.


Each symbol in each formula is as defined in [102].









TABLE 13





Table 102-1









embedded image

  [III-X-C]








embedded image

  [III-F-C]








embedded image

  [III-H-C]








embedded image

  [III-G-C]








embedded image

  [III-J-C]








embedded image

  [III-K-C]








embedded image

  [III-L-C]










Other preferred aspects include the following compounds.









TABLE 14





Table 102-2









embedded image

  [III-X-CUD-N5-QB]








embedded image

  [III-F-CUD-N5-QB]








embedded image

  [III-H-CUD-N5-QB]








embedded image

  [III-G-CUD-N5-QB]








embedded image

  [III-J-CUD-N5-QB]








embedded image

  [III-K-CUD-N5-QB]








embedded image

  [III-L-CUD-N5-QB]










Other preferred aspects include the following compounds.









TABLE 15





Table 102-3









embedded image

  [III-X-CUD-CNW-QB]








embedded image

  [III-F-CUD-CNW-QB]








embedded image

  [III-H-CUD-CNW-QB]








embedded image

  [III-G-CUD-CNW-QB]








embedded image

  [III-J-CUD-CNW-QB]








embedded image

  [III-K-CUD-CNW-QB]








embedded image

  [III-L-CUD-CNW-QB]










In Table 102-3, nw is an integer selected from 0 or 1 to 4, preferably 0 or 1 to 3.


Other preferred aspects include the following compounds.









TABLE 16





Table 102-4









embedded image

  [III-X-CUD-C5-QB]








embedded image

  [III-F-CUD-C5-QB]








embedded image

  [III-H-CUD-C5-QB]








embedded image

  [III-G-CUD-C5-QB]








embedded image

  [III-J-CUD-C5-QB]








embedded image

  [III-K-CUD-C5-QB]








embedded image

  [III-L-CUD-C5-QB]










Preferred examples of the combination of substituents in Tables 102-1, 102-2, 102-3, 102-4 are shown below.









TABLE17





Aspect 102-5


















Ra
selected from the following (1) to (3):




(1) C1-12 alkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group A,




(2) C3-7 cycloalkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group A,




(3) phenyl group which may optionally be substituted




with the same or different 1 to 5 substituents




selected from Group A,



Rb
selected from the following (1) or (2):




(1) C1-6 alkyl group which may optionally be




substituted with the same or different 1 to 5 halogen




atoms,




(2) C3-7 cycloalkyl group which may optionally be sub-




stituted with the same or different 1 to 5 substituents




selected from the group consisting of halogen atom and




C1-6 alkyl group,



Rw
each Rw is the same or different and selected from the




following (1) to (12):




(1) C1-12 alkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from the group consisting of




hydroxyl group and halogen atom,




(2) unsaturated heteromonocyclic group which may




optionally be substituted with the same or different 1




to 5 C1-6 alkyl groups wherein the unsaturated




heteromonocyclic ring has an unsaturated bond,




comprises the same or different 1 to 4 hetero atoms




selected from nitrogen atom, oxygen atom, or sulfur




atom besides carbon atom, and is 5 to 7-membered,




(3) —(CH2)wn1—C(═O)—ORww1,




(4) —(CH2)wn1—C(═O)—(CH2)wn1—NRww2Rww3,




(5) —(CH2)wn1—C(═O)—(CH2)wn1—C(═O)—ORww4,




(6) —NRww5Rww6,




(7) —ORww7,




(8) —C(═O)—Rww8,




(9) —S(═O)2—Rww9,




(10) ═O,




(11) methylene,




(12) —(CH2)wn2-ring P,



m
an integer selected from 0 or 1 to 4



Rd
selected from the following (1) to (3):




(1) halogen atom,




(2) C1-6 alkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group B,




(3) C3-7 cycloalkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group B,

















TABLE 18





Aspect 102-6
















Ra
selected from the following (1) to (3):



(1) C1-12 alkyl group which may optionally be



substituted with the same or different 1 to 5



substituents selected from Group A,



(2) cyclobutyl group which may optionally be



substituted with the same or different 1 to 5



substituents selected from Group A,



(3) phenyl group which may optionally be substituted



with the same or different 1 to 5 substituents selected



from Group A,


Rb
selected from the following (1) or (2):



(1) C1-3 alkyl group which may optionally be



substituted with the same or different 1 to 5 halogen



atoms,



(2) cyclopropyl group which may optionally be substituted



with the same or different 1 to 5 substituents



selected from the group consisting of halogen atom and



C1-6 alkyl group,


Rw
each Rw is the same or different and selected from the



following (1) to (12):



(1) C1-12 alkyl group which may optionally be



substituted with the same or different 1 to 5



substituents selected from the group consisting of



hydroxyl group and halogen atom,



(2) unsaturated heteromonocyclic group which may



optionally be substituted with the same or different 1



to 5 C1-6 alkyl groups wherein the unsaturated



heteromonocyclic ring has an unsaturated bond,



comprises the same or different 1 to 4 hetero atoms



selected from nitrogen atom, oxygen atom, or sulfur



atom besides carbon atom, and is 5 to 7-membered,



(3) —(CH2)wn1—C(═O)—ORww1,



(4) —(CH2)wn1—C(═O)—(CH2)wn1—NRww2Rww3,



(5) —(CH2)wn1—C(═O)—(CH2)wn1—C(═O)—ORww4,



(6) —NRww5Rww6,



(7) —ORww7,



(8) —C(═O)—Rww8,



(9) —S(═O)2—Rww9,



(10) ═O,



(11) —(CH2)wn2-ring P,


m
an integer selected from 0 or 1 to 3


Rd
selected from the following (1) to (3):



(1) halogen atom,



(2) C1-3 alkyl group which may optionally be



substituted with the same or different 1 to 5



substituents selected from Group B,



(3) cyclopropyl group which may optionally be substituted



with the same or different 1 to 5 substituents selected



from Group B,
















TABLE 19





Aspect 102-7


















Ra
selected from the following (1) to (3):




(1) C1-12 alkyl group,




(2) cyclobutyl group substituted with C1-7 alkyl




group,




(3) phenyl group substituted with C1-7 alkyl group,



Rb
selected from the following (1) or (2):




(1) C1-3 alkyl group which may optionally be




substituted with the same or different 1 to 5 halogen




atoms,




(2) cyclopropyl group,



Rw
each Rw is the same or different and selected from the




following (1) to (7):




(1) —(CH2)wn1—C(═O)—ORww1,




(2) —(CH2)wn1—C(═O)—(CH2)wn1—C(═O)—ORww4,




(3) —NRww5Rww6,




(4) —ORww7,




(5) —C(═O)—Rww8,




(6) —S(═O)2—Rww9,




(7) —(CH2)wn2-ring 2,



m
an integer selected from 0 or 1 to 3



Rd
selected from the following (1) to (3):




(1) halogen atom,




(2) C1-3 alkyl group,




(3) cyclopropyl group,










Preferred aspects of [102] include the following compounds:









TABLE 20









embedded image









embedded image









embedded image









embedded image











Preferred aspects of a compound described in [103] include compounds of the following formulas.


Each symbol in each formula is as defined in [103].









TABLE 21





Table 103-1









embedded image

  [III-X-D2]








embedded image

  [III-F-D2]








embedded image

  [III-H-D2]








embedded image

  [III-G-D2]








embedded image

  [III-J-D2]








embedded image

  [III-K-D2]








embedded image

  [III-L-D2]










Other preferred aspects include the following compounds.









TABLE 22





Table 103-2









embedded image

  [III-X-D2-U-QB]








embedded image

  [III-F-D2-U-QB]








embedded image

  [III-H-D2-U-QB]








embedded image

  [III-G-D2-U-QB]








embedded image

  [III-X-D2-D-QB]








embedded image

  [III-J-D2-U-QB]








embedded image

  [III-K-D2-U-QB]








embedded image

  [III-L-D2-U-QB]








embedded image

  [III-J-D2-D-QB]








embedded image

  [III-F-D2-D-QB]








embedded image

  [III-H-D2-D-QB]








embedded image

  [III-G-D2-D-QB]








embedded image

  [III-K-D2-D-QB]








embedded image

  [III-L-D2-D-QB]










Preferred examples of the combination of substituents in Tables 103-1 and 103-2 are shown below.









TABLE 23





Aspect 103-3


















Ra
selected from the following (1) to (3):




(1) C1-12 alkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group A,




(2) C3-7 cycloalkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group A,




(3) phenyl group which may optionally be substituted




with the same or different 1 to 5 substituents




selected from Group A,



Rb
selected from the following (1) or (2):




(1) C1-6 alkyl group which may optionally be




substituted with the same or different 1 to 5 halogen




atoms,




(2) C3-7 cycloalkyl group which may optionally be




substituted with the same or different 1 to 5 substituted




selected from the group consisting of halogen atom and




C1-6 alkyl group,



Rc
Rc is selected from the following (1) to (4):




(1) —(CH2)n1—C(═O)—ORcc1,




(2) —O—(CH2)n2—C(═O)—ORcc2,




(3) —(CH2)n3-ring P,




(4) —(CH2)n4—C(═O)—NH—S(═O)2—CH3



m
an integer selected from 0 or 1 to 4



Rd
selected from the following (1) to (3):




(1) halogen atom,




(2) C1-6 alkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group B,




(3) C3-7 cycloalkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group B,

















TABLE 24





Aspect 103-4
















Ra
selected from the following (1) to (3):



(1) C1-12 alkyl group which may optionally be



substituted with the same or different 1 to 5



substituents selected from Group A,



(2) cyclobutyl group which may optionally be



substituted with the same or different 1 to 5



substituents selected from Group A,



(3) phenyl group which may optionally be substituted



with the same or different 1 to 5 substituents selected



from Group A,


Rb
selected from the following (1) or (2):



(1) C1-3 alkyl group which may optionally be



substituted with the same or different 1 to 5 halogen



atoms,



(2) cyclopropyl group which may optionally be substituted



with the same or different 1 to 5 substituents selected



from the group consisting of halogen atom and C1-6



alkyl group,


Rc
Rc is selected from the following (1) to (4):



(1) —(CH2)n1—C(═O)—ORcc1



(2) —O—(CH2)n2—C(═O)—ORcc2,



(3) —(CH2)n3-ring P,



(4) —(CH2)n4—C(═O)—NH—S(═O)2—CH3


m
an integer selected from 0 or 1 to 3


Rd
selected from the following (1) to (3):



(1) halogen atom,



(2) C1-3 alkyl group which may optionally be



substituted with the same or different 1 to 5



substituents selected from Group B,



(3) cyclopropyl group which may optionally be substituted



with the same or different 1 to 5 substituents selected



from Group B,
















TABLE 25





Aspect 103-5
















Ra
selected from the following (1) to (3):



(1) C1-12 alkyl group,



(2) cyclobutyl group substituted with C1-7 alkyl



group,



(3) phenyl group substituted with C1-7 alkyl group,


Rb
selected from the following (1) or (2):



(1) C1-3 alkyl group which may optionally be



substituted with the same or different 1 to 5 halogen



atoms,



(2) cyclopropyl group,


Rc
Rc is selected from the following (1) to (4):



—(CH2)n1—C(═O)—ORcc1 wherein Rcc1 is hydrogen atom,



—O—(CH2)n2—C(═O)—ORcc2 wherein Rcc2 is hydrogen atom,



(3) —(CH2)n3-ring P,



(4) —(CH2)n4—C(═O)—NH—S(═O)2—CH3


m
an integer selected from 0 or 1 to 3


Rd
selected from the following (1) to (3):



(1) halogen atom,



(2) C1-3 alkyl group,



(3) cyclopropyl group,









Preferred aspects of a compound described in [103] include the following compounds:









TABLE 26









embedded image









embedded image









embedded image









embedded image











Preferred aspects of a compound described in [104], [105] and [106] include compounds of the following formulas. Each symbol in each of the following formulas is as defined in [104].









TABLE 27





Table 104-1









embedded image

  [III-X-D1]








embedded image

  [III-F-D1]








embedded image

  [III-H-D1]








embedded image

  [III-G-D1]








embedded image

  [III-J-D1]








embedded image

  [III-K-D1]








embedded image

  [III-L-D1]

















TABLE 28





Table 104-2









embedded image

  [III-X-D1-D-QB]








embedded image

  [III-J-D1-D-QB]








embedded image

  [III-F-D1-D-QB]








embedded image

  [III-H-D1-D-QB]








embedded image

  [III-K-D1-D-QB]








embedded image

  [III-G-D1-D-QB]








embedded image

  [III-L-D1-D-QB]








embedded image

  [III-X-D1-U-QB]








embedded image

  [III-J-D1-U-QB]








embedded image

  [III-F-D1-U-QB]








embedded image

  [III-H-D1-U-QB]








embedded image

  [III-K-D1-U-QB]








embedded image

  [III-G-D1-U-QB]








embedded image

  [III-L-D1-U-QB]

















TABLE 29





Table 104-3









embedded image

  [III-X-D12]








embedded image

  [III-F-D12]








embedded image

  [III-H-D12]








embedded image

  [III-K-D12]








embedded image

  [III-G-D12]








embedded image

  [III-L-D12]

















TABLE 30





Table 104-4









embedded image

  [III-X-D1-D-RCP-QB]








embedded image

  [III-J-D1-D-RCP-QB]








embedded image

  [III-F-D1-D-RCP-QB]








embedded image

  [III-H-D1-D-RCP-QB]








embedded image

  [III-K-D1-D-RCP-QB]








embedded image

  [III-G-D1-D-RCP-QB]








embedded image

  [III-L-D1-D-RCP-QB]










Preferred examples of the combination of substituents in Tables 104-1, 104-2, 104-3, and 104-4 are shown below.









TABLE 31





Aspect 104-5


















Ra
selected from the following (1) to (4):




(1) C1-12 alkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group A,




(2) C3-7 cycloalkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group A,




(3) phenyl group which may optionally be substituted




with the same or different 1 to 5 substituents




selected from Group A,




(4) unsaturated heteromonocyclic group which may optionally




be substituted with the same or different 1 to 5




substituents selected from Group A wherein the unsaturated




heteromonocyclic ring has an unsaturated bond, comprises




the same or different 1 to 4 hetero atoms selected




from nitrogen atom, oxygen atom, or sulfur atom




besides carbon atom, and is 5 to 6-membered,



Rb
selected from the following (1) or (2):




(1) C1-6 alkyl group which may optionally be




substituted with the same or different 1 to 5 halogen




atoms,




(2) C3-7 cycloalkyl group which may optionally be substituted




with the same or different 1 to 5 substituents




selected from the group consisting of halogen atom and




C1-6 alkyl group,



Rc
Rc is selected from the following (1) to (4):




(1) —(CH2)n1—C(═O)—ORcc1,




(2) —O—(CH2)n2—C(═O)—ORcc2,




(3) —(CH2)n3-ring P,




(4) —(CH2)n4—C(═O)—NH—S(═O)2—CH3



m
an integer selected from 0 or 1 to 4



Rd
selected from the following (1) to (3):




(1) halogen atom,




(2) C1-6 alkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group B,




(3) C3-7 cycloalkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group B,

















TABLE 32





Aspect 104-6


















Ra
selected from the following (1) to (4):




(1) C1-12 alkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group A,




(2) cyclobutyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group A,




(3) phenyl group which may optionally be substituted




with the same or different 1 to 5 substituents




selected from Group A,




(4) unsaturated heteromonocyclic group which may optionally




be substituted with the same or different 1 to 5




substituents selected from Group A wherein the unsaturated




heteromonocyclic ring has an unsaturated bond,




comprises the same or different 1 to 4 hetero atoms




selected from nitrogen atom, oxygen atom, or sulfur atom




besides carbon atom, and is 5 to 6-membered,



Rb
selected from the following (1) or (2):




(1) C1-3 alkyl group which may optionally be




substituted with the same or different 1 to 5 halogen




atoms,




(2) cyclopropyl group which may optionally be




substituted with the same or different 1 to 5 substituents




selected from the group consisting of halogen atom and




C1-6 alkyl group,



Rc
Rc is selected from the following (1) to (4):




(1) —(CH2)n1—C(═O)—ORcc1,




(2) —O—(CH2)n2—C(═O)—ORcc2,




(3) —(CH2)n3-ring P,




(4) —(CH2)n4—C(═O)—NH—S(═O)2—CH3



m
an integer selected from 0 or 1 to 3



Rd
selected from the following (1) to (3):




(1) halogen atom,




(2) C1-3 alkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group B,




(3) C3 cycloalkyl group which may optionally be




substituted with the same or different 1 to 5 substituents




selected from Group B,

















TABLE 33





Aspect 104-7
















Ra
selected from the following (1) to (4):



(1) C1-12 alkyl group,



(2) cyclobutyl group substituted with C1-7 alkyl



group,



(3) phenyl group substituted with C1-7 alkyl group,



(4) unsaturated heteromonocyclic group substituted with



C1-7 alkyl group wherein the unsaturated heteromonocyclic



ring has an unsaturated bond, comprises the same



or different 1 to 4 hetero atoms selected from nitrogen



atom, oxygen atom, or sulfur atom besides carbon atom,



and is 5 to 6-membered,


Rb
selected from the following (1) or (2):



(1) C1-3 alkyl group which may optionally be



substituted with the same or different 1 to 5 halogen



atoms,



(2) cyclopropyl group,


Rc
Rc is selected from the following (1) to (4):



—(CH2)n1—C(═O)—ORcc1 wherein Rcc1 is hydrogen atom,



—O—(CH2)n2—C(═O)—ORcc2 wherein Rcc2 is hydrogen atom,



(3) —(CH2)n3-ring P,



(4) —(CH2)n4—C(═O)—NH—S(═O)2—CH3


m
an integer selected from 0 or 1 to 3


Rd
selected from the following (1) to (3):



(1) halogen atom,



(2) C1-3 alkyl group,



(3) cyclopropyl group,









Aspect 104-8:

In Aspects 104-5, 104-6, and 104-7, preferred examples of Rf include hydrogen atom.


Aspect 104-9:

In Aspects 104-5, 104-6, and 104-7, preferred examples of Rf includes C1-3 alkyl group.


Aspect 104-10:

In Aspects 104-5, 104-6, 104-7, 104-8, and 104-9, preferred examples of “unsaturated heteromonocyclic group wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered” for the substituent Ra include




embedded image


In preferred aspects, the following compounds are included.









TABLE 34









embedded image









embedded image









embedded image









embedded image


















TABLE 35









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image


















TABLE 36









embedded image









embedded image











In preferred aspects, the following compounds are included.









TABLE 37









embedded image









embedded image


















TABLE 38









embedded image









embedded image









embedded image









embedded image











In preferred aspects, the following compounds are included.









TABLE 39









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image











In preferred aspects, the following compounds are included.









TABLE 40









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image











Preferred aspects of a compound described in [107] include compounds of the following formulas. Each symbol in each formula is as defined in [107].









TABLE 41





Table 107-1









embedded image

  [III-X-D1-D2H]








embedded image

  [III-X-D1-D-QB]








embedded image

  [III-K-D1-D-QB]








embedded image

  [III-G-D1-D-QB]








embedded image

  [III-X-D1-U-QB]








embedded image

  [III-K-D1-U-QB]








embedded image

  [III-G-D1-U-QB]










Preferred examples of the combination of substituents in the above Table 107-1 are shown below.









TABLE 42





Aspect 107-2


















Ra
selected from the following (1) to (3):




(1) C1-12 alkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group A,




(2) C3-7 cycloalkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group A,




(3) phenyl group which may optionally be substituted




with the same or different 1 to 5 substituents selected




from Group A,



Rb
selected from the following (1) or (2):




(1) C1-6 alkyl group which may optionally be




substituted with the same or different 1 to 5 halogen




atoms,




(2) C3-7 cycloalkyl group which may optionally be




substituted with the same or different 1 to 5 substituents




selected from the group consisting of halogen atom




and C1-6 alkyl group,



Rc
selected from the following (1) to (3):




(1) —(CH2)n3-ring P,




(2) —(CH2)n4—C(═O)—NH—S(═O)2—CH3,




(3) C1-6 alkyl group which may optionally be substituted




with the same or different 1 to 5 substituents




selected from Group C,



m
an integer selected from 0 or 1 to 4



Rd
selected from the following (1) to (3):




(1) halogen atom,




(2) C1-6 alkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group B,




(3) C3-7 cycloalkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group B,

















TABLE 43





Aspect 107-3
















Ra
selected from the following (1) to (3):



(1) C1-12 alkyl group which may optionally be



substituted with the same or different 1 to 5



substituents selected from Group A,



(2) cyclobutyl group which may optionally be



substituted with the same or different 1 to 5



substituents selected from Group A,



(3) phenyl group which may optionally be substituted



with the same or different 1 to 5 substituents selected



from Group A,


Rb
selected from the following (1) or (2):



(1) C1-3 alkyl group which may optionally be



substituted with the same or different 1 to 5 halogen



atoms,



(2) cyclopropyl group which may optionally be substituted



with the same or different 1 to 5 substituents



selected from the group consisting of halogen atom and



C1-6 alkyl group,


Rc
selected from the following (1) to (3):



(1) —(CH2)n3-ring P,



(2) —(CH2)n4—C(═O)—NH—S(═O)2—CH3,



(3) C1-6 alkyl group which may optionally be substituted



with the same or different 1 to 5 substituents



selected from Group C,


m
an integer selected from 0 or 1 to 3


Rd
selected from the following (1) to (3):



(1) halogen atom,



(2) C1-3 alkyl group which may optionally be



substituted with the same or different 1 to 5



substituents selected from Group B,



(3) cyclopropyl group which may optionally be substituted



with the same or different 1 to 5 substituents



selected from Group B,
















TABLE 44





Aspect 107-4


















Ra
selected from the following (1) to (3):




(1) C1-12 alkyl group,




(2) cyclobutyl group substituted with C1-7 alkyl




group,




(3) phenyl group substituted with C1-7 alkyl group,



Rb
selected from the following (1) or (2):




(1) C1-3 alkyl group which may optionally be




substituted with the same or different 1 to 5 halogen




atoms,




(2) cyclopropyl group,



Rc
selected from the following (1) to (3):




(1) —(CH2)n3-ring P,




(2)—(CH2)n4—C(═O)—NH—S(═O)2—CH3,



m
an integer selected from 0 or 1 to 3



Rd
selected from the following (1) to (3):




(1) halogen atom,




(2) C1-3 alkyl group,




(3) cyclopropyl group,










Aspect 107-5:

In Aspects 107-2, 107-3, 107-4, ring P is selected from the following heterocyclic groups:




embedded image









TABLE 45





Table 107-6









embedded image

  [III-X-D1-D-RCP-QB]








embedded image

  [III-K-D1-D-RCP-QB]








embedded image

  [III-G-D1-D-RCP-QB]










Preferred examples of the combination of substituents in Tables 107-6 are shown below.









TABLE 46





Aspect 107-7


















Ra
selected from the following (1) to (3):




(1) C1-12 alkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group A,




(2) C3-7 cycloalkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group A,




(3) phenyl group which may optionally be substituted




with the same or different 1 to 5 substituents




selected from Group A,



Rb
selected from the following (1) or (2):




(1) C1-6 alkyl group which may optionally be




substituted with the same or different 1 to 5 halogen




atoms,




(2) C3-7 cycloalkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from the group consisting




of halogen atom and C1-6 alkyl group,



m
an integer selected from 0 or 1 to 4



Rd
selected from the following (1) to (3):




(1) halogen atom,




(2) C1-6 alkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group B,




(3) C3-7 cycloalkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group B,

















TABLE 47





Aspect 107-8


















Ra
selected from the following (1) to (3):




(1) C1-12 alkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group A,




(2) cyclobutyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group A,




(3) phenyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group A,



Rb
selected from the following (1) or (2):




(1) C1-3 alkyl group which may optionally be




substituted with the same or different 1 to 5




halogen atoms,




(2) cyclopropyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from the group consisting




of halogen atom and C1-6 alkyl group,



m
an integer selected from 0 or 1 to 3



Rd
selected from the following (1) to (3):




(1) halogen atom,




(2) C1-3 alkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group B,




(3) cyclopropyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group B,

















TABLE 48





Aspect 107-9


















Ra
selected from the following (1) to (3):




(1) C1-12 alkyl group,




(2) cyclobutyl group substituted with C1-7




alkyl group,




(3) phenyl group substituted with C1-7 alkyl




group,



Rb
selected from the following (1) or (2):




(1) C1-3 alkyl group which may optionally be




substituted with the same or different 1 to 5




halogen atoms,




(2) cyclopropyl group,



m
an integer selected from 0 or 1 to 3



Rd
selected from the following (1) to (3):




(1) halogen atom,




(2) C1-3 alkyl group,




(3) cyclopropyl group,










Aspect 107-10:

In Aspects 107-7, 107-8, and 107-9, ring P is selected from the following heterocyclic groups:




embedded image


Preferred aspects of a compound described in [107] include the following compounds:









TABLE 49









embedded image









embedded image


















TABLE 50









embedded image









embedded image









embedded image









embedded image











Preferred aspects of a compound described in [108] include compounds of the following formulas.


Each symbol in each formula is as defined in [108].


Other preferred aspects include the following compounds.









TABLE 51





Table 108-1









embedded image

  [III-X-D11] [III-X-D11]








embedded image

  [III-X-D11] [III-K-D11]








embedded image

  [III-X-D11] [III-G-D11]








embedded image

  [III-K-D11-D-QB]








embedded image

  [III-G-D11-D-QB]








embedded image

  [III-K-D11-U-QB]








embedded image

  [III-G-D11-U-QB]










Preferred examples of the combination of substituents in Table 108-1 are shown below.









TABLE 52





Aspect 108-2
















Rau
the same or different and selected from the



following (1) or (2):



(1) C7-12 alkyl group,



(2) C1-12 alkyl group which is substituted with the



same or different 1 to 5 substituents selected from



Group AU;


Rb
selected from the following (1) or (2):



(1) C1-6 alkyl group which may optionally be



substituted with the same or different 1 to 5



halogen atoms,



(2) C3-7 cycloalkyl group which may optionally be



substituted with the same or different 1 to 5



substituents selected from the group consisting of



halogen atom and C1-6 alkyl group,


Rc
selected from the following (1) or (2):



(1) —(CH2)n1—C(═O)—ORcc1 wherein Rcc1 is hydrogen



atom,



(2) —O—(CH2)n2—C(═O)—ORcc2 wherein Rcc2 is hydrogen



atom,


Rd
the same or different and selected from the



following (1) to (3):



(1) halogen atom,



(2) C1-6 alkyl group which may optionally be



substituted with the same or different 1 to 5



substituents selected from Group B,



(3) C3-7 cycloalkyl group which may optionally be



substituted with the same or different 1 to 5



substituents selected from Group B,


m
each independently, an integer selected from 0 or 1



to 4;









Aspect 108-3:

In Aspect 108-2, Group AU consists of the following (a) to (c):


(a) —ORAU1,


(b) —C(═O)—ORAU2,


(c) —C(═O)—NRAU3RAU4;


wherein RAU1, RAU2, RAU3, and RAU4 are each independently, hydrogen atom or C1-6 alkyl group.









TABLE 53





Aspect 108-4
















Rau
the same or different and selected from the



following (1) or (2):



(1) C7-12 alkyl group,



(2) C1-12 alkyl group which is substituted with the



same or different 1 to 5 substituents selected from



Group AU;


cyclic
C3-7 cycloalkyl group


moiety


UU


Rb
selected from the following (1) or (2):



(1) C1-3 alkyl group which may optionally be



substituted with the same or different 1 to 5



halogen atoms,



(2) cyclopropyl group,


Rc
selected from the following (1) or (2):



(1) —(CH2)n1—C(═O)—ORcc1 wherein Rcc1 is hydrogen



atom,



(2) —O—(CH2)n2—C(═O)—ORcc2 wherein Rcc2 is hydrogen



atom,


Rd
the same or different and selected from the



following (1) to (3):



(1) halogen atom,



(2) C1-6 alkyl group,



(3) C3-7 cycloalkyl group,


m
an integer selected from 0 or 1 to 3;


nu
1









Aspect 108-5:

In Aspects 108-4, Group AU consists of the following (a) to (c):


(a) —ORAU1,


(b) —C(═O)—ORAU2,


(c) —C(═O)—NRAU3RAU4;


wherein RAU1, RAU2, RAU3, RAU4 are each independently, hydrogen atom or C1-6 alkyl group.


In other preferred aspects of a compound described in [108], the following are included.


Each symbol in each formula is as defined in [108].









TABLE 54





Table 108-6









embedded image

  [III-UU-C-K-D11]








embedded image

  [III-UU-C-G-D11]








embedded image

  [III-UU-B-K-D11]








embedded image

  [III-UU-B-G-D11]

















TABLE 55





Table 108-7









embedded image

  [III-UU-C-K-D11-QB]








embedded image

  [III-UU-C-G-D11-QB]








embedded image

  [III-UU-B-K-D11-QB]








embedded image

  [III-UU-B-G-D11-QB]








embedded image

  [III-UU-C-K-D11U-QB]








embedded image

  [III-UU-C-G-D11U-QB]








embedded image

  [III-RA-C-K-D11U-QB]








embedded image

  [III-RA-C-G-D11U-QB]










Preferred examples of the combination of substituents in Tables 108-6 and 108-7 are shown below.









TABLE 56





Aspect 108-8
















Rau
selected from the following (1) or (2):



(1) C7-12 alkyl group,



(2) C1-12 alkyl group which is substituted with the



same or different 1 to 5 substituents selected from



Group AU;


Rb
selected from the following (1) or (2):



(1) C1-6 alkyl group which may optionally be



substituted with the same or different 1 to 5



halogen atoms,



(2) C3-7 cycloalkyl group which may optionally be



substituted with the same or different 1 to 5



substituents selected from the group consisting of



halogen atom and C1-6 alkyl group,


Rc
selected from the following (1) or (2):



(1) —(CH2)n1—C(═O)—ORcc1 wherein Rcc1 is hydrogen



atom,



(2) —O—(CH2)n2—C(═O)—ORcc2 wherein Rcc2 is hydrogen



atom,


Rd
the same or different and selected from the



following (1) to (3):



(1) halogen atom,



(2) C1-6 alkyl group which may optionally be



substituted with the same or different 1 to 5



substituents selected from Group B,



(3) C3-7 cycloalkyl group which may optionally be



substituted with the same or different 1 to 5



substituents selected from Group B,


m
each independently, an integer selected from 0 or 1



to 4;.









Aspect 108-9:

In the above aspect D108-8, Group AU consists of the following (a) to (b):


(a) —ORAU1,


(b) —C(═O)—ORAU2,


(c) —C(═O)—NRAU3RAU4;


wherein RAU1, RAU2, RAU3, RAU4 are each independently, hydrogen atom or C1-6 alkyl group.


In other preferred aspects of a compound described in [108], the following are included.


Each symbol in each formula is as defined in [108].









TABLE 57





Table 108-10









embedded image

  [III-UU-C-K-D11UC-QB]








embedded image

  [III-UU-C-G-D11UC-QB]








embedded image

  [III-RA-C-K-D11UC-QB]








embedded image

  [III-RA-C-G-D11UC-QB]










Aspect 108-11:

In Table 108-10, “RAU” is selected from:




embedded image


Aspect 108-12

In Aspect 108-11, “Rb” is a group selected from the following:


(1) C1-3 alkyl group which may optionally be substituted with the same or different 1 to 5 halogen atoms,


(2) cyclopropyl group.


In preferred aspects of a compound described in [108], the following compounds are included:









TABLE 58









embedded image









embedded image









embedded image









embedded image











Preferred aspects of a compound described in [109] include compounds of the following formulas.


Each symbol in each formula is as defined in [109].









TABLE 59





Table 109-1









embedded image

  [III-X-D12]








embedded image

  [III-K-D12]








embedded image

  [III-G-D12]








embedded image

  [III-K-D12-QB]








embedded image

  [III-G-D12-QB]










Preferred examples of the combination of substituents in Table 109-1 are shown below.









TABLE 60





Aspect 109-2


















Ra
selected from the following (1) to (3):




(1) C1-12 alkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group A,




(2) C3-7 cycloalkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group A,




(3) phenyl group which may optionally be substituted




with the same or different 1 to 5 substituents




selected from Group A,



Rc
Rc is selected from the following (1) to (4):




(1) —(CH2)n1—C(═O)—ORcc1,




(2) —O—(CH2)n2—C(═O)—ORcc2,




(3) —(CH2)n3-ring P,




(4) —(CH2)n4—C(═O)—NH—S(═O)2—CH3



m
an integer selected from 0 or 1 to 4



Rd
selected from the following (1) to (3):




(1) halogen atom,




(2) C1-6 alkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group B,




(3) C3-7 cycloalkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group B,

















TABLE 61





Aspect 109-3


















Ra
selected from the following (1) to (3):




(1) C1-12 alkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group A,




(2) cyclobutyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group A,




(3) phenyl group which may optionally be substituted




with the same or different 1 to 5 substituents




selected from Group A,



Rc
selected from the following (1) to (4):




(1) —(CH2)n1—C(═O)—ORcc1,




(2) —O—(CH2)n2—C(═O)—ORcc2,




(3) —(CH2)n3-ring P,




(4 ) —(CH2)n4—C(═O)—NH—S(═O)2—CH3



m
an integer selected from 0 or 1 to 3



Rd
selected from the following (1) to (3):




(1) halogen atom,




(2) C1-3 alkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group B,




(3) cyclopropyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group B,

















TABLE 62





Aspect 109-4
















Ra
selected from the following (1) to (3):



(1) C1-12 alkyl group,



(2) cyclobutyl group substituted with C1-7 alkyl



group,



(3) phenyl group substituted with C1-7 alkyl group,


Rc
selected from the following (1) to (4):



(1) —(CH2)n1—C(═O)—ORcc1 wherein Rcc1 is hydrogen atom,



(2) —O—(CH2)n2—C(═O)—ORcc2 wherein Rcc2 is hydrogen



atom,



(3) —(CH2)n3-ring P,



(4) —(CH2)n4—C(═O)—NH—S(═O)2—CH3


m
an integer selected from 0 or 1 to 3


Rd
selected from the following (1) to (3):



(1) halogen atom,



(2) C1-3 alkyl group,



(3) cyclopropyl group,









In Preferred aspects of a compound of [109], the following compounds are included:









TABLE 63









embedded image











Preferred aspects of a compound described in [110] includes compounds of the following formulas.


Each symbol in each formula is as defined in [110].









TABLE 64





Table 110-1









embedded image

  [III-X-D13]








embedded image

  [III-K-D13]








embedded image

  [III-G-D13]










Preferred examples of the combination of substituents in the above table are shown below.









TABLE 65





Aspect 110-2
















Ra
selected from the following (1) to (3):



(1) C1-12 alkyl group,



(2) cyclobutyl group substituted with C1-7 alkyl



group,



(3) phenyl group substituted with C1-7 alkyl group,


Rc
selected from the following (1) to (4):



(1) —(CH2)n1—C(═O)—ORcc1 wherein Rcc1 is hydrogen atom,



(2) —O—(CH2)n2—C(═O)—ORcc2 wherein Rcc2 is hydrogen



atom,



(3) —(CH2)n3-ring P,



(4) —(CH2)n4—C(═O)—NH—S(═O)2—CH3


m
an integer selected from 0 or 1 to 3


Rd
selected from the following (1) to (3):



(1) halogen atom,



(2) C1-3 alkyl group,



(3) cyclopropyl group,









Aspect 110-3

In Aspects 110-2, Q is phenyl group, and Re is hydrogen atom.


Preferred aspects of a compound described in [111] includes compounds of the following formulas.


Each symbol in each formula is as defined in [111].









TABLE 66





Table 111-1









embedded image

  [III-X-D1-D2H]








embedded image

  [III-X-D1-D2H]








embedded image

  [III-X-D1-D2H]








embedded image

  [III-X-D1-D-D2H]








embedded image

  [III-X-D1-D-D2H]










Preferred examples of the combination of substituents in the above table are shown below.









TABLE 67





Aspect 111-2


















Ra
selected from the following (1) to (3):




(1) C1-12 alkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group A,




(2) C3-7 cycloalkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group A,




(3) phenyl group which may optionally be substituted




with the same or different 1 to 5 substituents




selected from Group A,



Rb
selected from the following (1) or (2):




(1) C1-6 alkyl group which may optionally be




substituted with the same or different 1 to 5 halogen




atoms,




(2) C3-7 cycloalkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from the group consisting of




halogen atom and C1-6 alkyl group,



Rc
selected from the following (1) to (4):




(1) —(CH2)n1—C(═O)—ORcc1,




(2) —O—(CH2)n2—C(═O)—ORcc2,




(3) —(CH2)n3-ring P,




(4) —(CH2)n4—C(═O)—NH—S(═O)2—CH3



m
an integer selected from 0 or 1 to 4



Rd
selected from the following (1) to (3):




(1) halogen atom,




(2) C1-6 alkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group B,




(3) C3-7 cycloalkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group B,

















TABLE 68





Aspect 111-3


















Ra
selected from the following (1) to (3):




(1) C1-12 alkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group A,




(2) cyclobutyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group A,




(3) phenyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group A,



Rb
selected from the following (1) or (2):




(1) C1-6 alkyl group which may optionally be




substituted with the same or different 1 to 5




halogen atoms,




(2) C3-7 cycloalkyl group which may optionally




be substituted with the same or different 1 to 5




substituents selected from the group consisting




of halogen atom and C1-6 alkyl group,



Rc
selected from the following (1) to (4):




(1) —(CH2)n1—C(═O)—ORcc1,




(2) —O—(CH2)n2—C(═O)—ORcc2,




(3) —(CH2)n3-ring P,




(4) —(CH2)n4—C(═O)—NH—S(═O)2—CH3



m
an integer selected from 0 or 1 to 3



Rd
selected from the following (1) to (3):




(1) halogen atom,




(2) C1-3 alkyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group B,




(3) cyclopropyl group which may optionally be




substituted with the same or different 1 to 5




substituents selected from Group B,

















TABLE 69





Aspect 111-4
















Ra
selected from the following (1) to (3):



(1) C1-12 alkyl group,



(2) cyclobutyl group substituted with C1-7 alkyl



group,



(3) phenyl group substituted with C1-7 alkyl group,


Rb
selected from the following (1) or (2):



(1) C1-6 alkyl group which may optionally be



substituted with the same or different 1 to 5 halogen



atoms,



(2) C3-7 cycloalkyl group which may optionally be



substituted with the same or different 1 to 5



substituents selected from the group consisting



of halogen atom and C1-6 alkyl group,


Rc
selected from the following (1) to (4):



(1) —(CH2)n1—C(═O)—ORcc1 wherein Rcc1 is hydrogen atom,



(2) —O—(CH2)n2—C(═O)—ORcc2 wherein Rcc2 is hydrogen



atom,



(3) —(CH2)n3-ring P,



(4) —(CH2)n4—C(═O)—NH—S(═O)2—CH3


m
an integer selected from 0 or 1 to 3


Rd
selected from the following (1) to (3):



(1) halogen atom,



(2) C1-3 alkyl group,



(3) cyclopropyl group,
















TABLE 70





Table 111-5









embedded image

  [III-K-D1-D2H-NY]








embedded image

  [III-G-D1-D2H-NY]








embedded image

  [III-K-D1-D-D2H]








embedded image

  [III-G-D1-D-D2H]










Preferred examples of the combination of substituents in Table 111-5 are shown below.









TABLE 71





Aspect 111-6
















Ra
selected from the following (1) to (3):



(1) C1-12 alkyl group,



(2) cyclobutyl group substituted with C1-7 alkyl



group,



(3) phenyl group substituted with C1-7 alkyl group,


Rc
selected from the following (1) to (4):



(1) —(CH2)n1—C(═O)—ORcc1 wherein Rcc1 is hydrogen atom,



(2) —O—(CH2)n2—C(═O)—ORcc2 wherein Rcc2 is hydrogen



atom,



(3) —(CH2)n3-ring P,



(4) —(CH2)n4—C(═O)—NH—S(═O)2—CH3


m
an integer selected from 0 or 1 to 3


Rd
selected from the following (1) to (3):



(1) halogen atom,



(2) C1-3 alkyl group,



(3) cyclopropyl group,









Aspect 111-7

In Aspects 111-2, 111-3, 111-4, and 111-6,


Q is selected from the following (1) to (6):


(1) C3-7 cycloalkyl group,


(2) C9-10 fused carbocyclic group selected from the group consisting of indanyl group and 1,2,3,4-tetrahydronaphthyl group,


(3) cross-linked C5-12 cycloalkyl group,


(4) saturated heteromonocyclic group wherein the saturated heteromonocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 4 to 6-membered,


(5) unsaturated fused heterocyclic group wherein the unsaturated fused heterocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered,


(6) unsaturated heteromonocyclic group wherein the unsaturated heteromonocyclic ring has an unsaturated bond, comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 5 to 6-membered


(7) saturated fused heterocyclic group wherein the saturated fused heterocyclic ring comprises the same or different 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom, or sulfur atom besides carbon atom, and is 8 to 10-membered.


Aspect 111-8:

In Aspects 111-2, 111-3, 111-4, and 111-6,


Q is selected from the following (1) to (6):


(1) C3-7 cycloalkyl group selected from the following:




embedded image


(2) indanyl group and 1,2,3,4-tetrahydronaphthyl group;


(3) cross-linked C5-12 cycloalkyl group selected from the following:




embedded image


(4) saturated heteromonocyclic group selected from the following:




embedded image


(5) unsaturated fused heterocyclic group selected from the following:




embedded image


(6) unsaturated heteromonocyclic group selected from the following:




embedded image


In Preferred aspects of [111], the following compounds are included:









TABLE 72









embedded image









embedded image









embedded image









embedded image


















TABLE 73









embedded image









embedded image









embedded image









embedded image











“Pharmaceutically acceptable salts” may be any nontoxic salt of the present invention compound, for example, include salts formed with inorganic acid, organic acid, inorganic base, organic base, amino acid and the like.


The inorganic acid salts include for example, salts formed with hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, hydrobromic acid and the like.


The organic acid salts include for example, salts formed with oxalic acid, maleic acid, citric acid, fumaric acid, lactic acid, malic acid, succinic acid, tartaric acid, acetic acid, trifluoroacetic acid, gluconic acid, ascorbic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid and the like.


The salts formed with inorganic base include for example, sodium salt, potassium salt, calcium salt, magnesium salt, ammonium salt and the like.


Preferred examples of the salts formed with inorganic base include sodium salt.


The salts formed with organic base include for example salts formed with methylamine, ethylamine, diethylamine, trimethylamine, triethylamine, ethanolamine, diethanolamine, triethanolamine, ethylenediamine, tris(hydroxymethyl)methylamine, cyclohexylamine, dicyclohexylamine, N,N′-dibenzyl ethylenediamine, guanidine, pyridine, picoline, choline, cinchonine, meglumine and the like.


The salts formed with amino acid include for example, salts formed with lysine, arginine, aspartic acid, glutamic acid and the like.


Hereinafter, “Formula [I] and the like” refers to the general formulas which are described herein such as Formula [I], [III-X-B], [III-J-B], [III-X-C], [III-J-C], [III-X-D2], [III-J-D2], [III-X-D1], [III-J-D1], [III-X-D1-D2H], [III-X-D11], and [III-X-D12].


Such salts can be formed by reacting compounds of Formula [I] and the like with inorganic base, organic base, inorganic acid, organic acid, or amino acid by conventional methods.


The term “solvate” refers to the compounds of Formula [I] and the like or pharmaceutically acceptable salts thereof which coordinate to the solvent molecules, and also includes hydrates. Such solvates are preferably pharmaceutically acceptable solvates. Such solvate includes for example hydrate, ethanol solvate, dimethyl sulfoxide solvate and the like of compounds of Formula [I] and the like or pharmaceutically acceptable salts thereof. The specific example includes hemihydrate, monohydrate, dihydrate or mono(ethanol)solvate of compounds of Formula [I] and the like or monohydrate of sodium salt of compounds of Formula [I] and the like, 2/3 (ethanol)solvate of dihydrochloride of the same and the like. Such solvates can be produced by conventional methods.


In addition, the compounds of Formula [I] and the like may have a variety of “isomer”. For example, the compounds can exist in E or Z forms or cis or trans isomers as geometric isomers. Moreover, the compounds which have asymmetric carbon atom(s) include enantiomers and diastereomers as stereoisomers according to said asymmetric carbon atom(s). Besides, the compounds which have axial chirality include stereoisomers according to said axial chirality. In some cases, tautomer may be included. Therefore, the present invention includes all of these isomers and mixtures thereof.




embedded image


When a specific relative or absolute configuration, especially, of geometric isomer or of the asymmetric carbon atom of the alpha position from the 5-membered ring:




embedded image


is not indicated in the structural formula such as Formula [I], except as otherwise provided, the compound of the structural formula may be any theoretically available stereoisomer, and may be a mixture thereof.


The preferred aspects of a compound represented by Formula [I] include compounds of the following formula:




embedded image


When a compound of the present invention may exist as a tautomer, the compound of the present invention may be a single tautomer or a mixture of tautomers.


When a compound of the present invention has a carbon double bond, the compound of the present invention may be E form, Z form, or a mixture of E form and Z form.


When a compound of the present invention may exist as a stereoisomer which is recognized as cis/trans isomer, the compound of the present invention may be cis form, trans form, or a mixture of cis form and trans form.


When a compound of the present invention has one or more asymmetric carbons, the compound of the present invention may be a single enantiomer, a single diastereomer, a mixture of enantiomers and/or a mixture of diastereomers.


When a compound of the present invention may exist as an atropisomer, the compound of the present invention may exist as a single atropisomer or a mixture of atropisomers.


A compound of the present invention may have plurality structural features which may derive the above isomers. A compound of the present invention may comprise the above isomers in the any ratio.


When a general formula, a chemical structure, or a compound name is described herein without indicating stereochemistry, the compound includes the above possible isomers, unless otherwise designated.


A diastereomer mixture can be separated into each diastereomer by a conventional method such as chromatography and crystallization. Alternatively, a single diastereomer can be produced by using a stereochemically-single starting material or by synthesis process using a stereoselective reaction.


An enantiomer mixture can be separated into each enantiomer by using a method well-known in the art.


For example, an enantiomer mixture is reacted with a compound which is a substantially pure enantiomer (known as a chiral auxiliary) to give a diastereomer mixture, and then by using a standard technique such as fractionated crystallization or chromatography the diastereomer mixture can be separated into a single diastereomer which has a high isomeric ratio (i.e. substantially pure). The resulting single diastereomer is cleaved to remove the added chiral auxiliary to give an enantiomer of interest.


An enantiomer mixture of a compound can be directly separated by using a chromatography using a chiral stationary phase which is well-known in the art.


Further, either enantiomer of a compound can be obtained by using a substantially pure optically-active starting material, or by stereoselective synthesis (asymmetric induction) wherein a prochiral intermediate is treated with a chiral auxiliary or an asymmetric catalysis.


An absolute configuration can be determined by X-ray crystallographic analysis of a crystalline or an intermediate. The crystalline or the intermediate may be derivatized with a reagent having an asymmetric center whose configuration is known.


In addition, the compound represented by Formula [I] and the like may be labeled with one or more isotopes such as 3H, 14C, 35S and the like. Besides, the compound represented by Formula [I] and the like also includes an isotopic compound thereof wherein one or more 1H are replaced with 2H(D).


The compounds of Formula [I] and the like or pharmaceutically acceptable salts thereof are preferably purified to be substantively pure, more preferably 80% or purer.


According to the present invention, prodrugs of compounds of Formula [I] and the like may also be a useful medicine. The “prodrug” as used herein refers to derivatives of the present invention compound having a chemically or metabolically decomposable group, which show the inherent pharmaceutical activity upon hydrolysis, solvolysis, or other decompositions under physiological conditions in vivo, and may also be a complex connected with bonds other than covalent bonds or a salt. Prodrugs can be used for example, for improving absorption of oral administration or targeting the object site. A modified site includes highly reactive functional groups in the present invention compounds, such as hydroxyl group, carboxyl group, amino group, thiol group and the like.


The group that modifies the hydroxyl group includes specifically acetyl group, propionyl group, isobutyryl group, pivaloyl group, palmitoyl group, benzoyl group, 4-methylbenzoyl group, dimethylcarbamoyl group, dimethylaminomethylcarbonyl group, sulfo group, alanyl group, fumary group and the like. In addition, 3-(sodium carboxylate)benzoyl group, 2-(sodium carboxylate)ethylcarbonyl group and the like are also included.


The group that modifies the carboxyl group includes specifically methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, tert-butyl group, pivaloyloxymethyl group, carboxymethyl group, dimethylaminomethyl group, 1-(acetyloxy)ethyl group, 1-(ethoxycarbonyloxy)ethyl group, 1-(isopropyloxycarbonyloxy)ethyl group, 1-(cyclohexyloxycarbonyloxy)ethyl group, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl group, benzyl group, phenyl group, o-tolyl group, morpholinoethyl group, N,N-diethylcarbamoylmethyl group, phthalidyl group and the like.


The group that modifies the amino group includes specifically tert-butyl group, docosanoyl group, pivaloylmethyloxy group, alanyl group, hexylcarbamoyl group, pentylcarbamoyl group, 3-methylthio-1-(acetylamino)propylcarbonyl group, 1-sulfo-1-(3-ethoxy-4-hydroxyphenyl)methyl group, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl group, (5-methyl-2-oxo-1,3-dioxol-4-yl)methoxycarbonyl group, tetrahydrofuranyl group, pyrrolidylmethyl group and the like.


The term “pharmaceutical composition” includes a mixture comprising one or more active ingredients and one or more pharmaceutically acceptable carriers, for example, oral preparations such as tablet, capsule, granule, powder, troche, syrup, emulsion suspension and the like or parenteral preparations such as external preparation, suppository, injection, eye drop, a preparation for transnasal administration and a preparation for lung administration and the like.


Pharmaceutical compositions of the present invention can be prepared by mixing suitably the compounds of Formula [I] and the like or pharmaceutically acceptable salts thereof with at least one pharmaceutically acceptable carrier and the like, by conventional methods in the art of medicinal preparations. Content rate of the compounds of Formula [I] and the like or pharmaceutically acceptable salts thereof in the pharmaceutical composition includes for example, 0.1 to 100%, preferably 0.1 to 70% by weight in the composition while it varies depending on dosage forms, dosage amounts and the like.


The term “pharmaceutically acceptable carriers” includes all sorts of organic or inorganic carriers which are commonly-used as a material for drug formulations, such as excipient, disintegrant, binder, fluidizer, lubricant and the like for solid preparations and solvent, solubilizing agent, suspending agent, tonicity agent, buffering agent, soothing agent and the like for liquid preparations. Such preparations may employ further additives such as preservative, antioxidant, colorant, sweetening agent and the like as necessary.


The term “excipient” includes for example, lactose, white soft sugar, D-mannitol, D-sorbitol, cornstarch, dextrin, microcrystalline cellulose, crystalline cellulose, carmellose, carmellose calcium, sodium carboxymethylstarch, low substituted hydroxypropylcellulose, gum arabic and the like.


The term “disintegrant” includes for example, carmellose, carmellose calcium, carmellose sodium, sodium carboxymethylstarch, croscarmellose sodium, crospovidone, low substituted hydroxypropylcellulose, hydroxypropylmethylcellulose, crystalline cellulose and the like.


The term “binder” includes for example, hydroxypropylcellulose, hydroxypropylmethylcellulose, povidone, crystalline cellulose, white soft sugar, dextrin, starch, gelatin, carmellose sodium, gum arabic and the like.


The term “fluidizer” includes for example, light anhydrous silicic acid, magnesium stearate and the like.


The term “lubricant” includes for example, magnesium stearate, calcium stearate, talc and the like.


The term “solvent” includes for example, purified water, ethanol, propyleneglycol, macrogol, sesame oil, corn oil, olive oil and the like.


The term “solubilizing agent” includes for example, propyleneglycol, D-mannitol, benzyl benzoate, ethanol, triethanolamine, sodium carbonate, sodium citrate and the like.


The term “suspending agent” includes for example, benzalkonium chloride, carmellose, hydroxypropylcellulose, propyleneglycol, povidone, methylcellulose, glyceryl monostearate and the like.


The term “tonicity agent” includes for example, glucose, D-sorbitol, sodium chloride, D-mannitol and the like.


The term “buffering agent” includes for example, disodium hydrogen phosphate, sodium acetate, sodium carbonate, sodium citrate and the like.


The term “soothing agent” includes for example, benzyl alcohol and the like.


The term “preservative” includes for example, methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, chlorobutanol, benzyl alcohol, sodium dehydroacetate, sorbic acid and the like.


The term “antioxidant” includes for example, sodium sulfite, ascorbic acid and the like.


The term “colorant” includes for example, food dye such as Food Red No. 2 and No. 3, Food Yellow No. 4 and No. 5 and the like, β-carotene and the like.


The term “sweetening agent” includes for example saccharin sodium, dipotassium glycyrrhizate, aspartame and the like.


The pharmaceutical compositions of the present invention can be administered to human as well as mammals other than human such as mice, rat, hamster, guinea pig, rabbit, cat, dog, pig, cattle, horse, sheep, monkey and the like orally or parenterally such as locally, rectally and intravenously. While the dosage amount may vary depending on subject, disease, symptom, dosage form, route of administration and the like, for example when it is administered orally to an adult patient with autoimmune disease, allergic disease, dry eye, fibrosis, or metabolic disease (body weight: about 60 kg) the dosage amount of the present invention compound of an active ingredient ranges generally from about 1 mg to about 1 g per day, which can be administered once to several times.


The compounds of Formula [I] and the like or pharmaceutically acceptable salts thereof can inhibit RORγ, thereby they can be used as an active ingredient for treating or preventing a disease such as autoimmune disease such as rheumatoid arthritis, psoriasis, inflammatory bowel disease such as Crohn's disease and ulcerative colitis, multiple sclerosis, systemic lupus erythematosus, ankylosing spondylitis, uveitis, polymyalgia rheumatica, and type I diabetes; allergic disease such as asthma; dry eye; fibrosis; and metabolic disease such as diabetes.


“Inhibit RORγ” means that a function of RORγ is inhibited to make the activity thereof disappear or reduced. It includes, for example, the function of RORγ is inhibited according to Biological assay 1 described hereafter.


The preferred aspect of “Inhibit RORγ” includes “Inhibit human RORγ”.


The compounds of Formula [I] and the like or pharmaceutically acceptable salts thereof can be used in combination with other one or more medicament (hereinafter called additional medicament(s)) according to methods commonly used in the art of medicine, which is hereinafter called combination use.


The timing of administration of the compounds of Formula [I] and the like or pharmaceutically acceptable salts thereof and additional medicament(s) is not limited and they may be administered to a subject in a form of combination drug or may be administered simultaneously or at regular intervals. In addition, the compounds of Formula [I] and the like or pharmaceutically acceptable salts thereof may be used as a kit comprising the pharmaceutical composition of the present invention and additional medicament(s).


The dosage amount of the additional medicament(s) may follow one employed in clinical practice, and may be determined appropriately depending on subject, disease, symptom, dosage form, route of administration, timing of administration, combination and the like. The mode of additional medicament(s) is not limited as long as the present invention compounds or salts thereof and the additional medicament(s) are combined.


The additional medicament(s) include for example,


(1) a medicament for treating or preventing autoimmune disease such as rheumatoid arthritis, psoriasis, inflammatory bowel disease such as Crohn's disease and ulcerative colitis, multiple sclerosis, systemic lupus erythematosus, ankylosing spondylitis, uveitis, polymyalgia rheumatica, and type I diabetes;


(2) a medicament for treating or preventing allergic disease such as asthma;


(3) a medicament for treating or preventing metabolic disease such as diabetes;


(4) a medicament for treating or preventing dry eye; and


(5) a medicament for treating or preventing fibrosis.


One to three medicament selected from the above (1) to (5) may be employed in combination with the compounds of Formula [I] and the like or pharmaceutically acceptable salts thereof.


The medicament for treating or preventing autoimmune disease includes, for example, methotrexate to treat or prevent rheumatoid arthritis, and ciclosporin A and methotrexate to treat or prevent psoriasis.


Next, some examples of processes for preparing the compound of the present invention described in the above [01] to [31] are shown as follows. However, the processes for preparing the present invention compound should not be limited thereto.


It is possible to modify the processes to carry out the preparation more effectively, for example, introducing a protecting group into a functional group followed by deprotecting it in a subsequent step; using a precursor having a functional group in a step followed by converting it to the desired functional group in a subsequent step; exchanging the order of preparation methods or steps thereof, even though not mentioned in these examples.


The workup after the reaction in each step can be carried out by a commonly-used method, wherein the isolation and purification may be carried out by a conventional method selected from crystallization, recrystallization, distillation, separating, silicagel chromatography, preparative HPLC and the like, or a combination thereof, as appropriate.


A racemic form of the compound can be obtained by using an achiral compound as a material, ligand, or reagent, or by mixing of enantiomers.


The following abbreviations are used in the preparation methods and Examples herein:

  • tert-butyldimethylsilyl group (TBDMS)
  • tert-butyldiphenylsilyl group (TBDPS)
  • tert-butoxycarbonyl group (Boc)
  • benzyl group (Bn)
  • phenyl group (Ph)
  • n-butyl group (nBu)
  • tert-butyl group (tBu)
  • isopropyl group (iPr)
  • ethyl group (Et)
  • methyl group (Me)
  • N,N-diisopropylethylamine (DIPEA)
  • lithium diisopropylamide (LDA)
  • diisobutylaluminium hydride (DIBAL)
  • 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (WSC.HCl)
  • 1-hydroxy-1H-benzotriazole monohydrate (HOBt.H2O)
  • O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU)
  • tetrabutylammonium fluoride (TBAF)
  • 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU)
  • trifluoroacetic acid (TFA)
  • trifluoroacetic anhydride (TFAA)
  • Dess-Martin reagent (DMP)
  • lithium hexamethyldisilazide (LHMDS)
  • 4-dimethylaminopyridine (DMAP)
  • 2,2,6,6-tetramethyl-1-piperidinyloxy radical (TEMPO)
  • 2-azaadamantane-N-oxyl (AZADO)
  • (diethylamino)sulfur trifluoride (DAST)
  • bis(2-methoxyethyl)aminosulfur trifluoride (Deoxo-Fluor (registered trademark))
  • 1,1′-bis(diphenylphosphino)ferrocene (dppf)
  • dimethyl sulfoxide (DMSO)
  • N,N-dimethylformamide (DMF)
  • tetrahydrofuran (THF)
  • N,N-dimethylacetamide (DMA)
  • hexamethylphosphoric triamide (HMPA)
  • enantiomer excess (ee)
  • room temperature (rt)
  • high-performance liquid chromatography (HPLC)


In the following schemes,


“X” is a leaving group such as halogen atom, trifluoromethanesulfonyloxy group and the like, preferably bromo group, and iodine group;


“PN1” is a protecting group for amine, and includes for example, tert-butoxycarbonyl group, benzyloxycarbonyl group and the like, preferably tert-butoxycarbonyl group.


“PO” and “PO1” is a protecting group for hydroxyl group, and includes for example, tert-butyldimethylsilyl group, tert-butyldiphenylsilyl group, acetyl group, benzyl group and the like, preferably tert-butyldimethylsilyl group, tert-butyldiphenylsilyl group, and benzyl group.


“PC” is a protecting group for carboxyl group, and includes for example, methyl group, ethyl group, tert-butyl group, benzyl group and the like, preferably methyl group, tert-butyl group, and benzyl group.


“AUX-H” is a chiral auxiliary reagent, and includes for example (R)-4-benzyl-2-oxazolidinone, (S)-4-benzyl-2-oxazolidinone, (R)-4-isopropyl-2-oxazolidinone, (S)-4-isopropyl-2-oxazolidinone, (4S,5R)-4-methyl-5-phenyl-2-oxazolidinone, (4R,5S)-4-methyl-5-phenyl-2-oxazolidinone and the like, preferably (R)-4-benzyl-2-oxazolidinone, (S)-4-benzyl-2-oxazolidinone.


“AUX” is a chiral auxiliary group.


“Q” is a group comprising boron, magnesium, zinc, tin or the like, and includes for example, boronic acid, dialkoxyboron, halogeno magnesium, halogeno zinc, and trialkyltin.


Unless otherwise instructed, each symbol is as defined in the above [01].


Preparation Method 1



embedded image


(In the formula [I], Rc is hydrogen atom.)


Each step in Preparation method 1 is explained as follows.


(Step 1)


Compound [Y-11] can be obtained from Compound [Y-10] in a solvent under the acidic condition of ester hydrolysis reaction.


Examples of the acid for the reaction include hydrochloric acid, hydrobromic acid, sulfuric acid, trifluoroacetic acid. The preferred acid for the reaction includes hydrochloric acid, hydrobromic acid, trifluoroacetic acid.


Examples of the solvent for the reaction include hydrocarbon solvent such as benzene, toluene, xylene, and hexane; halogenated solvent such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane; ethers solvent such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, and diglyme; esters solvent such as ethyl acetate, methyl acetate, and butyl acetate; polar solvent such as acetic acid and water. Preferred examples of the solvent for the reaction include dichloromethane, chloroform, toluene, acetic acid, and water.


The reaction temperature usually ranges about 0° C. to 120° C., preferably from room temperature to 100° C.


The reaction time usually ranges about 10 minutes to 3 days, preferably about 30 minutes to 1 day.


(Step 2)


Compound [Y-13] can be obtained by reacting Compound [Y-11] with [Y-12] under a commonly-used amide bond formation reaction. For example, Compound [Y-13] can be obtained by reacting Compound [Y-11] with [Y-12] in the presence of a condensation reagent in a solvent.


Examples of the solvent for the reaction include hydrocarbon solvent such as benzene and toluene; halogenated solvent such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane; ethers solvent such as tetrahydrofuran, dioxane, and 1,2-dimethoxyethane; polar solvent such as N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, and acetone; which may be used alone or as a mixture of two or more. Preferred examples of the solvent for the reaction include dichloromethane, chloroform, and N,N-dimethylformamide.


Examples of the condensation reagent for the reaction include water-soluble carbodiimide (WSC.HCl: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride), N,N′-dicyclohexylcarbodiimide (DCC), diphenylphosphoryl azide (DPPA), carbonyldiimidazole (CDI), and O-(7-azabenzotriazol-1-yl)-N,N,N′,N′,-tetramethyluronium hexafluorophosphate (HATU). As necessary, 1-hydroxy-1H-benzotriazole monohydrate (HOBt.H2O), 4-dimethylaminopyridine (DMAP), N,N-diisopropylethylamine, and the like may be added. Preferred examples of the condensation reagent include a mixture of water-soluble carbodiimide (WSC.HCl: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride) and 1-hydroxy-1H-benzotriazole monohydrate (HOBt.H2O) and a mixture of O-(7-azabenzotriazol-1-yl)-N,N,N′,N′,-tetramethyluronium hexafluorophosphate (HATU) and N,N-diisopropylethylamine.


The reaction temperature usually ranges about 0° C. to 120° C., preferably from room temperature to 100° C.


The reaction time usually ranges about 30 minutes to 3 days, preferably about 1 hr to 1 day.


Alternatively, in the above amidation reaction, Compound [Y-13] can be prepared by the reaction of an acid halide or mixed acid anhydride of Compound [Y-11] with Compound [Y-12].


The acid halide of Compound [Y-11] can be derived by the reaction of a carboxylic acid of Compound [Y-11] with thionyl chloride, oxalyl chloride etc. wherein a catalytic amount of N,N-dimethylformamide may be added.


The mixed acid anhydride of Compound [Y-11] can be derived by the reaction of a carboxylic acid of Compound [Y-11] with ethyl chlorocarbonate etc.


(Step 3)


Compound [Y-14] can be obtained by removal of the protecting group PO from Compound [Y-13] in a solvent.


When the protecting group PO is benzyl group, the protecting group may be removed by a reaction in the presence of Lewis acid.


Examples of Lewis acid for the reaction include boron tribromide, boron trichloride, and trimethylsilyl iodide.


Preferred examples of Lewis acid for the reaction include boron tribromide.


Examples of the solvent for the reaction include hydrocarbon solvent such as benzene, toluene, xylene, and hexane; halogenated solvent such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane; which may be used alone or as a mixture of two or more. Preferred examples of the solvent for the reaction include dichloromethane and chloroform.


The reaction temperature usually ranges about −78° C. to 50° C., preferably about −78° C. to room temperature.


The reaction time usually ranges about 30 minutes to 3 days, preferably about 1 hr to 1 day.


(Step 4)


Compound [I] (Rc═H) can be obtained by the reaction of Compound [Y-14] in the presence of an oxidant in a solvent.


Examples of the oxidant for the reaction include 2,2,6,6-tetramethyl-1-piperidinyloxy radical (TEMPO), sodium hypochlorite, sodium chlorite, potassium permanganate, aqueous hydrogen peroxide, pyridinium dichromate, and chromium oxide. Preferred examples of the oxidant for the reaction include a mixture of 2,2,6,6-tetramethyl-1-piperidinyloxy radical (TEMPO), sodium hypochlorite, and sodium chlorite.


Examples of the solvent for the reaction include halogenated solvent such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane; ethers solvent such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, and diglyme; polar solvent such as acetonitrile, acetone, and water; which may be used alone or as a mixture of two or more. Preferred examples of the solvent for the reaction include acetonitrile and water.


The reaction temperature usually ranges about −10° C. to 150° C., preferably about 0° C. to 80° C.


The reaction time usually ranges about 30 minutes to 5 days, preferably about 1 hr to 1 day.


(Step 5) Salt Formation Reaction


According to conventional methods, each salt can be obtained by reacting a compound represented by Formula [I] wherein Rc is hydrogen atom with an inorganic base. For example, carboxylic acid [I] wherein Rc is hydrogen atom is reacted with aqueous sodium hydroxide in a alcohol solvent at room temperature to give the sodium salt.


Preparation Method 2

The compound wherein




embedded image


is




embedded image


and




embedded image


is




embedded image


specifically, a compound of the following [II-A]:




embedded image


wherein na is 1 or 2, and Rc is hydrogen atom.


Preparation Method 2A-1



embedded image


embedded image


(Step 1)


Compound [Y-17] can be obtained by reacting Compound [Y-15] with AUX-H[Y-16] in the presence of a condensation reagent in a solvent.


Examples of the solvent for the reaction include hydrocarbon solvent such as benzene, toluene, xylene, and hexane; halogenated solvent such as dichloromethane and chloroform; ethers solvent such as tetrahydrofuran, dioxane, and 1,2-dimethoxyethane; polar solvent such as N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, and acetone; which may be used alone or as a mixture of two or more. Preferred examples of the solvent for the reaction include N,N-dimethylformamide and acetonitrile.


Examples of the condensation reagent for the reaction include water-soluble carbodiimide (WSC.HCl: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride), N,N′-dicyclohexylcarbodiimide (DCC), diphenylphosphoryl azide (DPPA), and carbonyldiimidazole (CDI). As necessary, 1-hydroxy-1H-benzotriazole monohydrate (HOBt.H2O), 4-dimethylaminopyridine (DMAP), and the like may be added. Preferred examples of the condensation reagent include a mixture of water-soluble carbodiimide (WSC.HCl: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride) and 4-dimethylaminopyridine (DMAP).


The reaction temperature usually ranges about room temperature to 120° C., preferably from room temperature to 80° C.


The reaction time usually ranges about 30 minutes to 3 days, preferably about 1 hr to 1 day.


Example of AUX-H



embedded image


(Step 2)


Compound [Y-19] can be obtained by reacting Compound [Y-17] with [Y-18] in the presence of a base in a solvent.


Examples of the solvent for the reaction include hydrocarbon solvent such as benzene, toluene, xylene, and hexane; ethers solvent such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, and diglyme; which may be used alone or as a mixture of two or more.


Preferred examples of the solvent for the reaction include tetrahydrofuran.


Examples of the base for the reaction include sodium hexamethyldisilazide, lithium hexamethyldisilazide, and lithium diisopropylamide (LDA). Preferred examples of the base for the reaction include sodium hexamethyldisilazide.


The reaction temperature usually ranges about −78° C. to 50° C., preferably about −78° C. to room temperature.


The reaction time usually ranges about 30 minutes to 3 days, preferably about 30 minutes to 1 day.


(Step 3)


Compound [Y-20] can be obtained by hydrolysis reaction of Compound [Y-19] in a solvent.


The hydrolysis reaction may be performed under the commonly-used condition, for example, under the alkaline condition.


Examples of the base for the reaction include an aqueous solution of alkali metal hydroxide such as lithium hydroxide, sodium hydroxide, and potassium hydroxide; inorganic peroxide such as lithium peroxide, potassium peroxide, and sodium peroxide. Preferred examples of the base for the reaction include lithium peroxide. Examples of the solvent for the reaction include hydrocarbon solvent such as benzene, toluene, xylene, and hexane; alcohols solvent such as methanol, ethanol, isopropyl alcohol, and tert-butanol; halogenated solvent such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane; ethers solvent such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, and diglyme; polar solvent such as N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, acetone, and water; which may be used alone or as a mixture of two or more. Preferred examples of the solvent for the reaction include tetrahydrofuran and water.


The reaction temperature usually ranges about −30° C. to 80° C., preferably about 0° C. to room temperature.


The reaction time usually ranges about 30 minutes to 3 days, preferably about 30 minutes to 1 day.


(Purification Process)


An optical purity of Compound [Y-20] can be increased by a method such as the preferential crystallization and the diastereomer method in a solvent.


Preferred examples of amine for the crystallization include (R)-1-phenyl-ethylamine.


Examples of the solvent for the crystallization include esters solvent such as isopropyl acetate and n-butyl acetate; ethers solvent such as methyl-tert-butylether; ketone solvent such as methyl isobutyl ketone; which may be used alone or as a mixture of two or more. Preferred examples of the solvent for the reaction include methyl-tert-butylether.


Then, demineralization is performed with by using hydrochloric acid, potassium hydrogen sulfate etc.


An example of the steps from the Step 1 to the above purification process is following.


(R)-4-benzyl-2-oxazolidinone is used as AUX-H [Y-16], and (R)-1-phenyl-ethylamine is used as the amine in the purification process.


A case where an enantiomer is synthesized, (S)-4-benzyl-2-oxazolidinone may used instead of (R)-4-benzyl-2-oxazolidinone.


Example of [Y-20]



embedded image


(Step 4)


Compound [Y-21] can be obtained by reacting Compound [Y-20] with N,O-dimethylhydroxylamine or a hydrochloride salt thereof in the presence of a condensation reagent in a solvent.


Examples of the solvent for the reaction include hydrocarbon solvent such as benzene, toluene, xylene, and hexane; halogenated solvent such as dichloromethane and chloroform; ethers solvent such as tetrahydrofuran, dioxane, and 1,2-dimethoxyethane; polar solvent such as N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, and acetone; which may be used alone or as a mixture of two or more. Preferred examples of the solvent for the reaction include N,N-dimethylformamide, and acetonitrile.


Examples of the condensation reagent for the reaction include water-soluble carbodiimide (WSC.HCl: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride), N,N′-dicyclohexylcarbodiimide (DCC), diphenylphosphoryl azide (DPPA), and carbonyldiimidazole (CDI). As necessary, 1-hydroxy-1H-benzotriazole monohydrate (HOBt.H2O), 4-dimethylaminopyridine (DMAP), and the like may be added. Preferred examples of the condensation reagent include a mixture of water-soluble carbodiimide (WSC.HCl: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride) and 1-hydroxy-1H-benzotriazole monohydrate (HOBt.H2O).


The reaction temperature usually ranges about room temperature to 120° C., preferably room temperature to 80° C.


The reaction time usually ranges about 30 minutes to 3 days, preferably about 1 hr to 1 day.


(Step 5)


Compound [Y-22] can be obtained by reacting Compound [Y-21] in the presence of a reducing agent in a solvent.


Examples of the solvent for the reaction include hydrocarbon solvent such as benzene, toluene, xylene, and hexane; halogenated solvent such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane; ethers solvent such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, and diglyme; which may be used alone or as a mixture of two or more. Preferred examples of the solvent for the reaction include toluene, dichloromethane, chloroform, hexane, and tetrahydrofuran.


Examples of the reducing agent for the reaction include diisobutylaluminium hydride and lithium aluminium hydride. Preferred examples of the reducing agent include diisobutylaluminium hydride.


The reaction temperature usually ranges about −78° C. to room temperature, preferably about −78° C. to 0° C.


The reaction time usually ranges about 30 minutes to 3 days, preferably about 1 hr to 1 day.


(Step 6)


Compound [Y-23] can be obtained by reacting Compound [Y-22] with hydroxylamine or a hydrochloride salt thereof in a solvent.


Examples of the solvent for the reaction include hydrocarbon solvent such as benzene, toluene, xylene, and hexane; ethers solvent such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, and diglyme; polar solvent such as methanol, ethanol, acetonitrile, and water; which may be used alone or as a mixture of two or more. Preferred examples of the solvent for the reaction include toluene, ethanol, tetrahydrofuran, and water.


When the hydrochloride salt of hydroxylamine is used, examples of the base for the reaction include pyridine, triethylamine, sodium hydroxide, sodium acetate, potassium carbonate, sodium carbonate, and sodium hydrogen carbonate. Preferred examples of the base for the reaction include sodium hydroxide.


The reaction temperature usually ranges about −10° C. to 130° C., preferably about 0° C. to room temperature.


The reaction time usually ranges about 30 minutes to 3 days, preferably about 1 hr to 1 day.


(Step 7)


Compound [Y-24] can be obtained by reacting Compound [Y-23] in the presence of a chlorinating agent in a solvent.


Examples of the solvent for the reaction include halogenated solvent such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane; polar solvent such as N,N-dimethylformamide and acetic acid; which may be used alone or as a mixture of two or more. Preferred examples of the solvent for the reaction include N,N-dimethylformamide.


Examples of the halogenating agent for the reaction include chlorine and N-chlorosuccinimide. Preferred examples of the for the reaction include chlorinating agent include N-chlorosuccinimide.


The reaction temperature usually ranges about −10° C. to 100° C., preferably about 0° C. to 60° C.


The reaction time usually ranges about 30 minutes to 3 days, preferably about 1 hr to 1 day.


Preparation Method 2A-2



embedded image


embedded image


wherein na is 1.


(Step 1)


Compound [Y-26] can be obtained by reacting Compound [Y-24] with propargyl alcohol [Y-25] in the presence of a base in a solvent.


Examples of the solvent for the reaction include hydrocarbon solvent such as benzene, toluene, xylene, and hexane; ethers solvent such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, and diglyme; water; which may be used alone or as a mixture of two or more. Preferred examples of the solvent for the reaction include toluene, and water.


Examples of the base for the reaction include triethylamine, sodium hydroxide, potassium carbonate, sodium carbonate, and sodium hydrogen carbonate. Preferred examples of the base for the reaction include potassium carbonate.


The reaction temperature usually ranges about 0° C. to 150° C., preferably from room temperature to 100° C.


The reaction time usually ranges about 30 minutes to 3 days, preferably about 1 hr to 1 day.


(Step 2)


Compound [Y-27] can be obtained by reacting Compound [Y-26] in the presence of a halogenating agent in a solvent.


Examples of the solvent for the reaction include halogenated solvent such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane; polar solvent such as N,N-dimethylformamide and acetic acid; which may be used alone or as a mixture of two or more. Preferred examples of the solvent for the reaction include N,N-dimethylformamide, and acetonitrile.


Examples of the halogenating agent for the reaction include bromine, iodine, iodine monochloride, N-bromosuccinimide, N-iodosuccinimide, and 1,3-dibromo-5,5-dimethylhydantoin. As necessary, cerium(IV) diammonium nitrate, trifluoroacetic acid, and the like may be added. Preferred examples of the halogenating agent for the reaction include a mixture of N-iodosuccinimide and cerium(IV) diammonium nitrate.


The reaction temperature usually ranges about −10° C. to 100° C., preferably about 0° C. to 50° C.


The reaction time usually ranges about 1 hr to 3 days, preferably about 3 hrs to 1 day.


(Step 3)


Compound [Y-28] can be obtained by the reaction of Compound [Y-27] in the presence of an oxidant in a solvent.


Examples of the oxidant for the reaction include 2,2,6,6-tetramethyl-1-piperidinyloxy radical (TEMPO), manganese dioxide, Dess-Martin reagent (DMP), and sulfur trioxide-pyridine complex. Preferred examples of the oxidant for the reaction include Dess-Martin reagent (DMP).


Examples of the solvent for the reaction include hydrocarbon solvent such as benzene, toluene, xylene, and hexane; halogenated solvent such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane; ethers solvent such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, and diglyme; polar solvent such as acetonitrile, acetone, and water; which may be used alone or as a mixture of two or more. Preferred examples of the solvent for the reaction include dichloromethane and chloroform.


The reaction temperature usually ranges about −78° C. to 80° C., preferably about 0° C. to room temperature.


The reaction time usually ranges about 10 minutes to 1 day, preferably about 10 minutes to 5 hrs.


(Step 4)


Compound [Y-29] can be obtained by reacting Compound [Y-28] with hydroxylamine or a hydrochloride salt thereof in a solvent.


The solvent, the reactant, the reaction temperature, the reaction time, for the reaction, are similar to those of Step 6 of Preparation method 2A-1.


(Step 5)


Compound [Y-30] can be obtained by reacting Compound [Y-29] in the presence of a chlorinating agent in a solvent.


The solvent, the reactant, the reaction temperature, and the reaction time, for the reaction are similar to those of Step 7 of Preparation method 2A-1.


(Step 6)


Compound [Y-32] can be obtained by reacting Compound [Y-30] with [Y-31] in the presence of a base in a solvent.


The solvent, the base, the reaction temperature, the reaction time, for the reaction, are similar to those of Step 1 of Preparation method 2A-2.


(Step 7)


Compound [Y-34] can be obtained by reacting Compound [Y-32] with Compound [Y-33] in the presence of a metal catalyst in a solvent.


As the Compound [Y-33], alkylboronic acid, alkylboronic acid ester, alkylzinc reagent, alkylmagnesium reagent, and the like may be used, preferably alkylboronic acid ester may be used.


Examples of the solvent for the reaction include hydrocarbon solvent such as benzene, toluene, xylene, and hexane; ethers solvent such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, and diglyme; polar solvent such as N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, acetone, and water; which may be used alone or as a mixture of two or more. Preferred examples of the solvent for the reaction include N,N-dimethylformamide.


Examples of the metal catalyst for the reaction include a palladium catalyst such as bis(triphenylphosphine)palladium(II) dichloride and 1,1′-bis(diphenylphosphino)ferrocene-palladium(II) dichloride; a nickel catalyst such as [1,2-bis(diphenylphosphino)ethane]nickel(II) dichloride and nickel(II) acetylacetonate; and an iron catalyst such as iron(III) chloride. Preferred examples of the metal catalyst include bis(triphenylphosphine)palladium(II) dichloride.


As necessary, a base or an inorganic salt may be added. Examples of the base or the inorganic salt for the reaction include alkali metal phosphate such as tripotassium phosphate; alkali metal carbonate such as sodium carbonate and potassium carbonate; alkali metal acetate such as sodium acetate; and fluoride salt such as cesium fluoride, preferred examples include preferably tripotassium phosphate.


The reaction temperature usually ranges about −10° C. to 150° C., preferably about 0° C. to 120° C.


The reaction time usually ranges about 30 minutes to 3 days, preferably about 1 hr to 1 day.


(Step 6A)


Example of reaction process of the compound wherein Ra1 is halogen atom:




embedded image


wherein Ra10 together with the —CF2— forms Ra1.


(Step 6A-1)


Compound [Y-36] can be obtained by reacting Compound [Y-30] with [Y-35] in the presence of a base in a solvent.


The solvent, the base, the reaction temperature, the reaction time, for the reaction, are similar to those of Step 6 of Preparation method 2A-2.


(Step 6A-2)


Compound [Y-37] can be obtained by the reaction of Compound [Y-36] in the presence of an oxidant in a solvent.


Examples of the oxidant for the reaction include 2-azaadamantane-N-oxyl (AZADO), 2,2,6,6-tetramethyl-1-piperidinyloxy radical (TEMPO), manganese dioxide, Dess-Martin reagent, and sulfur trioxide-pyridine complex. Preferred examples of the oxidant for the reaction include Dess-Martin reagent.


Examples of the solvent for the reaction include hydrocarbon solvent such as benzene, toluene, xylene, and hexane; halogenated solvent such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane; ethers solvent such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, and diglyme; water; which may be used alone or as a mixture of two or more. Preferred examples of the solvent for the reaction include dichloromethane and chloroform.


The reaction temperature usually ranges about −78° C. to 80° C., preferably about 0° C. to room temperature.


The reaction time usually ranges about 10 minutes to 3 days, preferably about 30 minutes to 1 day.


(Step 6A-3)


Compound [Y-38] can be obtained by reacting Compound [Y-37] with a fluorinating agent.


Examples of the fluorinating agent for the reaction include (diethylamino)sulfur trifluoride (CAST), and bis(2-methoxyethyl)aminosulfur trifluoride (Deoxo-Fluor (registered trademark)). Preferred examples of the fluorinating agent for the reaction include bis(2-methoxyethyl)aminosulfur trifluoride (Deoxo-Fluor (registered trademark)).


The reaction temperature usually ranges about −10° C. to 120° C., preferably from room temperature to 100° C.


The reaction time usually ranges about 30 minutes to 3 days, preferably about 1 hr to 1 day.


Preparation Method 2A-3

Preparation Method of Compound [Y-34] through Compound [Y-39]:




embedded image


Compound [Y-34] can also be prepared by obtaining Compound [Y-39] from Compound [Y-27].


(Step 1)


Compound [Y-39] can be obtained by reacting Compound [Y-27] with Compound [Y-33] in the presence of a metal catalyst in a solvent.


The solvent, the reactant, the reaction temperature, and the reaction time, for the reaction, are similar to those of Step 7 of Preparation method 2A-2.


(Step 2 and the Following Steps)


Compound [Y-34] can be obtained from Compound [Y-39] by oxidation (Step 2), oximation (Step 3), chlorination (Step 4), and isoxazole cyclization (Step 5).


The solvent, the reactant, the reaction temperature, and the reaction time, for the reaction, are similar to those of Steps 3 to 6 of Preparation method 2A-2.


Preparation Method 2B-1



embedded image


(Step 1)


Compound [Y-41] can be obtained by reacting Compound [Y-40] with N,O-dimethylhydroxylamine or a hydrochloride salt thereof in the presence of a condensation reagent in a solvent.


The solvent, the reactant, the reaction temperature, and the reaction time, for the reaction, are similar to those of Step 4 of Preparation method 2A-1.


(Step 2)


Compound [Y-42] can be obtained by reacting Compound [Y-41] in the presence of a reducing agent in a solvent.


The solvent, the reactant, the reaction temperature, and the reaction time, for the reaction, are similar to those of Step 5 of Preparation method 2A-1.


(Step 3)


Compound [Y-43] can be obtained by reacting Compound [Y-42] in the presence of carbon tetrabromide and triphenylphosphine in a solvent.


Examples of the solvent for the reaction include hydrocarbon solvent such as benzene, toluene, xylene, and hexane; halogenated solvent such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane; ethers solvent such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, and diglyme; which may be used alone or as a mixture of two or more. Preferred examples of the solvent for the reaction include toluene and dichloromethane.


The reaction temperature usually ranges about −30° C. to 100° C., preferably about −10° C. to room temperature.


The reaction time usually ranges about 30 minutes to 3 days, preferably about 30 minutes to 1 day.


Preparation Method 2B-2



embedded image


(Step 1)


Compound [Y-44] can be obtained by reacting Compound [Y-43] with Compound [Y-21] in the presence of a base in a solvent.


Examples of the solvent for the reaction include hydrocarbon solvent such as benzene, toluene, xylene, and hexane; halogenated solvent such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane; ethers solvent such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, and diglyme; which may be used alone or as a mixture of two or more. Preferred examples of the solvent for the reaction include tetrahydrofuran, toluene, and hexane.


Examples of the base for the reaction include n-butyllithium, methyllithium, ethylmagnesium bromide, and lithium diisopropylamide (LDA). Preferred examples of the base for the reaction include n-butyllithium.


The reaction temperature usually ranges about −78° C. to 50° C., preferably about −78° C. to room temperature.


The reaction time usually ranges about 30 minutes to 3 days, preferably about 1 hr to 1 day.


(Step 2)


Compound [Y-45] can be obtained by reacting Compound [Y-44] with O-methylhydroxylamine or a hydrochloride salt thereof in a solvent.


Examples of the solvent for the reaction include alcohols solvent such as methanol, ethanol, and isopropyl alcohol; hydrocarbon solvent such as benzene, toluene, xylene, and hexane; halogenated solvent such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane; ethers solvent such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, and diglyme; polar solvent such as N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, and acetone; water, pyridine; which may be used alone or as a mixture of two or more. Preferred examples of the solvent for the reaction include ethanol.


When the hydrochloride salt of hydroxylamine is used, examples of the base for the reaction include pyridine, triethylamine, sodium hydroxide, sodium acetate, potassium carbonate, sodium carbonate, and sodium hydrogen carbonate. Preferred examples of the base for the reaction include sodium carbonate.


The reaction temperature usually ranges about −10° C. to 120° C., preferably room temperature to 100° C.


The reaction time usually ranges about 30 minutes to 3 days, preferably about 1 hr to 1 day.


(Step 3)


Compound [Y-46] can be obtained by the cyclization reaction of Compound [Y-45] in the presence of halogen or organohalide in a solvent.


Examples of the solvent for the reaction include hydrocarbon solvent such as benzene, toluene, xylene, and hexane; halogenated solvent such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane; ethers solvent such as diethyl ether, tetrahydrofuran, dioxane, and 1,2-dimethoxyethane; polar solvent such as acetonitrile; which may be used alone or as a mixture of two or more. Preferred examples of the solvent for the reaction include dichloromethane. Examples of the halogen or the organohalide for the reaction include bromine, iodine, N-bromosuccinimide, N-iodosuccinimide, and iodine monochloride. Preferred examples of the halogen or the organohalide for the reaction include iodine, and iodine monochloride.


The reaction temperature usually ranges about −30° C. to 50° C., preferably about 0° C. to room temperature.


The reaction time usually ranges about 30 minutes to 3 days, preferably about 30 minutes to 1 day.


(Step 4)


Compound [Y-47] can be obtained by reacting Compound [Y-46] with Compound [Y-33] in the presence of a metal catalyst in a solvent.


The solvent, the reactant, the reaction temperature, and the reaction time, for the reaction, are similar to those of Step 7 of Preparation method 2A-2.


Preparation Method 2B-1 and Preparation method 2B-2 of a compound wherein Moiety U is isoxazole, thiazole, or furan correspond to the following.


Preparation Method 2B-3
Moiety U is Isoxazole:



embedded image


Compound [Y-49] can be obtained from Compound [Y-48]. The solvent, the reactant, the reaction temperature, the reaction time, for the reaction, are similar to those of Preparation method 2B-1.


Then, [Y-51] can be prepared by obtaining Compound [Y-50] from Compound [Y-49]. The solvent, the reactant, the reaction temperature, the reaction time, for the reaction, are similar to those of Preparation method 2B-2.


Preparation Method 2B-4
Moiety U is Thiazole:



embedded image


Compound [Y-53] can be obtained from Compound [Y-52]. The solvent, the reactant, the reaction temperature, the reaction time, for the reaction, are similar to those of Preparation method 2B-1.


Then, [Y-55] can be prepared by obtaining Compound [Y-54] from Compound [Y-53]. The solvent, the reactant, the reaction temperature, the reaction time, for the reaction, are similar to those of Preparation method 2B-2.


Preparation Method 2B-5
Moiety U is Furan:



embedded image


Compound [Y-57] can be obtained from Compound [Y-56]. The solvent, the reactant, the reaction temperature, the reaction time, for the reaction, are similar to those of Preparation method 2B-1.


[Y-59] can be prepared by obtaining Compound [Y-58] from Compound [Y-57]. The solvent, the reactant, the reaction temperature, the reaction time, for the reaction, are similar to those of Preparation method 2B-2.


Preparation Method 2C



embedded image


wherein:


na is 1 or 2; and


Rc is hydrogen atom.


Compound [II-A] (Rc═H) can be obtained from Compound [Y-34] by deprotection (Step 1), amidation reaction (Step 2), deprotection (Step 3), and oxidation (Step 4).


The solvent, the reactant, the reaction temperature, the reaction time, for the reaction, are similar to those of Steps 1 to 4 of Preparation method 1.


Likewise, Compound [I-A] (Rc═H) can be obtained from Compound [Y-47] by deprotection (Step 1), amidation reaction (Step 2), deprotection (Step 3), and oxidation (Step 4). The solvent, the reactant, the reaction temperature, the reaction time, for the reaction, are similar to those of Steps 1 to 4 of Preparation method 1.




embedded image


Preparation Method 3

Compound wherein




embedded image


is




embedded image


and




embedded image


is




embedded image


specifically, a compound of the following formula:




embedded image


wherein


na is 1 or 2; and


Rc is hydrogen atom.


Preparation Method 3A



embedded image


(Step 1)


Compound [Y-64] can be obtained by reacting Compound [Y-63] with hydroxylamine or a hydrochloride salt thereof in a solvent.


The solvent, the reactant, the reaction temperature, the reaction time, for the reaction, are similar to those of Step 6 of Preparation method 2A-1.


(Step 2)


Compound [Y-65] can be obtained by reacting Compound [Y-64] in the presence of a chlorinating agent in a solvent.


The solvent, the reactant, the reaction temperature, the reaction time, for the reaction, are similar to those of Step 7 of Preparation method 2A-1.


(Step 3)


Compound [Y-67] can be obtained by reacting Compound [Y-65] with [Y-66] in the presence of a base in a solvent.


The solvent, the reactant, the reaction temperature, the reaction time, for the reaction, are similar to those of Step 1 of Preparation method 2A-2.


(Step 4)


Compound [Y-68] can be obtained by removal of the protecting group PO from Compound [Y-67] in a solvent.


When the protecting group PO is tert-butyldimethylsilyl group, the protecting group may be removed by the reaction in the presence of tetrabutylammonium fluoride (TBAF).


Examples of the solvent for the reaction include alcohols solvent such as methanol, ethanol, isopropyl alcohol, and tert-butanol; esters solvent such as ethyl acetate, methyl acetate, and butyl acetate; hydrocarbon solvent such as benzene, toluene, xylene, and hexane; ethers solvent such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, and diglyme; polar solvent such as N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, and acetone; acetic acid, water; which may be used alone or as a mixture of two or more. Preferred examples of the solvent for the reaction include tetrahydrofuran.


The reaction temperature usually ranges about −10° C. to 80° C., preferably about 0° C. to 50° C.


The reaction time usually ranges about 30 minutes to 5 days, preferably about 1 hr to 1 day.


(Step 5)


Compound [Y-69] can be obtained by reacting Compound [Y-68] in the presence of a halogenating agent in a solvent.


The solvent, the reactant, the reaction temperature, the reaction time, for the reaction, are similar to those of Step 2 of Preparation method 2A-2.




embedded image


(Supplementary Step 1)


Compound [Y-66] can be obtained by reacting Compound [Y-22] with trimethylsilyldiazomethane in the presence of a base in a solvent.


Examples of the solvent for the reaction include hydrocarbon solvent such as benzene, toluene, xylene, and hexane; ethers solvent such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, and diglyme. Preferred examples of the solvent for the reaction include tetrahydrofuran and hexane.


Examples of the base for the reaction include n-butyllithium and lithium diisopropylamide (LDA). Preferred examples of the base for the reaction include n-butyllithium.


The reaction temperature usually ranges about −78° C. to 80° C., preferably about −78° C. to 0° C.


The reaction time usually ranges about 30 minutes to 3 days, preferably about 1 hr to 1 day.


Preparation Method 3B



embedded image


wherein na is 1 or 2.


Compound [Y-74] can be obtained from Compound [Y-69] by oxidation (Step 1), oximation reaction (Step 2), chlorination (Step 3), cyclization (Step 4), substitution reaction (Step 5).


The solvent, the reactant, the reaction temperature, the reaction time, for the reaction, are similar to those of Steps 3 to 7 of Preparation method 2A-2.


Preparation Method 3C



embedded image


Wherein

na is 1 or 2; and


Rc is hydrogen atom.


Compound [II-B] (Rc═H) can be obtained from Compound [Y-74] by deprotection (Step 1), amidation reaction (Step 2), deprotection (Step 3), oxidation (Step 4).


The solvent, the reaction temperature, and the reaction time, for the reaction, are similar to those of Steps 1 to 4 of Preparation method 1.


Preparation Method 4

Compound wherein




embedded image


is




embedded image


and




embedded image


is




embedded image


specifically, a compound of the following formula:




embedded image


wherein na is 1 or 2.


Preparation Method 4A



embedded image


(Step 1)


Compound [Y-79] can be obtained by reacting Compound [Y-78] with hydroxylamine or a hydrochloride salt thereof in a solvent.


The solvent, the reactant, the reaction temperature, the reaction time, for the reaction, are similar to those of Step 6 of Preparation method 2A-1.


(Step 2)


Compound [Y-80] can be obtained by reacting Compound [Y-79] in the presence of a chlorinating agent in a solvent.


The solvent, the reactant, the reaction temperature, the reaction time, for the reaction, are similar to those of Step 7 of Preparation method 2A-1.


Preparation Method 4B



embedded image


Wherein na is 1.

(Step 1)


Compound [Y-81] can be obtained by the reaction of Compound [Y-39] in the presence of an oxidant in a solvent.


The solvent, the reactant, the reaction temperature, the reaction time, for the reaction, are similar to those of Step 3 of Preparation method 2A-2.


(Step 2)


Compound [Y-82] can be obtained by reacting Compound [Y-81] with trimethylsilyldiazomethane in the presence of a base in a solvent.


The solvent, the reactant, the reaction temperature, the reaction time, for the reaction, are similar to those of Supplementary step 1 of Preparation method 3A.


(Step 3)


Compound [Y-83] can be obtained by reacting Compound [Y-82] with [Y-80] in the presence of a base in a solvent.


The solvent, the reactant, the reaction temperature, the reaction time, for the reaction, are similar to those of Step 1 of Preparation method 2A-2.


Preparation Method 4C



embedded image


wherein


na is 1 or 2; and


Rc═H.

Compound [II-C] (Rc═H) can be obtained from Compound [Y-83] by deprotection (Step 1), amidation reaction (Step 2), deprotection (Step 3), and oxidation (Step 4).


The solvent, the reaction temperature, and the reaction time, for the reaction, are similar to those of Steps 1 to 4 of Preparation method 1.


Preparation Method 5

Compound wherein




embedded image


is




embedded image


and




embedded image


is selected from the following heterocycle:




embedded image




embedded image


(Step 1)


Compound [Y-87] can be obtained by the reaction of Compound [Y-39] in the presence of an oxidant in a solvent.


The solvent, the reactant, the reaction temperature, the reaction time, for the reaction, are similar to those of Step 4 of Preparation method 1.


(Step 2A)


Moiety U is Pyrazole:



embedded image


Weinreb amide derived from carboxylic acid (Compound [Y-87]) is reacted with acetylene in the presence of base to form ynone. The resulting ynone is reacted with hydrazine to form a pyrazole ring.


(Step 2B)


Moiety U is Thiazole:



embedded image


carboxylic acid (Compound [Y-87]) is condensed with α-aminoketone hydrochloride salt followed by a reaction with Lawesson's reagent to form a thiazole ring.


(Step 2C)


Moiety U is Oxazole:



embedded image


Carboxylic acid (Compound [Y-87]) is condensed with α-aminoketone hydrochloride salt followed by a reaction with Burgess' reagent to form an oxazole ring.


(Step 2D)


Moiety U is [1,3,4]Thiadiazole:



embedded image


An acid chloride derived from carboxylic acid (Compound [Y-87]) is reacted with thiohydrazide to form a [1,3,4]thiadiazole ring.


(Step 2E)


Moiety U is [1,2,4]Oxadiazole:



embedded image


A nitrile derived from carboxylic acid (Compound [Y-87]) is reacted with hydroxylamine to form an amidoxime. The resulting amidoxime is reacted with an acid chloride to form an [1,2,4]oxadiazole ring.


(Step 3)




embedded image


wherein




embedded image


is




embedded image


and




embedded image


is selected from the following heterocycle:




embedded image


Compound [I] (Rc═H) can be obtained from Compound [Y-10] (Compound [Y-87], [Y-88], [Y-89], [Y-90], [Y-91], and the like) by deprotection (Step 1), amidation reaction (Step 2), deprotection (Step 3), oxidation (Step 4).


The solvent, the reaction temperature, and the reaction time, for the reaction, are similar to those of Steps 1 to 4 of Preparation method 1.


Next, some examples of processes for preparing the compounds described in [101] to [146] are shown as follows. However, the processes for preparing the compounds of the present invention should not be limited thereto.


Unless otherwise instructed, it is possible to modify the processes to carry out the preparation more effectively, for example, introducing a protecting group into a functional group followed by deprotecting it in subsequent step; using a precursor having a substituent from which a functional group of a final product can be derived, followed by converting it to the desired functional group in a subsequent and appropriate stage; exchanging the order of preparation methods or steps thereof.


The workup after the reaction in each step can be carried out by a commonly-used method, wherein the isolation and purification may be carried out by a conventional method selected from crystallization, recrystallization, distillation, separating, silicagel chromatography, preparative HPLC and the like, or a combination thereof, as appropriate.


A racemic form of the compound can be obtained by using an achiral compound as a material, ligand, or reagent, or by mixing of enantiomers.


The following abbreviations are used in the preparation methods and Examples herein:

  • tert-butyldimethylsilyl group (TBDPS)
  • tert-butyldiphenylsilyl group (TBDPS)
  • tert-butoxycarbonyl group (Boc)
  • benzyloxycarbonyl group (Z)
  • benzyl group (Bn)
  • phenyl group (Ph)
  • n-butyl group (nBu)
  • tert-butyl group (tBu)
  • isopropyl group (iPr)
  • ethyl group (Et)
  • methyl group (Me)
  • N,N-diisopropylethylamine (DIPEA)
  • lithium diisopropylamide (LDA)
  • diisobutylaluminium hydride (DIBAL)
  • 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (WSC.HCl)
  • 1-hydroxy-1H-benzotriazole monohydrate (HOBt.H2O)
  • O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU)
  • tetrabutylammonium fluoride (TBAF)
  • 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU)
  • trifluoroacetic acid (TFA)
  • trifluoroacetic anhydride (TFAA)
  • Dess-Martin reagent (DMP)
  • lithium hexamethyldisilazide (LHMDS)
  • 4-dimethylaminopyridine (DMAP)
  • 2,2,6,6-tetramethyl-1-piperidinyloxy radical (TEMPO)
  • 2-azaadamantane-N-oxyl (AZADO)
  • (diethylamino)sulfur trifluoride (DAST)
  • bis(2-methoxyethyl)aminosulfur trifluoride (Deoxo-Fluor (registered trademark))
  • 1,1′-bis(diphenylphosphino)ferrocene (dppf) dimethyl sulfoxide (DMSO)
  • N,N-dimethylformamide (DMF)
  • tetrahydrofuran (THF)
  • N,N-dimethylacetamide (DMA)
  • hexamethylphosphoric triamide (HMPA)
  • enantiomer excess (ee)
  • room temperature (rt)
  • high-performance liquid chromatography (HPLC)


In the following schemes,


“X” is a leaving group such as halogen atom, trifluoromethanesulfonyloxy group, preferably bromo group and iodo group.


“PC” is a protecting group for carboxyl group, and includes, for example, methyl group, ethyl group, tert-butyl group, and benzyl group, preferably methyl group, tert-butyl group, and benzyl group.


“AUX-H” is a chiral auxiliary reagent, and includes for example, (R)-4-benzyl-2-oxazolidinone, (S)-4-benzyl-2-oxazolidinone, (R)-4-isopropyl-2-oxazolidinone, (S)-4-isopropyl-2-oxazolidinone, (4S,5R)-4-methyl-5-phenyl-2-oxazolidinone, and (4R,5S)-4-methyl-5-phenyl-2-oxazolidinone, preferably (R)-4-benzyl-2-oxazolidinone, and (S)-4-benzyl-2-oxazolidinone.


Example of AUX-H



embedded image


“AUX” is a chiral auxiliary group.


In Preparation method 5′ to Preparation method 10, “Rw” means:


(i) “Rw” described in [102],


(ii) “Rw” protected by a protecting group,


(iii) a functional group which may be replaced with “Rw” by an appropriate reaction.


“Rc” means:


(i) “Rc” described in the above [103] to [111],


(ii) “Rc” protected by a protecting group, or


(iii) a functional group which may be replaced with “Rc” by an appropriate reaction.


“Ra” means:


(i) “Ra” described in the above [101] to [111],


(ii) “Ra” protected by a protecting group, or


(iii) a functional group which may be replaced with “Ra” by an appropriate reaction.


“Rau” means:


(i) “Rau” described in the above [108],


(ii) “Rau” protected by a protecting group, or


(iii) a functional group which may be replaced with “Rau” by an appropriate reaction.


“Ra11” may be selected from the following, depending on kinds of functional groups or types of reactions:


(i) “C1-12 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A” described in the above [101] to [111],


(ii) “C1-12 alkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group AU” described in the above [108],


(iii) a group of the above (i) and (ii) which are protected by a protecting group, or


(iv) a group of the above (i) and (ii) which may be replaced with “Ra11” by an appropriate reaction.


When “Rc” is “—(CH2)2—C(═O)—OH”, examples of “Rc” protected by a protecting group include “—(CH2)2—C(═O)—OCH3” and the like.


when “Rc” is “—(CH2)2-tetrazole”, examples of the functional group which may be replaced with “Rc” by an appropriate reaction includes “—(CH2)2—CN”, “—(CH2)2—CONH2” and “—(CH2)2—O-TBDPS”.


In Preparation method 10-1 (including the reduction reaction), examples of “Ra11” include C1-12 alkyl group.


Unless otherwise indicated, each symbol is as defined in the above [101] to [111], and is determined depending on the general formulas.


For example, “cyclic moiety UU” is “cyclic moiety UU” described in the above [108].


An optically-active compound can be obtained by separating a racemic compound by high-performance liquid chromatograph with a chiral stationary phase column.


The condition is, for example, as follows:


Instrument: Recycle preparative HPLC LC908 type (Japan Analytical Industry)


Column: DAICEL CHIRALPAK AD 20 mmφ×250 mm


Column temperature: room temperature


Mobile phase: ethanol


Flow rate: 0.5 ml/min


Detection: UV (254 nm).

In the formulas, the symbol “*” denotes an asymmetric carbon.


Preparation Method 5′

(5′-1) Amidation Reaction


Compound wherein Y is “single bond” or “C1-3 alkylene which may be substituted with hydroxyl group”:




embedded image


The above Preparation method 5′-1 is performed as follows.


(Amidation Reaction Step)

Compound [III-X-D1] can be obtained by reacting Compound [Z-X-D1-501] with [Z-X-D1-502] in the presence of a condensation reagent in a solvent under the condition of a commonly-used amide bond formation reaction.


Examples of the solvent for the reaction include hydrocarbon solvent such as benzene, toluene, xylene, and hexane; halogenated solvent such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane; ethers solvent such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, and diglyme; polar solvent such as N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, and acetone; which may be used alone or as a mixture of two or more. Preferred examples of the solvent for the reaction include methylene chloride, chloroform, and N,N-dimethylformamide.


Examples of the condensation reagent for the reaction include water-soluble carbodiimide (WSC.HCl: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride), N,N′-dicyclohexylcarbodiimide (DCC), diphenylphosphoryl azide (DPPA), carbonyldiimidazole (CDI), and O-(7-azabenzotriazol-1-yl)-N,N,N′,N′,-tetramethyluronium hexafluorophosphate (HATU). As necessary, 1-hydroxy-1H-benzotriazole monohydrate (HOBt.H2O), 4-dimethylaminopyridine (DMAP), N,N-diisopropylethylamine, and the like may be added. Preferred examples of the condensation reagent include a mixture of water-soluble carbodiimide (WSC.HCl: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride) and 1-hydroxy-1H-benzotriazole monohydrate (HOBt.H2O), and a mixture of O-(7-azabenzotriazol-1-yl)-N,N,N′,N′,-tetramethyluronium hexafluorophosphate (HATU) and N,N-diisopropylethylamine.


The reaction temperature usually ranges about room temperature to 120° C., preferably from room temperature to 100° C.


The reaction time usually ranges about 30 minutes to 3 days, preferably about 1 hr to 1 day.


Alternatively, in the above amidation reaction, Compound [III-X-D1] can be prepared by the reaction of an acid halide or mixed acid anhydride of Compound [Z-X-D1-501] with Compound [Z-X-D1-502].


The acid halide of [Z-X-D1-501] can be derived by the reaction of an carboxylic acid of compound [Z-X-D1-501] with thionyl chloride, oxalyl chloride etc., wherein a catalytic amount of N,N-dimethylformamide may be added.


The mixed acid anhydride of compound [Z-X-D1-501] can be derived by the reaction of a carboxylic acid of compound [Z-X-D1-501] with ethyl chlorocarbonate etc.


When Y is “C1-3 alkylene which is substituted with hydroxyl group” in the above amidation reaction, the hydroxyl group of the alkylene may be protected.


In a similar way, compound 5B (right column) can be prepared from compound 5A (left column), as listed in the following table(s).











TABLE 74






Compound 5A
Compound 5B







5-1


embedded image

  [Z-J-R-501]



embedded image

  [III-J-B]






5-2


embedded image

  [Z-X-C-501]



embedded image

  [III-X-C]






5-3


embedded image

  [Z-J-C-501]



embedded image

  [III-J-C]






5-4


embedded image

  [Z-X-D2-501]



embedded image

  [III-X-D2]






5-5


embedded image

  [Z-J-D2-501]



embedded image

  [III-J-D2]






5-6


embedded image

  [Z-X-D1-501]



embedded image

  [III-X-D1]






5-7


embedded image

  [Z-J-D1-501]



embedded image

  [III-J-D1]










In the following Table 75,




embedded image


is




embedded image











TABLE 75






Compound 5A
Compound 5B







5-8


embedded image

  [Z-X-D11-501]



embedded image

  [III-X-D11]






5-9


embedded image

  [Z-X-D12-501]



embedded image

  [III-X-D12]










(5′-2) Sulfonamidation Reaction

Compound wherein Y is “single bond” or “C1-3 alkylene which may be substituted with hydroxyl group”:




embedded image


Compound [III-X-D1-YS] can be obtained by reacting Compound [Z-X-D1-501] with [Z-X-D1-YS-502] in the presence of a condensation reagent in a solvent under a condition of a commonly-used sulfonamide bond formation reaction.


In a similar way, compound 5D (right column) can be prepared from compound 5C (left column), as listed in the following table(s).











TABLE 76






Compound 5C
Compound 5D







5-10


embedded image

  [Z-J-B-501]



embedded image

  [III-J-B-YS]






5-11


embedded image

  [Z-X-C-501]



embedded image

  [III-X-C-YS]






5-12


embedded image

  [Z-J-C-501]



embedded image

  [III-J-C-YS]






5-13


embedded image

  [Z-X-D2-501]



embedded image

  [III-X-D2-YS]






5-14


embedded image

  [Z-J-D2-501]



embedded image

  [III-J-D2-YS]






5-15


embedded image

  [Z-X-D1-501]



embedded image

  [III-X-D1-YS]






5-16


embedded image

  [Z-J-D1-501]



embedded image

  [III-J-D1-YS]










In the following table,




embedded image


is




embedded image


In a similar way, compound 5B (right column) can be prepared from compound 5A (left column), as listed in the following table(s).











TABLE 77






Compound 5A
Compound 5B







5-17


embedded image

  [Z-X-D11-501]



embedded image

  [III-X-YS-D11]






5-18


embedded image

  [Z-X-D12-501]



embedded image

  [III-X-YS-D12]










Preparation Method 6

Ring-forming reactions are explained below.




embedded image


Preparation Method 6F

When




embedded image


is




embedded image


(Step 1)

Compound [Z-F-D1-603] can be obtained by reacting Compound [Z-F-D1-601] with [Z-F-D1-602] in the presence of a condensation reagent in a solvent under a condition of a commonly-used amide bond formation reaction.


Examples of the solvent for the reaction include toluene, dichloromethane, chloroform, tetrahydrofuran, dioxane, N,N-dimethylformamide, acetonitrile; which may be used alone or as a mixture of two or more.


Examples of the condensation reagent for the reaction include water-soluble carbodiimide (WSC.HCl: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride), N,N′-dicyclohexylcarbodiimide (DCC), diphenylphosphoryl azide (DPPA), carbonyldiimidazole (CDI), and O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU). As necessary, 1-hydroxy-1H-benzotriazole monohydrate (HOBt.H2O) 4-dimethylaminopyridine (DMAP), N,N-diisopropylethylamine, and the like may be added.


The reaction temperature usually ranges about room temperature to 120° C.


The reaction time usually ranges about 30 minutes to 3 days.


Alternatively, in the above amidation reaction, Compound [Z-F-D1-603] can be prepared by the reaction of an acid halide or mixed acid anhydride of compound [Z-F-D1-601] with compound [Z-F-D1-602].


The acid halide of compound [Z-F-D1-601] can be derived by the reaction of an carboxylic acid of compound [Z-F-D1-601] with thionyl chloride, oxalyl chloride etc. wherein a catalytic amount of N,N-dimethylformamide may be added.


The mixed acid anhydride of compound [Z-F-D1-601] can be derived by the reaction of a carboxylic acid of compound [Z-F-D1-601] with ethyl chlorocarbonate etc.


(Step 2)


The Step 2 is a transformation reaction from an amide to an thioamide. Compound [Z-F-D1-604] can be obtained by reacting Compound [Z-F-D1-603] in the presence of a sulfating agent in a solvent.


Examples of the solvent for the reaction include toluene, dichloromethane, chloroform, tetrahydrofuran, dioxane; which may be used alone or as a mixture of two or more.


Examples of the sulfating agent for the reaction include Lawesson's reagent.


The reaction temperature usually ranges about room temperature to 120° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 3)


Compound [Z-F-D1-605] can be obtained by reacting Compound [Z-F-D1-604] with a methylating agent in a solvent.


Examples of the solvent for the reaction include toluene, dichloromethane, chloroform, tetrahydrofuran, dioxane, acetonitrile; which may be used alone or as a mixture of two or more.


Examples of the methylating agent for the reaction include methyl iodide, and trimethyloxonium tetrafluoroborate.


The reaction temperature usually ranges about room temperature to 120° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 4)


The Step 4 is an amide bond formation reaction. Compound [Z-F-D1-607] can be obtained by reacting Compound [Z-F-D1-606] with hydrazine monohydrate in the presence of a condensation reagent in a solvent.


Examples of the solvent for the reaction include toluene, dichloromethane, chloroform, tetrahydrofuran, dioxane, N,N-dimethylformamide, acetonitrile; which may be used alone or as a mixture of two or more.


Examples of the condensation reagent for the reaction include water-soluble carbodiimide (WSC.HCl: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride), and N,N′-dicyclohexylcarbodiimide (DCC). As necessary, 1-hydroxy-1H-benzotriazole monohydrate (HOBt.H2O), 4-dimethylaminopyridine (DMAP), and the like may be added.


The reaction temperature usually ranges about 0° C. to 100° C.


The reaction time usually ranges about 10 minutes to 3 days.


(Step 5)


Compound [Z-F-D1-608] can be obtained by reacting Compound [Z-F-D1-607] with Compound [Z-F-D1-605] in a solvent.


Examples of the solvent for the reaction include ethanol, dioxane, water; which may be used alone or as a mixture of two or more.


As necessary, sodium acetate, and the like may be added.


(Step 6)


Compound [Z-F-D1-609] can be obtained from Compound [Z-F-D1-608] in a solvent under a commonly-used condition of the ester hydrolysis reaction. The ester hydrolysis reaction may be performed under the alkaline or acidic condition.


Examples of the base for the alkaline condition include an aqueous solution of alkali metal hydroxide such as lithium hydroxide, sodium hydroxide, and potassium hydroxide.


Examples of the acid for the acidic condition include hydrochloric acid, hydrobromic acid, sulfuric acid, and trifluoroacetic acid.


Examples of the solvent for the reaction include toluene, methanol, ethanol, isopropyl alcohol, tetrahydrofuran, dioxane, water; which may be used alone or as a mixture of two or more.


The reaction temperature usually ranges about 0° C. to 120° C.


The reaction time usually ranges about 30 minutes to 3 days.


Preparation Method 6G-1

When




embedded image


is




embedded image


embedded image


(Step 1)

Compound [Z-G-D1-602] can be obtained by reacting Compound [Z-G-D1-601] with N,O-dimethylhydroxylamine or a hydrochloride salt thereof in the presence of a condensation reagent in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, and acetone; which may be used alone or as a mixture of two or more.


Examples of the condensation reagent for the reaction include water-soluble carbodiimide (WSC.HCl: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride), N,N′-dicyclohexylcarbodiimide (DCC), diphenylphosphoryl azide (DPPA), and carbonyldiimidazole (CDI). As necessary, 1-hydroxy-1H-benzotriazole monohydrate (HOBt.H2O) 4-dimethylaminopyridine (DMAP), and the like may be added.


The reaction temperature usually ranges about room temperature to 120° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 2)


Compound [Z-G-D1-603] can be obtained by reacting Compound [Z-G-D1-602] in the presence of a reducing agent in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme; which may be used alone or as a mixture of two or more.


Examples of the reducing agent for the reaction include diisobutylaluminium hydride and lithium aluminium hydride.


The reaction temperature usually ranges about −78° C. to room temperature.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 3)


Compound [Z-G-D1-604] can be obtained by reacting Compound [Z-G-D1-603] in the presence of carbon tetrabromide and triphenylphosphine in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, and diglyme; which may be used alone or as a mixture of two or more.


The reaction temperature usually ranges about −30° C. to 100° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 4)


Compound [Z-G-D1-606] can be obtained by reacting Compound [Z-G-D1-605] with N,O-dimethylhydroxylamine or a hydrochloride salt thereof in the presence of a condensation reagent in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, and acetone; which may be used alone or as a mixture of two or more.


Examples of the condensation reagent for the reaction include water-soluble carbodiimide (WSC.HCl: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride), N,N′-dicyclohexylcarbodiimide (DCC), diphenylphosphoryl azide (DPPA), and carbonyldiimidazole (CDI). As necessary, 1-hydroxy-1H-benzotriazole monohydrate (HOBt.H2O) 4-dimethylaminopyridine (DMAP), and the like may be added.


The reaction temperature usually ranges about room temperature to 120° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 5)


Compound [Z-G-D1-607] can be obtained by reacting Compound [Z-G-D1-606] with Compound [Z-G-D1-604] in the presence of a base in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme; which may be used alone or as a mixture of two or more.


Examples of the base for the reaction include butyllithium, methyllithium, ethylmagnesium bromide, and lithium diisopropylamide (LDA).


The reaction temperature usually ranges about −78° C. to 50° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 6)


Compound [Z-G-D1-608] can be obtained by reacting Compound [Z-G-D1-607] with O-methylhydroxylamine or hydrochloride salt thereof in a solvent.


Examples of the solvent for the reaction include methanol, ethanol, isopropyl alcohol, benzene, toluene, xylene, hexane, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, acetone, water, and pyridine; which may be used alone or as a mixture of two or more.


The reaction temperature usually ranges about −10° C. to 50° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 7)


Compound [Z-G-D1-609] can be obtained by the cyclization reaction of Compound [Z-G-D1-608] in the presence of halogen or organohalide in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, and acetone; which may be used alone or as a mixture of two or more.


Examples of the halogen or the organohalide for the reaction include bromine, iodine, N-bromosuccinimide, N-iodosuccinimide, and iodine monochloride.


The reaction temperature usually ranges about −10° C. to 50° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 8)


Compound [Z-G-D1-611] can be obtained by reacting Compound [Z-G-D1-609] with Compound [Z-G-D1-610] in the presence of a metal catalyst in a solvent.


As the Compound [Z-G-D1-610], alkylboronic acid, alkylboronic acid ester, alkylzinc reagent, alkylmagnesium reagent, and the like may be used.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, acetone, and water; which may be used alone or as a mixture of two or more.


Examples of the metal catalyst for the reaction include a palladium catalyst such as bis(triphenylphosphine)palladium(II) dichloride and 1,1′-bis(diphenylphosphino)ferrocene-palladium(II) dichloride; a nickel catalyst such as [1,2-bis(diphenylphosphino)ethane]nickel(II) dichloride and nickel(II) acetylacetonate; and an iron catalyst such as iron(III) chloride.


As necessary, a base or an inorganic salt may be added. Examples of the base or the inorganic salt for the reaction include tripotassium phosphate, sodium carbonate, potassium carbonate, sodium acetate, and cesium fluoride.


The reaction temperature usually ranges about −10° C. to 150° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 9)


Compound [Z-G-D1-612] can be obtained from Compound [Z-G-D1-611] in a solvent under a commonly-used condition of ester hydrolysis reaction.


The ester hydrolysis reaction may be performed under the alkaline or acidic condition.


Examples of the base for the alkaline condition include an aqueous solution of alkali metal hydroxide such as lithium hydroxide, sodium hydroxide, and potassium hydroxide.


Examples of the acid for the acidic condition include hydrochloric acid, hydrobromic acid, sulfuric acid, and trifluoroacetic acid.


Examples of the solvent for the reaction include toluene, methanol, ethanol, isopropyl alcohol, tetrahydrofuran, dioxane, water; which may be used alone or as a mixture of two or more.


The reaction temperature usually ranges about 0° C. to 120° C.


The reaction time usually ranges about 30 minutes to 3 days.


Preparation Method 6G-2



embedded image


embedded image


(Step 1)


Compound [Z-G-D1-602] can be obtained by reacting Compound [Z-G-D1-601] with N,O-dimethylhydroxylamine or a hydrochloride salt thereof in the presence of a condensation reagent in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, and acetone; which may be used alone or as a mixture of two or more.


Examples of the condensation reagent for the reaction include water-soluble carbodiimide (WSC.HCl: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride), N,N′-dicyclohexylcarbodiimide (DCC), diphenylphosphoryl azide (DPPA), and carbonyldiimidazole (CDI). As necessary, 1-hydroxy-1H-benzotriazole monohydrate (HOBt.H2O), 4-dimethylaminopyridine (DMAP), and the like may be added.


The reaction temperature usually ranges about room temperature to 120° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 2)


Compound [Z-G-D1-603] can be obtained by reacting Compound [Z-G-D1-602] in the presence of a reducing agent in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme; which may be used alone or as a mixture of two or more.


Examples of the reducing agent for the reaction include diisobutylaluminium hydride and lithium aluminium hydride.


The reaction temperature usually ranges about −78° C. to room temperature.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 3)


Compound [Z-G-D1-604] can be obtained by reacting Compound [Z-G-D1-603] in the presence of carbon tetrabromide and triphenylphosphine in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme; which may be used alone or as a mixture of two or more.


The reaction temperature usually ranges about −30° C. to 100° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 4)


Compound [Z-G-D1-605] can be obtained by reacting Compound [Z-G-D1-604] with a base in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme; which may be used alone or as a mixture of two or more.


Examples of the base for the reaction include butyllithium, methyllithium, ethylmagnesium bromide, and lithium diisopropylamide (LDA).


The reaction temperature usually ranges about −78° C. to 50° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 5)


Compound [Z-G-D1-607] can be obtained by reacting Compound [Z-G-D1-606] with N,O-dimethylhydroxyiamine or a hydrochloride salt thereof in the presence of a condensation reagent in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, and acetone; which may be used alone or as a mixture of two or more.


Examples of the condensation reagent for the reaction include water-soluble carbodiimide (WSC.HCl: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride), N,N′-dicyclohexylcarbodiimide (DCC), diphenylphosphoryl azide (DPPA), and carbonyldiimidazole (CDI). As necessary, 1-hydroxy-1H-benzotriazole monohydrate (HOBt.H2O) 4-dimethylaminopyridine (DMAP), and the like may be added.


The reaction temperature usually ranges about room temperature to 120° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 6)


Compound [Z-G-D1-608] can be obtained by reacting Compound [Z-G-D1-607] in the presence of a reducing agent in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme; which may be used alone or as a mixture of two or more.


Examples of the reducing agent for the reaction include diisobutylaluminium hydride and lithium aluminium hydride.


The reaction temperature usually ranges about −78° C. to room temperature.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 7)


Compound [Z-G-D1-609] can be obtained by reacting Compound [Z-G-D1-608] with hydroxylamine or a hydrochloride salt thereof in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, methanol, ethanol, acetonitrile, water; which may be used alone or as a mixture of two or more.


When the hydrochloride salt of hydroxylamine is used, examples of the base for the reaction include pyridine, triethylamine, sodium hydroxide, sodium acetate, potassium carbonate, sodium carbonate, and sodium hydrogen carbonate.


The reaction temperature usually ranges about −10° C. to 130° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 8)


Compound [Z-G-D1-610] can be obtained by reacting Compound [Z-G-D1-609] in the presence of a chlorinating agent in a solvent.


Examples of the solvent for the reaction include dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, N,N-dimethylformamide, acetic acid; which may be used alone or as a mixture of two or more.


Examples of the halogenating agent for the reaction include chlorine and N-chlorosuccinimide.


The reaction temperature usually ranges about −10° C. to 100° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 9)


Compound [Z-G-D1-611] can be obtained by reacting Compound [Z-G-D1-610] with [Z-G-D1-605] in the presence of a base in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, water; which may be used alone or as a mixture of two or more.


Examples of the base for the reaction include triethylamine, sodium hydroxide, potassium carbonate, sodium carbonate, and sodium hydrogen carbonate.


The reaction temperature usually ranges about 0° C. to 150° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 10)


Compound [Z-G-D1-612] can be obtained by reacting Compound [Z-G-D1-611] in the presence of a halogenating agent in a solvent.


Examples of the solvent for the reaction include dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, N,N-dimethylformamide, acetic acid; which may be used alone or as a mixture of two or more.


Examples of the halogenating agent for the reaction include bromine, iodine, iodine monochloride, N-bromosuccinimide, N-iodosuccinimide, and 1,3-dibromo-5,5-dimethylhydantoin. As necessary, cerium(IV) diammonium nitrate, trifluoroacetic acid, and the like may be added.


The reaction temperature usually ranges about −10° C. to 100° C.


The reaction time usually ranges about 1 hr to 3 days.


(Step 11)


Compound [Z-G-D1-614] can be obtained by reacting Compound [Z-G-D1-612] with Compound [Z-G-D1-613] in the presence of a metal catalyst in a solvent.


As the Compound [Z-G-D1-613], alkylboronic acid, alkylboronic acid ester, alkylzinc reagent, alkylmagnesium reagent, and the like may be used.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, acetone, and water; which may be used alone or as a mixture of two or more.


Examples of the metal catalyst for the reaction include a palladium catalyst such as bis(triphenylphosphine)palladium(II) dichloride and 1,1′-bis(diphenylphosphino)ferrocene-palladium(II) dichloride; a nickel catalyst such as [1,2-bis(diphenylphosphino)ethane]nickel(II) dichloride, nickel(II) acetylacetonate; and an iron catalyst such as iron(III) chloride.


As necessary, a base or an inorganic salt may be added. Examples of the base or the inorganic salt for the reaction include tripotassium phosphate, sodium carbonate, potassium carbonate, sodium acetate, and cesium fluoride.


The reaction temperature usually ranges about −10° C. to 150° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 12)


Compound [Z-G-D1-615] can be obtained from Compound [Z-G-D1-614] in a solvent under a commonly-used condition of ester hydrolysis reaction.


The ester hydrolysis reaction may be performed under the alkaline or acidic condition.


Examples of the base for the alkaline condition include an aqueous solution of alkali metal hydroxide such as lithium hydroxide, sodium hydroxide, and potassium hydroxide.


Examples of the acid for the acidic condition include hydrochloric acid, hydrobromic acid, sulfuric acid, and trifluoroacetic acid.


Examples of the solvent for the reaction include toluene, methanol, ethanol, isopropyl alcohol, tetrahydrofuran, dioxane, water; which may be used alone or as a mixture of two or more.


The reaction temperature usually ranges about 0° C. to 120° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Outline)


As described below, “compound B” can be prepared from “compound A” by the above preparation methods. Further, “compound B” is transformed to “compound C” by the above Preparation method 5′ (amidation reaction etc.). Specifically, Compound [Z-G-B-612] can be prepared from Compound [Z-G-B-605] in Table 78 by the above preparation methods.


Compound [Z-G-B-612] is transformed to Compound [III-G-B] by the above Preparation method 5′ (amidation reaction etc.).











TABLE 78







6G-1
Compound A
Compound B








embedded image




embedded image





[Z-G-B-605]
[Z-G-B-612]











6G-2
Compound C








embedded image





[III-G-B]









In a similar way, in Tables 79 to 81, compound B can be prepared from compound A. Compound B is transformed to compound C by Preparation method 5′ etc.











TABLE 79







6G-3
Compound A
Compound B








embedded image




embedded image





[Z-G-C-605]
[Z-G-C-612]











6G-4
Compound C








embedded image





[III-G-C]


















TABLE 80







6G-5
Compound A
Compound B








embedded image




embedded image





[Z-G-D2-605]
[Z-G-D2-612]











6G-6
Compound C








embedded image





[III-G-D2]


















TABLE 81








Compound A
Compound B





6G-7


embedded image




embedded image





[Z-G-D1-606]
[Z-G-D1-609]











6G-8
Compound C








embedded image





[III-G-D1]









Preparation Method 6H

When




embedded image


is




embedded image


embedded image


(Step 1)


Compound [Z-H-D1-602] can be obtained by reacting Compound [Z-H-D1-601] with N,O-dimethylhydroxylamine or a hydrochloride salt thereof in the presence of a condensation reagent in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, and acetone; which may be used alone or as a mixture of two or more.


Examples of the condensation reagent for the reaction include water-soluble carbodiimide (WSC.HCl: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride), N,N′-dicyclohexylcarbodiimide (DCC), diphenylphosphoryl azide (DPPA), and carbonyldiimidazole (CDI). As necessary, 1-hydroxy-1H-benzotriazole monohydrate (HOBt.H2O), 4-dimethylaminopyridine (DMAP), and the like may be added.


The reaction temperature usually ranges about room temperature to 120° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 2)


Compound [Z-H-D1-603] can be obtained by reacting Compound [Z-H-D1-602] in the presence of a reducing agent in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, and diglyme; which may be used alone or as a mixture of two or more.


Examples of the reducing agent for the reaction include diisobutylaluminium hydride and lithium aluminium hydride.


The reaction temperature usually ranges about −78° C. to room temperature.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 3)


Compound [Z-H-D1-604] can be obtained by reacting Compound [Z-H-D1-603] in the presence of carbon tetrabromide and triphenylphosphine in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme; which may be used alone or as a mixture of two or more.


The reaction temperature usually ranges about −30° C. to 100° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 4)


Compound [Z-H-D1-605] can be obtained by reacting Compound [Z-H-D1-604] with a base in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme; which may be used alone or as a mixture of two or more.


Examples of the base for the reaction include butyllithium, methyllithium, ethylmagnesium bromide, and lithium diisopropylamide (LDA).


The reaction temperature usually ranges about −78° C. to 50° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 5)


Compound [Z-H-D1-607] can be obtained by a reaction of Compound [Z-H-D1-606] with diphenylphosphoryl azide (DPPA) in the presence of a base in a solvent followed by a reaction with trimethylsilyloxy sodium.


Examples of the solvent for the reaction include methylene chloride, chloroform, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, ethyl acetate, methyl acetate, butyl acetate, N,N-dimethylformamide, acetonitrile, and toluene.


Examples of the base for the reaction include an organic base such as triethylamine, N,N-diisopropylethylamine, and pyridine.


The reaction temperature usually ranges about 0° C. to 150° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 6)


Compound [Z-H-D1-608] can be obtained by reacting Compound [Z-H-D1-607] with imidazole-1-sulfonyl azide hydrochloride in the presence of a base in a solvent.


Examples of the solvent for the reaction include methanol, ethanol, isopropyl alcohol, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, ethyl acetate, methyl acetate, butyl acetate, N,N-dimethylformamide, and acetonitrile.


Examples of the base for the reaction include potassium carbonate, and sodium carbonate.


The reaction temperature usually ranges about 0° C. to 150° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 7)


Compound [Z-H-D1-609] can be obtained by reacting Compound [Z-H-D1-608] with Compound [Z-H-D1-605] in the presence of copper(I) iodide in a solvent.


Examples of the solvent for the reaction include methanol, ethanol, isopropyl alcohol, tert-butanol, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, ethyl acetate, methyl acetate, butyl acetate, N,N-dimethylformamide, and acetonitrile.


The reaction temperature usually ranges about 0° C. to 150° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 8)


Compound [Z-H-D1-611] can be obtained by reacting Compound [Z-H-D1-609] with Compound [Z-H-D1-610] in the presence of a metal catalyst in a solvent.


As the Compound [Z-H-D1-610], alkylboronic acid, alkylboronic acid ester, alkylzinc reagent, alkylmagnesium reagent, and the like may be used.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, acetone, and water; which may be used alone or as a mixture of two or more.


Examples of the metal catalyst for the reaction include a palladium catalyst such as bis(triphenylphosphine)palladium(II) dichloride and 1,1′-bis(diphenylphosphino)ferrocene-palladium(II) dichloride; a nickel catalyst such as [1,2-bis(diphenylphosphino)ethane]nickel(II) dichloride and nickel(II) acetylacetonate; and an iron catalyst such as iron(III) chloride.


As necessary, a base or an inorganic salt may be added. Examples of the base or the inorganic salt for the reaction include tripotassium phosphate, sodium carbonate, potassium carbonate, sodium acetate, and cesium fluoride.


The reaction temperature usually ranges about −10° C. to 150° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 9)


Compound [Z-H-D1-612] can be obtained from Compound [Z-H-91-611] in a solvent under a commonly-used condition of ester hydrolysis reaction.


The ester hydrolysis reaction may be performed under the alkaline or acidic condition.


Examples of the base for the alkaline condition include an aqueous solution of alkali metal hydroxide such as lithium hydroxide, sodium hydroxide, and potassium hydroxide.


Examples of the acid for the acidic condition include hydrochloric acid, hydrobromic acid, sulfuric acid, and trifluoroacetic acid.


Examples of the solvent for the reaction include toluene, methanol, ethanol, isopropyl alcohol, tetrahydrofuran, dioxane, water; which may be used alone or as a mixture of two or more.


The reaction temperature usually ranges about 0° C. to 120° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Outline)


As described below, “compound B” can be prepared from “compound A” by the above preparation methods. Further, “compound B” is transformed to “compound C” by the above Preparation method 5′ (amidation reaction etc.). Specifically, Compound [Z-G-B-612] can be prepared from Compound [Z-H-B-605] in Table 78 by the above preparation methods.


Compound [Z-H-B-612] is transformed to Compound [III-H-B] by the above Preparation method 5′ (amidation reaction etc.).











TABLE 82








Compound A
Compound B





6H-1


embedded image

  [Z-H-B-606]



embedded image

  [Z-H-B-616]













Compound C





6H-2


embedded image

  [III-H-B]










In a similar way, in table 83 to 85, compound B can be prepared from compound A. Compound B is transformed to compound C by Preparation method 5° etc.











TABLE 83








Compound A
Compound B





6H-3


embedded image

  [Z-H-C-606]



embedded image

  [Z-H-C-612]













Compound C





6H-4


embedded image

  [III-H-C]



















TABLE 84








Compound A
Compound B





6H-5


embedded image

  [Z-H-D2-606]



embedded image

  [Z-H-D2-612]













Compound C





6H-6


embedded image

  [III-H-D2]



















TABLE 85








Compound A
Compound B





6H-7


embedded image

  [Z-H-D1-606]



embedded image

  [Z-H-D1-612]













Compound C





6H-8


embedded image

  [III-H-D1]










Preparation Method 6J



embedded image


embedded image


wherein “njj” is 0 or 1.


(Step 1)


Compound [Z-J-D1-602] can be obtained by reacting Compound [Z-J-D1-601] with N,O-dimethylhydroxylamine or a hydrochloride salt thereof in the presence of a condensation reagent in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, and acetone; which may be used alone or as a mixture of two or more.


Examples of the condensation reagent for the reaction include water-soluble carbodiimide (WSC.HCl: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride), N,N′-dicyclohexylcarbodiimide (DCC), diphenylphosphoryl azide (DPPA), and carbonyldiimidazole (CDI). As necessary, 1-hydroxy-1H-benzotriazole monohydrate (HOBt.H2O), 4-dimethylaminopyridine (DMAP), and the like may be added.


The reaction temperature usually ranges about room temperature to 120° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 2)


Compound [Z-J-D1-603] can be obtained by reacting Compound [Z-J-D1-602] in the presence of a reducing agent in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme; which may be used alone or as a mixture of two or more.


Examples of the reducing agent for the reaction include diisobutylaluminium hydride and lithium aluminium hydride.


The reaction temperature usually ranges about −78° C. to room temperature.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 3)


Compound [Z-J-D1-604] can be obtained by reacting Compound [Z-J-D1-603] with hydroxylamine or a hydrochloride salt thereof in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, methanol, ethanol, acetonitrile, water; which may be used alone or as a mixture of two or more.


When the hydrochloride salt of hydroxylamine is used, examples of the base for the reaction include pyridine, triethylamine, sodium hydroxide, sodium acetate, potassium carbonate, sodium carbonate, and sodium hydrogen carbonate.


The reaction temperature usually ranges about −10° C. to 130° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 4)


Compound [Z-J-D1-605] can be obtained by reacting Compound [Z-J-D1-604] in the presence of a chlorinating agent in a solvent.


Examples of the solvent for the reaction include dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, N,N-dimethylformamide, acetic acid; which may be used alone or as a mixture of two or more.


Examples of the halogenating agent for the reaction include chlorine and N-chlorosuccinimide.


The reaction temperature usually ranges about −10° C. to 100° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 5)


Compound [Z-J-D1-607] can be obtained by reacting Compound [Z-J-D1-605] with Compound [Z-J-D1-606] in the presence of a base in a solvent followed by a treatment with activated carbon for oxidation.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, acetone, water; which may be used alone or as a mixture of two or more.


Examples of the base for the reaction include potassium carbonate.


The reaction temperature usually ranges about room temperature to 120° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 6)


Compound [Z-J-D1-608] can be obtained by reacting Compound [Z-J-D1-607] with sodium tetrahydroborate in the presence of cerium(III) chloride heptahydrate in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, methanol, ethanol; which may be used alone or as a mixture of two or more.


The reaction temperature usually ranges about 0° C. to 120° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 7)


Compound [Z-J-D1-610] can be obtained by reacting Compound [Z-J-D1-608] with Compound [Z-J-D1-609] in the presence of 4-dimethylaminopyridine (DMAP) in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, and acetone; which may be used alone or as a mixture of two or more.


The reaction temperature usually ranges about room temperature to 120° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 8)


Compound [Z-J-D1-611] can be obtained by reacting Compound [Z-J-D1-610] with tri-n-butyltin hydride in the presence of 2,2′-azobis(isobutyronitrile) (AIBN) in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme; which may be used alone or as a mixture of two or more.


The reaction temperature usually ranges about room temperature to 120° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 9)


Compound [Z-J-D1-612] can be obtained from Compound [Z-J-D1-611] in a solvent under a commonly-used condition of ester hydrolysis reaction.


The ester hydrolysis reaction may be performed under the alkaline or acidic condition.


Examples of the base for the alkaline condition include an aqueous solution of alkali metal hydroxide such as lithium hydroxide, sodium hydroxide, and potassium hydroxide.


Examples of the acid for the acidic condition include hydrochloric acid, hydrobromic acid, sulfuric acid, and trifluoroacetic acid.


Examples of the solvent for the reaction include toluene, methanol, ethanol, isopropyl alcohol, tetrahydrofuran, dioxane, water; which may be used alone or as a mixture of two or more.


The reaction temperature usually ranges about 0° C. to 120° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Outline)


As described below, “compound B” can be prepared from “compound A” by the above preparation methods. Further, “compound B” is transformed to “compound C” by the above Preparation method 5′ (amidation reaction etc.). Specifically, in Table 86, Compound [Z-J-B-612]] can be prepared from Compound [Z-J-B-601] by the above preparation methods.


Compound [Z-G-B-612] is transformed to Compound [III-J-B] by the above Preparation method 5′ (amidation reaction etc.).











TABLE 86








Compound A
Compound B





6J-1


embedded image

  [Z-J-B-601]



embedded image

  [Z-J-B-612]













Compound C





6J-2


embedded image

  [III-J-B]










In a similar way, in Tables 87 to 89, compound B can be prepared from compound A. Compound B is transformed to compound C by Preparation method 5′ etc.











TABLE 87








Compound A
Compound B





6J-3


embedded image

  [Z-J-C-601]



embedded image

  [Z-J-C-612]













Compound C





6J-4


embedded image

  [III-J-C]



















TABLE 88








Compound A
Compound B





6J-5


embedded image

  [Z-J-D2-601]



embedded image

  [Z-J-D2-612]













Compound C





6J-6


embedded image

  [III-J-D2]



















TABLE 89








Compound A
Compound B





6J-7


embedded image

  [Z-J-D1-601]



embedded image

  [Z-J-D1-609]













Compound C





6J-8


embedded image

  [III-J-D1]










Preparation Method 6K

When




embedded image


is




embedded image


embedded image


(Step 1)


Compound [Z-K-D1-602] can be obtained by reacting Compound [Z-K-D1-601] with diphenylphosphoryl azide (DPPA) and an alcohol in the presence of a base in a solvent.


Examples of the solvent for the reaction include methanol, ethanol, isopropyl alcohol, tert-butanol, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, ethyl acetate, methyl acetate, butyl acetate, N,N-dimethylformamide, and acetonitrile.


Examples of the base for the reaction include an organic base such as triethylamine, N,N-diisopropylethylamine, and pyridine.


Examples of the alcohol for the reaction include methanol, ethanol, isopropyl alcohol, tert-butanol, and benzyl alcohol.


The reaction temperature usually ranges about 0° C. to 150° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 2)


Compound [Z-K-D1-603] can be obtained by removal of the protecting group PN1 from Compound [Z-K-D1-602] in the presence of an acid in a solvent.


Examples of the solvent for the reaction include methanol, ethanol, isopropyl alcohol, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, ethyl acetate, methyl acetate, butyl acetate, N,N-dimethylformamide, acetonitrile, acetic acid, and water.


Examples of the acid for the reaction include hydrochloric acid, hydrobromic acid, sulfuric acid, and trifluoroacetic acid.


The reaction temperature usually ranges about 0° C. to 150° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 3)


Compound [Z-K-D1-604] can be obtained by reacting Compound [Z-K-D1-603] with imidazole-1-sulfonyl azide hydrochloride in the presence of a base in a solvent.


Examples of the solvent for the reaction include methanol, ethanol, isopropyl alcohol, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, ethyl acetate, methyl acetate, butyl acetate, N,N-dimethylformamide, and acetonitrile.


Examples of the base for the reaction include potassium carbonate, and sodium carbonate.


The reaction temperature usually ranges about 0° C. to 150° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 4)


Compound [Z-K-D1-606] can be obtained by reacting Compound [Z-K-D1-605] with N,O-dimethylhydroxylamine or a hydrochloride salt thereof in the presence of a condensation reagent in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, and acetone; which may be used alone or as a mixture of two or more.


Examples of the condensation reagent for the reaction include water-soluble carbodiimide (WSC.HCl: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride), N,N′-dicyclohexylcarbodiimide (DCC), diphenylphosphoryl azide (DPPA), and carbonyldiimidazole (CDI). As necessary, 1-hydroxy-1H-benzotriazole monohydrate (HOBt.H2O), 4-dimethylaminopyridine (DMAP), and the like may be added.


The reaction temperature usually ranges about room temperature to 120° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 5)


Compound [Z-K-D1-607] can be obtained by reacting Compound [Z-K-D1-606] in the presence of a reducing agent in a solvent. Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme; which may be used alone or as a mixture of two or more.


Examples of the reducing agent for the reaction include diisobutylaluminium hydride and lithium aluminium hydride.


The reaction temperature usually ranges about −78° C. to room temperature.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 6)


Compound [Z-K-D1-608] can be obtained by reacting Compound [Z-K-D1-607] with dimethyl(1-diazo-2-oxopropyl)phosphonate in a solvent.


Examples of the solvent for the reaction include methanol, ethanol, isopropyl alcohol, tert-butanol, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, ethyl acetate, methyl acetate, butyl acetate, N,N-dimethylformamide, and acetonitrile.


The reaction temperature usually ranges about 0° C. to 150° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 7)


Compound [Z-K-D1-609] can be obtained by reacting Compound [Z-K-D1-608] with Compound [Z-K-D1-604] in a solvent.


Examples of the solvent for the reaction include methanol, ethanol, isopropyl alcohol, tert-butanol, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, ethyl acetate, methyl acetate, butyl acetate, N,N-dimethylformamide, and acetonitrile.


The reaction temperature usually ranges about 0° C. to 150° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 8)


Compound [Z-K-D1-611] can be obtained by reacting Compound [Z-K-D1-609] with Compound [Z-K-D1-610] in the presence of a metal catalyst in a solvent.


As the Compound [Z-K-D1-610], alkylboronic acid, alkylboronic acid ester, alkylzinc reagent, alkylmagnesium reagent, and the like may be used.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, acetone, and water; which may be used alone or as a mixture of two or more.


Examples of the metal catalyst for the reaction include a palladium catalyst such as bis(triphenylphosphine)palladium(II) dichloride and 1,1′-bis(diphenylphosphino)ferrocene-palladium(II) dichloride; a nickel catalyst such as [1,2-bis(diphenylphosphino)ethane]nickel(II) dichloride and nickel(II) acetylacetonate; and an iron catalyst such as iron(III) chloride.


As necessary, a base or an inorganic salt may be added. Examples of the base or the inorganic salt for the reaction include tripotassium phosphate, sodium carbonate, potassium carbonate, sodium acetate, and cesium fluoride.


The reaction temperature usually ranges about −10° C. to 150° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 9)


Compound [Z-K-D1-612] can be obtained from Compound [Z-K-D1-611] in a solvent under a commonly-used condition of ester hydrolysis reaction.


The ester hydrolysis reaction may be performed under the alkaline or acidic condition.


Examples of the base for the alkaline condition include an aqueous solution of alkali metal hydroxide such as lithium hydroxide, sodium hydroxide, and potassium hydroxide.


Examples of the acid for the acidic condition include hydrochloric acid, hydrobromic acid, sulfuric acid, and trifluoroacetic acid.


Examples of the solvent for the reaction include toluene, methanol, ethanol, isopropyl alcohol, tetrahydrofuran, dioxane, water; which may be used alone or as a mixture of two or more.


The reaction temperature usually ranges about 0° C. to 120° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Outline)


As described below, “compound B” can be prepared from “compound A” by the above preparation methods. Further, “compound B” is transformed to “compound C” by the above Preparation method 5′ (amidation reaction etc.). Specifically, in Table 90, Compound [Z-K-B-612] can be prepared from Compound [Z-K-B-606] by the above preparation methods.


Compound [Z-K-B-612] is transformed to Compound [III-K-B] by the above Preparation method 5′ (amidation reaction etc.).











TABLE 90








Compound A
Compound B





6K-1


embedded image

  [Z-K-B-605]



embedded image

  [Z-K-B-612]













Compound C





6K-2


embedded image

  [III-K-B]










In a similar way, in Tables 91 to 93, compound B can be prepared from compound A. Compound B is transformed to compound C by Preparation method 5′ etc.











TABLE 91








Compound A
Compound B





6K-3


embedded image

  [Z-K-C-605]



embedded image

  [Z-K-C-612]













Compound C





6K-4


embedded image

  [III-K-C]



















TABLE 92








Compound A
Compound B





6K-5


embedded image

  [Z-K-D2-605]



embedded image

  [Z-K-D2-612]













Compound C





6K-6


embedded image

  [III-K-D2]



















TABLE 93








Compound A
Compound B





6K-7


embedded image

  [Z-K-D1-605]



embedded image

  [Z-K-D1-612]













Compound C





6K-8


embedded image

  [III-K-D1]










Preparation Method 6L

When




embedded image


is




embedded image


(Step 1)


Compound [Z-L-D1-602] can be obtained by reacting Compound [Z-L-D1-601] with N,O-dimethylhydroxylamine or a hydrochloride salt thereof in the presence of a condensation reagent in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, and acetone; which may be used alone or as a mixture of two or more.


Examples of the condensation reagent for the reaction include water-soluble carbodiimide (WSC.HCl: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride), N,N′-dicyclohexylcarbodiimide (DCC), diphenylphosphoryl azide (DPPA), and carbonyldiimidazole (CDI). As necessary, 1-hydroxy-1H-benzotriazole monohydrate (HOBt.H2O), 4-dimethylaminopyridine (DMAP), and the like may be added.


The reaction temperature usually ranges about room temperature to 120° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 2)


Compound [Z-L-D1-603] can be obtained by reacting Compound [Z-L-D1-602] in the presence of a reducing agent in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme; which may be used alone or as a mixture of two or more.


Examples of the reducing agent for the reaction include diisobutylaluminium hydride and lithium aluminium hydride.


The reaction temperature usually ranges about −78° C. to room temperature.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 3)


Compound [Z-L-D1-604] can be obtained by reacting Compound [Z-L-D1-603] with hydroxylamine or a hydrochloride salt thereof in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, methanol, ethanol, acetonitrile, water; which may be used alone or as a mixture of two or more.


When the hydrochloride salt of hydroxylamine is used, examples of the base for the reaction include pyridine, triethylamine, sodium hydroxide, sodium acetate, potassium carbonate, sodium carbonate, and sodium hydrogen carbonate.


The reaction temperature usually ranges about −10° C. to 130° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 4)


Compound [Z-L-D1-605] can be obtained by reacting Compound [Z-L-D1-604] in the presence of a chlorinating agent in a solvent.


Examples of the solvent for the reaction include dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, N,N-dimethylformamide, acetic acid; which may be used alone or as a mixture of two or more.


Examples of the halogenating agent for the reaction include chlorine and N-chlorosuccinimide.


The reaction temperature usually ranges about −10° C. to 100° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 5)


Compound [Z-L-D1-607] can be obtained by reacting Compound [Z-L-D1-606] with N,O-dimethylhydroxylamine or a hydrochloride salt thereof in the presence of a condensation reagent in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, and acetone; which may be used alone or as a mixture of two or more.


Examples of the condensation reagent for the reaction include water-soluble carbodiimide (WSC.HCl: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride), N,N′-dicyclohexylcarbodiimide (DCC), diphenylphosphoryl azide (DPPA), and carbonyldiimidazole (CDI). As necessary, 1-hydroxy-1H-benzotriazole monohydrate (HOBt.H2O), 4-dimethylaminopyridine (DMAP), and the like may be added.


The reaction temperature usually ranges about room temperature to 120° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 6)


Compound [Z-L-D1-608] can be obtained by reacting Compound [Z-L-D1-607] in the presence of a reducing agent in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme; which may be used alone or as a mixture of two or more.


Examples of the reducing agent for the reaction include diisobutylaluminium hydride and lithium aluminium hydride.


The reaction temperature usually ranges about −78° C. to room temperature.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 7)


Compound [Z-L-D1-609] can be obtained by reacting Compound [Z-L-D1-608] with dimethyl(1-diazo-2-oxopropyl)phosphonate in a solvent.


Examples of the solvent for the reaction include methanol, ethanol, isopropyl alcohol, tert-butanol, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, ethyl acetate, methyl acetate, butyl acetate, N,N-dimethylformamide, and acetonitrile.


The reaction temperature usually ranges about 0° C. to 150° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 8)


Compound [Z-L-D1-610] can be obtained by reacting Compound [Z-L-D1-609] with [Z-L-D1-605] in the presence of a base in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, water; which may be used alone or as a mixture of two or more.


Examples of the base for the reaction include triethylamine, sodium hydroxide, potassium carbonate, sodium carbonate, and sodium hydrogen carbonate.


The reaction temperature usually ranges about 0° C. to 150° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 9)


Compound [Z-G-D1-611] can be obtained by reacting Compound [Z-L-D1-610] in the presence of a halogenating agent in a solvent.


Examples of the solvent for the reaction include dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, N,N-dimethylformamide, acetic acid; which may be used alone or as a mixture of two or more.


Examples of the halogenating agent for the reaction include bromine, iodine, iodine monochloride, N-bromosuccinimide, N-iodosuccinimide, and 1,3-dibromo-5,5-dimethylhydantoin. As necessary, cerium(IV) diammonium nitrate, trifluoroacetic acid, and the like may be added.


The reaction temperature usually ranges about −10° C. to 100° C.


The reaction time usually ranges about 1 hr to 3 days.


(Step 10)


Compound [Z-L-D1-613] can be obtained by reacting Compound [Z-L-D1-611] with Compound [Z-L-D1-612] in the presence of a metal catalyst in a solvent.


As the Compound [Z-L-D1-612], alkylboronic acid, alkylboronic acid ester, alkylzinc reagent, alkylmagnesium reagent, and the like may be used.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, acetone, and water; which may be used alone or as a mixture of two or more.


Examples of the metal catalyst for the reaction include a palladium catalyst such as bis(triphenylphosphine)palladium(II) dichloride and 1,1′-bis(diphenylphosphino)ferrocene-palladium(II) dichloride; a nickel catalyst such as [1,2-bis(diphenylphosphino)ethane]nickel(II) dichloride and nickel(II) acetylacetonate; and an iron catalyst such as iron(III) chloride.


As necessary, a base or an inorganic salt may be added. Examples of the base or the inorganic salt for the reaction include tripotassium phosphate, sodium carbonate, potassium carbonate, sodium acetate, and cesium fluoride.


The reaction temperature usually ranges about −10° C. to 150° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 11)


Compound [Z-L-D1-614] can be obtained from Compound [Z-L-D1-613] in a solvent under a commonly-used condition of ester hydrolysis reaction.


The ester hydrolysis reaction may be performed under the alkaline or acidic condition.


Examples of the base for the alkaline condition include an aqueous solution of alkali metal hydroxide such as lithium hydroxide, sodium hydroxide, and potassium hydroxide.


Examples of the acid for the acidic condition include hydrochloric acid, hydrobromic acid, sulfuric acid, and trifluoroacetic acid.


Examples of the solvent for the reaction include toluene, methanol, ethanol, isopropyl alcohol, tetrahydrofuran, dioxane, water; which may be used alone or as a mixture of two or more.


The reaction temperature usually ranges about 0° C. to 120° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Outline)


As described below, “compound B” can be prepared from “compound A” by the above preparation methods. Further, “compound B” is transformed to “compound C” by the above Preparation method 5° (amidation reaction etc.). Specifically, in Table 94, Compound [Z-L-B-614]] can be prepared from Compound [Z-L-B-606] by the above preparation methods.


Compound [Z-L-B-614] is transformed to Compound [III-L-B] by the above Preparation method 5′ (amidation reaction etc.).











TABLE 94








Compound A
Compound B





6L-1


embedded image

  [Z-L-B-606]



embedded image

  [Z-L-B-614]













Compound C





6L-2


embedded image

  [III-L-B]










In a similar way, in Tables 95 to 97, compound B can be prepared from compound A. Compound B is transformed to compound C by Preparation method 5′ etc.











TABLE 95








Compound A
Compound B





6L-3


embedded image

  [Z-L-C-606]



embedded image

  [Z-L-C-614]













Compound C





6L-4


embedded image

  [III-L-C]



















TABLE 96








Compound A
Compound B





6L-5


embedded image

  [Z-L-D2-606]



embedded image

  [Z-L-D2-614]













Compound C





6L-6


embedded image

  [III-L-D2]



















TABLE 97








Compound A
Compound B





6L-7


embedded image




embedded image





[Z-L-D1-606]
[Z-L-D1-609]











6L-8
Compound C








embedded image





[III-L-D1]









Preparation Method 7
Synthesis Process of [III-X-D2], [III-J-D2], [III-X-D1], and [III-J-D1]
Preparation Method 7-1 (Another Synthesis Process)



embedded image


(Step 1)


Compound [Z-X-D2-703] can be obtained by reacting Compound [Z-X-D2-701] with AUX-H [Z-X-D2-702] in the presence of a condensation reagent in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, dichloromethane, chloroform, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, and acetone; which may be used alone or as a mixture of two or more.


Examples of the condensation reagent for the reaction include water-soluble carbodiimide (WSC.HCl: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride), N,N′-dicyclohexylcarbodiimide (DCC), diphenylphosphoryl azide (DPPA), and carbonyldiimidazole (CDI). As necessary, 1-hydroxy-1H-benzotriazole monohydrate (HOBt.H2O), 4-dimethylaminopyridine (DMAP), and the like may be added.


The reaction temperature usually ranges about room temperature to 120° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 2)


Compound [Z-X-D2-705] can be obtained by reacting Compound [Z-X-D2-703] with [Z-X-D2-704] in the presence of a base in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme; which may be used alone or as a mixture of two or more.


Examples of the base for the reaction include sodium hexamethyldisilazide, lithium hexamethyldisilazide, and lithium diisopropylamide (LDA).


The reaction temperature usually ranges about −78° C. to 50° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 3)


Compound [Z-X-D2-706] can be obtained by hydrolysis reaction of Compound [Z-X-D2-705] in a solvent.


The hydrolysis reaction may be performed under the commonly-used condition, for example, under the alkaline condition.


Examples of the base for the reaction include lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium peroxide, potassium peroxide, and sodium peroxide.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, methanol, ethanol, isopropyl alcohol, tert-butanol, dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, acetone, water; which may be used alone or as a mixture of two or more.


The reaction temperature usually ranges about −30° C. to 80° C., preferably about 0° C. to room temperature.


The reaction time usually ranges about 30 minutes to 3 days, preferably about 30 minutes to 1 day.


(Supplementary Step)


For example, the following scheme is included.




embedded image


The same applies to the following 4,5,6,7-tetrahydro-benz[d]isoxazole.




embedded image


Preparation Method 7-2



embedded image


(Step 1)


Compound [Z-X-D1-H-D2-H-703] can be obtained by reacting Compound [Z-X-D1-H-D2-H-701] with AUX-H[Z-X-D1-H-D2-H-702] in the presence of a condensation reagent in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, dichloromethane, chloroform, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, and acetone; which may be used alone or as a mixture of two or more.


Examples of the condensation reagent for the reaction include water-soluble carbodiimide (WSC.HCl: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride), N,N′-dicyclohexylcarbodiimide (DCC), diphenylphosphoryl azide (DPPA), and carbonyldiimidazole (CDI). As necessary, 1-hydroxy-1H-benzotriazole monohydrate (HOBt.H2O) 4-dimethylaminopyridine (DMAP), and the like may be added.


The reaction temperature usually ranges about room temperature to 120° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 2)


Compound [Z-X-D1-H-D2-H-705] can be obtained by reacting Compound [Z-X-D1-H-D2-H-703] with [Z-X-D1-H-D2-H-704] in the presence of a base in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme; which may be used alone or as a mixture of two or more.


Examples of the base for the reaction include sodium hexamethyldisilazide, lithium hexamethyldisilazide, and lithium diisopropylamide (LDA).


The reaction temperature usually ranges about −78° C. to 50° C.


The reaction time usually ranges about 30 minutes to 3 days.


A reference for the above reaction is (J. Org. Chem. 1999, 64, 6411-6417).


(Step 3)


Compound [Z-X-D1-O-D2-O-701] can be obtained by hydrolysis reaction of Compound [Z-X-D1-H-D2-H-705] in a solvent.


The hydrolysis reaction may be performed under the commonly-used condition, for example, under the alkaline condition.


Examples of the base for the reaction include lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium peroxide, potassium peroxide, and sodium peroxide.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, methanol, ethanol, isopropyl alcohol, tert-butanol, dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, acetone, water; which may be used alone or as a mixture of two or more.


The reaction temperature usually ranges about −30° C. to 80° C.


The reaction time usually ranges about 30 minutes to 3 days.


For example, the following scheme is included.




embedded image


Preparation Method 7-3 (Synthesis of Stereoisomer)

The following “Rf” is C1-6 alkyl group.




embedded image


(Step 1)


Compound [Z-X-D1-H-D2-H-703] can be obtained by reacting Compound [Z-X-D1-H-D2-H-701] with AUX-H[Z-X-D1-H-D2-H-702] in the presence of a condensation reagent in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, dichloromethane, chloroform, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, and acetone; which may be used alone or as a mixture of two or more.


Examples of the condensation reagent for the reaction include water-soluble carbodiimide (WSC.HCl: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride), N,N′-dicyclohexylcarbodiimide (DCC), diphenylphosphoryl azide (APPA), and carbonyldiimidazole (CDI). As necessary, 1-hydroxy-1H-benzotriazole monohydrate (HOBt.H2O), 4-dimethylaminopyridine (DMAP), and the like may be added.


The reaction temperature usually ranges about room temperature to 120° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 2)


Compound [Z-X-D1-H-D2-H-705] can be obtained by reacting Compound [Z-X-D1-H-D2-H-703] with Compound [Z-X-D1-H-D2-H-704] in the presence of a base in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme; which may be used alone or as a mixture of two or more.


Examples of the base for the reaction include sodium hexamethyldisilazide, lithium hexamethyldisilazide, and lithium diisopropylamide (LDA).


The reaction temperature usually ranges about −78° C. to 50° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 3)


Compound [Z-X-D1-O-D2-O-701] can be obtained by hydrolysis reaction of Compound [Z-X-D1-H-D2-H-705] in a solvent.


The hydrolysis reaction may be performed under the commonly-used condition, for example, under the alkaline condition.


Examples of the base for the reaction include lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium peroxide, potassium peroxide, and sodium peroxide.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, methanol, ethanol, isopropyl alcohol, tert-butanol, dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, acetone, water; which may be used alone or as a mixture of two or more.


The reaction temperature usually ranges about −30° C. to 80° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 4)


Compound [Z-X-D1-O-D2-O-701] can be obtained by reacting Compound [Z-X-D1-O-D2-H-706] with Compound [Z-X-D1-H-D2-H-707] in the presence of lithium diisopropylamide (LDA) in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme; which may be used alone or as a mixture of two or more.


The reaction temperature usually ranges about −78° C. to 50° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Supplementary Step)


Compound [III-X-D1-O-D2-O-701] can be obtained from Compound [Z-X-D1-O-D2-O-701] by Preparation method 5′, Preparation method 6, and the like.




embedded image


Separation of Diastereomer (Intermediate, Product)

For example, silica-gel column chromatography, recrystallization, and the like are used for the separation. Separation of Racemic form (intermediate, product)


Each optically-active compound can be obtained by sepalating a racemic form by high-performance liquid chromatograph with a chiral stationary phase column.


For example, the condition is as follows:


Instrument: Recycle preparative HPLC LC908 type (Japan Analytical Industry)


Column: DAICEL CHIRALPAK AD 20 mmφ×250 mm


Column temperature: room temperature


Mobile phase: ethanol


Flow rate: 0.5 ml/min


Detection: UV (254 nm).

Each isomer can be obtained by the above process.


Preparation Method 8
Synthesis Process of [III-X-C] and [III-J-C]



embedded image


Each step of the above Preparation method 8 is as follows.


Preparation Method 8-1 (Ring-Forming Step)



embedded image


can be performed according to Preparation method 6.


Preparation Method 8-2 (Amide-Formation Step)



embedded image


can be performed according to Preparation method 5′.


(Supplementary)


When “Rw” has carbonyl group, a protection of the carbonyl group is appropriately selected.


For example, when “Rw” is “—(CH2)2—C(═O)—OH”,


“Rw” protected by a protecting group includes “—(CH2)2—C(═O)—OCH3” and the like.


Preparation Method 8-3 (Example of Preparation Method)

For example, the product (right column) can be prepared from the intermediate (left column) in a similar way to the above Preparation methods.











TABLE 98






Intermediate
Product







8-1


embedded image

[Z-X-C3-801]



embedded image






[III-X-C3]





8-2


embedded image

[Z-X-C4-801]



embedded image






[III-X-C4]





8-3


embedded image

[Z-X-C5-801]



embedded image






[III-X-C5]





8-4


embedded image

[Z-X-C6-801]



embedded image






[III-X-C6]


















TABLE 99






Intermediate
Product







8-5


embedded image

[Z-X-N5-801]



embedded image






[III-X-N5]





8-6


embedded image

[Z-X-N5O-801]



embedded image






[III-X-N5O]





8-7


embedded image

[Z-X-N5O-801]



embedded image






[III-X-N5O]





8-8


embedded image

[Z-X-N61-801]



embedded image






[III-X-N61]





8-9


embedded image

[Z-X-N62-801]



embedded image






[III-X-N62]


















TABLE 100






Intermediate
Product







8-10


embedded image

[Z-X-CO-801]



embedded image






[III-X-CO]





8-11


embedded image

[Z-X-CDU-801]



embedded image






[III-X-CDU]





8-12


embedded image

[Z-X-CUU-801]



embedded image






[III-X-CUU]


















TABLE 101







8-13


embedded image

[Z-X-CUD-801]



embedded image






[III-X-CUD]





8-14


embedded image

[Z-X-CDD-801]



embedded image






[III-X-CDD]









Preparation Method 9
Synthesis Process of “Ring P”
Preparation Method 9-1



embedded image


(Step 1)


Compound [III-X-D1-901] can be obtained by reacting Compound [Z-X-D1-901] with azidotrimethyltin or sodium azide in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, N,N-dimethylformamide, N,N-dimethylacetamide, dimethyl sulfoxide, acetone, water; which may be used alone or as a mixture of two or more.


The reaction temperature usually ranges about room temperature to 180° C.


The reaction time usually ranges about 30 minutes to 3 days.




embedded image


Preparation Method 9-2



embedded image


(Step 1)


Compound [Z-X-D1-902-2] can be obtained by reacting Compound [Z-X-D1-902] with hydroxylamine or a hydrochloride salt thereof in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, N,N-dimethylformamide, dimethyl sulfoxide, ethanol, methanol; which may be used alone or as a mixture of two or more.


The reaction temperature usually ranges about room temperature to 120° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 2)


Compound [III-X-D1-902] can be obtained by reacting Compound [Z-X-D1-902-2] with N,N′-carbonyldiimidazole (CDI) in the presence of a base in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, ethanol, methanol; which may be used alone or as a mixture of two or more.


Examples of the base for the reaction include 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU).


The reaction temperature usually ranges about 0° C. to 120° C.


The reaction time usually ranges about 30 minutes to 3 days.


Preparation Method 9-3



embedded image


(Step 1)


Compound [Z-X-D1-903-2] can be obtained by reacting Compound [Z-X-D1-903] with bromoethyl acetate in the presence of a base in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile; which may be used alone or as a mixture of two or more.


Examples of the base for the reaction include triethylamine, and N,N-diisopropylethylamine.


The reaction temperature usually ranges about room temperature to 120° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 2)


Compound [Z-X-D1-903-3] can be obtained by reacting Compound [Z-X-D1-903-2] with potassium cyanate in a solvent.


Examples of the solvent for the reaction include benzene, toluene, xylene, hexane, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, ethanol, methanol, and acetic acid; which may be used alone or as a mixture of two or more.


The reaction temperature usually ranges about room temperature to 120° C.


The reaction time usually ranges about 30 minutes to 3 days.


(Step 3)


Compound [III-X-D1-903] can be obtained by a reaction of Compound [Z-X-D1-903-3] in a solvent under an acidic condition.


Examples of the acid for the acidic condition include hydrochloric acid, hydrobromic acid, sulfuric acid, and trifluoroacetic acid.


Examples of the solvent for the reaction include toluene, methanol, ethanol, isopropyl alcohol, tetrahydrofuran, dioxane, water; which may be used alone or as a mixture of two or more.


The reaction temperature usually ranges about room temperature to 120° C.


The reaction time usually ranges about 30 minutes to 3 days.


Preparation Method 9
Supplementary

As for a synthesis process of “ring P”, CAMILLE G. WERMUTH (1996) Molecular Variations Based on Isosteric Replacements. In CAMILLE G. WERMUTH (ed.) The Practice of Medicinal Chemistry, pp. 203-237. ACADEMIC PRESS can be used as a reference, besides the above Preparation methods 9-1, 9-2, 9-3.




embedded image


Preparation Method 9
Outline

The following compound can be obtained by Preparation method 9.










TABLE 102









embedded image




embedded image




[III-X-C-RWP]
[III-J-C-RWP]







embedded image




embedded image




[III-X-D2-RCP]
[III-J-D2-RCP]







embedded image




embedded image




[III-X-D1-RCP]
[III-J-D1-RCP]









In the above table,




embedded image


(that is, ring P) is




embedded image


Preparation Method 10
Synthesis Process of “Ra
Preparation Method 10-1

Example of the synthesis process of “Ra




embedded image


(Step 1)


Compound [Z-X-RA-102] can be obtained by an amidation reaction of Compound [Z-X-RA-101] with piperidine in the presence of a condensation reagent in a solvent.


Examples of the solvent for the reaction include hydrocarbon solvent such as benzene, toluene, xylene, and hexane; halogenated solvent such as methylene chloride, chloroform, carbon tetrachloride, and 1,2-dichioroethane; ethers solvent such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, and diglyme; polar solvent such as N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, and acetone; which may be used alone or as a mixture of two or more. Preferred examples of the solvent for the reaction include methylene chloride, chloroform, and N,N-dimethylformamide.


Examples of the condensation reagent for the reaction include water-soluble carbodiimide (WSC.HCl: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride), N,N′-dicyclohexylcarbodiimide (DCC), diphenylphosphoryl azide (DPPA), and carbonyldiimidazole (CDI). As necessary, 1-hydroxy-1H-benzotriazole monohydrate (HOBt.H2O), 4-dimethylaminopyridine (DMAP), and the like may be added. Preferred examples of the condensation reagent include a mixture of water-soluble carbodiimide (WSC.HCl: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride) and 1-hydroxy-1H-benzotriazole monohydrate (HOBt.H2O), or a mixture of water-soluble carbodiimide (WSC.HCl: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride) and 4-dimethylaminopyridine (DMAP).


The reaction temperature usually ranges about room temperature to 120° C., preferably from about room temperature to 100° C.


The reaction time usually ranges about 30 minutes to 3 days, preferably about 1 hr to 1 day.


(Step 2)


Compound [Z-X-RA-103] can be obtained by reacting Compound [Z-X-RA-102] with 1,1,3,3-tetramethyldisiloxane in the presence of (Ph3P)IrCl(CO) in a solvent.


Examples of the solvent for the reaction include hydrocarbon solvent such as benzene, toluene, xylene, and hexane; halogenated solvent such as methylene chloride, chloroform, carbon tetrachloride, and 1,2-dichloroethane; ethers solvent such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, and diglyme; polar solvent such as acetonitrile; which may be used alone or as a mixture of two or more. Preferred examples of the solvent for the reaction include toluene.


The reaction temperature usually ranges about 0° C. to 120° C., preferably from about room temperature to 100° C. The reaction time usually ranges about 30 minutes to 2 days, preferably about 30 minutes to 1 day.


(Step 3)


Compound [Z-X-RA-104] can be obtained by reacting Compound [Z-X-RA-103] with ethyl acrylate in a solvent.


Examples of the solvent for the reaction include hydrocarbon solvent such as benzene, toluene, xylene, and hexane; halogenated solvent such as methylene chloride, chloroform, carbon tetrachloride, and 1,2-dichloroethane; ethers solvent such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, and diglyme; polar solvent such as N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, and acetone; which may be used alone or as a mixture of two or more. Preferred examples of the solvent for the reaction include acetonitrile.


The reaction temperature usually ranges about room temperature to 150° C., preferably from about room temperature to 120° C.


The reaction time usually ranges about 30 minutes to 2 days, preferably about 1 hr to 1 day.


(Step 4)


Compound [Z-X-RA-105] can be obtained by quaternizing the amino group of Compound [Z-X-RA-104] with p-toluenesulfonic acid and the like followed by reacting the quaternized Compound [Z-X-RA-104] with a base.


Examples of the base for the reaction include an aqueous solution of alkali metal hydroxide such as lithium hydroxide, sodium hydroxide, and potassium hydroxide. Preferred examples of the base for the reaction include an aqueous solution of potassium hydroxide.


The reaction temperature usually ranges about room temperature to 150° C., preferably from about room temperature to 120° C.


The reaction time usually ranges about 30 minutes to 2 days, preferably about 1 hr to 1 day.


(Step 5A)


3-Substituted cyclobutanecarboxylic acid [Z-X-RA-T-106] can be obtained by the catalytic hydrogenation reaction of Compound [Z-X-RA-105] in a solvent under normal pressure or medium pressure (for example, 3 atm).


Examples of the catalyst for the catalytic hydrogenation reaction include palladium on activated carbon, rhodium on activated carbon, palladium hydroxide, and Raney nickel. Preferred examples of the catalyst for the reaction include palladium on activated carbon and rhodium on activated carbon.


Examples of the solvent for the catalytic hydrogenation reaction include alcohols solvent such as methanol, ethanol, isopropyl alcohol, and tert-butanol; esters solvent such as ethyl acetate, methyl acetate, and butyl acetate; ethers solvent such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, and diglyme; acetic acid, water; which may be used alone or as a mixture of two or more. Preferred examples of the solvent for the reaction include methanol, and tetrahydrofuran.


The reaction temperature usually ranges about room temperature to 100° C., preferably from about room temperature to 80° C.


The reaction time usually ranges about 30 minutes to 7 days, preferably about 1 hr to 5 days.


(Step 5B)


3-Substituted cyclobutanecarboxylic acid [Z-X-RA-C-106] can be obtained by a reduction reaction of Compound [Z-X-RA-105] using zinc in the presence of hydrochloric acid in a solvent.


[Z-X-RA-C-106] is a stereoisomer (cis-trans isomer) of [Z-X-RA-T-106].


Examples of the solvent for the reaction include ethers solvent such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, and diglyme; acetic acid, water; which may be used alone or as a mixture of two or more. Preferred examples of the solvent for the reaction include tetrahydrofuran and water.


The reaction temperature usually ranges about room temperature to 150° C., preferably from about room temperature to 120° C.


The reaction time usually ranges about 30 minutes to 3 days, preferably about 1 hr to 1 day.


By Preparation method 5′, Preparation method 6, and the like, the following product (right column) wherein “Ra” is as shown in the following formulas can be obtained from [Z-X-RA-T-106] or [Z-X-RA-C-106] prepared in Preparation Method 10.











TABLE 103






Intermediate
Product







10-1C


embedded image




embedded image





[Z-X-RA-C-106]
[III-RA-C-X-B]





10-1T


embedded image




embedded image





[Z-X-RA-T-106]
[III-RA-T-X-B]









In a similar way, the product (right column) can be obtained.











TABLE 104






Intermediate
Product







10-2C


embedded image

[Z-X-RA-C-106]



embedded image






[III-RA-C-X-C]





10-2T


embedded image

[Z-X-RA-T-106]



embedded image






[III-RA-T-X-C]


















TABLE 105







10-3C


embedded image

[Z-X-RA-C-106]



embedded image






[III-RA-C-X-D2]





10-3T


embedded image

[Z-X-RA-T-106]



embedded image






[III-RA-T-X-D2]


















TABLE 106







10-4C


embedded image

[Z-X-RA-C-106]



embedded image






[III-RA-C-X-D1]





10-4T


embedded image

[Z-X-RA-T-106]



embedded image






[III-RA-T-X-D1]









For example, the following aspects are included.











TABLE 107







10-5C


embedded image

[Z-X-RA-C-106]



embedded image






[III-RA-C-F-D1]


















TABLE 108







10-6C


embedded image

[Z-X-RA-C-106]



embedded image






[III-RA-C-H-D1]


















TABLE 109







10-7C


embedded image

[Z-X-RA-C-106]



embedded image






[III-RA-C-K-D1]


















TABLE 110







10-8C


embedded image

[Z-X-RA-C-106]



embedded image






[III-RA-C-G-D1]


















TABLE 111







10-9C


embedded image

[Z-X-RA-C-106]



embedded image






[III-RA-C-L-D1]









Preparation Method 10-2

When Ra is “cross-linked cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A”, for example, the following commercially available carboxylic acid compounds can be used.




embedded image


For example, the following aspect is included.




embedded image


When Ra is “spirocyclic cycloalkyl group which may optionally be substituted with the same or different 1 to 5 substituents selected from Group A”, for example, the following commercially available carboxylic acid compounds or ester compounds, or derivatives therefrom can be used.




embedded image


When Ra is “a group which is substituted with amino group”; “a group which is substituted with alkylcarbonylamino group”; or “a group which is substituted with alkylsulfonylamino group”, for example, the following commercially available carboxylic acid compound, or derivatives therefrom can be used.




embedded image


For example, the following aspect is included.




embedded image


EXAMPLES

According to the above preparation methods, the compounds listed in Tables 112 to 359 were prepared.


The following working Examples serve to illustrate the present invention more specifically, which does not intend to limit the present invention.


Example E-58
Sodium (S)-4-[4′-cyclopropyl-5-(2,2-dimethyl-propyl)-[3,5′]biisoxazolyl-3′-yl]-5-(2,4-dichloro-phenylcarbamoyl)-pentanoate
E-58-1
5-Benzyloxy-pentanoic acid



embedded image


Toluene (1700 mL) and aqueous 48 w/v % potassium hydroxide (942 mL) were mixed. δ-Valerolactone (300 g) was added dropwise to the mixture at 95° C. Benzyl bromide (1425 mL) was added dropwise to the reaction mixture at 115° C., and then the mixture was stirred for 3 hrs. Aqueous 48 w/v % potassium hydroxide (353 mL) was added to the reaction mixture at 115° C., and then the mixture was stirred for 3 hrs. Water (2100 mL) and tert-butyl methyl ether (420 mL) was added to the reaction mixture at ice temperature. The aqueous layer was separated, and washed with tert-butyl methyl ether (1500 mL×3). Toluene (1500 mL) and concentrated hydrochloric acid (420 mL) were added to the aqueous layer at ice temperature. The organic layer was separated, and washed with water (1500 mL×2). The organic layer was concentrated under reduced pressure to give the title compound (416.5 g, containing toluene 6 w/w %, by NMR) as a crude product.


E-58-2
(R)-4-Benzyl-3-(5-benzyloxy-pentanoyl)-oxazolidin-2-one



embedded image


5-Benzyloxy-pentanoic acid (787 g, which is a corrected value regarding the amount of the contained solvent based on NMR) and acetonitrile (2200 mL) were mixed. (R)-4-Benzyl-2-oxazolidinone (559 g) and 4-dimethylaminopyridine (116 g) were added to the mixture. WSC.HCl (798 g) was added in two portions to the reaction mixture at room temperature. The resulting mixture was stirred overnight. Toluene (3500 mL) and aqueous 2 M hydrochloric acid (3000 mL) were added to the reaction mixture at room temperature. The organic layer was separated, and washed with aqueous 20 w/v % sodium chloride (2000 mL), a mixture of aqueous 7.5 w/v % sodium hydrogen carbonate (2000 mL) and aqueous 20 w/v % sodium chloride (1000 mL), and aqueous 20 w/v % sodium chloride (2000 mL) in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (1164 g, containing toluene, by NMR) as a crude product.


E-58-3
tert-Butyl (S)-3-((R)-4-benzyl-2-oxo-oxazolidine-3-carbonyl)-6-benzyloxy-hexanoate



embedded image


(R)-4-Benzyl-3-(5-benzyloxy-pentanoyl)-oxazolidin-2-one (1164 g, equivalent to 3.15 mol) and THF (2200 mL) were mixed. Sodium hexamethyldisilazide (1.9 M in THF) (2000 mL) was added dropwise to the mixture at −78° C. tert-Butyl bromoacetate (555 mL) was added dropwise to the reaction mixture at −78° C., and then the mixture was stirred for 3 hrs. N,N,N′-Trimethylethylenediamine (122 mL) was added dropwise to the reaction mixture. Aqueous 2 M hydrochloric acid (2810 mL) and THF (600 mL) were added to the reaction mixture at ice temperature. The organic layer was separated, and washed with water (2800 mL), aqueous 7.5 w/v % sodium hydrogen carbonate (2800 mL), and water (2800 mL) in this order. The organic layer was concentrated under reduced pressure to remove THF (about 1200 mL) partially. The resulting residue was directly used in the next step.


E-58-4
4-tert-butyl (S)-2-(3-benzyloxy-propyl)-succinate



embedded image


Lithium hydroxide monohydrate (145 g), THF (1120 mL), and water (1680 mL) were mixed. Aqueous 30 w/w % hydrogen peroxide (380 mL) was added dropwise to the mixture at ice temperature. The resulting mixture was stirred for 30 min tert-Butyl (S)-3-((R)-4-benzyl-2-oxo-oxazolidine-3-carbonyl)-6-benzyloxy-hexanoate (equivalent to 3.15 mol) was added dropwise to the reaction mixture at ice temperature with washing with THF (560 mL). The mixture was stirred for 1 hr at ice temperature, and for 2 hrs at room temperature. Aqueous 20 w/v % sodium hydrogen sulfite (3920 mL) was added dropwise to the reaction mixture at ice temperature. The organic layer was separated. Toluene (2800 mL) and water (1700 mL) were added to the organic layer. The resulting aqueous layer was separated and washed with toluene (2800 mL×2). Aqueous 2 M hydrochloric acid (1700 mL) was added to the combined aqueous layer, and the mixture was extracted with toluene (5000 mL). The organic layer was washed with water (2800 mL×2). The organic layer was concentrated under reduced pressure to give the title compound (870 g, containing toluene etc., by NMR) as a crude product.


E-58-5
4-tert-butyl (S)-2-(3-benzyloxy-propyl)-succinate (R)-1-phenyl-ethylamine salt



embedded image


4-tert-butyl (S)-2-(3-benzyloxy-propyl)-succinate (434 g, equivalent to 1.58 mol) and tert-butyl methyl ether (4200 mL) were mixed. (R)-1-Phenylethylamine (201 mL) was added dropwise to the mixture at room temperature. tert-Butyl methyl ether (840 mL) was added to the reaction mixture, and the resulting mixture was stirred for 1 hr at ice temperature. The resultant solid was collected by filtration, and dried under reduced pressure at room temperature. The solid (356 g) and tert-butyl methyl ether (2500 mL) were mixed, and the reaction temperature was risen to 85° C. The resulting mixture was stirred for 2 hrs at 55° C., and then overnight at room temperature. The resultant solid was collected by filtration, dried under reduced pressure at room temperature to give the title compound (321 g).


E-58-6
4-tert-Butyl (S)-2-(3-benzyloxypropyl)-succinate



embedded image


Aqueous 10 w/v % potassium hydrogen sulfate (1970 mL) and ethyl acetate (2180 mL) were mixed. 4-tert-butyl (S)-2-(3-benzyloxy-propyl)-succinate (R)-1-phenyl-ethylamine salt (544 g) was added in three portions to the mixture at room temperature. The resulting mixture was stirred for minutes at room temperature. The organic layer was separated, and washed with aqueous 10 w/v % potassium hydrogen sulfate, water, and aqueous 10 w/v % sodium chloride in this order. The organic layer was concentrated under reduced pressure, and then azeotroped with toluene to give the title compound (452 g, containing toluene) as a crude product. The resulting compound was analyzed using a chiral column. The retention time of the title compound was 13.1 min (the retention time of the optical isomer of the title compound was 12.1 min.), and the optical purity thereof was 99.9% ee.


The condition for the analysis using the chiral column was as follows:


Instrument: HPLC System Shimadzu High-performance liquid chromatograph Prominence


Column: DAICEL CHIRALPAK AD-3R 0.46 cm φ×15 cm

Column temperature: 40° C.


Mobile phase:


(Solution A) 10 mM phosphate buffer (pH=2.6), (Solution B) acetonitrile


Composition of Mobile phase: Solution A:Solution B=55:45


Flow rate: 0.5 mL/min


Detection: UV (220 nm)
E-58-7
tert-Butyl (S)-6-benzyloxy-3-(methoxy-methylcarbamoyl)-hexanoate



embedded image


4-tert-Butyl (S)-2-(3-benzyloxypropyl)-succinate (322 g), N,O-dimethylhydroxylamine hydrochloride salt (117 g), HOBt.H2O (30.6 g), and acetonitrile (480 mL) were mixed. Diisopropylethylamine (240 mL) was added to the mixture at ice temperature. WSC.HCl (230 g) was added in three portions to the reaction mixture at ice temperature, and the resulting mixture was stirred for 5 hrs at room temperature. Water was added to the reaction mixture. The resulting mixture was extracted with toluene. The organic layer was washed with aqueous 10 w/v % potassium hydrogen sulfate, aqueous 10 w/v % sodium chloride, aqueous 5 w/v % sodium hydrogen carbonate, and aqueous 10 w/v % sodium chloride in this order. The organic layer was concentrated under reduced pressure to give the title compound (500 g, containing toluene (13.4 w/w %), by NMR) as a crude product.


E-58-8
tert-Butyl (S)-6-benzyloxy-3-formyl-hexanoate



embedded image


tert-Butyl (S)-6-benzyloxy-3-(methoxy-methylcarbamoyl)-hexanoate (115 g, equivalent to 273 mmol) and THF (500 mL) were mixed. Diisobutylaluminium hydride (1.0 M in toluene) (356 mL) was added dropwise to the mixture at −78° C. The reaction mixture was stirred for 2 hrs at −78° C., and then was added dropwise to aqueous 1.0 M sulfuric acid (500 mL) at ice temperature. Ethyl acetate (500 mL) was added to the mixture. The organic layer was separated, and washed with 0.5 M sulfuric acid (500 mL×2), water (500 mL), and brine (500 mL) in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the organic layer was concentrated under reduced pressure to give the title compound (71.4 g) as a crude product.


E-58-9
tert-Butyl (S)-6-benzyloxy-3-(hydroxyimino-methyl)-hexanoate



embedded image


Hydroxylammonium chloride (11.6 g), ethanol (150 mL), and water (450 mL) were mixed. Aqueous 4 M sodium hydroxide (41.8 mL) was added dropwise to the mixture at ice temperature. A solution of tert-butyl (S)-6-benzyloxy-3-formyl-hexanoate (46.5 g, equivalent to 139 mmol) in ethanol (25 mL) and THF (50 m) was added dropwise to the reaction mixture at ice temperature. The mixture was stirred for 1 hr at ice temperature, and then toluene (300 mL) was added thereto. The organic layer was separated, and washed with water (300 mL) and brine (150 mL) in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (47.7 g) as a crude product.


E-58-10
tert-Butyl (S)-6-benzyloxy-3-(chloro-hydroxyimino-methyl)-hexanoate



embedded image


tert-Butyl (S)-6-benzyloxy-3-(hydroxyimino-methyl)hexanoate (15 g) and DMF (38 mL) were mixed. A solution of N-chlorosuccinimide (6.55 g) in DMF (23 mL) was added dropwise to the mixture under water-cooling. The resulting mixture was stirred for 1 hr at room temperature, and then toluene (90 mL) and water (90 mL) were added to the reaction mixture. The organic layer was separated, and washed with water (45 mL) and brine (45 mL) in this order, and the solution was directly used in the next step.


E-58-11
tert-Butyl (S)-6-benzyloxy-3-(5-hydroxymethyl-isoxazol-3-yl)-hexanoate



embedded image


Propargyl alcohol (37 g), toluene (40 mL), and aqueous 2 M potassium carbonate (25 mL) were mixed. The mixture was heated to 110° C. A solution of tert-butyl (S)-6-benzyloxy-3-(chloro-hydroxyimino-methyl)-hexanoate which was obtained in E-58-10 in toluene (equivalent to 46.7 mmol) was added dropwise to the reaction mixture, and the resulting mixture was stirred for 1 hr. Water was added to the reaction mixture. The organic layer was separated, and washed with water, and concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/1) to give the title compound (14.6 g).


E-58-12
tert-Butyl (S)-6-benzyloxy-3-(5-hydroxymethyl-4-iodo-isoxazol-3-yl)-hexanoate



embedded image


tert-Butyl (S)-6-benzyloxy-3-(5-hydroxymethyl-isoxazol-3-yl)-hexanoate (17.2 g) and acetonitrile (200 mL) were mixed. N-Iodosuccinimide (20.7 g) and ammonium cerium(IV) nitrate (12.6 g) were added to the mixture under water-cooling. The reaction mixture was stirred for 13 hrs at room temperature, and then added dropwise to aqueous 10 w/v % sodium sulfite (187 mL). To the mixture was added acetonitrile. And the mixture was filtered using Celite. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/2) to give the title compound (9.25 g).


E-58-13
tert-Butyl (S)-6-benzyloxy-3-(5-formyl-4-iodo-isoxazol-3-yl)-hexanoate



embedded image


tert-Butyl (S)-6-benzyloxy-3-(5-hydroxymethyl-4-iodo-isoxazol-3-yl)-hexanoate (9.25 g) and dichloromethane (70 mL) were mixed. Dess-Martin periodinane (8.77 g) was added to the mixture at ice temperature. The resulting mixture was stirred for 30 minutes at room temperature. Aqueous 20 w/v % sodium sulfite was added to the reaction mixture at ice temperature. Diethyl ether and aqueous saturated sodium hydrogen carbonate were added to the mixture. The resulting mixture was stirred for 1 hr at room temperature. The organic layer was separated, and washed with aqueous saturated sodium hydrogen carbonate (three times) and brine in this order. The organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (9.82 g).


E-58-14
tert-Butyl (S)-6-benzyloxy-3-[5-(hydroxyimino-methyl)-4-iodo-isoxazol-3-yl]-hexanoate



embedded image


Hydroxylammonium chloride (1.79 g), THF (20 mL), and water (15 mL) were mixed. Aqueous 4 M sodium hydroxide (6.45 mL) was added dropwise to the mixture at ice temperature. A mixture of tert-butyl (S)-6-benzyloxy-3-(5-formyl-4-iodo-isoxazol-3-yl)-hexanoate (9.8 g) and ethanol (50 mL) was added dropwise to the reaction mixture at ice temperature. The mixture was stirred at room temperature overnight. Then the pH of the reaction mixture was adjusted with aqueous 2 M hydrochloric acid to 4. Ethyl acetate was added to the reaction mixture. The organic layer was separated, and washed with water and brine in this order, and then concentrated under reduced pressure to give the title compound (9.48 g) as a crude product.


E-58-15
tert-Butyl (S)-6-benzyloxy-3-[5-(chloro-hydroxyimino-methyl)-4-iodo-isoxazol-3-yl]-hexanoate



embedded image


tert-Butyl (S)-6-benzyloxy-3-[5-(hydroxyimino-methyl)-4-iodo-isoxazol-3-yl]-hexanoate (2.5 g, equivalent to 4.38 mmol) and DMF (9.0 mL) were mixed. N-Chlorosuccinimide (646 mg) was added to the mixture under water-cooling. The resulting mixture was stirred for 1 hr at room temperature. Toluene and water were added to the reaction mixture. The organic layer was separated, and washed with water (twice) and brine in this order, and the solution was directly used in the next step.


E-58-16
1,1-Dibromo-4,4-dimethyl-1-pentene



embedded image


A solution of triphenylphosphine (29.2 g) in dichloromethane (60 mL) was added dropwise to a solution of carbon tetrabromide (18.5 g) in dichloromethane (60 mL) at ice temperature. The mixture was stirred at ice temperature for 10 min. A solution of 3,3-dimethyl-butylaldehyde (3.99 g) in dichloromethane (10 mL) was added dropwise to the reaction mixture at ice temperature. The mixture was stirred for 2 hrs at ice temperature. The resultant precipitate was filtered off with washing with hexane. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: hexane) to give the title compound (7.85 g).


E-58-17
4,4-Dimethyl-1-pentyne



embedded image


1,1-Dibromo-4,4-dimethyl-1-pentene (7.8 g), THF (16 mL), and hexane (16 mL) were mixed. n-Butyllithium (2.69 M in hexane) (23 mL) was added dropwise to the mixture at −78° C. The reaction mixture was stirred for 1 hr at −78° C., and then acetic acid (0.88 mL) was added to the reaction mixture. Hexane and aqueous saturated ammonium chloride was added thereto at ice temperature. The organic layer was separated, and dried over sodium sulfate. The sodium sulfate was filtered off. The title compound was obtained as a solution in THF-hexane (approximately 0.165 M) without purification.


E-58-18
tert-Butyl (S)-6-benzyloxy-3-[5-(2,2-dimethylpropyl)-4′-iodo-[3,5′]biisoxazolyl-3′-yl]-hexanoate



embedded image


A solution of the resulting 4,4-dimethyl-1-pentyne in THF-hexane which is obtained in E-58-17 (70 mL, equivalent to 11.5 mmol), potassium carbonate (666 mg), and water (4.0 mL) were mixed. The mixture was heated to 100° C. A solution of tert-butyl (S)-6-benzyloxy-3-[5-(chloro-hydroxyimino-methyl)-4-iodo-isoxazol-3-yl]-hexanoate which is obtained in E-58-15 in toluene (equivalent to 4.38 mmol) was added dropwise to the mixture. The resulting mixture was stirred for 20 min. Ethyl acetate was added to the reaction mixture. The organic layer was separated, and washed with aqueous saturated ammonium chloride (twice) and brine in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/10) to give the title compound (2.00 g, containing ethyl acetate (5.8 w/w %), by NMR).


E-58-19
tert-Butyl (S)-6-benzyloxy-3-[4′-cyclopropyl-5-(2,2-dimethyl-propyl)-[3,5′]biisoxazolyl-3′-yl]-hexanoate



embedded image


tert-Butyl (S)-6-benzyloxy-3-[5-(2,2-dimethyl-propyl)-4′-iodo-[3,5′]biisoxazolyl-3′-yl]-hexanoate (1.89 g), 2-cyclopropyl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (1.04 g), tripotassium phosphate (2.63 g), PdCl2(PPh3)2 (218 mg), and DMF (18 mL) were mixed. The reaction mixture was degassed by bubbling argon, and the resulting mixture was stirred at 90° C. overnight. Water was added to the reaction mixture, and the resulting mixture was filtered, and to the filtrate was added ethyl acetate. The organic layer was separated, and washed with aqueous 1 M hydrochloric acid, water (twice), and brine in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/13) to give the title compound (1.69 g).


E-58-20
(S)-6-Benzyloxy-3-[4′-cyclopropyl-5-(2,2-dimethyl-propyl)-[3,5′]biisoxazolyl-3′-yl]-hexanoic acid



embedded image


tert-Butyl (S)-6-benzyloxy-3-[4′-cyclopropyl-5-(2,2-dimethyl-propyl)-[3,5′]biisoxazolyl-3′yl]-hexanoate (1.68 g) and toluene (15 mL) were mixed. Trifluoroacetic acid (6.5 mL) was added to the mixture at ice temperature. The mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure. The resulting residue was azeotroped twice with toluene to give the title compound (1.60 g, containing toluene (18 w/w %), by NMR) as a crude product.


E-58-21
(S)-6-Benzyloxy-3-[4′-cyclopropyl-5-(2,2-dimethyl-propyl)-[3,5′]biisoxazolyl-3′-yl]-hexanoic acid (2,4-dichloro-phenyl)-amide



embedded image


(S)-6-Benzyloxy-3-[4′-cyclopropyl-5-(2,2-dimethyl-propyl)-[3,5′]biisoxazolyl-3′-yl]-hexanoic acid (300 mg, equivalent to 0.53 mmol) and dimethylacetamide (2.5 mL) were mixed. Thionyl chloride (0.051 mL) was added to the mixture at ice temperature. 2,4-Dichloro-phenylamine (104 mg) was added to the reaction mixture at ice temperature. The cooling bath was removed, and the reaction mixture was stirred for 1 hr. Diethyl ether and water was added to the reaction mixture. The organic layer was separated, and washed with aqueous saturated sodium bicarbonate and brine in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/5) to give the title compound (184 mg).


E-58-22
(S)-3-[4′-Cyclopropyl-5-(2,2-dimethyl-propyl)-[3,5′]biisoxazolyl-3′-yl]-6-hydroxy-hexanoic acid (2,4-dichloro-phenyl)-amide



embedded image


(S)-6-Benzyloxy-3-[4′-cyclopropyl-5-(2,2-dimethyl-propyl)-[3,5′]biisoxazolyl-3′-yl]-hexanoic acid (2,4-dichloro-phenyl)-amide (264 mg) and dichloromethane (4.0 mL) were mixed. Boron tribromide (1 M in dichloromethane) (1.1 mL) was added to the mixture at ice temperature. The cooling bath was removed, and the reaction mixture was stirred for 30 minutes. Aqueous saturated sodium hydrogen carbonate and diethyl ether were added to the reaction mixture at ice temperature. The organic layer was separated, and washed with brine. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/1) to give the title compound (183 mg).


E-58-23
(S)-4-[4′-Cyclopropyl-5-(2,2-dimethyl-propyl)-[3,5′]biisoxazolyl-3′-yl]-5-(2,4-dichloro-phenylcarbamoyl)-pentanoic acid



embedded image


(S)-3-[4′-cyclopropyl-5-(2,2-dimethyl-propyl)-[3,5′]biisoxazolyl-3′-yl]-6-hydroxy-hexanoic acid (2,4-dichloro-phenyl)-amide (180 mg), acetonitrile (1.3 mL), and 1.0 M phosphate buffer (pH=6.8) (1.3 mL) were mixed. 2,2,6,6-Tetramethyl-1-piperidinyloxy radical (TEMPO) (5.0 mg) and sodium chlorite (78 mg) were added to the mixture at room temperature. Aqueous sodium hypochlorite (Wako Pure Chemical Industries, 0.090 mL) was added dropwise to the reaction mixture at ice temperature. The resulting mixture was stirred for 1 hr at room temperature. Aqueous 20 w/v % sodium sulfite and ethyl acetate were added to the reaction mixture at ice temperature. The organic layer was separated, and washed with brine, and then dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/1), and then azeotroped twice with ethanol to give the title compound (237 mg, containing ethanol (31.9 w/w %), by NMR).



1H-NMR (400 MHz, DMSO-d6) 0.42-0.54 (m, 1H), 0.59-0.71 (m, 1H), 0.84-1.02 (m, 2H), 0.95 (s, 9H), 1.67-1.77 (m, 1H), 1.90-2.05 (m, 2H), 2.15-2.33 (m, 2H), 2.76 (s, 2H), 2.85 (dd, J=15.20, 6.40 Hz, 1H), 2.95 (dd, J=15.20, 8.40 Hz, 1H), 3.52-3.65 (m, 1H), 6.74 (s, 1H), 7.36 (dd, J=8.80, 2.00 Hz, 1H), 7.60 (d, J=2.00 Hz, 1H), 7.63 (d, J=8.80 Hz, 1H), 9.68 (s, 1H)


E-58-24
Sodium (S)-4-[4′-cyclopropyl-5-(2,2-dimethyl-propyl)-[3,5′]biisoxazolyl-3′-yl]-5-(2,4-dichloro-phenylcarbamoyl)-pentanoate



embedded image


(S)-4-[4′-Cyclopropyl-5-(2,2-dimethyl-propyl)-[3,5′]biisoxazolyl-3′-yl]-5-(2,4-dichloro-phenylcarbamoyl)-pentanoic acid (237 mg, equivalent to 0.300 mmol) and ethanol (4.0 mL) were mixed. Aqueous 1 M sodium hydroxide (0.300 mL) was added to the mixture at room temperature. The resulting solution was concentrated under reduced pressure to give the title compound (149 mg).


Example E-49
Sodium (S)-5-(4-chloro-2-fluoro-phenylcarbamoyl)-4-[4′-cyclopropyl-5-(1,1-difluoro-2,2-dimethylpropyl)-[3,5′]biisoxazolyl-3′-yl]-pentanoate
E-49-1
tert-Butyl (S)-6-benzyloxy-3-(4-cyclopropyl-5-hydroxymethyl-isoxazol-3-yl)-hexanoate



embedded image


tert-Butyl (S)-6-benzyloxy-3-(5-hydroxymethyl-4-iodo-isoxazol-3-yl)-hexanoate (17.2 g) which obtained by a similar reaction to that described in E-58-12, 2-cyclopropyl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (11.5 g), tripotassium phosphate (29.1 g), PdCl2(PPh3)2 (2.4 mg), and DMF (130 mL) were mixed. The reaction mixture was degassed by bubbling argon, and the resulting mixture was stirred at 90° C. overnight. Water (150 mL) was added to the reaction mixture. The resulting mixture was filtered. To the filtrate was added ethyl acetate. The organic layer was separated, and washed with aqueous 2 M hydrochloric acid, water (twice), and brine in this order. Then, the organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/2) to give the title compound (5.24 g).


E-49-2
tert-Butyl (S)-6-benzyloxy-3-(4-cyclopropyl-5-formyl-isoxazol-3-yl)-hexanoate



embedded image


tert-Butyl (S)-6-benzyloxy-3-(4-cyclopropyl-5-hydroxymethyl-isoxazol-3-yl)-hexanoate (5.2 g) and chloroform (42 mL) were mixed. Dess-Martin periodinane (6.6 g) was added to the mixture at ice temperature. The resulting mixture was stirred for 1 hr at room temperature. Aqueous 20 w/v % sodium sulfite was added to the reaction mixture at ice temperature. Diethyl ether and aqueous saturated sodium hydrogen carbonate were added to the mixture, and the resulting mixture was stirred for 1 hr at room temperature. The organic layer was separated, and washed with aqueous saturated sodium hydrogen carbonate (twice) and brine in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (4.87 g) as a crude product.


E-49-3
tert-Butyl (S)-6-benzyloxy-3-[4-cyclopropyl-5-(hydroxyimino-methyl)-isoxazol-3-yl]-hexanoate



embedded image


Hydroxylammonium chloride (1.32 g), THF (9.8 mL), and water (7.3 mL) were mixed. Aqueous 4 M sodium hydroxide (4.73 mL) was added dropwise to the mixture at ice temperature. A mixture of tert-butyl (S)-6-benzyloxy-3-(4-cyclopropyl-5-formyl-isoxazol-3-yl)-hexanoate (4.87 g) and ethanol (24.5 mL) was added dropwise to the reaction mixture at ice temperature. The resulting mixture was stirred at room temperature overnight. Then the pH of the reaction mixture was adjusted with aqueous 2 M hydrochloric acid to 3. Ethyl acetate was added to the mixture. The organic layer was separated, and washed with water (twice) and brine in this order, and then concentrated under reduced pressure to give the title compound (4.87 g).


E-49-4
tert-Butyl (S)-6-benzyloxy-3-[4-cyclopropyl-5-(chloro-hydroxyimino-methyl)-isoxazol-3-yl]-hexanoate



embedded image


tert-Butyl (S)-6-benzyloxy-3-[4-cyclopropyl-5-(hydroxyimino-methyl)-isoxazol-3-yl]-hexanoate (2.00 g, equivalent to 4.39 mmol) and DMF (8.0 mL) were mixed. N-chlorosuccinimide (647 mg) was added to the mixture at room temperature. The reaction mixture was stirred for 1 hr at room temperature, and then N-chlorosuccinimide (647 mg) was additionally added to the reaction mixture. The resulting mixture was stirred for 1 hr at room temperature, and then toluene and water were added to the reaction mixture. The organic layer was separated, and washed with water (three times) and brine in this order. The solution was used in the next step without purification.


E-49-5
4,4-Dimethyl-1-pentyn-3-ol



embedded image


Ethynyltrimethylsilane (5.40 g) and THF (50 mL) were mixed. n-Butyllithium (2.69 M in hexane) (19.5 mL) was added dropwise to the mixture at −78° C. The reaction mixture was stirred for 30 min at −78° C. 2,2-Dimethylpropionaldehyde (5.52 mL) was added to the mixture, and the resulting mixture was stirred for 1 hr at room temperature. Diethyl ether and water were added to the mixture at ice temperature. The organic layer was separated, and washed with brine, and then dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. Methanol (120 mL) and potassium carbonate (20.73 g) were added to the residue at room temperature. The resulting mixture was stirred for 30 minutes. The solid was filtered off, and the filtrate was concentrated under reduced pressure until reduced by approximately half in volume. Dichloromethane and aqueous saturated ammonium chloride were added to the mixture. The organic layer was separated, and dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (5.77 g, containing solvents (29 w/w %) including dichloromethane) as a crude product.


E-49-6
tert-Butyl (S)-6-benzyloxy-3-[4′-cyclopropyl-5-(1-hydroxy-2,2-dimethyl-propyl)-[3,5′]biisoxazolyl-3′-yl]-hexanoate



embedded image


4,4-Dimethyl-1-pentyn-3-ol which was obtained in E-49-(1.73 g, equivalent to 11.0 mmol), aqueous 1.0 M potassium carbonate (4.67 mL), and toluene (5.0 mL) were mixed, and the mixture was heated to 100° C. A solution of tert-butyl (S)-6-benzyloxy-3-[4-cyclopropyl-5-(chloro-hydroxyimino-methyl)-isoxazol-3-yl]-hexanoate which was obtained in E-49-4 (equivalent to 4.39 mmol) in toluene was added dropwise to the reaction mixture, and the resulting mixture was stirred for 40 min. Ethyl acetate was added to the reaction mixture. The organic layer was separated, and washed with aqueous saturated ammonium chloride (twice) and brine in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/4) to give the title compound (2.62 g, containing ethyl acetate (6.1 w/w %), by NMR).


E-49-7
tert-Butyl (S)-6-benzyloxy-3-[4′-cyclopropyl-5-(2,2-dimethyl-propionyl)-[3,5′]biisoxazolyl-3′-yl]-hexanoate



embedded image


tert-Butyl (S)-6-benzyloxy-3-[4′-cyclopropyl-5-(1-hydroxy-2,2-dimethyl-propyl)-[3,5′]biisoxazolyl-3′-yl]-hexanoate (2.45 g), chloroform (25 mL) were mixed. Dess-Martin periodinane (2.36 g) was added to the mixture at ice temperature. The reaction mixture was stirred for 1 hr at room temperature, and to the mixture was added aqueous 20 w/v % sodium sulfite at ice temperature. To the reaction mixture were added ethyl acetate and aqueous saturated sodium hydrogen carbonate. The resulting mixture was stirred for 30 minutes at room temperature. The organic layer was separated, and washed with aqueous saturated sodium hydrogen carbonate (twice) and brine in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (2.48 g) as a crude product.


E-49-8
tert-Butyl (S)-6-benzyloxy-3-[4′-cyclopropyl-5-(1,1-difluoro-2,2-dimethyl-propyl)-[3,5′]biisoxazolyl-3′-yl]-hexanoate



embedded image


tert-Butyl (S)-6-benzyloxy-3-[4′-cyclopropyl-5-(2,2-dimethyl-propionyl)-[3,5′]biisoxazolyl-3′-yl]-hexanoate (2.48 g) and bis(2-methoxyethyl)aminosulfur trifluoride (15 mL) were mixed. The mixture was stirred for 1 hr at 80° C. Chloroform (15 mL) was added to the reaction mixture at ice temperature. The reaction mixture was poured over ice. Aqueous saturated sodium hydrogen carbonate was added dropwise to the mixture at ice temperature. Ethyl acetate was added to the mixture. The organic layer was separated, and washed with aqueous saturated sodium hydrogen carbonate and brine in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/10) to give the title compound (2.38 g).


E-49-9
(S)-6-Benzyloxy-3-[4′-cyclopropyl-5-(1,1-difluoro-2,2-dimethyl-propyl)-[3,5′]biisoxazolyl-3′-yl]-hexanoic acid



embedded image


tert-Butyl (S)-6-benzyloxy-3-[4′-cyclopropyl-5-(1,1-difluoro-2,2-dimethyl-propyl)-[3,5′]biisoxazolyl-3′-yl]-hexanoate (1.68 g) and toluene (20 mL) were mixed. To the mixture was added trifluoroacetic acid (5.0 mL) at ice temperature. The reaction mixture was stirred at room temperature overnight, and concentrated under reduced pressure. The resulting residue was azeotroped twice with toluene to give the title compound (2.28 g, containing toluene (15.7 w/w %), by NMR) as a crude product.


E-49-10
(S)-6-Benzyloxy-3-[4′-cyclopropyl-5-(1,1-difluoro-2,2-dimethylpropyl)-[3,5′]biisoxazolyl-3′-yl]-hexanoic acid (4-chloro-2-fluoro-phenyl)-amide



embedded image


(S)-6-Benzyloxy-3-[4′-cyclopropyl-5-(1,1-difluoro-2,2-dimethyl-propyl)-[3,5′]biisoxazolyl-3′-yl]-hexanoic acid (356 mg, equivalent to 0.597 mmol), 4-chloro-2-fluoro-phenylamine (0.079 mL), and DMF (3.0 mL) were mixed. To the mixture were added diisopropylethylamine (0.144 mL) and HATU (273 mg) at ice temperature. The resulting mixture was stirred at room temperature overnight. To the reaction mixture was added aqueous saturated sodium bicarbonate at ice temperature. The mixture was extracted with ethyl acetate. The organic layer was washed with water (twice) and brine in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by preparative chromatography (Eluent: ethyl acetate/hexane=1/3) to give the title compound (322 mg).


E-49-11
(S)-3-[4′-Cyclopropyl-5-(1,1-difluoro-2,2-dimethyl-propyl)-[3,5′]biisoxazolyl-3′-yl]-6-hydroxy-hexanoic acid (4-chloro-2-fluoro-phenyl)-amide



embedded image


(S)-6-Benzyloxy-3-[4′-cyclopropyl-5-(1,1-difluoro-2,2-dimethyl-propyl)-[3,5′]biisoxazolyl-3′-yl]-hexanoic acid (4-chloro-2-fluoro-phenyl)-amide (322 mg), dichloromethane (3.2 mL) were mixed. To the mixture was added boron tribromide (1 M in dichloromethane) (1.5 mL) at ice temperature. The cooling bath was removed, and the reaction mixture was stirred for 1 hr. To the reaction mixture was added aqueous saturated sodium hydrogen carbonate. To the reaction mixture was added diethyl ether. The organic layer was separated, and washed with brine. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/2) to give the title compound (175 mg).


E-49-12
(S)-5-(4-Chloro-2-fluoro-phenylcarbamoyl)-4-[4′-cyclopropyl-5-(1,1-difluoro-2,2-dimethyl-propyl)-[3,5′]biisoxazolyl-3′-yl]-pentanoic acid



embedded image


(S)-3-[4′-Cyclopropyl-5-(1,1-difluoro-2,2-dimethyl-propyl)-[3,5′]biisoxazolyl-3′-yl]-6-hydroxy-hexanoic acid (4-chloro-2-fluoro-phenyl)-amide (175 mg), acetonitrile (1.3 mL), and 1.0 M phosphate buffer (pH=6.8) (1.3 mL) were mixed. To the mixture were added 2,2,6,6-tetramethyl-1-piperidinyloxy radical (TEMPO) (5.0 mg) and sodium chlorite (73 mg) at room temperature. Aqueous sodium hypochlorite (Wako Pure Chemical Industries, 0.088 mL) was added dropwise to the reaction mixture at room temperature. The reaction mixture was stirred for 1 hr at room temperature. Aqueous 20 w/v % sodium sulfite was added to the reaction mixture at ice temperature. Ethyl acetate was added to the mixture. The organic layer was separated, and washed with brine, and then dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/2), and then azeotroped twice with ethanol to give the title compound (177 mg, containing ethanol (5.1 w/w %), by NMR).



1H-NMR (400 MHz, DMSO-d6) 0.45-0.57 (m, 1H), 0.64-0.75 (m, 1H), 0.89-1.02 (m, 2H), 1.08 (s, 9H), 1.72-1.82 (m, 1H), 1.89-2.04 (m, 2H), 2.17-2.32 (m, 2H), 2.87 (dd, J=15.60, 6.40 Hz, 1H), 2.97 (dd, J=15.60, 8.80 Hz, 1H), 3.55-3.66 (m, 1H), 7.17-7.23 (m, 1H), 7.39 (s, 1H), 7.43 (dd, J=10.40, 2.00 Hz, 1H), 7.83 (t, J=8.80 Hz, 1H), 9.92 (s, 1H), 12.16 (brs, 1H)


E-49-13
Sodium (S)-5-(4-chloro-2-fluoro-phenylcarbamoyl)-4-[4′-cyclopropyl-5-(1,1-difluoro-2,2-dimethylpropyl)-[3,5′]biisoxazolyl-3′-yl]-pentanoate



embedded image


(S)-5-(4-Chloro-2-fluoro-phenylcarbamoyl)-4-[4′-cyclopropyl-5-(1,1-difluoro-2,2-dimethylpropyl)-[3,5′]biisoxazolyl-3′-yl]-pentanoic acid (177 mg, equivalent to 0.303 mmol) and ethanol (1.5 mL) were mixed. To the mixture was added aqueous 1 M sodium hydroxide (0.303 mL) at room temperature. The resulting solution was concentrated under reduced pressure to give the title compound (152 mg).


Example E-52
Sodium (S)-5-(2-chloro-4-methyl-phenylcarbamoyl)-4-[4-cyclopropyl-5′-(1,1-difluoro-2,2-dimethylpropyl)-[3,3′]biisoxazolyl-5′-yl]pentanoate
E-52-1
tert-Butyl (S)-6-benzyloxy-3-ethynyl-hexanoate



embedded image


Trimethylsilyldiazomethane (2 M in hexane) (47 mL) and THF (125 mL) were mixed. n-Butyllithium (2.6 M in hexane) (72.1 mL) was added dropwise to the mixture at −78° C. The reaction mixture was stirred for 20 min at −78° C. A solution of tert-butyl (S)-6-benzyloxy-3-formyl-hexanoate which is obtained in a similar way to E-58-8 (25 g) in THF (75 mL) was added dropwise to the reaction mixture. The reaction mixture was stirred for 20 min at −78° C., and then for 2 hrs at 0° C. To the reaction mixture was added aqueous saturated ammonium chloride at ice temperature. Ethyl acetate was added to the mixture. The organic layer was separated, and washed with water and brine in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/8) to give the title compound (12.9 g, containing toluene (14.9 w/w %), by NMR).


E-52-2
(tert-Butyl-dimethyl-silanyloxy)-acetaldehyde oxime



embedded image


Hydroxylammonium chloride (1.62 g), THF (5.5 mL), and water (4.0 mL) were mixed. Aqueous 4 M sodium hydroxide (5.81 mL) was added dropwise thereto at ice temperature. A mixture of (tert-butyl-dimethylsilanyloxy)-acetaldehyde (2.7 g) and ethanol (13 mL) was added dropwise to the reaction mixture at ice temperature. The reaction mixture was stirred at room temperature overnight. Then the pH of the reaction mixture was adjusted with aqueous 2 M hydrochloric acid to 4. Ethyl acetate was added to the mixture. The organic layer was separated, and washed with water (twice) and brine in this order, and then concentrated under reduced pressure to give the title compound (2.49 g).


E-52-3
(tert-Butyl-dimethylsilanyloxy)-1-chloro-acetaldehyde oxime



embedded image


tert-Butyl-dimethylsilanyloxy-acetaldehyde oxime (2.4 g) and DMF (7.0 mL) were mixed. A solution of N-chlorosuccinimide (2.04 g) in DMF (5.0 mL) was added to the mixture at room temperature. The reaction mixture was stirred for 30 minutes at room temperature. To the reaction mixture were added toluene and water. The organic layer was separated, and washed with water (three times) and brine in this order, and the solution was directly used in the next step.


E-52-4
tert-Butyl (S)-6-benzyloxy-3-[3-(tert-butyl-dimethylsilanyloxymethyl)-isoxazol-5-yl]hexanoate



embedded image


tert-Butyl (S)-6-benzyloxy-3-ethynylhexanoate which was obtained in E-52-1 (3.84 g), toluene (1.5 mL), potassium carbonate (139 mg), and water (1.0 mL) were mixed, and the mixture was heated to 100° C. A solution of (tert-butyl-dimethylsilanyloxy)-1-chloro-acetaldehyde oxime which was obtained in E-52-3 in toluene (equivalent to 12.7 mmol) was added dropwise to the reaction mixture, and the resulting mixture was stirred for 30 minutes. Ethyl acetate was added to the reaction mixture. The organic layer was separated, and washed with water and brine in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/12) to give the title compound (2.78 g, containing ethyl acetate (5.6 w/w %), by NMR).


E-52-5
tert-Butyl (S)-6-benzyloxy-3-(3-hydroxymethyl-isoxazol-5-yl)hexanoate



embedded image


tert-Butyl (S)-6-benzyloxy-3-[3-(tert-butyl-dimethylsilanyloxymethyl)-isoxazol-5-yl]hexanoate (2.63 g) and THF (11 mL) were mixed. To the mixture was added tetrabutylammonium fluoride (1 M in THF) (6.44 mL) at ice temperature. The mixture was stirred for 2 hrs at room temperature. To the reaction mixture were added ethyl acetate and aqueous saturated ammonium chloride. The organic layer was separated, and washed with brine, and then dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/1) to give the title compound (2.04 g, containing ethyl acetate (8.0 w/w %), by NMR).


E-52-6
tert-Butyl (S)-6-benzyloxy-3-(3-hydroxymethyl-4-iodo-isoxazol-5-yl)hexanoate



embedded image


tert-Butyl (S)-6-benzyloxy-3-(3-hydroxymethyl-isoxazol-5-yl)hexanoate (2.0 g, equivalent to 5.36 mmol) and acetonitrile (16 mL) were mixed. To the mixture were added N-iodosuccinimide (2.4 g) and ammonium cerium(IV) nitrate (1.18 g) at room temperature. The reaction mixture was stirred overnight at room temperature. Aqueous 20 w/v % sodium sulfite was added dropwise to the reaction mixture at ice temperature. Ethyl acetate was added to the mixture. The organic layer was separated, and washed with water and brine in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/3) to give the title compound (705 mg, containing ethyl acetate (5.7 w/w %), by NMR).


E-52-7
tert-Butyl (S)-6-benzyloxy-3-(3-formyl-4-iodo-isoxazol-5-yl)hexanoate



embedded image


tert-Butyl (S)-6-benzyloxy-3-(3-hydroxymethyl-4-iodo-isoxazol-5-yl)hexanoate (705 mg, equivalent to 1.24 mmol) and chloroform (5.5 mL) were mixed. Dess-Martin periodinane (650 mg) was added to the mixture at ice temperature. The reaction mixture was stirred for 1 hr at room temperature. Aqueous 20 w/v % sodium sulfite was added to the reaction mixture at ice temperature. To the reaction mixture were added ethyl acetate and aqueous saturated sodium hydrogen carbonate. The mixture was stirred for 1 hr at room temperature. The organic layer was separated, and washed with aqueous saturated sodium hydrogen carbonate (twice) and brine in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (645 mg).


E-52-8
tert-Butyl (S)-6-benzyloxy-3-(3-hydroxyiminomethyl-4-iodo-isoxazol-5-yl)hexanoate



embedded image


Hydroxylammonium chloride (129 mg), THF (1.4 mL), and water (1.4 mL) were mixed. Aqueous 4 M sodium hydroxide (0.465 mL) was added dropwise to the mixture at ice temperature. A mixture of tert-butyl (S)-6-benzyloxy-3-(3-formyl-4-iodo-isoxazol-5-yl)hexanoate (645 mg) and ethanol (4.0 mL) was added dropwise to the reaction mixture at ice temperature. The reaction mixture was stirred overnight at room temperature. The pH of the reaction mixture was adjusted with aqueous 2 M hydrochloric acid to 3. To the reaction mixture were added ethyl acetate and water. The organic layer was separated, and washed with water and brine in this order, and then concentrated under reduced pressure to give the title compound (654 mg) as a crude product.


E-52-9
tert-Butyl (S)-6-benzyloxy-3-(chloro-hydroxyimino-methyl)-4-iodo-isoxazol-5-yl)hexanoate



embedded image


tert-Butyl (S)-6-benzyloxy-3-(3-hydroxyiminomethyl-4-iodo-isoxazol-5-yl)hexanoate (654 mg), and DMF (3.0 mL) were mixed. To the mixture was added N-chlorosuccinimide (183 mg) at room temperature. The reaction mixture was stirred for 1 hr at room temperature. N-chlorosuccinimide (183 mg) was additionally added to the mixture. The reaction mixture was stirred for 1 hr at room temperature. To the reaction mixture were added toluene and water. The organic layer was separated, and washed with water and brine in this order, and the solution was directly used in the next step.


E-52-10
tert-Butyl (S)-6-benzyloxy-3-[5′-(1-hydroxy-2,2-dimethylpropyl)-4-iodo-[3,3′]biisoxazolyl-5-yl]-hexanoate



embedded image


4,4-Dimethyl-1-pentyn-3-ol which was obtained in E-49-5 (490 mg), toluene (1.5 mL), potassium carbonate (189 mg) and water (1.0 mL) were mixed, and the mixture was heated to 100° C. A solution of tert-butyl (S)-6-benzyloxy-3-(chloro-hydroxyimino-methyl)-4-iodo-isoxazol-5-yl)hexanoate which was obtained in E-52-9 (equivalent to 1.24 mmol) in toluene was added dropwise to the reaction mixture. The resulting mixture was stirred for 20 min. To the reaction mixture were added ethyl acetate and aqueous saturated ammonium chloride. The organic layer was separated, and washed with aqueous saturated ammonium chloride and brine in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/4) to give the title compound (719 mg).


E-52-11
tert-Butyl (S)-6-benzyloxy-3-[5′-(2,2-dimethylpropionyl)-4-iodo-[3,3′]biisoxazolyl-5-yl]-hexanoate



embedded image


tert-Butyl (S)-6-benzyloxy-3-[5′-(1-hydroxy-2,2-dimethylpropyl)-4-iodo-[3,3′]biisoxazolyl-5-yl]-hexanoate (715 mg) and chloroform (6.0 mL) were mixed. To the mixture was added Dess-Martin periodinane (583 mg) at ice temperature. The reaction mixture was stirred for 45 min at room temperature. To the reaction mixture was added aqueous 20 w/v % sodium sulfite under water-cooling. To the reaction mixture were added ethyl acetate and aqueous saturated sodium hydrogen carbonate. The resulting mixture was stirred for 30 minutes at room temperature. The organic layer was separated, and washed with aqueous saturated sodium hydrogen carbonate (twice) and brine in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (682 mg).


E-52-12
tert-Butyl (S)-6-benzyloxy-3-[5′-(1,1-difluoro-2,2-dimethyl-propyl)-4-iodo-[3,3′]biisoxazolyl-5-yl]-hexanoate



embedded image


tert-Butyl (S)-6-benzyloxy-3-[5′-(2,2-dimethylpropionyl)-4-iodo-[3,3′]biisoxazolyl-5-yl]-hexanoate (682 mg), bis(2-methoxyethyl)aminosulfur trifluoride (0.84 mL) were mixed. The mixture was stirred for 3 hrs at 80° C. To the reaction mixture was added chloroform (1.0 mL) at ice temperature. The reaction mixture was poured over ice, and then aqueous saturated sodium hydrogen carbonate was added dropwise thereto at ice temperature. Ethyl acetate was added to the reaction mixture. The organic layer was separated, and washed with aqueous saturated sodium hydrogen carbonate and brine in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/12) to give the title compound (573 mg).


E-52-13
tert-Butyl (S)-6-benzyloxy-3-[4-cyclopropyl-5′-(1,1-difluoro-2,2-dimethyl-propyl)[3,3′]biisoxazolyl-5-yl]-hexanoate



embedded image


tert-Butyl (S)-6-benzyloxy-3-[5′-(1,1-difluoro-2,2-dimethyl-propyl)-4-iodo-[3,3′]biisoxazolyl-5-yl]-hexanoate (570 mg), 2-cyclopropyl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (297 mg), tripotassium phosphate (751 mg), PdCl2(PPh3)2 (93 mg), and DMF (5.5 mL) were mixed. The reaction mixture was degassed by bubbling argon, and the resulting mixture was stirred at 90° C. overnight. To the reaction mixture were added ethyl acetate and aqueous 1 M hydrochloric acid. The organic layer was separated, and washed with water (twice) and brine in this order. Then, the organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/12) to give the title compound (284 mg).


E-52-14
tert-Butyl (S)-6-benzyloxy-3-[4-cyclopropyl-5′-(1,1-difluoro-2,2-dimethyl-propyl)[3,3′]biisoxazolyl-5-yl]-hexanoate



embedded image


tert-Butyl (S)-6-benzyloxy-3-[4-cyclopropyl-5′-(1,1-difluoro-2,2-dimethyl-propyl)[3,3′]biisoxazolyl-5-yl]-hexanoate (284 mg) and toluene (1.4 mL) were mixed. To the mixture was added trifluoroacetic acid (1.4 mL) at ice temperature. The reaction mixture was stirred for 2 hrs at room temperature, and then concentrated under reduced pressure. The resulting residue was azeotroped with toluene to give the title compound as a crude product.


E-52-15
(S)-6-Benzyloxy-3-[4-cyclopropyl-5′-(1,1-difluoro-2,2-dimethyl-propyl)[3,3′]biisoxazolyl-5-yl]-hexanoic acid (2-chloro-4-methyl-phenyl)-amide



embedded image


tert-Butyl (S)-6-benzyloxy-3-[4-cyclopropyl-5′-(1,1-difluoro-2,2-dimethyl-propyl)[3,3′]biisoxazolyl-5-yl]-hexanoate (equivalent to 0.508 mmol), 2-chloro-4-methylphenylamine (0.075 mL), and DMF (2.5 mL) were mixed. To the mixture were added diisopropylethylamine (0.131 mL), HATU (232 mg) at ice temperature. The resulting mixture was stirred at room temperature overnight. To the reaction mixture was added aqueous 1 M hydrochloric acid at ice temperature. The resulting mixture was extracted with ethyl acetate. The organic layer was washed with water and brine in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by preparative chromatography (Eluent: ethyl acetate/hexane=1/5) to give the title compound (279 mg).


E-52-16
(S)-3-[4-Cyclopropyl-5′-(1,1-difluoro-2,2-dimethyl-propyl)[3,3′]biisoxazolyl-5-yl]-6-hydroxy-hexanoic acid (2-chloro-4-methyl-phenyl)-amide



embedded image


(S)-6-Benzyloxy-3-[4-cyclopropyl-5′-(1,1-difluoro-2,2-dimethyl-propyl)[3,3′]biisoxazolyl-5-yl]-hexanoic acid (2-chloro-4-methyl-phenyl)-amide (279 mg), dichloromethane (4.0 mL) were mixed. To the mixture was added boron tribromide (1 M in dichloromethane) (1.1 mL) at ice temperature. The cooling bath was removed, and the reaction mixture was stirred for 1 hr. To the reaction mixture were added aqueous saturated sodium hydrogen carbonate and ethyl acetate at ice temperature. The organic layer was separated, and washed with brine. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/1) to give the title compound (235 mg).


E-52-17
(S)-5-(2-Chloro-4-methyl-phenylcarbamoyl)-4-[4-cyclopropyl-5′-(1,1-difluoro-2,2-dimethylpropyl)-[3,3′]biisoxazolyl-5′-yl]pentanoic acid



embedded image


(S)-3-[4′-Cyclopropyl-5-(1,1-difluoro-2,2-dimethyl-propyl)-[3,5′]biisoxazolyl-3′-yl]-6-hydroxy-hexanoic acid (4-chloro-2-fluorophenyl)amide (235 mg), acetonitrile (1.3 mL), and 1.0 M phosphate buffer (pH=6.8) (1.3 mL) were mixed. To the mixture were added 2,2,6,6-tetramethyl-1-piperidinyloxy radical (TEMPO) (5.0 mg) and sodium chlorite (73 mg) at room temperature. Aqueous sodium hypochlorite (Wako Pure Chemical Industries, 0.088 mL) was added dropwise to the reaction mixture at room temperature. The reaction mixture was stirred for 1 hr at room temperature. Aqueous 20 w/v % sodium sulfite was added to the reaction mixture at ice temperature. Ethyl acetate was added to the reaction mixture. The organic layer was separated, and washed with brine, and then dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/2), and then azeotroped twice with ethanol to give the title compound (218 mg, containing ethanol (10.3 w/w %), by NMR).



1H-NMR (400 MHz, DMSO-d6) 0.34-0.46 (m, 1H), 0.64-0.75 (m, 1H), 0.78-0.89 (m, 2H), 1.10 (s, 9H), 1.65-1.75 (m, 1H), 1.84-2.10 (m, 2H), 2.13-2.29 (m, 2H), 2.26 (s, 3H), 2.80-2.92 (m, 2H), 3.63-3.76 (m, 1H), 7.09 (d, J=8.00 Hz, 1H), 7.27 (s, 1H), 7.34 (s, 1H), 7.39 (d, J=8.00 Hz, 1H), 9.57 (s, 1H)


E-52-18
Sodium (S)-5-(2-Chloro-4-methyl-phenylcarbamoyl)-4-[4-cyclopropyl-5′-(1,1-difluoro-2,2-dimethylpropyl)-[3,3′]biisoxazolyl-5′-yl]pentanoate



embedded image


((S)-5-(2-Chloro-4-methyl-phenylcarbamoyl)-4-[4-cyclopropyl-5′-(1,1-difluoro-2,2-dimethylpropyl)-[3,3′]biisoxazolyl-5′-yl]pentanoic acid (218 mg, equivalent to 0.355 mmol) and ethanol (1.5 mL) were mixed. To the mixture was added aqueous 1 M sodium hydroxide (0.355 mL) at room temperature. The resulting solution was concentrated under reduced pressure to give the title compound (175 mg).


Example E-41
Sodium (S)-5-(2-chloro-4-methyl-phenylcarbamoyl)-4-[4-cyclopropyl-5-(2-isobutyl-thiazol-5-yl)-isoxazol-3-yl]-pentanoate
E-41-1
2-Isobutyl-thiazole-5-carboxylic acid methoxy-methyl-amide



embedded image


2-Isobutyl-thiazole-5-carboxylic acid (745 mg), N,O-dimethylhydroxylamine hydrochloride salt (471 mg), HOBt.H2O (185 mg), and acetonitrile (5.0 mL) were mixed. To the reaction mixture were added diisopropylethylamine (0.981 mL) and WSC.HCl (926 mg) at ice temperature. The resulting mixture was stirred for 7 hrs at room temperature. Water was added to the reaction mixture. The resulting mixture was extracted with ethyl acetate. The organic layer was washed with aqueous saturated sodium hydrogen carbonate, water, and aqueous saturated sodium chloride in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (947 mg) as a crude product.


E-41-2
2-Isobutyl-thiazole-5-carbaldehyde



embedded image


2-Isobutyl-thiazole-5-carboxylic acid methoxy-methyl-amide (947 mg, equivalent to 4.02 mmol) and toluene (4.0 mL) were mixed. Diisobutylaluminium hydride (1.0 M in toluene) (5.21 mL) was added dropwise to the mixture at −78° C. The reaction mixture was stirred for 1 hr at −78° C. To the reaction mixture was added aqueous 2.0 M hydrochloric acid at ice temperature. The reaction mixture was stirred for 1 hr at ice temperature. To the reaction mixture was added diethyl ether. The organic layer was separated, and washed with aqueous saturated sodium hydrogen carbonate and brine in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off. The filtrate was concentrated under reduced pressure to remove diethyl ether. The title compound was obtained as a toluene solution without purification.


E-41-3
5-(2,2-Dibromo-vinyl)-2-isobutyl-thiazole



embedded image


A solution of triphenylphosphine (2.95 g) in dichloromethane (9.4 mL) was added dropwise to a solution of carbon tetrabromide (1.87 g) in dichloromethane (4.7 mL) at ice temperature. The reaction mixture was stirred for min at ice temperature. A solution of 2-isobutyl-thiazole-5-carbaldehyde which was obtained in E-41-2 in toluene (equivalent to 4.02 mmol) and dichloromethane (9.4 mL) were mixed. The resulting mixture was added a opwise to the reaction mixture at ice temperature. The reaction mixture was stirred for 45 min at ice temperature. To the reaction mixture were added aqueous saturated sodium hydrogen carbonate and diethyl ether. The organic layer was separated, and washed with brine, and silica gel (2.0 g) was added thereto. The silica gel was filtered off with washing with diethyl ether, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: diethyl ether/hexane=1/15) to give the title compound (628 mg).


E-41-4
tert-Butyl (S)-3-(3-benzyloxy-propyl)-6-(2-isobutyl-thiazol-5-yl)-4-oxo-5-hexynoate



embedded image


5-(2,2-dibromo-vinyl)-2-isobutyl-thiazole (625 mg) THF (3.0 mL) were mixed. n-Butyllithium (2.69 M in hexane) (1.43 mL) was added dropwise to the mixture at −78° C. The reaction mixture was stirred for 20 min at −78° C. tert-Butyl (S)-6-benzyloxy-3-(methoxy-methylcarbamoyl)-hexanoate which was obtained in E-58-7 (597 mg, equivalent to 1.63 mmol) was added to the reaction mixture at −78° C. The reaction mixture was stirred for 30 minutes at ice temperature. To the reaction mixture were added aqueous 2.0 M hydrochloric acid and ethyl acetate at ice temperature. The organic layer was separated, and washed with water and brine in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/7) to give the title compound (433 mg).


E-41-5
tert-Butyl (S)-3-(3-benzyloxy-propyl)-6-(2-isobutyl-thiazol-5-yl)-4-methoxyimino-5-hexynoate



embedded image


tert-Butyl (S)-3-(3-benzyloxy-propyl)-6-(2-isobutyl-thiazol-5-yl)-4-oxo-5-hexynoate (425 mg) and ethanol (4.0 mL) were mixed. To the mixture were added sodium carbonate (480 mg), O-methylhydroxylammonium chloride (378 mg) at room temperature. The reaction mixture was stirred for 1.5 hrs at 80° C. To the reaction mixture were added ethyl acetate and water at room temperature. The organic layer was separated, and washed with water and brine in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (433 mg) as a crude product.


E-41-6
tert-Butyl (S)-6-benzyloxy-3-[4-iodo-5-(2-isobutyl-thiazol-5-yl)-isoxazol-3-yl]-hexanoate



embedded image


tert-Butyl (S)-3-(3-benzyloxy-propyl)-6-(2-isobutyl-thiazol-5-yl)-4-methoxyimino-5-hexynoate (438 mg) and dichloromethane (6.5 mL) were mixed. To the mixture was added iodine monochloride (1.0 M in dichloromethane) (0.88 mL) at ice temperature. The reaction mixture was stirred for 40 min at ice temperature, and then aqueous 20 w/v % sodium sulfite was added thereto. To the reaction mixture was added dichloromethane. The organic layer was separated, and dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/5) to give the title compound (460 mg).


E-41-7
tert-Butyl (S)-6-benzyloxy-3-[4-cyclopropyl-5-(2-isobutyl-thiazol-5-yl)-isoxazol-3-yl]-hexanoate



embedded image


tert-Butyl (S)-6-benzyloxy-3-[4-iodo-5-(2-isobutyl-thiazol-5-yl)-isoxazol-3-yl]-hexanoate (460 mg), 2-cyclopropyl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (253 mg), and DMF (4.0 mL) were mixed. To the mixture were added tripotassium phosphate (639 mg) and PdCl2(PPh3)2 (79 mg). The reaction mixture was degassed by bubbling argon, and was stirred for 7.5 hrs at 90° C. To the reaction mixture were added ethyl acetate, aqueous 1 M hydrochloric acid. The organic layer was separated, and washed with water and brine in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/7) to give the title compound (365 mg).


E-41-8
(S)-6-Benzyloxy-3-[4-cyclopropyl-5-(2-isobutyl-thiazol-5-yl)-isoxazol-3-yl]-hexanoic acid



embedded image


tert-Butyl (S)-6-benzyloxy-3-[4-cyclopropyl-5-(2-isobutyl-thiazol-5-yl)-isoxazol-3-yl]-hexanoate (365 mg) and toluene (2.1 mL) were mixed. To the mixture was added trifluoroacetic acid (0.70 mL) at ice temperature. The reaction mixture was stirred at room temperature overnight, and concentrated under reduced pressure. The resulting residue was azeotroped with toluene to give the title compound as a crude product.


E-41-9
(S)-6-Benzyloxy-3-[4-cyclopropyl-5-(2-isobutyl-thiazol-5-yl)-isoxazol-3-yl]-hexanoic acid (2-chloro-4-methyl-phenyl)-amide



embedded image


(S)-6-benzyloxy-3-[4-cyclopropyl-5-(2-isobutyl-thiazol-5-yl)-isoxazol-3-yl]-hexanoic acid (equivalent to 0.70 mmol), 2-chloro-4-methyl-phenylamine (0.103 mL), and DMF (3.0 mL) were mixed. To the mixture were added diisopropylethylamine (0.183 mL) and HATU (320 mg) at ice temperature. The resulting mixture was stirred overnight at room temperature. Diethyl ether and water were added to the reaction mixture. The organic layer was separated, and washed with water and brine in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/4) to give the title compound (385 mg).


E-41-10
(S)-3-[4-Cyclopropyl-5-(2-isobutyl-thiazol-5-yl)-isoxazol-3-yl]-6-hydroxy-hexanoic acid (2-chloro-4-methyl-phenyl)amide



embedded image


(S)-6-Benzyloxy-3-[4-cyclopropyl-5-(2-isobutyl-thiazol-5-yl)-isoxazol-3-yl]-hexanoic acid (2-chloro-4-methyl-phenyl)-amide (385 mg) and dichloromethane (5.0 mL) were mixed. To the mixture was added boron tribromide (1 M in dichloromethane) (1.1 mL) at ice temperature. The cooling bath was removed, and the reaction mixture was stirred for 40 minutes. To the reaction mixture were added aqueous saturated sodium hydrogen carbonate and ethyl acetate at ice temperature. The organic layer was separated, and washed with brine. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=2/1) to give a crude product (123 mg). The crude product was purified by preparative chromatography (Eluent: ethyl acetate/hexane=2/1) to give the title compound (115 mg, containing ethyl acetate (17.8 w/w %), by NMR).


E-41-11
(S)-5-(2-Chloro-4-methyl-phenylcarbamoyl)-4-[4-cyclopropyl-5-(2-isobutyl-thiazol-5-yl)-isoxazol-3-yl]-pentanoic acid



embedded image


(S)-3-[4-cyclopropyl-5-(2-isobutyl-thiazol-5-yl)-isoxazol-3-yl]-6-hydroxy-hexanoic acid (2-chloro-4-methyl-phenyl)amide (95 mg), acetonitrile (0.7 mL), and 1.0 M phosphate buffer (pH=6.8) (0.7 mL) were mixed. To the mixture were added 2,2,6,6-tetramethyl-1-piperidinyloxy radical (TEMPO) (3.0 mg), sodium chlorite (43 mg), and aqueous sodium hypochlorite (Wako Pure Chemical Industries, 0.038 mL) at ice temperature. The reaction mixture was stirred for 1 hr at room temperature. Aqueous 20 w/v % sodium sulfite and ethyl acetate was added to the reaction mixture at ice temperature. The organic layer was separated, and washed with water and brine in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/2), and then azeotroped with ethanol to give the title compound (98.5 mg, containing ethanol (17.9 w/w %), by NMR).



1H-NMR (400 MHz, CDCl3) 0.41-0.51 (m, 1H), 0.63-0.73 (m, 1H), 0.94-1.08 (m, 2H), 1.00 (d, J=6.80 Hz, 6H), 1.50-1.61 (m, 1H), 2.06-2.30 (m, 3H), 2.25 (s, 3H), 2.36-2.51 (m, 2H), 2.78 (dd, J=14.80, 5.60 Hz, 1H), 2.91 (d, J=7.20 Hz, 2H), 3.04 (dd, J=14.80, 9.60 Hz, 1H), 3.67-3.83 (m, 1H), 7.00 (d, J=8.40 Hz, 1H), 7.12 (s, 1H), 7.70 (s, 1H), 8.05 (d, J=8.40 Hz, 1H), 8.11 (s, 1H)


E-41-12
Sodium (S)-5-(2-chloro-4-methyl-phenylcarbamoyl)-4-[4-cyclopropyl-5-(2-isobutyl-thiazol-5-yl)-isoxazol-3-yl]-pentanoate



embedded image


(S)-5-(2-Chloro-4-methyl-phenylcarbamoyl)-4-[4-cyclopropyl-5-(2-isobutyl-thiazol-5-yl)-isoxazol-3-yl]-pentanoic acid (98.5 mg, equivalent to 0.157 mmol), ethanol (1.0 mL) were mixed. To the mixture was added aqueous 1 M sodium hydroxide (0.157 mL) at room temperature. The resulting solution was concentrated under reduced pressure to give the title compound (74.7 mg).


Example E-53
Sodium (R)-4-(2-chloro-4-methyl-phenylcarbamoyl)-3-[4′-cyclopropyl-5-(1,1-difluoro-2,2-dimethylpropyl)-[3,5′]biisoxazolyl-3′-yl]-butyrate
E-53-1
(S)-4-benzyl-3-(4-benzyloxy-butyryl)-oxazolidin-2-one



embedded image


4-Benzyloxy-butyric acid (238 g) and chloroform (1300 mL) were mixed. To the mixture was added (S)-4-benzyl-2-oxazolidinone (217 g). To the mixture were added 4-dimethylaminopyridine (45.0 g) and WSC.HCl (282 g) at ice temperature. The resulting mixture was stirred overnight at room temperature. The reaction mixture was concentrated under reduced pressure. Then, to the residue were added toluene (2000 mL) and aqueous 1 M hydrochloric acid (1500 mL). The organic layer was separated, and washed with aqueous saturated sodium hydrogen carbonate (2000 mL), aqueous saturated sodium chloride (1500 mL) in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off and the filtrate was concentrated under reduced pressure to give the title compound (425 g, containing toluene (3.2 w/w %), by NMR) as a crude product.


E-53-2
tert-Butyl (R)-3-((S)-4-benzyl-2-oxo-oxazolidine-3-carbonyl)-5-benzyloxy-pentanoate



embedded image


(S)-4-benzyl-3-(4-benzyloxy-butyryl)-oxazolidin-2-one (425 g, equivalent to 1.16 mol) and THF (1600 mL) were mixed. Sodium hexamethyldisilazide (1.9 M in THF) (702 mL) was added dropwise to the mixture at −78° C. tert-Butyl bromoacetate (275 mL) was added dropwise to the reaction mixture at −78° C. The resulting mixture was stirred for 2 hrs. The temperature of the reaction mixture was raised to −15° C. over 1.5 hrs, and then N,N,N′-trimethylethylenediamine (120 mL) was added dropwise to the mixture. To the reaction mixture were added water (1640 mL) and toluene (2460 mL) at ice temperature. The organic layer was separated, and washed with aqueous 20 w/v % citric acid (2460 mL), water (1640 mL), aqueous saturated sodium hydrogen carbonate (2050 mL), and aqueous saturated sodium chloride (1640 mL) in this order. The organic layer was concentrated under reduced pressure. The resulting residue (648.4 g, containing toluene (13 w/w %), by NMR) and methanol (2260 mL) were mixed. To the mixture was added activated carbon (85 g). The resoling mixture was stirred for 2 hrs at 75° C. The bath was removed, and then the mixture was stirred for 1 hr. The activated carbon was filtered off with washing with methanol (1130 mL). The filtrate was concentrated under reduced pressure to give the title compound (570 g, containing methanol (4.3 w/w %), by NMR) as a crude product.


E-53-3
tert-Butyl (R)-3-((S)-4-benzyl-2-oxo-oxazolidine-3-carbonyl)-5-hydroxy-pentanoate



embedded image


tert-Butyl (R)-3-((S)-4-benzyl-2-oxo-oxazolidine-3-carbonyl)-5-benzyloxy-pentanoate (500 g), ethyl acetate (750 mL), and THF (1510 mL) were mixed. To the mixture was added 20 w/w % palladium hydroxide (50 g). The reaction mixture was stirred for 4.5 hrs under hydrogen atmosphere (1 atm). Then, the reaction container was charged with nitrogen gas. The palladium hydroxide was filtered off with washing with ethyl acetate (1000 mL). The filtrate was concentrated under reduced pressure to give the title compound (456 g, containing ethyl acetate (7.0 w/w %), by NMR) as a crude product.


E-53-4
tert-Butyl (R)-3-((S)-4-benzyl-2-oxo-oxazolidine-3-carbonyl)-5-(tert-butyl-diphenyl-silanyloxy)-pentanoate



embedded image


tert-Butyl (R)-3-((S)-4-benzyl-2-oxo-oxazolidine-3-carbonyl)-5-hydroxy-pentanoate (431 g, equivalent to 1.06 mol) and DMF (2000 mL) were mixed. To the mixture were added imidazole (160 g) and tert-butylchlorodiphenylsilane (287 mL) at ice temperature. The reaction mixture was stirred for 1 hr at room temperature. To the mixture were added water (1200 mL) and toluene (2300 mL). The organic layer was separated, and washed with aqueous 20 w/v % citric acid (1600 mL), water (2000 mL), and aqueous 10 w/v % sodium chloride (1600 mL) in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off and the filtrate was concentrated under reduced pressure to give the title compound (744.2 g, containing toluene (17 w/w %), by NMR) as a crude product.


E-53-5
tert-Butyl (R)-2-[2-(tert-butyl-diphenyl-silanyloxy)-ethyl]-succinate



embedded image


Lithium hydroxide monohydrate (58 g), THF (1300 mL) and water (600 mL) were mixed. Aqueous 30 w/w % hydrogen peroxide (256 mL) was added dropwise to the mixture at ice temperature. The reaction mixture was stirred for 1 hr at ice temperature. A solution of tert-butyl (R)-3-((S)-4-benzyl-2-oxo-oxazolidine-3-carbonyl)-5-(tert-butyl-diphenyl-silanyloxy)-pentanoate (744 g, equivalent to 1.06 mol) in THF (1200 mL) was added dropwise to the reaction mixture at ice temperature. The reaction mixture was stirred for 2 hrs at room temperature, then aqueous 20 w/v % sodium hydrogen sulfite (1632 mL) was added dropwise thereto at ice temperature. To the reaction mixture was added ethyl acetate (3600 mL). The organic layer was separated, and washed with water (2000 mL) and aqueous 10 w/v % sodium chloride (2000 mL) in this order, and concentrated under reduced pressure. The resulting residue (706.7 g), hexane (3500 mL), aqueous 1 M sodium carbonate (2800 mL) were mixed. The aqueous layer was separated, and washed with hexane (1500 mL). Aqueous 6 M hydrochloric acid (865 mL) was added dropwise to the aqueous layer at ice temperature. The aqueous layer was extracted with ethyl acetate (2200 mL). The organic layer was washed with water (2200 mL) and aqueous 10 w/v % sodium chloride (1500 mL) in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. Diisopropylether (1100 mL) and hexane (1600 mL) were added thereto. The resulting mixture was stirred at room temperature. The resultant precipitate was collected by filtration to give the title compound (437.4 g, containing diisopropylether etc. by NMR).


E-53-6
tert-Butyl (R)-5-(tert-butyl-diphenyl-silanyloxy)-3-(methoxy-methyl-carbamoyl)-pentanoate



embedded image


tert-Butyl (R)-2-[2-(tert-butyl-diphenyl-silanyloxy)-ethyl]-succinate (437 g, equivalent to 874 mmol), triethylamine (171 mL), and DMF (2000 mL) were mixed. To the mixture were added N,O-dimethylhydroxylamine hydrochloride salt (111 g), HOBt.H2O (161 g), and WSC.HCl (201 g) at ice temperature. The reaction mixture was stirred overnight at room temperature. To the reaction mixture were added water (800 mL) and hexane (2400 mL). The organic layer was separated, and washed with water (1200 mL) and aqueous 10 w/v % sodium chloride (1200 mL) in this order: The combined aqueous layer was re-extracted with hexane (2400 mL). The combined organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (425 g, containing hexane (1.8 w/w %), by NMR) as a crude product.


E-53-7
tert-Butyl 5-(tert-butyl-diphenyl-silanyloxy)-3-(R)-formyl-pentanoate



embedded image


tert-Butyl (R)-5-(tert-butyl-diphenyl-silanyloxy)-3-(methoxy-methyl-carbamoyl)-pentanoate (30.9 g, equivalent to 60.0 mmol) and THF (150 mL) were mixed. Diisobutylaluminium hydride (1.0 M in toluene) (78.0 mL) was added dropwise to the mixture at −78° C. The reaction mixture was stirred for 30 minutes at −78° C. The reaction mixture was added dropwise to aqueous 1.0 M sulfuric acid (114 mL) at ice temperature. To the reaction mixture was added toluene. The organic layer was separated, and washed with aqueous 10 w/v % potassium hydrogen sulfate and water in this order, then concentrated under reduced pressure to give the title compound (31.5 g) as a crude product.


E-53-8
tert-Butyl 5-(tert-butyl-diphenyl-silanyloxy)-3-((R)-hydroxyimino-methyl)-pentanoate



embedded image


Hydroxylammonium chloride (7.06 g), ethanol (122 mL), and water (35 mL) were mixed. Aqueous 4 M sodium hydroxide (23.4 mL) was added dropwise to the mixture at ice temperature. A mixture of tert-Butyl 5-(tert-butyl-diphenyl-silanyloxy)-3-(R)-formyl-pentanoate (40.9 g, equivalent to 78.1 mmol), ethanol (18 mL), and THF (35 mL) was added dropwise to the reaction mixture at ice temperature. The reaction mixture was stirred for 3 hrs at ice temperature. To the reaction mixture was added toluene (210 mL). The organic layer was separated, and washed with water and brine in this order. The organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (40.7 g, containing toluene (13 w/w %), by NMR) as a crude product.


E-53-9
tert-Butyl 5-(tert-butyl-diphenyl-silanyloxy)-3-((R)-chloro-hydroxyimino-methyl)-pentanoate



embedded image


tert-Butyl 5-(tert-butyl-diphenyl-silanyloxy)-3-((R)-hydroxyimino-methyl)-pentanoate (23.0 g, equivalent to 43.9 mmol) and DMF (100 mL) were mixed. To the mixture was added N-chlorosuccinimide (7.03 g) at ice temperature. The reaction mixture was stirred for 2 hrs at room temperature. To the reaction mixture were added water and aqueous saturated sodium chloride at ice temperature. The reaction mixture was extracted with toluene (120 mL, 60 mL). The organic layer was washed with water and brine in this order. The organic layer was concentrated under reduced pressure until being reduced to approximately 120 mL in volume, and the resulting solution was used in the next step.


E-53-10
tert-Butyl (R)-5-(tert-butyl-diphenyl-silanyloxy)-3-(5-hydroxymethyl-isoxazol-3-yl)-pentanoate



embedded image


Propargyl alcohol (3.20 g), toluene (60 mL), potassium carbonate (6.37 g), and water (30 mL) were mixed. The mixture was heated to 110° C. A solution of tert-butyl (5-(tert-butyl-diphenyl-silanyloxy)-3-((R)-chloro-hydroxyimino-methyl)-pentanoate which was obtained in E-53-9 in toluene (equivalent to 43.9 mmol) was added dropwise to the reaction mixture. The resulting mixture was stirred for 30 minutes. The resulting organic layer was separated, and washed with water and aqueous saturated sodium chloride. The organic layer was concentrated under reduced pressure to give the title compound (26.0 g) as a crude product.


E-53-11
tert-Butyl (R)-3-(5-acetoxymethyl-isoxazol-3-yl)-5-(tert-butyl-diphenyl-silanyloxy)-pentanoate



embedded image


tert-Butyl (R)-5-(tert-butyl-diphenyl-silanyloxy)-3-(5-hydroxymethyl-isoxazol-3-yl)-pentanoate (26.0 g, equivalent to 43.9 mmol), triethylamine (11.0 mL), and chloroform (130 mL) were mixed. Acetyl chloride (4.39 mL) was added dropwise to the mixture at ice temperature. The reaction mixture was stirred for 1 hr at ice temperature, and water was added thereto. The reaction mixture was extracted with chloroform. The organic layer was washed with water and aqueous saturated sodium chloride in this order. The organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (30.1 g) as a crude product.


E-53-12
tert-Butyl (R)-3-(5-acetoxymethyl-isoxazol-3-yl)-5-hydroxy-pentanoate



embedded image


tert-Butyl (R)-5-(tert-butyl-diphenyl-silanyloxy)-3-(5-hydroxymethyl-isoxazol-3-yl)-pentanoate (17.62 g) and THF (150 mL) were mixed. To the mixture were added acetic acid/water=4/1 (4.8 mL) and tetrabutylammonium fluoride (1 M in THF) (48.3 mL) at ice temperature. The resulting mixture was stirred overnight at room temperature. To the reaction mixture was added water at ice temperature, and the resulting mixture was extracted with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride, and dried with magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/1) to give the title compound (11.0 g, containing ethyl acetate (5.0 w/w %), by NMR).


E-53-13
Mono-tert-butyl (R)-3-(5-acetoxymethyl-isoxazol-3-yl)-pentanedicarboxylate



embedded image


tert-Butyl (R)-3-(5-acetoxymethyl-isoxazol-3-yl)-5-hydroxy-pentanoate (2,4-dichloro-phenyl)-amide (10.4 g), acetonitrile (60 mL), and 1.0 M phosphate buffer (pH=6.8) (40 mL) were mixed. To the mixture were added 2,2,6,6-tetramethyl-1-piperidinyloxy radical (TEMPO) (260 mg) and sodium chlorite (7.50 g) at ice temperature. Aqueous sodium hypochlorite (Wako Pure Chemical Industries, 4.0 mL) was added dropwise to the reaction mixture at ice temperature. The reaction mixture was stirred for 2 hrs at room temperature, and then aqueous sodium sulfite was added thereto at ice temperature. The pH of the reaction mixture was adjusted with aqueous sodium hydrogen sulfate to 6. To the reaction mixture was added ethyl acetate. The organic layer was separated, and washed with water and brine, and dried with magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The residue was azeotroped with toluene to give the title compound (12.2 g) as a crude product.


E-53-14
Mono-tert-butyl (R)-3-(5-hydroxymethyl-isoxazol-3-yl)-pentanedicarboxylate



embedded image


Mono-tert-butyl (R)-3-(5-acetoxymethyl-isoxazol-3-yl)-pentanedicarboxylate (12.2 g, equivalent to 33.2 mmol), methanol (50 mL), and water (5 mL) were mixed. To the mixture was added potassium carbonate (9.18 g) at ice temperature. The reaction mixture was stirred for 1.5 hrs at room temperature, and aqueous 1 M hydrochloric acid (133 mL) was added thereto. The reaction mixture was extracted with chloroform (four times), and the combined organic layer was dried with magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The residue was azeotroped with toluene to give the title compound (10.9 g) as a crude product.


E-53-15
Benzyl tert-butyl (R)-3-(5-hydroxymethyl-isoxazol-3-yl)-pentanedicarboxylate



embedded image


Mono-tert-butyl (R)-3-(5-hydroxymethyl-isoxazol-3-yl)-pentanedicarboxylate (10.9 g, equivalent to 33.2 mmol) and DMF (50 mL) were mixed, and then benzyl bromide (4.73 mL) was added thereto. To the reaction mixture was added potassium hydrogen carbonate (4.65 g) at ice temperature. The resulting mixture was stirred overnight at room temperature. To the reaction mixture was added water at ice temperature. The resulting mixture was extracted with ethyl acetate. The organic layer was washed with water and aqueous saturated sodium chloride in this order. The organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/2) to give the title compound (11.0 g).


E-53-16
Benzyl tert-butyl (R)-3-(5-hydroxymethyl-4-iodo-isoxazol-3-yl)-pentanedicarboxylate



embedded image


Benzyl tert-butyl (R)-3-(5-hydroxymethyl-isoxazol-3-yl)-pentanedicarboxylate (11.0 g) and acetonitrile (50 mL) were mixed. To the mixture were added N-iodosuccinimide (11.2 g) and ammonium cerium(IV) nitrate (3.21 g) under water-cooling. The reaction mixture was stirred at room temperature overnight. Aqueous 10 w/v % sodium sulfite (121 mL) was added dropwise to the mixture at ice temperature. The reaction mixture was filtered using Celite with washing with ethyl acetate. To the filtrate was added ethyl acetate. The organic layer was separated, and washed with water and brine, and dried with magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/3) to give the title compound (3.90 g).


E-53-17
Benzyl tert-butyl (R)-3-(4-cyclopropyl-5-hydroxymethyl-isoxazol-3-yl)-pentanedicarboxylate



embedded image


Benzyl tert-butyl (R)-3-(5-hydroxymethyl-4-iodo-isoxazol-3-yl)-pentanedicarboxylate (3.90 g), 2-cyclopropyl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (2.06 mL), tripotassium phosphate (4.95 g), and DMF (18 mL) were mixed. To the reaction mixture was added PdCl2(PPh3)2 (546 mg) under argon atmosphere. The reaction mixture was stirred at 90° C. overnight under argon atmosphere. To the reaction mixture was added ethyl acetate, and the resulting mixture was filtered using Celite. The filtrate was washed with water (twice) and brine in this order, and then dried with magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/3) to give the title compound (595 mg).


E-53-18
Benzyl tert-butyl (R)-3-(4-cyclopropyl-5-formyl-isoxazol-3-yl)-pentanedicarboxylate



embedded image


Benzyl tert-butyl (R)-3-(4-cyclopropyl-5-hydroxymethyl-isoxazol-3-yl)-pentanedicarboxylate (596 mg), chloroform (5.0 mL) were mixed. To the mixture was added Dess-Martin periodinane (728 mg) at ice temperature. The reaction mixture was stirred for 30 minutes at room temperature, and added aqueous 20 w/v % sodium sulfite (10 mL) at ice temperature. To the reaction mixture were added ethyl acetate, water, aqueous saturated sodium hydrogen carbonate. The resulting mixture was stirred for 1 hr at room temperature. The organic layer was separated, washed with brine, and dried with magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (612 mg) as a crude product.


E-53-19
Benzyl tert-butyl (R)-3-(4-cyclopropyl-5-(hydroxyimino-methyl)-isoxazol-3-yl)-pentanedicarboxylate



embedded image


Benzyl tert-butyl (R)-3-(4-cyclopropyl-5-formyl-isoxazol-3-yl)-pentanedicarboxylate (612 mg), ethanol (4.0 mL), THF (1.0 mL), and water (1.0 mL) were mixed. Hydroxylammonium chloride (120 mg), aqueous 4 M sodium hydroxide (0.43 mL) were added to the reaction mixture at ice temperature. The reaction mixture was stirred at room temperature overnight. To the mixture were added ethyl acetate and water. The organic layer was separated, and washed with water and brine in this order. The organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (626 mg) as a crude product.


E-53-20
Benzyl tert-butyl (R)-3-(4-cyclopropyl-5-(chloro-hydroxyimino-methyl)-isoxazol-3-yl)-pentanedicarboxylate



embedded image


Benzyl tert-butyl (R)-3-(4-cyclopropyl-5-(hydroxyimino-methyl)-isoxazol-3-yl)-pentanedicarboxylate (626 mg), DMF (4.0 mL) were mixed. To the mixture was added N-chlorosuccinimide (200 mg) at room temperature. The reaction mixture was stirred for 1 hr at room temperature, and N-chlorosuccinimide (200 mg) was added again. To the reaction mixture were added toluene and water. The organic layer was separated, and washed with water, and the solution was directly used in the next step.


E-53-21
Benzyl tert-butyl (R)-3-[4′-cyclopropyl-5-(1-hydroxy-2,2-dimethyl-propyl)-[3,5′]biisoxazolyl-3′-yl]-pentanedicarboxylate



embedded image


4,4-dimethyl-1-pentyn-3-ol (0.321 mL) which was obtained in a similar way to E-49-5, toluene (1.0 mL), potassium carbonate (207 mg), water (1.0 mL) were mixed. The mixture was heated to 120° C. A solution of benzyl tert-butyl (R)-3-(4-cyclopropyl-5-(chloro-hydroxyimino-methyl)-isoxazol-3-yl)-pentanedicarboxylate in toluene which was obtained in E-53-20 (equivalent to 1.43 mmol) was added dropwise to the reaction mixture, and the resulting mixture was stirred for 30 minutes. To the reaction mixture were added water and ethyl acetate. The organic layer was separated, washed with brine, and dried with magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/1) to give the title compound (712 mg).


E-53-22
Benzyl tert-butyl (R)-3-[4′-cyclopropyl-5-(2,2-dimethyl-propionyl)-[3,5′]biisoxazolyl-3′-yl]-pentanedicarboxylate



embedded image


Benzyl tert-butyl (R)-3-[4′-cyclopropyl-5-(1-hydroxy-2,2-dimethyl-propyl)-[3,5′]biisoxazolyl-3′-yl]-pentanedicarboxylate (712 mg), chloroform (4.0 mL) were mixed. To the mixture was added Dess-Martin periodinane (672 mg) at ice temperature. The reaction mixture was stirred for 1 hr at room temperature, and to the mixture was added aqueous 20 w/v % sodium sulfite at ice temperature. The reaction mixture was stirred for 30 minutes at room temperature, and then ethyl acetate and water were added thereto. The organic layer was separated, washed with brine, and dried with magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (770 mg) as a crude product.


E-53-23
Benzyl tert-butyl (R)-3-[4′-cyclopropyl-5-(1,1-difluoro-2,2-dimethyl-propyl)-[3,5′]biisoxazolyl-3′-yl]-pentanedicarboxylate



embedded image


Benzyl tert-butyl (R)-3-[4′-cyclopropyl-5-(2,2-dimethyl-propionyl)-[3,5′]biisoxazolyl-3′-yl]-pentanedicarboxylate (769 mg) and bis(2-methoxyethyl)aminosulfur trifluoride (0.973 mL) were mixed. The mixture was stirred for 2 hrs 80° C. To the reaction mixture was added dichloromethane at ice temperature. The reaction mixture was added to aqueous sodium hydrogen carbonate at ice temperature. Ethyl acetate was added to the mixture. The organic layer was separated, and washed with water and brine in this order. The organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/4) to give the title compound (589 mg).


E-53-24
Mono-tert-butyl (R)-3-[4′-cyclopropyl-5-(1,1-difluoro-2,2-dimethyl-propyl)-[3,5′]biisoxazolyl-3′-yl]-pentanedicarboxylate



embedded image


Benzyl tert-butyl (R)-3-[4′-cyclopropyl-5-(1,1-difluoro-2,2-dimethyl-propyl)-[3,5′]biisoxazolyl-3′-yl]-pentanedicarboxylate (589 mg), and THF (5.0 mL) were mixed. To the mixture was added 20 w/w % palladium carbon (300 mg). The reaction mixture was stirred for 5.5 hrs under hydrogen atmosphere (0.4 MPa). Then, the reaction container was charged with nitrogen gas. The palladium carbon was filtered off with washing with THF. The filtrate was concentrated under reduced pressure to give the title compound (546 mg) as a crude product.


E-53-25
tert-Butyl (R)-4-(2-chloro-4-methyl-phenylcarbamoyl)-3-[4′-cyclopropyl-5-(1,1-difluoro-2,2-dimethyl-propyl)-[3,5′]biisoxazolyl-3′-yl]-butyrate



embedded image


Mono-tert-butyl (R)-3-[4′-cyclopropyl-5-(1,1-difluoro-2,2-dimethyl-propyl)-[3,5′]biisoxazolyl-3′-yl]-pentanedicarboxylate (200 mg) and DMF (2.0 mL) were mixed. To the mixture were added diisopropylethylamine (0.080 mL), 2-chloro-4-methyl-phenylamine (0.057 mL), and HATU (192 mg) at room temperature. The resulting mixture was stirred overnight. To the reaction mixture were added water and ethyl acetate. The organic layer was separated, and washed with aqueous saturated ammonium chloride, aqueous saturated sodium hydrogen carbonate, and brine in this order. The organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/4) to give the title compound (182 mg).


E-53-26
(R)-4-(2-chloro-4-methyl-phenylcarbamoyl)-3-[4′-cyclopropyl-5-(1,1-difluoro-2,2-dimethyl-propyl)-[3,5′]biisoxazolyl-3′-yl]-butyric acid



embedded image


tert-Butyl (R)-4-(2-chloro-4-methyl-phenylcarbamoyl)-3-[4′-cyclopropyl-5-(1,1-difluoro-2,2-dimethyl-propyl)-[3,5′]biisoxazolyl-3′-yl]-butyrate (182 mg) and toluene (2.0 mL) were mixed. To the mixture was added trifluoroacetic acid (2.0 mL) at room temperature. The reaction mixture was stirred for 30 min at room temperature and concentrated under reduced pressure. The residue was azeotroped with toluene (twice). The resulting residue was purified by preparative chromatography (Eluent: methanol/chloroform=1/10) to give the title compound (162 mg, containing chloroform (1.8 w/w %), by NMR).



1H-NMR (400 MHz, CDCl3) 0.71-0.78 (m, 2H), 1.05-1.09 (m, 2H), 1.14 (s, 9H), 1.72-1.79 (m, 1H), 2.28 (s, 3H), 2.87-3.10 (m, 4H), 4.07-4.14 (m, 1H), 6.87 (s, 1H), 7.04 (d, J=8.38 Hz, 1H), 7.16 (s, 1H), 7.71 (s, 1H), 8.12 (d, J=8.16 Hz, 1H)


E-53-27
Sodium (R)-4-(2-chloro-4-methyl-phenylcarbamoyl)-3-[4′-cyclopropyl-5-(1,1-difluoro-2,2-dimethylpropyl)-[3,5′]biisoxazolyl-3′-yl]-butyrate



embedded image


(R)-4-(2-Chloro-4-methyl-phenylcarbamoyl)-3-[4′-cyclopropyl-5-(1,1-difluoro-2,2-dimethyl-propyl)-[3,5′]biisoxazolyl-3′-yl]-butyric acid (162.1 mg, equivalent to 0.297 mmol), ethanol were mixed. To the mixture was added aqueous 1 M sodium hydroxide (0.297 mL) at room temperature. The resulting solution was concentrated under reduced pressure to give the title compound (156 mg).


Example E-04
(S)-5-(2-chloro-4-methyl-phenylcarbamoyl)-4-(4-cyclopropyl-3′-isobutyl-[5,5′]biisoxazolyl-3-yl)-pentanoic acid
E-04-1
tert-Butyl (S)-6-benzyloxy-3-(4-cyclopropyl-5-ethynyl-isoxazol-3-yl)-hexanoate



embedded image


Trimethylsilyldiazomethane (2 M in hexane) (0.529 mL) and THF (2.0 mL) were mixed. n-Butyllithium (2.6 M in hexane) (0.393 mL) was added dropwise to the mixture at −78° C. The reaction mixture was stirred for 30 minutes at −78° C. A solution of tert-butyl (S)-6-benzyloxy-3-(4-cyclopropyl-5-formyl-isoxazol-3-yl)-hexanoate (350 mg) which is obtained in a similar way to E-49-2 in THF (2.0 mL) was added dropwise to the reaction mixture at −78° C. The reaction mixture was stirred for 5 min at −78° C., and then stirred for 1 hr at 0° C. To the reaction mixture was added aqueous 1 M hydrochloric acid at ice temperature. Ethyl acetate was added to the mixture. The organic layer was separated, and washed with water and brine in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/15) to give the title compound (157 mg).


E-04-2
3-Methyl-butylaldehyde oxime



embedded image


Hydroxylammonium chloride (605 mg), THF (7.0 mL), water (7.0 mL) were mixed. Aqueous 4 M sodium hydroxide (2.18 mL) was added dropwise to the mixture at ice temperature. A mixture of 3-methyl-butylaldehyde (500 mg) and ethanol (20 mL) was added dropwise to the reaction mixture at ice temperature. The mixture was stirred at room temperature overnight. The pH of the reaction mixture was adjusted with aqueous 1 M hydrochloric acid to 6. To the mixture was added diethyl ether. The organic layer was separated, and washed with brine, and then dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound as a crude product.


E-04-3
1-Chloro-3-methyl-butylaldehyde oxime



embedded image


3-Methyl-butylaldehyde oxime (48 mg) and DMF (1.0 mL) were mixed. To the mixture was added N-chlorosuccinimide (69 mg) at room temperature. The reaction mixture was stirred for 1 hr at room temperature. To the reaction mixture were added toluene and water. The organic layer was separated, and washed with water and aqueous saturated sodium chloride in this order, and the solution was directly used in the next step.


E-04-4
tert-Butyl (S)-6-benzyloxy-3-(4-cyclopropyl-3′-isobutyl-[5,5′]biisoxazolyl-3-yl)-hexanoate



embedded image


A solution of 1-chloro-3-methyl-butylaldehyde oxime which was obtained in E-04-3 in toluene (equivalent to 0.467 mmol), potassium carbonate (0.078 g), water (3.0 mL), and tert-butyl (S)-6-benzyloxy-3-(4-cyclopropyl-5-ethynyl-isoxazol-3-yl)-hexanoate which was obtained in E-04-1 (153 mg) were mixed. The mixture was stirred for 3.5 hrs at 100° C. To the reaction mixture were added ethyl acetate and water. The organic layer was separated, and washed with water and brine in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/15) to give the title compound (162 mg) as a crude product.


E-04-5
(S)-6-Benzyloxy-3-(4-cyclopropyl-3′-isobutyl-[5,5′]biisoxazolyl-3-yl)-hexanoic acid



embedded image


tert-Butyl (S)-6-benzyloxy-3-(4-cyclopropyl-3′-isobutyl-[5,5′]biisoxazolyl-3-yl)-hexanoate (162 mg) and toluene (1.3 mL) were mixed. To the mixture was added trifluoroacetic acid (0.33 mL) at ice temperature. The reaction mixture was stirred at room temperature overnight, and concentrated under reduced pressure. The resulting residue was azeotroped with toluene to give the title compound (151 mg) as a crude product.


E-04-6
(S)-6-Benzyloxy-3-(4-cyclopropyl-3′-isobutyl-[5,5′]biisoxazolyl-3-yl)-hexanoic acid (2-chloro-4-methyl-phenyl)amide



embedded image


(S)-6-Benzyloxy-3-(4-cyclopropyl-3′-isobutyl-[5,5′]biisoxazolyl-3-yl)-hexanoic acid (151 mg), 2-chloro-4-methyl-phenylamine (0.050 mL), and DMF (1.5 mL) were mixed. To the mixture were added diisopropylethylamine (0.089 mL) and HATU (156 mg) at ice temperature. The resulting mixture was stirred overnight at room temperature. To the reaction mixture were added ethyl acetate and water. The organic layer was separated, and washed with water and brine in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography to give the title compound (161 mg).


E-04-7
(S)-3-(4-cyclopropyl-3′-isobutyl-[5,5′]biisoxazolyl-3-yl)-6-hydroxy-hexanoic acid (2-chloro-4-methyl-phenyl)amide



embedded image


(S)-6-benzyloxy-3-(4-cyclopropyl-3′-isobutyl-[5,5′]biisoxazolyl-3-yl)-hexanoic acid (2-chloro-4-methyl-phenyl)amide (160 mg) and dichloromethane (2.5 mL) were mixed. To the mixture was added boron tribromide (1 M in dichloromethane) (0.833 mL) at ice temperature. The cooling bath was removed, and the reaction mixture was stirred for 20 minutes. To the reaction mixture were added aqueous saturated sodium hydrogen carbonate, water, and ethyl acetate at ice temperature. The organic layer was separated, and washed with aqueous saturated sodium hydrogen carbonate and brine. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure.


The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/1) to give a crude product (109 mg). The crude product was purified by preparative chromatography (Eluent: acetone/hexane 1/2) to give the title compound (65.7 mg).


E-04-8
(S)-5-(2-chloro-4-methyl-phenylcarbamoyl)-4-(4-cyclopropyl-3′-isobutyl-[5,5′]biisoxazolyl-3-yl)-pentanoic acid



embedded image


(S)-3-(4-cyclopropyl-3′-isobutyl-[5,5′]biisoxazolyl-3-yl)-6-hydroxy-hexanoic acid (2-chloro-4-methyl-phenyl)amide (65.7 mg), acetonitrile (0.4 mL) and 1.0 M phosphate buffer (pH=6.8) (0.4 mL) were mixed. To the mixture were added 2,2,6,6-tetramethyl-1-piperidinyloxy radical (TEMPO) (2.1 mg), sodium chlorite (31 mg), aqueous sodium hypochlorite (Wako Pure Chemical Industries, 0.027 mL) at ice temperature. The reaction mixture was stirred for 1 hr at room temperature, and then aqueous 20 w/v % sodium sulfite and ethyl acetate were added to the mixture at ice temperature. The organic layer was separated, and washed with water and brine in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/1) to give the title compound (68.8 mg).


E-04-9
Sodium (S)-5-(2-chloro-4-methyl-phenylcarbamoyl)-4-(4-cyclopropyl-3′-isobutyl-[5,5′]biisoxazolyl-3-yl)-pentanoate



embedded image


(S)-5-(2-chloro-4-methyl-phenylcarbamoyl)-4-(4-cyclopropyl-3′-isobutyl-[5,5′]biisoxazolyl-3-yl)-pentanoic acid (68.0 mg) and ethanol (0.7 mL) were mixed. To the mixture was added aqueous 1 M sodium hydroxide (0.135 mL) at room temperature. The resulting solution was concentrated under reduced pressure to give the title compound (65.3 mg).


Example E-62
Sodium (S)-5-(4-chloro-2-fluoro-phenylcarbamoyl)-4-[5-(1,1-difluoro-2,2-dimethylpropyl)-4′-difluoromethyl-[3,5′]biisoxazolyl-3′-yl]-pentanoate
E-62-1
tert-Butyl (S)-6-benzyloxy-3-[5-(1-hydroxy-2,2-dimethyl-propyl)-4′-iodo-[3,5′]biisoxazolyl-3′-yl]-hexanoate



embedded image


4,4-dimethyl-1-pentyn-3-ol which is contained in a similar way to E-49-5 (700 mg), aqueous 2.0 M potassium carbonate (2.02 mL), and toluene (5.0 mL) were mixed. The mixture was heated to 110° C. A solution of tert-butyl (S)-6-benzyloxy-3-[5-(chloro-hydroxyimino-methyl)-4-iodo-isoxazol-3-yl]-hexanoate which is contained in a similar way to E-58-15 (equivalent to 3.85 mmol) in toluene was added dropwise to the mixture. The resulting mixture was stirred for 30 minutes. To the reaction mixture was added toluene. The organic layer was separated, washed with water, and concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/3) to give the title compound (2.51 g).


E-62-2
tert-Butyl (S)-6-benzyloxy-3-[5-(2,2-dimethyl-propionyl)-4′-iodo-[3,5′]biisoxazolyl-3′-yl]-hexanoate



embedded image


tert-Butyl (S)-6-benzyloxy-3-[5-(1-hydroxy-2,2-dimethyl-propyl)-4′-iodo-[3,5′]biisoxazolyl-3′-yl]-hexanoate (1.50 g) and chloroform (15 mL) were mixed. To the mixture was added Dess-Martin periodinane (1.23 g) at room temperature. The reaction mixture was stirred for 1 hr at room temperature. To the mixture was added aqueous sodium carbonate and aqueous saturated sodium hydrogen carbonate at ice temperature. To the reaction mixture was added ethyl acetate. The resulting mixture was stirred for minutes at room temperature. The organic layer was separated, and washed with aqueous saturated sodium hydrogen carbonate and brine in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Fluent: ethyl acetate/hexane=1/7.5) to give the title compound (1.46 g).


E-62-3
tert-Butyl (S)-6-benzyloxy-3-[5-(2,2-dimethyl-propionyl)-4′-vinyl-[3,5′]biisoxazolyl-3′-yl]-hexanoate



embedded image


tert-Butyl (S)-6-benzyloxy-3-[5′-(1,1-difluoro-2,2-dimethyl-propyl)-4-iodo-[3,3′]biisoxazolyl-5-yl]-hexanoate (800 mg), 4,4,5,5-tetramethyl-2-vinyl-[1,3,2]dioxaborolane (300 mg), cesium fluoride (880 mg), and N-methylpyrrolidone (5.5 mL) were mixed. To the mixture was added PdCl2 (dppf).CH2Cl2 (52.5 mg) under argon atmosphere. The reaction mixture was stirred at 90° C. overnight under argon atmosphere. To the reaction mixture were added ethyl acetate and water. The organic layer was separated, and washed with water. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/6) to give the title compound (257 mg).


E-62-4
tert-Butyl (S)-6-benzyloxy-3-[5-(2,2-dimethyl-propionyl)-4′-(2-phenyl[1,3,2]dioxaborolane-4-yl)-[3,5′]biisoxazolyl-3′-yl]-hexanoate



embedded image


tert-Butyl (S)-6-benzyloxy-3-[5-(2,2-dimethyl-propionyl)-4′-vinyl-[3,5′]biisoxazolyl-3′-yl]-hexanoate (257 mg) and dichloromethane (2.0 mL) were mixed. To the mixture were added phenylboric acid (120 mg), N-methylmorpholine N-oxide (115 mg), and microencapsulated osmium tetroxide (10 w/w %, 62 mg) at room temperature. The resulting mixture was stirred for 2 hrs at room temperature. To the reaction mixture were added aqueous saturated sodium dithionite and chloroform at room temperature. The organic layer was separated, and washed with brine, and then dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/2) to give the title compound (282 mg).


E-62-5
tert-Butyl (S)-6-benzyloxy-3-[5-(2,2-dimethyl-propionyl)-4′-formyl-[3,5′]biisoxazolyl-3′-yl]-hexanoate



embedded image


tert-Butyl (S)-6-benzyloxy-3-[5-(2,2-dimethyl-propionyl)-4′-(2-phenyl[1,3,2]dioxaborolane-4-yl)-[3,5′]biisoxazolyl-3′-yl]-hexanoate (282 mg), THF (30 mL), and water (3.0 mL) were mixed. To the mixture was added sodium periodate (282 mg) at room temperature. The reaction mixture was stirred for 30 minutes at 50° C. To the reaction mixture were added diethyl ether and water. The organic layer was separated, and dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/4) to give the title compound (145 mg).


E-62-6
tert-Butyl (S)-6-benzyloxy-3-[5-(1,1-difluoro-2,2-dimethylpropyl)-4′-difluoromethyl-[3,5′]biisoxazolyl-3′-yl]-hexanoate



embedded image


tert-Butyl (S)-6-benzyloxy-3-[5-(2,2-dimethyl-propionyl)-4′-formyl-[3,5′]biisoxazolyl-3′-yl]-hexanoate (145 mg) and bis(2-methoxyethyl)aminosulfur trifluoride (0.306 mL) were mixed. The mixture was stirred for 12 hrs at room temperature. The reaction mixture was stirred for 1 hr at 80° C. To the mixture was added chloroform at room temperature. The reaction mixture was added to aqueous saturated sodium hydrogen carbonate at ice temperature. To the reaction mixture was added chloroform. The organic layer was separated, and washed with brine, and then dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/6) to give the title compound (125 mg).


E-62-7
(S)-6-benzyloxy-3-[5-(1,1-difluoro-2,2-dimethylpropyl)-4′-difluoromethyl-[3,5′]biisoxazolyl-3′-yl]-hexanoic acid



embedded image


tert-Butyl (S)-6-benzyloxy-3-[5-(1,1-difluoro-2,2-dimethylpropyl)-4′-difluoromethyl-[3,5′]biisoxazolyl-3′-yl]-hexanoate (125 mg) and toluene (0.60 mL) were mixed. To the mixture was added trifluoroacetic acid (0.60 mL) at ice temperature. The reaction mixture was stirred for 2 hrs at room temperature, and concentrated under reduced pressure. The resulting residue was azeotroped with toluene to give the title compound (122 mg) as a crude product.


E-62-8
(S)-6-benzyloxy-3-[5-(1,1-difluoro-2,2-dimethylpropyl)-4′-difluoromethyl-[3,5′]biisoxazolyl-3′-yl]-hexanoic acid (2-chloro-4-methyl-phenyl)amide



embedded image


(S)-6-benzyloxy-3-[5-(1,1-difluoro-2,2-dimethylpropyl)-4′-difluoromethyl-[3,5′]biisoxazolyl-3′-yl]-hexanoic acid (122 mg), 4-chloro-2-fluoro-phenylamine (42 mg), and DMF (3.0 mL) were mixed. To the mixture were added diisopropylethylamine (0.083 mL), and HATU (109 mg) at room temperature. The resulting mixture was stirred overnight at room temperature. To the reaction mixture was added aqueous saturated sodium bicarbonate at ice temperature. The resulting was extracted with ethyl acetate. The organic layer was washed with water and brine in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=1/4) to give the title compound (146 mg).


E-62-9
(S)-3-[5-(1,1-difluoro-2,2-dimethylpropyl)-4′-difluoromethyl-[3,5′]biisoxazolyl-3′-yl]-6-hydroxy-hexanoic acid (2-chloro-4-methyl-phenyl)amide



embedded image


(S)-6-benzyloxy-3-[5-(1,1-difluoro-2,2-dimethylpropyl)-4′-difluoromethyl-[3,5′]biisoxazolyl-3′-yl]-hexanoic acid (2-chloro-4-methyl-phenyl)amide (146 mg) and dichloromethane (1.5 mL) were mixed. To the mixture was added boron tribromide (1 M in dichloromethane) (0.680 mL) at −78° C. The reaction mixture was stirred for 15 min at −78° C., and then stirred for 15 min at 0° C. To the reaction mixture were added aqueous saturated sodium hydrogen carbonate and ethyl acetate at ice temperature. The organic layer was separated, and washed with brine. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Eluent: ethyl acetate/hexane=2/3) to give the title compound (84.8 mg).


E-62-10
(S)-5-(4-chloro-2-fluoro-phenylcarbamoyl)-4-[5-(1,1-difluoro-2,2-dimethylpropyl)-4′-difluoromethyl-[3,5′]biisoxazolyl-3′-yl]-pentanoic acid



embedded image


(S)-3-[5-(1,1-difluoro-2,2-dimethylpropyl)-4′-difluoromethyl-[3,5′]biisoxazolyl-3′-yl]-6-hydroxy-hexanoic acid (2-chloro-4-methyl-phenyl)amide (84.8 mg), acetonitrile (0.43 mL), and 1.0 M phosphate buffer (pH=6.8) (0.17 mL) were mixed. To the mixture were added 2,2,6,6-tetramethyl-1-piperidinyloxy radical (TEMPO) (1.3 mg), sodium chlorite (40 mg), and aqueous sodium hypochlorite (Wako Pure Chemical Industries, 0.030 mL) at room temperature. The reaction mixture was stirred for 1.5 hrs at room temperature. To the reaction mixture were added aqueous sodium sulfite and aqueous sodium hydrogen sulfate at ice temperature. Ethyl acetate was added to the reaction mixture. The organic layer was separated, and washed with brine, and then dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by preparative chromatography (Eluent: methanol/chloroform=1/15) to give the title compound (67.0 mg).


E-62-11
Sodium (S)-5-(4-chloro-2-fluoro-phenylcarbamoyl)-4-[5-(1,1-difluoro-2,2-dimethylpropyl)-4′-difluoromethyl-[3,5′]biisoxazolyl-3′-yl]-pentanoate



embedded image


(S)-5-(4-chloro-2-fluoro-phenylcarbamoyl)-4-[5-(1,1-difluoro-2,2-dimethylpropyl)-4′-difluoromethyl-[3,5′]biisoxazolyl-3′-yl]-pentanoic acid (67.0 mg) and ethanol (0.119 mL) were mixed. To the mixture was added aqueous 1 M sodium hydroxide (0.119 mL) at room temperature. The resulting solution was concentrated under reduced pressure to give the title compound (70.3 mg).


Production Example of Example E-08



embedded image


Production Example of Example E-15



embedded image


Production Example of Example E-18



embedded image


Production Example of Example E-14



embedded image


Production Example of Example E-11



embedded image


Example F-499
4-(2-chloro-5-methylphenylcarbamoyl)-3-[4-cyclopropyl-5-(3-isobutylcyclobutyl) isoxazol-3-yl]butanoic acid
F-499-1
4-Methyl-1-piperidine-1-ylpentan-1-one



embedded image


4-Methyl valerate (238 g) and DMF (833 mL) were mixed. To the mixture were added piperidine (233 mL), HOBt.H2O (361 g), and WSC.HCl (452 g) at ice temperature. The resulting mixture was stirred overnight at room temperature. To the reaction mixture was added water (1000 mL) at ice temperature. The resulting mixture was extracted with toluene (500 mL×2). The organic layer was washed with aqueous 10 w/v % sodium carbonate (500 mL+300 mL) and water (500 mL×2) in this order, and concentrated under reduced pressure to give the title compound (414.29 g) as a crude product.


F-499-2
1-(4-Methyl-1-pentenyl)piperidine



embedded image


4-Methyl-1-piperidine-1-ylpentan-1-one (372.4 g) and toluene (1000 mL) were mixed. To the mixture was added (Ph3P)IrCl(CO) (633 mg). 1,1,3,3-Tetramethyldisiloxane (627 mL) was added dropwise to the mixture under cooling with water, and then the resulting mixture at was stirred for 2 hrs room temperature. The reaction mixture was concentrated under reduced pressure to give the title compound (844 g) as a crude product.


F-499-3
Ethyl 3-isobutyl-2-piperidine-1-ylcyclobutanecarboxylate



embedded image


1-(4-methyl-1-pentenyl)piperidine (844 g) and acetonitrile (70 mL) were mixed. To the mixture were added ethyl acrylate (443 mL) and hydroquinone (447 mg). The resulting mixture was stirred overnight at 95° C. The reaction mixture was concentrated under reduced pressure to give the title compound (994.08 g) as a crude product.


F-499-4
3-Isobutyl-1-cyclobutenecarboxylic acid



embedded image


Ethyl 3-isobutyl-2-piperidine-1-ylcyclobutanecarboxylate (994 g) and methyl p-toluenesulfonate (337 mL) were mixed. The mixture was stirred for 2 hrs at 110° C. To the reaction mixture was added water (1100 mL). The resulting mixture was washed with a mixture of tert-butyl methyl ether:hexane=1:1 (600 mL) and hexane (600 mL) in this order. To the aqueous layer was added potassium hydroxide (503 g) at ice temperature, and the mixture was stirred for hrs at 95° C. The reaction mixture was washed with diethyl ether (500 mL), a mixture of diethyl ether:hexane=1:1 (500 mL) in this order. To the aqueous layer was added concentrated hydrochloric acid (672 mL) at ice temperature, and the mixture was extracted with ethyl acetate (1 L×2). The organic layer was washed with water (500 mL×2) and brine (500 mL) in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (240 g) as a crude product.


F-499-5
3-Isobutylcyclobutanecarboxylic acid



embedded image


3-Isobutyl-1-cyclobutenecarboxylic acid (188 g) and tetrahydrofuran (2000 mL) were mixed. To the mixture was added 5 w/w % rhodium on activated carbon (5.64 g). The mixture was stirred for 7 hrs at room temperature under hydrogen atmosphere (1 atm). The 5 w/w % rhodium on activated carbon was filtered off and the filtrate was concentrated under reduced pressure to give the title compound (134.06 g) as a crude product.


F-499-6
3-Isobutyl-cyclobutanecarboxylic acid cyclopropylamide



embedded image


To a solution of 3-isobutyl-cyclobutanecarboxylic acid (20.5 g) and HOBt.H2O (24 g) in acetonitrile (300 mL) were added cyclopropylamine (10 mL) and WSC.HCl (30 g) at ice temperature. The resulting mixture was stirred overnight at room temperature. The reaction mixture was concentrated under reduced pressure, and then water and ethyl acetate were added thereto. The organic layer was separated, and washed with aqueous 10% citric acid, water, aqueous saturated sodium hydrogen carbonate, water, and brine in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (28 g) as a crude product.


F-499-7
3-Isobutyl-cyclobutanecarbothioic acid cyclopropylamide



embedded image


To a solution of 3-isobutyl-cyclobutanecarboxylic acid cyclopropylamide (2.93 g) in tetrahydrofuran (25 mL) was added Lawesson's reagent (3.64 g) at room temperature. The mixture was stirred for 2 hrs at room temperature, and then the reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate hexane=1:7) to give the title compound (2.75 g).


F-499-8
N-Cyclopropyl-3-isobutyl-cyclobutanecarboximidethioic acid methyl ester hydrogen iodide salt



embedded image


Methyl iodide (3.2 mL) was added dropwise to a solution of 3-isobutyl-cyclobutanecarbothioic acid cyclopropylamide (2.1 g) in acetonitrile (10 mL) at room temperature. The mixture was stirred for 2 hrs at room temperature, and then concentrated under reduced pressure. The residue was azeotroped with chloroform to give the title compound (3.8 g) as a crude product.


F-499-9
tert-Butyl 4-oxo-4-(2-oxo-oxazolidine-3-yl)butyrate



embedded image


To a solution of 2-oxazolidinone (2.5 g) and mono-tert-butyl succinate (5.0 g) in chloroform (30 mL) were added WSC.HCl (6.62 g) and DMAP (350 mg) at room temperature. The mixture was stirred overnight at room temperature. The reaction mixture was concentrated under reduced pressure, and then ethyl acetate was added. The organic layer was washed with aqueous saturated sodium hydrogen carbonate, water, and brine in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=4:1, followed by 1:1) to give the title compound (5.92 g).


F-499-10
tert-Butyl 3-(2-oxo-oxazolidine-3-carbonyl)-5-hexanoate



embedded image


A solution of 1 M NaH MDS in tetrahydrofuran (4.8 mL) was added dropwise to a solution of tert-butyl 4-oxo-4-(2-oxo-oxazolidine-3-yl)butyrate (2.57 g) in tetrahydrofuran (45 mL) over 5 minutes at −78° C. The mixture was stirred for 1 hr at −78° C. Allyl iodide (4.8 mL) was added dropwise to the mixture over 3 minutes. The reaction temperature was gradually risen. The mixture was stirred overnight at room temperature, and then aqueous saturated ammonium chloride and chloroform were added thereto. The organic layer was separated, and washed with aqueous 1 N HCl, aqueous 1 N NaGH, and brine in this order, and then dried with magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:3) to give the title compound (1.46 g).


F-499-11
4-tert-Butyl 2-allyl-succinate



embedded image


To a reaction solution of tert-butyl 3-(2-oxo-oxazolidine-3-carbonyl)-5-hexanoate (1.46 g) in tetrahydrofuran (20 mL) and H2O (5.0 mL) were added lithium hydroxide monohydrate (350 mg) and aqueous 30% hydrogen peroxide (2.34 mL) at ice temperature. The reaction mixture was stirred for 1 hr, and then, to the mixture were added water, aqueous 5% Na2SO3, and aqueous 10% citric acid. The resulting mixture was extracted with chloroform, and dried with magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (899 mg) as a crude product.


F-499-12
tert-Butyl 3-hydrazinocarbonyl-5-hexanoate



embedded image


4-tert-Butyl 2-allyl-succinate (899 mg) and acetonitrile (9.0 mL) were mixed. To the mixture were added HOBt.H2O (772 mg) and WSC.HCl (965 mg) at room temperature. The mixture was stirred for 1 hr and 30 minutes. The reaction mixture was added dropwise to a solution of NH2NH2.H2O (0.41 mL), cyclohexene (0.1 mL), and acetonitrile (4.0 mL) with washing with acetonitrile (3.0 mL) ice temperature. Then, the reaction mixture was stirred for 40 minutes at ice temperature. To the mixture were added water and ethyl acetate. The organic layer was separated, and washed with aqueous saturated sodium hydrogen carbonate and brine in this order. The organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (844 mg) as a crude product.


F-499-13
tert-Butyl (3-[4-cyclopropyl-5-(3-isobutyl-cyclobutyl)-4H-[1,2,4]triazol-3-yl]-hex-5-enoate



embedded image


tert-Butyl 3-hydrazinocarbonyl-5-hexanoate (228 mg), N-cyclopropyl-3-isobutyl-cyclobutanecarboximidethioic acid methyl ester hydrogen iodide salt (1.04 g), and ethanol (10 mL) were mixed. The mixture was stirred for 7 hrs at room temperature. The reaction mixture was concentrated under reduced pressure. To the mixture was added aqueous saturated sodium hydrogen carbonate. The mixture was extracted with ethyl acetate (twice). The organic layer was washed with brine, and was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. To the resulting residue were added 1,4-dioxane (5.0 mL) and acetic acid (0.5 mL). The resulting mixture was stirred overnight at 90° C. The reaction mixture was cooled to room temperature. Then the pH of the reaction mixture was adjusted with saturated sodium hydrogen carbonate to 8. To the mixture were added ethyl acetate and water. The organic layer was separated, and washed with brine, and then dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (A mixture of methanol and chloroform was used as an eluent. Eluent: methanol:chloroform=2:100) to give the title compound (703 mg).


F-499-14
Mono-tert-butyl 3-[4-cyclopropyl-5-(3-isobutyl-cyclobutyl)-4H-[1,2,4]triazol-3-yl]-pentanedioate



embedded image


tert-Butyl 3-[4-cyclopropyl-5-(3-isobutyl-cyclobutyl)-4H-[1,2,4]triazol-3-yl]-hex-5-enoate (301 mg), acetonitrile (3.0), carbon tetrachloride (3.0 mL), and H2O (3.0 mL) were mixed. To the mixture were added NaIO4 (831 mg) and RuCl3.H2O (18 mg) at ice temperature. The reaction mixture stirred for 4 hrs at room temperature. And then, isopropyl alcohol (3.0 mL) and Buffer were added. Ethyl acetate was added to the mixture. The organic layer was separated, and washed with aqueous 10% NaS2O4 and brine in this order. The organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (A mixture of methanol and chloroform was used as an eluent. Eluent: methanol:chloroform=4:100) to give the title compound (239 mg).


F-499-15
tert-Butyl (3-[4-cyclopropyl-5-(3-isobutyl-cyclobutyl)-4H-[1,2,4]triazol-3-yl]-4-(2,4-dimethyl-phenylcarbamoyl)-butyrate



embedded image


Mono-tert-butyl 3-[4-cyclopropyl-5-(3-isobutyl-cyclobutyl)-4H-[1,2,4]triazol-3-yl]-pentanedioate (228 mg) and DMF (2.0 mL) were mixed. To the mixture were added HOBt.H2O (103 mg), WSC.HCl (130 mg), and 2,4-dimethylaniline (0.084 mL) at room temperature. The mixture was stirred for 6 hrs and 30 minutes. To the reaction mixture were added water and ethyl acetate. The organic layer was separated, and washed with aqueous saturated sodium hydrogen carbonate. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (A mixture of methanol and chloroform was used as an eluent. Eluent: methanol:chloroform=3:100) to give the title compound (294 mg). A part thereof was purified by preparative chromatography (A mixture of methanol and chloroform was used as an eluent. Eluent: methanol:chloroform=1:10) to give the title compound (9.6 mg).


F-499-16
3-[4-Cyclopropyl-5-(3-isobutyl-cyclobutyl)-4H-[1,2,4]triazol-3-yl]-4-(2,4-dimethyl-phenylcarbamoyl)-butyl



embedded image


tert-Butyl 3-[4-cyclopropyl-5-(3-isobutyl-cyclobutyl)-4H-[1,2,4]triazol-3-yl]-4-(2,4-dimethyl-phenylcarbamoyl)-butyrate (271.5 mg) and chloroform (7.0 mL) were mixed. To the mixture was added trifluoroacetic acid (1.4 mL) at room temperature. The reaction mixture was stirred for 2 hrs and 40 min at room temperature, and stirred for 1 hr and 30 minutes at 50° C. Then the mixture was concentrated under reduced pressure, and the residue was azeotroped with toluene (three times). A part of the resulting residue was purified by preparative chromatography (A mixture of methanol and chloroform was used as an eluent. Eluent: methanol:chloroform=1:10) to give the title compound (6.8 mg).


Example F-644
(S)-3-[4-cyclopropyl-5-(3-isobutyl-cyclobutyl)-isoxazol-3-yl]-5-(1H-tetrazole-5-yl)-valeric acid (2,4-dimethyl-phenyl)-amide
F-644-1
3-Isobutylcyclobutanecarboxylic acid methoxymethylamide



embedded image


3-isobutylcyclobutanecarboxylic acid which was obtained in F-499-5 (62.7 g) and DMF (500 mL) were mixed. To the mixture were added N,O-dimethylhydroxylamine hydrochloride salt (46.9 g), triethylamine (83.9 mL), HOBt.H2O (73.8 g), and WSC.HCl (92.3 g). The resulting mixture was stirred overnight at room temperature. To the reaction mixture was added water (500 mL). The resulting mixture was extracted with a mixture of ethyl acetate:hexane=1:1 (250 mL×2). The organic layer was washed with water (250 mL), aqueous 10 w/v % sodium carbonate (250 mL), water (250 mL), 1 N hydrochloric acid (500 mL), water, aqueous saturated sodium bicarbonate (250 mL), and brine (250 mL) in this order. The organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (87.5 g) as a crude product.


F-644-2
3-Isobutylcyclobutanecarbaldehyde



embedded image


Diisobutylaluminium hydride (1.0 M in methylene chloride) (473.2 mL) was added dropwise to a solution of 3-isobutylcyclobutanecarboxylic acid methoxymethylamide (77 g) in methylene chloride (235 mL) at −78° C. The mixture was stirred for 2 hrs at −78° C. 1.5 M sulfuric acid (630 mL) was added dropwise to the mixture. The aqueous layer was separated, and extracted with methylene chloride. The combined organic layer was washed with 1.5 M sulfuric acid, water, and brine in this order. The organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off. The filtrate comprising the title compound was directly used in the next step.


F-644-3
1-(2,2-Dibromovinyl)-3-isobutylcyclobutane



embedded image


A solution of triphenylphosphine (266 g) in methylene chloride (350 mL) was added dropwise to a solution of carbon tetrabromide (168 g) in methylene chloride (252 mL) at ice temperature. The mixture was stirred for 20 min at ice temperature. Then, a solution of 3-isobutylcyclobutanecarbaldehyde in methylene chloride was added dropwise to the mixture at ice temperature. The mixture was stirred for 20 min at ice temperature. Aqueous 10 w/v % sodium carbonate (1 L) was added dropwise to the mixture. The aqueous layer was separated, and was extracted with methylene chloride (200 mL×2), then the organic layer was washed with water and brine in this order. The organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. To the resulting residue were added a mixture of hexane:chloroform=1:1 (750 mL), silica gel (750 mL), hexane (900 mL) in this order. The mixture was filtered and the filtrate was concentrated under reduced pressure. To the residue was added hexane (500 mL), and the mixture was filtered. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica-gel column chromatography (Hexane was used as an eluent.) to give the title compound (76.21 g).


F-644-4
5-(tert-Butyl-diphenyl-silanyloxy)pentanoic acid



embedded image


δ-Valerolactone (6.23 g) and methanol (200 mL) were mixed. To the mixture was added concentrated sulfuric acid (8 drops). The mixture was heated to reflux overnight. To the reaction mixture was added imidazole (600 mg) at room temperature, and then the mixture was concentrated under reduced pressure. To the resulting residue were added DMF (40 mL), imidazole (5.08 g), and tert-butylchlorodiphenylsilane (19.4 mL). The reaction mixture was stirred for 3 hrs at room temperature, and then to the mixture were added water, diethyl ether, and hexane at ice temperature. The mixture was extracted with diethyl ether, and then the resulting organic layer was washed with aqueous saturated ammonium chloride, and dried with magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. To the resulting residue were added methanol (50 mL) and aqueous 2N sodium hydroxide (34.2 mL). The reaction mixture was stirred for 5 hrs at room temperature, and concentrated under reduced pressure. The residue was extracted with ethyl acetate. The organic layer was washed with brine, and dried with magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (24.4 g) as a crude product.


F-644-5
(R)-4-Benzyl-3-[5-(tert-butyl-diphenyl-silanyloxy)pentanoyl]-oxazolidin-2-one



embedded image


5-(tert-Butyl-diphenyl-silanyloxy)pentanoic acid (23.51 g), (R)-4-benzyl-2-oxazolidinone (11 g), and chloroform (200 ml) were mixed. To the mixture were added 4-dimethylaminopyridine (3.8 g) and WSC.HCl (12.5 g), and the mixture was stirred for 7.5 hrs at room temperature. The reaction mixture was concentrated under reduced pressure. To the resulting residue was added ethyl acetate. To the mixture were added 2 N hydrochloric acid and water, and the mixture was extracted with ethyl acetate. The organic layer was washed with 2 N hydrochloric acid and brine in this order. The organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:10, followed by 1:6) to give the title compound (27.1031 g).


F-644-6
tert-Butyl (S)-3-((R)-4-benzyl-2-oxo-oxazolidine-3-carbonyl)-6-(tert-butyl-diphenyl-silanyloxy)-hexanoate



embedded image


Sodium hexamethyldisilazide (1.9 M in THF) (30.8 mL) and THF (125 mL) were mixed. A solution of (R)-4-benzyl-3-[5-(tert-butyl-diphenyl-silanyloxy)pentanoyl]-oxazolidin-2-one (25.12 g) in THF was added dropwise to the mixture at −78° C. tert-Butyl bromoacetate (11.5 mL) was added dropwise to the reaction mixture at −66° C. The temperature of the reaction mixture was raised to −26° C. over 0.5 hrs. The mixture was stirred for 0.5 hrs at ice temperature. Aqueous saturated ammonium chloride was added dropwise to the reaction mixture. The mixture was extracted with ethyl acetate, and the resulting organic layer was washed with aqueous saturated ammonium chloride and brine in this order, and dried with magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:50, 1:20, and 1:10 in this order) to give the title compound (26.04 g).


F-644-7
4-tert-Butyl (S)-2-[3-(tert-butyl-diphenyl-silanyloxy)-propyl]-succinate



embedded image


Lithium hydroxide monohydrate (2.79 g), THF (80 mL) and water (54 mL) were mixed. Aqueous 30 w/w % hydrogen peroxide (18.9 mL) was added dropwise to the mixture at ice temperature. The reaction mixture was stirred for 0.5 hrs at ice temperature. tert-Butyl (S)-3-((R)-4-benzyl-2-oxo-oxazolidine-3-carbonyl)-6-(tert-butyl-diphenyl-silanyloxy)-hexanoate (25.6 g) was added dropwise to the reaction mixture at ice temperature. The reaction mixture was stirred for 1.5 hrs, and then aqueous 10 w/v % sodium hydrogen sulfite (350 mL) was added dropwise to the mixture at ice temperature. The mixture was extracted with ethyl acetate, and the resulting organic layer was washed with aqueous sodium hydrogen sulfite, and citric acid aqueous in this order, and then dried with magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:9, 1:8, 1:6, and 1:4 in this order) to give the title compound (17.13 g).


F-644-8
tert-Butyl (S)-6-(tart-butyl-diphenyl-silanyloxy)-3-(methoxy-methyl-carbamoyl)-hexanoate



embedded image


4-tert-Butyl (S)-2-[3-(tert-butyl-diphenyl-silanyloxy)-propyl]-succinate (16.47 g), N,N-diisopropylethylamine (8.32 mL), N,O-dimethylhydroxylamine hydrochloride salt (4.1 g), and chloroform (170 mL) were mixed. To the mixture were added 4-(dimethylamino)pyridine (4.27 g), and WSC.HCl (7.38 g). The mixture was stirred for 2 hrs at room temperature. The reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:100, 1:20, 1:10, 1:9, 1:8, and 1:4 in this order) to give the title compound (14.93 g).


F-644-9
tert-Butyl (S)-3-[3-(tert-butyl-diphenyl-silanyloxy)-propyl]-6-(3-isobutyl-cyclobutyl)-4-oxo-5-hexynoate



embedded image


1-(2,2-Dibromovinyl)-3-isobutylcyclobutane which was obtained in F-644-3 (9.47 g) and tetrahydrofuran (100 mL) were mixed. n-Butyllithium (2.66 M in hexane) (25.8 mL) was added dropwise to the mixture at −78° C. The mixture was stirred at ice temperature. Then, a solution of tert-butyl (S)-6-(tert-butyl-diphenyl-silanyloxy)-3-(methoxy-methyl-carbamoyl)-hexanoate (11.52 g) in tetrahydrofuran (40 mL) was added dropwise to the mixture. The mixture was stirred for 0.5 hrs at ice temperature. To the reaction mixture was added aqueous saturated ammonium chloride, and the mixture was extracted with ethyl acetate. the resulting organic layer was washed with aqueous saturated ammonium chloride, and dried with magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:30, 1:25, and 1:20 in this order) to give the title compound (11.75 g).


F-644-10
tert-Butyl (S)-3-[3-(tert-butyl-diphenyl-silanyloxy)-propyl]-6-(3-isobutyl-cyclobutyl)-4-(methoxyimino)-5-hexynoate



embedded image


tert-Butyl (S)-3-[3-(tert-butyl-diphenyl-silanyloxy)-propyl]-6-(3-isobutyl-cyclobutyl)-4-oxo-5-hexynoate (11.57 g) and ethanol (100 mL) were mixed. To the mixture were added sodium carbonate (10.4 g), O-methylhydroxylammonium chloride (8.2 g) at ice temperature. The mixture was stirred for 1.5 hrs at 80° C. To the mixture was added water at room temperature, and the mixture was extracted with ethyl acetate, and the resulting organic layer was washed with brine, and dried with magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:40, 1:30, 1:20, and 1:1 in this order) to give the title compound (11.9569 g).


F-644-11
tert-Butyl (S)-6-(tert-butyl-diphenyl-silanyloxy)-3-[4-iodo-5-(3-isobutyl-cyclobutyl)-isoxazol-3-yl]-hexanoate



embedded image


tert-Butyl (S)-3-[3-(tert-butyl-diphenyl-silanyloxy)-propyl]-6-(3-isobutyl-cyclobutyl)-4-(methoxyimino)-5-hexynoate (2.38 g) and methylene chloride (38 mL) were mixed. To the mixture was added iodine monochloride (1 M in methylene chloride) (4.62 mL) at ice temperature. The mixture was stirred for 1 hr at room temperature, and then aqueous sodium thiosulfate was added dropwise to the reaction mixture. tert-Butyl (S)-3-[3-(tert-butyl-diphenyl-silanyloxy)-propyl]-6-(3-isobutyl-cyclobutyl)-4-(methoxyimino)-5-hexynoate (8.9679 g) was reacted in the same way as the above, and aqueous sodium thiosulfate was added dropwise to the reaction mixture. The two mixtures were combined, and the resulting mixture was extracted with chloroform, and the resulting organic layer was washed with brine and dried with magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica-gel column chromatography (A mixture of diethyl ether and hexane was used as an eluent. Eluent: diethyl ether:hexane=1:100, 1:80, 1:60, and 1:40 in this order) to give the title compound (7.9839 g).


F-644-12
tert-Butyl (S)-6-(tert-butyl-diphenyl-silanyloxy)-3-[4-cyclopropyl-5-(3-isobutyl-cyclobutyl)-isoxazol-3-yl]-hexanoate



embedded image


tert-Butyl (S)-6-(tert-butyl-diphenyl-silanyloxy)-3-[4-iodo-5-(3-isobutyl-cyclobutyl)-isoxazol-3-yl]-hexanoate (7.8643 g), 2-cyclopropyl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (3.33 g), tripotassium phosphate (8.42 g), DMF (78 mL), and water (24 mL) were mixed. The reaction mixture was degassed by bubbling argon, and then PdCl2(PPh3)2 (1.04 g) was added to the mixture. The resulting mixture was stirred for 2 hrs at 80° C. To the reaction mixture were added water, hexane, and diethyl ether. The mixture was extracted with a mixture solvent of hexane and diethyl ether. The organic layer was washed with brine, and dried with magnesium sulfate. The organic layer was washed with water (twice) and brine in this order. The organic layer was dried over sodium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:100, 1:60, 1:50, 1:40 in this order) to give the title compound (5.8318 g).


F-644-13
tert-Butyl (S)-3-[4-cyclopropyl-5-(3-isobutyl-cyclobutyl)-isoxazol-3-yl]-6-hydroxy-hexanoate



embedded image


To a mixture of tetrabutylammonium fluoride (1 M in THF) (9.8 mL) and acetic acid/water=4/1 (0.98 mL) was added a solution of tert-Butyl ((S)-6-(tert-butyl-diphenyl-silanyloxy)-3-[4-cyclopropyl-5-(3-isobutyl-cyclobutyl)-isoxazol-3-yl]-hexanoate (5.7314 g) in THF (57 mL) at ice temperature. The resulting mixture was stirred overnight at room temperature. The reaction mixture was concentrated under reduced pressure, and to the resulting residue was added water, and the mixture was extracted with ethyl acetate. The organic layer was washed with water, and dried with magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:80, 1:60, 1:40, 1:20, 1:8, 1:3 in this order) to give the title compound (2.94 g).


F-644-14
tert-Butyl (S)-3-[4-cyclopropyl-5-(3-isobutyl-cyclobutyl)-isoxazol-3-yl]-6-oxo-hexanoate



embedded image


tert-Butyl (S)-3-[4-cyclopropyl-5-(3-isobutyl-cyclobutyl)-isoxazol-3-yl]-6-hydroxy-hexanoate (2.85 g) and chloroform (60 mL) were mixed. To the mixture were added Dess-Martin periodinane (4.17 g) and sodium hydrogen carbonate (826 mg) at ice temperature. The reaction mixture was stirred for 2 hrs at room temperature, and to the mixture was added aqueous saturated sodium thiosulfate at ice temperature. The mixture was extracted with chloroform, and the organic layer was concentrated under reduced pressure. The resulting residue was extracted with ethyl acetate. The resulting organic layer was washed with aqueous saturated sodium thiosulfate and aqueous saturated sodium hydrogen carbonate in this order. The organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (2.4369 g) as a crude product.


F-644-15
1-tert-Butyl (S)-3-[4-cyclopropyl-5-(3-isobutyl-cyclobutyl)-isoxazol-3-yl]-adipate



embedded image


tert-Butyl (S)-3-[4-cyclopropyl-5-(3-isobutyl-cyclobutyl)-isoxazol-3-yl]-6-oxo-hexanoate (2.3715 g), THF (58 mL), and water (8 mL) were mixed. To the mixture were added sodium dihydrogen phosphate (1.06 g), sulfamic acid (800 mg), and sodium chlorite (1.13 g) at ice temperature. The reaction mixture was stirred for 2 hrs at room temperature. To aqueous saturated sodium thiosulfate was added the reaction mixture at ice temperature. The mixture was extracted with ethyl acetate, and the resulting organic layer was washed with aqueous saturated sodium thiosulfate, and dried with magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Fluent: ethyl acetate:hexane=1:9, 1:1 in this order) to give the title compound (2.5488 g).


F-644-16
tert-Butyl (S)-5-carbamoyl-3-[4-cyclopropyl-5-(3-isobutyl-cyclobutyl)-isoxazol-3-yl]-valerate



embedded image


1-tert-Butyl (S)-3-[4-cyclopropyl-5-(3-isobutyl-cyclobutyl)-isoxazol-3-yl]-adipate (1.35 g), ammonium chloride (688 mg), HOBt.H2O (741 mg), triethylamine (1.8 mL), and DMF (12 mL) were mixed. To the mixture was added WSC.HCl (591 mg). The resulting mixture was stirred overnight at room temperature. To the reaction mixture was added aqueous saturated sodium hydrogen carbonate at ice temperature, and the mixture was extracted with ethyl acetate. The organic layer was washed with aqueous sodium hydrogen carbonate and aqueous saturated sodium chloride in this order. The organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:10, 1:4, 1:1, and 2:1 in this order) to give the title compound (905.6 mg).


F-644-17
tert-Butyl (S)-5-cyano-3-[4-cyclopropyl-5-(3-isobutyl-cyclobutyl)-isoxazol-3-yl]-valerate



embedded image


tert-Butyl (S)-5-carbamoyl-3-[4-cyclopropyl-5-(3-isobutyl-cyclobutyl)-isoxazol-3-yl]-valerate (867 mg) and THF (10.4 mL) were mixed. To the mixture was added Burgess reagent (1.49 g). The mixture was stirred for 1.5 hrs at room temperature. To the reaction mixture was added water at ice temperature, and the mixture was extracted with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride, and dried with magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:20, 1:10, 1:8, 1:6 in this order) to give the title compound (716 mg).


F-644-18
(S)-5-cyano-3-[4-cyclopropyl-5-(3-isobutyl-cyclobutyl)-isoxazol-3-yl]-valeric acid



embedded image


tert-Butyl (S)-5-cyano-3-[4-cyclopropyl-5-(3-isobutyl-cyclobutyl)-isoxazol-3-yl]-valerate (371 mg) and chloroform (9.3 mL) were mixed. To the mixture was added trifluoroacetic acid (1.86 mL) at room temperature. The mixture was stirred for 3 hrs, and concentrated under reduced pressure. The resulting residue was azeotroped with toluene, and purified by silica gel thin-layer chromatography (A mixture of methanol and chloroform was used as an eluent. Eluent: methanol:chloroform=1:9) to give the title compound (124.8 mg).


F-644-19
(S)-5-cyano-3-[4-cyclopropyl-5-(3-isobutyl-cyclobutyl)-isoxazol-3-yl]-valeric acid (2,4-dimethyl-phenyl)-amide



embedded image


(S)-5-cyano-3-[4-cyclopropyl-5-(3-isobutyl-cyclobutyl)-isoxazol-3-yl]-valeric acid (103 mg), WSC.HCl (69 mg), HOBt.H2O (55 mg), and DMF (1.5 mL) were mixed. To the mixture was added 2,4-dimethylaniline (0.041 mL). The resulting mixture was stirred overnight at room temperature. To the reaction mixture was added water, and the mixture was extracted with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride and water. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure, and the resulting valeric acid was purified by silica gel thin-layer chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:2) to give the title compound (91.9 mg).


Further, the title compound (57.7 mg) was prepared in the same way.


F-644-20
(S)-3-[4-Cyclopropyl-5-(3-isobutyl-cyclobutyl)-isoxazol-3-yl]-5-(1H-tetrazole-5-yl)-valeric acid (2,4-dimethyl-phenyl)-amide



embedded image


(S)-5-Cyano-3-[4-cyclopropyl-5-(3-isobutyl-cyclobutyl)-isoxazol-3-yl]-valeric acid (2,4-dimethyl-phenyl)-amide (140 mg) and xylene (1.7 mL) were mixed. To the mixture was added trimethyltin azide (234 mg), and the mixture was stirred for 2.5 hrs at 125° C. To the reaction mixture was added water at room temperature, and the mixture was extracted with ethyl acetate. The organic layer was washed with water. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure, the resulting residue was purified by silica gel thin-layer chromatography (A mixture of methanol and chloroform was used as an eluent. Eluent: methanol:chloroform=3:25) to give the title compound (67 mg).


Example F-682
(S)-5-(2-chloro-4-methyl-phenylcarbamoyl)-4-{5-cyclopropyl-4-[3-(2,2-dimethyl-propyl)-cyclobutyl]-[1,2,3]triazol-1-yl}pentanoic acid
F-682-1
4,4-dimethyl-2-pentenoic acid



embedded image


Ethyl diethylphosphonoacetate (516 mL) was added dropwise to a solution of 20 w/w % sodium ethoxide in ethanol (1.02 L) at ice temperature. The mixture was stirred for 1.5 hrs at ice temperature. A solution of 2,2-dimethylpropionaldehyde (260 mL) in tetrahydrofuran (510 mL) was added dropwise to the mixture at ice temperature. The mixture was stirred for 3.5 hrs at room temperature. To the mixture was added aqueous 4 N sodium hydroxide (885 mL) at ice temperature. The resulting mixture was stirred overnight at room temperature. To the reaction mixture was added 6 N hydrochloric acid (802 mL) at ice temperature. To the mixture was added ethyl acetate (1 L). The organic layer was separated, and washed with water (1 L×5), brine (500 mL) in this order. The organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (289 g) as a crude product.


In the same way, 2,2-dimethylpropionaldehyde (50 mL) was treated to give the title compound (54 g) as a crude product.


F-682-2
4,4-dimethyl valerate



embedded image


4,4-dimethyl-2-pentenoic acid (343 g), methanol/tetrahydrofuran=3/1 (150 mL), and ethanol (1240 mL) were mixed. To the mixture was added 10 w/w % palladium on activated carbon (31 g). The mixture was stirred for 10.5 hrs at room temperature under hydrogen atmosphere (1 atm). The 10 w/w % palladium on activated carbon was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (354 g) as a crude product.


F-682-3
4,4-dimethyl-1-piperidine-1-ylpentan-1-one



embedded image


4,4-dimethyl valerate (348 g), piperidine (291 mL), and DMF (1.7 L) were mixed. To the mixture were added HOBt.H2O (450 g) and WSC.HCl (563 g) at ice temperature. The resulting mixture was stirred overnight at room temperature. To the reaction mixture was added water (1.7 L) at ice temperature. The mixture was extracted with toluene (500 mL, 400 mL×2). The organic layer was washed with aqueous 10 w/v % sodium carbonate (1 L) and water (1 L) in this order, and concentrated under reduced pressure to give the title compound (508 g) as a crude product.


F-682-4
1-(4,4-dimethyl-1-pentenyl)piperidine



embedded image


4,4-dimethyl-1-piperidine-1-ylpentan-1-one (508 g) and toluene (1220 mL) were mixed. To the mixture was added (Ph3P)IrCl(CO) (802 mg). 1,1,3,3-tetramethyldisiloxane (795 mL) was added dropwise to the mixture under water-cooling. The mixture was stirred for 3 hrs at room temperature. The reaction mixture was concentrated under reduced pressure to give the title compound (1171 g) as a crude product.


F-682-5
Ethyl 3-(2,2-dimethylpropyl)-2-piperidine-1-ylcyclobutanecarboxylate



embedded image


1-(4,4-Dimethyl-1-pentenyl)piperidine (1146 g) and acetonitrile (910 mL) were mixed. To the mixture were added ethyl acrylate (549 mL) and hydroquinone (553 mg). The resulting mixture was stirred at 90° C. overnight. The reaction mixture was concentrated under reduced pressure to give the title compound (1470 g) as a crude product.


F-682-6
3-(2,2-Dimethylpropyl)-1-cyclobutenecarboxylic acid



embedded image


Ethyl 3-(2,2-dimethylpropyl)-2-piperidine-1-ylcyclobutanecarboxylate (1470 g) and methyl p-toluenesulfonate (417 mL) were mixed. The mixture was stirred for 2 hrs at 105° C. To the reaction mixture was added water (2100 mL). The mixture was washed with a mixture of tert-butyl methyl ether:hexane=1:1 (800 mL) and hexane (600 mL) in this order. To the aqueous layer was added potassium hydroxide (663 g) at ice temperature. The mixture was stirred for 2 hrs at 100° C. The reaction mixture was washed with a mixture of tert-butyl methyl ether:hexane=1:1 (600 mL×2). To the aqueous layer were added concentrated hydrochloric acid (500 mL) and 6 N hydrochloric acid (606 mL) at ice temperature. The mixture was extracted with ethyl acetate (600 mL×2). The organic layer was washed with water (1 L×2) and brine (500 mL) in this order. The organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (278 g) as a crude product.


F-682-7
3-(2,2-dimethylpropyl)cyclobutanecarboxylic acid



embedded image


3-(2,2-Dimethylpropyl)-1-cyclobutenecarboxylic acid (163 g) and tetrahydrofuran (1300 mL) were mixed. To the mixture was added 5 w/w % rhodium on activated carbon (8.2 g). The mixture was stirred for 35 hrs at room temperature under hydrogen atmosphere (1 atm). The 5 w/w % rhodium on activated carbon was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (175.56 g) as a crude product.


F-682-8
3-(2,2-dimethylpropyl)cyclobutanecarboxylic acid methoxymethylamide



embedded image


3-(2,2-dimethylpropyl)cyclobutanecarboxylic acid (75.2 g) and DMF (600 mL) were mixed. To the mixture were added N,O-dimethylhydroxylamine hydrochloride salt (51.7 g), triethylamine (92.4 mL), HOBt.H2O (81.2 g), and WSC.HCl (101.6 g). The resulting mixture was stirred overnight at room temperature. To the reaction mixture was added water. The mixture was extracted with a mixture of ethyl acetate:hexane=1:1. The organic layer was washed with 1 N hydrochloric acid, water, aqueous 10 w/v % sodium carbonate, and water in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (95.2 g) as a crude product.


F-682-9
3-(2,2-dimethylpropyl)cyclobutanecarbaldehyde



embedded image


Diisobutylaluminium hydride (1.0 M in toluene) (486 mL) was added dropwise to a solution of 3-(2,2-dimethylpropyl)cyclobutanecarboxylic acid methoxymethylamide (95.2 g) in toluene (330 mL) at −78° C. The mixture was stirred for 3 hrs at −78° C., and then 1.5 M sulfuric acid (648 mL) was added dropwise to the mixture at ice temperature. The aqueous layer was separated, and extracted with toluene. The combined organic layer was washed with 1 M sulfuric acid, water, and brine in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off. The filtrate comprising the title compound was directly used in the next step.


F-682-10
1-(2,2-dibromovinyl)-3-(2,2-dimethylpropyl)cyclobutane



embedded image


A solution of triphenylphosphine (325 g) in methylene chloride (350 mL) was added dropwise to a solution of carbon tetrabromide (205 g) in methylene chloride (600 mL) at ice temperature. The mixture was stirred for 45 min at ice temperature. A solution of 3-(2,2-dimethylpropyl)cyclobutanecarbaldehyde in toluene was added dropwise to the mixture at ice temperature. The mixture was stirred for 1 hr at ice temperature. Aqueous 10 w/v % sodium carbonate (660 mL) was added dropwise to the mixture at ice temperature. The resultant precipitate was filtered off. The aqueous layer was separated, and extracted with chloroform. The organic layer was washed with water and brine in this order. The organic layer was dried over sodium sulfate. Silica gel was added thereto and the mixture was stirred at room temperature. The sodium sulfate and silica gel were filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Hexane was used as an eluent.) to give the title compound (120.33 g).


F-682-11
1-(2,2-dimethyl-propyl)-3-ethynyl-cyclobutane



embedded image


1-(2,2-dibromovinyl)-3-(2,2-dimethylpropyl)cyclobutane (473.4 g), THF (470 mL), and hexane (940 mL) were mixed. n-Butyllithium (1.65 M in hexane) (1832 mL) was added dropwise to the mixture at −78° C. The reaction mixture was stirred for 1 hr at −78° C., and then a solution of acetic acid (34.6 mL) in THF (19 mL) was added dropwise to the reaction mixture. The cooling bath was removed, and to the reaction mixture was added aqueous 25 w/v % ammonium chloride. The organic layer was separated, and washed with water and aqueous 10 w/v % sodium chloride, and dried with magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (Hexane was used as an eluent.) to give the title compound (217 g).


F-682-12
4-tert-butyl (S)-2-(3-benzyloxy-propyl)-succinate



embedded image


In a manner similar to E-58-6, the title compound (40.5 g, containing toluene) was prepared as a crude product from 4-tert-butyl (S)-2-(3-benzyloxy-propyl)-succinate (R)-1-phenyl-ethylamine salt (50 g).


F-682-13
tert-Butyl (S)-3-amino-6-benzyloxy-hexanoate



embedded image


4-tert-butyl (S)-2-(3-benzyloxy-propyl)-succinate (3.00 g) and toluene (60 mL) were mixed. To the mixture were added triethylamine (1.56 mL) and diphenylphosphoryl azide (2.11 mL) at room temperature. The mixture was stirred for 3 hrs at 120° C. To the mixture was added 1 M trimethylsilyloxy sodium (18.6 mL) at ice temperature. The mixture was stirred for 20 minutes at room temperature. The reaction mixture was added to aqueous 5 w/v % citric acid (100 mL) at ice temperature. The organic layer was concentrated under reduced pressure. The aqueous layer was washed with diethyl ether (20 mL×2), and aqueous 4N sodium hydroxide (60 mL) was added thereto, and the mixture was extracted with diethyl ether, and the organic layer was dried with magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (A mixture of methanol and chloroform was used as an eluent. Eluent: methanol:chloroform=1:50 and 1:15 in this order) to give the title compound (2.30 g).


F-682-14
Imidazole-1-sulfonyl azide hydrochloride



embedded image


Sodium azide (13.0 g) and acetonitrile (200 mL) were mixed. Sulfuryl chloride (16.1 mL) was added dropwise to the mixture at ice temperature. The mixture was stirred at room temperature overnight. To the mixture was added imidazole (25.9 g) at ice temperature. The mixture was stirred for 4 hrs at room temperature. To the mixture was added ethyl acetate. The mixture was washed with water (400 mL×2) and aqueous saturated sodium bicarbonate (400 mL×2) in this order. The organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off, and to the filtrate was added a solution of hydrochloric acid-ethyl acetate at ice temperature. The resultant precipitate was collected by filtration to give the title compound (27.7 g).


F-682-15
tert-Butyl (S)-3-azide-6-benzyloxy-hexanoate



embedded image


tert-Butyl (S)-3-amino-6-benzyloxy-hexanoate (1.17 g), copper(II) sulfate pentahydrate (10 mg), and methanol (18 mL) were mixed. To the mixture were added potassium carbonate (1.11 g) and imidazole-1-sulfonyl azide hydrochloride which was obtained in F-682-14 (1.01 g) at ice temperature. The mixture was stirred at room temperature overnight. To the mixture were added 1 N hydrochloric acid (16 mL), water and brine at ice temperature. The mixture was extracted with tetrahydrofuran. The organic layer was washed with aqueous ammonia and brine in this order. The organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate comprising the title compound was directly used in the next step.


F-682-16
tert-Butyl (S)-6-benzyloxy-3-{4-[3-(2,2-dimethyl-propyl)-cyclobutyl]-5-iodo-[1,2,3]triazol-1-yl}-hexanoate



embedded image


N-Bromosuccinimide (925 mg), copper(I) iodide (914 mg), N,N-diisopropylethylamine (0.766 mL) and tetrahydrofuran (20 mL) were mixed. 1-(2,2-Dimethyl-propyl)-3-ethynyl-cyclobutane which was obtained in F-682-11 (601 mg) and tert-butyl (S)-3-azide-6-benzyloxy-hexanoate which was obtained in F-682-15 as a tetrahydrofuran solution were added dropwise to the mixture over 30 minutes at room temperature. The mixture was stirred for 5 hrs at room temperature, and the reaction mixture was filtered. The filtrate was concentrated under reduced pressure. To the resulting residue was added aqueous 10 w/w % ammonia at ice temperature, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and brine in this order. The organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:12, and 1:10 in this order) to give the title compound (648 mg).


F-682-17
tert-Butyl (S)-6-benzyloxy-3-{5-cyclopropyl-4-[3-(2,2-dimethyl-propyl)-cyclobutyl]-[1,2,3]triazol-1-yl}-hexanoate



embedded image


tert-Butyl (S)-6-benzyloxy-3-{4-[3-(2,2-dimethyl-propyl)-cyclobutyl]-5-iodo-[1,2,3]triazol-1-yl}-hexanoate (445 mg), 2-cyclopropyl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (0.20 mL), cesium fluoride (504 mg) and N,N-dimethylacetamide (3.5 mL) were mixed. The mixture was degassed by bubbling argon. To the mixture was added PdCl2(PPh3)2 (77 mg) at room temperature. The mixture was stirred for 5 min, and then stirred for 8 hrs at 80° C. To the reaction mixture was added ethyl acetate at ice temperature, and the mixture was filtered. The filtrate was washed with water and brine in this order, and dried with magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate hexane=1:15) to give the title compound (110 mg).


F-682-18
tert-Butyl (S)-3-{5-cyclopropyl-4-[3-(2,2-dimethyl-propyl)-cyclobutyl]-[1,2,3]triazol-1-yl}-6-hydroxy-hexanoate



embedded image


tert-Butyl (S)-6-benzyloxy-3-{5-cyclopropyl-4-[3-(2,2-dimethyl-propyl)-cyclobutyl]-[1,2,3]triazol-1-yl}-hexanoate (110 mg) and tetrahydrofuran (1 mL) were mixed. To the mixture was added 10 w/w % palladium on activated carbon (55 mg). The mixture was stirred for 2 hrs at room temperature under hydrogen atmosphere (4 atm). The catalyst was freshened up, and then the mixture was stirred for 2 hrs under hydrogen atmosphere (4 atm). The catalyst was again freshened up, and then the mixture was stirred for 2 hrs under hydrogen atmosphere (4 atm). The 10 w/w % palladium on activated carbon was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (102 mg) as a crude product.


F-682-19
1-tert-Butyl (S)-3-{5-cyclopropyl-4-[3-(2,2-dimethyl-propyl)-cyclobutyl]-[1,2,3]triazol-1-yl}hexanedioate



embedded image


tert-Butyl (S)-3-{5-cyclopropyl-4-[3-(2,2-dimethyl-propyl)-cyclobutyl]-[1,2,3]triazol-1-yl}-6-hydroxy-hexanoate (102 mg), acetonitrile (0.5 mL) and 1 M phosphate buffer (0.3 mL) were mixed. To the mixture were added 2,2,6,6-tetramethyl-1-piperidinyloxy radical (TEMPO) (3.4 mg) and sodium chlorite (48.8 mg) at room temperature. Sodium hypochlorite solution (0.04 mL) was added dropwise to the mixture at ice temperature. The mixture was stirred for 3 hrs at room temperature. To the mixture were added aqueous 20 w/v % sodium sulfite (0.41 mL) and aqueous 1 M potassium hydrogen sulfate (0.22 mL). The mixture was extracted with ethyl acetate, and the organic layer was washed with brine, and dried with magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (102 mg) as a crude product.


F-682-20
1-tert-Butyl 6-methyl (S)-3-{5-cyclopropyl-4-[3-(2,2-dimethyl-propyl)-cyclobutyl]-[1,2,3]triazol-1-yl}hexanedioate



embedded image


1-tert-butyl (S)-3-{5-cyclopropyl-4-[3-(2,2-dimethyl-propyl)-cyclobutyl]-[1,2,3]triazol-1-yl}hexanedioate (102 mg) and DMF (0.8 mL) were mixed. To the mixture were added methyl iodide (0.027 mL) and potassium carbonate (36 mg) at ice temperature. The mixture was stirred for 4 hrs at room temperature, and then water was added at ice temperature. The mixture was extracted with ethyl acetate, and the organic layer was washed with water and brine in this order. The organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (99 mg) as a crude product.


F-682-21
6-Methyl (S)-3-{5-cyclopropyl-4-[3-(2,2-dimethyl-propyl)-cyclobutyl]-[1,2,3]triazol-1-yl}hexanedioate



embedded image


1-tert-butyl 6-methyl (S)-3-{5-cyclopropyl-4-[3-(2,2-dimethyl-propyl)-cyclobutyl]-[1,2,3]triazol-1-yl}hexanedioate (99 mg) and chloroform (0.5 mL) were mixed. To the mixture was added trifluoroacetic acid (0.2 mL) at ice temperature. The mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure, and then the residue was azeotroped with toluene (twice). To the residue was added ethyl acetate, and the organic layer was washed with brine, and dried with magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (92.6 mg) as a crude product.


F-682-22
Methyl (S)-5-(2-chloro-4-methyl-phenylcarbamoyl)-4-{5-cyclopropyl-4-[3-(2,2-dimethyl-propyl)-cyclobutyl]-[1,2,3]triazol-1-yl}pentanoate



embedded image


6-Methyl (S)-3-{5-cyclopropyl-4-[3-(2,2-dimethyl-propyl)-cyclobutyl]-[1,2,3]triazol-1-yl}hexanedioate (92.6 mg) and dimethylacetamide (0.6 mL) were mixed. To the mixture was added thionyl chloride (0.022 mL) at ice temperature. To the reaction mixture was added 2-chloro-4-methyl-phenylamine (0.029 mL) at ice temperature. The cooling bath was removed, and the reaction mixture was stirred for 1 hr. To the reaction mixture were added ethyl acetate, hexane, and water. The organic layer was separated, and washed with aqueous saturated potassium hydrogen sulfate, aqueous saturated sodium bicarbonate, and brine in this order. The organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (119 mg) as a crude product.


F-682-23
(S)-5-(2-chloro-4-methyl-phenylcarbamoyl)-4-{5-cyclopropyl-4-[3-(2,2-dimethyl-propyl)-cyclobutyl]-[1,2,3]triazol-1-yl}pentanoic acid



embedded image


Methyl (S)-5-(2-chloro-4-methyl-phenylcarbamoyl)-4-{5-cyclopropyl-4-[3-(2,2-dimethyl-propyl)-cyclobutyl]-[1,2,3]triazol-1-yl}pentanoate (119 mg) and methanol (0.88 mL) were mixed. To the mixture was added aqueous 2 M sodium hydroxide (0.216 mL) at room temperature. The mixture was stirred for 3 hrs at 55° C., and then to the mixture was added aqueous 2 M hydrochloric acid (0.216 mL) at room temperature. The mixture was extracted with ethyl acetate, and the organic layer was washed with water and brine in this order. The organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (A mixture of methanol and chloroform was used as an eluent. Eluent: methanol:chloroform=1:70) to give the title compound (41.5 mg).


Example F-684
(S)-4-(2-chloro-4-methyl-phenylcarbamoyl)-5-{4-cyclopropyl-5-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-3-yl}-pentanoic acid
F-684-1
N-Methoxy-N-methyl-succinamic acid tert-butyl ester



embedded image


Mono-tert-butyl succinate (17.4 g) and N,O-dimethylhydroxylamine hydrochloride salt (11.7 g), HOBt.H2O (3.1 g), and acetonitrile (35 mL) were mixed. To the mixture was added diisopropylethylamine (23.8 mL) at ice temperature. To the reaction mixture was added WSC.HCl (23.0 g) in three portions at ice temperature. The mixture was stirred for 2 hrs at room temperature. Water was added to the reaction mixture. The mixture was extracted with toluene. The organic layer was washed with aqueous 10 w/v % potassium hydrogen sulfate, brine, aqueous saturated sodium bicarbonate, and brine in this order. The organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off, and The organic layer was concentrated under reduced pressure to give the title compound (25.2 g, containing toluene (13.4 w/w %), by NMR) as a crude product.


F-684-2
tert-Butyl 4-oxo-butanoate



embedded image


N-Methoxy-N-methyl-succinamic acid tert-butyl ester (10.0 g, equivalent to 39.9 mmol) and THF (100 mL) were mixed. Diisobutylaluminium hydride (1.0 M in toluene) (52 mL) was added dropwise to the mixture at −78° C. The mixture was stirred for 1 hr at −78° C. Saturated ammonium chloride was added dropwise to the reaction mixture at ice temperature. To the mixture was added diethyl ether and water. The organic layer was separated, and washed with aqueous saturated ammonium chloride and brine in this order. The organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off, and the organic layer was concentrated under reduced pressure until being reduced to approximately 60 mL in volume. The resulting the solution was directly used in the next step.


F-684-3
tert-4-hydroxyimino-butanoate



embedded image


Hydroxylammonium chloride (3.32 g), ethanol (40 mL), and water (12 mL) were mixed. Aqueous 4 M sodium hydroxide (12 mL) was added dropwise to the mixture at ice temperature. A solution of tert-butyl 4-oxo-butanoate in toluene-THF (equivalent to 39.9 mmol), ethanol (10 mL), and THF (12 mL) were added dropwise to the reaction mixture at ice temperature. The mixture was stirred for 1 hr at ice temperature, and then toluene was added to the mixture. The organic layer was separated, and washed with water and brine in this order. The organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (7.60 g, containing toluene (25.9 w/w %), by NMR) as a crude product.


F-684-4
tert-Butyl 4-(chloro-hydroxyimino)-butanoate



embedded image


tert-4-hydroxyimino-butanoate (7.60 g) and DMF (30 mL) were mixed. To the mixture was added N-chlorosuccinimide (4.56 g) under water-cooling. The mixture was stirred for 30 minutes at room temperature. To the reaction mixture were added toluene and water. The organic layer was separated, and washed with water and brine in this order, and the solution was directly used in the next step.


F-684-5
tert-Butyl 3-{5-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-3-yl}-propionate



embedded image


1-(2,2-Dimethylpropyl)-3-ethynylcyclobutane which was obtained in F-682-11 (6.60 g), toluene (30 mL), water (18 mL), and potassium carbonate (4.71 g) were mixed. The mixture was heated to 120° C. A solution of tert-butyl 4-(chloro-hydroxyimino)-butanoate which was obtained in F-684-4 in toluene (equivalent to 32.5 mmol) was added dropwise to the reaction mixture, and the resulting mixture was stirred for 1 hr. Water was added to the reaction mixture. The organic layer was separated, and washed with water and brine in this order. The organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (11.4 g, containing toluene (8.2 w/w %), by NMR) as a crude product.


F-684-6
tert-Butyl 3-{4-bromo-5-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-3-yl}-propionate



embedded image


tert-Butyl 3-{5-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-3-yl}-propionate (11.4 g) and DMF (60 mL) were mixed. To the mixture was added N-bromosuccinimide (6.43 g) at room temperature. The reaction mixture was stirred for 1 hr at 60° C., and cooled to room temperature. To the mixture was added N-bromosuccinimide (6.00 g). The reaction mixture was again heated for 1 hr at 60° C., and then water was added to the reaction mixture. The mixture was extracted with hexane. The organic layer was washed with aqueous 10 w/v % sodium sulfite and brine in this order. The organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:50) to give the title compound (10.58 g).


F-684-7
tert-Butyl 3-{4-cyclopropyl-5-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-3-yl}-propionate



embedded image


tert-Butyl 3-{4-bromo-5-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-3-yl}-propionate (10.58 g), 2-cyclopropyl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (6.66 g), cesium fluoride (18.1 g), PdCl2 (dppf)2.CH2Cl2 (1.08 g), and NMP (61 mL) were mixed. The reaction mixture was stirred for 2 hrs at 90° C. under argon atmosphere. To the reaction mixture were added water and hexane. The mixture was filtered. The organic layer was separated, washed with water (twice) and brine in this order, and dried with magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:20) to give the title compound (9.90 g).


F-684-8
3-{4-cyclopropyl-5-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-3-yl}-propionic acid



embedded image


tert-Butyl 3-{4-cyclopropyl-5-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-3-yl}-propionate (9.90 g) and toluene (26 mL) were mixed. To the mixture was added trifluoroacetic acid (13.0 mL) at ice temperature. The mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure. The resulting residue azeotroped with toluene (twice), and then dissolved in a mixture solvent of hexane-ethyl acetate. The mixture was washed with water (five times) and brine in this order, and dried with magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (8.09 g, containing toluene (2.0 w/w %) and ethyl acetate (5.5 w/w %), by NMR) as a crude product.


F-684-9
(S)-4-benzyl-3-(3-{4-cyclopropyl-5-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-3-yl}-propionyl)-oxazolidin-2-one



embedded image


3-{4-cyclopropyl-5-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-3-yl}-propionic acid (4.32 g) and acetonitrile (30 mL) were mixed. To the mixture was added (S)-4-benzyl-2-oxazolidinone (2.44 g). To the mixture were added 4-dimethylaminopyridine (400 mg) and WSC.HCl (2.76 g) at ice temperature. The resulting mixture was stirred overnight at room temperature. Water was added to the reaction mixture. The mixture was extracted with ethyl acetate. The organic layer was washed with water and brine in this order. The organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:2) to give the title compound (4.80 g).


F-684-10
(S)-4-benzyl-3-((S)-2-{4-cyclopropyl-5-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-3-ylmethyl}-pent-4-enoyl)-oxazolidin-2-one



embedded image


((S)-4-benzyl-3-(3-{4-cyclopropyl-5-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-3-yl}-propionyl)-oxazolidin-2-one (1.50 g) and THF (15 mL) were mixed. Sodium hexamethyldisilazide (1.9 M in THF) (2.0 mL) was added dropwise to the mixture at −78° C. Allyl iodide (0.34 mL) was added dropwise to the reaction mixture at −78° C. The mixture was stirred for 2 hrs. To the reaction mixture were added 2 M hydrochloric acid and water at ice temperature. The mixture was extracted with ethyl acetate. The organic layer was washed with brine, and dried with magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:4) to give the title compound (1.05 g).


F-684-11
(S)-4-Benzyl-3-((S)-2-{4-cyclopropyl-5-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-3-ylmethyl}-5-hydroxy-pentanoyl)-oxazolidin-2-one



embedded image


(S)-4-benzyl-3-((S)-2-{4-cyclopropyl-5-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-3-ylmethyl}-pent-4-enoyl)-oxazolidin-2-one (1.05 g) and THF (14 mL) were mixed. 9-Borabicyclo[3.3.1]nonane (0.5 M in THF) (10.0 mL) was added dropwise to the mixture at ice temperature. The reaction mixture was stirred overnight at room temperature. Sodium acetate (409 mg), water (1 mL), and 30 w/w % aqueous hydrogen peroxide (4 mL) were added dropwise to the mixture at ice temperature. The reaction mixture was stirred for 2 hrs at room temperature. To the mixture were added aqueous sodium hydrogen sulfite and aqueous sodium hydrogen sulfate at ice temperature. Ethyl acetate was added to the reaction mixture. The organic layer was separated, washed with brine, and dried with magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:4) to give the title compound (724 mg).


F-684-12
(S)-5-((S)-4-benzyl-2-oxo-oxazolidine-3-yl)-4-{4-cyclopropyl-5-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-3-ylmethyl}-5-oxo-pentanoic acid



embedded image


(S)-4-benzyl-3-((S)-2-{4-cyclopropyl-5-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-3-ylmethyl}-5-hydroxy-pentanoyl)-oxazolidin-2-one (724 mg), acetonitrile (10 mL), and 1.0 M phosphate buffer (pH=6.8) (1.5 mL) were mixed. To the mixture were added 2,2,6,6-tetramethyl-1-piperidinyloxy radical (TEMPO) (11.0 mg) and sodium chlorite (359 mg) at room temperature. Aqueous sodium hypochlorite (Wako Pure Chemical Industries, 0.22 mL) was added dropwise to the reaction mixture at ice temperature. The mixture was stirred for 3 hrs at room temperature. To the reaction mixture were added aqueous 20 w/v % sodium sulfite and aqueous potassium hydrogen sulfate at ice temperature. The mixture was extracted with ethyl acetate. The organic layer was washed with water and brine in this order. The organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (785 mg) as a crude product.


F-684-13
Ethyl (S)-5-((S)-4-benzyl-2-oxo-oxazolidine-3-yl)-4-{4-cyclopropyl-5-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-3-ylmethyl}-5-oxo-pentanoate



embedded image


(S)-5-((S)-4-benzyl-2-oxo-oxazolidine-3-yl)-4-{4-cyclopropyl-5-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-3-ylmethyl}-5-oxo-pentanoic acid (785 mg) and DMF (5 mL) were mixed. To the mixture were added ethyl iodide (0.17 mL) and potassium carbonate (384 mg) at room temperature. The mixture was stirred for 3 hrs, and then ethyl acetate was added to the reaction mixture. The organic layer was separated, and washed with water and brine in this order. The organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:4) to give the title compound (779 mg).


F-684-14
5-Ethyl (S)-2-{4-cyclopropyl-5-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-3-ylmethyl}-pentanedicarboxylate



embedded image


Lithium hydroxide monohydrate (64 mg), THF (1 mL), and water (4 mL) were mixed. Aqueous 30 w/w % hydrogen peroxide (0.21 mL) was added dropwise to the mixture at ice temperature. The reaction mixture was stirred for 30 minutes at ice temperature. A solution of ethyl (S)-5-((S)-4-benzyl-2-oxo-oxazolidine-3-yl)-4-{4-cyclopropyl-5-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-3-ylmethyl}-5-oxo-pentanoate (778 mg) in THF (3 mL) was added dropwise to the reaction mixture at ice temperature. The reaction mixture was stirred for 3 hrs at room temperature. To the mixture were added aqueous 10 w/v % sodium sulfite and 2 M hydrochloric acid at ice temperature. The mixture was extracted with ethyl acetate. The organic layer was washed with brine, and dried with magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:2) to give the title compound (528 mg).


F-684-15
Ethyl (S)-4-(2-chloro-4-methyl-phenylcarbamoyl)-5-{4-cyclopropyl-5-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-3-yl}-pentanoate



embedded image


5-Ethyl (S)-2-{4-cyclopropyl-5-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-3-ylmethyl}-pentanedicarboxylate (80 mg) and dimethylacetamide (1.0 mL) were mixed. To the mixture was added thionyl chloride (0.019 mL) at ice temperature. To the reaction mixture was added 2-chloro-4-methyl-phenylamine (30 mg) at ice temperature. The cooling bath was removed, and the reaction mixture was stirred for 1 hr. Water was added to the reaction mixture. The mixture was extracted with ethyl acetate. The organic layer was washed with water and brine in this order. The organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (118 mg) as a crude product.


F-684-16
(S)-4-(2-chloro-4-methyl-phenylcarbamoyl)-5-{4-cyclopropyl-5-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-3-yl}-pentanoic acid



embedded image


Ethyl (S)-4-(2-chloro-4-methyl-phenylcarbamoyl)-5-{4-cyclopropyl-5-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-3-yl}-pentanoate (118 mg) and methanol (0.5 mL) were mixed. To the mixture was added aqueous 2 M sodium hydroxide (0.2 mL) at room temperature. The mixture was stirred for 30 minutes at 80° C. Then, to the mixture were added aqueous 2 M hydrochloric acid (0.2 mL) and water at room temperature. The mixture was extracted with ethyl acetate. The organic layer was washed with brine, and dried with magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by preparative chromatography (A mixture of methanol and chloroform was used as an eluent. Eluent: methanol:chloroform=1:20) to give the title compound (82.0 mg).


Example F-688
4-((3R,4R)-3-(2-Chloro-4-methyl-phenylcarbamoyl)-4-{4-cyclopropyl-5-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-3-yl}pyrrolidin-1-yl)-4-oxo-butanoic acid
F-688-1
Ethyl (E)-4-((R)-4-benzyl-2-oxo-oxazolidine-3-yl)-4-oxo-but-2-enoate



embedded image


Monoethyl fumarate (10 g) and chloroform (200 mL) were mixed. To the mixture were added (R)-4-benzyl-2-oxazolidinone (13.5 g), 2-chloro-1-methylpyridinium iodide (21.4 g), and triethylamine (23.2 mL). The mixture was stirred for 2 hrs at 55° C., and the reaction mixture was concentrated under reduced pressure, and the resulting residue was diluted with diethyl ether. The mixture was washed with aqueous 1 M hydrochloric acid, aqueous saturated sodium hydrogen carbonate, and brine in this order, and dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:3) to give the title compound (16.2 g).


F-688-2
Ethyl (3R,4R)-1-benzyl-4-((R-4-benzyl-2-oxo-oxazolidine-3-carbonyl)-pyrrolidine-3-carboxylate



embedded image


Ethyl (E)-4-((R)-4-benzyl-2-oxo-oxazolidine-3-yl)-4-oxo-but-2-enoate (16.2 g) and chloroform (162 mL) were mixed. To the mixture were added N-(methoxymethyl)-N-(trimethylsilylmethyl)benzylamine (16.4 mL) and trifluoroacetic acid (0.82 mL) at ice temperature. The ice bath was removed, and the reaction mixture was stirred overnight. To the reaction mixture were added aqueous saturated sodium hydrogen carbonate and chloroform at ice temperature. The organic layer was separated, and dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:2) to give the title compound (10.4 g).


F-688-3
1-tert-Butyl 3-ethyl (3R,4R)-4-((R-4-benzyl-2-oxo-oxazolidine-3-carbonyl)-pyrrolidine-1,3-dicarboxylate



embedded image


Ethyl (3R,4R)-1-benzyl-4-HR-4-benzyl-2-oxo-oxazolidine-3-carbonyl)-pyrrolidine-3-carboxylate (10.4 g), and ethanol (100 mL) were mixed. To the mixture were added di-tert-butyl dicarbonate (6.24 g) and 20 w/w % palladium hydroxide (1.5 g). The reaction mixture was stirred overnight under hydrogen atmosphere (medium pressure). The reaction container was charged with nitrogen gas, and then palladium hydroxide was filtered off using Celite with washing with ethyl acetate. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=2:3) to give the title compound (10.58 g).


F-688-4
1-tert-Butyl 3-ethyl (3R,4R)-pyrrolidine-1,3,4-tricarboxylate



embedded image


1-tert-Butyl 3-ethyl (3R,4R)-4-((R-4-benzyl-2-oxo-oxazolidine-3-carbonyl)-pyrrolidine-1,3-dicarboxylate (10.58 g), acetonitrile (74 mL), and water (32 mL) were mixed. To the mixture were added triethylamine (13.2 mL) and 4-dimethylaminopyridine (290 mg). The mixture was stirred for 1.5 hrs at 80° C., overnight at room temperature, and then for 3 hrs at 80° C. The reaction mixture was concentrated under reduced pressure, and the resulting residue was diluted with ethyl acetate. The mixture was washed with aqueous 0.5 M hydrochloric acid, water, and brine in this order, and dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:1) to give the title compound (5.03 g).


F-688-5
1-tert-Butyl 3-ethyl (3R,4R)-4-(methoxy-methyl-carbamoyl)-pyrrolidine-1,3-dicarboxylate



embedded image


1-tert-Butyl 3-ethyl (3R,4R)-pyrrolidine-1,3,4-tricarboxylate (5.03 g), and acetonitrile (15 mL) were mixed. To the mixture were added N,O-dimethylhydroxylamine hydrochloride salt (2.05 g) and HOBt.H2O (804 mg). Diisopropylethylamine (4.17 mL) was slowly added dropwise to the mixture at ice temperature, and then WSC.HCl (4.03 g) was added. The mixture was stirred at room temperature overnight. The reaction mixture was diluted with toluene. To the mixture was added aqueous 1 M hydrochloric acid at ice temperature. The organic layer was separated, and washed with water, aqueous saturated sodium hydrogen carbonate (twice), and brine in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (5.63 g) as a crude product.


F-688-6
1-tert-Butyl (3R,4R)-4-(methoxy-methyl-carbamoyl)-pyrrolidine-1,3-dicarboxylate



embedded image


1-tert-Butyl 3-ethyl (3R,4R)-4-(methoxy-methyl-carbamoyl)-pyrrolidine-1,3-dicarboxylate (5.63 g) and ethanol (56 mL) were mixed. To the mixture was added aqueous 1 M sodium hydroxide (17.89 mL) at ice temperature. The ice bath was removed, and the mixture was stirred for 3 hrs at room temperature. Then the pH of the mixture was adjusted with aqueous 1 M hydrochloric acid to 3. To the reaction mixture was added ethyl acetate. The organic layer was separated, and washed with water and brine. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (5.047 g) as a crude product.


F-688-7
Di-tert-butyl (3R,4R)-4-(methoxy-methyl-carbamoyl)-pyrrolidine-1,3-dicarboxylate



embedded image


1-tert-Butyl (3R,4R)-4-(methoxy-methyl-carbamoyl)-pyrrolidine-1,3-dicarboxylate (5.047 g) and toluene (41 ml) were mixed. While the mixture was heated to reflux, N,N-dimethylformamide di-tert-butyl acetal (25 was added dropwise to the mixture over 10 min. After the addition, the reaction mixture was cooled to room temperature, and concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:2) to give the title compound (5.47 g).


F-688-8
Di-tert-butyl (3R,4R)-4-formyl-pyrrolidine-1,3-dicarboxylate



embedded image


Di-tert-butyl (3R,4R)-4-(methoxy-methyl-carbamoyl)-pyrrolidine-1,3-dicarboxylate (5.47 g) and THF (50 mL) were mixed. A solution of lithium aluminium hydride (580 mg) in THF (20 mL) was added dropwise to the mixture under nitrogen atmosphere at −78° C. The resulting mixture was stirred for 30 min at −78° C. Water (10 mL) was added to the mixture at ice temperature, and then ethyl acetate and aqueous 1 M hydrochloric acid were added. The organic layer was separated, and washed with aqueous saturated sodium hydrogen carbonate, water, and brine in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the organic layer was concentrated under reduced pressure to give the title compound (4.78 g) as a crude product.


F-688-9
Di-tert-butyl (3R,4R)-4-(hydroxyimino-methyl)-pyrrolidine-1,3-dicarboxylate



embedded image


Hydroxylammonium chloride (1.38 g), ethanol (10 mL), and water (5 mL) were mixed. Aqueous 4 M sodium hydroxide (5.00 mL) was added dropwise to the mixture at ice temperature. A solution of di-tert-butyl (3R,4R)-4-formyl-pyrrolidine-1,3-dicarboxylate (4.78 g) in ethanol (10 mL) and THF (5 mL) was added dropwise to the reaction mixture at ice temperature. The ice-bath was removed, and the mixture was stirred at room temperature overnight. To the mixture were added ethyl acetate and water. The organic layer was separated, and washed with water and brine in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:2) to give the title compound (2.86 g).


F-688-10
Di-tert-butyl (3R,4R)-4-(chloro-hydroxyimino-methyl)-pyrrolidine-1,3-dicarboxylate



embedded image


Di-tert-butyl (3R,4R)-4-(hydroxyimino-methyl)-pyrrolidine-1,3-dicarboxylate (2.86 g) and DMF (9 mL) were mixed. A solution of N-chlorosuccinimide (1.34 g) in DMF (6 mL) was added dropwise to the mixture at room temperature. The mixture was stirred for 1 hr at room temperature. To the reaction mixture were added toluene and water at ice temperature. The organic layer was separated, and washed with water and brine in this order, and the solution was directly used in the next step.


F-688-11
Di-tert-butyl (3R,4R)-4-{5-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-3-yl}-pyrrolidine-1,3-dicarboxylate



embedded image


A solution of di-tert-butyl (3R,4R)-4-(chloro-hydroxyimino-methyl)-pyrrolidine-1,3-dicarboxylate (equivalent to 9.1 mmol) in toluene, 1-(2,2-dimethylpropyl)-3-ethynylcyclobutane (2.19 g) which was obtained in F-682-11, potassium carbonate (1.38 g), and water (6 mL) were mixed at room temperature. The mixture was heated to 110° C. The reaction mixture was heated to reflux for 6 hrs, and cooled to room temperature. To the reaction mixture was added water and ethyl acetate. The organic layer was separated, and washed with brine. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:8) to give the title compound (2.27 g).


F-688-12
Di-tert-butyl (3R,4R)-4-{5-[3-(2,2-dimethyl-propyl)-cyclobutyl]-4-iodo-isoxazol-3-yl}-pyrrolidine-1,3-dicarboxylate



embedded image


Di-tert-butyl (3R,4R)-4-{5-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-3-yl}-pyrrolidine-1,3-dicarboxylate (2.05 g), and acetonitrile (20 mL) were mixed. To the mixture were added N-iodosuccinimide (1.200 g) and ammonium cerium(IV) nitrate (1.214 g) at room temperature. The reaction mixture was stirred for 1 hr at 50° C., and then the reaction mixture was cooled to room temperature. Ammonium cerium(IV) nitrate (797 mg) was added. The reaction mixture was again heated for 2 hrs at 50° C. To the reaction mixture were added aqueous 20 w/v % sodium sulfite and ethyl acetate at ice temperature. The organic layer was separated, and washed with water and brine, and dried with magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:12) to give the title compound (1.048 g).


F-688-13
Di-tert-butyl (3R,4R)-4-{4-cyclopropyl-5-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-3-yl}-pyrrolidine-1,3-dicarboxylate



embedded image


Di-tert-butyl (3R,4R)-4-{5-[3-(2,2-dimethyl-propyl)-cyclobutyl]-4-iodo-isoxazol-3-yl}-pyrrolidine-1,3-dicarboxylate (1.0 g), 2-cyclopropyl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (571 mg), tripotassium phosphate (1.44 g), PdCl2(PPh3)2 (179 mg), and DMF (10 mL) were mixed. The reaction mixture was degassed by bubbling nitrogen gas. The resulting mixture was stirred overnight at 90° C. To the reaction mixture were added ethyl acetate, hexane, and water. The organic layer was separated, and washed with water and brine in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:15) to give the title compound (750 mg).


F-688-14
(3R,4R)-4-{4-cyclopropyl-5-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-3-yl}-pyrrolidine-3-carboxylic acid hydrochloride salt



embedded image


Di-tert-butyl (3R,4R)-4-{4-cyclopropyl-5-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-3-yl}-pyrrolidine-1,3-dicarboxylate (750 mg) and chloroform (7.5 mL) were mixed. To the mixture was added trifluoroacetic acid (2.2 mL) at ice temperature. The reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure, and the residue was repeatedly azeotroped with toluene. To the residue was added a solution of 4 M hydrochloric acid-ethyl acetate (0.56 mL), and the mixture concentrated under reduced pressure. The residue was repeatedly azeotroped with ethyl acetate. To the resulting residue was added a mixture of ethyl acetate:hexane=1:3. The resulting mixture was stirred for 1 hr at room temperature. The resultant precipitate collected by filtration to give the title compound (368 mg).


F-688-15
(3R,4R)-4-{4-Cyclopropyl-5-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-3-yl}-1-(3-methoxycarbonyl-propionyl)-pyrrolidine-3-carboxylic acid



embedded image


(3R,4R)-4-{4-Cyclopropyl-5-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-3-yl}-pyrrolidine-3-carboxylic acid hydrochloride salt (80 mg) and chloroform (1 mL) were mixed. To the mixture were added pyridine (0.084 mL) and methyl 4-chloro-4-oxobutyrate (0.077 mL) at ice temperature. The reaction mixture was stirred for 30 minutes at room temperature. Water, aqueous 1 M hydrochloric acid and ethyl acetate were added to the mixture at ice temperature. The organic layer was separated, and washed with water and brine in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (126 mg) as a crude product.


F-688-16
Methyl 4-((3R,4R)-3-(2-chloro-4-methyl-phenylcarbamoyl)-4-{4-cyclopropyl-5-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-3-yl}pyrrolidine-1-yl)-4-oxo-butanoate



embedded image


(3R,4R)-4-{4-Cyclopropyl-5-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-3-yl}-1-(3-methoxycarbonyl-propionyl)-pyrrolidine-3-carboxylic acid (126 mg) and DMA (1.2 mL) were mixed. To the mixture was added thionyl chloride (0.030 mL) at ice temperature. The reaction mixture was stirred for 30 min at ice temperature. To the reaction mixture was added 2-chloro-4-methylaniline (0.051 mL). The reaction mixture was stirred for 2 hrs at room temperature. To the reaction mixture were added water and ethyl acetate. The organic layer was separated, and washed with aqueous saturated sodium hydrogen carbonate and brine in this order, and was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:1) to give the title compound (86.9 mg).


F-688-17
4-((3R,4R)-3-(2-Chloro-4-methyl-phenylcarbamoyl)-4-{4-cyclopropyl-5-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-3-yl}pyrrolidine-1-yl)-4-oxo-butanoic acid



embedded image


Methyl 4-((3R,4R)-3-(2-chloro-4-methyl-phenylcarbamoyl)-4-{4-cyclopropyl-5-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-3-yl}pyrrolidine-1-yl)-4-oxo-butanoate (86 mg), THF (0.5 mL), and methanol (0.5 mL) were mixed. To the mixture was added aqueous 2 M sodium hydroxide (0.148 mL) at room temperature. The reaction mixture was stirred for 2.5 hrs at room temperature. Aqueous 2 M hydrochloric acid was added to make the mixture acidic. To the reaction mixture was added ethyl acetate. The organic layer was separated, and washed with water and brine in this order. The organic layer was dried over sodium sulfate. The sodium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (A mixture of methanol and chloroform was used as an eluent. Eluent: methanol:chloroform=1:10) to give the title compound (51.0 mg).


Example F-698
(S)-5-(2-Chloro-4-methyl-phenylcarbamoyl)-4-[7-(3-methyl-butyl)-4,5,6,7-tetrahydro-benz[d]isoxazol-3-yl]-pentanoic acid
F-698-1
3-Ethoxy-6-(3-methyl-butyl)-cyclohex-2-enone



embedded image


3-Ethoxy-cyclohex-2-enone (11.2 g) and THF (64 mL) were mixed. Lithium diisopropylamide (2.0 M in THF) (52 mL) was added dropwise to the reaction mixture at −78° C. The mixture was stirred for 30 minutes at −78° C. 1-Iodo-3-methyl-butane (22.0 mL) was added dropwise to the reaction mixture at −78° C. The mixture was stirred overnight at room temperature. To the reaction mixture was added water (100 mL) at ice temperature. The aqueous layer was separated, and extracted with diethyl ether (four times). The combined organic layer was washed with water and brine in this order. The organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:10) to give the title compound (3.68 g).


F-698-2
4-(3-Methyl-butyl)-cyclohex-2-enone



embedded image


3-Ethoxy-6-(3-methyl-butyl)-cyclohex-2-enone (3.65 g) and toluene (20 mL) were mixed. Diisobutylaluminium hydride (1.0 M in toluene) (20.8 mL) was added dropwise to the mixture at ice temperature. The reaction mixture was stirred for 2 hrs at ice temperature. To the reaction mixture were added methanol (10 mL), water (20 mL), and aqueous 10 w/v % potassium hydrogen sulfate (40 mL) in this order at ice temperature. The aqueous layer was separated, and extracted with toluene. The combined organic layer was washed with aqueous saturated sodium bicarbonate, water, and brine in this order. The organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:40) to give the title compound (2.44 g).


F-698-3
tert-Butyl (S)-6-benzyloxy-3-[7-(3-methyl-butyl)-4-oxo-3a,4,5,6,7,7a-hexahydro-benz[d]isoxazol-3-yl]-hexanoate



embedded image


4-(3-methyl-butyl)-cyclohex-2-enone (2.32 g), toluene (18 mL), and aqueous 1.5 M potassium carbonate (15 mL) were mixed. The mixture was heated to 90° C. A solution of tert-butyl (S)-6-benzyloxy-3-(chloro-hydroxyimino-methyl)-hexanoate obtained by a similar reaction to that described in E-58-10 in toluene (equivalent to 16.7 mmol) was added dropwise to the reaction mixture. The mixture was stirred for 1.5 hrs. To the reaction mixture was added toluene at room temperature. The organic layer was separated, and washed with water and brine in this order. The organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:10) to give the title compound (2.93 g).


F-698-4
tert-Butyl (S)-6-benzyloxy-3-[7-(3-methyl-butyl)-4-oxo-4,5,6,7-tetrahydro-benz[d]isoxazol-3-yl]-hexanoate



embedded image


tert-Butyl (S)-6-benzyloxy-3-[7-(3-methyl-butyl)-4-oxo-3a,4,5,6,7,7a-hexahydro-benz[d]isoxazol-3-yl]-hexanoate (2.90 g) and xylene (20 mL) were mixed. To the reaction mixture was added activated carbon for oxidation (Tokyo Chemical Industry Co., Ltd., 1.45 g) at room temperature. The mixture was stirred for 3 hrs at 150° C. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to give the title compound (3.44 g) as a crude product.


F-698-5
tert-Butyl (S)-6-benzyloxy-3-[7-(3-methyl-butyl)-4-hydroxy-4,5,6,7-tetrahydro-benz[d]isoxazol-3-yl]-hexanoate



embedded image


tert-Butyl (S)-6-benzyloxy-3-[7-(3-methyl-butyl)-4-oxo-4,5,6,7-tetrahydro-benz[d]isoxazol-3-yl]-hexanoate (952 mg, equivalent to 1.65 mmol) and methanol (6.4 mL) were mixed. To the mixture was added cerium chloride heptahydrate (656 mg) at ice temperature. The reaction mixture was stirred for 5 min at ice temperature. To the reaction mixture was added sodium borohydride (75.1 mg) at ice temperature. The mixture was stirred for 1 hr. To the reaction mixture were added acetone, water, ethyl acetate in this order at ice temperature. The organic layer was separated, and washed with water and brine in this order. The organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:12) to give the title compound (542 mg).


F-698-6
tert-Butyl (S)-6-benzyloxy-3-[4-(imidazole-1-carbothioyloxy)-7-(3-methyl-butyl)-4,5,6,7-tetrahydro-benz[d]isoxazol-3-yl]-hexanoate



embedded image


tert-Butyl (S)-6-benzyloxy-3-[7-(3-methyl-butyl)-4-hydroxy-4,5,6,7-tetrahydro-benz[d]isoxazol-3-yl]-hexanoate (350 mg) and THF (3.5 mL) were mixed. To the mixture were added 1,1′-thiocarbonyldiimidazole (285 mg) and N,N-dimethyl-4-aminopyridine (17.6 mg) at room temperature. The mixture was stirred for 1 hr at 70° C. The reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:4) to give the title compound (208 mg).


F-698-7
tert-Butyl (S)-6-benzyloxy-3-[7-(3-methyl-butyl)-4,5,6,7-tetrahydro-benz[d]isoxazol-3-yl]-hexanoate



embedded image


tert-Butyl (S)-6-benzyloxy-3-[4-(imidazole-1-carbothioyloxy)-7-(3-methyl-butyl)-4,5,6,7-tetrahydro-benz[d]isoxazol-3-yl]-hexanoate (200 mg) and toluene (2 mL) were mixed. To the mixture were added tri-n-butyltin (0.722 mL) and azobis(isobutyronitrile) (11.0 mg) at room temperature. The reaction mixture was stirred for 7 hrs at 90° C., and concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:10) to give the title compound (108 mg). The title compound (20.0 mg) was obtained in a similar way.


F-698-8
(S)-6-benzyloxy-3-[7-(3-methyl-butyl)-4,5,6,7-tetrahydro-benz[d]isoxazol-3-yl]-hexanoic acid



embedded image


tert-Butyl (S)-6-benzyloxy-3-[7-(3-methyl-butyl)-4,5,6,7-tetrahydro-benz[d]isoxazol-3-yl]-hexanoate (118 mg) and chloroform (0.600 mL) were mixed. To the mixture was added trifluoroacetic acid (0.240 mL) at ice temperature. The reaction mixture was stirred at room temperature overnight. To the mixture was added toluene. The mixture was concentrated under reduced pressure to give the title compound (111 mg) as a crude product.


F-698-9
(S)-6-benzyloxy-3-[7-(3-methyl-butyl)-4,5,6,7-tetrahydro-benz[d]isoxazol-3-yl]-hexanoic acid (2-chloro-4-methyl-phenyl)amide



embedded image


(S)-6-benzyloxy-3-[4′-cyclopropyl-5-(2,2-dimethyl-propyl)-[3,5′]biisoxazolyl-3′-yl]-hexanoic acid (111 mg, equivalent to 0.251 mmol) and dimethylacetamide (0.730 mL) were mixed. To the mixture was added thionyl chloride (0.020 mL) at ice temperature. To the reaction mixture was added 2-chloro-4-methyl-phenylamine (0.034 mL) at ice temperature. The cooling bath was removed, and the reaction mixture was stirred for 1 hr. To the reaction mixture were added a mixture of ethyl acetate:hexane=1:2, and water. The organic layer was separated, and washed with water and brine in this order, and dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:8) to give the title compound (94.1 mg).


F-698-10
(S)-6-hydroxy-3-[7-(3-methyl-butyl)-4,5,6,7-tetrahydro-benz[d]isoxazol-3-yl]-hexanoic acid (2-chloro-4-methyl-phenyl)amide



embedded image


(S)-6-benzyloxy-3-[7-(3-methyl-butyl)-4,5,6,7-tetrahydro-benz[d]isoxazol-3-yl]-hexanoic acid (2-chloro-4-methyl-phenyl)amide (94.1 mg) and dichloromethane (1 mL) were mixed. To the mixture was added boron tribromide (1 M in dichloromethane) (0.526 mL) at ice temperature. The reaction mixture was stirred for 15 min at ice temperature, and then stirred for 20 min at room temperature. To the reaction mixture were added aqueous saturated sodium hydrogen carbonate and chloroform at ice temperature. The organic layer was separated, and washed with water and brine in this order. The organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by preparative chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:1) to give the title compound (55.9 mg).


F-698-11
(S)-5-(2-Chloro-4-methyl-phenylcarbamoyl)-4-[7-(3-methyl-butyl)-4,5,6,7-tetrahydro-benz[d]isoxazol-3-yl]-pentanoic acid



embedded image


(S)-6-Hydroxy-3-[7-(3-methyl-butyl)-4,5,6,7-tetrahydro-benz[d]isoxazol-3-yl]-hexanoic acid (2-chloro-4-methyl-phenyl)amide (55.2 mg), acetonitrile (0.300 mL), and 1.0 M phosphate buffer (pH=6.8) (0.180 mL) were mixed. To the reaction mixture were added 2,2,6,6-tetramethyl-1-piperidinyloxy radical (TEMPO) (1.9 mg), sodium chlorite (27.8 mg), and aqueous sodium hypochlorite (Wako Pure Chemical Industries, 0.024 mL) at ice temperature. The reaction mixture was stirred for 1 hr at room temperature. To the mixture were added aqueous sodium sulfite and aqueous sodium hydrogen sulfate at ice temperature. Ethyl acetate was added to the reaction mixture. The organic layer was separated, and washed with water and brine in this order. The organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by preparative chromatography (A mixture of acetic acid, methanol, and chloroform was used as an eluent. Eluent: acetic acid:methanol:chloroform=0.05:1:20) to give the title compound (51.5 mg).


Example F-715
(S)-5-(2-Chloro-4-methyl-phenylcarbamoyl)-4-{4-cyclopropyl-3-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-5-yl}-pentanoic acid
F-715-1
3-(2,2-Dimethyl-propyl)-cyclobutanecarbaldehyde oxime



embedded image


To a solution of hydroxylammonium chloride (3.2 g) in water (20 mL) were added ethanol (80 mL) and aqueous 4 N sodium hydroxide (11.5 mL) at ice temperature. A solution of 3-(2,2-dimethyl-propyl)-cyclobutanecarbaldehyde which was obtained in F-682-7 in toluene was added dropwise slowly to the mixture. The mixture was stirred for 12 hrs at room temperature. To the mixture was added ethyl acetate (50 mL). The organic layer was separated, and washed with water (50 mL) and brine (50 mL), and dried over sodium sulfate. The desiccant was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (6.05 g) as a crude product.


F-715-2
tert-Butyl (S)-6-benzyloxy-3-{3-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-5-yl}-hexanoate



embedded image


To a solution of 3-(2,2-dimethyl-propyl)-cyclobutanecarbaldehyde oxime (1.64 g) in DMF (5.0 mL) was added a solution of N-chlorosuccinimide (1.56 g) in DMF (3.0 mL) at ice temperature. The mixture was stirred for 30 minutes at room temperature. To the reaction mixture were added toluene (19 mL) and water (19 mL). The organic layer was separated, and washed with brine (19 mL), and put into a dropping funnel. The organic layer was added dropwise slowly to a mixture of tert-butyl (S)-6-benzyloxy-3-ethynyl-hexanoate which was obtained in E-52-1 (2.94 g), toluene (9.0 mL), potassium carbonate (1.5 g), and water (4.0 mL) over 20 minutes at 100° C. To the reaction mixture were added ethyl acetate (9.0 mL) and water (9.0 mL). The organic layer was separated, and washed with water (9.0 mL) and brine (9.0 mL) and dried over sodium sulfate. The desiccant was filtered off, and the filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:15) to give the title compound (2.12 g).


F-715-3
tert-Butyl (S)-3-{3-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-5-yl}-6-hydroxy-hexanoate



embedded image


To a solution of tert-butyl (S)-6-benzyloxy-3-{3-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-5-yl}-hexanoate (2.12 g) in tetrahydrofuran (10 mL) was added 10% palladium on carbon (powder) PE-TYPE (220 mg). The mixture was stirred for 12 hrs at room temperature under hydrogen atmosphere (1 atm). The catalyst was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (1.86 g) as a crude product.


F-715-4
1-tert-Butyl (S)-3-{3-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-5-yl}-hexanedioate



embedded image


tert-Butyl (S)-3-{3-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-5-yl}-6-hydroxy-hexanoate (539 mg) was dissolved in a mixture of acetonitrile (2.7 mL) and 1.0 M phosphate buffer (pH=6.8) (1.1 mL). To the mixture were added 2,2,6,6-tetramethyl-1-piperidinyloxy radical (TEMPO) (11 mg) and sodium chlorite (321 mg) at room temperature. Then, aqueous sodium hypochlorite (0.162 mL) was added dropwise to the mixture. The resulting mixture was stirred for 1 hr at room temperature. Aqueous 20 w/v % sodium sulfite (2.0 mL) was added dropwise to the mixture at ice temperature. Then, ethyl acetate (7.0 mL) and water (2.0 mL) were added. The organic layer was separated, and washed with brine (4.0 mL), and dried over magnesium sulfate. The desiccant was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (560 mg) as a crude product.


F-715-5
1-tert-Butyl 6-methyl (S)-3-{3-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-5-yl}-hexanedioate



embedded image


1-tert-Butyl (S)-3-{3-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-5-yl}-hexanedioate (560 mg) was dissolved in DMF (3.0 mL). To the mixture were added methyl iodide (0.179 mL) and potassium carbonate (236 mg) at ice temperature. The mixture was stirred for 12 hrs at room temperature. To the mixture were added ice water (3.0 mL), n-hexane (2.0 mL), and ethyl acetate (2.0 mL). The resulting organic layer was washed with aqueous 5 w/v % potassium hydrogen sulfate (3.0 mL) and brine (3.0 mL), and dried with magnesium sulfate. The desiccant was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:4) to give the title compound (516 mg).


F-715-6
1-tert-Butyl 6-methyl (S)-3-{4-bromo-3-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-5-yl}-hexanedioate



embedded image


1-tert-Butyl 6-methyl (S)-3-{3-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-5-yl}-hexanedioate (516 mg) was dissolved in a mixture solvent of DMF:isopropyl acetate=1:1 (3.2 mL). To the mixture were added 1,3-dibromo-5,5-dimethylhydantoin (272 mg) and p-toluenesulfonic acid monohydrate (24 mg) at room temperature. The reaction mixture was stirred for 12 hrs at room temperature. Then, to the mixture were added ice water (5.0 mL) and ethyl acetate (5.0 mL). The organic layer was separated, and washed with aqueous saturated sodium thiosulfate (3.0 mL) and brine (3.0 mL), and dried with magnesium sulfate. The desiccant was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:4) to give the title compound (266 mg).


F-715-7
1-tert-Butyl 6-methyl (S)-3-{4-cyclopropyl-3-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-5-yl}-hexanedioate



embedded image


1-tert-butyl 6-methyl (S)-3-{4-bromo-3-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-5-yl}-hexanedioate (210 mg) was dissolved in a mixture solvent of toluene:water=10:1 (11 mL). To the mixture were added cyclopropylboronic acid (56 mg), tripotassium phosphate (183 mg), bis{di-tert-butyl(4-dimethylaminophenyl)phosphine}dichloropalladium (II) (15 mg) at room temperature. The reaction mixture was stirred for 12 hrs at 100° C. To the mixture were added ice water (5.0 mL) and ethyl acetate (5.0 mL). The organic layer was separated, and washed with brine (3.0 mL), and dried with magnesium sulfate. The desiccant was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:9) to give the title compound (134 mg).


F-715-8
6-Methyl (S)-3-{4-cyclopropyl-3-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-5-yl}-hexanedioate



embedded image


1-tert-Butyl 6-methyl (S)-3-{4-cyclopropyl-3-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-5-yl}-hexanedioate (134 mg) was dissolved in toluene (0.6 mL).


Trifluoroacetic acid (0.3 mL) was added dropwise to the mixture at ice temperature. The reaction mixture was stirred for 6 hrs at room temperature, and concentrated under reduced pressure. The resulting residue was azeotroped with toluene (twice) to give the title compound (117 mg) as a crude product.


F-715-9
Methyl (S)-5-(2-chloro-4-methyl-phenylcarbamoyl)-4-{4-cyclopropyl-3-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-5-yl}-pentanoate



embedded image


6-Methyl (S)-3-{4-cyclopropyl-3-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-5-yl}-hexanedioate (39 mg) was dissolved in DMF (1.5 mL). To the mixture were added 2-chloro-4-methylphenylamine (17 mg) diisopropylethylamine (0.053 mL), and HATU (46 mg) at ice temperature. The mixture was stirred for 12 hrs at room temperature. To the mixture were added ice water (3.0 mL), n-hexane (2.0 mL), and ethyl acetate (2.0 mL). The organic layer was separated, and washed with aqueous 5 w/v % potassium hydrogen sulfate (3.0 mL) and brine (3.0 mL). The organic layer was dried over sodium sulfate. The desiccant was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (A mixture of ethyl acetate and hexane was used as an eluent. Eluent: ethyl acetate:hexane=1:2) to give the title compound (34 mg).


F-715-10
(S)-5-(2-chloro-4-methyl-phenylcarbamoyl)-4-{4-cyclopropyl-3-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-5-yl}-pentanoic acid



embedded image


Methyl (S)-5-(2-chloro-4-methyl-phenylcarbamoyl)-4-{4-cyclopropyl-3-[3-(2,2-dimethyl-propyl)-cyclobutyl]-isoxazol-5-yl}-pentanoate (33 mg) was dissolved in methanol (0.1 mL). To the mixture was added aqueous 2N sodium hydroxide (0.064 mL) at room temperature. The reaction mixture was stirred for 2 hrs at 60° C., and then was concentrated under reduced pressure. To the residue was added 1 N hydrochloric acid (0.128 mL) at ice temperature. Then water (3.0 mL) and ethyl acetate (3.0 mL) were added. The organic layer was separated, and washed with aqueous 5 w/v % potassium hydrogen sulfate (3.0 mL) and brine (3.0 mL). The organic layer was dried over sodium sulfate. The desiccant was filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica-gel column chromatography (A mixture of methanol and chloroform was used as an eluent. Eluent: methanol:chloroform=1:10) to give the title compound (31 mg).


Production Example of Example F-1



embedded image


Production Example of Example F-9



embedded image


Production Example of Example F-19



embedded image


Production Example of Example F-62
Production Example of Example F-63



embedded image


Production Example of Example F-259



embedded image


Production Example of Example F-319
Production Example of Example F-320



embedded image


Production Example of Example F-35



embedded image


Production Example of Example F-36



embedded image


Production Example of Example F-145
Production Example of Example F-146



embedded image


embedded image


Production Example of Example F-227



embedded image


embedded image


Production Example of Example F-302
Production Example of Example F-303



embedded image


embedded image


Production Example of Example F-397
Production Example of Example F-398
Production Example of Example F-399
Production Example of Example F-400



embedded image


Production Example of Example F-448



embedded image


Production Example of Example F-431
Production Example of Example F-470
Production Example of Example F-471



embedded image


embedded image


embedded image


Production Example of Example F-500
Production Example of Example F-501
Production Example of Example F-502
Production Example of Example F-503



embedded image


embedded image


Production Example of Example F-517
Production Example of Example F-533
Production Example of Example F-534
Production Example of Example F-539



embedded image


embedded image


embedded image


Production Example of Example F-545



embedded image


Production Example of Example F-408
Production Example of Example F-547



embedded image


embedded image


Production Example of Example F-562
Production Example of Example F-563
Production Example of Example F-564
Production Example of Example F-565



embedded image


Production Example of Example F-570
Production Example of Example F-592
Production Example of Example F-593



embedded image


embedded image


Production Example of Example F-655



embedded image


Production Example of Example F-310



text missing or illegible when filed


text missing or illegible when filed


text missing or illegible when filed


Production Example of Example F-394
Production Example of Example F-395



embedded image


embedded image


Production Example of Example F-2



embedded image


embedded image


Production Example of Example F-283



embedded image


embedded image


Production Example of Example F-355



embedded image


embedded image


Production Example of Example F-433
Production Example of Example F-434



embedded image


embedded image


Production Example of Example F-310



embedded image


embedded image


Production Example of Example F-450



embedded image


embedded image


Production Example of Example F-459



embedded image


embedded image


Production Example of Example F-479



embedded image


embedded image


Production Example of Example F-490



embedded image


embedded image


Production Example of Example F-585



embedded image


embedded image


Production Example of Example F-621



embedded image


embedded image


embedded image


Production Example of Example F-647



embedded image


embedded image


embedded image


embedded image


Production Example of Example F-701



embedded image


embedded image


Production Example of Example F-710



embedded image


embedded image


embedded image


Production Example of Example F-494



embedded image


Production Example of Example F-704



embedded image


embedded image


Production Example of Example F-733



embedded image


Production Example of Example F-740



embedded image


embedded image


Production Example of Example F-744



embedded image


Production Example of Example F-745



embedded image


Production Example of Example F-645
Production Example of Example F-646



embedded image


embedded image


Production Example of Example F-687



embedded image


Production Example of Example F-636



embedded image


embedded image


Production Example of Example F-670



embedded image


embedded image


Production Example of Example F-640



embedded image


embedded image


Production Example of Example F-700



embedded image


embedded image


embedded image


Production Example of Example F-705



embedded image


embedded image


embedded image


Production Example of Example F-722



embedded image


embedded image


Production Example of Example F-725



embedded image


embedded image


embedded image


Production Example of Example F-727



embedded image


Production Example of Example F-668



embedded image


embedded image


Production Example of Example F-677



embedded image


embedded image


Production Example of Example F-678



embedded image


Production Example of Example F-690



embedded image


embedded image












TABLE 112










MS














M + H
M − H


Exam-


or
or


ple
Chemical structure
NMR
M − Na + H
M − Na − H





E-01


embedded image


(400 MHz, CDCl3) 0.52-0.64 (m, 1H), 0.69-0.81 (m, 1H), 0.92-1.06 (m, 2H), 1.00 (d, J = 6.40 Hz, 6H), 1.61-1.74 (m, 1H), 2.01-2.32 (m, 3H), 2.32 (s, 3H), 2.36-2.52 (m, 2H), 2.71 (d, J = 7.20 Hz, 2H), 2.82 (dd, J = 14.80, 5.20 Hz, 1H), 3.07 (dd, J = 14.80, 9.20 Hz, 1H), 3.71-3.84 (m, 1H),
500
498




6.41 (s, 1H), 7.02 (d, J = 8.40






Hz, 1H), 7.14 (s, 1H), 7.71






(s, 1H), 8.08 (d, J = 8.40 Hz,






1H)







E-02


embedded image


(400 MHz, DMSO-d6) 0.48- 0.55 (m, 1H), 0.63-0.71 (m, 1H), 0.90-0.98 (m, 2H), 0.94 (d, J = 7.20 Hz, 6H), 1.70-1.79 (m, 1H), 1.80-1.97 (m, 4H), 1.98-2.11 (m, 1H), 2.26 (s, 3H), 2.75 (d, J = 7.20 Hz, 2H), 2.79 (dd, J = 14.80, 6.00 Hz, 1H), 2.87 (dd, J = 14.80, 8.40 Hz, 1H), 3.48-3.58 (m, 1H), 6.76 (s, 1H), 7.07 (d, J = 8.40,
500
498




1H), 7.27 (s, 1H), 7.41 (d, J =






8.40 Hz, 1H), 9.77 (s, 1H)







E-03


embedded image


(400 MHz, CDCl3) 0.33-0.45 (m, 1H), 0.46-0.59 (m, 1H), 0.67-0.86 (m, 2H), 0.92 (d, J = 6.40 Hz, 6H), 1.44-1.58 (m, 1H), 1.83-2.35 (m, 5H), 2.24 (s, 3H), 2.60 (d, J = 6.80 Hz, 2H), 2.68-2.82 (m, 1H), 2.82-2.96 (m, 1H), 3.44-3.75 (m, 1H), 6.26 (s, 1H), 6.56- 6.76 (m, 2H), 7.62-7.78 (m, 1H), 8.87 (brs, 1H)
484
482





E-04


embedded image


(400 MHz, CDCl3) 0.30-0.59 (m, 2H), 0.73-0.99 (m, 2H), 0.93 (d, J = 6.40 Hz, 6H), 1.41-1.58 (m, 1H), 1.83-2.32 (m, 5H), 2.11 (2.73-2.99 (m, 2H), 3.46-3.71 (m, 1H), 6.41 (s, 1H), 6.66-6.99 (m, 2H), 7.60-7.83 (m, 1H)
500
498





E-05


embedded image


(400 MHz, CDCl3) 0.30-0.61 (m, 2H), 0.66-1.00 (m, 2H), 0.92 (d, J = 5.60 Hz, 6H), 1.42-1.67 (m, 4H), 1.80-234 (m, 4H), 2.12 (s, 3H), 2.54- 3.01 (m, 4H), 344-377 (m, 1H), 6.24 (s, 1H), 6.65-7.03 (m, 2H), 7.64-7.87 (m, 1H)
514
512



















TABLE 113










MS











Ex-


M + H
M − H


am-


or
or


ple
Chemical structure
NMR
M − Na + H
M − Na − H





E-06


embedded image


(400 MHz, DMSO-D6) 0.47- 0.55 (m, 1H), 0.62-0.71 (m, 1H), 0.88-0.95 (m, 2H), 0.95- 1.00 (m, 9H), 1.68-1.95 (m, 4H), 2.21-2.30 (m, 3H), 2.75- 2.79 (m, 2H), 2.79-2.92 (m, 1H), 3.39-349 (m, 1H), 3.49- 3.58 (m, 1H), 4.30-4.40 (m, 1H), 6.73 (s, 1H), 7.05-7.10 (m, 1H), 7.27 (br s, 1H), 7.38-7.44 (m, 1H), 9.83 (br
514
512




s, 1H).







E-07


embedded image


(400 MHz, DMSO-d6) 0.42- 0.55 (m, 1H), 0.60-0.71 (m, 1H), 0.83-0.96 (m, 2H), 0.90 (d, J = 6.40 Hz, 6H), 1.64- 1.73 (m, 1H), 1.86-2.03 (m, 3H), 2.17-2.34 (m, 2H), 2.26 (s, 3H), 2.53 (d, J = 6.80 Hz, 2H), 2.78 (dd, J = 15.20, 6.80 Hz, 1H), 2.90 (dd, J = 15.20, 8.00 Hz, 1H), 3.50- 3.63 (m, 1H), 6.46 (s, 1H),
483
481




6.92 (d, J = 8.00, 1H), 7.04






(d, J = 12.4 Hz, 1H), 7.58 (t,






J = 8.40 Hz, 1H), 9.69 (s, 1H)







E-08


embedded image


(400 MHz, DMSO-d6) 0.42- 0.52 (m, 1H), 0.58-0.67 (m, 1H), 0.80-0.92 (m, 2H), 0.88 (d, J = 6.80 Hz, 6H), 1.63- 1.74 (m, 1H), 1.78-1.96 (m, 5H), 2.24 (s, 3H), 2.51 (d, J = 7.20 Hz, 2H), 2.74 (dd, J = 15.20, 6.40 Hz, 1H), 2.83 (dd, J = 15.20, 8.00 Hz, 1H), 3.40-3.52 (m, 1H), 6.42 (s, 1H), 6.89 (d, J = 8.00, 1H),
483
481




7.01 (d, J = 11.2 Hz, 1H),






7.58 (t, J = 8.00 Hz, 1H), 9.91






(s, 1H), 13.06 (brs, 1H)







E-09


embedded image


(400 MHz, CDCl3) 0.31-0.62 (m, 2H), 0.66-0.99 (m, 2H), 0.91 (d, J = 6.00 Hz, 6H), 1.38-1.68 (m, 4H), 1.83-2.26 (m, 2H), 2.12 (s, 3H), 2.32- 2.53 (m, 2H), 2.62-2.98 (m, 4H), 3.43-3.67 (m, 1H), 6.23 (s, 1H), 6.54-6.78 (m, 2H), 7.60-7.78 (m, 1H), 8.84 (brs, 1H)
498
496





E-10


embedded image


(400 MHz, CDCl3) 0.20-0.49 (m, 2H), 0.64-0.84 (m, 2H), 0.93 (d, J = 6.00 Hz, 6H), 1.47-1.67 (m, 4H), 1.86-2.37 (m, 4H), 2.14 (s, 3H), 267-3.01 (m, 4H), 3.50-3.82 (m, 1H), 6.76-7.09 (m, 2H), 7.68-7.90 (m, 1H), 8.21-8.46 (m, 1H)
548
546



















TABLE 114










MS











Ex-


M + H
M − H


am-


or
or


ple
Chemical structure
NMR
M − Na + H
M − Na − H





E-11


embedded image


(400 MHz. DMSO-d6) 0.61-0.71 (m, 1H), 0.73- 0.81 (m, 1H), 0.90-0.95 (m, 2H), 0.99 (d, J = 6.62 Hz, 6H), 1,79-1.86 (m, 1H), 1.85-1.94 (m, 4H), 2.13-2.24 (m, 1H), 2.26 (s, 3H), 2.79-2.91 (m, 2H), 2.95 (d, J = 7.06 Hz, 2H), 3.49-3.56 (m, 1H), 7.07 (d, J = 8.38 Hz, 1H),
501
499




7.26 (s,1H), 7.41 (d, J =






8.16 Hz, 1H), 9.73 (s, 1H)







E-12


embedded image


(400 MHz, DMSO-D6) 0.91-0.96 (m, 6H), 1.79- 1.90 (m, 4H), 1.99-2.08 (m, 1H), 2.25-2.28 (m, 3H), 2.76-2.80 (m, 2H), 2.86-291 (m, 2H), 3.49- 3.56 (m, 1H), 6.88 (s, 1H), 6.89-6.94 (m, 1H), 7.00- 7.06 (m, 1H), 7.56-7.62 (m, 1H), 10.07 (br s, 1H).
512
510





E-13


embedded image


(400 MHz, DMSO-D6) 0.91 (d, J = 25.14 Hz, 6H), 1.54-1.64 (m, 3H), 1.81- 1.91 (m, 4H), 2.24-2.28 (m, 3H), 2.86-2.93 (m, 4H), 3.49-3.56 (m, 1H), 6.88 (s, 1H), 6.89-6.94 (m, 1H), 7.01-7.06 (m, 1H), 7.54-7.62 (m, 1H), 10.04 (br s, 1H).
526
524





E-14


embedded image


(400 MHz, CDCl3) 0.44- 0.57 (m, 1H), 0.59-0.72 (m, 1H), 0.80-0.93 (m, 2H), 0.96 (d, J = 6.40 Hz, 6H), 1.53-1.66 (m, 1H), 1.87-2.27 (m, 5H), 2.11 (s, 3H), 2.75-2.86 (m, 1H), 2.87-3.01 (m, 1H), 2.96 (d, J = 6.80 Hz, 2H), 3.53-3.66 (m, 1H), 6.78 (d, J = 8.00 Hz, 1H), 6.92
517
515




(s, 1H), 7.72 (d, J = 8.00






Hz, 1H), 8.40 (brs, 1H)







E-15


embedded image


(400 MHz, DMSO-d6) 0.63-0.70 (m, 1H), 0.79- 0.85 (m, 1H), 0.93 (d, J = 6.62 Hz, 6H), 0.94-0.99 (m, 2H), 1.76-1.94 (m, 6H), 2.25 (s, 3H), 2.73- 2.88 (m, 2H), 2.81 (d, J = 7.06 Hz, 2H), 3.47-3.54 (m, 1H), 7.06 (d, J = 7.94 Hz, 1H), 7.25 (s, 1H),
516
514




7.41 (d, J = 8.16 Hz, 1H),






7.80 (s, 1H), 9.81 (s, 1H)



















TABLE 115













MS











Ex-


M + H
M − H


am-


or
or


ple
Chemical structure
NMR
M − Na + H
M − Na − H














E-16


embedded image


(400 MHz, DMSO-D6) 0.92 (d, J = 16.92 Hz, 6H), 1.53-1.65 (m; 4H), 1.76-1.99 (m, 4H), 2.25-2.28 (m, 3H), 2.84-2.93 (m, 3H), 3.47-3.60 (m, 1H), 6.87 (s, 1H), 7.04-7.11 (m, 1H), 7.27 (br s, 1H), 7.39-7.43 (m, 1H), 9.89 (br s, 1H).
542
540





E-17


embedded image


(400 MHz, DMSO-d6) 0.47-0.56 (m, 1H), 0.63-0.72 (m, 1H), 0.86 (s, 9H), 0.91-0.94 (m, 2H), 1.37 (d, J = 6.62 Hz, 2H), 1.70-1.77 (m, 1H), 1.81-1.95 (m, 6H), 2.26 (s, 3H), 2.38-2.47 (m, 1H), 2.48-2.56 (m, 2H), 2.76-2.91 (m, 2H),
568
566




3.49-3.57 (m, 2H),






3.56-3.65 (m, 2H), 6.77






(s, 1H), 7.07 (d, J =






7.94 Hz, 1H), 7.27 (s,






1H), 7.41 (d, J = 8.16






Hz, 1H), 9.75 (s, 1H)







E-18


embedded image


(400 MHz, DMSO-d6) 0.66-0.73 (m, 1H), 0.76-0.83 (m, 1H), 0.90-0.94 (m, 2H), 0.93 (dd, J = 6.62 1.54 Hz, 6H), 1.78- 1.94 (m, 5H), 194-2.04 (m, 1H), 2.26 (s, 3H), 2.65 (d, J = 7.06 Hz, 2H), 2.76-2.90 (m, 2H), 3.47-3.54 (m,
500
498




1H), 7.07 (d, J = 7.94






Hz, 1H), 7.19 (s, 1H),






7.26 (s, 1H), 7.41 (d,






J = 8.16 Hz, 1H), 9.74






(s, 1H)







E-19


embedded image


(400 MHz, DMSO-D6) 0.19-0.27 (m, 1H), 0.39-0.48 (m, 1H), 0.81-0.90 (m, 2H), 0.93 (s, 9H), 1.53-1.66 (m, 1H), 1.73-1.84 (m, 2H), 1.85-2.02 (m, 5H), 2.22-2.28 (m, 3H), 2.72-2.90 (m, 2H), 3.47-3.58 (m, 1H), 4.21-4.37 (m, 2H), 6.87-6.97 (m, 1H),
579
577




6.98-7.07 (m, 1H),






7.52-7.62 (m, 1H),






8.48-8.57 (m, 1H),






9.87-9.94 (m, 1H).







E-20


embedded image


(400 MHz, DMSO-d6) 0.48-0.57 (m, 1H), 0.65-0.74 (m, 1H), 0.91-0.99 (m, 2H), 1.04 (d, J = 6.84 Hz, 6H), 1.75-1.82 (m, 1H), 1.84-1.95 (m, 4H), 2.26 (s, 3H), 2.58-2.72 (m, 1H, 2.79-2.93 (m, 2H), 3.52-3.59 (m, 1H, 7.08 (d, J = 8.16 Hz, 1H),
536
534




7.27 (s, 1H), 7.42 (d,






J = 8.16 Hz, 1H), 7.46






(s, 1H), 9.75 (s, 1H)



















TABLE 116










MS











Ex-


M + H
M − H


am-


or
or


ple
Chemical structure
NMR
M − Na + H
M − Na − H





E-21


embedded image


(400 MHz, DMSO-d6) 0.45-0.51 (m, 1H), 0.64-0.70 (m, 1H), 0.92 (d, J = 6.40 Hz, 6H), 0.93-0.96 (m, 2H), 1.39-1.47 (m, 2H), 1.55-1.62 (m, 3H), 1.67-1.77 (m, 3H), 1.84 (t, J = 7.28 Hz, 2H), 2.26 (s, 3H), 2.78-2.92 (m, 4H), 3.47-3.55 (m, 1H), 6.75 (s, 1H), 7.08 (d, J = 8.38 Hz, 1H),
528
526




7.27 (s, 1H), 7.42 (d, J =






8.16 Hz, 1H), 9.60






(s, 1H)







E-22


embedded image


(400 MHz, CDCl3) 0.34-0.59 (m, 2H), 0.70- 0.86 (m, 2H), 0.91 (s, 9H), 1.46-1.62 (m, 3H), 1.84-2.26 (m, 4H), 2.10 (s, 3H), 2.44-2.83 (m, 3H), 2.83-2.99 (m, 1H), 3.46-3.67 (m, 1H), 6.23 (s, 1H), 6.79 (d, J = 8.00 Hz, 1H), 6.93 (s, 1H), 7.71 (d, J = 8.00 Hz, 1H), 8.40 (s, 1H)
528
526





E-23


embedded image


(400 MHz, CDCl3) 0.34-0.58 (m, 2H), 0.72-0.93 (m, 4H), 0.85 (d, J = 8.00 Hz, 6H), 1.00-1.11 (m, 2H), 1.45- 1.60 (m, 1H), 1.55 (d, J = 6.80 Hz, 2H), 1.66- 1.81 (m, 1H), 1.84-2.26 (m, 4H), 2.10 (s, 3H), 2.69-2.97 (m, 2H), 3.47- 3.66 (m, 1H), 6.20 (s, 1H), 6.78 (d, J = 8.00 Hz, 1H), 6.93 (s, 1H),
540
538




7.72 (d, J = 8.00 Hz,






1H), 8.38 (s, 1H)







E-24


embedded image


(400 MHz, CDCl3) 0.34-0.61 (m, 2H), 0.67-0.90 (m, 2H), 1.42- 1.81 (m, 7H), 1.84-2.27 (m, 6H), 2.10 (s, 3H), 2.67-2.99 (m, 2H), 3.06- 3.24 (m, 1H), 3.44-3.77 (m, 1H), 6.22 (s, 1H), 6.67-6.85 (m, 1H), 6.93 (s, 1H), 7.60-7.84 (m, 1H), 8.26-8.53 (m, 1H)
512
510





E-25


embedded image


(400 MHz, CDCl3) 0.10-0.22 (m, 1H), 0.22-0.33 (m, 1H), 0.62-0.78 (m, 2H), 0.88 (d, J = 6.40 Hz, 6H), 1.36-1.48 (m, 1H), 1.78- 1.91 (m, 1H), 1.91-2.33 (m, 4H), 2.09 (s, 3H), 2.41 (d, J = 6.80 Hz, 2H), 2.60-3.05 (m, 2H), 3.50-3.81 (m, 1H),
513
511




3.72 (s, 3H), 6.21 (s,






1H), 6.77 (d, J = 7.60






Hz, 1H), 6.93 (s, 1H),






7.74 (d, J = 7.60 Hz,






1H), 8.33 (s, 1H)



















TABLE 117










MS











Ex-


M + H
M − H


am-


or
or


ple
Chemical structure
NMR
M − Na + H
M − Na − H





E-26


embedded image


(400 MHz, CDCl3) 0.24- 0.38 (m, 1H), 0.39-0.50 (m, 1H), 0.68-0.82 (m, 2H), 0.91 (d, J = 6.40 Hz, 6H), 1.42-1.55 (m, 1H), 1.76-1.92 (m, 2H), 1.93-2.19 (m, 3H), 2.12 (s, 3H), 2.40 (d, J = 7.20 Hz, 2H), 2.59-2.73 (m, 1H), 2.79-2.92 (m, 1H), 3.44-3.59 (m, 1H), 3.74
513
511




(s, 3H), 6.33 (s, 1H),






6.81 (d, J = 8.00 Hz,






1H), 6.98 (s, 1H), 7.67






(d, J = 8.00 Hz, 1H),






8.60 (s, 1H)







E-27


embedded image


(400 MHz, DMSO-d6) 0.60-0.69 (m, 1H), 0.77- 0.86 (m, 1H), 0.93 (d, J = 6.62 Hz, 6H), 0.94- 0.98 (m, 2H), 1.73-1.80 (m, 1H), 1.82-1.92 (m, 5H), 2.26 (s, 3H), 2.37 (s, 3H), 2.72 (d, J = 7.06 Hz, 2H), 2.75-2.90 (m, 2H), 3.47-3.54 (m, 1H), 7.07 (d, J = 8.16 Hz,
530
528




1H), 7.26 (s, 1H), 7.41






(d, J = 8.16 Hz, 1H),






9.75 (s, 1H)







E-28


embedded image


(400 MHz, DMSO-D6) 0.40-0.47 (m, 1H), 0.56-0.64 (m, 1H), 0.81- 0.91 (m, 2H), 0.92 (dd, J = 6.75, 1.16 Hz, 6H), 1.62 (td, J = 9.01, 4.73 Hz, 1H), 1.84-1.93 (m, 4H), 1.97 (td, J = 13.61, 6.90 Hz, 1H), 2.24 (s, 3H), 2.58 (d, J = 6.98 Hz, 2H), 2.63-2.83 (m,
499
497




2H), 3.50 (d, J = 6.75






Hz, 1H), 6.36 (d, J = 3.26






Hz, 1H), 6.89 (d, J = 3.49






Hz, 1H), 7.04 (d, J = 7.44






Hz, 1H), 7.23 (s, 1H),






7.42 (d, J = 8.37 Hz, 1H),






9.77 (s, 1H)







E-29


embedded image


(400 MHz, CDCl3) 0.24- 0.50 (m, 2H), 0.62-0.80 (m, 2H), 0.90 (d, J = 6.40 Hz, 6H), 1.47-1.61 (m, 1H), 1.75-2.28 (m, 5H), 1.90 (s, 3H), 2.11 (s, 3H), 2.52 (d, J = 6.80 Hz, 2H), 2.71-3.00 (m, 2H), 3.49-3.69 (m, 1H), 6.74-6.89 (m, 1H), 6.95 (s, 1H), 7.69-7.87 (m,
514
512




1H), 8.28-8.52 (m, 1H)







E-30


embedded image


(400 MHz, CDCl3) 0.33- 0.59 (m, 2H), 0.69-0.91 (m, 2H), 1.10 (s, 3H), 1.20 (s, 3H), 1.45-1.58 (m, 1H), 1.84-2.34 (m, 8H), 2.19 (s, 3H), 2.65- 2.99 (m, 2H), 3.44-3.73 (m, 2H), 6.23 (s, 1H), 6.70-6.85 (m, 1H), 6.94 (s, 1H, 7.63-7.83 (m, 1H), 8.28-8.48 (m, 1H)
526
524



















TABLE 118










MS











Ex-


M + H
M − H


am-


or
or


ple
Chemical structure
NMR
M − Na + H
M − Na − H





E-31


embedded image


(400 MHz, DMSO-D6) 0.51-0.56 (m, 1H), 0.66-0.71 (m, 1H), 0.91-0.93 (m, 2H), 0.94 (s, 9H), 1.59-1.63 (m, 2H), 1.71-1.78 (m, 1H), 1.80-1.91 (m, 4H), 2.23 (s, 3H), 2.66-2.77 (m, 2H), 2.80-2.84 (m, 2H), 3.48-3.55 (m, 1H), 6.75 (s, 1H), 6.83 (d,
512
510




J = 7.50 Hz, 1H), 6.92-






6.95 (m, 1H), 7.53 (dd,






J = 7.50, 7.50 Hz, 1H),






9.94 (br s, 1H)







E-32


embedded image


(400 MHz, DMSO-D6) 0.51-0.55 (m, 1H), 0.66-0.71 (m, 1H), 0.90-0.93 (m, 2H), 0.94 (s, 9H), 1.59-1.64 (m, 2H), 1.71-1.78 (m, 1H), 181-1.95 (m, 4H), 2.02 (s, 3H), 2.20 (s, 3H), 2.63-2.76 (m, 2H), 2.80-2.85 (m, 2H), 3.49-3.56 (m, 1H),
508
506




6.75 (s, 1H), 6.85 (d,






J = 8.16 Hz, 1H), 6.91






(s, 1H), 7.08 (d, J = 8.20






Hz, 1H), 9.59 (br s, 1H)







E-33


embedded image


(400 MHz, DMSO-d6) 0.46-0.55 (m, 1H), 0.62-0.72 (m, 1H), 0.89-0.98 (m, 2H), 0.94 (d, J = 6.51 Hz, 6H), 1.72-1.93 (m, 6H), 2.24 (s, 3H), 2.26-2.37 (m, 2H), 2.76-2.92 (m, 2H), 3.49-3.58 (m, 1H), 7.06 (d, J = 8.37 Hz, 1H), 7.25 (s, 1H), 7.40 (d,
550
548




J = 7.68 Hz, 1H), 7.48






(s, 1H), 9.75 (s, 1H)







E-34


embedded image


(400 MHz, DMSO-D6) 0.52-0.57 (m, 1H), 0.67-0.71 (m, 1H), 0.89-0.92 (m, 2H), 0.96 (s, 9H), 1.59-1.63 (m, 2H), 1.72-1.79 (m, 1H), 1.81-1.94 (m, 4H), 2.61- 2.76 (m, 2H), 2.80-2.85 (m, 2H), 3.50-3.57 (m, 1H), 6.74 (s, 1H), 6.99- 7.06 (m, 1H), 7.25-7.31
532
530




(m, 1H), 7.54-7.58 (m,






1H), 10.04 (br s, 1H)







E-35


embedded image


(400 MHz, DMSO-d6) 0.45-0.54 (m, 1H), 0.62-0.71 (m, 1H), 0.93-1.00 (m, 2H), 0.98 (s, 9H), 1.74-1.82 (m, 1H), 1.84-1.96 (m, 4H), 2.26 (s, 3H), 2.39 (t, J = 19.19 Hz, 2H), 2.79- 2.93 (m, 2H), 3.52-3.57 (m, 1H), 7.07 (d, J = 8.16 Hz, 1H), 7.26 (s,
564
562




1H), 7.41 (d, J = 8.16






Hz, 1H), 7.49 (s, 1H),






9.74 (s, 1H)



















TABLE 119










MS











Ex-


M + H
M − H


am-


or
or


ple
Chemical structure
NMR
M − Na + H
M − Na − H





E-36


embedded image


(400 MHz, DMSO-D6) 0.40- 0.48 (m, 1H), 0.60-0.68 (m, 1H), 0.90 (dd, J = 8.49, 1.98 Hz, 2H), 0.96 (d, J = 6.75 Hz, 6H), 1.72-1.76 (m, 1H), 1.79-1.93 (m, 4H), 2.06-2.13 (m, 1H), 2.26 (s, 3H), 2.71- 2.90 (m, 2H), 2.92 (d, J = 7.21 Hz, 2H), 3.51 (t, J = 6.16 Hz, 1H), 7.07 (d, J = 8.14 Hz, 1H), 7.27 (s, 1H),
516
514




7.43 (d, J = 8.14 Hz, 1H),






8.03 (s, 1H), 9.79 (s, 1H)







E-37


embedded image


(400 MHz, DMSO-D6) 0.51- 0.56 (m, 1H), 0.70-0.72 (m, 1H), 0.89-0.93 (m, 2H), 0.94 (s, 9H), 1.59-1.64 (m, 2H), 1.72-1.79 (m, 1H), 1.83-1.96 (m, 4H), 2.04 (s, 3H), 2.60- 2.75 (m, 2H), 2.80-2.85 (m, 2H), 3.49-3.57 (m, 1H), 6.74 (s, 1H), 6.82-6.86 (m, 1H), 6.92 (dd, J = 9.67, 2.01 Hz, 1H), 7.17-7.21 (m, 1H),
512
510




9.72 (br s, 1H)







E-38


embedded image


(400 MHz, DMSO-D6) 0.65- 0.70 (m, 1H), 0.90-0.93 (m, 2H), 0.94 (s, 9H), 1.28-1.57 (m, 1H), 1.59-1.63 (m, 2H), 1.71-1.78 (m, 1H), 1.83-1.95 (m, 4H), 2.08 (s, 3H), 2.67- 2.79 (m, 2H), 2.81-2.85 (m, 2H), 3.49-3.56 (m, 1H), 6.75 (s, 1H, 7.10 (dd, J = 8.66, 2.42 Hz, 1H), 7.18 (s, 1H), 7.31 (d, J = 8.66 Hz, 1H),
528
526




9.87 (br s, 1H)







E-39


embedded image


(400 MHz, DMSO-D6) 0.50- 0.54 (m, 1H), 0.66-0.70 (m, 1H), 0.91-0.99 (m, 2H), 1.49- 1.67 (m, 6H), 1.71-1.98 (m, 7H), 2.26 (s, 3H), 2.71-3.09 (m, 3H), 3.54 (dd, J = 14.45, 6.51 Hz, 1H), 7.08 (d, J = 8.38 Hz, 1H), 7.27 (s, 1H), 7.41 (d, J = 8.16 Hz, 1H), 7.48 (s, 1H), 9.79 (s, 1H)
562
560





E-40


embedded image


(400 MHz, DMSO-d6) 0.48- 0.55 (m, 1H), 0.64-0.70 (m, 1H), 0.91-0.94 (m, 2H), 1.08 (s, 9H), 1.74-1.81 (m, 1H), 1.81-1.93 (m, 4H), 2.24 (s, 3H), 2.77-2.90 (m, 2H), 3.50- 3.57 (m, 1H), 7.06 (d, J = 7.44 Hz, 1H), 7.25 (s, 1H), 7.38 (s, 1H), 7.40 (d, J = 8.14 Hz, 1H), 9.78 (s, 1H)
550
548



















TABLE 120










MS











Ex-


M + H
M − H


am-


or
or


ple
Chemical structure
NMR
M − Na + H
M − Na − H





E-41


embedded image


(400 MHz, CDCl3) 0.22-0.34 (m, 1H), 0.39-0.53 (m, 1H), 0.77-0.93 (m, 2H), 0.97 (d, J = 6.80 Hz, 6H), 1.34-1.48 (m, 1H), 1.86-2.34 (m, 5H), 2.11 (s, 3H), 2.72-3.05 (m, 2H), 2.83 (d, J = 8.00 Hz, 2H), 3.52- 3.68 (m, 1H), 6.77 (d, J = 8.00 Hz, 1H), 6.94 (s, 1H), 7.77 (d, J = 8.00 Hz, 1H), 7.94 (s, 1H), 8.33 (brs, 1H)
516
514





E-42


embedded image


(400 MHz, CDCl3) 0.36-0.63 (m, 2H), 0.71-0.91 (m, 2H), 1.34 (s, 3H), 1.46-1.59 (m, 1H), 1.59-1.82 (m, 6H), 1.87- 2.30 (m, 6H), 2.12 (s, 3H), 2.72- 3.00 (m, 2H), 3.50-3.71 (m, 1H), 6.25 (s, 1H), 6.79 (d, J = 7.20 Hz, 1H), 6.94 (s, 1H), 7.66-7.84 (m, 1H), 8.29-8.52 (m, 1H)
526
524





E-43


embedded image


(400 MHz, DMSO-d6) 0.51- 0.57 (m, 1H), 0.66-0.72 (m, 1H), 0.91-0.94 (m, 2H), 1.36 (s, 9H), 1.71-1.78 (m, 1H), 1.83-1.94 (m, 4H), 2.26 (s, 3H), 2.76-2.90 (m, 2H), 3.49- 3.56 (m, 1H), 6.71 (s, 1H), 7.07 (d, J = 8.16 Hz, 1H), 7.28 (s, 1H), 7.41 (d, J = 8.38 Hz, 1H), 9.77 (s, 1H)
500
498





E-44


embedded image


(400 MHz, DMSO-D6) δ: 0.48- 0.53 (1H, m), 0.63-0.69 (1H, m), 0.91 (2H, dd, J = 8.55, 1.85 Hz), 1.10 (6H, s), 1.26 (6H, s), 1.71-1.77 (2H, m), 1.82-1.92 (4H, m), 2.26 (3H, s), 2.83 (2H, ddd, J = 32.19, 15.43, 7.92 Hz), 3.53 (1H, t, J = 7.05 Hz), 6.64 (1H, s), 7.07 (1H, d, J = 7.86 Hz), 7.26 (1H, s), 7.42 (1H, d, J = 8.09 Hz), 9.76 (1H, br s).
540
538





E-45


embedded image


(400 MHz, CDCl3) 0.30-0.64 (m, 2H), 0.64-1.02 (m, 2H), 0.92 (s, 9H), 1.40-1.67 (m, 3H), 1.78-2.42 (m, 4H), 2.03 (s, 3H), 2.56-3.03 (m, 4H), 3.38-3.78 (m, 1H), 6.24 (s, 1H), 6.78-7.02 (m, 1H), 7.59- 7.90 (m, 1H), 8.29-8.56 (m, 1H)
546
544



















TABLE 121










MS














M + H
M − H





or
or


Example
Chemical structure
NMR
M − Na + H
M − Na − H





E-46


embedded image


(400 MHz, DMSO-d6) 0.51- 0.57 (m, 1H), 0.67-0.73 (m, 1H), 0.92-0.98 (m, 2H), 1.10 (s, 9H), 1.76-1.83 (m, 1H), 1.83-1.92 (m, 4H), 2.26 (s, 3H), 2.79-2.93 (m, 2H), 3.51- 3.58 (m, 1H), 6.91 (d, J = 7.94 Hz, 1H), 7.02 (d, J = 11.69 Hz, 1H), 7.40 (s, 1H), 7.58 (t, J = 8.27 Hz, 1H), 9.94 (s, 1H)
534
532





E-47


embedded image


(400 MHz, DMSO-D6) 0.59- 0.55 (m, 1H), 0.73-0.69 (m, 1H), 0.90-0.94 (m, 2H), 1.73- 1.80 (m, 1H), 1.80-1.95 (m, 4H), 2.21 (s, 3H), 2.61-2.75 (m, 2H), 2.87-3.00 (m, 2H), 3.06-3.18 (m, 2H), 3.50-3.56 (m, 1H), 3.69-3.77 (m, 1H), 6.94 (d, J = 8.16 Hz, 1H), 6.98 (s, 1H), 7.14 (s, 1H), 7.41 (d, J = 8.16 Hz, 1H), 9.77 (br s, 1H)
534
532





E-48


embedded image


(400 MHz, CDCl3) 0.30-0.61 (m, 2H), 0.74-0.95 (m, 2H), 1.06 (s, 9H), 1.45-1.62 (m, 1H), 1.89-2.28 (m, 4H), 2.75- 3.04 (m, 2H), 3.47-3.76 (m, 1H), 6.62-6.79 (m, 2H), 6.79- 6.94 (m, 1H), 7.67-7.89 (m, 1H), 8.42-8.69 (m, 1H)
554
552





E-49


embedded image


(400 MHz, CDCl3) 0.25-0.63 (m, 2H), 0.69-0.92 (m, 2H), 1.06 (s, 9H), 1.42-1.62 (m, 1H), 1.78-2.32 (m, 4H), 2.47- 3.07 (m, 2H), 3.43-3.76 (m, 1H), 6.60-6.99 (m, 3H), 7.70- 7.95 (m, 1H), 8.76-9.21 (m, 1H)
554
552





E-50


embedded image


(400 MHz, DMSO-d6) 0.48- 0.55 (m, 1H), 0.64-0.71 (m, 1H), 0.90-0.98 (m, 2H), 1.70- 1.77 (m, 1H), 1.82-1.95 (m, 4H), 2.26 (s, 3H), 2.74-2.91 (m, 4H), 3.15 (t, J = 7.61 Hz, 2H), 3.49-3.56 (m, 1H), 6.91 (s, 1H), 7.07 (d, J = 7.72 Hz, 1H), 7.26 (s, 1H), 7.41 (d, J = 8.16 Hz, 1H), 9.75 (s, 1H)
540
538



















TABLE 122










MS











Ex-


M + H
M − H


am-


or
or


ple
Chemical structure
NMR
M − Na + H
M − Na − H





E-51


embedded image


(400 MHz, DMSO-d6) 0.49- 0.56 (m, 1H), 0.65-0.73 (m, 3H), 0.94-0.97 (m, 2H), 1.00- 1.02 (m, 2H), 1.16 (s, 3H), 1.76- 1.83 (m, 1H), 1.83-1.95 (m, 4H), 2.26 (s, 3H), 2.79-2.93 (m, 2H), 3.52-3.59 (m, 1H), 7.08 (d, J = 8.16 Hz, 1H), 7.27 (s, 1H), 7.42 (d, J = 8.38 Hz, 1H), 7.46 (s, 1H), 9.76 (s, 1H)
548
546





E-52


embedded image


(400 MHz, DMSO-d6) 0.38- 0.51 (m, 1H), 0.59-0.70 (m, 1H), 0.74-0.87 (m, 2H), 1.09 (s, 9H), 1.61-2.00 (m, 5H), 2.23 (s, 3H), 2.68-2.90 (m, 2H), 3.57-3.73 (m, 1H), 7.02- 7.07 (m, 1H), 7.21-7.26 (m, 1H), 7.32 (s, 1H), 7.37 (d, J = 8.00 Hz, 1H), 9.71 (brs, 1H)
550
548





E-53


embedded image


(400 MHz, DMSO-d6) 0.66- 0.70 (m, 2H), 0.88-0.92 (m, 2H), 1.08 (s, 9H), 1.78-1.85 (m, 1H), 2.18-2.24 (m, 1H), 2.24 (s, 3H), 2.37 (dd, J = 14.91, 5.66 Hz, 1H), 2.77-2.83 (m, 1H), 2.89-2.94 (m, 1H), 3.75- 3.82 (m, 1H), 7.06 (d, J = 8.55 Hz, 1H), 7.25 (s, 1H), 7.36 (s, 1H), 7.45 (d, J = 8.09 Hz, 1H), 9.94 (s, 1H)
536
534





E-54


embedded image


(400 MHz, DMSO-D6) 0.55- 0.59 (m, 1H), 0.69-0.74 (m, 1H), 0.92 (dd, J = 8.38, 2.21 Hz, 2H), 1.63 (s, 6H), 1.76-1.95 (m, 5H), 2.19 (s, 3H), 2.55- 2.68 (m, 2H), 3.51-3.58 (m, 1H), 6.89 (d, J = 8.20 Hz, 1H), 7.09 (s, 1H), 7.17 (s, 1H), 7.41 (d, J = 8.16 Hz, 1H), 9.76 (br s, 1H)
554
552





E-55


embedded image


(400 MHz, DMSO-D6) δ: 0.52- 0.56 (1H, m), 0.57-0.71 (1H, m), 0.96 (2H, dq, J = 8.73, 2.08 Hz), 1.04 (6H, d, J = 6.94 Hz), 1.77-1.90 (5H, m), 2.64 (1H, ddd, J = 28.32, 13.76, 6.59 Hz), 2.89 (2H, ddd, J = 27.63, 15.26, 7.63 Hz), 3.55 (1H, t, J = 7.28 Hz), 7.20 (1H, d, J = 8.29 Hz), 7.43 (1H, dd, J = 10.52, 2.43 Hz), 7.46 (1H, s),
540
538




7.81 (1H, t, J = 8.67 Hz), 10.33






(1H, br s).



















TABLE 123










MS











Ex-


M + H
M − H


am-


or
or


ple
Chemical structure
NMR
M − Na + H
M − Na − H





E-56


embedded image


(400 MHz, DMSO-d6) 0.48- 0.58 (m, 1H), 0.62-0.72 (m, 1H), 0.87-1.02 (m, 2H), 0.97 (s, 9H), 1.69-1.80 (m, 1H), 1.80-1.95 (m, 4H), 2.77 (s, 2H), 2.81 (dd, J = 15.20, 6.40 Hz, 1H), 2.89 (dd, J = 15.20, 9.20 Hz, 1H), 3.48-3.58 (m, 1H), 6.74 (s, 1H), 7.13-7.21 (m, 1H), 7.35-7.44 (m, 1H), 7.81 (t, J = 8.40 Hz, 1H), 10.27 (brs, 1H)
518
516





E-57


embedded image


(400 MHz, DMSO-d6) 0.47-0.57 (m, 1H), 0.61-0.72 (m, 1H), 0.87- 1.02 (m, 2H), 0.97 (s, 9H), 1.69- 1.80 (m, 1H), 1.81-1.99 (m, 4H), 2.77 (s, 2H), 2.79 (dd, J = 14.80, 6.80 Hz, 1H), 2.87 (dd, J = 14.80, 8.00 Hz, 1H), 3.49-3.60 (m, 1H), 6.75 (s, 1H), 7.16 (ddd, J = 8.80, 8.80, 2.80 Hz, 1H), 7.43 (dd, J = 8.80, 2.80 Hz, 1H), 7.53 (dd, J = 8.80, 6.00 Hz, 1H), 10.04 (brs, 1H)
518
516





E-58


embedded image


(400 MHz, DMSO-d6) 0.43-0.55 (m, 1H), 0.59-0.72 (m, 1H), 0.85- 1.02 (m, 2H), 0.95 (s, 9H), 1.67- 1.78 (m, 1H), 1.78-1.98 (m, 4H), 2.76 (s, 2H), 2.82 (dd, J = 15.20, 6.80 Hz, 1H), 2.90 (dd, J = 15.20, 8.40 Hz, 1H), 3.47-3.59 (m, 1H), 6.73 (s, 1H), 7.34 (dd, J = 8.80, 2.40 Hz, 1H), 7.59 (d, J = 2.40 Hz, 1H), 7.61 (d, J = 8.80 Hz, 1H), 10.03 (brs, 1H)
534
532





E-59


embedded image


(400 MHz, DMSO-d6) 0.50-0.57 (m, 1H), 0.64-0.71 (m, 1H), 0.89- 0.97 (m, 2H), 1.63-1.78 (m, 8H), 1.83-1.92 (m, 4H), 2.03-2.12 (m, 2H), 2.81-2.94 (m, 2H), 3.49-3.56 (m, 1H), 6.74 (s, 1H), 7.20 (d, J = 8.82 Hz, 1H), 7.43 (dd, J = 10.59, 2.21 Hz, 1H), 7.81 (t, J = 8.60 Hz, 1H), 10.27 (s, 1H)
516
514





E-60


embedded image


(400 MHz, DMSO-d6) 0.48-0.56 (m, 1H), 0.64-0.71 (m, 1H), 0.89- 0.96 (m, 2H), 1.62-1.78 (m, 8H), 1.83-1.94 (m, 4H), 2.03-2.12 (m, 2H), 2.77-2.91 (m, 2H), 3.50-3.56 (m, 1H), 6.75 (s, 1H), 7.17 (td, J = 8.66, 2.79 Hz, 1H), 7.44 (dd, J = 8.71, 2.76 Hz, 1H), 7.52 (dd, J = 8.82, 5.95 Hz, 1H), 10.01 (s, 1H)
516
514



















TABLE 124










MS














M + H
M − H


Ex-


or
or


am-


M − Na +
M − Na −


ple
Chemical structure
NMR
H
H





E-61


embedded image


(400 MHz, DMSO-D6) δ: 0.49- 0.54 (1H, m), 0.65-0.69 (1H, m), 0.94 (2H, dd, J = 8.32, 1.85 Hz), 1.02 (6H, d, J = 6.94 Hz), 1.74-1.94 (5H, m), 2.63 (1H, ddd, J = 28.96, 14.51, 6.99 Hz), 2.84 (2H, ddd, J = 29.71, 15.14, 7.17 Hz), 3.54 (1H, t, J = 7.05 Hz), 7.15 (1H, td, J = 8.67, 3.01 Hz), 7.42 (1H, dd, J = 8.67, 2.89 Hz), 7.45 (1H, s),
540
538




7.52 (1H, dd, J = 9.02, 5.78






Hz), 10.04 (1H, br s).







E-62


embedded image


(400 MHz, DMSO-D6) δ: 1.10 (9H, s), 1.79-1.95 (4H, m), 2.91 (2H, dd, J = 7.39, 2.98 Hz), 3.61 (1H, t, J = 6.51 Hz), 7.20 (1H, dq, J = 8.44, 1.14 Hz), 7.44 (1H, dd, J = 10.59, 2.43 Hz), 7.49 (1H, t, J = 52.82 Hz), 7.56 (1H, s), 7.83 (1H, t, J = 8.60 Hz), 10.35 (1H, br s).
564
562





E-63


embedded image


(400 MHz, DMSO-D6) 0.37- 0.39 (m, 2H), 0.52-0.57 (m, 3H), 0.67-0.72 (m, 1H), 0.89- 0.94 (m, 2H), 1.05 (s, 3H), 1.74- 1.81 (m, 1H), 1.62-1.95 (m, 4H), 2.67-2.78 (m, 2H), 2.81 (s, 2H), 3.50-3.57 (m, 1H), 6.77 (s, 1H), 7.06 (d, J = 7.72 Hz, 1H), 7.32 (s, 1H), 7.53-7.58 (m, 1H), 10.04 (br s, 1H)
516
514





E-64


embedded image


(400 MHz, DMSO-D6) 0.37- 0.39 (m, 2H), 0.51-0.56 (m, 3H), 0.67-0.71 (m, 1H), 0.92- 0.95 (m, 2H), 1.05 (s, 3H), 1.72- 1.79 (m, 1H), 1.82-1.90 (m, 4H), 2.75-2.90 (m, 4H), 3.49- 3.56 (m, 1H), 6.78 (s, 1H), 7.14- 7.18 (m, 1H), 7.35-7.40 (m, 1H), 7.81 (dd, J = 8.70, 8.70 Hz, 1H), 10.31 (br s, 1H)
516
514





E-65


embedded image


(400 MHz, DMSO-d6) 0.43-0.56 (m, 1H), 0.60-0.71 (m, 1H), 0.82-0.71 (m, 2H), 0.95 (s, 9H), 1.67-1.79 (m, 1H), 1.79-1.95 (m, 4H), 2.24 (s, 3H), 2.75 (s, 2H), 2.81 (dd, J = 15.20, 6.00 Hz, 1H), 2.87 (dd, J = 15.20, 8.40 Hz, 1H), 3.45-3.57 (m, 1H), 6.73 (s, 1H), 6.90 (d, J = 8.40 Hz, 1H), 7.00 (d, J = 11.60 Hz, 1H), 7.57 (dd, J = 8.40, 8.00 Hz, 1H), 9.90 (brs, 1H)
498
496



















TABLE 125










MS











Ex-


M + H
M − H


am-


or
or


ple
Chemical structure
NMR
M − Na + H
M − Na − H





E-66


embedded image


(400 MHz, DMSO-D6) δ: 1.09 (9H, s), 1.81-1.92 (4H, m), 2.13 (3H, t, J = 19.30 Hz), 2.89 (2H, dd, J = 10.98, 9.13 Hz), 3.53 (1H, t, J = 7.40 Hz), 7.19 (1H, d, J = 8.09 Hz), 7.42 (1H, d, J = 11.56 Hz), 7.47 (1H, s), 7.81 (1H, t, J = 8.90 Hz), 10.31 (1H, br s).
578
576





E-67


embedded image


(400 MHz, DMSO-d6) 0.51- 0.57 (m, 1H), 0.66-0.73 (m, 3H), 0.93-0.98 (m, 2H), 0.99- 1.02 (m, 2H), 1.16 (s, 3H), 1.76- 1.83 (m, 1H), 1.85-1.93 (m, 4H), 2.83-2.97 (m, 2H), 3.52- 3.58 (m, 1H), 7.20 (d, J = 8.60 Hz, 1H), 7.44 (d, J = 11.03 Hz, 1H), 7.46 (s, 1H), 7.82 (t, J = 8.7 Hz, 1H), 10.27 (s, 1H)
552
550





E-68


embedded image


(400 MHz, DMSO-d6) 0.67-0.71 (m, 2H), 0.90-0.95 (m, 2H), 1.09 (s, 9H), 1.80-1.87 (m, 1H), 2.20 (dd, J = 14.78, 9.48 Hz, 1H), 2.37 (dd, J = 14.67, 5.18 Hz, 1H), 2.86 (dd, J = 15.22, 9.04 Hz, 1H), 2.96 (dd, J = 15.22, 5.29 Hz, 1H), 3.75-3.82 (m, 1H), 7.19 (d, J = 8.82 Hz, 1H), 7.38 (s, 1H), 7.43 (dd, J = 10.59, 2.43 Hz, 1H), 7.86 (t, J = 8.71 Hz, 1H), 10.59 (s, 1H)
540
538





E-69


embedded image


(400 MHz, DMSO-d6) 0.52-0.58 (m, 1H), 0.66-0.71 (m, 1H), 0.89- 0.97 (m, 2H), 1.36 (s, 9H), 1.71-1.78 (m, 1H), 1.83-1.91 (m, 4H), 2.61- 2.94 (m, 2H), 3.49-3.55 (m, 1H), 6.71 (s, 1H), 7.20 (d, J = 8.60 Hz, 1H), 7.43 (dd, J = 10.59, 2.21 Hz, 1H), 7.81 (t, J = 8.60 Hz, 1H), 10.29 (s, 1H)
504
502





E-70


embedded image


(400 MHz, DMSO-d6) 0.49-0.56 (m, 1H), 0.64-0.71 (m, 1H), 0.89- 0.96 (m, 2H), 1.60-1.79 (m, 8H), 1.82-1.95 (m, 4H), 2.02-2.13 (m, 2H), 2.80-2.94 (m, 2H), 3.49-3.56 (m, 1H), 6.74 (d, J = 0.66 Hz, 1H), 7.36 (dd, J = 8.60, 2.43 Hz, 1H), 7.60 (d, J = 0.88 Hz, 1H), 7.62 (d, J = 7.50 Hz, 1H), 10.05 (s, 1H)
532
530



















TABLE 126










MS














M + H
M − H


Ex-


or
or


am-


M − Na +
M − Na −


ple
Chemical structure
NMR
H
H





E-71


embedded image


(400 MHz, DMSO-d6) 0.47- 0.61 (m, 1H), 0.63-0.76 (m, 1H), 0.86-1.00 (m, 2H), 1.38 (s, 3H), 1.62-1.96 (m, 11H), 1.96-2.11 (m, 2H), 2.84 (dd, J = 15.20, 6.40 Hz, 1H), 2.91 (dd, J = 15.20, 8.40 Hz, 1H), 3.47- 3.60 (m, 1H), 6.74 (s, 1H), 7.16- 7.23 (m, 1H), 7.43 (dd, J = 10.40, 2.40 Hz, 1H), 7.81 (dd, J = 8.80, 8.80 Hz, 1H), 10.26 (brs, 1H)
530
528





E-72


embedded image


(400 MHz, DMSO-d6) 0.49-0.59 (m, 1H), 0.62-0.74 (m, 1H), 0.87- 0.98 (m, 2H), 1.39 (s, 3H), 1.65-1.97 (m, 11H), 1.97-2.11 (m, 2H), 2.80 (dd, J = 15.20, 6.40 Hz, 1H), 2.80 (dd, J = 15.20, 8.40 Hz, 1H), 3.48- 3.59 (m, 1H), 6.75 (s, 1H), 7.17 (ddd, J = 8.40, 8.40, 2.80 Hz, 1H), 7.44 (dd, J = 8.40, 2.80 Hz, 1H), 7.53 (dd, J = 9.20, 6.00 Hz, 1H), 10.03 (brs, 1H)
530
528





E-73


embedded image


(400 MHz, DMSO-D6) 0.52-0.58 (m, 1H), 0.67-0.73 (m, 1H), 0.75-0.80 (m, 2H), 0.80-0.87 (m, 2H), 0.91-0.99 (m, 2H), 1.76-1.99 (m, 6H), 2.25 (s, 3H), 2.74-2.87 (m, 2H), 3.51-3.58 (m, 1H), 7.04 (d, J = 8.30 Hz, 1H), 7.24 (s, 1H), 7.41 (d, J = 8.26 Hz, 1H), 7.48 (s, 1H), 9.83 (br s, 1H)
534
532





E-74


embedded image


(400 MHz, DMSO-D6) 0.42-0.51 (m, 1H), 0.58-0.68 (m, 1H), 0.76-0.85 (m, 2H), 0.97 (s, 9H), 1.51-1.71 (m, 1H), 1.72-1.98 (m, 4H), 2.76 (s, 2H), 2.77- 2.84 (m, 2H), 3.58-3.72 (m, 1H), 6.67 (s, 1H), 7.34 (dd, J = 8.60, 2.43 Hz, 1H), 7.56-7.62 (m, 2H), 9.98 (br s, 1H)
534
532





E-75


embedded image


(400 MHz, DMSO-D6) 0.41-0.51 (m, 1H), 0.60-0.68 (m, 1H), 0.74-0.85 (m, 2H), 0.97 (s, 9H), 1.61-1.70 (m, 1H), 1.71-1.99 (m, 4H), 2.25 (s, 3H), 2.71-2.84 (m, 4H), 3.57-3.70 (m, 1H), 6.66 (s, 1H), 7.07 (d, J = 8.38 Hz, 1H), 7.26 (s, 1H), 7.38 (d, J = 8.38 Hz, 1H), 9.70 (br s, 1H)
514
512



















TABLE 127










MS














M + H
M − H





or
or


Example
Chemical structure
NMR
M − Na + H
M − Na − H





E-76


embedded image


(400 MHz, DMSO-D6) 0.42- 0.51 (m, 1H), 0.58-0.68 (m, 1H), 0.75-0.84 (m, 2H), 0.97 (s, 9H), 1.60-1.71 (m, 1H), 1.71-1.94 (m, 4H), 2.76 (s, 2H), 2.78-2.90 (m, 2H), 3.59- 3.69 (m, 1H), 6.67 (s, 1H), 7.20 (dt, J = 8.75, 2.40 Hz, 1H), 7.43 (dd, J = 10.59, 2.40 Hz, 1H), 7.80 (t, J = 8.75 Hz, 1H), 10.20 (br s, 1H)
518
516




















TABLE 128











Infor-


Ex-



mation


am-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure





F-1


embedded image


(400 MHz, CDCl3) 1.34 (t, J = 7.28 Hz, 3H), 3.12 (t, J = 6.62 Hz, 2H), 3.21 (dd, J = 15.22, 8.38 Hz, 2H), 3.34 (td, J = 14.45, 8.45 Hz, 4H), 3.58 (dd, J = 17.97, 9.15 Hz, 1H), 3.94 (q, J = 7.28 Hz, 2H), 7.16 (s, 4H), 7.40 (t, J = 7.83 Hz, 3H), 7.64 (d, J = 8.16 Hz, 1H), 7.79 (t,
411
409





J = 10.03 Hz, 2H), 7.93 (d,







J = 9.26 Hz, 1H), 9.60 (s, 1H)








F2


embedded image


(400 MHz, DMSO-D6) 1.29-1.36 (m, 6H), 2.89 (t, J = 7.61 Hz, 1H), 3.13 (t, J = 11.69 Hz, 1H), 3.32 (dt, J = 29.55, 9.70 Hz, 4H), 3.48 (d, J = 7.28 Hz, 1H), 3.79 (t, J = 8.60 Hz, 1H), 4.05 (dd, J = 13.67, 7.06 Hz, 2H), 7.17 (dd, J = 5.51, 3.31 Hz, 2H), 7.25 (d, J = 3.97 Hz, 2H), 7.44-
425
423





7.52 (m, 3H), 7.57 (d, J = 7.28 Hz,







1H), 7.74 (d, J = 7.94 Hz, 1H), 7.91







(d, J = 8.38 Hz, 2H), 10.02 (s, 1H)








F-3


embedded image


(400 MHz, CDCl3) 1.37 (t, J = 7.28 Hz, 3H), 2.21 (s, 3H), 3.09 (d, J = 6.62 Hz, 2H), 3.16 (d, J = 6.84 Hz, 2H), 3.28 (dd, J = 15.22, 8.60 Hz, 2H), 3.39 (dd, J = 15.22, 9.26 Hz, 2H), 3.62 (dd, J = 17.97, 8.93 Hz, 1H), 3.97 (q, J = 7.28 Hz, 2H), 7.04 (t, J = 8.05 Hz, 1H), 7.14- 7.21 (m, 5H), 7.46 (d, J = 7.94 Hz, 1H), 9.26 (s, 1H)
409
407




















TABLE 129











Infor-


Ex-


MS
mation












am-


M +
M −
of


ple
Chemical structure
NMR
H
H
structure





F-4


embedded image


(400 MHz, CDCl3) 1.04 (dd, J = 9.15, 6.95 Hz, 2H), 1.23 (dd, J = 12.90, 6.95 Hz, 2H), 3.05 (td, J = 7.06, 3.68 Hz, 1H), 3.24 (t, J = 5.18 Hz, 4H), 3.35 (dd, J = 15.44, 8.60 Hz, 2H), 3.45 (dd, J = 15.33, 9.37 Hz, 2H), 3.82-3.91 (m, 1H), 7.17-7.25 (m, 4H), 7.42 (dd, J = 14.78, 7.06 Hz, 3H), 7.64 (d, J = 8.16 Hz, 1H), 7.80 (t, J = 4.52 Hz, 1H), 7.94 (dd, J = 13.12, 5.84 Hz, 2H), 9.14 (s, 1H)
423
421






F-5


embedded image


(400 MHz, CDCl3) 0.98 (t, J = 7.39 Hz, 3H), 3.15 (t, J = 6.18 Hz, 2H), 3.28 (dt, J = 12.28, 5.29 Hz, 4H), 3.41-3.49 (m, 2H), 3.59-3.68 (m, 1H), 3.85 (t, J = 7.83 Hz, 2H), 7.17-7.23 (m, 4H), 7.42 (t, J = 8.16 Hz, 3H), 7.65 (d, J = 8.38 Hz, 1H), 7.80 (t, J = 4.63 Hz, 1H), 7.87 (d, J = 7.50 Hz, 1H), 7.94 (t, J = 4.74 Hz, 1H), 9.24 (s, 1H)
425
423






F-6


embedded image


(400 MHz, CDCl3) 1.56 (d, J = 7.06 Hz, 6H), 3.30 (dd, J = 17.53, 10.48 Hz, 6H), 3.49 (dd, J = 15.44, 9.26 Hz, 2H), 3.68-3.77 (m, 1H), 4.48-4.55 (m, 1H), 7.21 (tt, J = 9.37, 3.23 Hz, 4H), 7.39-7.45 (m, 3H), 7.64 (d, J = 8.16 Hz, 1H), 7.81 (dd, J = 6.18, 3.53 Hz, 1H), 7.96 (d, J = 7.06 Hz, 2H), 9.92 (s, 1H)
425
423




















TABLE 130











Infor-


Ex-


MS
mation












am-


M +
M −
of


ple
Chemical structure
NMR
H
H
structure





F-7


embedded image


(400 MHz, CDCl3) 1.39 (t, J = 7.60 Hz, 2H), 1.76 (ddd, J = 25.33, 11.42, 6.20 Hz, 4H), 2.52 (t, J = 6.03 Hz, 2H), 2.75 (t, J = 5.91 Hz, 2H), 3.11 (s, 4H), 3.32 (dd, J = 15.07, 8.35 Hz, 2H), 3.48 (dd, J = 15.31, 9.51 Hz, 2H), 3.67 (dt, J = 25.28, 7.54 Hz, 1H), 3.98 (q, J = 7.34 Hz, 3H), 6.89 (d, J = 7.65 Hz, 1H), 7.08 (t, J = 7.88 Hz, 1H), 7.18-7.26 (m, 4H), 7.59 (d, J = 7.88 Hz, 1H), 8.08 (s, 1H)
415
413






F-8


embedded image


(400 MHz, CDCl3) 3.08 (t, J = 6.51 Hz, 2H), 3.27 (ddd, J = 31.54, 15.44, 8.71 Hz, 6H), 3.49 (t, J = 13.45 Hz, 3H), 3.55-3.68 (m, 1H), 7.14 (dd, J = 27.79, 8.82 Hz, 4H), 7.42 (dt, J = 22.57, 10.97 Hz, 3H), 7.61 (t, J = 13.56 Hz, 1H), 7.78 (d, J = 7.72 Hz, 2H), 7.92 (d, J = 7.72 Hz, 1H), 9.59 (s, 1H)
397
395






F-9


embedded image


(400 MHz, DMSO-D6) 2.95 (d, J = 34.63 Hz, 4H), 3.23 (dd, J = 22.72, 13.45 Hz, 4H), 3.72 (s, 1H), 7.19 (t, J = 16.54 Hz, 4H), 7.42-7.56 (m, 3H), 7.61-7.68 (m, 1H), 7.71-7.79 (m, 1H), 7.90-7.96 (m, 1H), 8.00-8.09 (m, 1H), 9.84-10.04 (m, 1H), 13.21-13.61 (m, 1H)
383
381




















TABLE 131











Infor-


Ex-



mation


am-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure





F-10


embedded image


(400 MHz, CDCl3) 1.40 (t, J = 7.30 Hz, 3H), 1.70-1.83 (m, 4H), 2.69-2.84 (m, 2H), 2.89 (t, J = 7.07 Hz, 2H), 3.04-3.10 (m, 2H), 3.33 (td, J = 10.03, 3.56 Hz, 2H), 3.45-3.52 (m, 2H), 3.62- 3.71 (m, 1H), 4.01 (q, J = 7.34 Hz, 2H), 5.14 (dd, J = 14.15, 6.03 Hz, 1H), 6.32 (d, J = 8.35 Hz, 1H), 7.06-7.26 (m, 8H)
415
413






F-11


embedded image


(400 MHz, CDCl3) 0.92 (t, J = 14.22 Hz, 6H), 2.02-2.09 (m, 1H), 3.15 (dd, J = 13.67, 7.06 Hz, 2H), 3.24-3.32 (m, 4H), 3.40-3.48 (m, 2H), 3.62 (dd, J = 17.75, 8.71 Hz, 1H), 3.72 (t, J = 8.49 Hz, 2H), 7.20 (td, J = 8.93, 4.04 Hz, 4H), 7.41-7.45 (m, 3H), 7.66 (t, J = 7.83 Hz, 1H), 7.80 (t, J = 4.63 Hz, 1H), 7.91 (dd, J = 13.78, 5.40 Hz, 2H), 9.17 (s, 1H)
439
437






F-12


embedded image


(400 MHz, CDCl3) 1.20 (t, J = 7.28 Hz, 3H), 2.96 (t, J = 8.05 Hz, 2H), 3.09-3.16 (m, 4H), 3.24 (t, J = 6.18 Hz, 2H), 3.73 (q, J = 7.35 Hz, 2H), 7.15-7.25 (m, 5H), 7.49 (tt, J = 19.74, 6.36 Hz, 3H), 7.66 (d, J = 7.94 Hz, 1H), 7.83 (d, J = 7.94 Hz, 1H), 7.97 (dd, J = 17.64, 8.16 Hz, 2H), 9.13 (s, 1H)
399
397




















TABLE 132











Infor-






mation


Ex-


MS
of












am-


M +
M −
struc-


ple
Chemical structure
NMR
H
H
ture





F-13


embedded image


(400 MHz, CDCl3) 0.73-0.82 (m, 2H), 1.09-1.22 (m, 4H), 1.27 (dt, J = 18.38, 5.13 Hz, 3H), 1.47-1.53 (m, 2H), 1.65 (dt, J = 30.07, 13.12 Hz, 5H), 2.56 (dd, J = 9.26, 7.28 Hz, 2H), 3.08 (t, J = 6.84 Hz, 2H), 3.32 (t, J = 6.84 Hz, 2H), 3.84 (q, J = 7.28 Hz, 2H), 7.42 (ddd, J = 17.31, 8.60, 5.18 Hz, 3H), 7.65 (d, J =
405
403





8.16 Hz, 1H), 7.78-7.81 (m, 2H), 7.93-







7.99 (m, 1H), 9.97 (s, 1H)








F-14


embedded image


(400 MHz, CDCl3) 1.12 (t, J = 7.50 Hz, 3H), 2.40 (d, J = 7.50 Hz, 2H), 3.08 (s, 4H), 3.25 (t, J = 8.38 Hz, 4H), 3.78 (t, J = 8.93 Hz, 1H), 7.22 (d, J = 9.70 Hz, 4H), 7.46 (t, J = 7.94 Hz, 3H), 7.67 (d, J = 8.16 Hz, 1H), 7.85 (s, 2H), 7.96 (d, J = 7.28 Hz, 1H), 8.30 (s, 1H)
411
409






F-15


embedded image


(400 MHz, CDCl3) 1.39 (t, J = 7.39 Hz, 3H), 2.28 (s, 3H), 3.12 (dd, J = 9.37, 4.74 Hz, 4H), 3.31 (dd, J = 15.11, 8.27 Hz, 2H), 3.49 (dt, J = 12.57, 5.68 Hz, 2H), 3.62-3.71 (m, 1H), 3.98 (q, J = 7.28 Hz, 2H), 7.08 (d, J = 8.60 Hz, 1H), 7.17- 7.20 (m, 2H), 7.24 (dd, J = 5.29, 3.53 Hz, 2H), 7.34 (s, 1H), 8.05 (d, J = 8.38
435
433





Hz, 1H), 8.10 (s, 1H)








F-16


embedded image


(400 MHz, CDCl3) 1.38 (t, J = 7.39 Hz, 3H), 2.24 (s, 6H), 3.07 (dd, J = 9.59, 4.96 Hz, 4H), 3.31 (dd, J = 15.11, 8.49 Hz, 2H), 3.47 (dd, J = 15.44, 9.48 Hz, 2H), 3.61-3.70 (m, 1H), 3.98 (q, J = 7.28 Hz, 2H), 6.69 (s, 1H), 7.16-7.24 (m, 6H), 8.96 (s, 1H)
389
387




















TABLE 133











Infor-


Ex-


MS
mation












am-


M +
M −
of


ple
Chemical structure
NMR
H
H
structure





F-17


embedded image


(400 MHz, CDCl3) 0.90-0.99 (m, 2H), 1.06-1.21 (m, 3H), 1.26-1.34 (m, 3H), 1.60-1.80 (m, 6H), 2.56 (dd, J = 12.24, 7.17 Hz, 2H), 3.12 (t, J = 6.51 Hz, 2H), 3.27 (t, J = 6.51 Hz, 2H), 3.83-3.91 (m, 2H), 7.47 (tt, J = 14.34, 6.36 Hz, 3H), 7.65 (d, J = 8.16 Hz, 1H), 7.83 (dd, J = 18.53, 7.50 Hz, 2H), 7.96 (d, J = 7.94 Hz, 1H), 9.47 (s, 1H)
391
389






F-18


embedded image


(400 MHz, DMSO-D6) 1.26 (t, J = 7.19 Hz, 3H), 2.70 (t, J = 7.20 Hz, 2H), 2.94 (t, J = 7.30 Hz, 2H), 3.12-3.41 (m, 4H), 3.77 (td, J = 16.12, 7.03 Hz, 1H), 4.00 (q, J = 7.27 Hz, 2H), 4.72 (d, J = 5.57 Hz, 2H), 7.16 (dt, J = 9.43, 3.71 Hz, 2H), 7.23-7.26 (m, 2H), 7.41-7.46 (m, 2H), 7.50-7.57 (m, 2H), 7.83 (dd, J = 5.80, 3.71 Hz, 1H), 7.92-7.95 (m, 1H), 8.04 (t, J = 4.41 Hz, 1H), 8.51 (t, J = 5.80 Hz, 1H)
425
423






F-19


embedded image


(400 MHz, CDCl3) 0.95 (d, J = 6.40 Hz, 6H), 1.33 (t, J = 7.28 Hz, 3H), 1.67 (t, J = 5.95 Hz, 3H), 2.68 (t, J = 7.83 Hz, 2H), 3.13 (t, J = 5.95 Hz, 2H), 3.23 (t, J = 6.18 Hz, 2H), 3.88 (q, J = 7.35 Hz, 2H), 7.48 (tt, J = 17.64, 6.65 Hz, 3H), 7.65 (d, J = 7.94 Hz, 1H), 7.82 (d, J = 8.16 Hz, 1H), 7.94 (t, J = 8.49 Hz, 2H), 9.14 (s, 1H)
365
363




















TABLE 134











Infor-


Ex-


MS
mation












am-


M +
M −
of


ple
Chemical structure
NMR
H
H
structure





F-20


embedded image


(400 MHz, CDCl3) 1.32-1.34 (m, 6H), 1.74- 1.77 (m, 3H), 1.87-1.90 (m, 4H), 2.57 (t, J = 12.02 Hz, 1H), 3.12 (t, J = 6.18 Hz, 2H), 3.24 (t, J = 6.18 Hz, 2H), 3.89 (q, J = 7.35 Hz, 2H), 7.47 (ddd, J = 24.92, 13.23, 5.51 Hz, 3H), 7.65 (d, J = 7.94 Hz, 1H), 7.82 (d, J = 8.16 Hz, 1H), 7.94 (dd, J = 13.56, 8.05 Hz, 2H), 9.25 (s, 1H)
377
375






F-21


embedded image


(400 MHz, CDCl3) 1.12 (t, J = 9.81 Hz, 3H), 1.33 (dt, J = 27.94, 9.92 Hz, 5H), 1.55 (s, 1H), 1.66 (d, J = 13.45 Hz, 2H), 1.81 (d, J = 12.57 Hz, 2H), 2.80 (t, J = 6.95 Hz, 2H), 3.02 (t, J = 6.95 Hz, 2H), 3.32 (dd, J = 15.22, 8.38 Hz, 2H), 3.48 (dd, J = 15.44, 9.48 Hz, 2H), 3.61-3.71 (m, 2H), 3.98 (q, J = 7.28 Hz, 2H), 6.23 (s, 1H), 7.21 (tt, J = 12.68, 4.23 Hz, 4H)
367
365






F-22


embedded image


(400 MHz, CDCl3) 1.35 (t, J = 7.28 Hz, 3H), 2.93 (t, J = 6.62 Hz, 2H), 3.02 (dd, J = 13.23, 6.62 Hz, 2H), 3.29 (dd, J = 15.11, 8.49 Hz, 2H), 3.43 (dd, J = 15.33, 9.37 Hz, 2H), 3.61 (q, J = 9.04 Hz, 1H), 3.95 (q, J = 7.35 Hz, 2H), 4.40 (d, J = 5.95 Hz, 2H), 7.17-7.24 (m, 9H), 7.43 (s, 1H)
375
373




















TABLE 135







Ex-


MS
Information of












ample
Chemical structure
NMR
M + H
M − H
structure















F-23


embedded image


(400 MHz, CDCl3) 1.39 (t, J = 7.28 Hz, 3H), 3.08 (dd, J = 5.07, 3.31 Hz, 4H), 3.32 (dd, J = 15.22, 8.38 Hz, 2H), 3.47 (dd, J = 15.33, 9.37 Hz, 2H), 3.65 (q, J = 8.97 Hz, 1H), 3.99 (q, J = 7.28 Hz, 2H), 7.04 (t, J = 7.50 Hz, 1H), 7.21 (ddd, J = 16.21, 7.83, 5.07 Hz, 6H), 7.54
361
359





(d, J = 7.50 Hz, 2H), 9.22 (s, 1H)








F-24


embedded image


(400 MHz, CDCl3) 1.36 (t, J = 7.28 Hz, 3H), 1.65 (s, 6H), 1.76 (s, 3H), 1.94 (d, J = 2.87 Hz, 6H), 2.73 (t, J = 6.95 Hz, 2H), 2.99 (t, J = 6.95 Hz, 2H), 3.32 (dd, J = 15.11, 8.27 Hz, 2H), 3.49 (dd, J = 15.22, 9.48 Hz, 2H), 3.65 (q, J = 9.04 Hz, 1H), 3.97 (q, J = 7.35 Hz, 2H), 5.68 (s, 1H), 7.17-7.20 (m, 2H), 7.24 (t,
419
417





J = 4.41 Hz, 2H)








F-25


embedded image


(400 MHz, CDCl3) 0.94 (t, J = 13.78 Hz, 9H), 1.33 (t, J = 7.28 Hz, 3H), 1.64-1.68 (m, 2H), 2.61- 2.66 (m, 2H), 3.13 (t, J = 6.40 Hz, 2H), 3.24 (t, J = 6.29 Hz, 2H), 3.88 (q, J = 7.28 Hz, 2H), 7.48 (ddd, J = 26.91, 14.22, 6.29 Hz, 3H), 7.66 (d, J = 8.16 Hz, 1H), 7.82 (d,
379
377





J = 7.94 Hz, 1H), 7.93 (dd, J = 13.23,







7.94 Hz, 2H), 9.22 (s, 1H)




















TABLE 136







Ex-


MS
Information












ample
Chemical structure
NMR
M + H
M − H
of structure





F-26


embedded image


(400 MHz, DMSO-D6) 1.37 (t, J = 7.17 Hz, 3H), 1.56 (dd, J = 8.71, 5.62 Hz, 2H), 2.66 (d, J = 9.26 Hz, 1H), 3.26-3.36 (m, 5H), 3.84 (t, J = 8.49 Hz, 1H), 4.17 (t, J = 4.85 Hz, 2H), 7.16-7.19 (m, 2H), 7.27 (dd, J = 5.29, 3.31 Hz, 2H), 7.48-7.58 (m, 3H), 7.77 (t, J = 6.84 Hz, 2H), 7.95 (dd, J = 6.18, 3.31 Hz, 1H), 8.11 (d, J = 9.26 Hz, 1H), 10.37 (s, 1H)
423
421
Racemic form





F-27


embedded image


(400 MHz, DMSO-D6) 1.34 (t, J = 7.06 Hz, 3H), 1.48 (d, J = 3.53 Hz, 1H), 1.88 (t, J = 10.59 Hz, 1H), 2.56 (dd, J = 14.00, 6.29 Hz, 1H), 3.18- 3.23 (m, 5H), 3.75 (dd, J = 17.09, 8.49 Hz, 1H), 4.10 (d, J = 6.84 Hz, 2H), 7.15 (dd, J = 5.29, 3.31 Hz, 2H), 7.22 (dd, J = 11.03, 4.19 Hz, 2H), 7.47 (tt, J = 18.86, 6.80 Hz, 4H), 7.72 (d, J = 7.06 Hz, 1H), 7.94 (dt, J = 22.50, 4.69 Hz, 2H), 10.20 (s, 1H)
423
421
Racemic form





F-28


embedded image


(400 MHz, CDCl3) 0.84 (t, J = 7.17 Hz, 6H), 1.18-1.38 (m, 11H), 2.83 (dd, J = 13.78, 6.95 Hz, 2H), 3.03 (t, J = 6.84 Hz, 2H), 3.31 (dd, J = 15.22, 8.38 Hz, 2H), 3.48 (dd, J = 15.44, 9.26 Hz, 2H), 3.61- 3.71 (m, 1H), 3.86 (s, 1H), 3.97 (q, J = 7.28 Hz, 2H), 6.00 (s, 1H), 7.17- 7.20 (m, 2H), 7.24 (dd, J = 5.29,
383
381





3.53 Hz, 2H)




















TABLE 137







Ex-



Informa-


am-


MS
tion of












ple
Chemical structure
NMR
M + H
M − H
structure





F-29


embedded image


(400 MHz, CDCl3) 1.43 (t, J = 7.28 Hz, 3H), 3.12 (dd, J = 9.04, 4.41 Hz, 4H), 3.35 (dd, J = 15.33, 8.49 Hz, 2H), 3.47 (dd, J = 15.33, 9.37 Hz, 2H), 3.70 (t, J = 9.04 Hz, 1H), 4.03 (q, J = 7.28 Hz, 2H), 6.98 (t, J = 1.87 Hz, 1H), 7.18 (dd, J = 5.18, 3.42 Hz, 2H), 7.23 (t, J = 4.41 Hz, 2H), 7.54 (d, J = 1.76
429
427





Hz, 2H), 10.15 (s, 1H)








F-30


embedded image


(400 MHz, CDCl3) 1.39 (t, J = 7.28 Hz, 3H), 3.10 (t, J = 6.40 Hz, 2H), 3.17 (t, J = 6.06 Hz, 2H), 3.32 (dd, J = 15.11, 8.27 Hz, 2H), 3.46- 3.52 (m, 2H), 3.62-3.71 (m, 1H), 3.98 (q, J = 7.28 Hz, 2H), 7.15-7.25 (m, 6H), 8.21 (d, J = 7.06 Hz, 1H), 8.57 (s, 1H)
429
427






F-31


embedded image


(400 MHz, CDCl3) 1.39 (t, J = 7.39 Hz, 3H), 3.12 (dd, J = 20.29, 6.40 Hz, 4H), 3.32 (dd, J = 15.11, 8.27 Hz, 2H), 3.48 (dd, J = 15.44, 9.48 Hz, 2H), 3.62-3.71 (m, 1H), 3.98 (q, J = 7.28 Hz, 2H), 7.17- 7.26 (m, 6H), 8.23 (d, J = 8.82 Hz, 1H), 8.52 (s, 1H)
429
427






F-32


embedded image


(400 MHz, CDCl3) 1.28-1.37 (m, 3H), 1.50 (t, J = 9.81 Hz, 3H), 2.85 (dd, J = 16.10, 3.53 Hz, 1H), 3.09- 3.69 (m, 7H), 3.83-4.02 (m, 2H), 7.21 (dt, J = 19.92, 4.74 Hz, 4H), 7.39-7.44 (m, 3H), 7.64 (d, J = 8.16 Hz, 1H), 7.83 (tt, J = 14.67, 5.77 Hz, 3H), 8.86 (s, 1H)
425
423
Racemic form




















TABLE 138







Ex-


MS
Information of












ample
Chemical structure
NMR
M + H
M − H
structure





F-33


embedded image


(400 MHz, DMSO-D6) 1.34 (dd, J = 15.55, 7.39 Hz, 6H), 2.94 (s, 1H), 3.33-3.90 (m, 9H), 7.17 (t, J = 2.65 Hz, 2H), 7.25 (s, 2H), 7.46- 7.58 (m, 4H), 7.75 (d, J = 9.26 Hz, 1H), 7.91 (d, J = 7.28 Hz, 2H), 10.04 (s, 1H)
425
423
Racemic form





F-34


embedded image


(400 MHz, DMSO-D6) 1.37 (t, J = 7.17 Hz, 3H), 3.19-3.42 (m, 6H), 3.87 (t, J = 8.60 Hz, 1H), 4.18 (dd, J = 16.87, 9.37 Hz, 2H), 5.27 (s, 1H), 6.03 (brs, 1H), 7.17-7.20 (m, 2H), 7.27 (s, 2H), 7.46-7.54 (m, 3H), 7.66 (d, J = 7.50 Hz, 1H), 7.76 (d, J = 8.16 Hz, 1H), 7.92 (t,
427
425
Racemic form




J = 4.63 Hz, 1H), 8.09 (d, J = 6.84 Hz,







1H), 10.11 (s, 1H)








F-35


embedded image


(400 MHz, CDCl3) 0.84-0.91 (m, 2H), 1.13-1.27 (m, 7H), 1.50- 1.68 (m, 9H), 1.80-1.99 (m, 5H), 2.20-2.25 (m, 1H), 2.55-2.61 (m, 2H), 2.98-3.04 (m, 1H), 3.17- 3.23 (m, 1H), 3.66-3.75 (m, 1H), 3.87-3.95 (m, 1H), 7.36 (t, J = 7.86 Hz, 1H), 7.42-7.50 (m, 2H), 7.52-7.64 (m, 3H), 7.81- 7.77 (m, 2H)
459
457
Racemic form





F-36


embedded image


(400 MHz, CDCl3) 0.62 (q, J = 12.28 Hz, 2H), 1.03-1.11 (m, 3H), 1.36-1.53 (m, 8H), 1.59 (d, J = 8.60 Hz, 3H), 1.75-1.80 (m, 2H), 2.50 (dt, J = 17.64, 6.56 Hz, 3H), 3.19 (s, 1H), 3.98 (q, J = 7.28 Hz, 2H), 7.45-7.49 (m, 3H), 7.71 (d, J = 8.38 Hz, 1H), 7.86 (d, J = 7.72 Hz, 2H), 8.14 (t, J = 4.63 Hz, 1H), 9.99 (s, 1H)
417
415
Racemic form




















TABLE 139







Ex-



Informa-


am-


MS
tion of












ple
Chemical structure
NMR
M + H
M − H
structure





F-37


embedded image


(400 MHz, CDCl3) 0.85-0.95 (m, 2H), 1.08-1.20 (m, 3H), 1.32 (dt, J = 15.07, 5.18 Hz, 3H), 1.67 (dt, J = 30.29, 11.08 Hz, 9H), 2.17 (dt, J = 23.23, 7.77 Hz, 2H), 2.46 (d, J = 7.28 Hz, 1H), 2.66 (ddt, J = 26.10, 13.75, 4.02 Hz, 2H), 3.96 (dtd, J = 40.91, 14.58, 7.24 Hz, 2H), 7.33 (td, J = 13.78, 7.06 Hz, 1H), 7.41- 7.52 (m, 3H), 7.66 (dd, J = 23.38, 7.28 Hz, 2H), 7.78 (d, J = 7.28 Hz, 1H), 8.73 (s, 1H)
417
415
Racemic form





F-38


embedded image


(400 MHz, DMSO-D6) 0.86-0.95 (m, 2H), 1.07-1.38 (m, 7H), 1.53- 1.76 (m, 7H), 2.16-2.25 (m, 6H), 2.63-2.69 (m, 2H), 2.83 (dd, J = 16.43, 9.81 Hz, 2H), 2.92 (t, J = 6.84 Hz, 2H), 3.91 (q, J = 7.20 Hz, 2H), 6.66 (s, 1H), 7.21 (t, J = 19.19 Hz, 2H), 9.90 (d, J = 18.97 Hz, 1H)
383
381






F-39


embedded image


(400 MHz, CDCl3) 0.92 (dt, J = 27.86, 7.11 Hz, 2H), 1.09-1.34 (m, 7H), 1.67 (ddt, J = 30.21, 13.45, 5.98 Hz, 7H), 2.25 (d, J = 16.76 Hz, 3H), 2.65-2.69 (m, 2H), 3.09 (dt, J = 34.92, 6.18 Hz, 4H), 3.88 (q, J = 7.28 Hz, 2H), 7.08 (t, J = 7.94 Hz, 1H), 7.17 (d, J = 7.72 Hz, 1H), 7.55 (t, J = 9.26 Hz, 1H), 9.15 (s, 1H)
403
401




















TABLE 140







Ex-



Informa-


am-


MS
tion of












ple
Chemical structure
NMR
M + H
M − H
structure















F-40


embedded image


(400 MHz, CDCl3) 0.90-0.99 (m, 2H), 1.10-1.38 (m, 7H), 1.62-1.78 (m, 7H), 2.17 (s, 3H), 2.28 (t, J = 9.15 Hz, 3H), 2.68 (dt, J = 7.87, 3.58 Hz, 2H), 3.07 (ddd, J = 15.82, 10.20, 3.58 Hz, 4H), 3.84-3.92 (m, 2H), 6.98 (d, J = 15.88 Hz, 2H), 7.56 (dd, J = 15.44, 11.03 Hz, 1H), 8.36 (s, 1H)
383
381






F-41


embedded image


(400 MHz, CDCl3) 0.91- 1.00 (m, 2H), 1.11-1.39 (m, 7H), 1.64-1.83 (m, 7H), 2.29 (d, J = 15.66 Hz, 3H), 2.65 (tt, J = 10.48, 6.10 Hz, 2H), 2.89 (dd, J = 10.48, 3.64 Hz, 2H), 2.97 (ddd, J = 16.82, 8.55, 4.47 Hz, 2H), 3.84-3.92 (m, 2H), 4.38 (dd, J = 12.13, 5.95 Hz, 2H), 6.93 (s, 1H), 6.99-
383
441 (+CH3CO2)








7.08 (m, 3H), 7.19 (ddd, J =







16.32, 9.26, 3.42 Hz, 1H)








F-42


embedded image


(400 MHz, CDCl3) 0.91-1.00 (m, 2H), 1.10-1.38 (m, 7H), 1.64-1.83 (m, 7H), 2.34 (dd, J = 10.26, 6.51 Hz, 3H), 2.65 (tt, J = 10.48, 6.03 Hz, 2H), 2.89 (dd, J = 10.37, 3.75 Hz, 2H), 2.98 (dt, J = 16.10, 4.02 Hz, 2H), 3.84-3.90 (m, 2H), 4.38 (dd, J = 12.13, 5.73 Hz, 2H), 6.94 (s, 1H), 7.02 (ddd, J = 12.46,
383
441 (+CH3CO2)








6.51, 4.96 Hz, 3H), 7.18 (dt,







J = 13.89, 5.57 Hz, 1H)




















TABLE 141







Ex-



Informa-


am-


MS
tion of












ple
Chemical structure
NMR
M + H
M − H
structure





F- 43


embedded image


(400 MHz, CDCl3) 0.88-1.00 (m, 2H), 1.11-1.37 (m, 7H), 1.64-1.78 (m, 7H), 2.32 (d, J = 10.14 Hz, 3H), 2.66 (tt, J = 8.27, 2.72 Hz, 2H),2.79- 2.89 (m, 2H), 2.96-3.00 (m, 2H), 3.83-3.92 (m, 2H), 4.37 (t, J = 8.71 Hz, 2H), 7.03 (d, J = 5.29 Hz, 1H), 7.10 (dt, J =
383
441 (+CH3CO2)





14.26, 4.14 Hz, 4H)








F- 44


embedded image


(400 MHz, CDCl3) 0.90- 0.99 (m, 2H), 1.16-1.34 (m, 7H), 1.69 (ddd, J = 35.56, 16.60, 10.53 Hz, 7H), 2.60-2.66 (m, 2H), 2.86 (t, J = 6.62 Hz, 2H), 2.97 (dd, J = 8.27, 4.52 Hz, 2H), 3.82 (q, J = 7.35 Hz, 2H),
419
477 (+CH3CO2)





4.86 (d, J = 5.51 Hz, 2H), 6.77







(s, 1H), 7.39 (q, J = 6.62 Hz,







2H), 7.46-7.53 (m,







2H), 7.76-7.80 (m, 1H),







7.85 (dd, J = 7.17, 2.10 Hz,







1H), 7.97 (t, J = 4.52 Hz, 1H)








F- 45


embedded image


(400 MHz, CDCl3) 0.96 (q, J = 11.25 Hz, 2H), 1.24 (dtt, J = 52.05, 17.31, 5.84 Hz, 7H), 1.59-1.79 (m, 7H), 2.67 (dt, J = 7.94, 3.53 Hz, 2H), 2.89 (t, J = 6.62 Hz, 2H), 2.96-3.02 (m, 2H), 3.86 (q, J = 7.35 Hz, 2H), 4.40 (d, J = 5.95 Hz, 2H), 6.77 (s, 1H), 7.20-7.32 (m, 5H)
369
427 (+CH3CO2)






F- 46


embedded image


(400 MHz, CDCl3) 0.82-1.03 (m, 9H), 1.28-1.39 (m, 3H), 1.66 (ddt, J = 25.33, 18.64, 8.10 Hz, 2H), 2.16- 2.38 (m, 6H), 2.64 (tt, J = 6.73, 3.90 Hz, 2H), 2.89-3.19 (m, 4H), 3.91 (ddd, J = 31.26, 14.83, 9.65 Hz, 2H), 6.71 (d, J = 11.47 Hz, 1H), 7.17 (t,
357
355





J = 9.04 Hz, 2H), 9.42 (s, 1H)




















TABLE 142







Ex-



Informa-


am-


MS
tion of












ple
Chemical structure
NMR
M + H
M − H
structure















F-47


embedded image


(400 MHz, CDCl3) 0.96 (dq, J = 26.96, 5.37 Hz, 9H), 1.30 (q, J = 11.10 Hz, 3H), 1.63-1.68 (m, 2H), 2.10-2.22 (m, 3H), 2.30 (t, J = 15.33 Hz, 3H), 2.66 (dt, J = 16.10, 7.00 Hz, 2H), 3.07 (ddd, J = 16.49, 10.20, 3.58 Hz, 4H), 3.88 (q, J = 7.35 Hz, 2H), 6.96 (s, 2H), 7.58 (t, J = 4.41 Hz, 1H), 8.40 (s, 1H)
357
355






F-48


embedded image


(400 MHz, CDCl3) 1.11 (s, 2H), 1.33 (dd, J = 17.09, 9.81 Hz, 3H), 1.56 (dd, J = 22.72, 13.89 Hz, 4H), 1.76 (dd, J = 15.77, 7.83 Hz, 5H), 2.17 (s, 3H), 2.26 (s, 3H), 2.67 (t, J = 7.94 Hz, 2H), 3.09 (dd, J = 15.55, 6.06 Hz, 4H), 3.90 (q, J = 7.35 Hz, 2H), 6.94 (d, J = 7.28 Hz, 2H), 7.49 (d, J = 8.38 Hz, 1H), 8.79 (s, 1H)
369
367






F-49


embedded image


(400 MHz, CDCl3) 1.12 (s, 2H), 1.34 (t, J = 7.28 Hz, 3H), 1.56 (d, J = 36.61 Hz, 4H), 1.79 (t, J = 7.72 Hz, 5H), 2.22 (d, J = 18.31 Hz, 6H), 2.69 (t, J = 7.83 Hz, 2H), 3.08 (s, 4H), 3.93 (q, J = 7.35 Hz, 2H), 6.69 (s, 1H), 7.20 (d, J = 17.86 Hz, 2H), 9.53 (s, 1H),
369
367






F-50


embedded image


(400 MHz, CDCl3) 0.96 (d, J = 6.45 Hz, 6H), 1.32 (t, J = 7.66 Hz, 3H), 1.65-1.71 (m, 3H), 2.27 (s, 6H), 2.66-2.70 (m, 2H), 2.99-3.07 (m, 4H), 3.88 (q, J = 7.39 Hz, 2H), 6.71 (s, 1H), 7.16 (s, 2H), 8.71 (s, 1H)
343
341




















TABLE 143







Ex-



Informa-


am-


MS
tion of












ple
Chemical structure
NMR
M + H
M − H
structure





F-51


embedded image


(400 MHz, CDCl3) 0.96 (d, J = 6.45 Hz, 6H), 1.32 (t, J = 7.45 Hz, 3H), 1.64-1.69 (m, 3H), 2.18 (s, 3H), 2.26 (s, 3H), 2.66-2.70 (m, 2H), 3.05-3.08 (m, 4H), 3.88 (q, J = 7.39 Hz, 2H), 6.96-6.98 (m, 2H), 7.61 (d, J = 8.87 Hz, 1H), 8.20 (s, 1H)
343
341






F-52


embedded image


(400 MHz, CDCl3) 0.95 (t, J = 5.64 Hz, 6H), 1.33 (t, J = 8.87 Hz, 3H), 1.64-1.69 (m, 3H), 2.28 (s, 3H), 2.66-2.70 (m, 2H), 3.04- 3.12 (m, 4H), 3.88 (q, J = 7.25 Hz, 2H), 7.08 (dd, J = 8.46, 8.06 Hz, 1H), 7.16 (d, J = 8.06 Hz, 1H), 7.63 (d, J = 7.66 Hz, 1H), 8.79 (s, 1H)
363
361






F-53


embedded image


(400 MHz, CDCl3) 0.96 (s, 9H), 1.34 (t, J = 7.28 Hz, 3H), 1.63-1.68 (m, 2H), 2.28 (s, 3H), 2.62-2.66 (m, 2H), 3.09 (dt, J = 27.49, 6.06 Hz, 4H), 3.88 (q, J = 7.35 Hz, 2H), 7.08 (t, J = 7.94 Hz, 1H), 7.17 (d, J = 8.16 Hz, 1H), 7.60 (d, J = 7.94 Hz, 1H), 8.98 (s, 1H)
377
375






F-54


embedded image


(400 MHz, CDCl3) 1.12 (s, 2H), 1.33 (t, J = 7.28 Hz, 3H), 1.57 (dd, J = 22.94, 13.89 Hz, 4H), 1.79 (dd, J = 22.27, 14.34 Hz, 5H), 2.27 (s, 3H), 2.68 (t, J = 7.94 Hz, 2H), 3.09 (dd, J = 24.92, 6.62 Hz, 4H), 3.88 (q, J = 7.35 Hz, 2H), 7.08 (t, J = 8.05 Hz, 1H), 7.16 (d, J = 7.72 Hz, 1H), 7.58 (d, J = 7.94 Hz, 1H), 9.04 (s, 1H)
389
387




















TABLE 144







Ex-



Information


am-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure





F-55


embedded image


(400 MHz, CDCl3) 0.93-0.99 (m, 8H), 1.14-1.22 (m, 2H), 1.61- 1.70 (m, 3H), 2.29 (s, 3H), 2.79 (t, J = 7.72 Hz, 2H), 2.94-3.00 (m, 1H), 3.08 (t, J = 6.06 Hz, 2H), 3.17 (t, J = 6.06 Hz, 2H), 7.08 (t, J = 7.94 Hz, 1H), 7.17 (t, J = 8.16 Hz, 1H), 7.63 (d, J = 7.50 Hz, 1H), 8.85 (s, 1H)
375
373






F-56


embedded image


(400 MHz, CDCl3) 0.93-1.00 (m, 8H), 1.21 (q, J = 6.57 Hz, 2H), 1.61-1.70 (m, 3H), 2.80 (t, J = 7.77 Hz, 2H), 2.98 (td, J = 7.13, 3.48 Hz, 1H), 3.04 (t, J = 6.49 Hz, 2H), 3.18 (t, J = 6.49 Hz, 2H), 7.06 (t, J = 7.30 Hz, 1H), 7.28 (t, J = 7.28 Hz, 2H), 7.54 (d, J = 8.35 Hz, 2H), 9.17 (s, 1H)
327
325






F-57


embedded image


(400 MHz, CDCl3) 0.92-1.00 (m, 8H), 1.16-1.21 (m, 2H), 1.65- 1.75 (m, 3H), 2.76-2.80 (m, 2H), 2.79 (dt, J = 11.98, 4.58 Hz, 2H), 2.88 (t, J = 6.84 Hz, 1H), 3.12 (t, J = 6.84 Hz, 2H), 4.41 (d, J = 6.03 Hz, 2H), 6.83 (brs, 1H), 7.20-7.34 (m, 5H)
341
339






F-58


embedded image


(400 MHz, CDCl3) 0.93-0.99 (m, 8H), 1.16-1.21 (m, 2H), 1.62- 1.72 (m, 3H), 2.77-2.81 (m, 6H), 2.93-2.99 (m, 1H), 3.06 (t, J = 6.96 Hz, 2H), 3.48 (q, J = 6.72 Hz, 2H), 6.43 (brs, 1H), 7.17-7.30 (m, 5H)
355
353




















TABLE 145







Ex-



Informa-


am-


MS
tion of












ple
Chemical structure
NMR
M + H
M − H
structure





F-59


embedded image


(400 MHz, CDCl3) 0.92-0.98 (m, 8H), 1.15-1.20 (m, 2H), 1.65- 1.70 (m, 3H), 2.28 (s, 3H), 2.75- 2.79 (m, 2H), 2.86 (t, J = 6.84 Hz, 2H), 2.92-2.98 (m, 1H), 3.11 (t, J = 6.84 Hz, 2H), 4.39 (d, J = 5.51 Hz, 2H), 6.56 (brs, 1H), 7.11-7.19 (m, 4H)
355
353






F-60


embedded image


(400 MHz, CDCl3) 0.92-0.97 (m, 8H), 1.15-1.20 (m, 2H), 1.64- 1.71 (m, 3H), 2.32 (s, 3H), 2.76- 2.80 (m, 2H), 2.87 (t, J = 6.95 Hz, 2H), 2.93-2.98 (m, 1H), 3.12 (t, J = 6.84 Hz, 2H), 4.36 (d, J = 5.95 Hz, 2H), 6.66 (brs, 1H), 7.00-7.06 (m, 3H), 7.18 (t, J = 7.60, 1H)
355
353






F-61


embedded image


(400 MHz, CDCl3) 0.92-1.00 (m, 8H), 1.18 (td, J = 6.96, 5.95 Hz, 2H), 1.67-1.72 (m, 3H), 2.32 (s, 3H), 2.78 (t, J = 7.68 Hz, 2H), 2.86 (t, J = 6.84 Hz, 2H), 2.93-2.98 (m, 1H), 3.12 (t, J = 6.84 Hz, 2H), 4.36 (d, J = 5.80 Hz, 2H), 6.69 (brs, 1H), 7.11 (s, 4H)
355
353






F-62


embedded image


(400 MHz, CDCl3) 0.89 (dt, J = 8.01, 3.47 Hz, 2H), 0.97 (d, J = 6.18 Hz, 6H), 1.14 (td, J = 8.44, 4.19 Hz, 2H), 1.42 (d, J = 7.06 Hz, 3H), 1.68 (dt, J = 13.75, 5.68 Hz, 3H), 2.76-2.85 (m, 4H), 2.88- 2.94 (m, 1H), 3.06-3.11 (m, 2H), 4.99-5.07 (m, 1H), 6.65 (d, J = 7.06 Hz, 1H), 7.19-7.30 (m, 5H)
355
353




















TABLE 146







Ex-



Informa-


am-


MS
tion of












ple
Chemical structure
NMR
M + H
M − H
structure





F-63


embedded image


(400 MHz, CDCl3) 0.90 (dt, J = 7.88, 3.48 Hz, 2H), 0.98 (d, J = 6.26 Hz, 6H), 1.15 (td, J = 8.41, 4.17 Hz, 2H), 1.43 (d, J = 6.96 Hz, 3H), 1.65-1.75 (m, 3H), 2.77- 2.86 (m, 4H), 2.89-2.95 (m, 1H), 3.07-3.12 (m, 2H), 5.00-5.07 (m, 1H), 6.68 (d, J = 7.88 Hz, 1H), 7.20- 7.31 (m, 5H)
355
353






F-64


embedded image


(400 MHz, CDCl3) 0.95-0.99 (m, 8H), 1.16-1.22 (m, 2H), 1.62- 1.70 (m, 3H), 2.25 (s, 3H), 2.79 (t, J = 7.83 Hz, 2H), 2.94-3.00 (m, 1H), 3.08 (dd, J = 11.58, 4.96 Hz, 2H), 3.17 (dd, J = 11.36, 4.74 Hz, 2H), 7.02 (t, J = 7.61 Hz, 1H), 7.13- 7.18 (m, 2H), 7.83 (d, J = 7.94 Hz, 1H), 8.44 (s, 1H)
341
339






F-65


embedded image


(400 MHz, CDCl3) 0.95-0.99 (m, 8H), 1.20 (q, J = 6.65 Hz, 2H), 1.61- 1.72 (m, 3H), 2.32 (s, 3H), 2.80 (t, J = 7.88 Hz, 2H), 2.95-3.04 (m, 3H), 3.17 (t, J = 6.61 Hz, 2H), 6.88 (d, J = 7.42 Hz, 1H), 7.16 (t, J = 7.65 Hz, 1H), 7.34 (d, J = 8.35 Hz, 1H), 7.37 (s, 1H), 8.96 (s, 1H)
341
339






F-66


embedded image


(400 MHz, CDCl3) 0.95-0.99 (m, 8H), 1.20 (q, J = 6.65 Hz, 2H), 1.63- 1.71 (m, 3H), 2.29 (s, 3H), 2.80 (t, J = 7.77 Hz, 2H), 2.95-3.03 (m, 3H), 3.17 (t, J = 6.61 Hz, 2H), 7.08 (d, J = 8.12 Hz, 2H), 7.41 (d, J = 8.35 Hz, 2H), 8.95 (s, 1H)
341
339




















TABLE 147











Infor-






ma-


Ex-



tion of


am-


MS
struc-












ple
Chemical structure
NMR
M + H
M − H
ture





F- 67


embedded image


(400 MHz, CDCl3) 0.90-0.98 (m, 8H), 1.15-1.20 (m, 2H), 1.66-1.72 (m, 3H), 2.31 (s, 3H), 2.71-12.81 (m, 6H), 2.92-2.98 (m, 1H), 3.06 (t, J = 6.95 Hz, 2H), 3.45 (dd, J = 13.12, 7.17 Hz, 2H), 6.31 (brs, 1H), 7.05 (d, J = 8.40 Hz, 2H), 7.09 (d, J = 7.94 Hz, 2H)
369
367






F- 68


embedded image


(400 MHz, CDCl3) 0.94- 0.99 (m, 8H), 1.16-1.21 (m, 2H), 1.67-1.72 (m, 3H), 2.33 (s, 3H), 2.73-2.81 (m, 6H), 2.94-2.99 (m, 1H), 3.08 (t, J = 6.96 Hz, 2H), 3.47 (dd, J = 13.10, 7.07 Hz, 2H), 6.33 (brs, 1H), 6.97 (d, J = 7.88 Hz, 1H), 7.01 (s, 1H), 7.03 (d, J = 8.12 Hz, 1H), 7.18 (t, J = 7.54 Hz, 1H)
369
367






F- 69


embedded image


(400 MHz, CDCl3) 0.98 (t, J = 6.84 Hz, 11H), 1.18 (d, J = 5.73 Hz, 2H), 1.63-1.67 (m, 2H), 2.19 (s, 3H), 2.26 (s, 3H), 2.74-2.79 (m, 2H), 2.96-2.99 (m, 1H), 3.05 (t, J = 6.40 Hz, 2H), 3.17 (t, J = 6.40 Hz, 2H), 6.96 (s, 2H), 7.60 (d, J = 8.60 Hz, 1H), 8.35 (s, 1H)
369
367






F- 70


embedded image


(400 MHz, CDCl3) 0.95-1.00 (m, 8H), 1.18-1.23 (m, 2H), 1.65-1.70 (m, 3H), 2.12 (s, 6H), 2.79-2.82 (m, 2H), 2.97-3.02 (m, 1H), 3.17-3.12 (m, 2H), 3.20-3.23 (m, 2H), 7.01-7.09 (m, 3H), 7.98 (brs, 1H)
355
353




















TABLE 148







Ex-



Informa-


am-


MS
tion of












ple
Chemical structure
NMR
M + H
M − H
structure





F-71


embedded image


(400 MHz, CDCl3) 0.95-0.98 (m, 8H), 1.16-1.21 (m, 2H), 1.63- 1.70 (m, 3H), 2.19 (s, 3H), 2.29 (s, 3H), 2.77-2.81 (m, 2H), 2.94- 3.00 (m, 1H), 3.06 (t, J = 6.29 Hz, 2H), 3.17 (t, J = 6.40 Hz, 2H), 6.84 (d, J = 7.72 Hz, 1H), 7.02 (d, J = 7.72 Hz, 1H), 7.65 (s, 1H), 8.30 (brs, 1H)
355
353






F-72


embedded image


(400 MHz, CDCl3) 0.96-0.99 (m, 8H), 1.15-1.23 (m, 5H), 1.67- 1.71 (m, 3H), 2.58 (q, J = 7.50 Hz, 2H), 2.79-2.83 (m, 2H), 2.95- 3.01 (m, 1H), 3.09 (t, J = 6.00 Hz, 2H), 3.19 (t, J = 6.40 Hz, 2H), 7.09 (t, J = 6.96 Hz, 1H), 7.16-7.19 (m, 2H), 7.76 (d, J = 7.88 Hz, 1H), 8.39 (brs, 1H)
355
353






F-73


embedded image


(400 MHz, CDCl3) 0.94-1.00 (m, 8H), 1.17-1.22 (m, 2H), 1.64- 1.70 (m, 3H), 2.79 (dd, J = 9.48, 6.40 Hz, 2H), 2.96-3.02 (m, 1H), 3.06 (t, J = 6.95 Hz, 2H), 3.18 (t, J = 6.84 Hz, 2H), 3.88 (s, 3H), 6.86 (dd, J = 8.05, 1.21 Hz, 1H), 6.93 (td, J = 7.83, 1.32 Hz, 1H), 7.02 (td, J = 7.77, 1.62 Hz, 1H), 8.25 (brs, 1H), 8.31 (dd, J = 7.94, 1.32 Hz, 1H)
357
355






F-74


embedded image


(400 MHz, CDCl3) 0.94-0.98 (m, 8H), 1.16-1.21 (m, 2H), 1.62- 1.71 (m, 3H), 2.19 (s, 3H), 2.21 (s, 3H), 2.79 (t, J = 7.94 Hz, 2H), 2.94- 3.01 (m, 3H), 3.16 (t, J = 6.62 Hz, 2H), 7.02 (d, J = 7.94 Hz, 1H), 7.24- 7.29 (m, 2H), 8.73 (brs, 1H)
355
353




















TABLE 149







Ex-



Informa-


am-


MS
tion of












ple
Chemical structure
NMR
M + H
M − H
structure





F-75


embedded image


(400 MHz, CDCl3) 0.95-0.99 (m, 8H), 1.16-1.23 (m, 8H), 1.63- 1.70 (m, 3H), 2.78-2.82 (m, 2H), 2.95-3.03 (m, 2H), 3.08 (t, J = 6.29 Hz, 2H), 3.18 (t, J = 6.29 Hz, 2H), 7.14-7.16 (m, 2H), 7.24- 7.26 (m, 1H), 7.58-7.60 (m, 1H), 8.27 (brs, 1H)
369
367






F-76


embedded image


(400 MHz, CDCl3) 0.94-0.98 (m, 8H), 1.16-1.22 (m, 2H), 1.62- 1.71 (m, 3H), 2.27 (s, 6H), 2.78- 2.81 (m, 2H), 2.94-3.01 (m, 3H), 3.14-3.17 (m ,2H), 6.70 (s, 1H), 7.16 (s, 2H), 8.77 (brs, 1H)
355
353






F-77


embedded image


(400 MHz, CDCl3) 0.92 (t, J = 7.39 Hz, 3H), 0.95-0.99 (m, 8H), 1.17-1.22 (m, 2H), 1.57 (td, J = 14.94, 7.50 Hz, 2H), 1.63-1.68 (m, 3H), 2.53 (t, J = 7.61 Hz, 2H), 2.78-2.82 (m, 2H), 2.95-3.01 (m, 1H), 3.07 (t, J = 6.40 Hz, 2H), 3.18 (t, J = 6.29 Hz, 2H), 7.07 (t, J = 7.39 Hz, 1H), 7.14-7.19 (m, 2H), 7.73 (d, J = 7.94 Hz, 1H), 8.33 (brs, 1H)
369
367






F-78


embedded image


(400 MHz, CDCl3) 0.99-0.96 (m, 8H), 1.17-1.22 (m, 2H), 1.64- 1.71 (m, 3H), 2.13 (s, 3H), 2.27 (s, 3H), 2.78-2.82 (m, 2H), 2.95- 3.01 (m, 1H), 3.07 (t, J = 5.33 Hz, 2H), 3.19 (t, J = 6.49 Hz, 2H), 6.97 (d, J = 9.51 Hz, 1H), 7.06 (dd, J = 8.12, 7.88 Hz, 1H), 7.49 (d, J = 10.20 Hz, 1H), 8.33 (s, 1H
355
353




















TABLE 150










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-79


embedded image


(400 MHz, CDCl3) 0.94-0.97 (m, 8H), 1.16-1.21 (m, 2H), 1.64- 1.67 (m, 3H), 2.19 (s, 3H), 2.26 (s, 3H), 2.77-2.81 (m, 2H), 2.94- 2.99 (m, 1H), 3.05 (t, J = 6.85 Hz, 2H), 3.17 (t, J = 6.45 Hz, 2H), 6.95- 6.97 (m, 2H), 7.62 (d, J = 8.87 Hz, 1H), 8.28 (s, 1H)
355
353






F-80


embedded image


(400 MHz, CDCl3) 0.95-0.99 (m, 8H), 1.18-1.23 (m, 2H), 1.65- 1.70 (m, 3H), 2.32 (s, 3H), 2.83- 2.79 (m, 2H), 2.94-3.00 (m, 1H), 3.08-3.17 (m, 4H), 8.18 (d, J = 5.64 Hz, 1H), 8.31 (s, 1H), 8.34 (d, J = 5.64 Hz, 1H), 9.53 (s, 1H)
342
340






F-81


embedded image


(400 MHz, CDCl3) 0.92-0.98 (m, 8H), 1.18 (dd, J = 12.68, 6.73 Hz, 2H), 1.60-1.69 (m, 3H), 2.76- 2.80 (m, 2H), 2.94-3.00 (m, 1H), 3.23 (s, 4H), 7.41-7.48 (m, 2H), 7.52 (t, J = 7.17 Hz, 1H), 7.65 (d, J = 8.16 Hz, 1H), 7.82 (d, J = 8.16 Hz, 1H), 7.93 (d, J = 7.50 Hz, 1H), 7.99 (d, J = 8.38 Hz, 1H), 9.30 (s, 1H)
377
375






F-82


embedded image


(400 MHz, CDCl3) 0.95-0.99 (m, 8H), 1.19 (dd, J = 12.79, 7.06 Hz, 2H), 1.63-1.70 (m, 3H), 2.18 (s, 3H), 2.77-2.81 (m, 2H), 2.94- 3.00 (m, 1H), 3.04 (t, J = 6.40 Hz, 2H), 3.17 (t, J = 6.40 Hz, 2H), 3.76 (s, 2H), 6.68-6.70 (m, 2H), 7.51- 7.54 (m, 1H), 8.20 (brs, 1H)
371
369




















TABLE 151










Ms
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-83


embedded image


(400 MHz, CDCl3) 0.96-1.00 (m, 8H), 1.21 (q, J = 6.65 Hz, 2H), 1.67- 1.71 (m, 3H), 1.72-1.82 (m, 1H), 2.49-2.58 (m, 1H), 2.77-2.89 (m, 5H), 2.93-3.02 (m, 2H), 3.14 (t J = 6.96 Hz, 2H), 5.43 (q, J = 7.73 Hz, 1H), 6.45 (d, J = 7.88 Hz, 1H), 7.16- 7.23 (m, 4H)
367
365
Racemic form





F-84


embedded image


(400 MHz, CDCl3) 0.95-0.98 (m, 8H), 1.17-1.22 (m, 2H), 1.63- 1.70 (m, 3H), 2.34 (s 3H), 2.77- 2.81 (m, 2H), 2.94-3.00 (m, 1H), 3.08 (t, J = 5.95 Hz, 3H), 3.17 (d, J = 5.20 Hz, 3H), 7.01 (t, J = 8.16 Hz, 1H), 7.34 (d, J = 8.16 Hz, 1H), 7.68 (d, J = 8.16 Hz, 1H), 8.84 (brs, 1H)
419
417






F-85


embedded image


(400 MHz, CDCl3) 0.95-0.98 (m, 8H), 1.16-1.21 (m, 2H), 1.61- 1.70 (m, 3H), 2.09 (s, 3H), 2.77- 2.81 (m, 2H), 2.94-2.99 (m, 1H), 3.06 (t, J = 6.40 Hz, 2H), 3.17 (t, J = 6.29 Hz, 2H), 3.80 (s, 3H), 6.66 (d, J = 7.94 Hz, 1H), 7.11 (t, J = 8.16 Hz, 1H), 7.38 (d, J = 8.16 Hz, 1H), 8.29 (brs, 1H)
371
369






F-86


embedded image


(400 MHz, DMSO-D6) 0.92 (d, J = 6.26 Hz, 6H), 0.95-0.99 (m, 2H), 1.05-1.10 (m, 2H), 1.55- 1.63 (m, 3H), 2.03 (s, 3H), 2.70- 2.74 (m, 2H), 2.81 (t, J = 7.54 Hz, 2H), 3.01 (t, J = 7.54 Hz, 2H), 3.09- 3.14 (m, 1H), 3.72 (s, 3H), 6.78 (d, J = 7.65 Hz, 1H), 6.84 (d, J = 8.12 Hz, 1H), 7.10 (t, J = 8.00 Hz, 1H), 9.18 (s, 1H)
371
369




















TABLE 152










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-87


embedded image


(400 MHz, CDCl3) 0.95-0.99 (m, 8H), 1.17-1.22 (m, 2H), 1.63- 1.70 (m, 3H), 2.20 (s, 3H) 2.78- 2.82 (m, 2H), 2.94-3.00 (m, 1H), 3.08 (t, J = 5.64 Hz, 2H) 3.18 (t, J = 6.45 Hz, 2H), 4.69 (d, J = 4.84 Hz, 2H), 7.18-7.16 (m, 2H), 7.63 (t, J = 4.63 Hz, 1H), 8.47 (s, 1H)
371
369






F-88


embedded image


(400 MHz, CDCl3) 0.95-0.98 (m, 8H), 1.16-1.22 (m, 2H), 1.64- 1.70 (m, 3H), 2.25 (s, 3H), 2.78- 2.82 (m, 2H), 2.94-3.00 (m, 1H), 3.06 (t, J = 6.04 Hz, 2H), 3.17 (t, J = 6.25 Hz, 2H), 4.61 (d, J = 4.43Hz, 2H), 7.16-7.14 (m, 2H), 7.81 (d, J = 8.87 Hz, 1H), 8.51 (s, 1H)
371
369






F-89


embedded image


(400 MHz, CDCl3) 0.95-0.98 (m, 8H), 1.16-1.21 (m, 2H), 1.64- 1.71 (m, 3H), 2.22 (s, 3H), 2.78- 2.82 (m, 2H), 2.97-3.02 (m, 1H), 3.11-3.21 (m, 4H), 7.05 (dd, J = 7.66, 4.84 Hz, 1H), 7.51 (dd, J = 7.45, 1.01 Hz, 1H), 8.26 (dd, J = 4.63, 1.41 Hz, 1H), 8.60 (s, 1H)
342
340






F-90


embedded image


(400 MHz, CDCl3) 0.95-0.98 (m, 8H), 1.18-1.23 (m, 2H),1.64- 1.68 (m, 3H), 2.28 (s, 3H), 2.78- 2.82 (m, 2H), 2.95-3.01 (m, 1H), 3.08-3.11 (m, 2H), 3.16-3.19 (m, 2H), 7.08 (d, J = 4.84 Hz, 1H), 8.24 (d, J = 4.84 Hz 1H), 8.97 (s, 1H), 9.08 (s, 1H)
342
340




















TABLE 153










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-91


embedded image


(400 MHz, CDCl3) 0.95-0.98 (m, 8H), 1.18-1.23 (m, 2H), 1.63- 1.68 (m, 3H), 2.53 (s, 3H), 2.79- 2.82 (m, 2H), 2.95-3.01 (m, 1H), 3.09-3.18 (m, 4H), 7.10 (dd, J = 7.25, 5.64 Hz, 1H), 8.25-8.23 (m, 2H), 9.17 (s, 1H)
342
340






F-92


embedded image


(400 MHz, CDCl3) 0.95-0.99 (m, 8H), 1.20 (dd, J = 12.64, 7.07 Hz, 2H), 1.65-1.70 (m, 3H), 2.20 (s, 3H), 2.78-2.82 (m, 2H), 2.95- 3.00 (m, 1H), 3.08 (t, J = 6.03 Hz, 2H), 3.18 (t, J = 6.03 Hz, 2H), 3.78 (s, 3H), 6.59 (dd, J = 8.46, 2.43 Hz, 1H), 7.03 (d, J = 8.35 Hz, 1H), 7.64 (d, J = 2.55 Hz, 1H), 8.47 (s, 1H)
371
369






F-93


embedded image


(400 MHz, CDCl3) 0.96-1.01 (m, 8H), 1.19-1.24 (m,2H), 1.62- 1.72 (m, 3H), 2.79-2.83 (m, 2H), 2.98-3.03 (m, 1H), 3.11-3.21 (m, 4H), 7.03 (t, J = 8.80 Hz, 1H), 7.24 (t, J = 8.00 Hz, 1H), 7.36 (dd, J = 8.12, 1.39 Hz, 1H), 8.29 (d, J = 8.35 Hz, 1H), 8.42 (s, 1H)
361
359






F-94


embedded image


(400 MHz, CDCl3) 0.89-0.98 (m, 4H), 1.13-1.27 (m, 6H), 1.59- 1.74 (m, 7H), 2.24 (d, J = 22.94 Hz, 3H), 2.77 (dt, J = 8.01, 3.58 Hz, 2H), 2.94-2.99 (m, 1H), 3.14 (dd, J = 10.48, 4.74 Hz 4H),7.07 (t, J = 7.94 Hz, 1H), 7.16 (d, J = 7.50 Hz, 1H), 7.56 (d, J = 7.94 Hz, 1H), 9.24 (s, 1H)
415
413




















TABLE 154










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-95


embedded image


(400 MHz, CDCl3) 0.94 (dt, J = 10.44, 5.62 Hz, 4H), 1.13-1.27 (m, 6H), 1.61-1.76 (m, 7H), 2.18 (s, 3H), 2.26 (s, 3H), 2.78 (t, J = 8.16 Hz, 2H), 2.94-2.98 (m, 1H), 3.06 (t, J = 6.18 Hz, 2H), 3.16 (t, J = 6.06 Hz, 2H), 6.96 (s, 2H), 7.57 (d, J = 8.82 Hz, 1H), 8.51 (s, 1H)
395
393






F-96


embedded image


(400 MHz, CDCl3) 1.12 (ddd, J = 23.82, 11.80, 6.51 Hz, 4H), 2.15 (s, 3H), 2.25 (s, 3H), 2.99 (t, J = 6.73 Hz, 2H), 3.05-3.09 (m, 1H), 3.15 (t, J = 6.73 Hz, 2H), 4.78 (s, 2H), 6.94 (s, 2H), 7.51 (d, J = 7.28 Hz, 1H), 8.29 (s, 1H)
315
313






F-97


embedded image


(400 MHz, CDCl3) 1.12 (dd, J = 6.51, 4.96 Hz, 4H), 1.24 (d, J = 20.95 Hz, 9H), 2.19 (s, 3H), 2.26 (s, 3H) 3.07 (dd, J = 12.13, 5.29 Hz, 3H), 3.19 (t, J = 6.51 Hz, 2H), 4.61 (d, J = 17.20 Hz, 2H), 6.95 (s, 2H), 7.60 (d, J = 8.82 Hz, 1H), 8.37 (s. 1H)
371
369






F-98


embedded image


(400 MHz, CDCl3) 0.87 (d, J = 6.40 Hz, 6H), 0.97 (d, J = 3.97 Hz, 2H), 1.20 (dd, J = 6.95, 2.98 Hz, 2H), 1.27 (d, J = 6.84 Hz, 3H), 1.51 (dq, J = 28.78, 6.65 Hz, 2H), 1.69 (dd, J = 13.12, 7.17 Hz, 1H) 2.24 (s, 3H), 2.93 (td, J = 10.53, 8.16 Hz, 1H), 3.16 (dt, J = 15.73, 6.45 Hz, 5H), 7.07 (t, J = 7.94 Hz, 1H), 7.16 (d, J = 7.72 Hz, 1H), 7.53 (d, J = 7.94 Hz, 1H), 9.28 (s, 1H)
389
387
Racemic form




















TABLE 155










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-99 


embedded image


(400 MHz, CDCl3) 0.95-1.00 (m, 8H), 1.21 (dd, J = 12.87, 7.07 Hz, 2H), 1.64-1.70 (m, 3H), 2.34 (s, 3H), 2.89-2.83 (m, 2H), 2.96- 3.01 (m, 1H), 3.11 (t, J = 7.20 Hz, 2H), 3.18 (t, J = 7.20 Hz, 2H), 7.25 (t, J = 8.00 Hz, 1H), 7.43 (d, J = 7.65 Hz, 1H), 7.93 (d, J = 7.88 Hz, 1H), 9.01 (brs, 1H)
409
407






F-100


embedded image


(400 MHz, DMSO-D6) 0.92 (d, J = 6.18 Hz, 6H), 0.98-1.03 (m, 2H), 1.07-1.11 (m, 2H), 1.58- 1.61 (m, 3H), 2.73 (t, J = 7.83 Hz, 2H), 2.94 (t, J = 6.84 Hz, 2H), 3.03 (t, J = 6.73 Hz, 2H), 3.10-3.13 (m, 1H), 7.17 (td, J = 8.27, 1.54 Hz, 1H), 7.29-7.33 (m, 1H), 7.84 (t, J = 6.95 Hz, 1H), 10.03 (s, 1H)
379
377






F-101


embedded image


(400 MHz, DMSO-D6) 0.92 (d, J = 6.40 Hz, 6H), 0.97-0.99 (m, 2H), 1.06-1.11 (m, 2H), 1.58- 1.61 (m, 3H), 2.06 (d, J = 1.98 Hz, 3H), 2.73 (t, J = 7.72 Hz, 2H) 2.89 (t, J = 7.17 Hz, 2H), 3.03 (t, J = 7.17 Hz, 2H), 3.10-3.13 (m, 1H), 6.97 (t, J = 8.71 Hz, 1H), 7.17 (dd, J = 14.67, 8.05 Hz, 1H), 7.25 (d, J = 7.50 Hz, 1H), 9.58 (s, 1H)
359
357






F-102


embedded image


(400 MHz, CDCl3) 0.73-1.83 (m, 27H), 2.75-2.87 (m, 2H), 2.93- 2.99 (m, 1H), 3.09-3.13 (m, 2H), 3.35-4.00 (m, 1H), 6.02-6.40 (m, 1H)
347
345
Mixtures of four stereoisomers (Stereochemistry on Cyclohexane ring: Mixture of Trans-isomer and Cis-isomer)




















TABLE 156










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-103


embedded image


(400 MHz, DMSO-D6) 0.93 (d, J = 5.80 Hz, 6H), 0.95-0.99 (m, 2H), 1.05-1.09 (m, 2H), 1.59- 1.63 (m, 3H), 2.59 (t, J = 7.65 Hz, 2H), 2.69-2.75 (m, 2H), 2.88- 2.96 (m, 2H), 3.09-3.14 (m, 2H), 4.59-4.63 (m, 1H), 5.47 (d, J = 4.41 Hz, 1H), 7.23-7.28 (m, 1H), 7.32-7.35 (m, 4H), 8.05 (t, J = 6.72 Hz, 1H)
371
369






F-104


embedded image


(400 MHz, CDCl3) 0.94-0.99 (m, 8H), 1.18-1.24 (m, 2H), 1.64- 1.68 (m, 3H), 2.28 (s, 3H), 2.78- 2.80 (m, 2H), 2.95-3.00 (m, 1H), 3.05 (dd, J = 7.39, 4.96 Hz, 2H), 3.20 (dd, J = 7.61, 4.96 Hz, 2H), 6.72 (d, J = 7.28 Hz, 1H), 6.86 (d, J = 7.72 Hz, 1H), 7.04 (t, J = 7.83 Hz, 1H), 8.63 (s, 1H)
357
355






F-105


embedded image


(400 MHz, CDCl3) 0.93-0.99 (m, 2H), 0.95 (t, J = 7.39 Hz, 3H), 1.16- 1.22 (m, 2H), 1.42 (td, J = 14.89, 7.39 Hz, 2H), 1.69-1.82 (m, 2H), 2.28 (s, 3H), 2.75-2.83 (m, 2H), 2.97 (tt, J = 7.52, 3.96 Hz, 1H), 3.05- 3.12 (m, 2H), 3.13-3.20 (m, 2H), 7.07 (t, J = 7.94 Hz, 1H), 7.16 (d, J = 7.94 Hz, 1H), 7.62 (d, J = 7.94 Hz, 1H), 8.91 (brs, 1H)
361
359






F-106


embedded image


(400 MHz, CDCl3) 0.95 (d, J = 6.40 Hz, 6H) 0.96-1.00 (m, 2H), 1.17-1.24 (m, 2H), 1.62- 1.72 (m, 3H), 1.84 (s, 3H), 2.17 (s, 3H), 2.76-2.82 (m, 2H), 2.99 (tt, J = 7.12, 3.96 Hz, 1H), 3.07-3.21 (m, 4H), 10.21 (brs, 1H)
346
344




















TABLE 157










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-107


embedded image


(400 MHz, CDCl3) 0.93-0.97 (m, 9H), 0.99 (d, 6.62 Hz, 6H), 1.16- 1.23 (m, 2H), 2.16-2.26 (m, 1H), 2.29 (s, 3H), 2.69 (d, J = 7.28 Hz 2H), 2.96 (tt, J = 7.12, 4.35 Hz, 1H), 3.05-3.12 (m, 2H), 3.14-3.21 (m, 2H), 7.07 (dd, J = 7.94, 7.72 Hz, 1H), 7.15 (d, J = 7.94 Hz, 1H), 7.63 (d, J = 7.72 Hz, 1H), 8.85 (brs, 1H)
361
359






F-108


embedded image


(400 MHz, CDCl3) 0.94-0.97 (m, 2H), 0.97 (d, J = 6.49 Hz, 6H), 1.15- 1.21 (m, 2H), 1.67-1.71 (m, 1H), 2.26 (s, 3H), 2.76-2.86 (m, 6H), 2.94-2.99 (m, 1H), 3.12 (t, J = 6.96 Hz, 2H), 3.78 (s, 3H), 4.33 (d, J = 5.57 Hz, 2H), 6.39 (brs, 1H), 6.69 (td, J = 8.35, 2.55 Hz, 2H), 7.10 (d, J = 8.35 Hz, 1H)
385
383






F-109


embedded image


(400 MHz, CDCl3) 0.97 (d, J = 6.49 Hz, 6H), 0.98-1.01 (m, 2H), 1.22 (t, J = 6.96 Hz, 2H), 1.66- 1.71 (m, 3H), 2.80-2.84 (m, 2H), 2.97-3.05 (m, 3H), 3.15-3.18 (m, 2H), 6.77 (dt, J = 8.35, 2.09 Hz, 1H), 7.33-7.35 (m, 1H), 7.38 (dt, J = 10.51, 2.15 Hz, 1H), 9.90 (s, 1H)
379
377






F-110


embedded image


(400 MHz, CDCl3) 0.95 (d, J = 6.04 Hz, 6H), 0.97-0.99 (m, 2H), 1.17-1.21 (m, 2H), 1.67- 1.71 (m, 3H), 2.27 (s, 3H), 2.77- 2.81 (m, 2H), 2.96-3.02 (m, 3H), 3.19-3.15 (m, 2H) 4.48 (d, J = 4.03 Hz, 2H), 7.13 (dd, J = 7.66, 4.84 Hz, 1H), 7.46 (d, J = 6.85 Hz, 1H), 7.61 (s, 1H), 8.38 (d, J = 4.03 Hz, 1H)
356
354




















TABLE 158










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-111


embedded image


(400 MHz, CDCl3) 0.94-0.97 (m, 8H), 1.16-1.21 (m, 2H), 1.65- 1.70 (m, 3H), 2.27 (s, 3H) 2.76- 2.80 (m, 2H), 2.94-2.99 (m, 3H), 3.11-3.14 (m, 2H), 4.39 (d, J = 5.64 Hz, 2H), 7.09 (d, J = 5.24 Hz, 1H), 7.45 (t, J = 6.45 Hz, 1H), 8.35- 8.33 (m, 2H)
356
354






F-112


embedded image


(400 MHz, CDCl3) 0.92 (d, J = 11.69 Hz, 2H), 1.20 (dd, J = 22.05, 10.37 Hz, 4H), 1.57-1.75 (m, 7H), 1.86-1.96 (m, 2H), 2.19 (s, 3H), 2.26 (s, 3H), 2.55 (dd, J = 18.86, 8.49 Hz, 4H), 2.73 (t, J = 8.16 Hz, 2H), 3.11 (dd, J = 18.75, 6.18 Hz, 4H), 4.53 (t, J = 8.71 Hz, 1H), 6.95 (s, 2H), 7.61 (d, J = 8.60 Hz, 1H), 8.58 (s, 1H)
409
407






F-113


embedded image


(400 MHz, CDCl3) 0.95-1.04 (m, 2H), 1.11-1.19 (m, 2H), 2.30 (s, 3H), 2.97 (s, 3H), 3.05-3.10 (m, 2H), 3.13-3.22 (m, 6H), 3.96 (s, 2H),7.08 (dd, J = 8.38, 7.72 Hz, 2H), 7.15 (d, J = 7.72 Hz, 2H), 7.67 (d, J = 8.38 Hz, 1H), 8.73 (brs, 1H)
390
388






F-114


embedded image


(400 MHz, DMSO-D6) 0.92 (d, J = 6.26 Hz, 6H), 0.93-0.97 (m, 2H), 1.03-1.08 (m, 2H), 1.54- 1.64 (m, 3H), 2.14 (s, 3H), 2.61 (t, J = 7.54 Hz, 2H), 2.71 (t, J = 7.77 Hz, 2H), 2.94 (t, J = 7.54 Hz, 2H), 3.04- 3.09 (m, 1H), 4.11 (d, J = 5.33 Hz, 2H), 6.50 (dd, J = 8.23, 2.67 Hz, 1H), 6.55 (d, J = 2.55 Hz, 1H), 6.96 (d, J = 8.12 Hz, 1H), 8.13 (t, J = 5.57 Hz, 1H), 9.14 (s, 1H)
371
369




















TABLE 159










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-115


embedded image


(400 MHz, DMSO-D6) 0.93 (d, J = 6.03 Hz, 6H), 1.13-1.28 (m, 7H), 1.63 (t, J = 6.15 Hz, 3H), 2.81 (t, J = 7.19 Hz, 2H), 2.93 (t, J = 7.42 Hz, 2H), 3.16 (t, J = 7.07 Hz, 2H), 3.32-3.36 (m, 1H), 4.64 (d, J = 5.57 Hz, 2H), 6.54 (s, 1H), 7.40 (d, J = 7.42 Hz, 1H), 7.52 (t, J = 7.88 Hz, 1H), 7.72 (d, J = 8.35 Hz, 1H), 8.82 (t, J = 5.80 Hz, 1H), 9.53 (s, 1H)
381
379






F-116


embedded image


(400 MHz, CDCl3) 0.93-0.98 (m, 8H), 1.15-1.20 (m, 2H), 1.65- 1.72 (m, 3H), 2.32 (s, 3H), 2.77- 2.81 (m, 6H), 2.93-2.98 (m, 1H), 3.07 (t, J = 6.95 Hz, 2H), 3.41-3.46 (m, 2H), 6.42 (brs, 1H), 7.07-7.14 (m, 4H)
369
367






F-117


embedded image


(400 MHz, CDCl3) 0.81-0.97 (m, 11H), 1.19 (s, 2H), 1.62 (s, 1H), 1.94 (s, 1H), 2.27 (s, 3H), 2.58 (dd, J = 14.67, 9.59 Hz, 1H), 2.82 (dd, J = 14.78, 5.07 Hz, 1H), 2.96 (s, 1H), 3.14 (d, J = 6.62 Hz, 4H), 7.07 (t, J = 7.94 Hz, 1H), 7.16 (d, J = 7.94 Hz, 1H), 7.54 (s, 1H), 9.25 (s, 1H)
389
387
Racemic form





F-118


embedded image


(400 MHz, CDCl3) 0.93-0.97 (m, 8H), 1.18 (dd, J = 12.68, 6.95 Hz, 2H), 1.65-1.71 (m, 3H), 2.16 (s, 3H), 2.28 (s, 3H), 2.76-2.80 (m, 2H), 2.84 (t, J = 6.84 Hz, 2H), 2.93- 2.99 (m, 1H), 3.11 (t, J = 6.84 Hz, 2H), 4.41 (d, J = 5.51 Hz, 2H), 6.34 (brs, 1H), 7.02-7.09 (m, 3H)
369
367




















TABLE 160










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-119


embedded image


(400 MHz, CDCl3) 0.92-0.97 (m, 8H), 1.15-1.20 (m, 2H), 1.65- 1.70 (m, 3H), 2.24 (s, 3H), 2.29 (s, 3H), 2.76-2.80 (m, 2H), 2.84 (t, J = 6.95 Hz, 2H) 2.93-2.97 (m, 1H), 3.11 (t J = 6.95 Hz, 2H), 4.35 (d, J = 5.51 Hz, 2H), 6.37 (brs, 1H), 6.94-6.96 (m, 2H), 7.05 (d, J = 7.28 Hz, 1H)
369
367






F-120


embedded image


(400 MHz, CDCl3) 0.89 (d, J = 6.62 Hz, 6H), 0.93-0.99 (m, 2H), 1.16-1.23 (m, 2H), 1.24- 1.33 (m, 0H), 1.53-1.64 (m, 1H), 1.74-1.84 (m, 2H), 2.29 (s, 3H), 2.77 (t, J = 7.83 Hz, 2H) 2.97 (tt, J = 7.12, 3.96 Hz, 1H), 3.04-3.12 (m, 2H), 3.13-3.21 (m, 2H), 7.08 (dd, J = 7.94, 7.72 Hz, 1H), 7.16 (d, J = 7.94 Hz, 1H), 7.63 (d, J = 7.72 Hz, 1H), 8.82 (brs, 1H)
389
387






F-121


embedded image


(400 MHz, CDCl3) 0.91-0.96 (m, 2H), 0.96 (d, J = 5.73 Hz, 6H), 1.13- 1.20 (m, 2H), 1.63-1.69 (m, 3H), 2.74-2.80 (m, 2H), 2.89 (t, J = 6.95 Hz, 2H), 2.94 (tt, J = 6.77, 3.96 Hz, 1H), 3.10 (t, J = 6.95 Hz, 2H), 4.49 (d, J = 6.18 Hz, 2H), 6.94 (brs, 1H), 7.15-7.22 (m, 2H), 7.28- 7.35 (m, 2H)
375
373






F-122


embedded image


(400 MHz, CDCl3) 0.90-0.95 (m, 2H), 0.97 (d, J = 5.51 Hz, 6H), 1.14- 1.21 (m, 2H), 1.63-1.69 (m, 3H), 2.73-2.80 (m, 2H), 2.88 (t, J = 6.73 Hz, 2H), 2.94 (tt, J = 6.73, 3.96 Hz, 1H), 3.09 (t, J = 6.73 Hz, 2H), 4.36 (d, J = 5.95 Hz, 2H), 7.15 (d, J = 8.27 Hz, 2H), 7.19 (brs, 1H), 7.24 (d, J = 8.27 Hz, 2H)
375
373




















TABLE 161










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-123


embedded image


(400 MHz, CDCl3) 0.90-0.95 (m, 2H), 0.96 (d, J = 5.51 Hz, 6H), 1.13- 1.21 (m, 2H), 1.62-1.70 (m, 3H), 2.29 (s, 3H), 2.73-2.79 (m, 2H), 2.88 (t, J = 6.62 Hz, 2H), 2.94 (tt, J = 6.73, 3.96 Hz, 1H), 3.08 (t, J = 6.62 Hz, 2H), 4.40 (d, J = 5.73 Hz, 2H), 6.98 (brs, 1H), 7.01-7.11 (m, 2H), 7.23-7.27 (m, 1H)
389
387






F-124


embedded image


(400 MHz, DMSO-D6) 0.90-0.99 (m, 8H), 1.03-1.11 (m, 2H), 1.11- 1.20 (m, 3H), 1.53-1.68 (m, 3H), 2.53-2.61 (m, 2H), 2.61-2.68 (m, 2H), 2.68-2.75 (m, 2H), 2.93- 3.01 (m, 2H), 3.04-3.12 (m, 1H), 4.19-4.25 (m, 2H), 7.09-7.18 (m, 4H), 8.34-8.43 (m, 1H)
369
367






F-125


embedded image


(400 MHz, DMSO-D6) 0.86-0.99 (m, 8H), 1.01-1.10 (m, 2H), 1.10- 1.19 (m, 3H), 1.52-1.68 (m, 3H), 2.56-2.76 (m, 6H), 2.92-3.00 (m, 2H), 3.02-3.12 (m, 1H), 4.23- 4.31 (m, 2H), 7.09-7.23 (m, 4H), 8.27-8.36 (m, 1H)
369
367






F-126


embedded image


(400 MHz, DMSO-D6) 0.88-1.00 (m, 8H), 1.02-1.11 (m, 2H), 1.53- 1.66 (m, 3H), 2.14 (s, 3H), 2.63- 2.77 (m, 4H), 2.92-3.01 (m, 2H), 3.02-3.12 (m, 1H) 4.22-4.29 (m, 2H), 6.98-7.09 (m, 2H), 7.11- 7.20 (m, 1H), 8.30-8.40 (m, 1H)
373
371




















TABLE 162










MS
Information












Example
Chemical structure
NMS
M + H
M − H
of structure





F-127


embedded image


(400 MHz, DMSO-D6) 0.89-1.00 (m, 8H), 1.02-1.12 (m, 2H), 1.51- 1.65 (m, 2H), 2.07 (s, 3H), 2.61- 2,68 (m, 2H), 2.68-2.75 (m, 2H), 2.92-3.00 (m, 2H), 3.03-3.13 (m, 1H), 3.14-3.20 (m, 1H), 3.76 (s, 3H), 4.18-4.26 (m, 2H), 6.78- 6.84 (m, 1H), 6.84-6.90 (m, 1H), 7.06-7.13 (m, 1H), 8.22-8.30 (m, 1H)
385
383






F-128


embedded image


(400 MHz, DMSO-D6) 0.94 (d, J = 5.73 Hz, 6H), 1.17-1.21 (m, 4H), 1.63 (t, J = 6.62 Hz, 3H), 2.78 (t, J = 6.95 Hz, 2H), 2.94 (t, J = 7.64 Hz, 2H), 3.18 (t, J = 6.84 Hz, 2H), 3.34-3.37 (m, 1H), 4 58 (d, J = 5.73 Hz, 2H), 6.97 (d, J = 6.84 Hz, 1H), 7.28 (t, J = 7.39 Hz, 1H), 7.43 (d, J = 8.60 Hz, 1H), 8.08 (s, 1H), 8.65 (t, J = 6.00 Hz 1H)
381
379






F-129


embedded image


(400 MHz, CDCl3) 0.93-0.99 (m, 8H), 1.14-1.22 (m, 2H), 1.66- 1.71 (m, 1H), 2.76-2.83 (m, 3H), 2.88-2.99 (m, 3H), 3.12 (t, J = 6.61 Hz, 2H), 3.50 (s, 1H), 4.46 (d, J = 5.80 Hz, 2H), 7.19-7.24 (m, 1H), 7.33 (d, J = 8.12 Hz, 2H), 7.54 (d, J = 8.12 Hz, 2H)
409
407






F-130


embedded image


(400 MHz, CDCl3) 0.95-0.98 (m, 8H), 1.16-1.21 (m, 2H), 1.67- 1.71 (m, 2H), 2.77-2.83 (m, 3H), 2.90 (t, J = 6.84 Hz, 2H), 2.94-3.00 (m, 1H), 3.13 (t, J = 6.84 Hz, 2H), 4.61 (d, J = 6.26 Hz, 2H), 6.75-6.79 (m, 1H), 7.32-7.36 (m, 1H), 7.47- 7.52 (m, 2H), 7.63 (d, J = 8.12 Hz, 1H)
409
407




















TABLE 163










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-131


embedded image


(400 MHz, CDCl3) 0.89-1.01 (m, 2H), 0.95 (d, J = 5.60 Hz, 6H), 1.20 (dd, J = 12.80, 7.20 Hz, 2H), 1.58- 1.73 (m, 3H), 2.24 (t, 3H), 2.73- 2.86 (m, 2H), 2.93-3.02 (m, 1H), 3.02-3.23 (m, 4H), 6.97 (dd, J = 8.00, 0.80 Hz, 1H), 7.05 (d, J = 8.00 Hz, 1H), 8.01 (s, 1H), 8.82 (brs, 1H)
375
373






F-132


embedded image


(400 MHz, CDCl3) 0.92-1.00 (m, 8H), 1.16-1.25 (m, 5H). 1.63- 1.73 (m, 3H), 2.61 (q, J = 7.57 Hz, 2H), 2.76-2.84 (m, 2H), 2.94- 3.05 (m, 3H), 3.13-3.20 (m, 2H), 6.88-6.94 (m, 1H), 7.16-7.22 (m, 1H), 7.32-7.41 (m, 2H), 8.87 (brs, 1H)
355
353






F-133


embedded image


(400 MHz, DMSO-D6) 0.87-0.99 (m, 8H), 1.02-1.11 (m, 2H), 1.53- 1.65 (m, 3H), 2.03 (s, 3H), 2.62- 2.69 (m, 2H), 2.69-2.76 (m, 2H), 2.91-3.01 (m, 2H), 3.04-3.13 (m, 1H), 4.16-4.22 (m, 2H) 6.61- 6.68 (m, 1H), 6.68-6.74 (m, 1H), 6.87-6.95 (m, 1H), 8.18-8.25 (m, 1H), 9.20 (brs, 1H)
371
369






F-134


embedded image


(400 MHz, CDCl3) 0.92 (d, J = 5.95 Hz, 6H), 0.95-1.02 (m, 2H), 1.16-1.23 (m, 2H), 1.57- 1.68 (m, 3H), 2.72-2.82 (m, 2H), 2.99 (tt, J = 7.12, 3.56 Hz, 1H), 3.15- 3.25 (m, 4H), 6.73 (dd, J = 6.62, 5.94 Hz, 1H), 7.11 (dd, J = 8.91, 5.94 Hz, 1H), 7.53 (d, J = 8.91 Hz, 1H), 7.54 (s, 1H), 7.90 (d, J = 6.62 Hz, 1H), 9.92 (brs, 1H)
367
365




















TABLE 164










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-135


embedded image


(400 MHz, CDCl3) 0.94-1.95 (m, 16H), 2.27-2.28 (m, 3H), 2.86- 2.96 (m, 2H), 3.09-3.11 (m, 2H), 3.17-3.20 (m, 2H), 7.08 (t, J = 8.00 Hz, 1H), 7.17 (d, J = 7.88 Hz, 1H), 7.63 (d, J = 7.42 Hz, 1H), 8.91 (s, 1H)
401
399
Mixtures of four stereoisomers (Stereochemistry on Cyclohexane ring: Mixture of Trans-isomer and Cis-isomer)





F-136


embedded image


(400 MHz, CDCl3) 0.95-0.98 (m, 8H), 1.16-1.21 (m, 2H), 1.64- 1.70 (m, 3H), 2.25 (s, 3H), 2.78- 2.81 (m, 2H), 2.94-2.99 (m, 1H), 3.05-3.09 (m, 2H) 3.14-3.18 (m, 2H), 3.34 (s, 3H), 4.37 (s, 2H), 7.13-7.11 (m, 2H), 7.84 (d, J = 8.87 Hz, 1H), 8.46 (s, 1H)
385
383






F-137


embedded image


(400 MHz, CDCl3) 0.95-0.98 (m, 8H), 1.17-1.22 (m, 2H), 1.64- 1.70 (m, 3H), 2.22 (s, 3H), 2.78- 2.82 (m, 2H), 2.94-3.00 (m, 1H), 3.04-3.09 (m, 2H), 3.13-3.18 (m, 2H), 6.82-6.87 (m, 2H), 7.68 (dd, J = 7.05, 3.53 Hz, 1H) 6.55 (s, 1H)
359
357






F-138


embedded image


(400 MHz, CDCl3) 0.95-0.98 (m, 8H), 1.17-1.22 (m, 2H), 1.63- 1.69 (m, 3H), 2.24 (s, 3H), 2.78- 2.82 (m, 2H), 2.94-2.99 (m, 1H), 3.04-3.08 (m, 2H), 3.13-3.17 (m, 2H), 7.13-7.11 (m, 2H), 7.82 (d, J = 9.27 Hz, 1H), 8.74 (s, 1H)
375
373






F-139


embedded image


(400 MHz, CDCl3) 0.83-0.96 (m, 6H), 0.96-1.02 (m, 2H), 1.15- 1.23 (m, 2H), 1.57-1.66 (m, 3H), 2.74-2.82 (m, 2H), 2.97-3.05 (m, 1H), 3.19-3.30 (m, 2H), 3.30- 3.41 (m, 2H), 6.73-6.81 (m, 1H), 7.16-7.23 (m, 1H), 7.61-7.68 (m, 1H), 7.88-7.98 (m, 1H), 11.41 (brs, 1H)
368
366




















TABLE 165










ms
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-140


embedded image


(400 MHz, CDCl3) 0.90-1.04 (m, 2H), 0.95 (d, J = 6.00 Hz, 6H), 1.20 (dd, J = 12.92, 7.00 Hz, 2H), 1.58-1.77 (m, 3H), 2.22 (s, 3H), 2.74-2.87 (m, 2H), 2.93-3.02 (m, 1H), 3.03-3.24 (m, 4H),
420
418





6.99 (d, J = 8.24 Hz, 1H),







7.13 (d, J = 8.24 Hz,







1H), 8.13 (s, 1H),







8.87 (brs, 1H)








F-141


embedded image


(400 MHz, CDCl3) 0.85-1.02 (m, 3H), 1.05-1.38 (m, 9H), 1.56-1.93 (m, 7H), 2.18 (s, 3H), 2.26 (s, 3H), 2.57-2.66 (m, 1H), 2.70-2.82 (m, 2H), 2.99-3.19 (m, 4H), 6.91-7.01 (m, 2H),
409
407
Racemic form




7.59 (d, J = 8.68 Hz,







1H), 8.43 (s, 1H)








F-142


embedded image


(400 MHz, CDCl3) 0.87-1.01 (m, 2H), 1.09-1.40 (m, 4H), 1.61-1.80 (m, 7H), 2.13 (s, 3H), 2.26 (s, 3H), 2.67 (t, J = 8.32 Hz, 2H), 3.00-3.13 (m, 4H), 4.57 (dd, J = 16.44, 8.12 Hz, 2H),
437
435





6.92-7.00 (m, 2H),







7.42 (d, J = 7.88 Hz,







1H), 7.73 (s, 1H)








F-143


embedded image


(400 MHz, CDCl3) 0.91-1.02 (m, 2H), 0.96 (d, J = 5.12 Hz, 6H), 1.21 (dd, J = 12.96, 6.72 Hz, 2H), 1.60-1.72 (m, 3H), 2.37 (s, 3H), 2.75-2.86 (m, 2H), 2.94-3.03 (m, 1H), 3.05-3.21 (m, 4H), 7.22 (d, J = 7.84 Hz, 1H), 7.28 (d, J = 7.84 Hz, 1H),
366
364





8.36 (s, 1H), 9.32 (brs, 1H)




















TABLE 166










ms
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-144


embedded image


(400 MHz, CDCl3) 1.12-1.30 (m, 8H), 1.53 (s, 1H), 1.70 (d, J = 4.63 Hz, 2H), 1.85-1.96 (m, 3H), 2.28 (s, 3H), 3.11 (t, J = 7.39 Hz, 3H), 3.18 (d, J = 6.84 Hz, 2H), 3.36 (s, 1H), 4.66 (s, 2H), 7.07 (t, J = 7.94 Hz,
417
415





1H), 7.16 (d, J = 7.94 Hz,







1H), 7.57 (d, J = 7.94 Hz,







1H), 9.00 (s, 1H)








F-145


embedded image


(400 MHz, CDCl3) 0.95-1.01 (m, 8H), 1.25 (s, 2H), 1.67 (t, J = 6.06 Hz, 3H), 2.13 (s, 3H), 2.25 (s, 3H), 2.77-2.84 (m, 2H), 3.01 (s, 1H), 3.31 (t, J = 10.92 Hz, 1H), 3.73 (d, J = 8.82 Hz, 1H), 3.95 (d, J = 8.16 Hz, 1H), 4.20 (dd, J = 19.08, 12.68 Hz, 2H), 4.45 (t, J = 9.92 Hz, 1H), 7.07 (t, J = 8.05 Hz, 1H), 7.16 (t, J = 8.38 Hz, 1H),
458
456
Racemic form




7.73 (d, J = 7.94 Hz, 1H),







9.47 (s, 1H)








F-146


embedded image


(400 MHz, CDCl3) 0.94 (t, J = 6.18 Hz, 8H), 1.26 (s, 2H), 1.66 (t, J = 7.17 Hz, 3H), 1.84 (s, 2H), 2.22 (s, 2H), 2.77-2.84 (m, 2H), 3.01 (s, 1H), 3.41 (t, J = 11.14 Hz, 2H), 3.81 (dd, J = 21.61, 9.26 Hz, 1H), 4.04 (t, J = 10.48 Hz, 1H), 4.19 (s, 2H), 4.26 (t, J = 10.03 Hz, 1H), 4.48 (t, J = 9.81
474
472
Racemic form




Hz, 1H), 7.07 (t, J = 8.16 Hz,







1H), 7.16 (d, J = 8.16 Hz,







1H), 7.67 (d, J = 8.16 Hz,







1H), 9.50 (s, 1H)




















TABLE 167










ms
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-147


embedded image


(400 MHz, CDCl3) 0.92-0.99 (m, 8H), 1.14-1.27 (m, 5H), 1.62-1.72 (m, 3H), 2.15 (s, 3H), 2.63 (q, J = 7.57 Hz, 2H), 2.76-2.83 (m, 2H), 2.94-3.00 (m, 1H),
369
367





3.05-3.10 (m, 2H),







3.15-3.21 (m, 2H),







6.97 (d, J = 7.50 Hz,







1H), 7.09 (t, J = 7.83 Hz,







1H), 7.50 (d, J = 7.94 Hz,







1H), 8.32 (brs, 1H)








F-148


embedded image


(400 MHz, CDCl3) 0.89-0.95 (m, 2H), 0.96 (d, J = 6.40 Hz, 6H), 1.12-1.18 (m, 2H), 1.64-1.70 (m, 3H), 2.33 (s, 3H), 2.73-2.78 (m, 2H), 2.80 (t, J = 7.23 Hz, 2H), 2.92 (tt, J = 7.12, 4.35 Hz, 1H), 3.09 (t, J =
385
383





7.23 Hz, 2H), 3.83 (s, 3H),







4.35 (d, J = 5.95 Hz, 2H),







6.44 (brs, 1H), 6.67 (s, 1H),







6.70 (d, J = 7.72 Hz, 1H),







7.08 (d, J = 7.50 Hz, 1H)








F-149


embedded image


(400 MHz, CDCl3) 0.69-0.95 (m, 2H), 0.97 (d, J = 5.73 Hz, 6H), 1.14-1.21 (m, 2H), 1.63-1.72 (m, 3H), 2.25 (s, 3H), 2.72-2.78 (m, 2H), 2.85 (t, J = 6.95 Hz, 2H), 2.92 (tt, J = 7.12, 3.96 Hz, 1H), 3.07 (t, J =
371
369





6.95 Hz, 2H), 4.24 (d, J =







6.40 Hz, 2H), 6.58 (d, J =







7.50 Hz, 1H), 6.72 (s, 1H),







6.95 (d, J = 7.50 Hz, 1H),







8.31 (brs, 1H), 9.52 (brs, 1H)




















TABLE 168










ms
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-150


embedded image


(400 MHz, DMSO-D6) 0.87-1.02 (m, 8H), 1.04-1.09 (m, 2H), 1.60 (tt, J = 13.91, 4.83 Hz, 3H), 2.69-2.74 (m, 4H), 2.99 (t, J = 7.42 Hz, 2H), 3.06-3.11 (m, 1H), 4.56 (d, J = 5.80 Hz, 2H), 7.05 (dd, J = 7.88,
381
379





7.19 Hz, 1H), 7.16







(d, J = 6.96 Hz, 1H),







7.64 (d, J = 7.88 Hz, 1H),







8.08 (d, J = 1.39 Hz,







1H), 8.55 (t, J = 5.80 Hz,







1H), 12.99 (brs, 1H)








F-151


embedded image


(400 MHz, CDCl3) 0.91-1.00 (m, 2H), 0.95 (d, J = 6.48 Hz, 6H), 1.16-1.24 (m, 2H), 1.59-1.71 (m, 3H), 2.34 (s, 3H), 2.76-2.84 (m, 2H), 2.94-3.01 (m, 1H), 3.06-3.21 (m, 4H), 7.23-7.29 (m, 2H), 8.28 (s, 1H), 9.04 (brs, 1H)
409
407






F-152


embedded image


(400 MHz, CDCl3) 0.60-0.69 (m, 2H), 0.82-1.04 (m, 4H), 0.95 (d, J = 6.44 Hz, 6H), 1.15-1.23 (m, 2H), 1.57-1.74 (m, 3H), 1.80-1.89 (m, 1H), 2.19 (s, 3H), 2.74-2.85 (m, 2H), 2.93-3.00 (m, 1H), 3.02-3.22 (m, 4H), 6.74 (d,
381
379





J = 8.04 Hz, 1H), 7.01 (d, J =







8.04 Hz, 1H), 7.61 (s,







1H), 8.30 (brs, 1H)








F-153


embedded image


(400 MHz, CDCl3) 0.89-0.99 (m, 2H), 0.92 (t, J = 7.20 Hz, 3H), 0.95 (d, J = 6.48 Hz, 6H), 1.15-1.22 (m, 2H), 1.54-1.72 (m, 5H), 2.20 (s, 3H), 2.53 (t, J = 7.44 Hz, 2H), 2.75-2.83 (m, 2H), 2.93-3.00 (m, 1H), 3.03-3.10 (m, 2H), 3.12-3.20 (m, 2H), 6.85 (d, J = 7.16 Hz,
383
381





1H), 7.04 (d, J = 7.64 Hz,







1H), 7.69 (s, 1H),







8.30 (brs, 1H)




















TABLE 169










ms
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-154


embedded image


(400 MHz, CDCl3) 0.91-1.02 (m, 2H), 0.95 (d, J = 6.28 Hz, 6H), 1.17-1.24 (m, 2H), 1.60-1.70 (m, 3H), 2.33 (s, 3H), 2.74-2.83 (m, 2H), 2.93-3.04 (m, 1H), 3.05-3.21 (m, 4H), 7.21-7.28 (m, 1H), 7.54-7.63 (m, 1H), 8.25 (s, 1H),
384
382





8.99 (brs, 1H)








F-155


embedded image


(400 MHz, DMSO-D6) 0.92-0.98 (m, 4H), 1.13-1.26 (m, 6H), 1.57-1.76 (m, 7H), 1.99 (d, J = 12.35 Hz, 3H), 2.11 (d, J = 3.31 Hz, 3H), 2.75 (t, J = 6.95 Hz, 2H), 3.10 (s, 1H), 3.45-3.54 (m, 1H), 3.73 (t, J = 8.71 Hz, 1H), 3.85-4.11 (m, 4H), 7.17 (t, J = 8.05 Hz, 1H), 7.28-
498
496
Racemic form




7.31 (m, 2H), 9.89







(d, J = 10.14 Hz, 1H)








F-156


embedded image


(400 MHz, CDCl3) 0.57-0.61 (m, 2H), 0.87-0.92 (m, 2H), 0.94-1.00 (m, 8H), 1.16-1.22 (m, 2H), 1.64-1.72 (m, 3H), 1.82-1.90 (m, 1H), 2.30 (s, 3H), 2.77-2.83
381
379





(m, 2H), 2.94-3.00 (m, 1H),







3.05-3.10 (m, 2H),







3.16-3.21 (m, 2H),







6.87 (d, J = 7.65 Hz,







1H), 7.07 (t, J = 7.88 Hz,







1H), 7.54 (d, J = 7.88 Hz,







1H), 8.28 (brs, 1H)








F-157


embedded image


(400 MHz, DMSO-D6) 0.92 (d, J = 6.18 Hz, 6H), 0.96-1.01 (m, 2H), 1.07-1.12 (m, 2H), 1.56- 1.65 (m, 3H), 2.24 (s, 3H), 2.70-2.77 (m, 2H), 2.88-2.95 (m, 2H), 3.02-3.08 (m, 2H), 3.10-3.16 (m, 1H),
384
382





7.22 (brs, 1H), 7.58 (d,







J = 7.94 Hz, 2H), 7.65 (d,







J = 7.94 Hz, 2H), 7.71







(s, 1H), 7.83 (brs, 1H),







9.47 (brs, 1H)




















TABLE 170










ms
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-158


embedded image


(400 MHz, CDCl3) 1.09-1.20 (m, 4H), 1.30 (s, 3H), 1.32 (d, J = 4.87 Hz, 3H), 2.28 (d, J = 16.23 Hz, 3H), 2.82-2.89 (m, 1H), 3.08 (tt, J = 9.04, 3.71 Hz, 3H), 3.19 (t, J = 6.15
371
369





Hz, 2H), 7.09 (t, J = 8.12







Hz, 1H), 7.18 (d, J = 7.88







Hz, 1H), 7.57 (t, J = 15.19







Hz, 1H), 8.58 (s, 1H)








F-159


embedded image


(400 MHz, CDCl3) 0.95 (d, J = 6.49 Hz, 6H), 1.15-1.27 (m, 3H), 1.62-1.72 (m, 2H), 2.78- 2.86 (m, 2H), 3.01-3.10 (m, 1H), 3.29-3.38 (m, 1H), 3.39-3.47 (m, 1H), 3.47-3.51 (m, 2H), 4.10-4.23 (m, 2H), 4.66 (dd, J = 9.86, 4.75 Hz, 1H), 7.06 (t, J = 8.12 Hz, 1H), 7.17 (d, J = 8.12 Hz, 1H),
447
445
Racemic form




7.45 d, J = 8.12 Hz,







1H), 8.14 (brs, 1H)








F-160


embedded image


(400 MHz, CDCl3) 0.73-0.82 (m, 1H), 0.86-1.01 (m, 2H), 0.91 (d, J = 6.24 Hz, 3H), 1.09-1.42 (m, 6H), 1.58-1.80 (m, 7H), 2.18 (s, 3H), 2.26 (s, 3H), 2.71-2.83 (m, 2H), 2.96-3.20 (m, 5H),
425
423
Racemic form




6.92-6.99 (m, 2H),







7.60 (d, J = 8.56 Hz,







1H), 8.27 (s, 1H)








F-161


embedded image


(400 MHz, CDCl3) 0.92-1.00 (m, 8H), 1.18-1.24 (m, 2H), 1.61-1.71 (m, 3H), 2.36 (s, 3H), 2.77-2.83 (m, 2H), 2.94-3.00 (m, 1H), 3.07-3.19 (m, 4H), 7.42 (s, 1H),
366
364





7.45 (d, J = 8.58







Hz, 1H), 8.25 (d,







J = 8.58 Hz, 1H),







9.50 (brs, 1H)




















TABLE 171










ms
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-162


embedded image


(400 MHz, CDCl3) 0.96-0.99 (m, 8H), 1.24 (t, J = 5.62 Hz, 3H), 1.67 (d, J = 8.16 Hz, 3H), 2.13 (s, 3H), 2.14 (s, 3H), 2.25 (s, 3H), 2.77-2.84 (m, 2H), 2.99 (d, J = 3.97 Hz, 1H), 3.30 (t, J = 11.03 Hz, 1H), 3.75 (d, J = 8.60 Hz, 1H), 3.94 (t, J = 7.72 Hz, 1H), 4.20 (t, J = 6.29 Hz, 2H), 4.43 (dd, J =
438
436
Racemic form




11.47, 8.38 Hz, 1H),







6.95 (d, J = 9.04 Hz,







2H), 7.71 (d, J = 7.94 Hz,







1H), 9.05 (s, 1H)








F-163


embedded image


(400 MHz, CDCl3) 1.02-1.06 (m, 2H), 1.12-1.19 (m, 11H), 2.28 (s, 3H), 3.03-3.15 (m, 7H), 3.77 (t, J = 6.62 Hz, 2H), 7.08 (d, J = 7.94 Hz, 1H), 7.15 (d, J = 7.94 Hz, 1H), 7.61 (d, J =
405
403





8.16 Hz, 1H), 8.88 (s, 1H)








F-164


embedded image


(400 MHz, DMSO-D6) 0.86-1.03 (m, 1H), 0.93 (d, J = 6.04 Hz, 6H), 1.05-1.17 (m, 3H), 1.54-1.69 (m, 3H), 2.16 (s, 3H), 2.76 (t, J = 7.56 Hz, 2H), 3.02 (dd, J = 15.16, 7.60 Hz, 1H),
391
389
Racemic form




3.08-3.17 (m, 2H),







5.26-5.35 (m, 1H),







5.68 (d, J = 6.72 Hz, 1H),







7.12-7.20 (m, 1H), 7.23-7.32







(m, 2H), 9.68 (s, 1H)








F-165


embedded image


(400 MHz, CDCl3) 0.89-1.01 (m, 2H), 0.96 (d, J = 6.48 Hz, 6H), 1.16-1.23 (m, 2H), 1.59-1.71 (m, 3H), 2.35 (s, 3H), 2.74-2.84 (m, 2H), 2.93-3.01 (m, 1H), 3.03-3.20 (m, 4H), 7.26 (d,
409
407





J = 8.68 Hz, 1H), 7.63







(d, J = 8.68 Hz, 1H),







9.06 (s, 1H)




















TABLE 172










ms
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-166


embedded image


(400 MHz, CDCl3) 1.02-1.15 (m, 4H), 2.29 (s, 3H), 3.00-3.07 (m, 1H), 3.07-3.14 (m, 2H), 3.15-3.21 (m, 2H), 4.55 (s, 2H), 4.70 (s, 2H), 7.07 (dd, J = 7.94, 7.72 Hz, 1H),
425
423





7.16 (d, J = 7.94 Hz,







1H), 7.27-7.38 (m,







5H), 7.60 (d, J = 7.72







Hz, 1H), 8.78 (brs, 1H)








F-167


embedded image


(400 MHz, CDCl3) 0.91 (dd, J = 6.26, 2.32 Hz, 6H), 0.95-1.02 (m, 1H), 1.07-1.14 (m, 1H), 1.15-1.25 (m, 2H), 1.54-1.64 (m, 3H), 2.18 (s, 3H), 2.69- 2.79 (m, 2H), 2.96-3.12
405
403
Racemic form




(m, 3H), 3.85-4.00 (m,







3H), 7.06 (t, J = 8.00







Hz, 1H), 7.18 (d, J =







7.42 Hz, 1H),







7.38 (d, J = 8.12 Hz,







1H), 8.63 (brs, 1H)








F-168


embedded image


(400 MHz, CDCl3) 0.88-0.94 (m, 2H), 1.10-1.23 (m, 5H), 2.02-2.10 (m, 2H), 2.30 (s, 3H) 2.40-2.64 (m, 3H), 2.87-2.93 (m, 1H), 3.08-3.10 (m, 2H), 3.14-3.17 (m,
373
371
Mixture of two stereoisomers (Stereochemistry on Cyclobutane ring: Mixture of Trans-isomer and Cis-isomer)




2H), 3.38-3.72 (m,







1H), 7.09 (t, J = 8.00







Hz, 1H), 7.17 (d, J =







8.12 Hz, 1H), 7.62 (d,







J = 7.65 Hz, 1H),







8.90 (s, 1H)








F-169


embedded image


(400 MHz, CDCl3) 0.98 (s, 2H), 1.19 (t, J = 6.51 Hz, 2H), 1.45 (s, 2H), 1.59 (t, J = 5.51 Hz, 4H), 2.27 (s, 3H), 2.46 (s, 4H), 2.78 (t, J = 7.50 Hz, 2H), 3.00
416
414





(t, J = 7.83 Hz, 3H),







3.11-3.16 (m, 4H),







7.07 (t, J = 7.94 Hz,







1H), 7.16 (d, J = 7.94







Hz, 1H), 7.55 (d,







J = 7.50 Hz, 1H),







9.11 (s, 1H)




















TABLE 173










ms
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-170


embedded image


(400 MHz, CDCl3) 0.95-1.00 (m, 2H), 1.18-1.21 (m, 2H), 1.31-1.33 (m, 2H), 1.62-1.65 (m, 3H), 1.72 (t, J = 7.72 Hz, 2H), 2.29 (s, 3H),
416
414





2.80 (t, J = 7.94 Hz,







2H), 2.96-2.99 (m, 1H),







3.11 (d, J = 6.40 Hz, 2H),







3.16 (d, J = 6.62 Hz,







2H), 3.37 (t, J = 10.92 Hz,







2H), 3.94-3.97 (m, 2H),







7.08 (t, J = 7.94 Hz, 1H),







7.17 (d, J = 8.16 Hz, 1H),







7.57 (s, 1H), 8.93 (s, 1H)








F-171


embedded image


(400 MHz, CDCl3) 0.98 (s, 2H), 1.17-1.19 (m, 8H), 2.29 (s, 3H), 3.05-3.16 (m, 11H), 7.08 (d, J = 7.94 Hz, 1H), 7.15 (d, J = 10.00 Hz, 1H), 7.55 (s, 1H), 8.81 (s, 1H)
390
388






F-172


embedded image


(400 MHz, CDCl3) 0.80-0.84 (m, 2H), 1.14 (d, J = 6.18 Hz, 2H), 2.26 (s, 3H), 2.71 (s, 1H), 3.08 (s, 2H), 3.12 (d, J = 6.40 Hz, 2H), 3.37 (t, J = 6.73 Hz, 2H), 4.63 (q, J = 6.47 Hz,
399
397





2H), 6.14 (dd, J = 5.18,







3.20 Hz, 1H), 7.09 (t, J =







8.05 Hz, 1H), 7.17 (d, J =







7.94 Hz, 1H), 7.30 (s, 1H),







7.49 (s, 1H), 7.61 (s,







1H), 8.67 (s, 1H)








F-173


embedded image


(400 MHz, CDCl3) 0.78 (s, 2H), 0.96-0.99 (m, 2H), 1.15-1.24 (m, 6H), 1.68-1.73 (m, 7H), 2.07 (d, J = 2.65 Hz, 3H), 2.32 (s, 3H), 2.73-2.80 (m, 3H), 3.27 (t, J = 11.03 Hz, 1H), 3.67-3.71 (m, 2H), 3.79 (d, J = 6.40 Hz, 3H), 3.90-3.99 (m, 2H), 4.28 (q, J = 6.40 Hz, 3H), 6.63 (t, J = 9.26 Hz, 2H), 6.97 (d, J = 7.50 Hz, 1H), 7.23 (s, 1H)
508
506
Racemic form




















TABLE 174










ms
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-174


embedded image


(400 MHz, CDCl3) 0.95-0.99 (m, 8H), 1.16-1.21 (m, 2H), 1.64-1.70 (m, 3H), 2.24 (s, 3H), 2.78- 2.81 (m, 2H), 2.94- 3.00 (m, 1H), 3.05- 3.09 (m, 2H), 3.14- 3.18 (m, 2H), 3.35 (s, 3H), 4.40 (s, 2H), 7.02 (d, J = 5.84 Hz, 1H), 7.13 (d, J = 7.66
385
383





Hz, 1H), 7,84 (s,







1H), 8.45(s, 1H)








F-175


embedded image


(400 MHz, CDCl3) 0.92-0.99 (m, 8H), 1.08-1.12 (m, 1H), 1.18-1.21 (m, 2H), 1.59-1.65 (m, 3H), 1.94-2.01 (m, 1H), 2.05-2.12 (m, 1H), 2.17 (s, 3H), 2.76-2.80 (m, 2H), 2.92 (dd, J =
419
417
Racemic form




14.10, 4.84 Hz, 1H),







2.98-3.04 (m, 1H), 3.16







(dd, J = 14.10, 10.07 Hz,







1H), 3.67-3.80 (m, 2H),







3.94-4.01 (m, 1H), 7.06







(dd, J = 8.87, 7.25 Hz,







1H), 7.16 (d, J = 7.66 Hz,







1H), 7.44 (d, J = 8.46 Hz,







1H), 8.25 (s, 1H)








F-176


embedded image


(400 MHz, CDCl3) 0.75-0.84 (m, 1H), 0.96 (d, J = 6.40 Hz, 6H), 0.98-1.04 (m, 1H), 1.06-1.15 (m, 2H), 1.58-1.70 (m, 4H), 1.83-1.94 (m, 1H), 1.95-2.07 (m, 1H), 2.32 (s, 3H), 2.55-2.66 (m, 1H), 2.66-2.73
429
427
Racemic form




(m, 2H), 2.78-2.88







(m, 1H), 2.88-2.96







(m, 1H), 3.53-3.69







(m, 2H), 3.81 (s, 3H),







3.85-3.96 (m, 1H),







4.19-4.31 (m, 2H),







6.28-6.37 (m, 1H),







6.63 (s, 1H), 6.66 (d,







J = 7.50 Hz, 1H), 6.97







(d, J = 7.50 Hz, 1H)




















TABLE 175










ms
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-177


embedded image


(400 MHz, DMSO-D6) 0.81-0.92 (m, 5H), 0.94-0.98 (m, 2H), 1.05-1.10 (m, 2H), 1.17-1.29 (m, 2H), 1.55-1.61 (m, 2H), 1.63-1.67 (m, 2H), 1.73-1.77 (m, 2H),
429
427





2.17 (s, 3H), 2.73







(t, J = 8.00 Hz, 2H),







2.87 (t, J = 7.19 Hz,







2H), 3.03 (t, J = 7.19







Hz, 2H), 3.07-3.13







(m, 1H), 7.16 (t, J =







7.88 Hz, 1H), 7.25







(d, J = 7.42 Hz, 1H),







7.30 (dd, J = 7.88, 1.16







Hz, 1H), 9.66 (s, 1H)








F-178


embedded image


(400 MHz, CDCl3) 0.97 (tt, J = 9.86, 3.40 Hz, 2H), 1.09-1.21 (m, 2H), 1.46 (dt, J = 9.35, 4.00 Hz, 9H), 2.28 (dd, J = 15.65, 9.62 Hz, 3H), 3.06-3.10
419
417





(m, 3H), 3.19 (t, J =







6.15 Hz, 2H), 3.86







(ddd, J = 16.99, 10.15,







4.12 Hz, 2H), 7.09







(dd, J = 18.44, 10.32







Hz, 1H), 7.16 (d, J =







7.88 Hz, 1H), 7.56 (dd,







J = 18.90, 9.16 Hz,







1H), 8.88 (s, 1H)








F-179


embedded image


(400 MHz, CDCl3) 0.89-0.94 (m, 2H), 0.96 (d, J = 5.95 Hz, 6H), 1.12-1.18 (m, 2H), 1.63-1.71 (m, 3H), 2.73-2.78 (m, 2H), 2.82 (t, J = 7.06 Hz, 2H), 2.92 (tt, J = 7.12,
371
369





3.96 Hz, 1H), 3.10







(t, J = 7.17 Hz,







2H), 3.85 (s, 3H),







4.40 (d, J = 5.95 Hz,







2H), 6.53 (brs, 1H),







6.85 (d, J = 7.94 Hz,







1H), 6.88 (t, J = 7.39 Hz,







1H), 7.18-7.26 (m, 2H)




















TABLE 176










ms
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-180


embedded image


(400 MHz, CDCl3) 1.03-1.09 (m, 2H), 1.17-1.24 (m, 2H), 2.25 (s, 3H), 2.29 (s, 3H), 3.03-3.12 (m, 3H), 3.15-3.22 (m, 2H), 4.46 (s, 2H), 6.65 (d, J = 8.58 Hz, 2H), 7.02 (d, J =
424
422





8.58 Hz, 2H), 7.08 (dd,







J = 7.88, 7.65 Hz, 1H),







7.16 (d, J = 7.88 Hz, 1H),







7.63 (d, J = 7.65 Hz,







1H), 8.53 (brs, 1H)








F-181


embedded image


(400 MHz, DMSO-D6) 0.87 (s, 9H), 0.94-0.98 (m, 2H), 1.05-1.10 (m, 2H), 1.22-1.27 (m, 2H), 1.67 (tt, J = 11.71, 4.10 Hz, 2H), 2.18 (s, 3H), 2.69 (t, J = 7.65 Hz, 2H), 2.88 (t, J = 7.07
403
402





Hz, 2H), 3.03 (t, J = 7.30







Hz, 2H), 3.07-3.13 (m,







1H), 7.16 (t, J = 7.88 Hz,







1H), 7.25 (d, J = 7.42 Hz,







1H), 7.30 (dd, J = 7.88,







1.16 Hz, 1H), 9.66







(brs, 1H)








F-182


embedded image


(400 MHz, CDCl3) 0.95-1.04 (m, 8H), 1.14-1.28 (m, 3H), 1.75-1.97 (m, 3H), 2.26 (s, 3H), 3.05 (tt, J = 9.26, 4.67 Hz, 3H), 3.19 (dd, J = 14.00, 8.93 Hz, 2H), 4.97 (dd,
391
389
Racemic form




J = 8.93, 4.74 Hz, 1H),







7.08 (t, J = 7.94 Hz, 1H),







7.17 (d, J = 7.94 Hz, 1H),







7.58 (d, J = 7.72 Hz, 1H),







8.58 (s, 1H)








F-183


embedded image


(400 MHz, CDCl3) 0.99-1.03 (m, 2H), 1.20-1.23 (m, 2H), 1.26 (t, J = 7.19 Hz, 3H), 2.28 (s, 3H), 2.95 (t, J = 6.80 Hz, 2H), 3.00-3.10 (m, 5H), 3.18 (t, J = 6.03 Hz, 2H),
405
403





4.15 (q, J = 7.19 Hz, 2H),







7.09 (t, J = 8.12 Hz, 1H),







7.17 (d, J = 8.35 Hz, 1H),







7.64 (d, J = 7.65 Hz, 1H),







8.68 (brs, 1H)




















TABLE 177











Infor-





ms
mation of












Example
Chemical structure
NMR
M + H
M − H
structure





F-184


embedded image


(400 MHz, CDCl3) 0.99-1.03 (m, 2H), 1.18-1.24 (m, 2H), 2.27 (s, 3H), 2.93 (s, 3H), 2.96 (t, J = 7.06 Hz, 2H), 3.01- 3.08 (m, 3H), 3.06
404
402





(s, 3H), 3.11 (t, J =







6.95 Hz, 2H), 3.17







(t, J = 6.18 Hz,







2H), 7.08 (t, J =







8.05 Hz, 1H), 7.15







(d, J = 7.72 Hz,







1H), 7.65 (d, J =







7.94 Hz, 1H),







8.73 (brs, 1H)








F-185


embedded image


(400 MHz, DMSO- D6) 0.97-1.01 (m, 2H), 1.07-1.12 (m, 2H), 2.19 (s, 3H), 2.73 (t, J = 7.19 Hz, 2H), 2.88 (t, J = 7.19 Hz, 2H), 2.94 (t, J = 7.19 Hz, 2H), 3.03
377
375





(t, J = 7.30 Hz, 2H),







3.09-3.14 (m, 1H),







7.17 (t, J = 7.88 Hz,







1H), 7.26 (d, J =







8.00 Hz, 1H), 7.31







(dd, J = 7.60, 0.80







Hz, 1H), 9.66 (brs,







1H), 12.17 (brs, 1H)








F-186


embedded image


(400 MHz, CDCl3) 0.96 (s, 2H), 1.16- 1.20 (m, 3H), 1.45 (s, 9H), 1.53-1.73 (m, 6H), 1.85 (s, 1H), 2.29 (s, 3H), 2.82 (t, J = 8.05
516
514
Racemic form




Hz, 3H), 2.96-2.99







(m, 1H), 3.09 (d, J =







6.84 Hz, 2H), 3.16







(d, J = 6.84 Hz, 2H),







3.92 (s, 2H), 7.08







(t, J = 7.94 Hz, 1H),







7.16 (d, J = 7.72







Hz, 1H), 7.62 (d, J =







7.72 Hz, 1H),







8.84 (s, 1H)








F-187


embedded image


(400 MHz, CDCl3) 0.98-1.01 (m, 2H), 1.21-1.24 (m, 3H), 1.73-1.75 (m, 3H), 2.23 (t, J = 6.29 Hz, 2H), 2.31 (s, 3H), 3.05-3.20 (m, 7H), 3.35 (t, J = 5.51
430
428





Hz, 2H), 3.75 (t, J =







7.06 Hz, 2H), 7.08 (t,







J = 8.05 Hz, 1H), 7.16







(d, J = 7.94 Hz, 1H),







7.64 (d, J = 7.94 Hz,







1H), 8.73(s, 1H)




















TABLE 178











Infor-





ms
mation of












Example
Chemical structure
NMR
M + H
M − H
structure





F-188


embedded image


(400 MHz, CDCl3) 0.90-0.99 (m, 4H), 1.17-1.28 (m, 6H), 1.67-1.75 (m, 7H), 2.33 (s, 3H), 2.74-2.82 (m, 4H), 2.90-2.93 (m, 1H), 3.09 (t, J = 7.17
425
423





Hz, 2H), 3.83 (s,







3H), 4.35 (d, J = 5.95







Hz, 2H), 6.50 (s,







1H), 6.67-6.69 (m,







2H), 7.08 (d, J =







7.50 Hz, 1H)








F-189


embedded image


(400 MHz, MeOH- D4) 1.31-1.35 (m, 5H), 1.86-1.91 (m, 6H), 2.26 (s, 3H), 2.75 (t, J = 12.46 Hz, 1H), 2.93 (t, J = 12.79 Hz, 1H), 3.14 (t, J = 6.62 Hz, 4H), 3.35-3.39 (m,
416
414
Racemic form




3H), 3.66 (s, 4H),







7.15 (t, J = 7.94 Hz,







1H), 7.25 (dd, J =







13.67, 7.94 Hz, 2H)








F-190


embedded image


(400 MHz, CDCl3) 0.94-1.00 (m, 2H), 1.19-1.23 (m, 3H), 1.42-1.48 (m, 2H), 1.69-1.73 (m, 3H), 2.08 (s, 3H), 2.27 (s, 3H), 2.43 (t, J = 11.58 Hz, 1H),
458
456
Racemic form




2.77-2.82 (m, 3H),







2.97-3.19 (m, 6H),







3.67-3.72 (m, 1H),







4.33 (d, J = 8.82 Hz,







1H), 7.08 (t, J = 7.94







Hz, 1H), 7.16 (d, J =







7.50 Hz, 1H), 7.58 (d,







J = 7.50 Hz, 1H), 8.95







(d, J = 58.88 Hz, 1H)








F-191


embedded image


(400 MHz, CDCl3) 0.95-0.98 (m, 4H), 1.17-1.25 (m, 6H), 1.67-1.72 (m, 7H), 2.13 (s, 3H), 2.15 (s, 3H), 2.27 (s, 3H), 2.78-2.82 (m, 2H), 2.98 (s, 1H), 3.28-3.33 (m, 1H), 3.72 (dd, J = 8.38, 4.19 Hz, 1H), 3.92 (s, 1H), 4.19-4.26 (m, 2H), 4.44 (t, J = 9.92 Hz, 1H), 6.95-
478
476
Racemic form




6.97 (m, 2H), 7.74







(d, J = 7.94 Hz,







1H), 9.07 (s, 1H)




















TABLE 179










ms
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-192


embedded image


(400 MHz, CDCl3) 0.92 (d, J = 6.45 Hz, 6H), 0.94-0.98 (m, 2H), 1.15-1.20 (m, 2H), 1.57-1.63 (m, 3H), 2.14 (s, 3H), 2.71-2.75 (m, 2H), 2.93-2.99 (m, 1H), 3.08 -3.11 (m, 2H), 3.16-3.19 (m, 2H),
357
355





6.51 (dd, J = 8.06,







2.42 Hz, 1H), 6.93







(d, J = 8.46 Hz, 1H),







7.27 (d, J = 2.82 Hz, 1H),







7.59 (s, 1H), 8.78 (s, 1H)








F-193


embedded image


(400 MHz, CDCl3) 0.89-0.94 (m, 8H), 1.13-1.19 (m, 2H), 1.59-1.63 (m, 3H), 2.15 (s, 3H), 2.42-2.54 (m, 2H), 2.74-2.87 (m, 3H), 2.94-3.00 (m, 1H), 3.15 (dd, J = 13.90, 11.48 Hz, 1H), 3.75-3.82 (m, 1H),
415
413
Racemic form




5.04-5.08 (m, 2H),







5.71-5.81 (m, 1H),







7.04 (dd, J = 8.06,







8.06 Hz, 1H), 7.15







(d, J = 7.66 Hz, 1H),







7.43 (d, J = 8.06 Hz, 1H),







8.08 (s, 1H)








F-194


embedded image


(400 MHz, CDCl3) 0.88-0.95 (m, 11H), 1.12-1.18 (m, 3H), 1.25-1.34 (m, 1H), 1.37-1.44 (m, 1H), 1.60-1.66 (m, 2H), 1.69-1.76 (m, 2H), 2.14 (s, 3H), 2.76-2.85 (m, 3H), 2.93-2.98
417
415
Racemic form




(m, 1H), 3.13 (dd,







J = 13.70, 10.88 Hz,







1H), 3.66-3.74 (m, 1H),







7.04 (dd, J = 8.46, 8.46







Hz, 1H), 7.14 (d, J = 8.06







Hz, 1H), 7.43 (d, J = 8.06







Hz, 1H), 8.23 (s, 1H)




















TABLE 180










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-195


embedded image


(400 MHz, CDCl3) 0.83-0.90 (m, 1H), 0.94 (d, J = 6.40 Hz, 6H), 1.05-1.18 (m, 3H), 1.48-1.70 (m, 5H), 1.73-1.83 (m, 2H), 2.10 (s, 3H), 2.72-2.80 (m, 2H), 2.83-2.97 (m, 2H), 3.11- 3.20 (m, 1H), 3.31-3.42 (m, 2H), 3.68-3.77 (m, 1H), 4.43 (s, 2H), 7.01 (t, J = 8.05 Hz, 1H), 7.13 (d, J = 7.72 Hz, 1H), 7.25-7.38 (m, 6H),
523
521
Racemic form




8.79 (brs, 1H)








F-196


embedded image


(400 MHz, CDCl3) 0.86-0.98 (m, 7H), 1.15-1.23 (m, 3H), 1.49-1.71 (m, 4H), 1.77-1.96 (m, 3H), 2.12 (s, 3H), 2.73- 2.80 (m, 2H), 2.89 (dd, J = 14.22, 4.30 Hz, 1H), 2.96-3.03 (m, 1H), 3.15 (dd, J = 14.00, 10.45 Hz, 1H), 3.60 (t, J = 6.18
433
431
Racemic form




Hz, 2H), 3.74-3.83 (m,







1H), 7.03 (t, J = 8.05 Hz,







1H), 7.15 (d, J = 7.94 Hz,







1H), 7.34 (d, J = 7.72







Hz, 1H), 8.80 (brs, 1H)








F-197


embedded image


(400 MHz, CDCl3) 0.86-0.94 (m, 7H), 1.09-1.30 (m, 5H), 1.54-1.61 (m, 1H), 1.72-1.81 (m, 2H), 2.16 (s, 3H), 2.44-2.56 (m, 2H), 2.73-2.80 (m, 2H), 2.84 (dd, J = 14.03, 3.59 Hz, 1H), 2.93-3.00 (m, 1H), 3.17 (dd, J = 13.45,
429
427
Racemic form




11.13 Hz, 1H), 3.73-3.81







(m, 1H), 5.04-5.11 (m,







2H), 5.71-5.82 (m







1H), 7.05 (t, J = 7.77 Hz,







1H), 7.15 (d, J = 8.12







Hz, 1H), 7.46 (d,







J = 7.65 Hz, 1H), 7.96







(brs, 1H)




















TABLE 181










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-198


embedded image


(400 MHz, CDCl3) 0.84-0.92 (m, 7H), 1.09-1.19 (m, 3H), 1.20-1.28 (m, 2H), 1.52-1.62 (m, 1H), 1.75 (d, J = 38.82 Hz, 2H), 2.06 (s, 3H), 2.24 (s, 3H), 2.47- 2.55 (m, 2H), 2.75 (t, J = 7.72 Hz, 2H), 2.81 (dd, J = 14.00, 3.86 Hz, 1H), 2.93-
409
407
Racemic form




2.99 (m, 1H), 3.11 (dd,







J = 14.00, 11.14 Hz, 1H),







3.75-3.84 (m, 1H), 5.04-







5.12 (m, 2H), 5.71-







5.82 (m, 1H), 6.90-6.96







(m, 2H), 7.43 (d,







J = 8.60 Hz, 1H), 7.50







(brs, 1H)








F-199


embedded image


(400 MHz, CDCl3) 0.88 (d, J = 6.62 Hz, 6H), 0.93-0.99 (m, 1H), 1.06-1.13 (m, 1H), 1.17-1.21 (m, 2H), 1.24- 1.29 (m, 2H), 1.52-1.62 (m, 1H), 1.71-1.81 (m, 2H), 1.93-2.13 (m, 2H), 2.17 (s, 3H), 2.76 (dd, J = 7.83, 3.91 Hz, 2H), 2.92 (dd, J = 14.11, 4.41 Hz, 1H), 2.99-3.04 (m, 1H), 3.18 (dd, J = 14.22, 10.26 Hz, 1H), 3.66-3.81 (m, 2H), 3.93-4.01 (m, 1H), 7.06 (t, J = 8.05 Hz, 1H), 7.16 (d, J = 7.50 Hz, 1H), 7.45 (d, J = 7.72 Hz, 1H), 8.23 (brs, 1H)
433
431
Racemic form





F-200


embedded image


(400 MHz, CDCl3) 0.67-0.73 (m, 1H), 0.89 (dd, J = 6.49, 0.70 Hz, 6H), 1.00-1.13 (m, 3H), 1.21-1.30 (m, 2H), 1.54-1.63 (m, 1H), 1.72-1.80 (m, 2H), 2.32 (s, 3H), 2.37-2.49 (m, 2H), 2.57-2.71 (m, 3H), 2.80-2.88 (m, 2H), 3.68-3.75 (m, 1H), 3.81 (s, 3H), 4.17- 4.27 (m, 2H), 4.95-5.02
439
437
Racemic form




(m, 2H), 5.63-5.74







(m, 1H), 6.19 (brs, 1H),







6.61 (s, 1H), 6.64 (d,







J = 7.42 Hz, 1H), 6.95







(d, J = 7.42 Hz, 1H)




















TABLE 182










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-201


embedded image


(400 MHz, CDCl3) 0.87 (d, J = 6.62 Hz, 6H), 0.92-0.99 (m, 1H), 1.06-1.11 (m, 1H), 1.12-1.30 (m, 4H), 1.51-1.62 (m, 1H), 1.69-1.79 (m, 2H), 1.93-2.14 (m, 2H), 2.07 (s, 3H), 2.25 (s, 3H), 2.74 (t, J = 7.94 Hz, 2H), 2.87 (dd,
413
411
Racemic form




J = 14.11, 4.63 Hz, 1H),







2.97-3.05 (m, 1H), 3.12







(dd, J = 14.00, 10.03 Hz,







1H), 3.66-3.78 (m, 2H),







3.94-4.02 (m, 1H), 6.91-







6.96 (m, 2H), 7.42 (d,







J = 8.60 Hz, 1H), 7.75







(brs, 1H)








F-202


embedded image


(400 MHz, CDCl3) 0.77-0.83 (m, 1H), 0.90 (d, J = 6.62 Hz, 6H), 0.96-1.03 (m, 1H), 1.07-1.15 (m, 2H), 1.23- 1.31 (m, 2H), 1.54- 1.64 (m, 1H), 1.73-1.81 (m, 2H), 1.85-1.93 (m, 1H), 1.98-2.07 (m, 1H), 2.32 (s, 3H), 2.60 (dd, J = 14.22, 5.62 Hz, 1H), 2.63-2.69 (m, 2H), 2.33 (dd, J = 14.11, 9.26 Hz, 1H), 2.88-2.94 (m, 1H),
443
441
Racemic form




3.56-3.67 (m, 2H), 3.82







(s, 3H), 3.87-3.94 (m,







1H), 4.21-4.30 (m, 2H),







6.27 (brt, J = 5.73 Hz,







1H), 6.63 (s, 1H), 6.66







(d, J = 8.16 Hz, 1H), 6.98







(d, J = 7.28 Hz, 1H)








F-203


embedded image


(400 MHz, CDCl3) 0.82-0.91 (m, 1H), 0.94-0.97 (m, 2H), 1.17-1.19 (m, 2H), 1.60-1.64 (m, 6H), 1.76-1.85 (m, 2H), 2.25 (s, 3H), 2.28 (s, 3H), 2.76-2.79 (m, 4H), 2.95-2.99 (m, 1H), 3.11-3.15 (m, 4H), 7.07
430
428
Racemic form




(t, J = 8.05 Hz, 1H), 7.16







(d, J = 7.72 Hz, 1H), 7.56







(s, 1H),







9.12 (s, 1H)




















TABLE 183










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-204


embedded image


(400 MHz, CDCl3) 0.89-1.00 (m, 8H), 1.11-1.20 (m, 2H), 1.62-1.70 (m, 3H), 2.33 (s, 3H), 2.70- 2.80 (m, 2H), 2.80- 2.87 (m, 2H), 2.89- 2.98 (m, 1H), 3.06- 3.12 (m, 2H), 3.81 (s, 3H), 4.28-4,34 (m, 2H), 6.62-6.71 (m, 2H), 7.08 (brs, 1H)
419
417






F-205


embedded image


(400 MHz, CDCl3) 0.86-0.94 (m, 2H), 0.94-1.00 (m, 6H), 1.11-1.19 (m, 2H), 1.64-1.72 (m, 3H), 2.16 (s, 3H), 2.23 (s, 3H), 2.72- 2.82 (m, 4H), 2.88-2.97 (m, 1H), 3.06-3.13 (m, 2H), 3.81 (s, 3H), 4.31-4.36 (m, 2H), 6.38 (brs, 1H), 6.64 (brs, 1H), 6.98 (brs, 1H)
399
397






F-206


embedded image


(400 MHz, CDCl3) 1.04-1.10 (m, 2H), 1.16-1.23 (m, 2H), 2.13 (s, 3H), 2.24 (s, 3H), 2.27 (s, 3H), 3.03- 3.14 (m, 3H), 3.15- 3.23 (m, 2H), 4.48 (s, 2H), 6.66 (d, J = 7.94 Hz, 1H), 6.91 (s,
438
436





1H), 6.94 (d, J = 7.94







Hz, 1H), 7.07 (dd,







J = 8.05, 4.02 Hz, 1H),







7.16 (d, J = 7.72 Hz,







1H), 7.59 (d, J = 7.94







Hz, 1H), 8.62 (brs, 1H)








F-207


embedded image


(400 MHz, CDCl3) 1.04-1.10 (m, 2H), 1.17-1.24 (m, 2H), 2.16 (s, 3H), 2.20 (s, 3H), 2.29 (s, 3H), 3.04-3.13 (m, 3H), 3.15-3.22 (m, 2H), 4.46 (s, 2H), 6.50 (dd, J = 8.16, 2.21 Hz, 1H), 6.55 (d,
438
436





J = 2.21 Hz, 1H), 6.96







(d, J = 8.16 Hz, 1H),







7.08 (t, J = 8.05 Hz,







1H), 7.16 (d, J = 7.94







Hz, 1H), 7.62 (d,







J = 7.94 Hz, 1H),







8.56 (brs, 1H)




















TABLE 184










MS
information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-208


embedded image


(400 MHz, CDCl3) 0.91-0.95 (m, 2H), 0.96 (d, J = 6.40 Hz, 6H), 1.14-1.20 (m, 2H), 1.63-1.71 (m, 3H), 2.74-2.80 (m, 2H), 2.86 (t, J = 6.95 Hz, 2H), 2.94 (tt, J = 7.12, 3.96 Hz, 1H), 3.10 (t, J = 6.95 Hz, 2H), 3.82 (s, 3H), 4.36 (d, J = 6.18 Hz, 2H), 6.74 (dd, J = 8.93, 4.30 Hz,
389
387





1H), 6.77 (brs, 1H),







6.81-6.91 (m, 2H)








F-209


embedded image


(400 MHz, CDCl3) 1.10-1.15 (m, 2H), 1.22-1.31 (m, 2H), 2.20 (s, 3H), 3.04 (t, J = 5.95 Hz, 2H), 3.15- 3.21 (m, 3H), 5.05 (s, 2H), 7.06 (t, J = 7.94 Hz, 1H), 7.15 (d, J = 7.94 Hz, 1H), 7.56 (d, J =
464
462





8.60 Hz, 1H), 7.74







(dd, J = 5.51,







3.09 Hz, 2H), 7.88







(dd, J = 5.18,







2.98 Hz, 2H),







8.46 (s, 1H)








F-210


embedded image


(400 MHz, CDCl3) 0.95 (dd, J = 9.70, 7.06 Hz, 2H), 1.14- 1.22 (m, 2H), 1.24 (dd, J = 12.90, 6.29 Hz, 6H), 1.97-2.01 (m, 2H), 2.28 (s, 3H), 2.73-2.77 (m, 2H), 2.96-3.02 (m, 1H), 3.09 (t, J = 6.29 Hz,
433
431





2H), 3.16 (t, J = 6.18







Hz, 2H), 3.66 (s, 3H),







7.05 (dd, J = 23.27,







15.11 Hz, 1H),







7.17 (t, J = 8.38 Hz,







1H), 7.56 (t, J =







12.68 Hz, 1H),







8.96 (s, 1H)








F-211


embedded image


(400 MHz, CDCl3) 0.86-0.99 (m, 2H), 1.10-1.37 (m, 4H), 1.61- 1.79 (m, 7H), 1.90-2.00 (m, 1H), 2.16 (s, 3H), 2.18- 2.32 (m, 1H), 2.26 (s, 3H), 2.71-2.79 (m, 2H), 2.97-3.15 (m, 4H), 3.57-3.67 (m, 1H), 6.93-7.00 (m,
431
429
Racemic form




2H), 7.54 (d, J =







8.82 Hz, 1H), 7.84







(brs, 1H)




















TABLE 185










Ms
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-212


embedded image


(400 MHz, CDCl3) 0.84-0.94 (m, 7H), 1.13-1.31 (m, 5H), 1.48- 1.94 (m, 7H), 2.12 (s, 3H), 2.71- 2.78 (m, 2H), 2.88 (dd, J = 14.11, 4.41 Hz, 1H), 2.96- 3.02 (m, 1H), 3.16 (dd, J = 14.11, 10.59 Hz, 1H), 3.60 (t, J = 6.18 Hz,
447
445
Racemic form




2H), 3.74-3.82







(m, 1H), 7.03 (t,







J = 8.05 Hz, 1H),







7.15 (d, J = 7.72 Hz,







1H), 7.35 (d, J =







7.72 Hz, 1H), 8.71







(s, 1H)








F-213


embedded image


(400 MHz, DMSO- D6) 0.85 (d, J = 6.72 Hz, 6H), 1.03-1.10 (m, 4H), 1.17-1.25 (m, 2H), 1,60-1.59 (m, 1H), 1.62- 1.72 (m, 2H), 2.06 (s, 3H), 2,54-2.92 (m, 6H), 3.08-3.12 (m, 1H), 3.90- 4.00 (m, 1H), 7.11-7.27 (m, 3H) 9.63 (s, 1H)
447
445
Racemic form





F-214


embedded image


(400 MHz, CDCl3) 0.83-0.91 (m, 7H), 1.14-1.20 (m, 3H), 1.22-1.28 (m, 2H), 1.49-1.96 (m, 7H), 2.03 (s, 3H), 2.23 (s, 3H), 2.69-2.77 (m, 2H), 2.82 (dd, J = 14.00, 4.74 Hz, 1H), 2.94-3.02 (m, 1H), 3.09 (dd, J = 14.11, 10.59 Hz, 1H), 3.61 (t, J = 6.18 Hz, 2H), 3.74-3.84 (m, 1H), 6.87-
427
425
Racemic form




8.95 (m, 2H), 7.31 (d,







J = 7.94 Hz, 1H),







8.17 (brs, 1H)








F-215


embedded image


(400 MHz, CDCl3) 0.89 (d, J = 6.62 Hz, 6H), 0.93-0.98 (m, 2H), 1.15-1.21 (m, 2H), 1.25-1.32 (m, 2H), 1.53- 1.64 (m, 1H), 1.74-1.83 (m, 2H), 2.19 (s, 3H), 2.26 (s, 3H), 2.73-279 (m, 2H), 2.96 (tt, J = 7.12, 3.96 Hz, 1H), 3.02-3.00 (m,
369
367





2H), 3.14-3.19 (m, 2H),







6.93-6.98 (m, 2H), 7.62







(d, J = 8.82 Hz, 1H), 8.28







(brs, 1H)




















TABLE 186










Ms
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-216


embedded image


(400 MHz, CDCl3) 0.89 (d, J = 6.62 Hz, 6H), 0.93-0.99 (m, 2H), 1.15-1.22 (m, 2H), 1.24-1.33 (m, 2H), 1.53-1.65 (m, 1H), 1.74-1.84 (m, 2H), 2.11 (s, 3H), 2.26 (s, 3H), 2.77 (t, J = 7.83 Hz, 2H), 2.96 (tt, J = 7.12, 3,96
369
367





Hz, 1H), 3.07 (t, J = 6.40







Hz, 2H), 3.18 (t, J =







6.29 Hz, 2H), 6.96 (d,







J = 7.50 Hz, 1H), 7.06







(dd, J = 7.94, 7.50 Hz,







1H), 7.47 (d, J =







7.94 Hz, 1H), 8.33







(brs, 1H)








F-217


embedded image


(400 MHz. CDCl3) 0.90 (d, J = 6.62 Hz, 6H), 0.90-0.94 (m, 2H), 1.12-1.19 (m, 2H), 1.25-1.33 (m, 2H), 1.54-165 (m, 1H), 1.74-1.84 (m, 2H), 2.33 (s, 3H), 2.73 (t, J = 7.83 Hz, 2H), 2.80 (t, J = 7.28 Hz, 2H), 292 (tt, J = 7.12, 3.96 Hz, 1H), 3.09
399
397





(t, J = 7.28 Hz, 2H),







3.83 (s, 3H), 4.35 (d,







J = 5.95 Hz, 2H), 6.43







(brs, 1H), 6.67 (s, 1H),







6.69 (d, J = 7.50 Hz,







1H), 7.08 (d, J = 7.50







Hz, 1H)








F-218


embedded image


(400 MHz, CDCl3) 0.99-1.03 (m, 2H), 1.12 (t, J = 7.77 Hz, 6H), 1.19 (dd, J = 12.75, 7.19 Hz, 2H), 2.28 (s, 3H), 2.98-3.18 (m, 7H), 3.53-3.59 (m, 1H), 3.81 (t, J = 6.96 Hz, 2H), 7.08 (t, J = 8.00
391
389





Hz, 1H), 7.16 (d,







J = 7.65 Hz, 1H),







7.60 (d, J = 7.65







Hz, 1H), 9.03 (s, 1H)




















TABLE 187










Ms
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-219


embedded image


(400 MHz, CDCl3) 0.89 (s, 9H), 0.94- 1.02 (m, 2H), 1.19-1.32 (m, 4H), 1.73-1.81 (m, 2H), 2.14 (s, 3H), 2.16 (d, J = 3.75 Hz, 3H), 2.25 (s, 3H), 2.77 (tt, J = 11.03, 4.70 Hz, 2H), 2.96- 3.01 (m, 1H), 3.30 (t, J = 11.03 Hz, 1H), 3.72 (dt, J = 18.01, 5.24 Hz, 1H), 3.91 (dt, J = 15.36, 4.80 Hz, 1H), 4.22 (ddd, J =
466
464
Racemic form




12.52, 8.10, 4.80 Hz, 2H),







4.45 (dd, J = 11.47, 8.38 Hz,







1H), 6.95 (d, J = 10.14 Hz,







2H), 7.74 (d, J = 7.94 Hz,







1H), 9.03 (s, 1H)








F-220


embedded image


(400 MHz, CDCl3) 0.89 (s, 3H), 0.90 (s, 3H), 0.97 (td, J = 9.92, 4.78 Hz, 2H), 1.22-1.32 (m, 3H), 1.56-1.63 (m, 2H), 1.76-1.84 (m, 2H), 2.14 (s, 3H), 2.16 (s, 3H), 2.25 (s, 3H), 2.78 (dq, J = 30.77, 7.54 Hz, 2H), 2.96-3.01 (m, 1H), 3.30 (t, J = 10.92 Hz, 1H), 3.71 (dd, J = 19.08, 10.70 Hz, 1H), 3.88-3.95 (m, 1H), 4.16-4.26 (m,
452
450
Racemic form




2H), 4.45 (dd, J = 11.47,







8.38 Hz, 1H), 6.95 (d,







J = 11.25 Hz, 2H), 7.76







(d, J = 8.16 Hz, 1H),







9.03 (s, 1H)








F-221


embedded image


(400 MHz, CDCl3) 1.00-1.04 (m, 2H), 1.17-1.35 (m, 8H), 2.29 (s, 3H), 2.42-2.49 (m, 1H), 3.00-3.09 (m, 3H), 3.20 (t, J = 6.29 Hz, 2H), 4.62 (d, J = 5.07 Hz, 2H), 6.61 (brs, 1H), 7.09 (t, J = 8.05 Hz, 1H), 7.17 (d, J = 7.50
404
402





Hz, 1H), 7.63 (d,







J = 7.72 Hz, 1H), 8.31







(brs, 1H)





















TABLE 188








Ms

Information


Example
Chemical structure
NMR
M + H
M − H
of structure







F-222


embedded image


(400 MHz, DMSO-D6) 1.09-1.10 (m, 13H), 1.96-1.99 (m, 3H), 2.04-2.05 (m, 3H), 2.22 (s, 3H), 2.92 (t, J = 6.26 Hz, 2H), 3.08-3.15 (m, 1H), 3.24- 4.13 (m, 8H), 6.93 (d, J = 8.12 Hz, 1H), 6.98 (s, 1H), 7.20 (dd, J = 16.46, 8.12Hz, 1H), 9.52 (d, J = 12.06 Hz, 1H)
468
466
Racemic form





F-223


embedded image


(400 MHz, DMSO-D6) 0.93-1.14 (m, 13H), 1.56-1.61 (m, 2H), 1.96-1.99 (m, 3H), 2.03-2.04 (m, 3H), 2.22 (s, 3H), 2.69- 2.74 (m, 2H), 3.08- 3.14 (m, 1H), 3.19-4.12 (m, 6H), 6.93 (d, J = 7.88 Hz, 1H), 6.99 (s, 1H), 7.19 (dd, J = 14.15, 7.88 Hz, 1H), 9.53 (d, J = 10.44 Hz, 1H)
452
450
Racemic form





F-224


embedded image


(400 MHz, CDCl3) 0.85-0.92 (m, 7H), 1.01-1.12 (m, 3H), 1.24- 1.30 (m, 3H), 1.54- 1.62 (m, 2H), 1.70- 1.79 (m, 2H), 2.14- 2.26 (m, 2H), 2.21 (s, 3H), 2.66-2.79 (m, 2H), 2.95-3.07 (m, 2H), 3.26-3.35 (m, 1H), 3.68-3.76 (m, 2H), 3.82-3.90 (m, 1H), 7.05 (t, J = 8.12 Hz, 1H), 7.14 (d, J = 8.35 Hz, 1H), 7.51 (d, J = 8.58 Hz, 1H), 7.72 (dd, J = 5.45, 2.90
562
560
Racemic form




Hz, 2H), 7.83 (dd,







J = 5.45, 3.13 Hz,







2H), 8.22 (brs, 1H)




















TABLE 189










Ms
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-225


embedded image


(400 MHz, CDCl3) 0.85-0.97 (m, 7H), 1.13-1.20 (m, 3H), 1.24-1.31 (m, 2H), 1.52-1.63 (m, 1H), 1.71-1.94 (m, 4H), 2.13 (s, 3H), 2.68-2.80 (m, 4H), 2.88 (dd, J = 14.00, 4.08 Hz, 1H), 2.96-3.04 (m, 1H), 3.16 (dd, J = 13.89, 10.59 Hz,
432
430
Racemic form




1H), 3.80-3.89 (m, 1H),







7.04 (t, J = 7.94 Hz, 1H),







7.15 (d, J = 7.72 Hz,







1H), 7.38 (d, J = 7.94 Hz,







1H), 8.69 (brs, 1H)








F-226


embedded image


(400 MHz, DMSO- D6) 0.99 (t, J = 9.15 Hz, 2H), 1.03-1.11 (m, 2H), 1.19 (d, J = 15.66 Hz, 6H), 1.87 (t, J = 8.60 Hz, 2H), 2.19 (s, 3H), 2.69 (dd, J = 10.26, 6.73 Hz, 2H), 2.88 (t, J = 6.95 Hz, 2H), 3.03 (t, J = 7.17 Hz, 2H), 3.11-
419
417





3.13 (m, 1H), 7.17 (t, J =







7.94 Hz, 1H), 7.26







(d, J = 7.72 Hz, 1H),







7.31 (d, J = 7.94 Hz, 1H),







9.66 (s, 1H), 12.24







(s, 1H)








F-227


embedded image


(400 MHz, CDCl3) 0.86-0.95 (m, 4H), 1.06-1.43 (m, 9H), 1.58-1.65 (m, 4H), 2.04 (s, 3H), 2.05 (s, 3H), 2.28 (s, 3H), 2.35- 2.47 (m, 1H), 2.58-2.63 (m, 1H), 2.77 (t, J = 8.35 Hz, 2H), 3.32- 3.37 (m, 1H), 3.79-3.95 (m, 3H), 5.57 (d, J = 7.65 Hz, 1H), 6.98- 7.00 (m, 2H), 7.47 (d, J = 7.65 Hz, 1H), 7.54
478
476





(s, 1H)




















TABLE 190










Ms
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-228


embedded image


(400 MHz, CDCl3) 0.64-0.69 (m, 1H), 0.81-1.37 (m, 9H), 1.57- 1.91 (m, 6H), 1.99 (s, 3H), 2.23- 2.42 (m, 5H), 2.68- 2.74 (m, 2H), 3.11- 3.15 (m, 1H) (3.38- 3.46 (m, 1H), 3.69- 3.86 (m, 2H), 3,77 (s, 3H), 4.24 (dd, J = 14.26, 5.22 Hz, 1H), 4.38 (dd, J =
508
506





14.15, 6.49 Hz,







1H), 5.36 (d, J =







7.88 Hz, 1H), 6.21







(t, J = 5.80 Hz,







1H), 6.63 (s, 1H),







6.69 (d, J = 7.65







Hz, 1H), 7.03 (d,







J = 7.42 Hz, 1H)








F-229


embedded image


(400 MHz, CDCl3) 0.89-0.93 (m, 2H), 0.94-0.98 (m, 6H), 1.11- 1.19 (m, 2H), 1.62-1.71 (m, 3H), 2.72-2.80 (m, 2H), 2.80-2.85 (m, 2H), 2.88-2.96 (m, 1H), 3.05- 3.11 (m, 2H), 3.83 (s, 3H), 4.31-
389
387





4.35 (m, 2H), 6.53-







6.60 (m, 2H),







6.64 (brs, 1H),







7.11-7.18 (m, 1H)








F-230


embedded image


(400 MHz, CDCl3) 0.95 (dt, J = 6.69, 2.37 Hz, 2H), 1.15- 1.23 (m, 8H), 1.61- 1.84 (m, H), 2.28 (d, J = 3.75 Hz, 3H), 2.78 (q, J = 7.42 Hz, 2H), 2.94- 3.02 (m, 1H), 3.07 (t, J = 6.06 Hz, 2H), 3.17
447
445





(dd, J = 7.17, 4.96







Hz, 2H), 3.65 (dd,







J = 22.27, 6.18 Hz,







3H), 7.05 (dd,







J = 24.37, 16.43







Hz, 1H), 7.16 (d,







J = 7.72 Hz, 1H),







7.63 (d, J = 8.16 Hz







1H), 8.76 (s, 1H)




















TABLE 191










Ms
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-231


embedded image


(400 MHz, CDCl3) 0.94 (dt, J = 7.65, 3.91 Hz, 2H), 1.17- 1.27 (m, 8H), 1.99 (dd, J = 9.15, 7.17 Hz, 2H), 2.28 (d, J = 10.37 Hz, 3H), 2.72- 2.78 (m, 5H), 3.04 (ddd, J = 15.82, 8.66, 4.36 Hz, 3H),
432
430





3.15 (dd, J = 15.11,







8.71 Hz,







2H), 5.76 (d, J =







3.75 Hz, 1H), 7.08







(t, J = 8.05 Hz, 1H),







7.16 (d, J = 7.94 Hz,







1H), 7.63 (d, J = 7.94







Hz, 1H), 8.87 (s, 1H)








F-232


embedded image


(400 MHz, DMSO- D6) 0.97 (t, J = 3.86 Hz, 2H), 1.07-1.10 (m, 8H), 1.54 (t, J = 7.94 Hz, 2H), 1.60-1.68 (m, 2H), 2.19 (s, 3H), 2.71 (t, J = 7.50 Hz, 2H), 2.88 (t, J = 7.06 Hz, 2H), 3.02- 3.10 (m, 3H),
433
431





7.17 (t, J = 8.05 Hz,







1H), 7.26 (d, J =







7.28 Hz, 1H), 7.31







(d, J = 7.94 Hz,







1H), 9.65 (s, 1H),







12.07 (s, 1H)








F-233


embedded image


(400 MHz, CDCl3) 1.00-1.02 (m, 2H), 1.17 (d, J = 6.72 Hz, 1H), 1.22- 1.24 (m, 7H), 2.13 (s, 3H), 2.28 (s, 3H), 3.02-3.11 (m, 5H), 3.19 (d, J = 6.72 Hz, 2H), 3.58-3.60 (m,
432
430





2H), 4.00-4.07 (m,







1H), 7.08 (t,







J = 8.00 Hz, 1H),







7.16 (d, J = 7.65 Hz,







1H), 7.57 (d, J =







8.12 Hz, 1H), 8.89







(s, 1H)








F-234


embedded image


(400 MHz, CDCl3) 0.89-0.90 (m, 2H), 1.18 (t, J = 6.18 Hz, 2H), 1.45 (s, 9H), 2.29 (s, 3H), 2.93-2.97 (m, 1H), 3.08 (s, 2H), 3.17 (t, J = 6.40 Hz, 2H), 3.94 (q, J = 7.65 Hz,
460
458





1H), 4.27-4.29 (m,







4H), 7.09 (t, J =







8.05 Hz, 1H),







7.17 (d, J = 7.94







Hz, 1H), 7.61 (d. J =







8.16 Hz, 1H), 8.47







(s, 1H)




















TABLE 192










Ms
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-235


embedded image


(400 MHz, CDCl3) 0.89 (t, J = 7.28 Hz, 3H), 0.94 (d, J = 6.62 Hz, 3H), 0.95-1.00 (m, 2H), 1.14-1.29 (m, 3H), 1.34-1.48 (m, 2H), 1.53-1.64 (m, 1H), 1.75-1.86 (m, 1H), 2.29 (s, 3H), 2.71- 2.88 (m, 2H),
389
387
Racemic form




2.97 (tt, J = 7.12,







3.96 Hz, 1H), 3.04-







3.12 (m, 2H), 3.13-







3.21 (m, 2H), 7.08 (dd,







J = 7.94, 7.72 Hz, 1H),







7.15 (d, J = 7.94 Hz,







1H), 7.64 (d, J = 7.72







Hz, 1H), 8.83







(brs, 1H)








F-236


embedded image


(400 MHz, CDCl3) 0.89 (t, J = 7.28 Hz, 3H), 0.94 (d, J = 6.40 Hz, 3H), 0.94-0.99 (m, 2H), 1.14-1.28 (m, 3H), 1.34-1.48 (m, 2H), 1.52- 1.63 (m, 1H), 1.75-1.85 (m, 1H), 2.18 (s, 3H), 2.26 (s, 3H), 2.70-2.87 (m, 2H), 2.97 (tt, J = 7.12, 3.96 Hz, 1H), 3.05 (t, J = 6.46 Hz, 2H), 3.17 (t, J = 6.46 Hz, 2H), 6.93-6.98 (m, 2H), 7.61 (d, J = 8.60 Hz,
369
367
Racemic form




1H), 8.28 (brs, 1H)








F-237


embedded image


(400 MHz, CDCl3) 0.93-0.97 (m, 2H), 1.14-1.22 (m, 8H), 1.62-1.68 (m, 2H), 1.82 (dq, J = 15.99, 4.48 Hz, 2H), 2.29 (s, 3H), 2.78 (dt, J = 15.29, 5.90 Hz, 5H), 2.94-2.99 (m, 1H), 3.07 (t,
446
444








J = 5.95 Hz, 2H),







3.17 (t, J = 6.06







Hz, 2H), 6.57 (s,







1H), 7.08 (t, J =







7.94 Hz, 1H), 7.17







(t, J = 7.83 Hz,







1H), 7.62 (d,







J = 7.94 Hz, 1H),







8.60 (s, 1H)




















TABLE 193










Ms
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-238


embedded image


(400 MHz, CDCl3) 0.94-0.98 (m, 2H), 1.17-1.23 (m, 2H), 1.26 (dd, J = 9.48, 4.85 Hz, 6H), 1.67- 1.81 (m, 4H), 2.29 (s, 3H), 2.80 (t, J = 7.06 Hz, 2H), 2.95-3.01 (m, 7H), 3.04-3.09 (m, 2H),
460
458





3.17 (t, J = 6.18 Hz,







2H), 7.05 (dd, J =







23.38, 15.44 Hz,







1H), 7.16 (d, J =







7.94 Hz, 1H),







7.53-7.62 (m, 1H),







8.82 (s, 1H)








F-239


embedded image


(400 MHz, CDCl3) 0.94-0.96 (m, 2H), 1.19-1.21 (m, 2H), 1.36 (d, J = 2.65 Hz, 6H), 1.55-1.61 (m, 2H), 2.12-2.18 (m, 2H), 2.31 (d, J = 2.21 Hz, 3H), 2.80 (dd, J = 15.00, 9.26 Hz, 2H), 3.01 (d, J = 14.56 Hz, 7H), 3.16 (d, J = 2.87 Hz,
446
444





2H), 7.09 (t, J =







7.39 Hz, 1H), 7.16







(d, J = 7.94 Hz, 1H),







7.66 (d, J = 6.84 Hz,







1H), 8.72 (s, 1H)








F-240


embedded image


(400 MHz, CDCl3) 0.88-1.02 (m, 3H), 1.20-1.28 (m, 7H), 1.37-1.47 (m, 2H), 1.64 (tt, J = 16.43, 5.99 Hz, 2H), 1.81- 1.86 (m, 2H) 1.98 (dt, J = 11.76, 2.92 Hz, 2H), 2.21 (ddd, J =
487
485








16.21, 8.27, 3.97







Hz, 1H), 2.26 (s, 3H),







2.77 (dq, J = 8.05,







2.46 Hz, 2H),







2.99 (ddd, J = 17.15,







9.76, 6.23 Hz, 1H),







3.12-3.18 (m, 4H),







4.14 (ddt, J = 23.80,







13.67, 4.00 Hz, 2H),







7.05 (dd, J = 21.17,







13.23 Hz, 1H), 7.16







(d, J = 7.94 Hz,







1H), 7,53 (d, J =







7.72 Hz, 1H),







9.20 (s, 1H)




















TABLE 194










Ms
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-241


embedded image


(400 MHz, CDCl3) 0.88-1.03 (m, 9H), 1.13-1.30 (m, 6H), 1.70- 1.77 (m, 4H), 2.34 (m, 3H), 2.76- 2.32 (m, 4H), 2.90- 2.95 (m, 1H), 3.10 (t, J = 7.07 Hz, 2H), 3.84 (s, 3H), 4.36 (d, J = 6.03 Hz, 2H), 6.44-
439
437





6.48 (brm, 1H), 6.67-







6.73 (m, 2H), 7.09 (d,







J = 7.42 Hz, 1H)








F-242


embedded image


(400 MHz, CDCl3) 0.95-0.99 (m, 2H), 1.15-1.27 (m, 3H), 1.34- 1.46 (m, 4H), 1.62- 1.56 (m, 2H), 1.69-1.75 (m, 2H), 1.89 (d, J = 11.36 Hz, 2H), 2.30 (s, 3H), 2.82
445
443





(t, J = 8.12 Hz, 2H),







2-94-3.00 (m, 1H),







3.06-3.11 (m, 2H),







3.15-3.20 (m, 2H),







3.31 (s, 3H), 3.41-







3.45 (brn, 1H), 7.09







(t, J = 8.12 Hz,







1H), 7.17 (d,







J = 7.65 Hz, 1H),







7.65 (d, J = 7.88 Hz,







1H), 8.76 (brs, 1H)








F-243


embedded image


(400 MHz, DMSO- D6) 0.96 (q, J = 11.76 Hz, 4H), 1.09 (t, J = 7.06 Hz, 2H), 1.24-1.33 (m, 3H), 1.59 (dd, J = 15.44, 7.06 Hz, 2H), 1.85 (dd, J = 30.66, 12.13 Hz, 4H), 2.12 (dd, J = 13.89, 10.37
459
457





Hz, 1H), 2.18 (s, 3H),







2.74 (t, J = 7.94 Hz,







2H), 2.88 (t, J = 6.84







Hz, 2H), 3.03 (t, J =







7.17 Hz, 2H), 3.11







(t, J = 3.53 Hz, 1H),







7.17 (t, J = 7.94







Hz, 1H), 7.26 (d,







J = 7.50 Hz, 1H),







7.30 (d, J = 8.16 Hz,







1H), 9.66 (s, 1H),







12.00 (s, 1H)




















TABLE 195











Infor-






mation


Exam-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure








F-244


embedded image


(400 MHz, CDCl3) 0.88-0.98 (m, 3H), 1.10-1.33 (m, 8H), 1.61- 1.79 (m, 6H), 2.15 (s, 3H), 2.43- 2.56 (m, 2H), 2.72-2 85 (m, 3H), 2.93- 2.99 (m, 1H), 3.16 (dd, J = 1370, 11.28 Hz, 1H), 3.75-3.82 (m, 1H), 5.07 (d, J = 12.09 Hz, 2H), 5.71-5.81 (m, 1H), 7.04 (dd, J = 8 06, 8 06 Hz, 1H), 7.15 (d, J = 7.66 Hz, 1H), 7.43 (d, J = 7.66 Hz, 1H), 8.03 (s, 1H)
455
453
Racemic form





F-245


embedded image


(400 MHz, CDCl3) 0.86-0.97 (m, 3H), 1.11-1.32 (m, 8H), 1.59- 1.76 (m, 6H), 2.05 (s, 3H), 2.24 (s, 3H), 2.44-2.57 (m, 2H), 2.75- 2.83 (m, 3H), 2.93-2.98 (m, 1H), 3.11 (dd, J = 13.70, 11.28 Hz, 1H), 3.77-3.84, (m, 1H), 5.05-5.09 (m, 2H), 5.71-5.81 (m, 1H), 6.93- 6.91 (m, 2H), 7.40 (d, J = 8.46 Hz, 1H), 7.61 (s, 1H)
435
433
Racemic form





F-246


embedded image


(400 MHz, CDCl3) 0.68-0.73 (m, 1H), 0.90-1.34 (m, 10H), 1.62- 1.79 (m, 6H), 2.32 (s, 3H), 2.38- 2.47 (m, 2H), 2.59 (dd, J = 14.10, 4.43 Hz, 1H), 2.64-2.74 (m, 2H), 2.80 -2.88 (m, 2H), 3.68-3.75 (m, 1H), 3.81 (s, 3H), 4.17-4.26 (m, 2H), 4.97-5.01 (m, 2H), 5.63- 5.73 (m, 1H), 6.22 (t, J = 6.04 Hz, 1H), 6.65-6.61 (m, 2H), 6.94 (d, J = 7.66 Hz, 1H)
465
463
Racemic form




















TABLE 196







Exam-


MS
Information












ple
Chemical structure
NMR
M + H
M − H
of structure








F-247


embedded image


(400 MHz, CDCl3) 0.85-0.98 (m, 3H), 1.09-1.32 (m, 7H), 1.57- 1.73 (m, 7H), 1.91-1.99 (m, 1H), 2.03-2.11 (m, 1H), 2.14 (s, 3H), 2,74-2.78 (m, 2H), 2.92-3.03 (m, 2H), 3.17 (dd, J = 14.31, 9.67 Hz, 1H), 3.65-3.78 (m, 2H), 4.02- 3.95 (m, 1H),7.04 (dd, J = 9.27, 8.06 Hz, 1H), 7.17 (d, J = 8.06 Hz, 1H), 7.37 (t, J = 7.25 Hz, 1H), 8.66 (s, 1H)
459
457
Racemic form





F-248


embedded image


(400 MHz, CDCl3) 0.87-0.97 (m, 3H), 1.08-1.30 (m, 8H), 1.58- 1.75 (m, 6H), 1.92-2.00 (m, 1H), 2.07 (s, 3H), 2.07-2.14 (m, 1H), 2.25 (s, 3H), 2.75-2.79 (m, 2H), 2.87 (dd, J = 13.90, 5.04 Hz, 1H), 2.97-3.02 (m, 1H), 3.11 (dd, J = 14.10, 10.07 Hz, 1H), 3.65-3.78 (m, 2H), 3.95-4.02 (m, 1H), 6.94- 6.92 (m, 2H), 7.40 (d, J = 8.46 Hz, 1H), 7.81 (s, 1H)
439
437
Racemic form





F-249


embedded image


(400 MHz, CDCl3) 0.77-0.82 (m, 1H), 0.90-1.02 (m, 3H), 1.07- 1.35 (m, 6H), 1.62-1.78 (m, 7H), 1.84-1.92 (m, 1H), 1.98-2.06 (m, 1H), 2.33 (s, 3H), 2.60 (dd, J = 14.10, 5.64 Hz, 1H), 2.68-2.72 (m, 2H), 2.83 (dd, J = 14.10, 9.27 Hz, 1H), 2.88-2.93 (m, 1H), 3.57-3.67 (m, 2H), 3.82 (s, 3H), 3.87-3.94 (m, 1H), 4.21-4.30 (m, 2H), 6.27 (t, J = 4.84 Hz, 1H), 6.63- 6.67 (m, 2H), 6.98 (d, J = 5.64 Hz, 1H)
409
467
Racemic form




















TABLE 197











Infor-






mation


Exam-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure








F-250


embedded image


(400 MHz, CDCl3) 0.91-1.05 (m, 4H), 1.16-1.23 (m, 2H), 1.23- 1.41 (m, 3H), 1.66-1.75 (m, 2H), 1.86-2.00 (m, 5H), 2.29 (s, 3H), 2.80 (t, J = 8.05 Hz, 2H), 2.97 (tt, J = 7.12, 3.96 Hz, 1H), 3.09 (t, J = 6.29 Hz, 2H), 3.17 (t, J = 6.29 Hz, 2H), 7.08 (dd, J = 7.94, 7.72 Hz, 1H), 7.16 (d, J = 7.94 Hz, 1H), 7.62 (d, J = 7.72 Hz, 1H),
483
481





8.79 (brs, 1H)








F-251


embedded image


(400 MHz, CDCl3) 0.89-1.06 (m, 4H), 1.13-1.19 (m, 2H), 1.24- 1.43 (m, 3H), 1.68-1.77 (m, 2H), 1.88-2.03 (m, 5H), 2.33 (s, 3H), 2.74-2.79 (m, 2H), 2.80 (t, J = 7.23 Hz, 2H), 2.93 (tt, J = 7.12, 3.96 Hz, 1H), 3.09 (t, J = 7.23 Hz, 2H), 3.83 (s, 3H), 4.35 (d, J = 5.95 Hz, 2H), 6.39 (brs, 1H), 6.67 (s, 1H), 6.70 (d, J = 7.61 Hz, 1H), 7.08 (d, J = 7.61 Hz, 1H)
493
491






F-252


embedded image


(400 MHz, DMSO-D6) 0.86 (d, J = 6.62 Hz, 6H), 1.04-1.11 (m, 4H), 1.19-1.26 (m, 2H), 1.51- 1.59 (m, 1H), 1.64-1.72 (m, 2H), 2.02 (s, 3H), 2.22 (s, 3H), 2.59- 2.74 (m, 4H), 2.77-2.88 (m, 2H), 3.06-3.14 (m, 1H), 3.90-4.00 (m, 1H), 6.91 (d, J = 7.72 Hz, 1H), 6.97 (s, 1H), 7.12 (d, J = 8.16 Hz, 1H), 9.25 (s, 1H), 12.18 (brs, 1H)
427
425
Racemic form




















TABLE 198











Infor-






mation


Exam-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure





F-253


embedded image


(400 MHz, CDCl3) 0.88 (d, J = 6.62 Hz, 6H), 1.05-1.32 (m, 6H), 1.50-1.80 (m, 3H), 2.09 (s, 3H), 2.25 (s, 3H), 2.70-2.84 (m, 4H), 2.93 (d, J = 7.28 Hz, 2H), 3.03-3.11 (m, 1H), 4.14-4.24 (m, 1H), 5.36 (brs, 1H), 6.48 (brs, 1H), 6.91-6.97 (m, 2H), 7.40 (d, J = 7.94 Hz, 1H), 8.14 (brs, 1H)
428
424
Racemic form





F-254


embedded image


(400 MHz, CDCl3) 0.85-1.01 (m, 2H), 1.24-1.83 (m, 10H), 2.06 (ddd, J = 18.97, 11.91, 8.49 Hz, 3H), 2.27 (s, 3H), 2.80 (t, J = 7.94 Hz, 2H), 2.95-3.00 (m, 1H), 3.10 (t, J = 6.06 Hz, 2H), 3.17 (t, J = 6.06 Hz, 2H), 7.07 (t, J = 8.05 Hz, 1H), 7.17 (d, J = 7.94 Hz, 1H), 7.55 (t, J = 6.95 Hz, 1H), 8.92 (s, 1H)
451
449






F-255


embedded image


(400 MHz, CDCl3) 0.97-1.92 (m, 13H), 2.30 (s, 3H), 2.78-2.83 (m, 2H), 2.94-2.97 (m, 5H), 3.04- 3.08 (m, 5H), 3.17 (t, J = 5.95 Hz, 2H), 7.08 (t, J = 8.16 Hz, 1H), 7.16 (d, J = 7.72 Hz, 1H), 7.65 (d, J = 8.16 Hz, 1H), 8.72 (s, 1H)
472
470






F-256


embedded image


(400 MHz, CDCl3) 0.96 (dt, J = 8.23, 3.53 Hz, 2H), 1.17-1.23 (m, 2H), 1.26-1.36 (m, 2H), 1.45 (s, 1H), 1.66-1.79 (m, 6H), 2.08 (ddd, J = 15.27, 8.22, 4.69 Hz, 2H), 2.19 (s, 3H), 2.26 (s, 3H), 2.72-2.83 (m, 2H), 2.94-2.99 (m, 1H), 3.05 (t, J = 6.40 Hz, 2H), 3.16 (q, J = 7.65 Hz, 2H), 6.98 (d, J = 14.11 Hz, 2H), 7.60 (t,
431
429





J = 4.41 Hz, 1H), 8.17 (s, 1H)




















TABLE 199











Infor-






mation


Exam-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure





F-257


embedded image


(400 MHz, CDCl3) 0.90-0.97 (m, 2H), 1.17 (ddd, J = 22.72, 10.59, 5.84 Hz, 2H), 1.32 (td, J = 15.38, 6.10 Hz, 2H), 1.48 (s, 1H), 1.63- 1.86 (m, 6H), 2.09 (ddd, J = 15.82, 8.66, 3.58 Hz, 2H), 2.33 (s, 3H), 2.79 (q, J = 7.20 Hz, 4H), 2.95 (ddd, J = 16.65, 9.26, 5.73 Hz, 1H), 3.10 (t, J = 7.17 Hz, 2H), 3.81 (s, 3H), 4.37 (t, J = 8.82 Hz, 2H), 6.40 (s, 1H), 6.69 (t, J = 7.61 Hz, 2H), 7.09 (t, J = 7.28 Hz, 1H)
461
459






F-258


embedded image


(400 MHz, CDCl3) 0.99-1.69 (m, 15H), 2.30 (s, 3H), 2.45-2.49 (m, 1H), 2.78-2.83 (m, 2H), 2.92- 2.99 (m, 4H), 3.04-3.08 (m, 5H), 3.17 (t, J = 5.95 Hz, 2H), 7.08 (t, J = 8.16 Hz, 1H), 7.16 (d, J = 7.72 Hz, 1H), 7.65 (d, J = 8.16 Hz, 1H), 8.72 (s, 1H)
488
484






F-259


embedded image


(400 MHz, CDCl3) 0.91 (t, J = 3.97 Hz, 2H), 1.11 (t, J = 6.62 Hz, 6H), 1.19 (dd, J = 6.84, 4.41 Hz, 2H), 2.28 (s, 3H), 2.44-2.50 (m, 1H), 2.96-2.99 (m, 1H), 3.13- 3.18 (m, 4H), 4.00 (dd, J = 10.70, 4.52 Hz, 1H), 4.18 (t, J = 7.94 Hz, 1H), 4.39 (t, J = 9.04 Hz, 1H), 4.49 (t, J = 8.49 Hz, 1H), 4.75 (t, J = 7.17 Hz, 1H), 7.08 (t, J = 8.05
430
428





Hz, 1H), 7.17 (d, J = 7.94 Hz, 1H),







7.57 (d, J = 7.94 Hz, 1H), 8.51







(s, 1H)




















TABLE 200







Exam-


MS
Information












ple
Chemical structure
NMR
M + H
M − H
of structure








F-260


embedded image


(400 MHz, CDCl3) 0.89 (d, J = 6.62 Hz, 8H), 1.15-1.18 (m, 2H), 1.58-1.65 (m, 1H), 2.28- 2.30 (m, 5H), 2.90-2.93 (m, 1H), 3.13-3.15 (m, 4H), 3.32 (t, J = 7.50 Hz, 2H), 3.80 (t, J = 7.28 Hz, 2H), 3.90 (dd, J = 15.66, 7.94 Hz, 1H), 7.08 (t, J = 7.94 Hz, 1H), 7.17 (d, J = 7.94 Hz, 1H), 7.56 (d, J = 7.94 Hz, 1H), 8.92 (s, 1H)
416
414






F-261


embedded image


(400 MHz, CDCl3) 0.97-0.99 (m, 2H), 1.19-1.26 (m, 2H), 1.93- 2.03 (m, 4H), 2.27 (s, 3H), 2.60 (t, J = 5.51 Hz, 4H), 2 87 (t, J = 7.06 Hz, 2H), 2.96-3.00 (m, 3H), 3.11 (d, J = 6.40 Hz, 2H), 3.16 (d, J = 6.40 Hz, 2H), 7.08 (t, J = 7.94 Hz, 1H), 7.17 (d, J = 7.72 Hz, 1H), 7.57 (d, J = 7.94 Hz, 1H), 8.91 (s, 1H)
452
450






F-262


embedded image


(400 MHz, CDCl3) 0.92-1.00 (m, 8H), 1.12-1.21 (m, 2H),1.35- 1.48 (m, 1H), 1.63-1.71 (m, 2H), 2.16 (s, 3H), 2.24 (s, 3H), 2.74- 2.81(m, 2H), 2.81-2.88 (m, 2H), 2.92-2.99 (m, 1H), 3.07-3.14 (m, 2H), 3.71 (s, 3H), 4.38-4.43 (m, 2H), 6.61 (brs, 1H), 6.84-6.89 (m, 1H), 6.92-6.98 (m, 1H)
399
397






F-263


embedded image


(400 MHz, CDCl3) 0.87-0.94 (m, 2H), 0.94-0.98 (m, 6H), 1.12- 1.19 (m, 2H), 1.63-1.69 (m, 3H), 2.71-2.79 (m, 2H), 2.84-2.89 (m, 2H), 2 89-2.96 (m, 1H), 3.06- 3.12 (m, 2H), 3.89 (s, 3H), 4.38- 4.44 (m, 2H), 6.85-6.93 (m, 1H), 7.02 (brs, 1H), 7.11-7.16 (m, 1H), 7.27-7.30 (m, 1H)
439
437




















TABLE 201











Infor-






mation


Exam-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure





F-264


embedded image


(400 MHz, DMSO-D6) 0.95-1.04 (m, 4H), 2.21 (t, J = 14.89 Hz, 3H), 2.88 (t, J = 7.28 Hz, 2H), 3.04-3.08 (m, 3H), 3.42 (s, 2H), 7.17 (t, J = 7.94 Hz, 1H), 7.25 (d, J = 7.50 Hz, 1H), 7.34 (d, J = 7.28 Hz, 1H), 9.87 (s, 1H)
363
361



F-265


embedded image


(400 MHz, CDCl3) 0.88 (d, J = 6.85 Hz, 6H), 1.05-1.09 (m, 2H), 1.20-1.30 (m, 5H), 1.71- 1.79 (m, 2H), 2.11 (s, 3H), 2.25 (s, 3H), 2.70-2.77 (m, 7H), 2.91 (d, J = 7.25 Hz, 2H), 3.03-3.09 (m, 1H), 4.13-4.20 (m, 1H), 6.28 (s, 1H), 6.93-6.95 (m, 2H), 7.44 (d, J = 8.06 Hz, 1H), 8.14 (s, 1H)
440
438
Racemic form


F-266


embedded image


(400 MHz, CDCl3) 0.87 (d, J = 6.45 Hz, 6H), 1.07-1.17 (m, 4H), 1.22-1.28 (m, 2H), 1.53- 1.64 (m, 1H), 1.68-1.76 (m, 2H), 2.08 (s, 3H), 2.25 (s, 3H), 2.71- 2.92 (m, 5H), 2.88 (s, 3H), 2.97 (s, 3H), 3.04-3.16 (m, 2H), 4.25- 4.32 (m, 1H), 6.93-6.94 (m, 2H), 7.46 (d, J = 8.46 Hz, 1H), 7.63 (s, 1H)
454
452
Racemic form


F-267


embedded image


(400 MHz, CDCl3) 0.56-0.66 (m, 1H), 0.79-1.35 (m, 12H), 1.54- 1.88 (m, 9H), 1.88-1.98 (m, 1H), 2.02 (s, 3H), 2.21-2.34 (m, 4H), 2.52-2.68 (m, 2H), 2.74-3.07 (m, 2H), 3.64-3.70 (m, 1H), 3.82 (s, 3H), 4.02-4.19 (m, 2H), 6.17- 6.25 (m, 1H), 6.57-6.64 (m, 2H), 6.82-6.87 (m, 1H)
494
492




















TABLE 202











Infor-






mation


Exam-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure





F-268


embedded image


(400 MHz, CDCl3) 0.97 (dq, J = 9.98, 3.31 Hz, 5H), 1.18 (t, J = 6.40 Hz, 2H), 1.27-1.34 (m, 5H), 1.47-1.68 (m,7H), 2.29 (s, 3H), 2.75 (dt, J = 8.53, 4.25 Hz, 2H), 2.98 (ddd, J = 14.83, 7.33, 3.80 Hz, 1H), 3.08 (t, J = 6.29 Hz, 2H), 3.15- 3.20 (m, 2H), 7.08 (t, J = 7.94 Hz, 1H), 7.16 (d, J = 7.94 Hz, 1H), 7.62 (d, J = 7.94 Hz, 1H), 8.89 (s, 1H)
415
413






F-269


embedded image


(400 MHz, CDCl3) 0.91-0.99 (m, 5H), 1.19 (dt, J = 13 38, 4.69 Hz, 2H), 1.30 (dd, J = 12.35, 7.06 Hz, 5H), 1.47 (d, J = 5.29 Hz, 5H), 1.69 (t, J = 4.41 Hz, 2H), 2.19 (t, J = 6.29 Hz, 3H), 2.26 (s, 3H), 2.73- 2.77 (m, 2H), 2.95-3.00 (m, 1H), 3.05 (t, J = 6.40 Hz, 2H), 3.17 (t, J = 6.40 Hz, 2H), 6.96 (s, 2H), 7.61 (dd, J = 8.71, 4.74 Hz, 1H). 8.27 (s,
409
407





1H)








F-270


embedded image


(400 MHz, CDCl3) 0.91-0.94 (m, 5H), 1.13-1.19 (m, 2H), 1.32 (t, J = 5.51 Hz, 5H), 1.47 (d, J = 5.29 Hz, 5H), 1.71 (ddd, J = 20.29, 11.91, 6.18 Hz, 2H), 2.33 (d, J = 5.51 Hz, 3H), 2.70-2.75 (m, 2H), 2.80 (t, J = 7.17 Hz, 2H), 2.91-2.97 (m, 1H), 3.11 (q, J = 7.13 Hz, 2H), 3.83 (s, 3H), 4.35 (d, J = 5.73 Hz, 2H), 6.44 (s, 1H), 6.69 (t, J = 8.05 Hz, 2H), 7.09 (t, J = 7.50 Hz, 1H)
439
437




















TABLE 203











Infor-






mation


Exam-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure





F-271


embedded image


(400 MHz, CDCl3) 0.89 (d, J = 6.72 Hz, 6H), 0.90-0.98 (m, 1H), 1.03-1.11 (m, 1H), 1.15- 1.32 (m, 4H), 1.51-1.61 (m, 1H), 1.73-1.82 (m, 2H), 2.12 (s, 3H), 2.26 (s, 3H), 2.76 (dd, J = 8.58, 6.26 Hz, 2H), 2.92-3.09 (m, 3H), 3.37 (brs, 1H), 3.87-3.98 (m, 3H), 6.93-6 98 (m, 2H), 7.46 (d, J = 8.81 Hz, 1H), 7.56 (brs, 1H)
399
397
Racemic form





F-272


embedded image


(400 MHz, CDCl3) 0.84-0.91 (m, 7H), 1.02-1.12 (m, 3H), 1.23- 1.29 (m, 3H), 1.54-1.59 (m, 1H), 1.69-1.77 (m, 2H), 2.11 (s, 3H), 2.17-2.27 (m, 1H), 2.24 (s, 3H), 2.68-2.74 (m, 2H), 2 93 (dd, J = 14.00, 4.08 Hz, 1H), 3.01-3.07 (m, 1H), 3.24 (dd, J = 13.78, 10.48 Hz, 1H), 3.68-3.88 (m, 3H), 6.90-6.95 (m, 2H), 7.48 (d, J = 8.82 Hz, 1H), 7.71 (dd, J = 5.51, 3.09 Hz, 2H), 7.74 (brs, 1H), 7.82 (dd, J = 5.40, 3.20 Hz, 2H)
542
540
Racemic form





F-273


embedded image


(400 MHz CDCl3) 0.85-0.95 (m, 7H), 1.11-1.19 (m, 3H), 1.23- 1.29 (m, 2H), 1.51-1.60 (m, 1H), 1.70- 1.79 (m, 2H), 1.87-2.01 (m, 2H), 2.06 (s, 3H), 2.24 (s, 3H), 2.71-2.78 (m, 4H), 2.82 (dd, J = 13.78, 4.30 Hz, 1H), 2.94-3.01 (m, 1H), 3.10 (dd, J = 13.89, 10.59 Hz, 1H), 3.81-3.89 (m, 1H), 6.89-6.96 (m, 2H), 7.40 (d, J = 8.60 Hz, 1H), 7.82 (brs, 1H)
412
410
Racemic form




















TABLE 204











Infor-






mation


Exam-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure





F-274


embedded image


(400 MHz, CDCl3) 0.88 (d, J = 6.62 Hz, 6H), 0.94-1.00 (m, 1H), 1.07-1.13 (m, 1H), 1.15- 1.22 (m, 2H), 1.24-1.30 (m, 2H), 1.52 -1.61 (m, 1H), 1.72-1.81 (m, 2H), 2.08 (s, 3H), 2.25 (s, 3H), 2.75 (t, J = 7.94 Hz, 2H), 2.92 (dd, J = 13.89, 5.07 Hz, 1H), 2.99-3.16 (m, 4H), 3.79-3.87 (m, 1H), 6.90- 6.97 (m, 2H), 7.44 (d, J = 8.60 Hz, 1H), 7.93 (brs, 1H)
398
396
Racemic form





F-275


embedded image


(400 MHz, CDCl3) 0.86-0.91 (m, 7H), 1.07-1.31 (m, 5H), 1.54- 1.61 (m, 1H), 1.72-1.81 (m, 2H), 1.91 (s, 3H), 1.92-2.00 (m, 1H), 2.07-2.16 (m, 1H), 2.09 (s, 3H), 2.25 (s, 3H), 2.71-2.77 (m, 2H), 2.86 (dd, J = 14.11, 4.63 Hz, 1H), 2.98-3.05 (m, 1H), 3.12 (dd, J = 14.11, 9.70 Hz, 1H), 3.20-3.29 (m, 1H), 3.37-3.46 (m, 1H), 3.75- 3.83 (m, 1H), 6.05 (brs, 1H), 6.92- 6.97 (m, 2H), 7.43 (d, J = 8.60 Hz, 1H), 7.98 (brs, 1H)
454
452
Racemic form





F-276


embedded image


(400 MHz, CDCl3) 0.88 (d, J = 6.62 Hz, 6H), 0.93-0.99 (m, 1H), 1.10-1.17 (m, 3H), 1.21- 1.29 (m, 2H), 1.52-1.62 (m, 1H), 1.68-1.78 (m, 2H), 1.86-2.02 (m, 2H), 2.05 (s, 3H), 2.16 (s, 6H), 2.24 (s, 3H), 2.28 (t, J = 7.17 Hz, 2H), 2.71-2.77 (m, 2H), 2.83 (dd, J = 13.78, 4.52 Hz, 1H), 2.94-3.01 (m, 1H), 3.06 (dd, J = 13.76, 10.70 Hz, 1H), 3.78-3.87 (m, 1H), 6.89-6.94 (m, 2H), 7.37 (d, J = 8.38 Hz, 1H), 7.98 (brs, 1H)
440
438
Racemic form




















TABLE 205







Exam-


MS
Information












ple
Chemical structure
NMR
M + H
M − H
of structure





F-277


embedded image


(400 MHz, CDCl3) 0.87-0.98 (m, 7H), 1.04-1.13 (m, 1H), 1.20- 1.33 (m, 4H), 1.53-1.64 (m, 1H), 1.75-1.84 (m, 2H), 2.01 (s, 3H), 2.17 (s, 3H), 2.26 (s, 3H), 2.73- 2.80 (m, 2H), 2.85-2.95 (m, 2H) 3.06-3.13 (m, 1H), 3.38 (dt, J = 13.67, 4.85 Hz, 1H), 3.85-3.92 (m, 1H), 3.96-4.04 (m, 1H), 6.87- 7.05 (m, 3H), 7.42 (d, J = 7.94 Hz, 1H), 8.53 (brs, 1H)
440
438
Racemic form





F-278


embedded image


(400 MHz, CDCl3) 0.81-0.96 (m, 7H), 1.08-1.29 (m, 5H), 1.52- 1.62 (m, 1H), 1.71-1.81 (m, 2H), 2.05 (s, 3H), 2.24 (s, 3H), 2.24 (s, 6H), 2.49 (dd, J = 12.35, 6.84 Hz, 1H), 2.62 (dd, J = 12.35, 8.38 Hz, 1H), 2.71-2.78 (m, 2H), 2.96- 3.03 (m, 3H), 3.86-3.93 (m, 1H), 6.89-6.95 (m, 2H), 7.36 (d, J = 8.16 Hz, 1H), 7.76 (brs, 1H)
426
424
Racemic form





F-279


embedded image


(400 MHz, CDCl3) 0.80 (t, J = 5.18 Hz, 1H), 0.91 (d, J = 6.62 Hz, 6H), 1.15 (s, 2H), 1.27-1.32 (m, 2H), 1.57-1.64 (m, 1H), 1.80 (d, J = 3.97 Hz, 2H), 2.04 (s, 3H), 2.30 (s, 3H), 2.65-2.73 (m, 2H), 2.83-2.85 (m, 1H), 3.27 (t, J = 10.92 Hz, 1H), 3.66 (dd, J = 18.53, 10.37 Hz, 1H), 3.76-4.06 (m, 7H), 4.29 (q, J = 6.54 Hz, 3H), 6.63 (t, J = 8.49 Hz, 2H), 6.97 (t, J = 5.73 Hz, 1H), 7.23 (s, 1H)
482
480
Racemic form




















TABLE 206







Exam-


MS
Information












ple
Chemical structure
NMR
M + H
M − H
of structure





F-280


embedded image


(400 MHz, CDCl3) 0.90 (d, J = 6.84 Hz, 6H), 0.94-0.98 (m, 2H), 1.04-1.23 (m, 4H), 1.41- 1.51 (m, 2H), 1.62-1.74 (m, 2H), 1.87 (d, J = 10.14 Hz, 2H), 2.00 (d, J = 10.81 Hz, 2H), 2.27 (s, 3H), 2.78 (tt, J = 12.13, 3.46 Hz, 1H), 2.93-2.98 (m, 1H), 3.07 (t, J = 5.73 Hz, 2H), 3.17 (t, J =
429
427





5.95 Hz, 2H), 7.08 (t, J = 8.05







Hz, 1H), 7.16 (d, J = 7.50 Hz,







1H), 7.62 (d, J = 8.38 Hz, 1H),







8.84 (brs, 1H)








F-281


embedded image


(400 MHz, CDCl3) 0.82-0.90 (m, 7H), 1.14-1.30 (m, 5H), 1.53-1.61 (m, 1H), 1.65-1.95 (m, 6H), 2.03 (s, 3H), 2.23 (s, 3H), 2.71-2.80 (m, 3H), 2.98-3.12 (m, 2H), 3.58-3.81 (m, 3H), 6 88-6.93 (m, 2H), 7.37 (d, J = 8.16 Hz, 1H), 7.46 (brs, 1H), 7.71 (dd, J = 5.51, 3.09 Hz, 2H), 7.62 (dd, J = 5.51, 3.09 Hz, 2H)
556
554
Racemic form





F-282


embedded image


(400 MHz, CDCl3) 0.84-0.91 (m, 7H), 1.12-1.30 (m, 5H), 1.37-1.47 (m, 1H), 1.50-1.90 (m, 6H), 2.05 (s, 3H), 2.24 (s, 3H), 2.66-2.77 (m, 4H), 2.81 (dd, J = 13.89, 4.19 Hz, 1H), 2.93-3.00 (m, 1H), 3.10 (dd, J = 13.78, 10.92 Hz, 1H), 3.70-3.78 (m, 1H), 6.90-6.95 (m, 2H), 7.39 (d, J = 8.82 Hz, 1H), 7.77 (brs, 1H)
426
424
Racemic form




















TABLE 207







Exam-


MS
Information












ple
Chemical structure
NMR
M + H
M − H
of structure





F-283


embedded image


(400 MHz, CDCl3) 0.82-0.98 (m, 1H), 0.87 (d, J = 6.62 Hz, 6H), 1.15- 1.28 (m, 5H), 1.50-1.60 (m, 1H), 1.68-1.79 (m, 2H), 2.01 (s, 3H), 2.12-2.51 (m, 2H), 2.23 (s, 3H), 2.44-2.52 (m, 2H), 2.69-2.75 (m, 2H), 2.77-2.83 (m, 1H), 2.99- 3.06 (m, 1H), 3.13-3.22 (m, 1H), 3.96-4.05 (m, 1H), 6.88-6.93 (m, 2H), 7.24-7.28 (m, 1H), 8.27 (brs, 1H)
441
439
Racemic form





F-284


embedded image


(400 MHz, CDCl3) 0.85-0.94 (m, 7H), 1.08-1.30 (m, 5H) 1.51- 1.61 (m, 1H), 1.66-1.79 (m, 2H), 2.06 (s, 3H), 2.08-2.20 (m, 2H), 2.24 (s, 3H), 2.26-2.39 (m, 2H), 2.72 (t, J = 7.83 Hz, 2H), 2.84 (dd, J = 14.22, 4.74 Hz, 1H), 3.00-3.07 (m, 1H), 3.13 (dd, J = 14.22, 10.03 Hz, 1H), 3.83-3.91 (m, 1H), 5.59 (brs, 1H), 6.33 (brs, 1H), 6.89- 6.96 (m, 2H), 7.33 (d, J = 7.94 Hz, 1H), 8.51 (brs, 1H)
440
438
Racemic form





F-295


embedded image


(400 MHz, CDCl3) 0.85-0.93 (m, 7H), 1.06-1.30 (m, 5H), 1.51- 1.62 (m, 1H), 1.69-1.81 (m, 2H), 2.00-2.34 (m, 10H), 2.68-2.76 (m, 5H), 2.85 (dd, J = 14.11, 4.85 Hz, 1H), 3.01-3.16 (m, 2H), 3.77-3.87 (m, 1H), 6.21 (brs, 1H), 6.89-6.97 (m, 2H), 7.36 (d, J = 7.94 Hz, 1H), 8.49 (brs, 1H)
454
452
Racemic form




















TABLE 208











Infor-






mation


Exam-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure





F-286


embedded image


(400 MHz, CDCl3) 0.87-0.94 (m, 7H), 1.04-1.32 (m, 5H), 1.53- 1.63 (m, 1H), 1.71-1.81 (m, 2H), 2.09 (s, 3H), 2.11-2.22 (m, 2H), 2.24 (s, 3H), 2.33-2.44 (m, 2H), 2.71-2.83 (m, 3H), 2.90 (s, 3H), 2.98 (s, 3H), 3.02-3.08 (m, 1H), 3.14 (dd, J = 13.67, 10.81 Hz, 1H), 3.80-3.88 (m, 1H), 6.91-6.96 (m, 2H), 7.46 (d, J = 8.60 Hz, 1H), 8.12 (brs, 1H)
468
466
Racemic form





F-287


embedded image


(400 MHz, CDCl3) 0.83-0.91 (m, 7H), 1.12-1.30 (m, 5H), 1.39- 1.50 (m, 1H), 1.52-1.67 (m, 2H), 1.70-1.91 (m, 2H), 1.93 (s, 3H), 2.05 (s, 3H), 2.24 (s, 3H), 2.70- 2.77 (m, 2H), 2.84 (dd, J = 14.00, 4.52 Hz, 1H), 2.96-3.08 (m, 2H), 3.16-3.23 (m, 2H), 3.70-3.78 (m, 1H), 5.88 (brs, 1H), 6.89-6.96 (m, 2H), 7.37 (d, J = 8.16 Hz, 1H), 8.09 (brs, 1H)
468
466
Racemic form





F-288


embedded image


(400 MHz, CDCl3) 0.85-0.92 (m, 7H), 1.12-1.31 (m, 5H), 1.34- 1.46 (m, 1H), 1.51-1.63 (m, 2H), 1.69-1.83 (m, 4H), 2.04 (s, 3H), 2.10-2.26 (m, 2H), 2.19 (s, 3H), 2.24 (s, 3H), 2.74 (t, J = 7.88 Hz, 2H), 2.82 (dd, J = 13.80, 4.29 Hz, 1H), 2.94-3.02 (m, 1H), 3.12 (dd, J = 13.80, 11.02 Hz, 1H), 3.71-3.78 (m, 1H), 6.89-6.94 (m, 2H), 7.36 (d, J = 8.12 Hz, 1H), 8.01 (brs, 1H)
454
452
Racemic form




















TABLE 209











Infor-






mation


Exam-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure





F-289


embedded image


(400 MHz, CDCl3) 0.86 (d, J = 6.62 Hz, 6H), 0.89-0.96 (m, 2H), 1.13-1.23 (m, 2H), 1.35 (t, J = 7.06 Hz, 2H), 1.50-1.60 (m, 1H), 2.03-2.12 (m, 1H), 2.13 (s, 3H), 2.14 (s, 3H), 2.25 (s, 3H), 2.35-2.63 (m, 4H), 2.85-2.95 (m, 1H), 3.25-3.35 (m, 1H), 3.39- 3.50 (m, 1H), 3.56-3.75 (m, 1H), 3.84-3.98 (m, 1H), 4.16-4.28 (m, 2H), 4.39-4.48 (m, 1H), 6.94 (s, 1H), 6.95 (d, J = 7.94 Hz, 1H), 7.72 (d, J = 7.94 Hz, 1H) 8.96 (brs, 1H)
478
476
Racemic form





F-290


embedded image


(400 MHz, CDCl3) 0.94-1.03 (m, 2H), 1.16 (dd, J = 13.80, 8.45 Hz, 6H), 1.23-1.28 (m, 2H), 1.55 (tt, J = 13.68, 4.96 Hz, 2H), 1.81-1.89 (m, 2H), 2.14 (s, 3H), 2.15 (s, 3H), 2.26 (t, J = 10.55 Hz, 3H), 2.82 (ddd, J = 17.22, 9.22, 6.20 Hz, 2H), 2.97- 3.03 (m, 1H), 3.16 (s, 3H), 3.26- 3.34 (m, 1H), 3.75 (dt, J = 18.01, 6.09 Hz, 1H), 3.89-3.97 (m, 1H), 4.18-4.22 (m, 2H), 4.44 (dd, J = 11.59, 8.35 Hz, 1H), 6.96 (dd, J = 5.80, 5.33 Hz, 2H), 7.72 (d, J = 8.12 Hz, 1H), 9.04 (s, 1H)
482
480
Racemic form





















TABLE 210












Infor-







mation











Exam-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure





F-291


embedded image


(400 MHz, MeOH-D4) 0.90 (d, J = 6.62 Hz, 6H), 1.07-1.22 (m, 4H), 1.24-1.33 (m, 2H), 1.54- 1.65 (m, 1H), 1.74-1.83 (m, 2H), 1.96 (s, 3H), 2.07 (s, 3H), 2.25 (s, 3H), 2.84 (t, J = 7.83 Hz, 2H), 3.03 (dd, J = 15.11, 5.84 Hz, 1H), 3.10- 3.16 (m, 1H), 3.26 (dd, J = 15.00, 9.48 Hz, 1H), 5.88 (dd, J = 9.48, 5.95 Hz, 1H), 6.93 (d, J = 7.94 Hz, 1H), 6.99 (s, 1H), 7.06 (d, J = 7.94 Hz, 1H)
426
424






F-292


embedded image


(400 MHz, CDCl3) 0.94-1.02 (m, 2H), 1.19-1.28 (m, 2H), 2.21- 2.34 (m, 2H), 2.30 (s, 3H), 2.80 (t, J = 6.92 Hz, 2H), 2.90-3.04 (m, 7H), 3.06-3.22 (m, 4H), 7.09 (dd, J = 8.12, 7.88 Hz, 1H), 7.17 (d, J = 8.12 Hz, 1H), 7.63 (d, J = 7.88 Hz, 1H), 8.76 (s, 1H)
454
452






F-293


embedded image


(400 MHz, CDCl3) 0.88 (d, J = 6.40 Hz, 6H), 0.89-0.97 (m, 2H), 1.11-1.21 (m, 2H), 1.44 (t, J = 6.84 Hz, 2H), 1.51-1.61 (m, 1H), 2.04-2.12 (m, 1H), 2.13 (s, 3H), 2.14 (s, 3H), 2.25 (s, 3H), 2.47-2.66 (m, 4H), 2.86-2.94 (m, 1H), 3.26-3.35 (m, 1H), 3.56- 3.75 (m, 2H), 3.85-3.98 (m, 1H), 4.17-4.28 (m, 2H), 4.40-4.48 (m, 1H), 6.94 (s, 1H), 6.96 (d, J = 8.16 Hz, 1H), 7.73 (d, J = 8.16 Hz, 1H), 8.98 (brs, 1H)
478
476
Racemic form





















TABLE 211












Infor-







mation











Exam-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure





F-294


embedded image


(400 MHz, CDCl3) 0.99-1.01 (m, 2H), 1.16-1.26 (m, 10H), 1.72 (brs, 3H), 2.31 (s, 3H), 2.45 (brs, 2H), 3.07-3.21 (m, 8H), 7.09 (t, J = 8.12 Hz, 1H), 7.17 (d, J = 7.88 Hz, 1H), 7.63 (d, J = 7.65 Hz, 1H), 8.72 (s, 1H)
418
416






F-295


embedded image


(400 MHz, CDCl3) 0.80-0.96 (m, 3H), 1.08-1.33 (m, 3H), 1.39- 1.58 (m, 2H), 1.58-1.74 (m, 5H), 1.74-1.95 (m, 7H), 2.02 (s, 3H), 2.10-2.19 (m, 4H), 2.23 (s, 3H), 2.38-2.49 (m, 1H), 2.71-2.80 (m, 2H), 2.88-2.97 (m, 1H), 3.04- 3.19 (m, 2H), 3.91-3.99 (m, 1H), 6.87-6.93 (m, 2H), 7.34-7.41 (m, 1H), 7.54-7.69 (m, 1H)
464
462






F-296


embedded image


(400 MHz, CDCl3) 0.87-0.93 (m, 11H), 1.08-1.19 (m, 2H), 1.29 (dd, J = 10.09, 7.30 Hz, 2H), 1.77 (td, J = 15.07, 7.50 Hz, 2H), 2.04 (s, 3H), 2.04 (s, 3H), 2.28 (s, 3H), 2.41- 2.48 (m, 1H), 2.55-2.62 (m, 1H), 2.75 (t, J = 7.88 Hz, 2H), 3.33-3.38 (m, 1H), 3.73-3.95 (m, 3H), 5.56 (d, J = 7.88 Hz, 1H), 6.97-7.01 (m, 2H), 7.24 (brs, 1H), 7.51 (d, J = 8.12 Hz, 1H)
466
464




















TABLE 212







Exam-


MS
Information












ple
Chemical structure
NMR
M + H
M − H
of structure





F-297


embedded image


(400 MHz, CDCl3) 0.65-0.75 (m, 1H), 0.85-1.11 (m, 2H), 0.90 (s, 9H), 1.26-1.32 (m, 3H), 1.75- 1.81 (m, 1H), 2.00 (s, 3H), 2.28- 2.41 (m, 2H), 2.34 (s, 3H), 2.68 (t, J = 7.88 Hz, 2H), 3.15-3.20 (m, 1H), 3.39-3.46 (m, 1H), 3.76- 3.85 (m, 2H), 3.78 (s, 3H), 4.26 (dd, J = 14.15, 5.33 Hz, 1H), 4.38 (dd, J = 14.26, 6.61 Hz, 1H), 5.38 (d, J = 7.65 Hz, 1H), 6.16 (t, J = 6.03 Hz, 1H), 6.64 (s, 1H), 6.69 (d, J = 7.42 Hz, 1H), 7.04 (d, J = 7.65 Hz,1H)
4796
494






F-298


embedded image


(400 MHz, CDCl3) 0.78-1.00 (m, 8H), 1.12-1.24 (m, 2H), 1.47- 1.67 (m, 1H), 1.92-2.23 (m, 9H), 2.25 (s, 3H), 2.40-2.54 (m, 2H), 2.85-2.96 (m, 1H), 3.25-3.44 (m, 1.5H), 3.46-3.57 (m, 0.5H), 3.63- 3.75 (m, 0.8H), 3.84-3.97 (m, 1.2H), 3.99-4.11 (m, 0.4H), 4.13- 4.29 (m, 1.8H), 4.37-4.50 (m, 0.8H), 6.91-7.00 (m, 2H), 7.59 (d, J = 7.88 Hz, 0.2H), 7.73 (d, J = 8.12 Hz, 0.8H), 8.07 (s, 0.2H), 8.98 (s, 0.8H)
464
462
Mixtures of four stereoisomers (Stereo- chemistry on Pyrrolidine ring: Mixture of two Trans-isomers) (Stereo- chemistry on Cyclobutane







ring:







Mixture of







Trans-isomer







and







Cis-isomer)





















TABLE 213












Infor-







mation











Exam-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure





F-299


embedded image


(400 MHz, CDCl3) 0.82-1.35 (m, 14H), 1.63 (ddt, J = 18.97, 10.51, 4.16 Hz, 2H), 2.13 (s, 3H), 2.17 (t, J = 5.40 Hz, 3H), 2.21-2.23 (m, 3H), 2.74 (dtt, J = 27.67, 10.86, 3.66 Hz, 3H), 3.01 (ddd, J = 15.11, 7.61, 4.08 Hz, 1H), 3.32 (q, J = 11.03 Hz, 1H), 3.73 (tt, J = 14.67, 5.00 Hz, 1H), 3.94 (tt, J = 14.78, 4.23 Hz, 1H), 4.15-4.27 (m, 2H), 4.36-4.45 (m, 1H), 6.90-7.01 (m, 2H), 7.72 (d, J = 7.94 Hz, 1H), 9.13 (t, J = 29.77 Hz, 1H)
466
464
Racemic form





F-300


embedded image


(400 MHz, CDCl3) 0.88 (d, J = 7.06 Hz, 3H), 0.91 (d, J = 5.95 Hz, 3H), 0.97-1.88 (m, 14H), 2.10-2.12 (m, 6H), 2.24 (d, J = 11.03 Hz, 3H), 2.77 (tt, J = 12.13, 3.42 Hz, 1H), 2.95-3.01 (m, 1H), 331 (t, J = 10.92 Hz, 1H), 3.74 (dt, J = 14.78, 6.23 Hz, 1H), 3.93 (ddd, J = 13.45, 8.71, 4.63 Hz, 1H), 4.16-4.26 (m, 2H), 4.42 (dd, J = 11.47, 8.38 Hz, 1H), 6.95 (d, J = 10.14 Hz, 2H), 7.68 (t, J = 7.83 Hz, 1H), 9.11 (s, 1H)
492
490
Racemic form





F-301


embedded image


(400 MHz, CDCl3) 0.87-0.88 (m, 6H), 0.96-1.04 (m, 1H), 1.12- 1.19 (m, 3H), 1.19-1.31 (m, 2H), 1.21 (s, 3H), 1.27(s, 3H), 1.53- 1.60 (m, 1H), 1.68-1.78 (m, 2H), 1.86 (brs, 1H), 1.92 (dd, J = 14.56, 5.73 Hz, 1H), 2.09 (s, 3H), 2.16 (dd, J = 14.34, 7.50 Hz, 1H), 2.25 (s, 3H), 2.71-2.77 (m, 2H), 2.92- 3.05 (m, 3H), 3.90-3.99 (m, 1H), 6.91-6.97 (m, 2H), 7.43 (d, J = 8.82 Hz, 1H), 7.88 (brs, 1H)
441
439
Racemic form





















TABLE 214












Infor-







mation











Exam-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure





F-302


embedded image


(400 MHz, CDCl3) 0.89-0.90 (m, 9H), 1.18-1.34 (m, 5H), 1.79- 1.82 (m, 3H), 2.27 (s, 3H), 2.29 (s, 3H), 2.79 (t, J = 7.94 Hz, 2H), 2.98 (s, 3H), 3.26 (s, 1H), 3.71 (dd, J = 8.82, 3.31 Hz, 2H), 4.20 (d, J = 9.48 Hz, 1H), 4.45 (t, J = 9.04 Hz, 1H), 6.96 (d, J = 12.13 Hz, 2H), 7.66 (d, J = 7.94 Hz, 1H), 9.44 (s, 1H)
452
450






F-303


embedded image


(400 MHz, CDCl3) 0.87-0.88 (m, 9H), 1.12-1.30 (m, 5H), 1.76 (t, J = 7.06 Hz, 2H), 2.06 (s, 3H), 2.26- 2.28 (m, 4H), 2.76 (t, J = 7.83 Hz, 2H), 2.91 (s, 3H), 3.42-3.46 (m, 1H), 3.65 (t, J = 9.26 Hz, 1H), 3.94 (t, J = 9.37 Hz, 1H), 4.38 (d, J = 11.03 Hz, 1H), 4.58-4.63 (m, 1H), 6.95 (t, J = 5.84 Hz, 2H), 7.60 (d, J = 7.94 Hz, 1H), 8.69 (s, 1H)
452
450






F-304


embedded image


(400 MHz, CDCl3) 0.97-1.03 (m, 2H), 1.17-1.22 (m, 2H), 1.29 (s, 6H), 2.30 (s, 3H), 2.97-3.03 (m, 1H), 3.05-3.12 (m, 3H), 3.18 (t, J = 6.29 Hz, 2H), 3.49 (q, J = 2.87 Hz, 1H), 3.94 (t, J = 6.62 Hz, 2H), 7.08 (t, J = 8.05 Hz, 1H), 7.16 (d, J = 7.72 Hz, 1H), 7.67 (d, J = 7.50 Hz, 1H), 8.62 (brs, 1H)
459
457






F-305


embedded image


(400 MHz, CDCl3) 0.90 (s, 9H), 0.95 (d, J = 2.65 Hz, 2H), 1.18 (d, J = 5.73 Hz, 2H), 1.28 (dd, J = 11.14, 5.06 Hz, 2H), 1.73-1.76 (m, 2H), 2.18 (s, 3H), 2.26 (s, 3H), 2.75 (t, J = 7.83 Hz, 2H), 2.96 (s, 1H), 3.06 (t, J = 6.40 Hz, 2H), 3.17 (t, J = 6.40 Hz, 2H), 6.95 (s, 2H), 7.59 (d, J = 8.60 Hz, 1H), 8.38 (s, 1H)
383
381




















TABLE 215











Infor-






mation


Exam-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure





F-306


embedded image


(400 MHz, CDCl3) 0.86-0.90 (m, 2H), 0.87 (s, 9H), 1.12-1.18 (m, 3H), 1.22-1.27 (m, 2H), 1.68- 1.76 (m, 1H), 2.06 (m, 3H) 2.24 (s, 3H), 2.44-2.56 (m, 2H), 2.74 (dd, J = 6.85, 6.85 Hz, 2H), 2.82 (dd, J = 13.70, 4.03 Hz, 1H), 2.93-2.99 (m, 1H), 3.12 (dd, J = 14.10, 11.28 Hz, 1H), 3.77-3.85 (m, 1H), 5.05-5.09 (m, 2H), 5.71-5.81 (m, 1H), 6.91-6.92 (m, 2H), 7.41 (d, J = 8.87 Hz, 1H), 7.64 (s, 1H)
423
421
Racemic form





F-307


embedded image


(400 MHz, CDCl3) 0.87 (s, 9H), 0.93-0.98 (m, 1H), 1.07-1.12 (m, 1H), 1.15-1.20 (m, 2H), 1.24- 1.29 (m, 2H), 1.68-1.76 (m, 2H), 1.94-2.02 (m, 1H), 2.06-2.14 (m, 1H), 2.07 (s, 3H), 2.24 (s, 3H), 2.73 (dd, J = 8.06, 8.06 Hz, 2H), 2.88 (dd, J = 13.90, 5.04 Hz, 1H), 2.98-3.04 (m, 1H), 3.12 (dd, J = 14.31, 9.87 Hz, 1H), 3.66-3.78 (m, 2H), 3.95-4.02 (m, 1H), 6.92- 6.94 (m, 2H) 7.40 (d, J = 8.46 Hz 1H), 7.81 (s, 1H)
427
425
Racemic form





F-308


embedded image


(400 MHz, CDCl3) 0.86-0.92 (m, 9H), 0.93-1.12 (m, 1H), 1.12- 1.22 (m, 1H), 1.24-1.36 (m, 3H), 1.74 -1.99 (m, 3H), 1.99-2.08 (m, 1H), 2.11 (s, 3H), 2.27 (s, 3H), 2.44 -2.58 (m, 1H), 2.71-2.79 (m, 2H), 3.02-3.12 (m, 1H), 3.25- 3.32 (m, 1H), 3.39-3.51 (m, 2H), 3.67-3.82 (m, 1H), 4.08-4.25 (m, 2H), 6.29-6.40 (m, 1H), 6.95- 7.02 (m, 2H), 7.26-7.32 (m, 1H), 7.49 -7.57 (m, 1H)
496
494





















TABLE 216












Infor-







mation











Exam-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure





F-309


embedded image


(400 MHz, CDCl3) 0.84-0.91 (m, 10H), 0.92-1.00 (m, 1H), 1.07- 1.14 (m, 2H), 1.22-1.30 (m, 5H) 1.67-1.86 (m, 2H), 2.00-2.15 (m, 4H), 2.19-2.29 (m, 4H), 2.67- 2.83 (m, 3H), 2.95-3.04 (m, 1H), 3.08-3.21 (m, 2H), 4.27-4.33 (m, 1H), 6.88-6.93 (m, 2H), 7.34- 7.38 (m, 1H), 7.45 (brs, 1H)
438
436






F-310


embedded image


(400 MHz, CDCl3) 0.81-0.96 (m, 11H), 1.09-1.33 (m, 6H), 1.75- 1.96 (m, 2H), 1.99-2.08 (m, 4H), 2.10-2.19 (m, 4H), 2.23 (s, 3H), 2.38-2.49 (m, 1H), 2.63-2.79 (m, 2H), 2.89-2.97 (m, 1H), 3.07- 3.19 (m, 2H), 3.94-3.99 (m, 1H), 6.87-6.95 (m, 2H), 7.33-7.41 (m, 1H), 7.69 (brs, 1H)
452
450






F-311


embedded image


(400 MHz, CDCl3) 0.79-0.94 (m, 11H), 1.13-1.34 (m, 5H), 1.65- 1.81 (m, 2H), 1.97 (s, 3H), 2.14- 2.30 (m, 5H), 2.51-2.84 (m, 6H), 2.96 -3.07 (m, 1H), 3.57-3.68 (m, 1H), 5.29-5.36 (m, 1H), 6.88- 6.96 (m, 2H), 7.10-7.23 (m, 1H), 7.93 (brs, 1H)
466
464
Mixture of two stereoisomers (Mixture of diastereomers)





F-312


embedded image


(400 MHz, MeOH-D4) 0.91 (d, J = 6.62 Hz, 6H), 1.04-1.19 (m, 4H), 1.25-1.32 (m, 2H), 1.55- 1.65 (m, 1H), 1.73-1.83 (m, 2H), 1.91 (s, 3H), 2.30 (s, 3H), 2.77- 2.87 (m, 3H), 3.00-3.08 (m, 2H), 3.79 (s, 3H), 4.18 (d, J = 15.00 Hz, 2H), 4.26 (d, J = 15.00 Hz, 2H), 5.77 (dd, J = 9.48, 5.95 Hz, 1H), 6.66 (d, J = 7.50 Hz, 1H), 6.73 (s, 1H), 6.92 (d, J = 7.50 Hz, 1H)
456
454





















TABLE 217












Infor-







mation











Exam-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure





F-313


embedded image


(400 MHz, CDCl3) 0.88 (d, J = 6.62 Hz, 6H), 0.93-0.99 (m, 1H), 1.06-1.31 (m, 5H), 1.52- 1.60 (m, 1H), 1.69-1.81 (m, 2H), 1.94-2.02 (m, 1H), 2.06-2.15 (m, 1H), 2.08 (s, 3H), 2.25 (s, 3H), 2.54 (brs, 1H), 2.74 (t, J = 7.83 Hz, 2H), 2.87 (dd, J = 14.00, 4.74 Hz, 1H), 2.97-3.04 (m, 1H), 3.11 (dd, J = 14.11, 10.14 Hz, 1H), 3.64-3.81 (m, 2H), 3.94-4.03 (m, 1H), 6.91- 6.97 (m, 2H), 7.41 (d, J = 8.60 Hz, 1H), 7.72 (brs, 1H)
413
411






F-314


embedded image


(400 MHz, CDCl3) 0.88 (d, J = 6.62 Hz, 6H), 0.93-0.99 (m, 1H), 1.06-1.31 (m, 5H), 1.52- 1.60 (m, 1H), 1.69-1.81 (m, 2H), 1.94-2.02 (m, 1H), 2.06-2.15 (m, 1H), 2.08 (s, 3H), 2.25 (s, 3H), 2.54 (brs, 1H), 2.74 (t, J = 7.83 Hz, 2H), 2.87 (dd, J = 14.00, 4.74 Hz, 1H), 2.97-3.04 (m, 1H), 3.11 (dd, J = 14.11, 10.14 Hz, 1H), 3.64-3.81 (m, 2H), 3.94-4.03 (m, 1H), 6.91- 6.97 (m, 2H), 7.41 (d, J = 8.60 Hz, 1H), 7.72 (brs, 1H)
413
411






F-315


embedded image


(400 MHz, CDCl3) 0.85-1.10 (m, 8H), 1.17-1.35 (m, 4H), 1.53- 1.64 (m, 1H), 1.74-1.84 (m, 2H), 2.02-2.27 (m, 9H), 2.71-4.49 (m, 9H), 6.91-7.00 (m, 2H), 7.56 and 7.74 (each d, J = 8.82 and 8.16 Hz, total 1H), 8.17 and 9.03 (each brs, total 1H)
452
450




















TABLE 218











Infor-






mation


Exam-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure





F-316


embedded image


(400 MHz, CDCl3) 0.85-1.10 (m, 8H), 1.17-1.35 (m, 4H), 1.53- 1.64 (m, 1H), 1.74-1.84 (m, 2H), 2.02-2.27 (m, 9H), 2.71-4.49 (m, 9H), 6.91-7.00 (m, 2H), 7.56 and 7.74 (each d, J = 8.82 and 8.16 Hz, toal 1H), 8.17 and 9.03 (each brs, total 1H)
452
450






F-317


embedded image


(400 MHz, MeOH-D4) 0.89 (d, J = 6.62 Hz, 6H), 0.92-1.39 (m, 6H), 1.45-1.63 (m, 1H), 1.91- 2.07 (m, 2H), 2.03 (s, 3H) 2.09 and 2.12 (each s, total 3H), 2.26 (s, 3H), 2.41-2.61 (m, 3H), 3.02- 3.11 (m, 1H), 3.41-3.91 (m, 4H), 4.09-4.31 (m, 3H), 6.96 (d, J = 7.94 Hz, 1H), 7.01 (s, 1H), 7.10 and 7.13 (each d, J = 7.94 and 7.94 Hz, total 1H)
478
476









F-318


embedded image


(400 MHz, MeOH-D4) 0.89 (d, J = 6.62 Hz, 6H), 0.92-1.39 (m, 6H), 1.45-1.63 (m, 1H), 1.91- 2.07 (m, 2H), 2.03 (s, 3H), 2.09 and 2.12 (each s, total 3H), 2.26 (s, 3H), 2.41-2.61 (m, 3H), 3.02- 3.11 (m, 1H), 3.41-3.91 (m, 4H), 4.09-4.31 (m, 3H), 6.96 (d, J = 7.94 Hz, 1H), 7.01 (s, 1H), 7.10 and 7.13 (each d, J = 7.94 and 7.94 Hz, total 1H)
478
476




















TABLE 219











Infor-






mation


Exam-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure





F-319


embedded image


(400 MHz, MeOH-D4) 0.57-0.81 (m, 2H), 1.03-1.18 (m, 2H), 1.28- 1.36 (m, 6H), 2.08 (s, 3H), 2.15 and 2.16 (each s, total 3H), 2.28 (s, 3H), 2.95-3.06 (m, 1H), 3.43- 4.47 (m, 7H), 6.96-7.01 (m, 1H), 7.04 (s, 1H), 7.13-7.22 (m, 1H), 7.40 -7.47 (m, 2H), 7.66-7.74 (m, 2H)
486
484
Racemic form





F-320


embedded image


(400 MHz, MeOH-D4) 0.63-0.75 (m, 2H), 1.03-1.12 (m, 2H), 1.31 (d, J = 6.96 Hz, 6H), 2.17 (s, 3H), 2.27 (s, 3H), 2.94-3.10 (m, 3H), 3.27-3.35 (m, 2H), 3.44-3.52 (m, 1H), 6.97 (d, J = 7.88 Hz, 1H), 7.03 (s, 1H), 7.18 (d, J = 8.12 Hz, 1H), 7.42 (d, J = 8.12 Hz, 2H), 7.69 (d, J = 8.12 Hz, 2H)
403
401






F-321


embedded image


(400 MHz, CDCl3) 0.84-1.02 (m, 15H), 1.20-1.28 (m, 3H),1.52- 1.59 (m, 1H), 2.14 (s, 3H), 2.16 (s, 3H), 2.25 (s, 3H), 2.68-2.85 (m, 2H), 2.97-3.03 (m, 1H), 3.30 (t, J = 11.03 Hz, 1H), 3.68-3.75 (m, 1H), 3.85-3.94 (m, 1H), 4.15- 4.25 (m, 2H), 4.45 (dd, J = 11.47, 8.38 Hz, 1H), 6.97 (t, J = 10.14 Hz, 2H), 7.75 (d, J = 8.16 Hz, 1H), 9.04 (s, 1H)
480
478
Racemic form





F-322


embedded image


(400 MHz, CDCl3) 0.78-0.92 (m, 11H), 1.17-1.31 (m, 4H), 1.66- 1.80 (m, 2H), 1.97 (s, 3H), 2.22- 2.33 (m, 5H), 2.57-2.82 (m, 5H), 2.95-3.02 (m, 1H), 3.46-3.59 (m, 3H) 5.27-5.33 (m, 1H), 6.90- 6.95 (m, 2H), 7.27-7.32 (m, 1H)
466
464




















TABLE 220











Infor-






mation


Exam-


MS
of












ple
Chemical structure
NMR
M + H
M −H
structure





F-323


embedded image


(400 MHz, CDCl3) 0.51-0.58 (m, 1H), 0.90 (m, 10H), 1.00-1.14 (m, 3H), 1.23-1.30 (m, 2H), 1.70- 1.81 (m, 2H), 2.04-2.22 (m, 2H), 2.33 (s, 3H), 2.52-2.62 (m, 3H), 2.65 (s, 3H), 2.75-2.83 (m, 1H), 3.18-3.26 (m, 1H), 3.81 (s, 3H), 4.06-4.14 (m, 1H), 4.23-4.31 (m, 1H), 5.09-5.15 (m, 1H), 6.20- 6.28 (m, 1H), 6.60 (brs, 1H), 6.62- 6.66 (m, 1H), 6.88-6.93 (m, 1H)
496
494






F-324


embedded image


(400 MHz, CDCl3) 0.90 (s, 9H), 0.94-1.03 (m, 2H), 1.18-1.35 (m, 4H), 1.72-1.85 (m, 2H), 2.09 (s, 3H), 2.14 (s, 3H), 2.25 (s, 3H), 2.70-2.84 (m, 2H), 2.95-3.04 (m, 1H), 3.26-3.35 (m, 1H), 3.66- 3.77 (m, 1H), 3.84-3.97 (m, 1H), 4.17-4.29 (m, 2H), 4.41-4.50 (m, 1H), 6.91-6.98 (m, 1H), 7.02- 7.08 (m, 1H), 7.60-7.66 (m, 1H), 9.05 (brs, 1H)
466
464
Racemic form





F-325


embedded image


(400 MHz, CDCl3) 0.96-1.07 (m, 2H), 1.19-1.30 (m, 6H), 2.11- 2,22 (m, 7H), 2.24-2.30 (m, 4H), 3.01-3.06 (m, 1H), 3.08-3.14 (m, 2H), 3.27 (t, J = 11.02 Hz, 1H), 3.46-3.52 (m, 1H) 3.69-3.77 (m, 1H), 3.88-4.02 (m, 3H), 4.06-4.28 (m, 2H), 4.48 (dd, J = 11.48, 8.46 Hz, 1H), 6.94-6.99 (m, 2H), 7.76 (d, J = 8.12Hz, 1H), 8.99 (brs, 1H)
522
520
Racemic form




















TABLE 221











Infor-






mation


Exam-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure





F-326


embedded image


(400 MHz, CDCl3) 0.87 (s, 9H), 0.93-0.98 (m, 1H), 1.08-1.19 (m, 3H), 1.24-1.28 (m, 2H), 1.68- 1.76 (m, 2H), 1.93-2.01 (m, 1H), 2.06-2.14 (m, 1H), 2.06 (s, 3H), 2.24 (s, 3H), 2.72 (dd, J = 8.06, 7.66 Hz, 2H), 2.86 (dd, J = 14.10, 4.84 Hz, 1H), 2.98-3.04 (m, 1H), 3.11 (dd, J = 14.10, 10.07 Hz, 1H), 3.66-3.79 (m, 2H), 3.96-4.03 (m, 1H), 6.91-6.93 (m, 2H), 7.38 (d, J = 8.06 Hz, 1H), 7.90 (s, 1H)
427
425






F-327


embedded image


(400 MHz, CDCl3) 0.87 (s, 9H), 0.92-0.97 (m, 1H), 1.08-1.18 (m, 3H), 1.24-1.28 (m, 2H), 1.68- 1.76 (m, 2H), 1.93-2.01 (m, 1H), 2.06 (s, 3H), 2.07-2.13 (m, 1H), 2.24 (s, 3H), 2.73 (dd, J = 8.46, 7.66 Hz, 2H), 2.88 (dd, J = 14.10, 4.43 Hz, 1H), 2.98-3.04 (m, 1H), 3.11 (dd, J = 11.28, 10.88 Hz, 1H), 3.66-3.66 (m, 2H), 3.95-4.03 (m, 1H), 6.91-6.93 (m, 2H), 7.37 (d, J = 7.66 Hz, 1H), 7.94 (s, 1H)
427
425






F-328


embedded image


(400 MHz, CDCl3) 1.11-1.51 (m, 13H), 2.14 (s, 3H), 2.17 (s, 3H), 2.23 (s, 3H), 2.42-2.56 (m, 2H), 2.77-2.92 (m, 2H), 2.97 (ddd, J = 14.34, 7.06, 3.53 Hz, 1H), 3.28 (t, J = 11.03 Hz, 1H), 3.70 (dd, J = 18.86, 10.46 Hz, 1H), 3.90 (dt, J = 20.88, 7.94 Hz, 1H), 4.20 (dt, J = 16.17, 6.62 Hz, 2H), 4.46 (dd, J = 11.47, 8.38 Hz, 1H), 6.95 (d, J = 10.37 Hz, 2H), 7.77 (dd, J = 7.61, 4.52 Hz, 1H), 9.05 (s, 1H)
464
462
Racemic form (Stereo- chemistry on Cyclopropane ring: Undetermined)




















TABLE 222











Infor-






mation


Exam-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure





F-329


embedded image


(400 MHz, CDCl3) 0.76-1.36 (m, 4H), 1.16 (J = 6.00 Hz, 6H), 2.06 (s, 0.6H), 2.08 (s, 0.6H), 2.13 (s, 4.8H), 2.26 (s, 3H), 2.40-2.52 (m, 2H), 2.60-2.74 (m, 2H), 2.87- 2.97 (m, 1H), 3.11 (t, 10.92 Hz, 0.8H), 3.54-3.77 (m, 3H), 3.81- 3.98 (m, 1.2H), 4.15-4.48 (m, 4H), 6.89-7.01 (m, 2H), 7.55 (d, J = 7.88 Hz, 0.2H), 7.71 (d, J = 8.12 Hz, 0.8H), 8.11 (s, 0.2H), 8.92 (s, 0.8H)
480
478
Racemic form





F-330


embedded image


(400 MHz, CDCl3) 0.78-1.07(m, 2H), 1.09-1.32 (m, 8H), 2.06 (s, 0.5H), 2.09 (s, 0.6H), 2.13 (s, 2.5H), 2.15 (s, 2.4H), 2.25 (s, 3H), 2.34 -2.51 (m, 2H), 2.65-2.79 (m, 2H), 2.87-2.98 (m, 1H), 3.04- 3.16 (m, 1H), 3.28 (t, J = 11.12 Hz, 0.8H), 3.54-3.73 (m, 2H), 3.84- 3.96 (m, 1.2H), 4.01-4.14 (m, 1.4H), 4.14-4.27 (m, 1.8H), 4.44 (dd, J = 11.12, 8.36 Hz, 0.8H), 6.91- 6.99 (m, 2H), 7.59 (d, J = 8.20 Hz, 0.2H), 7.74 (d, J = 5.12 Hz, 0.8 H),
480
478
Racemic form




8.01 (s, 0.2H), 8.96 (s, 0.8H)








F-331


embedded image


(400 MHz, CDCl3) 0.90 (s, 9H), 0.94-1.03 (m, 2H), 1.19-1.35 (m, 4H), 1.73-1.83 (m, 2H), 2.14 (s, 3H), 2.18 (s, 3H), 2.28 (s, 3H), 2.70-2.84 (m, 2H), 2.96-3.04 (m, 1H), 3.25-3.35 (m, 1H), 3.64- 3.74 (m, 1H), 3.85-3.97 (m, 1H). 4.17-4.29 (m, 2H), 4.43-4.51 (m, 1H), 6.80-6.86 (m, 1H), 6.98- 7.03 (m, 1H), 7.78 (brs, 1H), 9.10 (brs, 1H)
466
464
Racemic form




















TABLE 223











Infor-






mation


Exam-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure





F-332


embedded image


(400 MHz, CDCl3) 0.90 (s, 9H), 0.93-1.02 (m, 2H), 1.17-1.32 (m, 4H), 1.71-1.84 (m, 2H), 2.06 (s, 3H), 2.14 (s, 3H), 2.67-2.85 (m, 2H), 2.93-3.03 (m, 1H), 3.27- 3.35 (m, 1H), 3.66-3.76 (m, 1H), 3.79 (s, 3H), 3.88-3.97 (m, 1H), 4.17-4.28 (m, 2H), 4.42-4.49 (m, 1H), 6.62-6.68 (m, 1H), 7.08- 7.14 (m, 1H), 7.47-7.52 (m, 1H), 9.05 (brs, 1H)
482
480
Racemic form


F-333


embedded image


(400 MHz, CDCl3) 0.84-0.93 (m, 11H), 0.93-1.03 (m, 2H), 1.18- 1.35 (m, 3H), 1.71-1.84 (m, 2H), 2.14 (s, 3H), 2.20 (s, 3H), 2.67- 2.85 (m, 1H), 2.94-3.04 (m, 1H), 3.25-3.35 (m, 1H), 3.63-3.75 (m, 1H), 3.85-4.13 (m, 1H), 4.14- 4.28 (m, 2H), 4.44-4.52 (m, 1H), 6.81-6.88 (m, 2H), 7.79-7.86 (m, 1H), 9.25 (brs, 1H)
470
468
Racemic form


F-334


embedded image


(400 MHz, CDCl3) 0.76-1.36 (m, 4H), 1.16 (J = 6.00 Hz, 6H), 2.06 (s, 0.6H), 2.08 (s, 0.6H), 2.13 (s, 4.8H), 2.26 (s, 3H), 2.40-2.52 (m, 2H), 2.60-2.74 (m, 2H), 2.87- 2.97 (m, 1H), 3.11 (t, J = 10.88 Hz, 0.8H), 3.54-3.77 (m, 3H), 3.81- 3.98 (m, 1.2H), 4.15-4.28 (m, 2H) 4.34 -4.48 (m, 2H), 6.89-7.01 (m, 2H),7.55 (d, J = 7.88 Hz, 0.2H), 7.71 (d, J = 6.12 Hz, 0.8H), 8.11 (s, 0.2H), 8.92 (s, 0.8H)
480
478




















TABLE 224











Infor-






mation


Exam-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure





F-335


embedded image


(400 MHz, CDCl3) 0.76-1.36 (m, 4H), 1.16 (J = 6.00 Hz, 6H), 2.06 (s, 0.6H), 2.08 (s, 0.6H), 2.13 (s, 4.8H), 2.26 (s, 3H), 2.40-2.52 (m, 2H), 2.60-2.74 (m, 2H), 2.87- 2.97 (m, 1H), 3.11 (t, J = 10.88 Hz, 0.8H), 3.54-3.77 (m, 3H), 3.81- 3.98 (m, 1.2H), 4.15-4.28 (m, 2H), 4.34-4.48 (m, 2H), 6.89-7.01 (m, 2H), 7.55 (d, J = 7.68 Hz, 0.2H), 7.71 (d, J = 8.12 Hz, 0.8H), 8.11 (s, 0.2H), 8.92 (s, 0.8H)
480
478






F-336


embedded image


(400 MHz, CDCl3) 0.78-1.07 (m, 2H), 1.09-1.32 (m, 8H) 2.06 (s, 0.5H), 2.09 (s, 0.6H), 2.13 (s, 2.5H), 2.15 (s, 2.4H), 2.25 (s, 3H), 2.34-2.51 (m, 2H), 2.65-2.79 (m, 2H), 2.87-2.98 (m, 1H), 3.04- 3.16 (m, 1H), 3.28 (t, J = 11.12 Hz, 0.8H), 3.54-3.73 (m, 2H), 3.84- 3.96 (m, 1.2H), 4.01-4.14 (m, 1.4H), 4.14-4.27 (m, 1.8H), 4.44 (dd, J = 11.12, 8.36 Hz, 0.8H), 6.91-6.99 (m, 2H), 7.59 (d, J = 8.20 Hz, 0.2H), 7.74 (d, J = 8.12
480
478





Hz, 0.8 H), 8.01 (s, 0.2H), 8.96 (s,







0.8H)




















TABLE 225











Informa-





MS
tion of












Example
Chemical structure
NMR
M + H
M − H
structure





F-337


embedded image


(400 MHz, CDCl3) 0.78-1.07 (m, 2H), 1.09-1.32 (m, 8H), 2.06 (s, 0.5H), 2.09 (s, 0.6H), 2.13 (s, 2.5H), 2.15 (s, 2.4H), 2.25 (s, 3H), 2.34-2.51 (m, 2H), 2.65-2.79 (m, 2H), 2.87-2.98 (m, 1H), 3.04- 3.16 (m, 1H), 3.28 (t, J = 11.12Hz, 0.8H), 3.54-3.73 (m, 2H), 3.84- 3.96 (m, 1.2H), 4.01-4.14 (m, 1.4H), 4.14-4.27 (m, 1.8H), 4.44 (dd, J = 11.12, 8.36Hz, 0.8H), 6.91- 6.99 (m, 2H), 7.59 (d, J = 8.20Hz, 0.2H), 7.74 (d, J = 8.12Hz, 0.8H), 8.01 (s, 0.2H), 8.96 (s, 0.8H)
480
478






F-338


embedded image


(400 MHz, CDCl3) 0.89 (d, J = 1.98Hz, 9H), 0.99 (t, J = 5.40Hz, 2H), 1.23-1.28 (m, 4H), 1.74- 1.78 (m, 2H), 2.13 (s, 3H), 2.16 (s, 3H), 2.25 (s, 3H), 2.77 (td, J = 7.77, 4.26Hz, 2H), 2.99 (t, J = 3.86Hz. 1H), 3.30 (t, J = 11.03Hz, 1H), 3.71 (d, J = 8.38Hz, 1H), 3.92 (s, 1H), 4.20-4.24 (m, 2H), 4.45 (dd, J = 11.36, 8.49Hz, 1H), 6.95 (d, J = 10.14Hz, 2H), 7.76 (d, J = 7.94Hz, 1H), 9.05 (s, 1H)
466
464






F-339


embedded image


(400 MHz, CDCl3) 0.89 (s, 9H), 0.96-0.98 (m, 2H), 1.24-1.28 (m, 4H), 1.73-1.77 (m, 2H), 2.13 (s, 3H), 2.16 (s, 3H), 2.25 (s, 3H), 2.76 (td, J = 7.77, 4.04Hz, 2H), 2.99 (t, J = 3.86Hz, 1H), 3.30 (t, J = 11.03Hz, 1H), 3.71 (d, J = 9.26Hz, 1H), 3.90-3.94 (m, 1H), 4.22 (t, J = 6.29Hz, 2H), 4.43- 4.46 (m, 1H), 6.94-6.96 (m, 2H), 7.75 (d, J = 7.94Hz, 1H), 9.06 (s, 1H)
466
464




















TABLE 226







Ex-



Informa-


am-


MS
tion of












ple
Chemical structure
NMR
M + H
M − H
structure





F-340


embedded image


(400 MHz, CDCl3) 0.64-1.50 (m, 8H), 0.96 (d, J = 6.84Hz, 6H), 1.59- 1.82 (m, 2H), 2.11 (s, 3H), 2.13 (s, 3H), 2.25 (s, 3H), 3.04 (tt, J = 7.12, 3.96Hz, 1H), 3.26-3.35 (m, 1H), 3.64-3.74 (m, 1H), 3.86-4.28 (m, 4H), 4.46 (dd, J = 11.47, 8.60Hz, 1H), 6.93 (s, 1H), 6.95 (d, J = 7.94Hz, 1H), 7.73 (d, J = 7.94Hz, 1H), 8.97 (brs, 1H)
464
462
Racemic form (Stereo- chemistry or Pyrrolidine ring and Cyclopropyl ring: Trans isomer, both) (Diastereomer of F-341)





F-341


embedded image


(400 MHz. CDCl3) 0.84-1.57 (m, 8H), 0.95 (d, J = 6.62Hz, 6H), 1.62- 1.81 (m, 2H), 2.11 (s, 3H), 2.13 (s, 3H), 2.25 (s, 3H), 3.04 (tt, J = 7.12, 3.96Hz, 1H), 3.24-3.34 (m, 1H), 3.64-3.75 (m, 1H), 3.83-4.28 (m, 4H), 4.45 (dd, J = 11.36, 8.49Hz, 1H), 6.94 (s, 1H), 6.96 (d, J = 8.16Hz, 1H), 7.73 (d, J = 8.16Hz, 1H), 8.92 (brs, 1H)
464
462
Racemic form (Stereo- chemistry or Pyrrolidine ring and Cyclopropyl ring: Trans isomer, both) (Diastereomer of F-340)





F-342


embedded image


(400 MHz. CDCl3) 0.87 (d, J = 6.62Hz, 6H), 0.92-0.98 (m, 1H), 1.09-1.30 (m, 5H), 1.50- 1.61 (m, 1H), 1.68-1.83 (m, 3H), 1.90-1.98 (m, 1H), 2.07 (s, 3H), 2.24 (s, 3H), 2.69-2.76 (m, 2H), 2.94-3.04 (m, 2H), 3.11 (dd, J = 14.45, 9.15Hz, 1H), 3.46 (dd, J = 11.25, 7.06Hz, 1H), 3.58 (dd, J = 11.14, 3.42Hz, 1H), 3.84-3.91 (m, 1H), 3.98-4.06 (m, 1H), 6.89- 6.95 (m, 2H), 7.34 (d, J = 7.94Hz, 1H), 8.27 (brs, 1H)
443
441




















TABLE 227







Ex-



Informa-


am-


MS
tion of












ple
Chemical structure
NMR
M + H
M − H
structure





F-343


embedded image


(400 MHz, CDCl3) 0.87 (d, J = 6.62Hz, 6H), 1.00-1.30 (m, 6H), 1.50-1.60 (m, 1H), 1.66- 1.77 (m, 2H), 1.86-1.96 (m, 1H), 1.97-2.06 (m, 1H), 2.04 (s, 3H), 2.24 (s, 3H), 2.68-2.76 (m, 2H), 2.87 (dd, J = 14.11, 5.07Hz, 1H), 2.99-3.08 (m, 2H), 3.44 (dd, J = 10.92, 6.73Hz, 1H), 3.59-3.70 (m, 2H), 4.02-4.11 (m, 1H), 6.89- 6.96 (m, 2H), 7.34 (d, J = 7.72Hz, 1H), 7.83 (brs, 1H)
443
441






F-344


embedded image


(400 MHz, MeOH-D4) 0.90 (s, 9H), 1.07-1.23 (m, 4H), 1.25-1.32 (m, 2H), 1.71-1.82 (m, 2H), 1.96 (s, 3H), 2.07 (s, 3H), 2.24 (s, 3H), 2.82 (t, J = 7.83Hz, 2H), 3.03 (dd, J = 15.00, 5.95Hz, 1H), 3.10-3.17 (m, 1H), 3.26 (dd, J = 15.00, 9.48Hz, 1H), 5.89 (dd, J = 9.48, 5.95Hz, 1H), 6.92 (d, J = 8.16Hz, 1H), 6.98 (s, 1H), 7.06 (d, J = 8.16Hz, 1H)
440
438






F-345


embedded image


(400 MHz, CDCl3) 0.83-1.01 (m, 2H), 1.14-1.24 (m, 2H), 2.07 (s, 0.6H), 2.12 (s, 0.6H), 2.14 (s, 2.6H), 2.18 (s, 2.2H), 2.26 (s, 3H), 2.59-2.73 (m, 2H), 2.79-3.00 (m, 3H), 3.34 (t, J = 11.12Hz, 0.8H), 3.65-3.78 (m, 2.2H), 3.85-4.00 (m, 2H), 4.05-4.13 (m, 0.4H), 4.18- 4.30 (m, 1.8H), 4.46 (dd, J = 11.60, 8.56Hz, 0.8H), 6.92- 7.00 (m, 2H), 7.18-7.40 (m, 5H), 7.60 (d, J = 7.88Hz, 0.2H), 7.76 (d, J = 8.12Hz, 0.8H), 8.09 (s, 0.2H), 8.98 (s, 0.8H)
498
496
Racemic form




















TABLE 228







Ex-



Informa-


am-


MS
tion of












ple
Chemical structure
NMR
M + H
M − H
structure





F- 346


embedded image


(400 MHz, DMSO-D6) 0.89-1.05 (m, 2H), 1.06-1.20 (m, 2H), 1.97 (s, 1.5H), 2.00 (s, 1.5H), 2.03 (s, 3H), 2.22 (s, 3H), 2.31-2.55 (m, 2H), 2.71-2.86 (m, 2H), 3.03- 3.14 (m, 1H), 3.28-3.50 (m, 1H), 3.53-3.65 (m, 1.5H), 3.65-3.78 (m, 2H), 3.78-3.88 (m, 0.5H), 3.89- 4.15 (m, 3H), 6.93 (d, J = 8.24Hz, 1H), 6.98 (s, 1H), 7.16-7.38 (m, 6H), 9.52 (d, J = 8.68Hz, 1H)
498
496
Racemic form





F- 347


embedded image


(400 MHz, DMSO-D6) 0.90-1.18 (m, 10H), 1.21-1.37 (m, 0.3H), 1.48-1.59 (m, 1.7H), 1.65-1.75 (m, 0.3H), 1.82-1.92 (m, 1.7H), 1.97 (s, 1.5H), 2.00 (s, 1.5H), 2.02- 2.06 (m, 3H), 2.22 (s, 3H), 2.65- 2.77 (m, 12H), 2.78-2.89 (m, 1.8H), 3.03-3.13 (m, 1H), 3.28- 3.38 (m, 0.5H), 3.40-3.48 (m, 0.5H), 3.51-3.61 (m, 0.5H), 3.64- 3.75 (m, 1H), 3.76-3.85 (m, 0.5H), 3.88-4.14 (m, 3H), 6.93 (d, J = 8.00Hz, 1H), 6.99 (s, 1H), 7.15- 7.25 (m, 1H), 9.47-9.59 (m, 1H)
464
462
Racemic form





F- 348


embedded image


(400 MHz, CDCl3) 0.90 (t, J = 5.62Hz, 9H), 0.93-1.49 (m, 5H), 1.95-2.01 (m, 3H), 2.12 (t, J = 4.85Hz, 6H), 2.27 (d, J = 9.26Hz, 3H), 2.87 (d, J = 8.60Hz, 1H), 3.02 (dt, J = 12.79, 4.47Hz, 1H), 3.29 (t, J = 11.03Hz, 1H), 3.83 (dt, J = 20.51, 7.28Hz, 1H), 3.89-3.98 (m, 1H), 4.16 (ddd, J = 19.02, 11.63, 5.57Hz, 2H), 4.42 (dd, J = 11.47, 8.38Hz, 1H), 4.85 (d, J = 5.95Hz, 1H), 6.95 (d, J = 9.92Hz, 2H), 7.66 (d, J = 7.94Hz, 1H), 8.88 (s, 1H)
482
480
Racemic form (Stereo- chemistry of Hydroxyl group: Undeter- mined) (Dia- stereomer of F-349)




















TABLE 229







Ex-



Informa-


am-


MS
tion of












ple
Chemical structure
NMR
M + H
M − H
structure





F-349


embedded image


(400 MHz, CDCl3) 0.90 (d, J = 2.65Hz, 9H), 0.96-1.48 (m, 5H), 1.97-2.03 (m, 1H), 2.11- 2.13 (m, 6H), 2.25 (s, 3H), 3.09 (dd, J = 13.12, 8.93Hz, 1H), 3.19- 3.25 (m, 1H), 3.61 (dd, J = 18.08, 8.16Hz, 1H), 3.75-3.83 (m, 1H), 3.96 (dt, J = 15.22, 4.63Hz, 1H), 4.10 (dt, J = 12.06, 5.68Hz, 2H), 4.33 (dd, J = 11.47, 8.60Hz, 1H), 4.83 (dd, J = 13.56, 7.39Hz, 1H), 6.96 (d, J = 8.16Hz, 2H), 7.63 (d, J = 7.94Hz, 1H), 8.85 (s, 1H)
482
480
Racemic form (Stereo- chemistry of Hydroxyl group: Undeter- mined) (Dia- stereomer of F-348)





F-350


embedded image


(400 MHz, CDCl3) 0.77-0.94 (m, 1H), 0.95-1.11 (m, 1H), 1.20- 1.44 (m, 2H), 1.38 (d, J = 6.92Hz, 6H), 2.08 (s, 0.7H), 2.12 (s, 0.7H), 2.15 (s, 2.3H), 2.18 (s, 2.3H), 2.26 (s, 3H), 3.11-3.22 (m, 1H), 3.27- 3.43 (m, 1.8H), 3.60-3.69 (m, 0.2H), 3.78-4.02 (m, 2H), 4.12- 4.31 (m, 2.2H), 4.53 (dd, J = 11.56, 8.44Hz, 0.8H), 6.57 (s, 1H), 6.95 (s, 1H), 6.97 (d, J = 8.48Hz, 1H), 7.59 (d, J = 7.80Hz, 0.2H), 7.74 (d, J = 8.24Hz, 0.8H), 7.95 (s, 0.2H), 8.77 (s, 0.8H)
477
475
Racemic form




















TABLE 230







Ex-



Informa-


am-


MS
tion of












ple
Chemical structure
NMR
M + H
M − H
structure





F-351


embedded image


(400 MHz, CDCl3) 0.89 (s, 9H), 1.21-1.39 (m, 2H), 1.33 (t, J = 7.36Hz, 3H), 1.71-1.84 (m, 2H), 2.05-2.07 (m, 1.2H), 2.09 (s, 2.4H), 2.13 (s, 2.4H), 2.25 (s, 3H), 2.67 (dd, J = 15.60, 7.36Hz, 2H), 3.27 (t, J = 11.12Hz, 0.8H), 3.47- 3.59 (m, 0.8H), 3.79-3.96 (m, 3.4H), 3.96-4.06 (m, 0.4H), 4.15- 4.33 (m, 1.8H), 4.37 (dd, J = 11.60, 8.24Hz, 0.8H), 6.91-6.99 (m, 2H), 7.53 (d, J = 8.92Hz, 0.2H), 7.69 (d, J = 8.04Hz, 0.8H), 7.72 (s, 0.2H), 8.62 (s, 0.8H)
454
452
Racemic form





F-352


embedded image


(400 MHz, DMSO-D6) 0.61-1.08 (m, 4H), 0.86 (s, 9H), 1.17-1.27 (m, 2H), 1.61-1.74 (m, 2H), 2.06 (s, 3H), 2.22 (s, 3H), 2.66-2.76 (m, 5H), 2.80-2.99 (m, 2H), 3.27- 3.36 (m, 1H), 5.03-5.19 (m, 2H), 6.01-6.19 (m, 1H), 6.91 (d, J = 8.60Hz, 1H), 6.97 (s, 1H), 7.14 (d, J = 8.16Hz, 1H), 7.28-7.45 (m, 5H), 9.36-9.44 (m, 1H)
546
544






F-353


embedded image


(400 MHz, MeOH-D4) 0.90 (s, 9H), 1.02-1.10 (m, 1H), 1.19-1.32 (m, 5H), 1.72-1.83 (m, 2H), 2.05 (s, 3H), 2.25 (s, 3H), 2.38 (s, 3H), 2.84 (t, J = 7.72Hz, 2H), 3.04-3.09 (m, 2H), 3.16-3.22 (m, 1H), 4.63 (t, J = 7.39Hz, 1H), 6.93 (d, J = 7.50Hz, 1H), 6.98(8, 1H), 7.10 (d, J = 8.16Hz, 1H)
412
410




















TABLE 231











Infor-






ma-


Ex-



tion of


am-


MS
struc-












ple
Chemical structure
NMR
M + H
M − H
ture





F-354


embedded image


(400 MHz, DMSO- D6) 0.80-1.30 (m, 6H), 0.87 (s, 9H), 1.61-1.74 (m, 2H), 2.00-2.29 (m, 9H), 2.60- 3.34 (m, 8H), 5.75 and 6.47 (t and dd, J = 7.72 and 9.37, 5.84Hz, total 1H), 6.88-7.01 (m, 2H), 7.10- 7.17 (m, 1H), 9.33
454
452





and 9.48 (each







s, total 1H)








F-355


embedded image


(400 MHz, MeOH- D4) 0.90 (s, 9H), 1.06-1.32 (m, 6H), 1.70-1.81 (m, 2H), 2.07 (s, 3H), 2.25 (s, 3H), 2.77-2.86 (m, 2H), 3.00-3.14 (m, 2H), 3.23-3.35 (m, 1H), 5.08 (s, 2H), 5.65 (t, J = 7.39Hz, 1H), 6.93 (d, J = 8.16Hz, 1H), 6.99 (s, 1H), 7.07 (d, J = 8.16Hz, 1H), 7.25-7.35
532
530





(m, 5H)








F-356


embedded image


(400 MHz, DMSO- D6) 0.87 (s, 9H), 1.21-1.31 (m, 2H), 1.63- 1.75 (m, 2H), 1.94-2.03 (m, 6H), 2.22 (s, 3H), 2.62- 2.72 (m, 2H), 3.37-3.46 (m, 0.5H), 3.48-3.58 (m, 0.7H), 3.62- 3.73 (m, 1H), 3.75-3.90 (m, 1H), 3.90-4.15 (m,
508
506
Race- mic form




2.8H), 5.00-5.24







(m, 2H), 6.93 (d,







J = 8.24Hz, 1H),







6.99 (s, 1H), 7.11-







7.20 (m, 1H), 9.43-







9.52 (m, 1H)








F-357


embedded image


(400 MHz, CDCl3) 0.83-0.91 (m, 2H), 0.87 (d, J = 6.85Hz, 6H), 1.08- 1.15 (m, 2H), 1.43 (dd, J = 6.80, 7.20Hz. 2H), 1.50- 1.63 (m, 1H), 2.00-2.12 (m, 2H), 2.19 (s, 3H),
395
393





2.26 (s, 3H),







2.48-2.63 (m, 3H),







2.88 (tt, J = 7.20,







4.00Hz, 1H), 3.05







(t, J = 6.35Hz,







2H), 3.16 (t,







J = 6.35Hz, 2H),







3.55-3.66 (m,







1H), 6.92-6.99







(m, 2H), 7.60 (d,







J = 8.87Hz, 1H),







8.30 (brs, 1H)




















TABLE 232











Infor-






ma-


Ex-



tion of


am-


MS
struc-












ple
Chemical structure
NMR
M + H
M − H
ture





F- 358


embedded image


(400 MHz, CDCl3) 0.86 (d, J = 6.62Hz, 6H), 0.87-0.93 (m, 2H), 1.09-1.17 (m, 2H), 1.34 (dd, J = 7.12, 6.73Hz, 2H), 1.49-1.60 (m, 1H), 2.01-2.12 (m, 2H), 2.19 (s, 3H), 2.26 (s,
395
393





3H), 2.34-2.59







(m, 3H), 2.89 (tt,







J = 7.12, 4.35Hz,







1H), 3.00-3.09







(m, 2H), 3.11-







3.19 (m, 2H), 3.43







(tt, J = 9.50,







7.92Hz, 1H), 6.93-







7.00 (m, 2H),







7.60 (d, J = 8.60Hz,







1H), 8.31 (s, 1H)








F- 359


embedded image


(400 MHz, MeOH- D4) 0.90 (s, 9H), 1.22 (d, J = 96.38Hz, 6H), 1.77 (d, J = 39.04Hz, 2H), 2.07 (s, 3H), 2.25 (s, 3H), 2.83 (t, J = 7.83Hz, 2H), 2.99 (dd, J = 15.11, 6.73Hz, 1H), 3.10-3.24 (m, 2H), 4.78 (t, J = 7.83Hz, 1H), 6.93 (d, J = 7.50Hz,
398
396





1H), 6.99 (s, 1H), 7.09 (d,







J = 7.94Hz, 1H)








F- 360


embedded image


(400 MHz, CDCl3) 0.85 (d, J = 6.72Hz, 6H), 0.87-0.93 (m, 1H), 0.99-1.05 (m, 1H), 1.08- 1.17 (m, 2H), 1.28-1.35 (m, 2H), 1.48-1.58 (m, 1H), 1.91-2.14 (m, 4H), 2.07 (s, 3H), 2.25 (s, 3H), 2.31-2.52 (m, 3H), 2.83-2.96 (m,
439
437





2H), 3.10 (dd, J =







14.03, 9.86Hz,







1H), 3.36-346







(m, 1H), 3.67-







3.79 (m, 2H), 3.91-







3.99 (m, 1H),







6.90-6.97 (m,







2H), 7.39 (d,







J = 8.12Hz, 1H),







7.76 (brs, 1H)




















TABLE 233







Ex-



Informa


am-


MS
tion of












ple
Chemical structure
NMR
M + H
M − H
structure





F-361


embedded image


(400 MHz, CDCl3) 0.85 (d, J = 6.72Hz, 6H), 0.87-0.93 (m, 1H), 0.99-1.05 (m, 1H), 1.08- 1.17 (m, 2H), 1.28-1.35 (m, 2H), 1.48-1.58 (m, 1H), 1.91-2.14 (m, 4H), 2.07 (s, 3H), 2.25 (s, 3H), 2.31-2.52 (m, 3H), 2.83-2.96 (m, 2H), 3.10 (dd, J = 14.03, 9.86Hz, 1H), 3.36-3.46 (m, 1H), 3.67- 3.79 (m, 2H), 3.91-3.99 (m, 1H), 6.90-697 (m, 2H), 7.39 (d, J = 8.12Hz, 1H), 7.76 (brs, 1H)
439
437






F-362


embedded image


(400 MHz, CDCl3) 0.79-0.83 (m, 1H), 0.87 (d, J = 7.05Hz, 6H), 0.91- 1.01 (m, 3H), 1.19-1.23 (m, 2H), 1.26 (d, J = 6.04Hz, 3H), 1.49-1.59 (m, 1H), 1.61-1.69 (m, 2H), 2.04 (s, 3H), 2.06-2.15 (m, 2H), 2.24 (s, 3H), 2.54-2.68 (m, 2H), 2.75- 2.81 (m, 2H), 3.03 (dd, J = 13.50, 10.68Hz, 1H), 3.49-3.56 (m, 1H), 3.90-3.97 (m, 1H), 4.15 (d, J = 11.69Hz, 1H), 4.49 (d, J = 11.69Hz, 1H), 6.91-6.92 (m, 2H), 7.26-7.22 (m, 3H), 7.28- 7.32 (m, 2H), 7.41 (d, J = 5.64Hz, 1H), 7.54 (s, 1H)
517
515




















TABLE 234







Ex-



Informa-


am-


MS
tion of












ple
Chemical structure
NMR
M + H
M − H
structure





F-363


embedded image


(400 MHz, CDCl3) 0.84-0.91 (m, 1H), 0.87 (d, J = 6.45Hz, 6H), 0.95- 1.07 (m, 3H), 1.21 (d, J = 5.64Hz, 3H), 1.23-1.28 (m, 2H), 1.51- 1.60 (m, 1H), 1.68-1.77 (m, 2H), 1.79-1.86 (m, 1H), 1.92-1.99 (m, 1H), 2.07 (s, 3H), 2.24 (s, 3H), 2.70 (dd, J = 7.86, 7.66Hz, 2H), 2.83-2.90 (m, 2H), 2.98 (dd, J = 13.90, 10.68Hz, 1H), 3.74-3.81 (m, 1H), 3.96-4.03 (m, 1H), 4.47 (d, J = 11.28Hz, 1H), 4.64 (d, J = 11.69Hz, 1H), 6.91-6.93 (m, 2H), 7.25-7.28 (m, 1H), 7.32- 7.38 (m, 4H), 7.47 (d, J = 8.46Hz, 1H), 7.98 (s, 1H)
517
515






F-364


embedded image


(400 MHz, CDCl3) 0.86-0.90 (m, 7H), 0.92-0.97 (m, 1H), 1.07- 1.29 (m, 10H), 1.51-1.61 (m, 1H), 1.71-1.79 (m, 1H), 2.09 (s, 3H), 2.25 (s, 3H), 2.71-2.80 (m, 2H), 2.93-3.02 (m, 2H), 3.12 (dd, J = 14.31, 9.47Hz, 1H), 3.93-4.01 (m, 2H), 6.92-6.94 (m, 2H), 7.40 (d, J = 8.06Hz, 1H), 8.04 (s, 1H)
427
425






F-365


embedded image


(400 MHz. CDCl3) 0.87 (d, J = 6.45Hz, 6H), 0.98-1.03 (m, 1H), 1.06-1.28 (m, 8H), 1.51- 1.89 (m, 4H), 2.01-2.03 (m, 1H), 2.05 (s, 3H), 2.24 (s, 3H), 2.73 (dd, J = 8.06, 8.46Hz, 2H), 2.83 (dd, J = 13.90, 4.63Hz, 1H), 3.00-3.09 (m, 2H), 3.72-3.77 (m, 1H), 3.99- 4.06 (m, 1H), 6.92-6.93 (m, 2H), 7.40 (d, J = 8.87Hz, 1H), 7.59 (s, 1H)
427
425




















TABLE 235







Ex-



Informa-


am-


MS
tion of












ple
Chemical structure
NMR
M + H
M − H
structure





F-366


embedded image


(400 MHz, CDCl3) 0.94 (s, 9H), 1.19-1.32 (m, 4H), 1.49-1.53 (m, 2H), 1.94-2.05 (m, 1H), 2.03 (s, 3H), 2.07-2.15 (m, 1H), 2.25 (s, 3H), 2.41-2.54 (m, 2H), 2.91 (dd, J = 14.51, 4.84Hz, 1H), 3.11-3.21 (m, 2H), 3.65-3.79 (m, 2H), 4.05- 4.13 (m, 1H), 6.93-5.95 (m, 2H), 7.32 (d, J = 8.87Hz, 1H),7.52 (s, 1H)
463
461
Racemic form





F-367


embedded image


(400 MHz, CDCl3) 0.89 (s, 9H), 1.00 (ddd, J = 10.53, 5.57, 3.03Hz, 1H), 1.14-1.25 (m, 5H), 1.42 (td, J = 12.79, 4.70Hz, 1H), 1.92-2.06 (m, 2H), 2.18 (s, 3H), 2.26 (s, 3H), 2.68 (d, J = 7.94Hz, 1H), 3.03 (dt, J = 12.57, 5.35Hz, 3H), 3.14-3.21 (m, 2H), 4.82 (dd, J = 13.34, 7.61Hz, 1H), 6.97 (t, J = 7.94Hz, 2H), 7.58 (t, J = 4.41Hz, 1H), 8.06 (s, 1H)
399
397
Racemic form





F-368


embedded image


(400 MHz, CDCl3) 0.76-0.92 (m, 1H), 0.92-1.04 (m, 1H), 1.15- 1.35 (m, 2H), 1.56 (d, J = 6.92Hz, 6H), 2.08 (m, 0.6H), 2.11 (s, 0.6H), 2.14 (s, 2.4H), 2.19 (s, 2.4H), 2.26 (s, 3H), 3.16-3.27 (m, 1H), 3.36 (t, J = 10.92Hz, 0.8H), 3.67 (t, J = 9.84Hz, 0.2H), 3.72-3.84 (m, 0.8H), 3.84-4.01 (m, 1.2H), 4.07- 4.31 (m, 2.2H), 4.46-4.64 (m, 1.8H), 6.92-7.00 (m, 2H), 7.57 (d, J = 8.04Hz, 0.2H), 7.76 (d, J = 8.04Hz, 0.8H), 7.90 (s, 0.2H), 7.92 (s, 0.8H), 7.97 (s, 1H), 8.11 (s, 0.2H), 8.96 (s, 0.8H)
476
474
Racemic form




















TABLE 236







Ex-



Informa-


am-


MS
tion of












ple
Chemical structure
NMR
M + H
M − H
structure





F-369


embedded image


(400 MHz, CDCl3) 0.82 (s, 9H) 1.20-1.24 (m, 2H), 1.30 (t, J = 7.54Hz, 3H), 1.61-1.69 (m, 2H), 2.04 (s, 3H), 2.09 (s, 3H), 2.27 (s, 3H), 2.36-2.43 (m, 1H), 2.56 (ddd, J = 31.25, 15.48, 8.06Hz, 2H), 2.71-2.78 (m, 1H), 3.82- 4.05 (m, 4H), 4.55 (td, J = 14.73, 7.27Hz, 1H), 5.30 (d, J = 6.72Hz, 1H), 6.92-7.01 (m, 2H), 7.41 (d, J = 8.81Hz, 1H), 8.09 (brs, 1H)
454
452






F-370


embedded image


(400 MHz, CDCl3) 0.90 (s, 9H), 1.18 (t, J = 7.42Hz, 3H), 1.28-1.33 (m, 2H), 1.72-1.80 (m, 2H), 2.00 (s, 3H), 2.22-2.31 (m, 1H), 2.33 (s, 3H), 2.44-2.51 (m, 1H), 2.59 (t, J = 8.00Hz, 2H), 3.46-3.52 (m, 1H), 3.74-3.89 (m, 3H), 3.80 (s, 3H), 4.32 (d, J = 6.03Hz, 2H), 4.45 (td, J = 14.78, 7.34Hz, 1H), 5.12 (d, J = 7.19Hz, 1H), 6.12-6.14 (brm, 1H), 6.64-6.70 (m, 2H), 7.03 (d, J = 7.42Hz, 1H)
484
482






F-371


embedded image


(400 MHz, CDCl3) 0.53-0.60 (m, 1H), 0.77-0.84 (m, 1H), 1.00- 1.07 (m, 1H), 1.11-1.20 (m, 1H), 1.29 (s, 3H), 1.31 (s, 3H), 2.16 (s, 3H), 2.20 (s, 3H), 2.27 (s, 3H), 2.95-3.02 (m, 1H), 3.23-3.28 (m, 1H), 3.43 (t, J = 10.90Hz, 1H), 3.81- 3.86 (m, 1H), 3.92-4.00 (m, 1H), 4.24-4.29 (m, 2H), 4.54 (dd, J = 11.36, 8.81Hz, 1H), 6.96-7.00 (m, 2H), 7.33-7.37 (m, 2H), 7.62 (d, J = 8.12Hz, 2H), 7.78 (d, J = 7.88Hz, 1H), 8.99 (brs, 1H)
486
484




















TABLE 237







Ex-



Informa-


am-


MS
tion of












ple
Chemical structure
NMR
M + H
M − H
structure





F-372


embedded image


(400 MHz, CDCl3) 0.52-0.61 (m, 1H), 0.77-0.84 (m, 1H), 1.00- 1.20 (m, 2H), 1.29 (s, 3H), 1.31 (s, 3H), 2.16 (s, 3H), 2.20 (s, 3H), 2.27 (s, 3H), 2.95-3.02 (m, 1H), 3.23-3.28 (m, 1H), 3.43 (t, J = 11.02Hz, 1H), 3.49 (d, J = 4.41Hz, 1H), 3.83 (dd, J = 18.90, 10.55Hz, 1H), 3.91-4.00 (m, 1H), 4.20-4.31 (m, 2H), 4.54 (dd, J = 11.36, 8.58Hz, 1H), 6.94-7.00 (m, 2H), 7.32-7.36 (m, 2H), 7.59- 7.65 (m, 2H), 7.77 (d, J = 7.88Hz, 1H), 9.00 (brs, 1H)
486
484






F-373


embedded image


(400 MHz, CDCl3) 0.88 (s, 9H), 1.28 (t, J = 8.49Hz, 2H), 1.76 (dd, J = 15.66, 7.94Hz, 2H), 2.02 (s, 3H), 2.25 (s, 3H), 2.49-2.71 (m, 4H), 2.86-2.99 (m, 2H), 3.35-3.42 (m, 1H), 4.21-4.29 (m, 1H), 5.03- 5.17 (m, 3H), 5.75-5.83 (m, 1H), 6.91-6.97 (m, 2H), 7.06 (brs, 1H), 7.24-7.27 (m, 1H)
465
463
Racemic form





F-374


embedded image


(400 MHz, CDCl3) 0.92-1.79 (m, 17H), 2.15 (s, 3H), 2.17 (s, 3H), 2.26 (s, 3H), 2.74-2.89 (m, 2H), 2.96-3.02 (m, 1H), 3.30 (t, J = 11.02Hz, 1H), 3.70 (td, J = 10.67, 8.43Hz, 1H), 3.92 (td, J = 7.13, 2.01Hz, 1H), 4.23 (tt, J = 12.37, 5.64Hz, 2H), 4.45 (dd, J = 11.48, 8.46Hz, 1H), 6.95-6.98 (m, 2H), 778 (d, J = 8.12Hz, 1H), 9.04 (s, 1H)
478
476




















TABLE 238







Ex-



Informa-


am-


MS
tion of












ple
Chemical structure
NMR
M + H
M − H
structure





F-375


embedded image


(400 MHz, CDCl3) 0.92-1.79 (m, 17H), 2.15 (s, 3H), 2.17 (s, 3H), 2.26 (s, 3H), 2.74-2.89 (m, 2H), 2.96-3.02 (m, 1H), 3.30 (t, J = 11.02Hz, 1H), 3.70 (td, J = 10.67, 8.43Hz, 1H), 3.92 (td, J = 7.13, 2.01Hz, 1H), 4.23 (tt, J = 12.87, 5.64Hz, 2H), 4.46 (dd, J = 11.48, 8.46Hz, 1H), 6.95-6.98 (m, 2H), 7.78 (d, J = 8.12Hz, 1H), 9.04 (s, 1H)
478
476






F-376


embedded image


(400 MHz, CDCl3) 0.94 (s, 9H), 1.14-1.20 (m, 3H), 1.31-1.36 (m, 1H), 1.48-1.52 (m, 2H), 2.02 (s, 3H), 2.24 (s, 3H), 2.41-2.59 (m, 4H), 2.86 (dd, J = 13.30, 4.43Hz, 1H), 3.10-3.17 (m, 2H), 3.88- 3.95 (m, 1H), 5.07-5.11 (m, 2H), 5.71-5.82 (m, 1H), 6.93-6.94 (m, 2H), 7.31-7.33 (m, 2H)
459
457
Racemic form





F-377


embedded image


(400 MHz, DMSO-D6) 0.86 (d, J = 6.68Hz, 6H), 1.06-1.28 (m, 4H), 1.29-1.40 (m, 2H), 1.43- 1.60 (m, 1H), 1.93-2.18 (m, 8H), 2.33 (s, 3H), 2.38-2.62 (m, 3H), 3.24-3.35 (m, 1H), 3.44-3.55 (m, 1H), 3.63-3.93 (m, 3H), 3.96- 4.18 (m, 2.5H), 4.19-4.30 (m, 0.5H), 6.95 (d, J = 8.24Hz, 1H), 7.01 (s, 1H), 7.13-7.25 (m, 1H), 9.63-9.74 (m, 1H)
478
476
(Hydro- chloride salt of F-318)




















TABLE 239







Ex-



Informa-


am-


MS
tion of












ple
Chemical structure
NMR
M + H
M − H
structure





F-378


embedded image


(400 MHz, DMSO-D6) 0.86 (d, J = 6.68Hz, 6H), 1.05-1.36 (m, 6H), 1.41-1,60 (m, 1H), 1.90- 2.15 (m, 8H), 2.23 (s, 3H), 2.29 (s, 3H), 2.40-2.61 (m, 3H), 3.21- 3.33 (m, 1H), 3.42-3.53 (m, 1H), 3.60-3.88 (m, 3H), 3.95-4.28 (m, 3H), 6.95 (d, J = 8.04Hz, 1H), 7.02 (s, 1H), 7.11 (d, J = 7.80Hz, 2H), 7.14-7.24 (m, 1H), 7.47 (d, J = 8.00Hz, 2H), 9.56 (s, 1H)
478
476
(Tosilate salt of F-318)





F-379


embedded image


(400 MHz, CDCl3) 0.89 (s, 9H), 1.26-1.32 (m, 2H), 1.78 (dd, J = 15.19, 7.54Hz, 2H), 2.05 (s, 3H), 2.09-2.15 (m, 2H), 2.26 (s, 3H), 2.54-2.68 (m, 3H), 3.02 (ddd, J = 39.60, 15.02, 7.48Hz, 2H), 3.62-3.80 (m, 3H), 4.42-4.50 (m, 1H), 4.94-5.02 (m, 1H), 6.92-6.98 (m, 2H), 7.27-7.33 (m, 1H)
469
467






F-380


embedded image


(400 MHz, CDCl3) 0.89 (s, 9H), 1.29 (dd, J = 9.51, 7.42Hz, 2H), 1.74-1.82 (m, 2H), 2.05 (s, 3H), 2.08-2.14 (m, 2H), 2.26 (s, 3H), 2.53-2.70 (m, 3H), 2.97 (dd, J = 14.96, 4.75Hz, 1H), 3.07 (dd, J = 15.07, 10.20Hz, 1H), 3.62-3.80 (m, 3H), 4.42-4.50 (m, 1H), 4.94- 5.03 (m, 1H), 6.93-6.98 (m, 2H), 7.28-7.33 (m, 2H)
469
467




















TABLE 240











Informa-





MS
tion of












Example
Chemical structure
NMR
M + H
M − H
structure





F-381


embedded image


(400 MHz, CDCl3) 0.88 (s, 9H), 1.01-1.11 (m, 1H), 1.17-1.40 (m, 4H), 1.57-1.68 (m, 1H), 1.73- 1.87 (m, 2H), 2.18 (s, 3H), 2.24 (s, 3H), 2.68 (t, J = 7.12 Hz, 2H), 2.85 (t, J = 7.36Hz, 2H), 2.94-3.05 (m, 1H), 3.13-3.25 (m, 1H), 4.00- 4.27 (m, 2H), 5.06-5.17 (m, 2H), 5.69-5.84 (m, 1H), 6.90 (d, J = 8.24Hz, 1H), 6.94 (s, 1H), 7.23- 7.32 (m, 1H), 8.41 (brs, 1H)
423
421






F-382


embedded image


(400 MHz, CDCl3) 0.83-1.00 (m, 2H), 1.12-1.33 (m, 2H), 1.20 (s, 9H), 2.03-2.16 (m, 6H), 2.25 (s, 3H), 2.35-2.53 (m, 2H), 2.62- 2.75 (m, 2H), 2.87-2.98 (m, 1H), 3.02-3.15 (m, 1H), 3.28 (t, J = 11.16Hz, 0.8H), 3.62-3.75 (m, 0.8H), 3.83-4.10 (m, 1.6H), 4.10- 4.28 (m, 3H), 4,43 (dd, J = 11.56, 8.68Hz, 0.8H), 6.91-7.01 (m, 2H), 7.57 (d, J = 8.68Hz, 0.2H), 7.72 (d, J = 8.00Hz, 0.8H), 8.06 (s, 0.2H), 8.97 (s, 0.8H)
494
492
Racemic form





F-383


embedded image


(400 MHz, DMSO-D6) 0.86 (d, J = 6.72Hz, 6H), 1.02-1.27 (m, 4H), 1.27-1.37 (m, 2H), 1.41- 1.60 (m, 1H), 1.93-2.16 (m, 8H), 2.23 (s, 3H), 2.36-2.60 (m, 3H), 3.18-3.30 (m, 1H), 3.32-4.29 (m 7H), 6.95 (d, J = 8.24Hz, 1H), 7.01 (s, 1H), 7.13-7.24 (m, 1H), 9.57- 9.67 (m, 1H)
478
476




















TABLE 241











Informa-





MS
tion of












Example
Chemical structure
NMR
M + H
M − H
structure





F-384


embedded image


(400 MHz, CDCl3) 0.84-1.36 (m, 10H), 1.54-1.76 (m, 7H), 1.93- 2.03 (m, 1H), 2.04-2.15 (m, 1H), 2.06 (s, 3H), 2.25 (s, 3H), 2.74- 2.79 (m, 2H), 2.78 (brs, 1H), 2.88 (dd, J = 14.05, 4.85Hz, 1H), 3.00 (tt, J = 7.12, 3.96Hz, 1H), 3.10 (dd, J = 14.05, 10.03Hz, 1H), 3.64-3.81 (m, 2H), 3.94-4.03 (m, 1H), 6.93 (d, J = 7.94Hz, 1H), 6.94 (s, 1H), 7.39 (d, J = 7.94Hz, 1H), 7.86 (brs, 1H)
439
437






F-385


embedded image


(400 MHz. CDCl3) 0.84-1.35 (m, 10H), 1.55-1.77 (m,7H), 1.92- 2.03 (m, 1H), 2.04-2.15 (m, 1H), 2.06 (s, 3H), 2.25 (s, 3H), 2.73- 2.79 (m, 2H), 2.81 (brs, 1H), 2.88 (dd, J = 14.11, 4.85Hz, 1H), 3.00 (tt, J = 7.12, 3.96Hz, 1H), 3.10 (dd, J = 14.11, 10.14Hz, 1H), 3.64-3.80 (m, 2H), 3.93-4.03 (m, 1H), 6.93 (d, J = 7.94Hz, 1H), 6.94 (s, 1H), 7.38 (d, J = 7.94Hz, 1H), 7.87 (brs, 1H)
439
437






F-386


embedded image


(400 MHz, CDCl3) 0.87 (d, J = 6.72Hz, 6H), 0.97-1.03 (m, 1H), 1.10-1.30 (m, 5H), 1.23 (s, 3H), 1.28 (s, 3H), 1.51-1.61 (m, 1H), 1.66-1.78 (m, 1H), 1.89- 1.99 (m, 2H), 2.09 (s, 3H), 2.17 (dd, J = 14.38, 7.65Hz, 1H), 2.25 (s, 3H), 2.74 (t, J = 7.88Hz, 2H), 2.92- 3.05 (m, 3H), 3.90-3.98 (m, 1H), 6.91-6.96 (m, 2H), 7.43 (d, J = 8.58Hz, 1H), 7.87 (brs, 1H)
441
439




















TABLE 242











Informa-





MS
tion of












Example
Chemical structure
NMR
M + H
M − H
structure





F-387


embedded image


(400 MHz, CDCl3) 0.87 (d, J = 6.72Hz, 6H), 0.97-1.03 (m, 1H), 1.10-1.30 (m, 5H), 1.23 (s, 3H), 1.28 (s, 3H), 1.51-1.61 (m, 1H), 1.66-1.78 (m. 1H), 1.89- 1.99 (m, 2H), 2.09 (s, 3H), 2.17 (dd, J = 14.38, 7.65Hz, 1H), 2.25 (s, 3H), 2.74 (t, J = 7.88Hz, 2H), 2.92- 3.05 (m, 3H), 3.90-3.98 (m, 1H), 6.91-6.96 (m, 2H), 7.43 (d, J = 8.58Hz, 1H), 7.87 (brs, 1H)
441
439






F-388


embedded image


(400 MHz, CDCl3) 0.88-0.90 (m, 10H), 1.11 (s, 1H), 1.27-1.29 (m, 5H), 1.80 (s, 3H), 2.09 (s, 3H), 2.27 (s, 3H), 2.72 (s, 3H), 2.84- 2.99 (m, 3H), 3.94-3.98 (m, 1H), 5.43 (d, J = 7.72Hz, 1H), 6.97-6.99 (m, 2H), 7.46 (d, J = 8.60Hz, 1H), 7.54 (s, 1H)
452
450






F-389


embedded image


(400 MHz, CDCl3) 0.88 (s, 9H), 1.00-1.12 (m, 1H), 1.17-1.42 (m, 4H), 1.56-1.70 (m, 1H), 1.72- 1.89 (m, 2H), 2.18 (s, 3H), 2.24 (s, 3H), 2.62-2.74 (m, 2H), 2.79- 2.91 (m, 2H), 2.93-3.06 (m, 1H), 3.13-3.25 (m, 1H), 4.02-4.25 (m, 2H), 5.05-5.17 (m, 2H), 5.69- 5.84 (m, 1H), 6.91 (d, J = 7.88Hz, 1H), 6.94 (s, 1H), 7.23-7.32 (m, 1H), 8.43 (brs, 1H)
423
421




















TABLE 243











Informa-





MS
tion of












Example
Chemical structure
NMR
M + H
M − H
structure





F-390


embedded image


(400 MHz, CDCl3) 0.88 (d, J = 6.85Hz, 6H), 0.92-0.97 (m, 1H), 1.07-1.12 (m, 1H), 1.14- 1.30 (m, 8H), 1.52-1.62 (m, 1H), 1.73-1.80 (m, 2H), 1.83-1.88 (m, 1H), 2.09 (s, 3H), 2.25 (s, 3H), 2.74 (dd, J = 8.06, 8.06Hz, 2H), 2.92-3.01 (m, 2H), 3.12 (dd, J = 14.10, 9.27Hz, 1H), 3.94-4.01 (m, 2H), 6.93-6.94 (m, 2H), 7.42 (d, J = 8.46Hz, 1H), 7.96 (s, 1H)
427
425






F-391


embedded image


(400 MHz, CDCl3) 0.87 (d, J = 6.45Hz, 6H), 0.98-1.03 (m, 1H), 1.06-1.28 (m, 9H), 1.51- 1.89 (m, 3H), 2.01-2.09 (m, 1H), 2.05 (s, 3H), 2.24 (s, 3H), 2.73 (dd, J = 8.06, 7.66Hz, 2H), 2.83 (dd, J = 13.70, 4.84Hz, 1H), 3.00-3.09 (m, 2H), 3.70-3.77 (m, 1H), 3.99- 4.06 (m, 1H), 6.92-6.93 (m, 2H), 7.40 (d, J = 8.87Hz, 1H), 7.60 (s, 1H)
427
425






F-392


embedded image


(400 MHz. CDCl3) 0.86-0.95 (m, 9H), 1.17-1.34 (m, 2H), 1,76- 1.89 (m, 2H), 2.03-2.15 (m, 4H), 2.25-2.30 (m, 3H), 2.52-2.73 (m, 2H), 3.36-3.45 (m, 1H), 3.47- 3.52 (m, 2H), 3.58-3.77 (m, 2H), 3.91-4.18 (m, 2H), 4.27-4.42 (m, 2H), 6.94-7.02 (m, 2H), 7.29- 7.56 (m, 1H), 8.05 (brs, 1H)
508
506




















TABLE 244











Informa-





MS
tion of












Example
Chemical structure
NMR
M + H
M − H
structure





F-393


embedded image


(400 MHz, CDCl3) 0.85-0.95 (m, 9H), 1.19-1.33 (m, 2H), 1.75- 1.87 (m, 1H), 2.03-2.15 (m, 6H), 2.24-2.29 (m, 3H), 2.54-2.74 (m, 2H), 3.38-3.50 (m, 2H), 3.60- 3.77 (m, 2H), 3.92-4.19 (m, 2H), 4.25-4.43 (m, 2H), 4.54-5.25 (m, 1H), 6.94-7.01 (m, 2H), 7.28- 7.55 (m, 1H), 8.09 (brs, 1H)
508
506






F-394


embedded image


(400 MHz, CDCl3) 0.83-0.88 (m, 9H), 1.06-1.30 (m, 6H), 1.63- 1.74 (m, 2H), 2.00-2.07 (m, 4H), 2.14-2.19 (m, 1H), 2.21-2.24 (m, 4H), 2.25-2.31 (m, 1H), 2.35 (s, 3H), 2.66-2.73 (m, 2H), 2.88- 3.09 (m, 4H), 3.62-3.76 (m, 1H), 6.85-6.93 (m, 2H), 7.35-7.42 (m, 1H)
452
450
Racemic form





F-395


embedded image


(400 MHz, CDCl3) 0.82-0.92 (m, 10H), 1.03-1.34 (m, 5H), 1.72- 1.79 (m, 2H), 1.92-2.07 (m, 2H), 2.10 (s, 3H), 2.23 (s, 3H), 2.26- 2.36 (m, 1H), 2.39 (s, 3H), 2.49- 2.65 (m, 1H), 2.67-2.74 (m, 2H), 2.88-2.97 (m, 1H), 2.97-3.06 (m, 1H), 3.12-3.20 (m, 1H), 3.22- 3.32 (m, 1H), 3.35-3.45 (m, 1H), 6.89-6.95 (m, 2H), 7.41-7.51 (m, 1H)
452
450
Racemic form




















TABLE 245











Informa-





MS
tion of












Example
Chemical structure
NMR
M + H
M − H
structure





F-396


embedded image


(400 MHz, CDCl3) 0.88-0.97 (m, 3H), 1.09-1.31 (m, 8H), 1.57- 1.75 (m, 5H), 1.97-2.13 (m, 3H), 2.06 (s, 3H), 2.24 (s, 3H), 2.76- 2.87 (m, 3H), 2.93-2.98 (m, 1H), 3.06 (dd, J = 14.10, 12.89Hz, 1H), 3.23-3.31 (m, 1H), 3.27 (s, 3H), 3.43-3.49 (m, 1H), 3.89-3.97 (m, 1H), 6.91-6.93 (m, 2H), 7.43 (d, J = 8.46Hz, 1H), 7.75 (s, 1H)
453
451
Racemic form





F-397


embedded image


(400 MHz, CDCl3) 0.83-1.09 (m, 2H), 0.90 (s, 9H), 1.18-1.35 (m, 4H), 1.72-1.84 (m, 2H), 2.14 (s, 3H), 2.25 (s, 3H), 2.70-2.83 (m, 2H), 2.92-3.01 (m, 1H), 2.96 (s, 3H), 3.40 (t, J = 9.80Hz, 1H), 3.81- 3.92 (m, 2H), 4.00-4.18 (m, 3H), 6.92-6.99 (m, 2H), 7.71 (d, J = 8.24Hz, 1H), 8.56 (s, 1H)
502
500
Racemic form





F-398


embedded image


(400 MHz, CDCl3) 0.81-0.99 (m, 1H), 0.89 (s, 9H), 0.99-1.09 (m, 1H), 1.19-1.37 (m, 4H), 1.71- 1.84 (m, 2H), 2.13 (s, 3H), 2.25 (s, 3H), 2.69-2.84 (m, 2H), 2.90- 2.99 (m, 1H), 3.53 (t, J = 9.80Hz, 1H), 3.86-3.98 (m, 1H), 4.06 (t, J = 8.72Hz, 1H) 4.13-4.34 (m, 3H), 6.91-6.99 (m, 2H), 7.69 (d, J = 8.24Hz, 1H), 8.62 (s, 1H)
556
554
Racemic form




















TABLE 246











Informa-





MS
tion of












Example
Chemical structure
NMR
M + H
M − H
structure





F-399


embedded image


(400 MHz, CDCl3) 0.82-1.08 (m, 2H), 0.89 (s, 9H), 1.15-1.36 (m, 4H), 1.71-1.83 (m, 2H), 2.12- 2.19 (m, 3H), 2.25 (s, 3H), 2.68- 2.83 (m, 2H), 2.92-3.02 (m, 1H), 3.29-3.42 (m, 1H), 3.65-3.80 (m, 3.7H), 3.82-4.18 (m, 3.6H), 4.24- 4.34 (m, 0.7H), 6.92-6.99 (m, 2H), 7.67-7.79 (m, 1H), 8.42 (s, 0.3H), 8.76 (s, 1H)
482
480
Racemic form





F-400


embedded image


(400 MHz, CDCl3) 0.84-1.10 (m, 2H), 0.89 (s, 9H), 1.12-1.37 (m, 7H), 1.71-1.84 (m, 2H), 2.10 (s, 0.6H), 2.17 (s, 2.4H), 2.20-2.47 (m, 2H), 2.25 (s, 3H), 2.70-2.85 (m, 2H), 2.93-3.04 (m, 1H), 3.31 (t, J = 11.16Hz, 0.8H), 3.49-3.75 (m, 1H), 3.84-3.97 (m, 1.2H), 4.00-4.12 (m, 0.4H), 4.14-4.28 (m, 1.8H), 4.47 (dd, J = 11.56, 8.44Hz, 0.8H), 6.91-6.99 (m, 2H), 7.62 (d, J = 8.24Hz, 0.2H), 7.77 (d, J = 8.24Hz, 0.8H), 8.04 (s, 0.2H), 9.02 (s, 0.8H)
480
478
Racemic form





F-401


embedded image


(400 MHz, CDCl3) 0.88 (s, 9H), 1.25-1.31 (m, 2H), 1.49-2.10 (m, 7H), 2.02 (s, 3H), 2.26 (s, 3H), 2.49-2.56 (m, 1H), 2.63-2.71 (m, 1H), 2.90-2.96 (m, 2H), 3.37- 3.45 (m, 1H), 3.57-3.68 (m, 2H), 4.25-4.33 (m, 1H), 5.07-5.15 (m, 1H), 6.92-6.96 (m, 2H), 7.22- 7.29 (m, 2H)
483
481
Racemic form




















TABLE 247











Informa-


Exam-


MS
tion of












ple
Chemical structure
NMR
M + H
M − H
structure





F-402


embedded image


(400 MHz, DMSO- D6) 0.88-1.76 (m, 17H), 1.97- 2.00 (m, 3H), 2.08- 2.09 (m, 3H), 2.22 (s, 3H), 2.91- 2.95 (m, 2H), 3.30- 4.22 (m, 8H), 6.93 (d, J = 8.12Hz, 1H), 7,00 (s, 1H). 7.17 (dd, J = 13.91, 8.12Hz, 1H), 9.61 (d, J = 9.74Hz, 1H)
478
476






F-403


embedded image


(400 MHz, CDCl3) 0.89 (s, 9H), 1.08-1.16 (m, 1H), 1.22-1.38 (m, 3H), 1.44-1.52 (m, 1H), 1.65- 1.74 (m, 1H), 1.79- 1.90 (m, 2H), 1.92-2.02 (m, 1H), 2.04-2.14 (m, 1H), 2.20 (s, 3H), 2.24 (s, 3H), 2.29-2.50 (m, 2H), 2.85-2.94 (m,
466
464





2H), 3.02-3.11







(m, 1H), 3.25-







3.35 (m, 1H),







3.48-3.57 (m, 1H),







3.66-3.76 (m, 1H),







4.35-4.48 (m,







1H), 6.43 (dd, J =







11.80, 4.52Hz,







1H), 6.90 (d, J =







7.94Hz, 1H), 6.95







(s, 1H), 7.22-







7.27 (m, 1H), 8.44







(brs, 1H)








F-404


embedded image


(400 MHz, CDCl3) 0.63-0.68 (m, 2H), 0.92 (d, J = 6.62Hz, 6H), 1.02- 1.09 (m, 2H), 1.86- 1.96 (m, 1H), 2.21 (s, 3H), 2.26 (s, 3H), 2.54 (d, J = 7.28Hz, 2H), 3.10-3.15 (m,
417
415





2H), 3.20-3.30







(m, 3H), 6.95-







6.99 (m, 2H), 7.24







(d, J = 8.16Hz,







2H), 7.61 (d, J =







8.38Hz, 2H), 7.64







(d, J = 8.82Hz, 1H),







8.17 (brs, 1H)




















TABLE 248











Informa-


Exam-


MS
tion of












ple
Chemical structure
NMR
M + H
M − H
structure





F-405


embedded image


(400 MHz, CDCl3) 0.87-0.94 (m, 2H), 1.00 (d, J = 6.62Hz. 6H), 1.24- 1.31 (m, 2H), 2.05-2.15 (m, 1H), 2.21 (s, 3H), 2.26 (s, 3H), 2.71 (d, J = 7.06Hz, 2H), 3.12 (t, J = 6.62Hz, 2H), 3.26-3.35 (m, 3H), 6.58 (d,
408
406





J = 0.66Hz, 1H),







6.95-7.00 (m,







2H), 7.60 (d, J =







8.82Hz, 1H), 7.95







(brs, 1H)








F-406


embedded image


(400 MHz, DMSO- D6) 0.53-0.63 (m, 1H), 0.70- 0.78 (m, 1H), 0.90 (d, J = 6.62Hz, 6H), 0.96-1.05 (m, 1H), 1.07-1.16 (m, 1H), 1.87- 1.96 (m, 1H), 2.00 and 2.03 (each s, total 3H), 2.09 and 2.10 (each s, total 3H), 2.24 (s, 3H), 2.56 (d,
500
498





J = 7.28Hz, 2H),







3.44-4.29 (m,







7H), 6.96 (d, J =







7.72Hz, 1H), 7.01







(s, 1H), 7.21 and







7.24 (each d,







J = 7.94 and 8.16Hz,







total 1H), 7.37







(d, J = 7.50Hz,







2H), 7.71 (d,







J = 7.72Hz, 2H),







9.61 (d, J = 9.70Hz,







1H)








F-407


embedded image


(400 MHz, DMSO- D6) 0.53-0.63 (m, 1H), 0.70- 0.78 (m, 1H), 0.90 (d, J = 6.62Hz, 6H), 0.96-1.05 (m, 1H), 1.07-1.16 (m, 1H), 1.87- 1.96 (m, 1H), 2.00 and 2.03 (each s, total 3H), 2.09 and 2.10 (each s, total 3H), 2.24 (s, 3H), 2.56 (d,
500
496





J = 7.28Hz, 2H),







3.44-4.29 (m,







7H), 6.96 (d, J =







7.72Hz, 1H), 7.01







(s, 1H), 7.21 and







7.24 (each d,







J = 7.94 and 8.16Hz,







total 1H), 7.37







(d, J = 7.50Hz,







2H), 7.71 (d,







J = 7.72Hz, 2H),







9.61 (d, J = 9.70Hz,







1H)




















TABLE 249











Informa-


Exam-


MS
tion of












ple
Chemical structure
NMR
M + H
M − H
structure





F-408


embedded image


(400 MHz, DMSO- D6) 0.78-0.98 (m, 2H), 0.95 (d, J = 6.96Hz, 6H), 1.06-1.20 (m, 2H), 1.95-2.10 (m, 1H), 1.99 and 2.02 (each s, total 3H), 2.06 (s, 3H), 2.23 (s, 3H), 2.77 (d, J = 6.96Hz, 2H), 3.36-4.24 (m, 7H), 6.77 (d, J = 1.86Hz, 1H),
491
489





6.94 (d, J = 8.12Hz,







1H), 7.00 (s,







1H), 7.19 and 7.22







(each d, J = 8.12







and 7.88Hz, total







1H), 9.58(d,







J = 6.49Hz, 1H)








F-409


embedded image


(400 MHz, DMSO- D6) 0.78-0.98 (m, 2H), 0.95 (d, J = 6.96Hz, 6H), 1.06-1.20 (m, 2H), 1.95-2.10 (m, 1H), 1.99 and 2.02 (each s, total 3H), 2.06 (s, 3H), 2.23 (s, 3H), 2.77 (d, J = 6.96Hz, 2H), 3.36-4.24 (m, 7H), 6.77 (d, J = 1.86Hz, 1H),
491
489





6.94 (d, J = 8.12Hz,







1H), 7.00 (s,







1H), 7.19 and 7.22







(each d, J = 8.12







and 7.88Hz, total







1H), 9.58 (d,







J = 6.49Hz, 1H)








F-410


embedded image


(400 MHz, CDCl3) 0.86 (d, J = 6.62Hz, 6H), 1.05-1.12 (m, 1H), 1.24-1.37 (m, 4H), 1.47- 1.57 (m, 2H), 1.98- 2.28 (m, 4H), 2.16 (s, 3H), 2.24 (s, 3H), 2.39- 2.59 (m, 3H), 3.01 (dd, J = 15.44, 4.41Hz, 1H), 3.31-
439
437





3.39 (m, 1H),







3.50-3.61 (m, 1H),







3.70-3.87 (m,







2H), 3.95-4.07







(m, 1H), 4.13-







4.23 (m, 1H), 6.91







(d, J = 7.72Hz,







1H), 6.95 (s,







1H), 7.22 (d,







J = 7.94Hz, 1H),







8.63 (brs, 1H)




















TABLE 250











Informa-


Exam-


MS
tion of












ple
Chemical structure
NMR
M + H
M − H
structure





F-411


embedded image


(400 MHz, DMSO- D6) 0.50-0.80 (m, 2H), 0.94- 1.14 (m, 2H), 1.24 (s, 3H), 1.26 (s, 3H), 2.01 (d, J = 10.20Hz, 3H), 2.08 (d, J = 4.17Hz, 3H), 2.22 (s, 3H), 2.95- 3.02 (m, 1H), 3.43- 3.60 (m, 2H), 3.65-4.24 (m, 5H), 6.93-7.01 (m,
486
484





2H), 7.21 (dd, J =







13.33, 8.00Hz,







1H), 7.43 (d, J =







8.35Hz, 2H), 7.71







(d, J = 8.12Hz,







2H), 9.59 (d,







J = 9.04Hz, 1H)








F-412


embedded image


(400 MHz, CDCl3) 0.92 (s, 9H), 1.32-1.39 (m, 5H), 1.58 (s, 1H), 1.89 (s, 2H), 2.27 (s, 3H), 2.29 (s, 3H), 2.99-3.02 (m, 4H), 3.13 (d, J = 8.60Hz, 1H), 3.62 (s, 1H), 3.91 (t, J = 9.59Hz, 1H), 4.04 (t,
452
450





J = 9.46Hz, 1H),







4.34 (s, 1H), 4.47







(t, J = 9.26Hz,







1H), 6.96-6.98 (m,







2H), 7.61 (d, J =







8.16Hz, 1H), 9.62







(s, 1H)








F-413


embedded image


(400 MHz, CDCl3) 0.90 (s, 9H), 1.13 (s, 1H), 1.27- 1.29 (m, 5H), 1.86 (s, 2H), 2.24 (s, 3H), 2.26 (s, 3H), 2.92 (s, 5H), 3.58 (s, 1H), 3.71 (s, 1H), 4.05 (s, 1H), 4.75 (s, 1H), 4.88 (d, J = 9.92Hz, 1H), 6.92-
452
450





6.94 (m, 2H), 7.35







(d, J = 7.94Hz,







1H), 9.61 (s, 1H)




















TABLE 251











Informa-


Exam-


MS
tion of












ple
Chemical structure
NMR
M + H
M − H
structure





F-414


embedded image


(400 MHz, DMSO- D6) 0.85 (d, J = 6.49Hz, 2H), 1.06-1.22 (m, 4H), 1.41-1.45 (m, 2H), 1.53 (td, J = 12.81, 6.03Hz, 1H), 1.97-2.01 (m, 3H), 2.09- 2.17 (m, 5H), 2.22 (s, 3H), 2.53- 2.61 (m, 3H), 3.27- 4.25 (m, 9H), 6.94 (d, J = 8.35Hz,
478
476





1H), 7.00 (s,







1H), 7.18 (dd,







J = 13.33, 8.00Hz,







1H), 9.67 (d,







J = 13.91Hz, 1H)








F-415


embedded image


(400 MHz, DMSO- D6) 0.85 (d, J = 6.49Hz, 2H), 1.06-1.22 (m, 4H), 1.41-1.45 (m, 2H), 1.53 (td, J = 12.81, 6.03Hz, 1H), 1.97-2.01 (m, 3H), 2.09- 2.17 (m, 5H), 2.22 (s, 3H), 2.53-2.61 (m, 3H), 3.27- 4.25 (m, 9H), 6.94 (d, J = 8.35Hz,
478
476





1H), 7.00 (s,







1H), 7.18 (dd,







J = 13.33, 8.00Hz,







1H), 9.67 (d,







J = 13.91Hz, 1H)








F-416


embedded image


(400 MHz, CDCl3) 0.75-0.91 (m, 1H), 0.91-1.07 (m, 1H), 1.17- 1.30 (m, 2H), 1.45 (s, 9H), 2.04- 2.18 (m, 6H), 2.26 (s, 3H), 2.89- 3.02 (m, 1H), 3.30 (t, J = 11, 12Hz, 0.8H), 3.58-3.65 (m, 0.2H), 3,66- 3.78 (m, 0.8H), 3.80-4.00 (m, 2H),
523
521
Racemic form




4.02-4.52 (m,







7.2H), 6.90-7.01







(m, 2H), 7.55 (d,







J = 9.04Hz, 0.2H),







7.73 (d, J = 8.08Hz,







0.8H), 7.85 (s,







0.2H), 8.76 (s, 0.8H)




















TABLE 252











Informa-


Exam-


MS
tion of












ple
Chemical structure
NMR
M + H
M − H
structure





F-417


embedded image


(400 MHz, CDCl3) 0.74-0.92 (m, 1H), 0.92-1.14 (m, 10H), 1.19- 1.33 (m, 2H), 1.97-2.20 (m, 8H), 2.26 (s, 3H), 2.92-3.05 (m, 1H), 3.24-3.37 (m, 0.8H), 3.56-4.08 (m, 3.4H), 4.08- 4.33 (m, 3H), 4.36- 4.56 (m, 2.8H), 4.63-4.70 (m,
521
519
Racemic form




0.4H), 4.71-4.80







(m, 0.6H), 6.91-







7.03 (m, 2H), 7.48-







7.58 (m, 0.2H),







7.66-7.78 (m,







0.8H), 7.81-7.95







(m, 0.2H), 8.63-







8.82 (m, 0.8H)








F-418


embedded image


(400 MHz, CDCl3) 0.75-0.88 (m, 1H), 0.92-1.07 (m, 1H), 1.17- 1.33 (m, 2H), 1.37 (d, J = 6.88Hz, 6H), 2.07 (s, 0.6H), 2.09-2.18 (m, 5.4H), 2.26 (s, 3H), 2.92-3.02 (m, 1.2H), 3.08-3.20 (m, 1H), 3.27- 3.36 (m, 0.8H), 3.59-3.79 (m, 1H),
529
527
Racemic form




3.80-4.49 (m, 9H),







6.93-7.01 (m,







2H), 7.55 (d, J =







8.92Hz, 0.2H),







7.73 (d, J = 8.00Hz,







0.8H), 7.82 (s,







0.2H), 8.72







(m, 0.8H)








F-419


embedded image


(400 MHz, CDCl3) 0.76-0.91 (m, 1H), 0.92-1.07 (m, 1H), 1.12 (d, J = 6.88Hz, 6H), 1.17-1.31 (m, 2H), 2.04-2.19 (m, 6H), 2.26 (s, 3H), 2.69 (s, 3H), 2.91-3.03 (m, 1H), 3.26-3.36 (m, 0.8H), 3.57- 3.66 (m, 0.2H), 3.67-3.79 (m,
522
520
Racemic form




0.8H), 3.82-4.00







(m, 2.2H), 4.02-







4.51 (m, 8H), 6.92-







7.01 (m, 2H),







7.55 (d, J = 8.88Hz,







0.2H), 7.72 (d,







J = 8.24Hz, 0.8H),







7.94 (s, 0.2H),







8.79 (m, 0.8H)




















TABLE 253











Informa-


Exam-


MS
tion of












ple
Chemical structure
NMR
M + H
M − H
structure





F-420


embedded image


(400 MHz, CDCl3) 0.87-0.93 (m, 2H), 1.09-1.17 (m, 2H), 1.59- 1.67 (m, 4H), 1.71-1.78 (m, 2H), 2.19 (s, 3H), 2.22- 2.31 (m, 7H), 2.37-2.46 (m, 2H), 2.85-2.92 (m,
393
391





1H), 3.00-3.08







(m, 2H), 3.13-







3.19 (m, 2H), 3.48-







3.58 (m, 1H),







6.93-6.99 (m, 2H),







7.59-7.64 (m,







1H), 8.24 (brs, 1H)








F-421


embedded image


(400 MHz, CDCl3) 0.81-0.96 (m, 8H), 1.08-1.21 (m, 2H), 1.29- 1.35 (m, 2H), 1.48-1.55 (m, 2H), 1.92-2.00 (m, 1H), 2.01-2.11 (m, 2H), 2.15 (s, 3H), 2.26 (s, 3H), 2.27-2.33 (m, 2H), 2.34-2.63 (m,
451
449
Racemic form




4H), 2.85-2.92







(m, 1H), 3.37-







3.48 (m, 1H),







3.80-3.91 (m, 2H),







4.52-4.57 (m, 1H),







6.94-6.99 (m,







2H), 7.60-7.65 (m,







1H), 8.06 (brs,







1H)








F-422


embedded image


(400 MHz, DMSO- D6) 0.86 (d, J = 6.45Hz, 6H), 0.95-1.03 (m, 1H), 1.11-1.15 (m, 2H), 1.21- 1.25 (m, 1H), 1.31 (t, J = 7.05Hz, 2H), 1.49-1.56 (m, 1H), 1.86- 1.96 (m, 2H), 2.03 (s, 3H), 2.21 (s, 3H), 2.39-2.54 (m, 3H), 2.87-
486
484
Racemic form




2.95 (m, 2H), 3.04-







3.10 (m, 1H),







3.27-3.35 (m,







2H), 3.69-3.77 (m,







1H), 4.20-4.27







(m, 1H), 6.91 (d,







J = 7.66Hz, 1H),







6.97 (s, 1H), 7.08







(d, J = 8.06Hz, 1H),







7.44-7.38 (m,







2H), 7.88 (s, 1H),







8.52 (s, 1H),







9.44 (s, 1H)




















TABLE 254











Informa-


Exam-


MS
tion of












ple
Chemical structure
NMR
M + H
M − H
structure





F-423


embedded image


(400 MHz, CDCl3) 0.86-0.93 (m, 2H), 1.04-1.17 (m, 4H), 1.49- 1.75 (m, 9H), 2.05-2.12 (m, 2H), 2.20 (s, 3H), 2.27 (s, 3H), 2,50- 2.58 (m, 3H), 2.85-2.91 (m, 1H),
419
421





3.04-3.10 (m, 2H),







3.13-3.19 (m,







2H), 3.57-3.64







(m, 1H), 6.94-







6.98 (m, 2H), 7.62







(d, J = 8.58Hz,







1H), 8.30 (brs, 1H)








F-424


embedded image


(400 MHz, CDCl3) 0.88-0.94 (m, 2H), 1.04-1.10 (m, 2H), 1.11- 1.18 (m, 2H), 1.45-1.51 (m, 4H), 1.54-1.61 (m, 2H), 1.67-1.76 (m, 3H), 2.04-2.14 (m, 2H), 2.20 (s,
419
421





3H), 2.27 (s,







3H), 2.36 (dd,







J = 16.93, 7.65Hz,







1H), 2.50 (ddd,







J = 16.12, 7.77,







2.55Hz, 2H), 2.86-







2.92 (m, 1H), 3.01-







3.07 (m, 2H),







3.13-3.18 (m, 2H),







3.38-3.47 (m,







1H), 6.94-6.99







(m, 2H), 7.60-







7.65 (m, 1H),







8.25 (brs, 1H)








F-425


embedded image


(400 MHz, CDCl3) 0.83-0.92 (m, 2H), 0.86 (s, 9H), 1.07-1.16 (m, 2H), 1.45 (d, J = 6.72Hz, 2H) 2.06- 2.18 (m, 2H), 2.19 (s, 3H), 2.26 (s, 3H), 2.50-2.61 (m, 2H), 2.63-
409
407





2.77 (m, 1H), 2.83-







2.93 (m, 1H),







2.99-3.21 (m, 4H),







3.51-3.62 (m,







1H), 6.93-7.00







(m, 2H), 7.62 (d,







J = 8.80Hz, 1H),







8.31 (s, 1H)




















TABLE 255







Exam-


MS
Information












ple
Chemical structure
NMR
M + H
M − H
of structure





F-426


embedded image


(400 MHz, CDCl3) 0.79-0.94 (m, 2H), 0.87 (s, 9H), 1.08- 1.17 (m, 2H), 1.38 (d, J = 6.48 Hz, 2H) 2.04-2.16 (m, 2H), 2.19 (s, 3H), 2.26 (s, 3H), 2.38-2.57 (m, 3H), 2.84-2.93
409
407





(m, 1H), 2.97-3.19







(m, 4H), 3.37-3.49







(m, 1H), 6.91-7.00







(m, 2H), 7.62 (d,







J = 8.80 Hz, 1H),







8.27 (s, 1H)








F-427


embedded image


(400 MHz, CDCl3) 0.88-0.92 (m, 2H), 1.12-1.17 (m, 2H), 1.37-1.48 (m, 9H), 2.13-2.23 (m, 5H), 2.26 (s, 3H), 2.35- 2.49 (m, 2H), 2.55- 2.75 (m, 3H), 2.80-
453
451
Mixture of two stereoisomers (Stereo- chemistry on Cyclobutane ring: Mixture of Cis-isomer




2.93 (m, 1H), 3.03-


and




3.07 (m, 2H), 3.14-


Trans-isomer)




3.19 (m, 2H), 3.44-







3.72 (m, 1H), 6.98







(d, J = 14.11 Hz,







2H), 7.58 (t, J = 4.41







Hz, 1H), 8.28 (s, 1H)








F-428


embedded image


(400 MHz, CDCl3) 0.88 (d, J = 6.62 Hz, 6H), 1.08-1.15 (m, 1H), 1.21-1.38 (m, 4H), 1.29 (s, 3H), 1.36 (s, 3H), 1.51-1.62 (m, 1H), 1.74-1.84 (m, 2H), 1.88- 1.95 (m, 1H), 2.00 (dd, J = 14.45, 2.98 Hz, 1H), 2.13 (s, 3H), 2.24 (s, 3H), 2.43 (dd, J = 14.56, 10.59 Hz, 1H), 2.83 (t, J = 7.72 Hz, 2H), 3.01 (dd, J =
441
439





15.33, 5.62 Hz, 1H), 3.32-







3.42 (m, 1H), 3.93-4.06







(m, 1H), 4.14-4.25 (m,







1H), 6.90 (d, J = 8.16 Hz,







1H), 6.93 (s, 1H), 7.20 (d,







J = 8.16 Hz, 1H), 8.53







(brs, 1H)




















TABLE 256







Exam-


MS
Information












ple
Chemical structure
NMR
M + H
M − H
of structure





F-429


embedded image


(400 MHz, CDCl3) 0.84 (d, J = 6.40 Hz, 6H), 1.04-1.11 (m, 2H), 1.17-1.24 (m, 2H), 1.41 (t, J = 6.62 Hz, 2H), 1.48-1.59 (m, 1H), 1.93-2.07 (m, 3H), 2.19 (s, 3H), 2.26 (s, 3H), 2.93-3.22 (m, 8H), 6.95 (s, 1H), 6.96 (d, J = 8.60 Hz, 1H), 7.59 (d, J = 8.60
411
409
Single isomer (Stereochemistry on Cyclobutane ring: Undetermined) (Isomer of F-430)




Hz, 1H), 8.17 (brs, 1H)








F-430


embedded image


(400 MHz, CDCl3) 0.85 (d, J = 6.62 Hz, 6H), 1.03-1.16 (m, 4H), 1.30 (t, J = 7.17 Hz, 2H), 1.46-1.58 (m, 1H), 2.19 (s, 3H), 2.26 (s, 3H), 2.34-2.44 (m, 2H), 2.50-2.59 (m, 2H), 2.68-2.80 (m, 1H), 2.93-3.05 (m, 4H), 3.14 (t, J = 6.62 Hz, 2H), 6.93-6.99 (m,
411
409
Single isomer (Stereochemistry on Cyclobutane ring: Undetermined) (Isomer of F-429)




2H), 7.58 (d, J = 8.82 Hz, 1H),







8.19 (brs, 1H)








F-431


embedded image


(400 MHz, CDCl3) 0.83-0.99 (m, 8H), 1.11-1.20 (m, 2H), 1.31-1.39 (m, 2H), 1.48-1.61 (m, 1H), 1.78-1.90 (m, 1H), 2.01-2.17 (m, 5H), 2.26 (s, 3H), 2.28-2.34 (m, 2H), 2.35- 2.46 (m, 1H), 2.46-2.56 (m, 3H), 2.85-2.92 (m, 1H), 3.38- 3.50 (m, 2H), 3.69-3.81 (m,
451
449
Racemic form




1H), 3.97-4.05 (m, 1H), 4.46-







4.53 (m, 1H), 6.92-7.00 (m,







2H), 7.65-7.72 (m, 1H), 8.32







(brs, 1H)








F-432


embedded image


(400 MHz, DMSO-D6) 0.89 (s, 9H), 1.09-1.34 (m, 6H), 1.67- 1.82 (m, 2H), 1.94-2.05 (m, 3H), 2.05-2.15 (m, 3H), 2.23 (s, 3H), 2.86-3.00 (m, 2H), 3.27-4.34 (m, 7H), 6.95 (d, J = 8.24 Hz, 1H), 7.01 (s, 1H), 7.13-7.24 (m, 1H), 9.60-9.71 (m, 1H)
466
464




















TABLE 257











Infor-






mation


Exam-


MS
of struc-












ple
Chemical structure
NMR
M + H
M − H
ture





F-433


embedded image


(400 MHz, CDCl3) 0.85 (d, J = 8.50 Hz, 6H), 1.02 (s, 1H), 1.12-1.14 (m, 2H), 1.23 (t, J = 7.17 Hz, 3H), 1.31 (t, J = 7.06 Hz, 2H), 1.50-1.54 (m, 1H), 2.04-2.08 (m, 2H), 2.14 (s, 3H), 2.26 (s, 3H), 2.39-2.48 (m, 3H), 2.80 (s, 2H), 3.10 (s, 1H), 3.28 (dd, J = 14.11, 5.73 Hz, 1H), 3.39-3.48 (m, 2H), 4.11-4.17 (m, 2H), 4.22 (d, J = 7.72 Hz, 1H), 5.45 (dd, J = 7.94, 5.73 Hz, 1H), 6.94-6.96 (m, 2H), 7.47 (d, J = 8.60 Hz, 1H), 8.48 (s, 1H)
497
495






F-434


embedded image


(400 MHz, CDCl3) 0.86 (d, J = 6.40 Hz, 6H), 0.99 (s, 2H), 1.16 (d, J = 7.06 Hz, 2H), 1.31 (t, J = 6.95 Hz, 2H), 1.51 (dd, J = 13.45, 6.62 Hz, 1H), 2.05 (t, J = 10.26 Hz, 2H), 2.17 (s, 3H), 2.25 (s, 3H), 2.37-2.50 (m, 3H), 3.03 (d, J = 3.97 Hz, 1H), 3.26-3.33 (m, 2H), 3.43-3.47 (m, 1H), 3.76 (dd, J = 10.81, 6.62 Hz, 4H), 5.22 (dd, J = 7.28, 5.29 Hz, 1H), 6.93-6.95 (m, 2H), 7.50 (d, J = 7.72 Hz,
455
453





1H), 8.89 (s, 1H)








F-435


embedded image


(400 MHz, CDCl3) 0.83-0.90 (m, 9H), 0.97-1.02 (m, 1H), 1.13-1.21 (m, 2H), 1.22-1.30 (m, 2H), 1.69-1.75 (m, 2H), 2.01-2.05 (m, 4H), 2.06-2.15 (m, 2H), 2.17 (s, 3H), 2.23 (s, 3H), 2.61-2.76 (m, 3H), 2.94-3.03 (m, 1H), 3.20-3.51 (m, 3H), 3.94-4.04 (m, 1H), 4.79-4.89 (m, 1H), 6.87-6.95 (m, 2H), 7.33-7.38 (m, 1H), 7.63 (brs, 1H)
480
478
Racemic form




















TABLE 258







Exam-


MS
Information












ple
Chemical structure
NMR
M + H
M − H
of structure





F-436


embedded image


(400 MHz, CDCl3) 0.42-0.52 (m, 1H), 0.82-0.93 (m, 12H), 0.98- 1.06 (m, 1H), 1.18-1.28 (m, 2H), 1.53-1.63 (m, 2H), 1.65-1.73 (m, 1H), 2.01 (s, 3H), 2.56 (s, 3H), 2.62-2.74 (m, 1H), 2.85-3.02 (m, 2H), 3.02-3.11 (m, 1H), 3.22- 3.32 (m, 1H), 3.90-4.00 (m, 1H), 6.89-6.94 (m, 2H). 6.94-7.00 (m, 2H), 7.15-7.22 (m, 3H), 7.31- 7.36 (m, 1H), 7.67 (brs, 1H)
473
471
Racemic form





F-437


embedded image


(400 MHz, DMSO-D6) 0.82-0.90 (m, 8H), 0.93-1.02 (m, 1H), 1.05- 1.17 (m, 3H), 1.18-1.28 (m, 2H), 1.61-1.73 (m, 2H), 2.00 (s, 3H), 2.20 (s, 3H), 2.54-2.63 (m, 2H), 2.66-2.74 (m, 2H), 2.80-2.90 (m, 2H), 2.93-3.05 (m, 1H), 3.08- 3.15 (m, 1H), 3.73-3.84 (m, 1H), 6.86-6.93 (m, 1H), 6.95 (brs, 1H), 7.06-7.11 (m, 1H), 9.31 (brs, 1H)
421
419
Racemic form





F-438


embedded image


(400 MHz, CDCl3) 0.87-0.89 (m, 2H), 0.87 (s, 9H), 0.95 (d, J = 5.24 Hz, 6H), 1.14-1.28 (m, 5H), 1.60-1.76 (m, 4H), 2.06 (s, 3H), 2.24 (s, 3H), 2.73 (dd, J = 8.87, 8.06 Hz, 2H), 2.82 (dd, J = 13.70, 4.03 Hz, 1H), 2.91- 2.96 (m, 1H), 3.04 (dd, J = 13.70, 10.88 Hz, 1H), 3.72-3.80 (m, 1H), 6.91-6.92 (m, 2H), 7.41 (d, J = 8.87 Hz, 1H), 7.75 (s, 1H)
439
437
Racemic form




















TABLE 259











Infor-






mation


Exam-


MS
of struc-












ple
Chemical structure
NMR
M + H
M − H
ture





F-439


embedded image


(400 MHz, CDCl3) 0.64-0.68 (m, 1H), 0.84-0.88 (m, 1H), 0.86 (d, J = 6.85 Hz, 6H), 1.00-1.06 (m, 3H), 1.32 (t, J = 7.05 Hz, 2H), 1.50-1.57 (m, 1H), 1.95-2.04 (m, 2H), 2.06 (s, 3H), 2.24 (s, 3H), 2.32-2.55 (m, 3H), 2.94 (dd, J = 13.70, 4.43 Hz, 1H), 3.16 (dd, J = 14.10, 10.88 Hz, 1H), 3.31-3.41 (m, 1H), 3.48 (d, J = 7.25 Hz, 2H), 4.16-4.24 (m, 1H), 6.91-6.93 (m, 2H), 7.19 (d, J = 3.22 Hz, 1H),
492
490
Racemic form




7.38 (d, J = 8.06 Hz, 1H),







7.59 (s, 1H), 7.69 (d, J =







3.22 Hz, 1H)








F-440


embedded image


(400 MHz, CDCl3) 0.85-0.92 (m, 11H), 0.92-0.99 (m, 1H), 1.18-1.31 (m, 4H), 1.69-1.80 (m, 2H), 2.05 (s, 3H), 2.25 (s, 3H), 2.72-2.78 (m, 2H), 2.79- 2.84 (m, 1H), 2.93-3.01 (m, 1H), 3.13-3.25 (m, 2H), 4.15- 4.25 (m, 1H), 6.91-6.96 (m, 2H), 7.29-7.34 (m, 1H), 7.51 (brs, 1H)
422
420
Racemic form





F-441


embedded image


(400 MHz, CDCl3) 0.65-0.71 (m, 2H), 1.08 (q, J = 6.65 Hz, 2H), 1.38 (s, 3H), 1.39 (s, 3H), 2.22 (s, 3H), 2.27 (s, 3H), 3.13 (t, J = 6.61 Hz, 2H), 3.19-3.29 (m, 3H), 4.60-4.66 (m, 1H), 6.96-7.00 (m, 4H), 7.61-7.67 (m, 3H), 8.19 (brs, 1H)
419
417




















TABLE 260











Infor-






mation


Exam-


MS
of struc-












ple
Chemical structure
NMR
M + H
M − H
ture





F-442


embedded image


(400 MHz, DMSO-D6) 0.57- 0.60 (brm, 2H), 0.99 (d, J = 6.26 Hz, 2H), 2.12 (s, 3H), 2.22 (s, 3H), 2.91 (t, J = 7.07 Hz, 2H), 3.10 (t, J = 7.19 Hz, 2H), 3.44-3.47 (brm, 1H), 6.86 (d, J = 8.35 Hz, 2H), 6.93 (d, J = 7.65 Hz, 1H), 6.99 (s, 1H), 7.23 (d, J = 8.12 Hz, 1H), 7.56 (d, J = 8.58 Hz, 2H), 9.35
377
375





(s, 1H), 9.85 (s, 1H)








F-443


embedded image


(400 MHz, CDCl3) 0.64-0.74 (m, 2H), 0.91-1.07 (m, 4H), 1.10-1.38 (m, 4H), 1.51-1.62 (m, 1H), 1.62-1.82 (m, 5H), 2.12 (s, 3H), 2.26 (s, 3H), 2.92 (t, J = 6.84 Hz, 2H), 3.07 (t, J = 6.84 Hz, 2H), 4.34 (t, J = 7.61 Hz, 2H), 6.88-7.02 (m, 2H), 7.59 (d, J = 7.72 Hz, 1H), 7.77 (brs, 1H)
395
393






F-444


embedded image


(400 MHz, CDCl3) 0.82-0.93 (m, 3H), 1.06-1.17 (m, 4H), 1.40-1.54 (m, 3H), 2.02-2.11 (m, 2H), 2.19 (s, 3H), 2.24- 2.32 (m, 1H), 2.27 (s, 3H), 2.46-2.57 (m, 2H), 2.87-2.93 (m, 1H), 3.02-3.07 (m, 2H), 3.13-3.19 (m, 2H), 3.39-3.48 (m, 1H), 6.94-6.99 (m, 2H),
409
407





7.59-7.64 (m, 1H), 8.28







(brs, 1H)








F-445


embedded image


(400 MHz, CDCl3) 0.89 (s, 9H), 1.26-1.32 (m, 2H), 1.84-1.90 (m, 2H), 2.14 (s, 3H), 2.25 (s, 3H), 2.29-2.34 (m, 2H), 2.66-2.86 (m, 2H), 3.31 (d, J = 12.99 Hz, 1H), 3.64-3.73 (m, 2H), 3.74-3.84 (m, 3H), 4.70-4.78 (m, 1H), 5.32-5.40 (m, 1H), 6.91-6.97 (m, 2H), 7.19- 7.22 (m, 1H), 8.58 (brs, 1H)
467
469




















TABLE 261







Exam-


MS
Information












ple
Chemical structure
NMR
M + H
M − H
of structure





F-446


embedded image


(400 MHz, DMSO-D6) 0.87 (s, 9H), 0.91-1.18 (m, 4H), 1.19- 1.30 (m, 2H), 1.60-1.74 (m, 2H), 2.05 (s, 3H), 2.22 (s, 3H), 2.58 (d, J = 4.44 Hz, 3H), 2.66-2.75 (m, 2H), 3.01-3.11 (m, 1H), 3.24- 3.38 (m, 1H), 3.39-3.47 (m, 1H), 3.72-3.88 (m, 2H), 3.90-4.03 (m, 2H), 6.19 (q, J = 4.44 Hz, 1H), 6.93 (d, J = 8.00 Hz, 1H), 6.98 (s, 1H), 7.19 (d, J = 8.24 Hz, 1H), 9.51 (s, 1H)
481
479
Racemic form





F-447


embedded image


(400 MHz, DMSO-D6) 0.87 (s, 9H), 0.90-1.04 (m, 2H), 1.05- 1.18 (m, 2H), 1.20-1.30 (m, 2H), 1.61-1.73 (m, 2H), 2.03 (s, 3H), 2.22 (s, 3H), 2.66-2.82 (m, 2H), 2.77 (s, 6H), 3.03-3.12 (m, 1H), 3.42-3.50 (m, 1H), 3.55-3.63 (m, 1H), 3.64-3.99 (m, 4H), 6.92 (d, J = 8.28 Hz, 1H), 6.98 (s, 1H), 7.19 (d, J = 8.28 Hz, 1H), 9.48 (s, 1H)
495
493
Racemic form





F-448


embedded image


(400 MHz, CDCl3) 0.84-1.09 (m, 2H), 0.90 (s, 9H), 1.19-1.36 (m, 4H), 1.70-1.84 (m, 2H), 2.17 (s, 3H), 2.25 (s, 3H), 2.27 (s, 3H), 2.70-2.86 (m, 2H), 2.99-3.08 (m, 1H), 3.53 (t, J = 10.04 Hz, 1H), 3.79-3.88 (m, 1H), 3.89-4.01 (m, 1H), 4.16 (t, J = 9.80 Hz, 1H), 4.21-4.32 (m, 1H), 4.32-4.41 (m, 1H), 6.11 (s, 1H), 6.91-7.01 (m, 2H), 7.77 (d, J = 8.24 Hz, 1H), 8.78 (s, 1H)
521
519
Racemic form




















TABLE 262











Infor-






mation


Exam-


MS
of struc-












ple
Chemical structure
NMR
M + H
M − H
ture





F-449


embedded image


(400 MHz, CDCl3) 0.87 (s, 9H), 1.15-1.51 (m, 6H), 1.72- 1.95 (m, 2H), 2.13 (s, 3H), 2.21 (s, 3H), 2.76-3.06 (m, 2H), 3.40-3.56 (m, 1H), 3.56- 3.74 (m, 1H), 3.97-4.67 (m, 5H), 6.84 (d, J = 7.80 Hz, 1H), 6.88 (s, 1H), 7.18 (d, J = 7.80 Hz, 1H), 9.81 (brs, 2H), 10.26 (brs, 1H)
424
422
Racemic form





F-450


embedded image


(400 MHz, CDCl3) 0.84 (d, J = 6.62 Hz, 6H), 1.15 (d, J = 6.84 Hz, 3H), 1.26-1.30 (m, 3H), 1.51 (t, J = 6.73 Hz, 1H), 1.91 (d, J = 9.26 Hz, 1H), 2.01 (s, 3H), 2.05-2.07 (m, 1H), 2.23 (s, 3H), 2.42-2.44 (m, 3H), 2.86 (s, 2H), 3.05-3.09 (m, 2H), 3.28 (t, J = 13.12 Hz, 1H), 3.38 (d, J = 8.16 Hz, 1H), 4.25 (s, 1H), 5.67 (s, 1H), 6.89-6.91 (m,
492
490
Racemic form




2H), 7.22-7.25 (m, 1H), 8.44 (s,







1H)








F-451


embedded image


(400 MHz, CDCl3) 0.74 (t, J = 7.39 Hz, 3H), 0.86 (t, J = 7.20 Hz, 3H), 0.88-0.91 (m, 2H), 1.03-1.15 (m, 3H), 1.46 (q, J = 7.50 Hz, 2H), 1.57-1.62 (m, 2H), 2.12-2.22 (m, 6H), 2.26 (s, 3H), 2.85-2.91 (m, 1H), 3.04 (t, J = 6.40 Hz, 0H), 3.15 (t, J = 6.40 Hz, 0H), 3.4-3.54 (m, 1H), 6.96-
395
393





7.00 (m, 2H), 7.60 (d, J = 8.82







Hz, 1H), 8.26 (brs, 1H)




















TABLE 263











Infor-






mation


Exam-


MS
of struc-












ple
Chemical structure
NMR
M + H
M − H
ture





F-452


embedded image


(400 MHz, CDCl3) 0.83-0.98 (m, 2H), 1.13-1.23 (m, 2H), 1.32-1.41 (m, 4H), 1.43-1.52 (m, 4H), 1.58-1.64 (m, 1H), 2.12-2.15 (m, 6H), 2.15-2.23 (m, 2H), 2.25 (s, 3H), 2.86- 2.95 (m, 1H), 3.25-3.35 (m, 1H), 3.46-3.60 (m, 2H), 3.63- 3.73 (m, 1H), 3.85-3.97 (m, 2H), 4.16-4.27 (m, 2H), 4.37- 4.49 (m, 1H), 6.92-6.98 (m, 2H), 7.70-7.75 (m, 1H), 9.00 (brs, 1H)
490
488
Racemic form





F-453


embedded image


(400 MHz, CDCl3) 0.83-0.91 (m, 2H), 0.87 (s, 9H), 0.98 (d, J = 6.85 Hz, 3H), 1.00 (d, J = 7.25 Hz, 3H), 1.13-1.18 (m, 2H), 1.21-1.28 (m, 3H), 1.68- 1.77 (m, 1H), 2.03 (s, 3H), 2.07-2.15 (m, 1H), 2.23 (s, 3H), 2.72-2.79 (m, 3H), 2.89- 2.95 (m, 1H), 3.09 (dd, J = 12.89, 12.09 Hz, 1H), 3.52- 3.58 (m, 1H), 6.90-6.92 (m, 2H), 7.37 (d, J = 8.87 Hz, 1H), 7.49 (s, 1H)
425
423
Racemic form





F-454


embedded image


(400 MHz, CDCl3) 0.82-0.90 (m, 2H), 0.85 (d, J = 6.85 Hz, 6H), 1.06-1.12 (m, 3H), 1.32 (t, J = 6.85 Hz, 2H), 1.48-1.56 (m, 1H), 1.94-2.04 (m, 1H), 2.06 (s, 3H), 2.24 (s, 3H), 2.31-2.51 (m, 3H), 2.75-2.81 (m, 1H), 2.92 (dd, J = 13.90, 4.63 Hz, 1H), 3.18 (dd, J = 11.28, 10.88 Hz, 1H), 3.24 (d, J = 7.66 Hz, 2H), 3.35- 3.44 (m, 1H), 4.16-4.24 (m,
476
474
Racemic form




1H), 6.91-6.93 (m, 2H), 7.01







(s, 1H), 7.38 (d, J = 8.06 Hz,







1H), 7.55 (s, 1H), 7.66 (s, 1H)




















TABLE 264











Infor-






mation


Exam-


MS
of struc-












ple
Chemical structure
NMR
M + H
M − H
ture





F-455


embedded image


(400 MHz, CDCl3) 0.72- 0.80 (m, 1H), 1.01 (d, J = 6.62 Hz, 6H), 1.08-1.20 (m, 3H), 2.04-2.27 (m, 3H), 2.07 (s, 3H), 2.24 (s, 3H), 2.71 (d, J = 7.06 Hz, 2H), 2.91 (dd, J = 14.11, 4.41 Hz, 1H), 3.16 (dd, J = 14.11, 10.59 Hz, 1H), 3.20-3.26 (m, 1H), 3.44- 3.51 (m, 1H), 3.59-3.66
542
540
Racemic form




(m, 1H), 4.05-4.14 (m,







1H), 4.46 (s, 2H), 6.53 (s,







1H), 6.91-6.96 (m, 2H),







7.23-7.34 (m, 5H), 7.44







(d, J = 8.60 Hz, 1H), 7.47







(brs, 1H)








F-456


embedded image


(400 MHz, CDCl3) 0.82- 0.89 (m, 7H), 0.94-1.05 (m, 3H), 1.30-1.33 (m, 2H), 1.48-1.56 (m, 1H), 1.92 (q, J = 9.63 Hz, 1H), 1.99-2.20 (m, 3H), 2.04 (s, 3H), 2.24 (s, 3H), 2.32- 2.50 (m, 3H), 2.74-2.86 (m, 2H), 3.03 (dd, J = 13.67, 10.81 Hz, 1H), 3.31-3.48 (m, 2H), 3.56-
529
527





3.63 (m, 1H), 3.87-3.97







(m, 1H), 4.41 (d, J = 11.69







Hz, 1H), 4.47 (d, J = 11.91







Hz, 1H), 6.90-6.95 (m,







2H), 7.25-7.35 (m, 5H),







7.42 (d, J = 8.60 Hz, 1H),







7.60 (brs, 1H)








F-457


embedded image


(400 MHz, CDCl3) 0.79- 0.86 (m, 1H), 0.99 (d, J = 6.62 Hz, 6H), 1.10-1.30 (m, 3H), 1.98-2.20 (m, 3H), 2.08 (s, 3H), 2.25 (s, 3H), 2.69 (d, J = 7.06 Hz, 2H), 2.88 (brs, 1H), 2.98 (dd, J = 14.56, 5.29 Hz, 1H), 3.19 (dd, J = 14.56, 9.48 Hz, 1H), 3.31-3.38 (m, 1H), 3.68-3.83 (m,
452
450





2H), 4.08-4.17 (m, 1H),







6.49 (s, 1H), 6.91-6.97







(m, 2H), 7.37 (d, J = 8.60







Hz, 1H), 7.90 (brs,1H)




















TABLE 265











Infor-






mation


Exam-


MS
of struc-












ple
Chemical structure
NMR
M + H
M − H
ture





F-458


embedded image


(400 MHz, CDCl3) 0.79-0.86 (m, 1H), 0.99 (d, J = 6.62 Hz, 6H), 1.10-1.30 (m, 3H), 1.98-2.20 (m, 3H), 2.08 (s, 3H), 2.25 (s, 3H), 2.69 (d, J = 7.06 Hz, 2H), 2.98 (dd, J = 14.56, 5.29 Hz, 1H), 3.09 (brs, 1H), 3.19 (dd, J = 14.56, 9.48 Hz, 1H), 3.31-3.38 (m, 1H), 3.68- 3.83 (m, 2H), 4.08-4.17 (m, 1H), 6.49 (s, 1H), 6.91-6.97 (m, 2H), 7.37 (d, J = 8.60 Hz, 1H), 7.90 (brs, 1H)
452
450






F-459


embedded image


(400 MHz, CDCl3) 0.73-0.80 (m, 1H), 0.85 (d, J = 6.62 Hz, 6H), 1.09-1.22 (m, 3H), 1.31 (t, J = 7.17 Hz, 2H), 1.48-1.57 (m, 1H), 1.89-2.13 (m, 2H), 1.99 (s, 3H), 2.24 (s, 3H), 2.32-2.52 (m, 3H), 2.73 (dd, J = 13.89, 3.97 Hz, 1H), 2.84-2.91 (m, 1H), 2.98 (dd, J = 13.56, 11.14 Hz, 1H), 3.04-3.13 (m, 1H), 3.35-3.44 (m, 1H), 3.69-3.80 (m, 1H), 3.87-3.97 (m, 2H), 4.01 (t, J = 8.71 Hz, 1H), 4.14 (t, J = 8.60 Hz, 1H), 5.09 (s, 2H), 6.89-6.97 (m, 2H), 7.15-7.40
584
582
Racemic form




(m, 7H)








F-460


embedded image


(400 MHz, CDCl3) 0.65-0.69 (m, 2H), 1.05-1.11 (m, 2H), 2.22 (s, 3H), 2.27 (s, 3H), 3.12-3.13 (m, 2H), 3.19-3.30 (m, 3H), 4.59- 4.62 (m, 2H), 5.31-5.36 (m, 1H), 5.42-5.49 (m, 1H), 6.05-6.12 (m, 1H), 6.96-7.03 (m, 4H), 7.63- 7.66 (m, 3H), 8.16 (brs, 1H)
417
415




















TABLE 266











Infor-






mation


Exam-


MS
of struc-












ple
Chemical structure
NMR
M + H
M − H
ture





F-461


embedded image


(400 MHz, DMSO-D6) 0.87 (s, 9H), 1.06-1.28 (m, 4H), 1.32-1.40 (m, 2H), 1.92-2.18 (m, 8H), 2.23 (s, 3H), 2.44- 2.63 (m, 3H), 3.21-3.33 (m, 1H), 3.42-3.52 (m, 1H), 3.61- 3.91 (m, 3H), 3.96-4.16 (m, 2.5H), 4.18-4.26 (m, 0.5H), 6.95 (d, J = 8.12 Hz, 1H), 7.02 (s, 1H), 7.12-7.24 (m, 1H), 9.60-9.74 (m, 1H)
492
490






F-462


embedded image


(400 MHz, DMSO-D6) 0.87 (s, 9H), 1.06-1.28 (m, 4H), 1.32-1.40 (m, 2H), 1.92-2.18 (m, 8H), 2.23 (s, 3H), 2.44- 2.63 (m, 3H), 3.21-3.33 (m, 1H), 3.42-3.52 (m, 1H), 3.61-3.91 (m, 3H), 3.96-4.16 (m, 2.5H), 4.18-4.26 (m, 0.5H), 6.95 (d, J = 8.12 Hz, 1H), 7.02 (s, 1H), 7.12-7.24 (m, 1H), 9.60-9.74 (m, 1H)
492
490






F-463


embedded image


(400 MHz, CDCl3) 0.64-0.70 (m, 2H), 1.01-1.12 (m, 5H), 1.85 (td, J = 14.09, 7.27 Hz, 2H), 2.22 (s, 3H), 2.27 (s, 3H), 3.13-3.28 (m, 5H), 3.98 (t, J = 6.61 Hz, 2H), 6.95-7.00 (m, 4H), 7.61-7.66 (m, 3H), 8.23 (brs, 1H)
419
417






F-464


embedded image


(400 MHz, CDCl3) 0.81-0.94 (m, 7H), 1.11-1.21 (m, 3H), 1.27-1.35 (m, 2H), 1.45-1.56 (m, 1H), 1.92-2.14 (m, 5H), 2.26 (s, 3H), 2.30-2.55 (m, 3H), 2.81-2.87 (m, 2H), 2.92- 3.02 (m, 1H), 3.03-3.12 (m, 1H), 3.14-3.25 (m, 1H), 3.37- 3.49 (m, 1H), 4.10-4.20 (m, 1H), 6.91-6.97 (m, 2H), 7.28- 7.34 (m, 1H), 7.39 (brs, 1H)
434
432




















TABLE 267







Exam-


MS
Information












ple
Chemical structure
NMR
M + H
M − H
of structure





F-465


embedded image


(400 MHz, CDCl3) 0.81-0.94 (m, 7H), 1.11-1.21 (m, 3H), 1.27- 1.35 (m, 2H), 1.45-1.56 (m, 1H), 1.92-2.14 (m, 5H), 2.26 (s, 3H), 2.30-2.55 (m, 3H), 2.81-2.87 (m, 2H), 2.92-3.02 (m, 1H), 3.03- 3.12 (m, 1H), 3.14-3.25 (m, 1H), 3.37-3.49 (m, 1H), 4.10-4.20 (m, 1H), 6.91-6.97 (m, 2H), 7.28- 7.34 (m, 1H), 7.39 (brs, 1H)
434
432






F-466


embedded image


(400 MHz, CDCl3) 0.73-0.81 (m, 1H), 0.86 (d, J = 6.40 Hz, 6H), 1.12-1.26 (m, 3H), 1.28-1.36 (m, 2H), 1.49-1.58 (m, 1H), 1.82 and 1.89 (each s, total 3H), 1.87-2.17 (m, 2H), 2.00 (s, 3H), 2.25 (s, 3H), 2.32-2.54 (m, 3H), 2.69-2.81 (m, 1H), 2.85-3.21 (m, 3H), 3.36- 3.47 (m, 1H), 3.66-3.75 (m, 1H), 3.90-4.30 (m, 4H), 6.91-6.97 (m, 2H), 7.25-7.43 (m, 2H)
492
490






F-467


embedded image


(400 MHz, CDCl3) 0.73-0.81 (m, 1H), 0.86 (d, J = 6.40 Hz, 6H), 1.12- 1.26 (m, 3H), 1.28-1.36 (m, 2H), 1.49-1.58 (m, 1H), 1.82 and 1.89 (each s, total 3H), 1.87-2.17 (m, 2H), 2.00 (s, 3H), 2.25 (s, 3H), 2.32-2.54 (m, 3H), 2.69-2.81 (m, 1H), 2.85-3.21 (m, 3H), 3.36- 3.47 (m, 1H), 3.66-3.75 (m, 1H), 3.90-4.30 (m, 4H), 6.91-6.97 (m, 2H), 7.25-7.43 (m, 2H)
492
490




















TABLE 268







Exam-


MS
Information












ple
Chemical structure
NMR
M + H
M − H
of structure





F-468


embedded image


(400 MHz, CDCl3) 0.74-1.00 (m, 8H), 1.13-1.52 (m, 6H), 1.85- 1.98 (m, 2H), 2.03 (s, 3H), 2.22 (s, 3H), 2.30-2.52 (m, 3H), 2.99- 3.24 (m, 3H), 3.42-3.54 (m, 1H), 3.63-3.78 (m, 1H), 4.04-4.33 (m, 4H), 6.82-6.92 (m, 2H), 7.11 (d, J = 7.65 Hz, 1H), 9.37 (brs, 1H), 9.55 (brs, 1H), 9.78 (brs, 1H)
450
448
Racemic form





F-469


embedded image


(400 MHz, CDCl3) 0.78-0.89 (m, 7H), 1.12-1.19 (m, 3H), 1.27- 1.33 (m, 2H), 1.47-1.57 (m, 1H), 1.89-2.10 (m, 2H), 2.00 (s, 3H), 2.24 (s, 3H), 2.29 (s, 3H), 2.33- 2.58 (m, 3H), 2.76 (dd, J = 13.78, 4.30 Hz, 1H), 2.85-3.05 (m, 5H), 3.32-3.51 (m, 3H), 3.87-3.96 (m, 1H), 6.89-6.95 (m, 2H), 7.29 (d, J = 7.72 Hz, 1H), 7.68 (brs, 1H)
464
462
Racemic form





F-470


embedded image


(400 MHz, CDCl3) 0.83-0.99 (m, 8H), 1.11-1.20 (m, 2H), 1.31- 1.39 (m, 2H), 1.48-1.61 (m, 1H), 1.78-1.90 (m, 1H), 2.01-2.17 (m, 5H), 2.26 (s, 3H), 2.28-2.34 (m, 2H), 2.35-2.46 (m, 1H), 2.46- 2.56 (m, 3H), 2.85-2.92 (m, 1H), 3.38-3.50 (m, 2H), 3.69-3.81 (m, 1H), 3.97-4.05 (m, 1H), 4.46- 4.53 (m, 1H), 6.92-7.00 (m, 2H),
451
449





7.65-7.72 (m, 1H), 8.32 (brs, 1H)




















TABLE 269











Infor-






mation


Exam-


MS
of struc-












ple
Chemical structure
NMR
M + H
M − H
ture





F-471


embedded image


(400 MHz, CDCl3) 0.83-0.99 (m, 8H), 1.11-1.20 (m, 2H), 1.31- 1.39 (m, 2H), 1.48-1.61 (m, 1H), 1.78-1.90 (m, 1H), 2.01-2.17 (m, 5H), 2.26 (s, 3H), 2.28-2.34 (m, 2H), 2.35-2.46 (m, 1H), 2.46- 2.56 (m, 3H), 2.85-2.92 (m, 1H), 3.38-3.50 (m, 2H), 3.69-3.81 (m, 1H), 3.97-4.05 (m, 1H), 4.46- 4.53 (m, 1H), 6.92-7.00 (m, 2H), 7.65-7.72 (m, 1H), 8.32 (brs, 1H)
451
449






F-472


embedded image


(400 MHz, CDCl3) 0.72-0.78 (m, 1H), 0.78-0.92 (m, 8H), 0.95- 1.05 (m, 1H), 1.11-1.21 (m, 1H), 1.21-1.28 (m, 1H), 1.42-1.50 (m, 1H), 1.59-1.73 (m, 1H), 1.87- 1.95 (m, 1H), 1.95-1.98 (m, 1H), 2.20-2.26 (m, 6H), 2.31-2.49 (m, 2H), 2.81-2.89 (m, 1H), 2.91- 2.98 (m, 1H), 2.99-3.16 (m, 1H), 3.17-3.25 (m, 1H), 3.26-3.42 (m, 2H), 3.61-3.73 (m, 1H), 4.56- 4.67 (m, 1H), 6.86-6.94 (m, 2H),
493
491
Racemic form




7.17-7.23 (m, 1H), 8.79-8.86 (m,







1H)








F-473


embedded image


(400 MHz, CDCl3) 1.11-1.69 (m, 16H), 2.11-2.66 (m, 12H), 3.22- 3.45 (m, 1H), 3.57-3.88 (m, 2H), 4.13-4.55 (m, 3H), 4.59-4.85 (m, 1H), 6.91-7.02 (m, 2H), 7.37- 7.42 (m, 1H), 9.28-9.51 (m, 1H)
490
488






F-474


embedded image


(400 MHz, CDCl3) 1.02-1.67 (m, 16H), 2.11-2.47 (m, 12H), 3.08- 3.89 (m, 3H), 4.09-4.40 (m, 3H), 4.46-5.00 (m, 1H), 6.92-7.01 (m, 2H), 7.38-7.46 (m, 1H), 9.14- 9.48 (m, 1H)
490
488




















TABLE 270







Exam-


MS
Information












ple
Chemical structure
NMR
M + H
M − H
of structure















F-475


embedded image


(400 MHz, CDCl3) 0.64- 0.68 (m, 1H), 0.86 (d, J = 6.72 Hz, 6H), 1.01-1.07 (m, 3H), 1.33 (t, J = 7.07 Hz, 2H), 1.49-1.57 (m, 1H), 1.95-2.03 (m, 2H), 2.06 (s, 3H), 2.25 (s, 3H), 2.33-2.53 (m, 4H), 2.94 (dd, J = 13.80, 4.52 Hz, 1H), 3.18 (dd, J = 13.91, 10.90 Hz, 1H), 3.32- 3.39 (m, 1H), 3.49 (d, J = 7.19 Hz, 2H), 4.21 (td, J = 8.41, 5.18 Hz, 1H), 6.92-
492
490





6.94 (m, 2H), 7.20 (d, J =







3.25 Hz, 1H), 7.38 (d, J =







8.12 Hz, 1H), 7.61 (s, 1H),







7.70 (d, J = 3.25 Hz, 1H)








F-476


embedded image


(400 MHz, CDCl3) 0.64- 0.68 (m, 1H), 0.86 (d, J = 6.72 Hz, 6H), 1.01-1.07 (m, 3H), 1.33 (t, J = 7.07 Hz, 2H), 1.49-1.57 (m, 1H), 1.95-2.03 (m, 2H), 2.06 (s, 3H), 2.25 (s, 3H), 2.33-2.53 (m, 4H), 2.94 (dd, J = 13.80, 4.52 Hz, 1H), 3.18 (dd, J = 13.91, 10.90 Hz, 1H), 3.32- 3.39 (m, 1H), 3.49 (d, J = 7.19 Hz, 2H), 4.21 (td, J = 8.41, 5.18 Hz, 1H), 6.92-
492
490





6.94 (m, 2H), 7.20 (d, J =







3.25 Hz, 1H), 7.38 (d, J =







8.12 Hz, 1H), 7.61 (s, 1H),







7.70 (d, J = 3.25 Hz, 1H)








F-477


embedded image


(400 MHz, CDCl3) 0.91 (dd, J = 9.51, 6.96 Hz, 2H), 1.08-1.27 (m, 9H), 2.19- 2.23 (m, 5H), 2.27 (s, 3H), 2.50-2.61 (m, 2H), 2.88- 2.92 (m, 1H), 3.05 (t, J = 6.49 Hz, 2H), 3.16 (t, J = 6.38 Hz, 2H), 3.44 (d, J = 6.49 Hz, 2H), 3.48-3.57
411
409
Single isomer (stereo- chemistry on Cyclobutane ring: Undeter- mined)




(m, 2H), 6.95-6.99 (m,







2H), 7.62 (d, J = 8.81 Hz,







1H), 8.22 (brs, 1H)




















TABLE 271







Exam-


MS
Information












ple
Chemical structure
NMR
M + H
M − H
of structure















F-478


embedded image


(400 MHz, CDCl3) 0.87- 0.91 (m, 2H), 1.12-1.20 (m, 9H), 2.18-2.27 (m, 8H), 2.57-2.67 (m, 2H), 2.87-2.91 (m, 1H), 3.05 (t, J = 6.49 Hz, 2H), 3.17 (t, J = 6.26 Hz, 2H), 3.55- 3.71 (m, 4H), 6.94-7.00 (m, 2H), 7.62 (d, J =
411
409
Single isomer (Stereo- chemistry on Cyclobutane ring: Undeter- mined




8.58 Hz, 1H), 8.24







(brs, 1H)








F-479


embedded image


(400 MHz, CDCl3) 0.85 (d, J = 6.40 Hz, 6H), 1.18-1.22 (m, 3H), 1.32 (t, J = 6.95 Hz, 2H), 1.50-1.53 (m, 1H), 1.99 (t, J = 9.15 Hz, 3H), 2.06 (s, 3H), 2.23 (s, 3H), 2.38-2.46 (m, 3H), 2.95-2.99 (m, 2H), 3.30- 3.48 (m, 3H), 3.69-3.79 (m, 2H), 3.89-3.93 (m, 1H), 4.12 (s, 1H), 6.90- 6.92 (m, 2H), 7.25-7.26 (m, 1H), 8.62 (s, 1H), 10.86 (s, 1H)
507
505






F-480


embedded image


(400 MHz, CDCl3) 0.84 (d, J = 7.06 Hz, 6H), 0.96-1.00 (m, 2H), 1.17 (d, J = 7.06 Hz, 2H), 1.24 (t, J = 6.95 Hz, 2H), 1.48 (t, J = 6.62 Hz, 1H), 1.98 (dd, J = 18.86, 9.15 Hz, 2H), 2.16 (s, 3H), 2.27 (s, 3H), 2.37-2.46 (m, 3H), 2.79 (d, J = 4.85 Hz, 3H), 2.97 (d, J = 10.59 Hz, 1H), 3.22-3.26 (m, 1H), 3.43-3.50 (m, 2H), 4.02-4.13 (m, 2H), 5.40 (t, J = 6.73 Hz, 1H), 6.95-6.98 (m, 2H), 7.20
482
480





(s, 1H), 7.39 (d, J = 7.94







Hz, 1H), 8.89 (s, 1H)




















TABLE 272







Exam-


MS
Information












ple
Chemical structure
NMR
M + H
M − H
of structure















F-481


embedded image


(400 MHz, DMSO-D6) 0.71- 0.83 (m, 6H), 0.83-0.88 (m, 1H), 1.01-1.20 (m, 6H), 1.95- 2.05 (m, 3H), 2.18-2.23 (m, 4H), 2.27-2.46 (m, 5H), 2.96- 3.08 (m, 1H), 3.13-3.20 (d, J = 5.20 Hz, 3H), 3.38-3.48 (m, 1H), 3.48-3.60 (m, 1H), 4.04-4.13 (m, 1H), 6.85-6.92 (m, 1H), 6.95 (brs, 1H), 7.10- 7.19 (m, 1H), 9.19 (brs, 1H)
477
475
Racemic form





F-482


embedded image


(400 MHz, CDCl3) 0.82-1.11 (m, 2H), 1.00 (d, J = 6.62 Hz, 6H), 1.13-1.28 (m, 2H), 1.68 (d, J = 5.29 Hz, 2H), 1.80- 1.92 (m, 1H), 2.13 (s, 6H), 2.25 (s, 3H), 2.34-2.47 (m, 2H), 2.53-2.68 (m, 2H), 2.89- 2.97 (m, 1H), 3.16 (s, 3H), 3.24-3.35 (m, 1H), 3.63-4.12 (m, 3H), 4.14-4.28 (m, 2H), 4.44 (dd, J = 11.47, 8.60 Hz, 1H), 6.94 (s, 1H), 6.95 (d, J = 10.81 Hz, 1H), 7.72 (d, J = 8.16 Hz, 1H), 8.95 (brs, 1H)
508
506
Racemic form (Stereo- chemistry of Cyclobutane ring: Undeter- mined)





F-483


embedded image


(400 MHz, DMSO-D6) 0.82- 1.00 (m, 8H), 1.01-1.15 (m, 2H), 1.52 (d, J = 6.62 Hz, 2H), 1.63-1.75 (m, 1H), 1.97 (s, 1.5H), 2.00 (s, 1.5H), 2.04 (s, 3H), 2.14-2.35 (m, 2H), 2.22 (s, 3H), 3.00-3.08 (m, 1H), 3.13 (s, 3H), 3.35-4.13 (m, 9H), 6.93 (d, J = 7.94 Hz, 1H), 6.99 (s, 1H), 7.18 (d, J = 7.94 Hz, 0.5 H), 7.22 (d, J = 7.94 Hz, 0.5H), 9.52 (s, 0.5H), 9.54 (s, 0.5H)
508
506
Racemic form (stereo- chemistry on Cyclobutane ring: Undeter- mined




















TABLE 273







Exam-


MS
Information












ple
Chemical structure
NMR
M + H
M − H
of structure















F-484


embedded image


(400 MHz, DMSO-D6) 0.69- 0.81 (m, 1H), 0.85 (d, J = 6.62 Hz, 6H), 0.99-1.15 (m, 3H), 1.28 (t, J = 6.95 Hz, 2H), 1.46-1.58 (m, 1H), 1.76-2.11 (m, 4H), 1.98 (s, 3H), 2.21 (s, 3H), 2.30-2.49 (m, 2H), 2.68- 2.82 (m, 2H), 2.77 (s, 6H), 2.84-3.00 (m, 2H), 3.42-3.56 (m, 1H), 3.65-3.76 (m, 1H), 3.84-3.94 (m, 1H), 3.99-4.08 (m, 1H), 6.90 (d, J = 7.94 Hz, 1H), 6.96 (s, 1H), 7.08 (d, J = 7.94 Hz, 1H), 9.28 (brs, 1H)
510
508
Racemic form





F-485


embedded image


(400 MHz, CDCl3) 0.86 (d, J = 24.58 Hz, 6H), 0.93-1.03 (m, 1H), 1.03-1.24 (m, 4H), 1.27-1.34 (m, 2H), 1.47-1.57 (m, 1H), 1.84-1.95 (m, 1H), 2.00-2.10 (m, 1H), 2.13 (s, 3H), 2.27 (s, 3H), 2.33-2.46 (m, 2H), 2.46-2.56 (m, 2H), 2.86-2.98 (m, 1H), 3.00-3.13 (m, 1H), 3.15-3.25 (m, 1H), 3.36-3.47 (m, 1H), 3.65 (s, 3H), 4.26-4.36 (m, 1H), 6.93- 7.01 (m, 2H), 7.51 (d, J = 8.40 Hz, 1H),7.75 (brs, 1H)
507
505
Racemic form




















TABLE 274







Exam-


MS
Information












ple
Chemical structure
NMR
M + H
M − H
of structure















F-486


embedded image


(400 MHz, CDCl3) 0.85 (d, J = 6.49 Hz, 6H), 0.86-0.88 (m, 1H), 1.16-1.29 (m, 5H), 1.37 (s, 3H), 1.44 (s, 3H), 1.52 (t, J = 6.72 Hz, 1H), 1.97 (t, J = 9.97 Hz, 2H), 2.07 (s, 3H), 2.24 (s, 3H), 2.45 (d, J = 8.12 Hz, 3H), 2.85-2.88 (m, 1H), 3.08- 3.12 (m, 2H), 3.41 (t, J = 8.81 Hz, 1H), 3.64-3.66 (m, 1H), 3.72-3.74 (m, 1H), 3.99 (s, 1H), 6.90-6.92 (m,
510
508





2H), 7.24 (d, J = 7.88 Hz,







1H), 7.68 (t, J = 10.00 Hz,







1H), 8.53 (s, 1H)








F-487


embedded image


(400 MHz, CDCl3) 0.85- 0.88 (m, 7H), 1.03 (s, 1H), 1.20 (d, J = 7.42 Hz, 2H), 1.33 (t, J = 6.72 Hz, 2H), 1.54 (t, J = 6.61 Hz, 1H), 2.02-2.08 (m, 3H), 2.13 (s, 3H), 2.26 (s, 3H), 2.42- 2.47 (m, 3H), 2.86 (s, 1H), 3.00 (s, 2H), 3.42 (d, J = 1.62 Hz, 3H), 3.46 (d, J = 7.88 Hz, 1H), 3.88-3.94 (m, 4H), 6.93-6.96 (m, 2H), 7.41 (d, J = 7.88 Hz,
496
494





2H), 8.28 (s, 1H)








F-488


embedded image


(400 MHz, CDCl3) 0.78- 1.02 (m, 10H), 1.19-1.70 (m, 4H), 1.38 (d, J = 6.84 Hz, 3H), 1.96-2.48 (m, 6H), 2.07 (s, 3H), 2.23 (s, 3H), 2.66-2.72 (m, 1H), 2.88- 2.98 (m, 1H), 3.25-3.35 (m, 2H), 3.50-3.59 (m, 2H), 4.36 (d, J = 11.69 Hz, 1H), 4.41 (d, J = 11.69 Hz, 1H), 6.86-6.93 (m, 2H), 7.20- 7.52 (m, 7H)
543
541
Racemic form (Stereo- chemistry of Methyl group and Benzyloxyethyl group: Undetermined)




















TABLE 275







Exam-


MS
Information












ple
Chemical structure
NMR
M + H
M − H
of structure















F-489


embedded image


(400 MHz, CDCl3) 0.75- 1.08 (m, 10H), 1.17-1.69 (m, 7H), 1.96-2.56 (m, 12H), 2.65-3.09 (m, 2H), 3.24-3.75 (m, 4H), 4.29- 4.44 (m, 2H), 6.86-7.02 (m, 2H), 7.20-7.88 (m, 7H)
543
541
Mixtures of four stereoisomers





F-490


embedded image


(400 MHz, CDCl3) 0.79- 0.93 (m, 1H), 0.82 (d, J = 6.72 Hz, 6H), 0.99-1.11 (m, 1H), 1.08 (d, J = 6.96 Hz, 3H), 1.15-1.25 (m, 4H), 1.39-1.51 (m, 1H), 1.87-2.01 (m, 3H), 2.17- 2.49 (m, 4H), 2.26 (s, 3H), 2.29 (s, 3H), 2.86- 2.95 (m, 1H), 3.31-3.54 (m, 3H), 3.57-3.79 (m, 3H), 6.95-7.03 (m, 2H), 7.54 (d, J = 7.88 Hz,
453
451
Single isomer (Stereochemistry of Methyl group and Hydroxyethyl group: Undetermined) (Optical isomer of F-491)




1H), 8.83 (brs, 1H)








F-491


embedded image


(400 MHz, CDCl3) 0.79- 0.93 (m, 1H), 0.82 (d, J = 6.72 Hz, 6H), 0.99-1.11 (m, 1H), 1.08 (d, J = 6.96 Hz, 3H), 1.15-1.25 (m, 4H), 1.39-1.51 (m, 1H), 1.87-2.01 (m, 3H), 2.17- 2.49 (m, 4H), 2.26 (s, 3H), 2.29 (s, 3H), 2.86- 2.95 (m, 1H), 3.17-3.26 (m, 1H), 3.38-3.49 (m, 2H), 3.57-3.79 (m, 3H), 6.95-7.03 (m, 2H), 7.54
453
451
Single isomer (Stereochemistry of Methyl group and Hydroxyethyl group: Undetermined) (Optical isomer of F-490)




(d, J = 7.88 Hz, 1H),







8.83 (brs, 1H)








F-492


embedded image


(400 MHz, CDCl3) 0.78- 0.93 (m, 1H), 0.85 (d, J = 6.49 Hz, 6H), 0.97-1.15 (m, 3H), 1.19-1.35 (m, 2H), 1.39 (d, J = 6.72 Hz, 3H), 1.44-1.57 (m, 1H), 1.64-1.77 (m, 1H), 1.90- 2.19 (m, 3H), 2.04 (s, 3H), 2.23 (s, 3H), 2.27- 2.51 (m, 3H), 2.84-2.92 (m, 1H), 2.99-3.11 (m, 1H), 3.21-3.40 (m, 2H), 3.53-3.74 (m, 3H), 6.83-
453
451
Single isomer (Stereochemistry of Methyl group and Hydroxyethyl group: Undetermined) (Optical isomer of F-493)




6.93 (m, 2H), 7.21-7.29







(m, 1H), 7.62 (brs, 1H)




















TABLE 276







Exam-


MS
Information












ple
Chemical structure
NMR
M + H
M − H
of structure















F-493


embedded image


(400 MHz, CDCl3) 0.79- 0.92 (m, 1H), 0.85 (d, J = 6.96 Hz, 6H), 0.98-1.15 (m, 3H), 1.21-1.33 (m, 2H), 1.38 (d, J = 6.96 Hz, 3H), 1.45-1.55 (m, 1H), 1.67-1.75 (m, 1H), 1.90- 2.19 (m, 3H), 2.02 (s, 3H), 2.23 (s, 3H), 2.28- 2.50 (m, 3H), 2.85-2.92 (m, 1H), 3.00-3.10 (m, 1H), 3.29-3.41 (m, 1H), 3.45-3.73 (m, 4H), 6.88 (d, J = 8.12 Hz, 1H),
453
451
Single isomer (Stereo- chemistry of Methyl group and Hydroxyethyl group: Undetermined) (Optical isomer of F-492)




6.91 (s, 1H), 7.23 (d,







J = 8.12 Hz, 1H), 7.72







(brs, 1H)








F-494


embedded image


(400 MHz, CDCl3) 0.40- 0.50 (m, 2H), 0.77-1.00 (m, 4H), 1.08-1.32 (m, 4H), 1.33-1.44 (m, 1H) 1.48-1.60 (m, 2H), 1.60- 1.81 (m, 5H), 2.16 (s, 3H), 2.27 (s, 3H), 2.66- 2.76 (m, 2H), 2.86-2.95 (m, 2H), 3.04-3.12 (m, 2H), 6.94-7.03 (m, 2H), 7.52 (s, 1H), 7.65 (d,
395
393





J = 8.04 Hz, 1H)








F-495


embedded image


(400 MHz, CDCl3) 0.80- 0.91 (m, 8H), 1.10-1.31 (m, 7H), 1.47 (t, J = 6.96 Hz, 2H), 2.04-2.10 (m, 2H), 2.20 (s, 3H), 2.27 (s, 3H), 2.49-2.61 (m, 3H), 2.86-2.91 (m, 1H), 3.03-3.09 (m, 2H), 3.15- 3.20 (m, 2H), 3.58-3.65 (m, 1H), 6.95-6.99 (m,
423
421





2H), 7.58-7.65 (m, 1H),







8.28 (s, 1H)




















TABLE 277







Exam-


MS
Information












ple
Chemical structure
NMR
M + H
M − H
of structure















F-496


embedded image


(400 MHz, CDCl3) 0.81- 0.93 (m, 8H), 1.12-1.30 (m, 7H), 1.39 (t, J = 6.84 Hz, 2H), 2.04-2.12 (m, 2H), 2.20 (s, 3H), 2.27 (s, 3H) 2.36-2.53 (m, 3H), 2.87-2.92 (m, 1H), 3.00-3.09 (m, 2H), 3.11- 3.19 (m, 2H), 3.37-3.47
423
421





(m, 1H), 6.94-6.99 (m,







2H), 7.59-7.64 (m, 1H),







8.27 (brs, 1H)








F-497


embedded image


(400 MHz, CDCl3) 0.87 (s, 9H), 0.91-1.00 (m, 1H), 1.02-1.12 (m, 1H), 1.13-1.32 (m, 4H), 1.69- 1.80 (m, 2H), 2.11 (s, 3H), 2.25 (s, 3H), 2.73 (t, J = 7.94 Hz, 2H), 2.92- 3.10 (m, 3H), 3.66-3.68 (brm, 1H), 3.92-3.94 (brm, 3H), 6.95 (d, J = 8.60 Hz, 1H), 6.95 (s, 1H), 7.43 (d, J = 8.60 Hz, 1H), 7.78 (s, 1H)
413
411
Racemic form





F-498


embedded image


(400 MHz, CDCl3) 0.80- 0.89 (m, 7H), 1.09-1.15 (m, 2H), 1.28-1.34 (m, 2H), 1.39 (s, 9H), 1.48- 1.58 (m, 1H), 1.89-2.01 (m, 1H), 2.03-2.11 (m, 3H), 2.25 (s, 3H), 2.29- 2.53 (m, 4H), 2.63-2.73 (m, 1H), 2.76-2.87 (m, 2H), 2.94-3.09 (m, 2H), 3.36-3.47 (m, 1H), 4.02- 4.15 (m, 1H), 6.90-6.96 (m, 2H), 7.41 (d, J = 8.40 Hz, 1H), 7.61 (brs, 1H)
509
507
Racemic form




















TABLE 278







Exam-


MS
Information












ple
Example
NMR
M + H
M − H
of structure















F-499


embedded image


(400 MHz, DMSO-D6) 0.80- 0.89 (m, 6H), 0.92-1.09 (m, 4H), 1.22-1.31 (m, 2H), 1.45- 1.57 (m, 1H), 1.75-1.96 (m, 2H), 2.01 (s, 3H), 2.23 (s, 3H), 2.30-2.42 (m, 1H), 2.55- 2.73 (m, 2H), 2.74-2.87 (m, 1H), 2.95-3.05 (m, 1H), 3.43- 3.56 (m, 1H), 3.86-3.97 (m, 1H), 6.86-6.95 (m, 1H), 6.97 (brs, 1H), 7.12 (d, J = 8.40 Hz, 1H), 9.26 (brs, 1H)
453
451
Racemic form





F-500


embedded image


(400 MHz, CDCl3) 0.83-0.88 (m, 6H), 0.97-1.04 (m, 1H), 1.04-1.14 (m, 2H), 1.28-1.35 (m, 2H), 1.47-1.56 (m, 1H), 1.83-1.94 (m, 1H), 2.07-2.11 (m, 4H), 2.25 (s, 3H), 2.28- 2.53 (m, 4H), 2.72-2.82 (m, 1H), 2.82-2.90 (m, 5H), 2.97 (s, 3H), 3.00-3.14 (m, 2H), 3.34-3.47 (m, 1H), 4.19-4.30 (m, 1H), 6.90-6.98 (m, 2H), 7.41-7.47 (m, 1H), 7.60- 7.66 (m, 1H)
480
478
Racemic form





F-501


embedded image


(400 MHz, CDCl3) 0.81-0.90 (m, 7H), 0.95-1.16 (m, 4H), 1.21-1.35 (m, 4H), 1.74-1.98 (m, 4H), 2.01-2.12 (m, 4H), 2.25 (brs, 3H), 2.28-2.53 (m, 2H), 2.68-2.77 (m, 1H), 2.78- 2.82 (m, 2H), 2.84-2.93 (m, 1H), 2.96-3.10 (m, 2H), 3.25- 3.48 (m, 4H), 4.21-4.35 (m, 1H), 6.90-6.99 (m, 2H), 7.39- 7.48 (m, 1H), 7.58-7.65 (m, 1H)
506
504
Racemic form




















TABLE 279







Exam-


MS
Information












ple
Chemical structure
NMR
M + H
M − H
of structure















F-502


embedded image


(400 MHz, CDCl3) 0.81- 0.89 (m, 6H), 0.97-1.18 (m, 4H), 1.24-1.36 (m, 2H), 1.46-1.58 (m, 1H), 1.83-1.97 (m, 2H), 1.98- 2.12 (m, 6H), 2.25 (s, 3H), 2.29-2.54 (m, 3H), 2.62-2.82 (m, 1H), 2.82- 2.97 (m, 2H), 2.97-3.08 (m, 2H), 3.28-3.69 (m, 5H), 4.20-4.33 (m, 1H), 4.40-4.52 (m, 1H), 6.88- 6.96 (m, 2H), 7.30-7.44 (m, 1H), 7.79-8.15 (m, 1H)
522
520
Mixture of two stereoisomers (Mixture of diastereomers)





F-503


embedded image


(400 MHz, CDCl3) 0.80- 0.90 (m, 6H), 0.97-1.17 (m, 5H), 1.22-1.36 (m, 1H), 1.46-1.58 (m, 1H), 1.83-1.96 (m, 1H), 1.96- 2.12 (m, 6H), 2.22-2.27 (m, 3H), 2.29-2.53 (m, 4H), 2.63-2.81 (m, 1H), 2.81-2.95 (m, 2H), 2.96- 3.08 (m, 2H), 3.30-3.67 (m, 5H), 4.19-4.33 (m, 1H), 4.40-4.51 (m, 1H), 6.89-6.96 (m, 2H), 7.32- 7.44 (m, 1H), 7.75-8.09 (m, 1H)
522
520
Mixture of two stereoisomers (Mixture of diastereomers)





F-504


embedded image


(400 MHz, CDCl3) 0.82- 0.90 (m, 8H), 0.93-1.04 (m, 3H), 1.29-1.36 (m, 2H), 1.48-1.59 (m, 1H), 1.93-2.02 (m, 1H), 2.03 (s, 3H), 2.23 (s, 3H), 2.26-2.47 (m, 4H), 3.05- 3.11 (m, 2H), 3.12-3.23 (m, 1H), 3.28-3.39 (m, 1H), 3.86-3.91 (m, 4H), 4.18-4.28 (m, 1H), 6.53- 6.60 (m, 2H), 6.89-6.94 (m, 2H), 7.33-7.44 (m,
516
514
Racemic form




2H), 7.62 (brs, 1H)




















TABLE 280







Exam-


MS
Information












ple
Chemical structure
NMR
M + H
M − H
of structure















F-505


embedded image


(400 MHz, CDCl3) 0.54- 0.65 (m, 1H), 0.77-0.89 (m, 6H), 0.92-1.03 (m, 2H), 1.07-1.18 (m, 1H), 1.21-1.33 (m, 1H), 1.46- 1.59 (m, 1H), 1.74-1.90 (m, 1H), 1.93 (s, 3H), 2.20 (s, 3H), 2.29-2.45 (m, 4H), 2.61-2.95 (m, 3H), 2.98-3.09 (m, 1H), 3.38-3.50 (m, 1H), 3.82- 4.01 (m, 1H), 5.61-5.72 (m, 1H), 6.10-6.19 (m,
502
500
Racemic form




1H), 6.83-6.93 (m, 1H),







6.93-6.97 (m, 1H), 7.00-







7.08 (m, 1H), 7.19-7.30







(m, 1H), 9.29 (brs, 1H),







11.72 (brs, 1H)








F-506


embedded image


(400 MHz, CDCl3) 0.77- 1.06 (m, 8H), 1.24-1.34 (m, 2H), 2.01-2.15 (m, 1H), 2.16 (s, 3H), 2.19 (s, 3H), 2.27 (s, 3H), 2.65 (d, J = 7.19 Hz, 2H), 3.36-3.49 (m, 2H), 3.91 (dd, J = 31.77, 18.32 Hz, 2H), 4.12-4.27 (m, 2H), 4.52 (t, J = 9.86 Hz, 1H), 6.76 (s, 1H), 6.95-7.01 (m, 2H), 7.75 (d, J = 7.88 Hz, 1H), 8.65 (brs, 1H)
491
489






F-507


embedded image


(400 MHz, CDCl3) 0.78- 0.85 (m, 1H), 0.96-1.02 (m, 7H), 1.28-1.32 (m, 2H), 2.01-2.17 (m, 1H), 2.16 (s, 3H), 2.19 (s, 3H), 2.27 (s, 3H), 2.66 (d, J = 6.96 Hz, 2H), 3.34-3.41 (m, 2H), 3.91 (tdd, J = 23.86, 11.67, 7.03 Hz, 2H), 4.10-4.27 (m, 2H), 4.53 (dd, J = 11.48, 8.46 Hz, 1H), 6.77 (s, 1H), 6.95-7.00 (m, 2H), 7.75 (d, J = 8.12 Hz, 1H), 8.65
491
489





(s, 1H)




















TABLE 281







Exam-


MS
Information












ple
Chemical structure
NMR
M + H
M − H
of structure















F-508


embedded image


(400 MHz, CDCl3) 0.90 (s, 9H), 0.99-1.39 (m, 6H), 1.32 (s, 3H), 1.35 (s, 3H), 1.66-1.83 (m, 2H), 2.16 (s, 3H), 2.25 (s, 3H), 2.75 (t, J = 7.83 Hz, 2H), 2.84 (s, 3H), 2.98 (dd, J = 14.34, 6.62 Hz, 1H), 3.13 (dd, J = 14.34, 8.38 Hz, 1H), 3.22 (tt, J = 7.12, 3.96 Hz, 1H), 3.77 (dd, J = 13.89, 1.76 Hz, 1H), 3.98 (dd, J = 13.89, 6.62 Hz, 1H), 4.02-4.10 (m, 1H), 6.94 (d, J = 8.60 Hz, 1H), 6.95 (s, 1H), 7.53 (d,
537
535
Racemic form




J = 8.60 Hz, 1H), 7.83 (s,







1H)








F-509


embedded image


(400 MHz, DMSO-D6) 0.74- 0.81 (m, 1H), 0.85 (d, J = 6.62 Hz, 6H), 1.01-1.13 (m, 3H), 1.28 (t, J = 7.06 Hz, 2H), 1.46- 1.58 (m, 1H), 1.78-1.96 (m, 2H), 1.98 (s, 3H), 2.21 (s, 3H), 2.30-2.48 (m, 5H), 2.66-2.76 (m, 1H), 2.88-3.02 (m, 2H), 3.42-3.55 (m, 1H), 3.60-3.72 (m, 1H), 5.00 (d, J = 4.85 Hz, 1H), 5.04 (d, J = 11.91 Hz, 1H), 5.68-5.83 (m, 1H), 6.90 (d, J = 8.16 Hz, 1H), 6.95 (s,
435
433
Racemic form




1H), 7.08 (d, J = 8.16 Hz,







1H), 9.27 (brs, 1H)




















TABLE 282







Exam-


MS
Information












ple
Chemical structure
NMR
M + H
M − H
of structure















F-510


embedded image


(400 MHz, CDCl3) 0.79- 0.85 (m, 1H), 0.85 (d, J = 6.62 Hz, 6H), 1.05-1.16 (m, 3H), 1.32 (t, J = 7.06 Hz, 2H), 1.47-1.71 (m, 3H), 1.79-2.13 (m, 5H), 2.04 (s, 3H), 2.24 (s, 3H), 2.30-2.53 (m, 3H), 2.81 (dd, J = 13.67, 4.41 Hz, 1H), 2.90 (tt, J = 6.73, 4.35 Hz, 1H), 3.08 (dd, J = 13.67, 10.59 Hz, 1H), 3.35-3.47 (m, 1H), 3.59- 3.67 (m, 2H), 3.68-3.79
453
451





(m, 1H), 6.92 (d, J =







7.72 Hz, 1H), 6.93 (s,







1H), 7.35 (d, J = 7.72







Hz, 1H), 7.87 (brs, 1H)








F-511


embedded image


(400 MHz, CDCl3) 0.76- 0.86 (m, 1H), 0.85 (d, J = 6.62 Hz, 6H), 1.05-1.19 (m, 3H), 1.31 (t, J = 7.06 Hz, 2H), 1.47-1.72 (m, 3H), 1.78-2.13 (m, 5H), 2.04 (s, 3H), 2.24 (s, 3H), 2.31-2.53 (m, 3H), 2.81 (dd, J = 13.67, 4.41 Hz, 1H), 2.90 (tt, J = 6.73, 4.35 Hz, 1H), 3.08 (dd, J = 13.67, 10.59 Hz, 1H), 3.35-3.46 (m, 1H), 3.59-3.68 (m, 2H), 3.68-
453
451





3.80 (m, 1H), 6.92 (d, J =







7.72 Hz, 1H),6.93 (s,







1H), 7.34 (d, J = 7.72 Hz,







1H), 7.89 (brs, 1H)








F-512


embedded image


(400 MHz, CDCl3) 0.80- 0.90 (m, 7H), 0.91-1.01 (m, 1H), 1.07-1.18 (m, 2H), 1.30-1.37 (m, 2H), 1.48-1.61 (m, 2H), 1.91- 2.11 (m, 5H), 2.24 (s, 3H), 2.34-2.59 (m, 7H), 2.83-2.91 (m, 1H), 3.34- 3.85 (m, 6H), 6.89-6.97 (m, 2H), 7.61-7.68 (m, 1H), 8.28 (brs, 1H)
465
463
Racemic form (Stereo- chemistry of Hydroxymethyl group: Undetermined)




















TABLE 283











Informa-


Exam-


MS
tion of












ple
Chemical structure
NMR
M + H
M − H
structure















F-513


embedded image


(400 MHz, CDCl3) 0.84- 0.90 (m, 6H), 1.16 (s, 1H), 1.33-1.40 (m, 3H), 1.50- 1.56 (m, 2H), 2.04-2.28 (m, 5H), 2.48-2.54 (m, 4H), 3.11 (d, J = 11.91 Hz, 1H), 3.44-3.61 (m, 3H), 3.74- 3.77 (m, 2H), 4.11 (s, 1H), 6.89-6.94 (m, 1H), 7.08- 7.10 (m, 1H), 7.66 (d, J = 9.04 Hz, 1H), 8.90 (s, 1H)
463
461






F-514


embedded image


(400 MHz, DMSO-D6) 0.69- 0.77 (m, 1H), 0.85 (d, J = 6.62 Hz, 6H), 1.06-1.11 (m, 2H), 1.17-1.24 (m, 1H), 1.28 (t, J = 6.73 Hz, 2H), 1.34- 1.44 (m, 1H), 1.47-1.56 (m, 1H), 1.58-1.67 (m, 1H), 1.80-2.00 (m, 6H), 2.03-2.12 (m, 1H), 2.20 (s, 3H), 2.26- 2.69 (m, 5H), 2.83 (dd, J = 14.45, 10.03 Hz, 1H), 2.93 (s, 1H), 3.44-3.58 (m, 2H), 3.79-3.87 (m, 1H), 4.95 (d, J = 6.40 Hz, 1H), 6.89 (d, J = 7.06 Hz, 1H), 6.94 (s,
465
463





1H), 7.05 (d, J = 7.94 Hz,







1H), 9.23 (brs, 1H)








F-515


embedded image


(400 MHz, DMSO-D6) 0.69- 0.77 (m, 1H), 0.85 (d, J = 6.62 Hz, 6H), 1.06-1.12 (m, 2H), 1.17-1.23 (m, 1H), 1.28 (t, J = 6.84 Hz, 2H), 1.35- 1.44 (m, 1H), 1.47-1.56 (m, 1H), 1.57-1.66 (m, 1H), 1.78- 2.00 (m, 2H), 1.93 (s, 5H), 2.03-2.11 (m, 1H), 2.20 (s, 3H), 2.33-2.67 (m, 5H), 2.78- 2.87 (m, 1H), 2.90-2.96 (m, 1H), 3.17 (d, J = 4.41 Hz, 1H), 3.44-3.59 (m, 2H), 3.79-3.88 (m, 1H), 4.95 (d, J = 6.84 (s, 1H), 7.05 (d, J = 7.94 Hz, 1H),
465
463





9.23 (brs, 1H)




















TABLE 284







Exam-


MS
Information












ple
Chemical structure
NMR
M + H
M − H
of structure















F-516


embedded image


(400 MHz, CDCl3) 0.82- 0.95 (m, 7H), 1.01-1.14 (m, 3H), 1.32-1.40 (m, 2H), 1.47-1.61 (m, 1H), 1.99-2.19 (m, 4H), 2.25 (s, 3H), 2.30-2.36 (m, 6H), 2.36-2.45 (m, 1H), 2.45-2.57 (m, 2H), 2.83- 3.02 (m, 2H), 3.20-3.30 (m, 1H), 3.40-3.53 (m, 2H), 4.43-4.50 (m, 1H), 6.90-6.98 (m, 2H), 7.54- 7.67 (m, 1H), 8.41 (brs,
438
436





1H)








F-517


embedded image


(400 MHz, CDCl3) 0.83- 0.98 (m, 8H), 1.07-1.17 (m, 2H), 1.32-1.39 (m, 2H), 1.49-1.61 (m, 1H), 1.99-2.16 (m, 5H), 2.24 (s, 3H), 2.35-2.55 (m, 5H), 2.83-2.89 (m, 1H), 3.00-3.16 (m, 2H), 3.37- 3.57 (m, 2H), 3.73-3.86 (m, 1H), 4.92 (brs, 1H), 5.00 (brs, 1H), 6.89-6.98 (m, 2H), 7.70-7.77 (m, 1H), 8.39 (brs, 1H)
447
445
Racemic form





F-518


embedded image


(400 MHz, CDCl3) 0.83- 0.87 (m, 6H), 0.90-1.07 (m, 2H), 1.09-1.18 (m, 2H), 1.30-1.36 (m, 2H), 1.47-1.57 (m, 1H), 1.93- 2.17 (m, 4H), 2.27 (s, 3H), 2.32-2.56 (m, 4H), 2.83-2.96 (m, 2H), 3.09- 3.19 (m, 1H), 3.36-3.48 (m, 1H), 3.64-3.76 (m, 2H), 3.91-4.01 (m, 1H), 6.97-7.04 (m, 1H), 7.12- 7.16 (m, 1H), 7.85 (brs, 1H), 7.95-8.02 (m, 1H)
459
457




















TABLE 285











Infor -


Exam-


MS
mation of












ple
Chemical structure
NMR
M + H
M − H
structure















F-519


embedded image


(400 MHz, CDCl3) 0.81- 0.90 (m, 7H), 0.91-0.96 (m, 1H), 1.02-1.09 (m, 1H), 1.11- 1.20 (m, 2H), 1.28-1.35 (m, 2H), 1.47-1.57 (m, 1H), 1.90-2.15 (m, 4H), 2.29-2.57 (m, 3H), 2.87-2.99 (m, 2H), 3.11-3.20 (m, 1H), 3.37- 3.49 (m, 1H), 3.65-3.81 (m, 2H), 3.89-3.98 (m, 1H), 6.98-7.10 (m, 2H), 7.99-8.10 (m, 1H), 8.47 (brs, 1H)
463
461






F-520


embedded image


(400 MHz, CDCl3) 0.82-0.85 (m, 6H), 1.16 (d, J = 10.00 Hz, 1H), 1.36-1.46 (m, 6H), 2.07-2.56 (m, 7H), 3.13-3.17 (m, 1H), 3.38 (s, 1H), 3.53-3.65 (m, 4H), 3.84 (s, 3H), 4.05 (s, 1H), 7.17- 7.21 (m, 2H), 7.41 (s, 1H), 10.12 (s, 1H)
475
473






F-521


embedded image


(400 MHz, CDCl3) 0.87 (d, J = 5.84 Hz, 6H), 1.06 (d, J = 10.00 Hz, 1H), 1.26 (s, 2H), 1.33-1.55 (m, 4H), 2.04-2.11 (m, 4H), 2.45-2.54 (m, 3H), 2.94 (d, J = 11.03 Hz, 1H), 3.36 (s, 1H), 3.55-3.57 (m, 2H), 3.69-3.72 (m, 2H), 4.05 (s, 1H), 4.32-4.36 (m, 2H), 7.17-7.18 (m, 2H), 7.29 (d, J = 1.54 Hz, 1H), 8.07 (s, 1H)
493
491




















TABLE 286











Infor-






mation


Exam-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure





F-522


embedded image


(400 MHz, CDCl3) 0.78-0.82 (m, 1H), 0.86 (d, J = 6.72 Hz, 6H), 1.09-1.19 (m, 2H), 1.19-1.28 (m, 1H), 1.29-1.37 (m, 2H), 1.48-1.58 (m, 1H), 1.86-1.99 (m, 1H), 1.97 (s, 3H), 2.01-2.24 (m, 4H), 2.24 (s, 3H), 2.34- 2.52 (m, 4H), 2.70-2.77 (m, 1H), 2.79-2.92 (m, 2H), 2.95-3.02 (m, 1H), 3.37-3.46 (m, 1H), 3.70-3.79 (m, 2H), 4.32-4.40 (m, 1H), 6.89-6.95 (m, 2H), 7.24- 7.28 (m, 1H), 7.48 (s, 1H)
465
463






F-523


embedded image


(400 MHz, CDCl3) 0.72-0.83 (m, 1H), 0.86 (d, J = 6.72 Hz, 6H), 1.02-1.18 (m, 2H), 1.19-1.33 (m, 3H), 1.48-1.58 (m, 1H), 1.88-2.24 (m, 5H), 1.96 (s, 3H), 2.24 (s, 3H), 2.32-2.60 (m, 4H), 2.74 (dd, J = 13.68, 3.94 Hz, 1H), 2.81-2.92 (m, 2H), 2.99 (dd, J = 13.68, 11.59 Hz, 1H), 3.35-3.46 (m, 1H), 3.69- 3.81 (m, 2H), 4.31-4.40 (m, 1H), 6.88-6.95 (m, 2H), 7.22-7.29 (m, 1H), 7.57 (brs, 1H)
465
463






F-524


embedded image


(400 MHz, CDCl3) 0.86 (d, J = 8.16 Hz, 6H), 0.94-0.96 (m, 1H), 1.06- 1.08 (m, 1H), 1.15-1.18 (m, 2H), 1.32 (t, J = 6.95 Hz, 2H), 1.50-1.56 (m, 1H), 1.95-2.09 (m, 4H), 2.37-2.53 (m, 3H), 2.96-2.98 (m, 2H), 3.23-3.27 (m, 1H), 3.44-3.48 (m, 1H), 3.68-3.73 (m, 2H), 3.94 (t, J = 7.39 Hz, 1H), 7.75 (d, J = 8.82 Hz, 1H), 7.84 (s, 1H), 8.18 (d, J = 8.60 Hz, 1H), 8.42 (s, 1H)
547
545




















TABLE 287











Infor-






mation


Exam-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure





F-525


embedded image


(400 MHz, CDCl3) 0.83- 0.87 (m, 7H), 1.12 (d, J = 10.00 Hz, 1H), 1.27-1.34 (m, 4H), 1.51-1.53 (m, 2H), 2.02 (s, 1H), 2.18-2.21 (m, 5H), 2.46-2.50 (m, 4H), 3.12-3.15 (m, 1H), 3.41 (s, 1H), 3.57-3.59 (m, 1H), 3.77-3.79 (m, 2H), 4.10 (s, 1H), 7.07-7.10 (m, 2H), 7.33 (d, J = 8.38 Hz, 1H), 9.07 (s, 1H)
459
457






F-526


embedded image


(400 MHz, CDCl3) 0.82 (d, J = 7.06 Hz, 6H), 1.14 (s, 1H), 1.29-1.31 (m, 4H), 1.49-1.51 (m, 3H), 2.10-2.13 (m, 7H), 2.42- 2.53 (m, 4H), 3.09 (d, J = 10.00 Hz, 1H), 3.41 (s, 1H), 3.55-3.58 (m, 2H), 3.75 (s, 3H), 4.08 (s, 1H), 6.94 (d, J = 8.16 Hz, 1H), 7.05-7.07 (m, 1H), 7.19 (s, 1H), 9.75 (s, 1H)
455
453






F-527


embedded image


(400 MHz, CDCl3) 0.89 (s, 9H), 1.10-1.47 (m, 6H), 1.84-2.01 (m, 2H), 2.22 (s, 3H), 2.25 (s, 3H), 2.94-3.17 (m, 2H), 3.38-3.51 (m, 1H), 3.72-3.94 (m, 2H), 4.03-4.16 (m, 1H), 4.40-4.69 (m, 3H), 6.89-6.97 (m, 2H), 7.35 (d, J = 8.00 Hz, 1H), 9.30 (s, 1H)
556
554
Racemic form





F-528


embedded image


(400 MHz, DMSO-D6) 0.75-0.93 (m, 3H), 0.87 (s, 9H), 0.99-1.11 (m, 1H), 1.13-1.43 (m, 7H), 1.62-1.80 (m, 4H), 2.05 (s, 3H), 2.21 (s, 3H), 2.81- 3.80 (m, 6H), 6.90 (d, J = 7.88 Hz, 1H), 6.97 (s, 1H), 7.11 (d, J = 7.88 Hz, 1H), 9.44 (s, 1H)
425
423




















TABLE 288











Informa-






tion


Exam-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure





F-529


embedded image


(400 MHz, CDCl3) 0.74- 0.82 (m, 1H), 0.85 (d, J = 6.84 Hz, 6H), 1.05-1.20 (m, 3H), 1.25-1.33 (m, 5H), 1.46-1.57 (m, 1H), 1.88-1.96 (m, 1H), 2.01 (s, 3H), 2.02-2.10 (m, 1H), 2.24 (s, 3H), 2.31- 2.53 (m, 3H), 2.93-3.11 (m, 3H), 3.36-3.48 (m, 1H), 3,77-3.84 (m, 1H), 4.07-4.21 (m, 2H), 6.91 (d, J = 7.94
439
437
Racemic form




Hz, 1H), 6.93 (s, 1H),







7.26 (d, J = 7.94







Hz, 1H), 7.76 (s, 1H)








F-530


embedded image


(400 MHz, CDCl3) 0.72- 0.82 (m, 1H), 0.81-0.91 (m, 7H), 1.00-1.31 (m, 7H), 1.31-1.38 (m, 2H), 1.48-1.60 (m, 1H), 1.96- 2.17 (m, 5H), 2.25 (s, 3H), 2.33-2.44 (m, 1H), 2.44-2.54 (m, 2H), 2.69-2.90 (m, 6H), 2.91-2.96 (m, 2H), 3.36- 3.52 (m, 1H), 6.65-6.73 (m, 1H), 6.89-6.97 (m, 2H), 7.45-7.51 (m, 1H), 7.87 (brs, 1H)
494
492






F-531


embedded image


(400 MHz, CDCl3) 1.10-1.40 (m, 12H), 1.40-1.68 (m, 6H), 2.13-2.40 (m, 12H), 3.19-3.87 (m, 4H), 4.04- 4.41 (m, 3H), 4.45-4.85 (m, 2H), 6.91-7.00 (m, 2H), 7.36- 7.44 (m, 1H), 9.18-9.49 (m, 1H)
518
516






F-532


embedded image


(400 MHz, CDCl3) 1.08-1.42 (m, 12H), 1.49-1.68 (m, 6H), 2.14-2.47 (m, 13H), 3.15-3.46 (m, 1H), 3.54-3.88 (m, 3H), 4.07-4.87 (m, 4H), 6.89-7.02 (m, 2H), 7.36-7.44 (m, 1H), 9.23-9.47 (m, 1H)
518
516




















TABLE 289











Infor-






mation


Exam-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure





F-533


embedded image


(400 MHz, CDCl3) 0.82-0.91 (m, 7H), 0.91-1.04 (m, 1H), 1.07-1.23 (m, 2H), 1.33-1.40 (m, 2H), 1.48-1.60 (m, 1H), 2.01-2.15 (m, 4H), 2.25 (m, 4H), 2.31-2.56 (m, 4H), 2.68- 2.78 (m, 1H), 2.82-2.90 (m, 1H), 2.90-3.01 (m, 1H), 3.07- 3.20 (m, 1H), 3.38-3.47 (m, 1H), 3.68-3.80 (m, 1H), 4.04- 4.18 (m, 1H), 6.91-6.99 (m, 2H), 7.68-7.75 (m, 1H), 8.54 (brs, 1H)
449
447
Racemic form





F-534


embedded image


(400 MHz, CDCl3) 0.80-0.97 (m, 8H), 1.04-1.18 (m, 2H), 1.32-1.39 (m, 2H), 1.50-1.61 (m, 1H), 1.95-2.15 (m, 7H), 2.20-2.34 (m, 12H), 2.35-2.57 (m, 2H), 2.75-2.93 (m, 2H), 3.34-3.49 (m, 1H), 3.56-3.74 (m, 2H), 6.88-6.98 (m, 2H), 7.70-7.78 (m, 1H), 8.59 (brs, 1H)
478
476
Racemic form (Stereo- chemistry of Dimethyl- amino group: Undeter- mined)





F-535


embedded image


(400 MHz, CDCl3) 0.87 (d, J = 5.95 Hz, 6H), 0.96-0.98 (m, 1H), 1.22- 1.57 (m, 6H), 2.06-2.08 (m, 4H), 2.29-2.31 (m, 3H), 2.44-2.52 (m, 3H), 2.76 (q, J = 15.22 Hz, 1H), 3.33 (s, 1H), 3.45- 3.47 (m, 2H), 3.64 (s, 2H), 3.83 (s, 3H), 4.02 (s, 1H), 4.21 (d, J = 5.73 Hz, 2H), 6.62-6.64 (m, 2H), 6.98 (d, J = 7.50 Hz, 1H), 7.07 (t, J = 6.51 Hz, 1H)
469
467




















TABLE 290











Infor-






mation


Exam-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure





F-536


embedded image


(400 MHz, CDCl3) 0.83-0.90 (m, 7H), 0.90-1.03 (m, 1H), 1.04-1.22 (m, 7H), 1.31- 1.39 (m, 2H), 1.48-1.60 (m, 1H), 2.01-2.18 (m, 3H), 2.20 (s, 3H), 2.27 (s, 3H), 2.34-2.57 (m, 3H), 2.74-2.80 (m, 1H), 2.83- 3.01 (m, 3H), 3.38-3.50 (m, 2H), 4.47-4.53 (m, 1H), 6.93-7.00 (m, 2H), 7.58-7.66 (m, 1H), 9.33 (brs, 1H)
452
450






F-537


embedded image


(400 MHz, CDCl3) 0.81-0.94 (m, 8H), 0.98-1.11 (m, 8H), 1.12-1.19 (m, 2H), 1.31-1.39 (m, 2H), 1.50-1.60 (m, 1H), 1.98-2.15 (m, 4H), 2.19-2.28 (m, 5H), 2.33-2.44 (m, 1H), 2.44-2.56 (m, 2H),2.78-2.86 (m, 1H), 2.91-3.02 (m, 2H), 3.35-3.49 (m, 2H), 4.66- 4.71 (m, 1H), 6.89-6.96 (m, 2H), 7.54-7.61 (m, 1H), 8.21 (brs, 1H)
466
464






F-538


embedded image


(400 MHz, CDCl3) 0.87- 0.92 (m, 11H), 0.94-1.07 (m, 2H), 1.18-1.33 (m, 2H), 1.71-1.83 (m, 2H), 2.17 (s, 3H), 2.22-2.29 (m, 3H), 2.71-2.83 (m, 2H), 2.93-3.02 (m, 1H), 3.33-3.42 (m, 1H), 3.68-3.78 (m, 1H), 3.98-4.40 (m, 4H), 6.90-6.99 (m, 2H), 7.74-7.82 (m, 1H), 8.26-8.31 (m, 1H), 8.97 (brs, 1H)
452
450
Racemic form




















TABLE 291











Infor-






mation


Exam-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure





F-539


embedded image


(400 MHz, CDCl3) 0.80- 0.93 (m, 8H), 0.97-1.16 (M, 9H), 1.30-1.40 (m, 2H), 1.97-2.14 (m, 6H), 2.16- 2.28 (m, 6H), 2.34- 2.45 (m, 1H), 2.46- 2.56 (m, 2H), 2.82- 2.91 (m, 1H), 2.97-3.33 (m, 2H), 3.36-3.51 (m, 2H), 3.53-3.77 (m, 2H), 6.89-6.98 (m, 2H), 7.67-7.76 (m, 1H), 8.56 (brs, 1H)
506
504
Racemic form (Stereo- chemistry of isopropyl- methyl- amino group: Undeter- mined)





F-540


embedded image


(400 MHz, CDC13) 0.79- 1.04 (m, 2H), 0.87 (s, 9H), 1.12-1.23 (m, 2H), 1.39 (d, J = 6.48 Hz, 2H), 1.42-1.53 (m, 9H), 2.04-2.20 (m, 2H), 2.13 (s, 3H), 2.25 (s, 3H), 2.39-2.59 (m, 3H), 2.81-2.93 (m, 1H), 3.23-3.50 (m, 2H), 3.63-4.26 (m, 5H), 6.90-6.99 (m, 2H), 7.65-7.77 (m, 1H), 8.17 (s, 0.3H), 8.72 (s, 0.7H)
550
548






F-541


embedded image


(400 MHz, DMSO-D6) 0.87 (s, 9H), 1.01-1.26 (m, 4H), 1.37 (d, J = 6.48 Hz, 2H), 2.05-2.20 (m, 2H), 2.12 (s, 3H), 2.24 (s, 3H), 2.43- 2.64 (m, 3H), 2.92-3.02 (m, 1H), 3.15-3.35 (m, 3H), 3.36-3.53 (m, 3H), 3.71- 3.85 (m, 2H), 4.25 (dd, J = 15.60, 6.88 Hz, 1H), 6.95 (d, J = 8.44 Hz, 1H), 7.01 (s, 1H), 7.18 (d, J = 8.24 Hz, 1H), 8.33 (s, 1H)
532
530




















TABLE 292











Infor-






mation


Exam-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure















F-542


embedded image


(400 MHz, DMSO-D6) 0.87 (s, 9H), 1.00- 1.26 (m, 4H), 1.36 (d, J = 6.68 Hz, 2H), 1.97-2.17 (m, 2H), 2.12 (s, 3H), 2.24 (s, 3H), 2.38-2.62 (m, 3H), 3.19-3.32 (m, 1H), 3.68-3.95 (m, 4H), 4.04-4.20 (m, 2H), 4.27-4.37 (m, 1H), 6.97 (d, J = 8.44 Hz, 1H), 7.02 (s, 1H), 7.21 (d, J = 8.24 Hz, 1H), 9.73 (s, 1H)
582
580






F-543


embedded image


(400 MHz, CDCl3) 0.84-0.93 (m, 2H), 0.85 (d, J = 7.06 Hz, 6H), 0.99-1.05 (m, 1H), 1.08- 1.17 (m, 2H), 1.24-1.36 (m, 2H), 1.46-1.57 (m, 1H), 1.85- 2.14 (m, 6H), 2.30-2.51 (m, 3H), 2.70 (t, J = 7.50 Hz, 2H), 2.83-2.96 (m, 4H), 3.04-3.15 (m, 1H), 3.35-3.46 (m, 1H), 3.65-3.79 (m, 2H), 3.90-3.99 (m, 1H), 6.97 (d, J = 7.50 Hz, 1H), 7.07 (t, J = 7.72 Hz, 1H), 7.58 (d, J = 7.94 Hz, 1H), 7.99 (s, 1H)
451
449






F-544


embedded image


(400 MHz, CDCl3) 0.80-0.89 (m, 7H), 0.89-0.95 (m, 1H), 1.18-1.24 (m, 1H), 1.32-1.37 (m, 2H), 1.50-1.57 (m, 1H), 1.96-2.04 (m, 2H), 2.08 (s, 3H), 2.17 (s, 3H), 2.25-2.29 (m, 3H), 2.33-2.62 (m, 6H), 2.84-2.92 (m, 1H), 3.35-3.51 (m, 2H), 3.74-3.86 (m, 1H), 4.16-4.26 (m, 1H), 4.87 (brs, 1H), 6.84-7.03 (m, 4H), 7.41- 7.48 (m, 1H), 8.53 (brs, 1H)
468
466




















TABLE 293











Infor-


Exam-


MS
mation of












ple
Chemical structure
NMR
M + H
M − H
structure





F-545


embedded image


(400 MHz, CDCl3) 0.77- 0.92 (m, 8H), 0.91-1.01 (m, 1H), 1.08-1.20 (m, 2H), 1.21- 1.31 (m, 2H), 1.42-1.53 (m, 1H), 1.88-2.04 (m, 3H), 2.10 (s, 3H), 2.13-2.22 (m, 1H), 2.26 (s, 3H), 2.30-2.56 (m, 7H), 2.70-2.82 (m, 1H), 2.84- 2.95 (m, 1H), 3.33-3.47 (m, 1H), 3.90-4.16 (m, 2H), 6.91- 7.00 (brm, 1H), 7.42-7.51 (m, 1H), 8.47 (brs, 1H)
519
517
Racemic form (Stereo- chemistry of Hydroxyl group and Trifluoro- methyl group: Undeter- mined)





F-546


embedded image


(400 MHz, CDCl3) 0.85 (t, J = 5.73 Hz, 6H), 1.13-1.54 (m, 8H), 2.17- 2.42 (m, 10H), 3.18 (s, 1H), 3.40 (s, 1H), 3.67-3.74 (m, 3H), 4.11 (s, 1H), 7.29-7.42 (m, 2H), 7.63 (d, J = 7.94 Hz, 1H), 9.21 (s, 1H)
493
491






F-547


embedded image


(400 MHz CDCl3) 0.99- 1.01 (m, 7H), 1.22 (s, 1H), 1.41 (s, 2H), 2.08-2.11 (m, 1H), 2.19 (s, 3H), 2.25 (s, 3H), 2.74 (d, J = 7.06 Hz, 2H), 3.55 (s, 1H), 3.87-3.93 (m, 2H), 4.25 (s, 1H), 4.44-4.49 (m, 2H), 4.59 (s, 1H), 6.89 (s, 1H), 6.93- 6.95 (m, 2H), 7.41 (d, J = 7.72 Hz, 1H), 9.06 (s, 1H)
581
579






F-548


embedded image


(400 MHz, CDCl3) 0.87 (d, J = 35.73 Hz, 6H), 1.22-1.47 (m, 7H), 2.05-2.22 (m, 9H), 2.42-2.56 (m, 5H), 3.05 (d, J = 10.37 Hz, 1H), 3.42 (s, 1H), 3.59-3.63 (m, 1H), 3.75 (s, 2H), 4.16 (s, 1H), 6.62-6.65 (m, 1H), 6.75 (s, 1H), 8.94 (s, 1H)
457
455





















TABLE 294











Infor-






mation


Exam-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure





F-549


embedded image


(400 MHz, DMSO-D6) 0.87 (s, 9H), 0.97-1.24 (m, 4H), 1.36 (d, J = 6.48 Hz, 2H), 1.97-2.17 (m, 2H), 2.13 (s, 3H), 2.24 (s, 3H), 2.42-2.64 (m, 3H), 2.85-3.01 (m, 3H), 3.11-3.26 (m, 1H), 3.33-3.59 (m, 1H), 3.62-4.50 (m, 6H), 6.96 (d, J = 8.24 Hz, 1H), 7.02 (s, 1H), 7.20-7.27 (m, 1H), 9.83 (s, 0.4H), 9.91 (s, 0.6H), 10.95 (brs, 1H)
464
462






F-550


embedded image


(400 MHz, DMSO-D6) 0.87 (s, 9H), 1.00-1.26 (m, 4H), 1.36 (d, J = 6.68 Hz, 2H), 1.97-2.15 (m, 2H), 2.11 (s, 3H), 2.23 (s, 3H), 2.43-2.62 (m, 3H), 3.18- 3.28 (m, 1H), 3.66-3.81 (m, 3H), 3.81-3.93 (m, 1H), 4.03-4.14 (m, 2H), 4.20-4.32 (m, 1H), 6.96 (d, J = 8.44 Hz, 1H), 7.02 (s, 1H), 7.10-7.37 (m, 1H), 7.20 (d, J = 8.04 Hz, 1H), 9.69 (s, 1H)
564
562






F-551


embedded image


(400 MHz, DMSO-D6) 0.87 (s, 9H), 1.03-1.26 (m, 4H), 1.36 (d, J = 6.44 Hz, 2H), 1.98-2.18 (m, 5H), 2.24 (s, 3H), 2.44-2.63 (m, 3H), 3.20-3.32 (m, 1H), 3.60-3.94 (m, 4H), 3.99-4.32 (m, 3H), 6.44-6.81 (m, 1H), 6.96 (d, J = 8.24 Hz, 1H), 7.02 (s, 1H), 7.16-7.25 (m, 1H), 9.66-9.77 (m, 1H)
528
526




















TABLE 295











Infor-






mation


Exam-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure





F-552


embedded image


(400 MHz, DMSO-D6) 0.87 (s, 9H), 1.04-1.33 (m, 10H), 1.36 (d, J = 6.68 Hz, 2H), 2.00-2.16 (m, 2H), 2.11 (s, 3H), 2.23 (s, 3H), 2.43-2.62 (m, 3H), 3.19- 3.29 (m, 1H), 3.41-3.52 (m, 1H), 3.52-3.61 (m, 2H), 3.69-3.89 (m, 2H), 3.91-4.05 (m, 2H), 4.22 (q, J = 8.04 Hz, 1H), 6.95 (d, J = 8.24 Hz, 1H), 7.01 (s, 1H), 7.19 (d, J = 8.24 Hz, 1H), 9.67 (s, 1H)
556
554






F-553


embedded image


(400 MHz, DMSO-D6) 0.87 (s, 9H), 0.96-1.27 (m, 10H), 1.36 (d, J = 6.48 Hz, 2H), 1.98- 2.19 (m, 5H), 2.23 (s, 3H), 2.40-2.80 (m, 4H), 3.21-3.32 (m, 1H), 3.44-3.55 (m, 1H), 3.64-3.91 (m, 3H), 3.94-4.05 (m, 1H), 4.07-4.27 (m, 2H), 6.95 (d, J = 8.24 Hz, 1H), 7.01 (s, 1H), 7.13-7.26 ( m, 1H), 9.59- 9.73 (m, 1H)
520
518






F-554


embedded image


(400 MHz, CDCl3) 0.83-0.96 (m, 8H), 1.06-1.19 (m, 2H), 1.33-1.40 (m, 2H), 1.50-1.62 (m, 1H), 1.77-1.86 (m, 1H), 2.02-2.13 (m, 2H), 2.15 (s, 3H), 2.16-2.23 (m, 1H), 2.25 (s, 3H), 2.35-2.56 (m, 4H), 2.65-2.74 (m, 1H), 2.82-2.91 (m, 1H), 3.30 (s, 3H), 3.32- 3.47 (m, 2H), 3.91-4.09 (m, 2H), 6.90-6.99 (m, 2H), 7.76- 7.81 (m, 1H), 8.61 (brs, 1H)
405
403
Single isomer (Stereo- chemistry of Methoxy group: Undeter- mined) (Optical isomer of F-555)




















TABLE 296











Infor-






mation


Exam-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure





F-555


embedded image


(400 MHz, CDCl3) 0.84-0.99 (m, 8H), 1.02-1.20 (m, 2H), 1.32-1.40 (m, 2H), 1.48-1.61 (m, 1H), 1.77-1.87 (m, 1H), 1.99-2.17 (m, 5H), 2.18-2.23 (m, 1H), 2.26 (s, 3H), 2.35- 2.57 (m, 4H), 2.64-2.76 (m, 1H), 2.83-2.91 (m, 1H), 3.29 (s, 3H), 3.32-3.48 (m, 2H), 3.90-4.09 (m, 2H), 6.88-6.99 (m, 2H), 7.74-7.82 (m, 1H), 8.62 (brs, 1H)
465
463
Single isomer (Stereo- chemistry of Methoxy group: Undeter- mined) (Optical isomer of F-554)





F-556


embedded image


(400 MHz, CDCl3) 0.81-0.90 (m, 7H), 0.90-0.98 (m, 1H), 1.08-1.18 (m, 2H), 1.33-1.39 (m, 2H), 1.49-1.61 (m, 1H), 1.97-2.10 (m, 3H), 2.10-2.13 (m, 3H), 2.23-2.27 (m, 3H), 2.34-2.46 (m, 4H), 2.46-2.57 (m, 2H), 2.83-2.94 (m, 1H), 3.38 (s, 3H), 3.40-3.49 (m, 1H), 3.60-3.71 (m, 2H), 4.00- 4.08 (m, 1H), 6.90-6.99 (m, 2H), 7.74-7.81 (m, 1H), 8.43 (brs, 1H)
465
463
Single isomer (Stereo- chemistry of Methoxy group: Undeter- mined) (Optical isomer of F-557)





F-557


embedded image


(400 MHz, CDCl3) 0.82-0.90 (m, 7H), 0.90-0.98 (m, 1H), 1.08-1.16 (m, 2H), 1.32-1.39 (m, 2H), 1.49-1.62 (m, 1H), 1.93-2.10 (m, 3H), 2.12 (s, 3H), 2.25 (s, 3H), 2.35-2.45 (m, 4H), 2.45-2.54 (m, 2H), 2.85-2.94 (m, 1H), 3.38 (s, 3H), 3.40-3.49 (m, 1H), 3.58- 3.74 (m, 2H), 4.00-4.08 (m, 1H), 6.90-6.99 (m, 2H), 7.76- 7.83 (m, 1H), 8.44 (brs, 1H)
465
463
Single isomer (Stereo- chemistry of Methoxy group: Undeter- mined) (Optical isomer of F-556)




















TABLE 297











Infor-






mation


Exam-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure





F-558


embedded image


(400 MHz, CDCl3) 0.86 (d, J = 6.62 Hz, 6H), 1.11-1.22 (m, 2H), 1.19 (d, J = 5.95 Hz, 3H), 1.24 (d, J = 5.95 Hz, 3H), 1.33-1.40 (m, 4H), 1.51-1.58 (m, 1H), 2.13-2.27 (m, 2H), 2.21 (s, 3H), 2.24 (s, 3H), 2.45-2.58 (m, 3H), 3.18-3.32 (m, 2H), 3.50-3.61 (m, 1H), 3.90-4.00 (m, 1H), 4.13 (brs, 1H), 5.57-5.65 (m, 1H), 6.89- 6.97 (m, 2H), 7.27-7.32 (m, 1H), 8.85 (brs, 1H)
453
451






F-559


embedded image


(400 MHz, DMSO-D6) 0.86 (s, 9H), 1.04 (s, 2H), 1.15 (t, J = 8.58 Hz, 2H), 1.34 (d, J = 6.49 Hz, 2H), 1.97-2.05 (m, 1H), 2.09 (s, 3H), 2.23 (s, 3H), 3.16 (s, 1H), 3.54-3.86 (m, 9H), 3.99 (dt, J = 15.61, 6.15 Hz, 2H), 4.17 (q, J = 7.96 Hz, 1H), 4.68 (q, J = 10.20 Hz, 2H), 6.95 (d, J = 8.12 Hz, 1H), 7.01 (s, 1H), 7.19 (d, J = 8.12 Hz, 1H), 9.61 (s, 1H)
596
630 (Salt)






F-560


embedded image


(400 MHz, MeOH-D4) 0.88-0.92 (m, 7H), 1.16- 1.59 (m, 10H), 1.86- 2.13 (m, 4H), 2.10 (d, J = 6.40 Hz, 3H), 2.26 (s, 3H), 2.55-2.68 (m, 3H), 3.00-3.15 (m, 2H), 3.57-3.70 (m, 1H), 3.79-3.92 (m, 1H), 3.93-4.11 (m, 2H), 6.92-6.98 (m, 1H), 7.01-7.08 (m, 2H)
453
451




















TABLE 298











Infor-






mation


Exam-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure





F-561


embedded image


(400 MHz, DMSO-D6) 0.86 (s, 9H), 1.04-1.37 (m, 4H), 1.34 (d, J = 6.40 Hz, 2H), 1.81-2.08 (m, 4H), 2.05 (s, 3H), 2.22 (s, 3H), 2.44- 2.64 (m, 3H), 2.90-3.08 (m, 2H), 3.22-3.32 (m, 1H), 3.38-3.55 (m, 2H), 3.73-3.94 (m, 2H), 6.92 (d, J = 8.16 Hz, 1H), 6.98 (s, 1H), 7.09 (d, J = 8.16 Hz, 1H), 9.47 (brs, 1H)
453
451






F-562


embedded image


(400 MHz, CDCl3) 0.83-0.96 (m, 8H), 1.10-1.19 (m, 2H), 1.31-1.37 (m, 2H), 1.44 (s, 3H), 1.47-1.59 (m, 1H), 1.73- 1.83 (m, 1H), 2.02-2.17 (m, 6H), 2.24-2.33 (m, 4H), 2.36- 2.57 (m, 4H), 2.84-2.92 (m, 1H), 3.37-3.49 (m, 1H), 3.75- 3.85 (m, 1H), 4.05-4.14 (m, 2H), 6.92-7.00 (m, 2H), 7.61- 7.68 (m, 1H), 8.32-8.40 (m, 1H)
465
463
Single isomer (Stereo- chemistry of Hydroxyl group and Methyl group: Undeter- mined)







(Optical







isomer of







F-563)





F-563


embedded image


(400 MHz, CDCl3) 0.83-0.95 (m, 8H), 1.10-1.19 (m, 2H), 1.31-1.38 (m, 2H), 1.44 (s, 3H), 1.50-1.60 (m, 1H), 1.74- 1.83 (m, 1H), 2.02-2.17 (m, 4H), 2.23-2.33 (m, 6H), 2.33- 2.58 (m, 5H), 2.83-2.92 (m, 1H), 3.37-3.49 (m, 1H), 3.68- 3.84 (m, 1H), 3.97-4.14 (m, 2H), 6.93-7.00 (m, 2H), 7.63- 7.70 (m, 1H), 8.25-8.40 (m, 1H)
465
463
Single isomer (Stereo- chemistry of Hydroxyl group and Methyl group: Undeter- mined)







(Optical







isomer of







F-562)




















TABLE 299











Infor-






mation


Exam-


MS
of












ple
Chemical structure
NMR
M + H
M − H
structure





F-564


embedded image


(400 MHz, CDCl3) 0.78-0.88 (m, 9H), 0.88-0.97 (m, 1H), 1.06-1.20 (m, 2H), 1.24-1.32 (m, 2H), 1.45 (s, 3H), 1.46- 1.55 (m, 1H), 1.96-2.07 (m, 4H), 2.09-2.16 (m, 3H), 2.24-2.27 (m, 2H), 2.29-2.50 (m, 4H), 2.84-2.93 (m, 1H), 3.33-3.45 (m, 1H), 3.92-4.04 (m, 2H), 4.44-4.66 (m, 1H), 6.92-7.01 (m, 2H), 7.52-7.60 (m, 1H), 8.15-8.30 (m, 1H)
465
463
Single isomer (Stereo- chemistry of Hydroxyl group and Methyl group: Undeter- mined)







(Optical







isomer of







F-565)





F-565


embedded image


(400 MHz, CDCl3) 0.79-0.88 (m, 8H), 0.88-0.95 (m, 1H), 1.06-1.20 (m, 2H), 1.24- 1.30 (m, 2H), 1.45 (s, 3H), 1.47-1.54 (m, 1H), 1.97-2.06 (m, 2H), 2.12-2.20 (m, 4H), 2.26 (s, 3H), 2.28-2.54 (m, 6H), 2.84-2.92 (m, 1H), 3.34-3.46 (m, 1H), 3.89-4.05 (m, 1H), 4.34-4.61 (m, 1H), 6.92-7.00 (m, 2H), 7.53-7.59 (m, 1H), 8.09-8.22 (m, 1H)
465
463
Single isomer (Stereo- chemistry of Hydroxyl group and Methyl group: Undeter- mined)







(Optical







isomer of







F-564)





F-566


embedded image


(400 MHz, CDCl3) 0.79-0.84 (m, 7H), 1.12-1.19 (m, 3H), 1.29 (dd, J = 12.57, 5.73 Hz, 2H), 1.51 (td, J = 13.34, 6.69 Hz, 1H), 1.94-2.04 (m, 7H), 2.25 (s, 3H), 2.33-2.72 (m, 3H), 2.94 (dq, J = 18.69, 4.63 Hz, 2H), 3.16 (dt, J = 18.38, 6.89 Hz, 1H), 3.39 (dd, J = 17.20, 7.94 Hz, 1H), 4.11 (d, J = 5.51 Hz, 1H), 6.92 (d, J = 9.26 Hz, 2H), 7.25-7.28 (m, 2H)
477
475




















TABLE 300











Infor-





MS
mation












Ex-


M +
M −
of


ample
Chemical structure
NMR
H
H
structure





F-567


embedded image


(400 MHz, CDCl3) 0.77 (dd, J = 10.03, 4.74 Hz, 1H), 1.00 (t, J = 4.74 Hz, 6H), 1.27 (dd, J = 10.92, 5.84 Hz, 4H), 2.06-2.14 (m, 5H), 2.25 (s, 3H), 2.71 (d, J = 7.06 Hz, 2H), 3.00 (dd, J = 14.67, 4.74 Hz, 1H), 3.21-3.33 (m, 2H), 4.26 (d, J = 5.29 Hz, 1H), 6.55 (s, 1H), 6.94 (d, J = 6.62 Hz, 2H), 7.15 (s, 1H), 7.32 (t, J = 10.48 Hz, 1H)
490
488






F-568


embedded image


(400 MHz, DMSO-D6) 1.00-1.01 (m, 6H), 1.10 (d, J = 11.25 Hz, 1H), 1.33 (t, J = 7.06 Hz, 2H), 1.45 (t, J = 6.95 Hz, 3H), 1.64-1.70 (m, 1H), 2.09 (ddd, J = 30.32, 13.67, 7.94 Hz, 5H), 2.36 (d, J = 6.18 Hz, 3H), 2.60-2.62 (m, 4H), 3.05 (tt, J = 24.59, 8.23 Hz, 1H), 3.25 (dd, J = 15.77, 9.37 Hz, 1H), 3.34 (s, 1H), 3.87 (t, J = 8.60 Hz, 1H), 4.12-4.19 (m, 1H), 7.07 (d, J = 8.38 Hz, 1H), 7.13 (s, 1H), 7.24 (d, J = 8.16 Hz, 1H), 9.62 (s, 1H)
477
475






F-569


embedded image


(400 MHz, CDCl3) 0.93-0.98 (m, 1H), 1.01 (d, J = 6.62 Hz, 6H), 1.24 (dt, J = 19.41, 6.01 Hz, 6H), 2.12 (dd, J = 13.34, 6.73 Hz, 1H), 2.20 (s, 3H), 2.26 (s, 3H), 2.72 (d, J = 7.06 Hz, 2H), 3.23 (dd, J = 13.78, 4.96 Hz, 1H), 3.41 (dt, J = 13.82, 4.36 Hz, 2H), 3.63-3.69 (m, 1H), 3.77 (dt, J = 15.59, 7.00 Hz, 1H), 5.29 (dd, J = 8.38, 5.07 Hz, 1H), 6.60 (s, 1H), 6.97 (t, J = 7.17 Hz, 2H), 7.61 (d, J = 8.82 Hz, 1H), 8.07 (s, 1H)
452
450




















TABLE 301











Infor-





MS
mation












Ex-


M +
M −
of


ample
Chemical structure
NMR
H
H
structure





F-570


embedded image


(400 MHz, CDCl3) 0.85-0.88 (m, 1H), 1.01 (d, J = 6.62 Hz, 6H), 1.08 (d, J = 6.62 Hz, 1H), 1.33 (d, J = 7.50 Hz, 2H), 2.04-2.16 (m, 4H), 2.25 (s, 3H), 2.46 (t, J = 13.12 Hz, 1H), 2.72-2.87 (m, 5H), 3.36 (t, J = 3.64 Hz, 1H), 3.97- 4.02 (m, 1H), 4.20-4.25 (m, 1H), 6.61 (s, 1H), 6.94-6.95 (m, 2H), 7.62 (d, J = 8.82 Hz, 1H), 8.62 (s, 1H)
484
482
Racemic form





F-571


embedded image


(400 MHz, CDCl3) 0.85 (d, J = 23.82 Hz, 6H), 1.09 (s, 1H), 1.30- 1.37 (m, 5H), 1.51-1.54 (m, 1H), 2.17 (s, 3H), 2.20-2.24 (m, 4H), 2.30 (d, J = 9.70 Hz, 1H), 2.46 (s, 1H), 2.58 (s, 3H), 2.80-2.83 (m, 3H), 3.29 (s, 1H), 3.62 (t, J = 10.00 Hz, 1H), 4.14 (q, J = 9.26 Hz, 1H), 4.24 (s, 1H), 6.92- 6.93 (m, 2H), 7.39 (d, J = 7.94 Hz, 1H), 8.97 (s, 1H)
471
469






F-572


embedded image


(400 MHz, CDCl3) 0.85 (d, J = 6.62 Hz, 6H), 1.11 (s, 1H), 1.30- 1.38 (m, 5H), 1.51-1.54 (m, 1H), 2.18-2.35 (m, 8H), 2.44-2.58 (m, 4H), 2.76-2.89 (m, 3H), 3.33 (s, 1H), 3.63 (t, J = 8.05 Hz, 1H), 4.15- 4.24 (m, 2H), 6.91-6.93 (m, 2H), 7.36 (t, J = 6.29 Hz, 1H), 9.09 (s, 1H)
471
469




















TABLE 302











Infor-





MS
mation












Ex-


M +
M −
of


ample
Chemical structure
NMR
H
H
structure





F-573


embedded image


(400 MHz, CDCl3) 0.91 (tt, J = 12.79, 4.52 Hz, 6H), 1.00-1.02 (m, 6H), 1.26 (dt, J = 13.45, 4.96 Hz, 2H), 1.85 (td, J = 13.34, 6.54 Hz, 2H), 2.12 (dd, J = 13.56, 6.73 Hz, 2H), 2.19 (s, 3H), 2.25 (s, 3H), 2.73 (d, J = 7.06 Hz, 2H), 3.22 (dd, J = 13.78, 4.74 Hz, 1H), 3.42 (dtd, J = 31.91, 11.83, 6.47 Hz, 4H), 5.29 (dd, J = 8.71, 4.74 Hz, 1H), 6.62 (d, J = 10.37 Hz, 1H), 6.97 (t, J = 8.49 Hz, 2H), 7.59 (t, J = 4.30 Hz, 1H), 8.10 (d, J = 10.37 Hz, 1H)
480
478






F-574


embedded image


(400 MHz, CDCl3) 0.85-1.60 (m, 8H), 0.85 (d, J = 6.40 Hz, 6H), 1.20 (d, J = 5.07 Hz, 3H), 1.83-2.12 (m, 4H), 2.07 (d, J = 18.53 Hz, 3H), 2.25 (d, J = 2.21 Hz, 3H), 2.37-2.50 (m, 3H), 2.79-2.95 (m, 2H), 3.01- 3.14 (m, 1H), 3.36-3.46 (m, 1H), 3.54-4.05 (m, 2H), 6.91-6.96 (m, 2H), 7.38-7.52 (m, 2H), 7.83 (s, 1H)
453
451






F-575


embedded image


(400 MHz, MeOH-D4) 1.02 (d, J = 6.62 Hz, 6H), 1.11-1.26 (m, 2H), 1.24 (d, J = 6.18 Hz, 3H), 1.28- 1.36 (m, 2H), 1.30 (d, J = 6.18 Hz, 3H), 2.07-2.19 (m, 1H), 2.18 (s, 3H), 2.28 (s, 3H), 2.82 (d, J = 7.06 Hz, 2H), 3.21-3.26 (m, 2H), 3.63-3.69 (m, 1H), 3.89- 3.99 (m, 1H), 5.60 (t, J = 5.95 Hz, 1H), 6.75-6.81 (m, 1H), 6.98 (d, J = 8.16 Hz, 1H), 7.05 (s, 1H), 7.12 (d, J = 7.94 Hz, 1H)
466
464




















TABLE 303











Infor-





MS
mation












Ex-


M +
M −
of


ample
Chemical structure
NMR
H
H
structure





F-576


embedded image


(400 MHz, MeOH-D4) 1.02 (d, J = 6.62 Hz, 6H), 1.12-1.38 (m, 4H), 1.24 (d, J = 5.95 Hz, 3H), 1.30 (d, J = 5.95 Hz, 3H), 2.08-2.16 (m, 1H), 2.23 (s, 3H), 2.82 (d, J = 7.06 Hz, 2H), 3.21-3.26 (m, 2H), 3.57-3.69 (m, 1H), 3.86- 3.99 (m, 1H), 5.60 (t, J = 5.95 Hz, 1H), 6.79 (s, 1H), 6.90 (td, J = 8.38, 2.72 Hz, 1H), 6.99 (dd, J = 9.81, 2.76 Hz, 1H), 7.24 (dd, J = 8.71, 5.62 Hz, 1H)
470
468






F-577


embedded image


(400 MHz, DMSO-D6) 0.81-0.97 (m, 2H), 0.95 (d, J = 6.62 Hz, 6H), 1.13-1.24 (m, 2H), 1.99-2.06 (m, 1H), 2.00 (d, J = 13.01 Hz, 3H), 2.06 (s, 3H), 2.23 (s, 3H), 2.62 (d, J = 7.06 Hz, 2H), 3.41-3.52 (m, 2H), 3.65-3.93 (m, 2H), 3.97- 4.25 (m, 3H), 4.95 (brs, 1H), 6.94 (d, J = 8.16 Hz, 1H), 7.00 (s, 1H), 7.05 (d, J = 3.97 Hz, 1H), 7.20 (dd, J = 11.36, 8.05 Hz, 1H), 9.58 (d, J = 7.50 Hz, 1H)
491
489






F-578


embedded image


(400 MHz, CDCl3) 0.35-0.53 (m, 2H), 0.77-0.92 (m, 2H), 0.87 (d, J = 6.68 Hz, 6H), 1.29-1.44 (m, 3H), 1.48-1.61 (m, 1H), 1.86- 2.45 (m, 8H), 2.08 (s, 3H), 2.26 (s, 3H), 2.81 (dd, J = 14.24, 6.80 Hz, 1H), 2.99 (dd, J = 14.24, 8.68 Hz, 1H), 3.43-3.57 (m, 1H), 3.65- 3.82 (m, 3H), 6.93-7.04 (m, 2H), 7.40 (s, 1H), 7.51 (d, J = 8.68 Hz, 1H)
439
437




















TABLE 304











Infor-






mation


Ex-


MS
of












ample
Chemical structure
NMR
M + H
M − H
structure





F-579


embedded image


(400 MHz, CDCl3) 0.33-0.51 (m, 2H), 0.77-0.96 (m, 2H), 0.88 (d, J = 6.44 Hz, 6H), 1.31-1.47 (m, 3H), 1.50-1.68 (m, 1H), 1.87- 2.63 (m, 8H), 2.09 (s, 3H), 2.26 (s, 3H), 2.82 (dd, J = 14.24. 5.64 Hz, 1H), 3.01 (dd, J = 14.24, 8.92 Hz, 1H), 3.58-3.83 (m, 4H), 6.92- 7.04 (m, 2H), 7.42 (s, 1H), 7.52 (d, J = 8.24 Hz, 1H)
439
437






F-580


embedded image


(400 MHz, CDCl3) 0.35-0.52 (m, 2H), 0.78-0.93 (m, 8H), 1.30- 1.46 (m, 3H), 1.49-1.68 (m, 1H), 1.85-2.65 (m, 11H), 2.26 (s, 3H), 2.75-2.88 (m, 1H), 2.94-3.08 (m, 1H), 3.45-3.56 (m, 0.5H), 3.59- 3.83 (m, 3.5H), 6.93-7.04 (m, 2H), 7.35-7.46 (m, 1H), 7.48-7.57 (m, 1H)
439
437
Mixtures of four stereo- isomers





F-581


embedded image


(400 MHz, CDCl3) 0.86 (d, J = 6.62 Hz, 6H), 0.89-0.95 (m, 4H), 0.95-1.08 (m, 1H), 1.34 (t, J = 7.06 Hz, 2H), 1.47-1.58 (m, 1H), 1.99-2.11 (m, 2H), 2.14 (s, 3H), 2.25 (s, 3H), 2.31-2.55 (m, 3H), 2.77-2.87 (m, 1H), 3.28 (dd, J = 13.56, 4.52 Hz, 1H), 3.35-3.53 (m, 2H), 4.62 (d, J = 11.47 Hz, 1H), 4.72 (d, J = 11.47 Hz, 1H), 5.28 (dd, J = 8.71, 4.52 Hz, 1H), 6.90-6.99 (m, 2H), 7.27-7.35 (m, 5H), 7.59 (d, J = 8.82 Hz, 1H), 8.40 (brs, 1H)
501
499




















TABLE 305











Infor-





MS
mation












Ex-


M +
M −
of


ample
Chemical structure
NMR
H
H
structure





F-582


embedded image


(400 MHz, CDCl3) 0.78-1.05 (m, 14H), 1.13 (ddd, J = 15.93, 8.99, 4.91 Hz, 2H), 1.35 (q, J = 7.20 Hz, 2H), 1.51 (tt, J = 17.97, 6.32 Hz, 1H), 1.76-1.86 (m, 1H), 2.01- 2.16 (m, 5H), 2.25 (s, 3H), 2.36- 2.53 (m, 3H), 2.96-3.01 (m, 1H), 3.15 (dt, J = 18.01, 6.23 Hz, 1H), 3.29-3.33 (m, 1H), 3.37-3.52 (m, 3H), 5.11 (dd, J = 9.04, 4.41 Hz, 1H), 6.96 (t, J = 10.14 Hz, 2H), 7.53- 7.57 (m, 1H), 8.50 (s, 1H)
467
465






F-583


embedded image


(400 MHz, CDCl3) 0.74-0.81 (m, 1H), 0.82-0.88 (m, 7H), 1.07- 1.16 (m, 2H), 1.27-1.35 (m, 2H), 1.47-1.58 (m, 2H), 1.85-1.94 (m, 2H), 1.98-2.02 (m, 3H), 2.02- 2.12 (m, 1H), 2.21-2.24 (m, 4H), 2.31-2.35 (m, 4H), 2.35-2.52 (m, 2H), 2.80-2.88 (m, 1H), 2.93- 3.06 (m, 4H), 3.32-3.43 (m, 1H), 3.58-3.70 (m, 1H), 6.86-6.94 (m, 2H), 7.31-7.36 (m, 1H), 7.43- 7.50 (m, 1H)
464
462
Racemic form





F-584


embedded image


(400 MHz, DMSO-D6) 0.73-0.80 (m, 1H), 0.95 (d, J = 6.72 Hz, 6H), 1.07-1.26 (m, 9H), 1.96-2.13 (m, 1H), 2.76 (d, J = 7.19 Hz, 2H), 3.14- 3.29 (m, 2H), 3.44-3.48 (m, 1H), 3.72-3.81 (m, 1H), 5.40 (t, J = 6.84 Hz, 1H), 6.80 (s, 1H), 7.12- 7.17 (m, 2H), 7.41-7.47 (m, 1H), 10.39 (s, 1H)
518
516




















TABLE 306











Infor-





MS
mation












Ex-


M +
M −
of


ample
Chemical structure
NMR
H
H
structure





F-585


embedded image


(400 MHz, DMSO-D6) 0.71-0.81 (m, 1H), 0.95 (d, J = 6.49 Hz, 6H), 1.05-1.26 (m, 9H), 2.76 (d, J = 6.96 Hz, 2H), 3.15 (d, J = 6.96 Hz, 2H), 3.43-3.50 (m, 1H), 3.73- 3.79 (m, 1H), 5.40 (t, J = 7.07 Hz, 1H), 6.79 (s, 1H), 7.23 (dd, J = 8.70, 1.97 Hz, 1H), 7.34 (d, J = 8.81 Hz, 1H), 7.74 (d, J = 2.09 Hz, 1H), 10.41 (s, 1H)
518
516






F-586


embedded image


(400 MHz, CDCl3) 0.69-0.74 (m, 1H), 1.00 (dt, J = 17.64, 7.94 Hz, 13H), 1.23-1.30 (m, 3H), 1.65- 1.67 (m, 2H), 2.07-2.13 (m, 4H), 2.24 (s, 3H), 2.71 (d, J = 7.06 Hz, 2H), 2.88 (dd, J = 14.11, 3.97 Hz, 1H), 3.14 (dd, J = 13.89, 10.81 Hz, 1H), 3.25-3.31 (m, 1H), 3.91 (dd, J = 10.70, 4.08 Hz, 1H), 6.55 (s, 1H), 6.93 (d, J = 5.73 Hz, 2H), 7.42 (d, J = 8.60 Hz, 1H), 7.54 (d, J = 10.37 Hz, 1H)
464
462






F-587


embedded image


(400 MHz, DMSO-D6) 1.02-1.34 (m, 4H), 1.78-1.98 (m, 2H), 2.05 (s, 3H), 2.11-2.48 (m, 2H), 2.22 (s, 3H), 2.28 (d, J = 5.29 Hz, 2H), 2.54-2.74 (m, 3H), 2.90-3.08 (m, 2H), 3.21-3.31 (m, 1H), 3.33- 3.54 (m, 2H), 3.73-3.94 (m, 2H), 6.92 (d, J = 8.60 Hz, 1H), 6.98 (s, 1H), 7.10 (d, J = 8.60 Hz, 1H), 9.46 (brs, 1H)
465
463






F-588


embedded image


(400 MHz, DMSO-D6) 0.78-1.35 (m, 4H), 1.76-2.74 (m, 9H), 2.10 (s, 3H), 2.88-3.09 (m, 2H), 3.12- 4.20 (m, 5H), 6.90-7.38 (m, 3H), 9.57 (brs, 1H)
469
467




















TABLE 307











Infor-





MS
mation












Ex-


M +
M −
of


ample
Chemical structure
NMR
H
H
structure





F-589


embedded image


(400 MHz, DMSO-D6) 0.77-1.35 (m, 4H), 1.77-2.76 (m, 9H), 2.06 (s, 3H), 2.90-3.11 (m, 2H), 3.21- 3.56 (m, 3H), 3.73-4.45 (m, 2H), 6.59-7.31 (m, 3H), 9.77 (s, 1H)
469
467






F-590


embedded image


(400 MHz, CDCl3) 0.86 (d, J = 6.62 Hz, 6H), 0.95-1.73 (m, 17H), 1.97-2.09 (m, 5H), 2.24 (s, 3H), 2.33-2.51 (m, 3H), 2.77- 2.88 (m, 2H), 3.04 (ddd, J = 15.77, 8.82, 4.85 Hz, 1H), 3.36-3.45 (m, 1H), 3.73 (dd, J = 10.92, 4.08 Hz, 1H), 6.92 (d, J = 7.06 Hz, 2H), 7.38 (t, J = 6.06 Hz, 1H), 7.70 (s, 1H)
451
449






F-591


embedded image


(400 MHz, CDCl3) 0.71 (brs, 1H), 1.00 (t, J = 1.98 Hz, 12H), 1.24 (brs, 4H), 1.65 (d, J = 17.42 Hz, 2H), 2.00-2.09 (m, 4H), 2.25 (s, 3H), 2.63 (dd, J = 7.06, 1.32 Hz, 2H), 2.89 (dd, J = 14.11, 3.31 Hz, 1H), 3.13 (t, J = 12.46 Hz, 1H), 3.33 (brs, 1H), 3.90 (brs, 1H), 6.70 (s, 1H), 6.94 (d, J = 6.18 Hz, 2H), 7.41 (t, J = 10.59 Hz, 2H)
464
462






F-592


embedded image


(400 MHz, CDCl3) 0.99-1.01 (m, 7H), 1.23 (s, 1H), 1.41 (d, J = 7.50 Hz, 2H), 2.07-2.14 (m, 1H), 2.21 (s, 3H), 2.71-2.74 (m, 4H), 2.93 (s, 2H), 3.53 (s, 1H), 4.28 (q, J = 8.16 Hz, 1H), 4.44 (q, J = 9.92 Hz, 1H), 6.69 (s, 1H), 6.79- 6.86 (m, 2H), 7.49 (dd, J = 8.71, 5.40 Hz, 1H), 9.14 (s, 1H)
488
486




















TABLE 308











Infor-






mation


Ex-


MS
of












ample
Chemical structure
NMR
M + H
M − H
structure





F-593


embedded image


(400 MHz, CDCl3) 1.02-1.06 (m, 7H), 1.24 (s, 1H), 1.42 (d, J = 7.50 Hz, 2H), 2.07-2.14 (m, 1H), 2.20 (d, J = 3.31 Hz, 3H), 2.73- 2.75 (m, 4H), 2.87-2.95 (m, 2H), 3.55 (s, 1H), 4.32 (q, J = 9.59 Hz, 1H), 4.46 (q, J = 9.92 Hz, 1H), 6.70 (s, 1H), 6.80-6.84 (m, 2H), 7.47 (dd, J = 8.71, 5.40 Hz, 1H), 9.16 (s, 1H)
488
486






F-594


embedded image


(400 MHz, CDCl3) 0.85-0.88 (m, 7H), 1.09-1.61 (m, 7H), 2.03- 2.19 (m, 7H), 2.32-2.62 (m, 4H), 3.01-3.09 (m, 1H), 3.33-3.60 (m, 1H), 3.77-3.80 (m, 2H), 4.14 (s, 1H), 6.77-6.89 (m, 3H), 8.99 (d, J = 12.35 Hz, 1H)
443
441






F-595


embedded image


(400 MHz, DMSO-D6) 0.61-0.67 (m, 1H), 0.90 (dt, J = 21.80, 7.88 Hz, 12H), 1.07-1.17 (m, 3H), 1.54-1.61 (m, 2H), 1.64-1.72 (m, 1H), 1.99-2.06 (m, 4H), 2.20 (s, 3H), 2.79 (dt, J = 22.03, 7.77 Hz, 3H), 2.97 (dd, J = 15.19, 9.16 Hz, 1H), 3.38 (ddd, J = 14.32, 7.13, 3.77 Hz, 2H), 3.77 (t, J = 7.54 Hz, 1H), 4.29 (s, 1H), 6.77 (s, 1H), 6.90 (d, J = 8.35 Hz, 1H), 6.95 (s, 1H), 7.09 (d, J = 8.12 Hz, 1H), 9.36 (s, 1H)
464
462




















TABLE 309











Infor-





MS
mation












Ex-


M +
M −
of


ample
Chemical structure
NMR
H
H
structure





F-596


embedded image


(400 MHz, CDCl3) 0.81-0.89 (m, 8H), 1.07-1.19 (m, 8H), 1.23- 1.32 (m, 1H), 1.35-1.43 (m, 1H), 2.20-2.25 (m, 4H), 2.25-2.28 (m, 3H), 2.39-2.52 (m, 1H), 2.52- 2.65 (m, 3H), 3.07-3.16 (m, 3H), 3.52-3.60 (m, 1H), 3 63-3.73 (m, 1H), 4.05-4.16 (m, 1H), 4.31- 4.43 (m, 1H), 4.61-4.76 (m, 2H), 4.79-4.97 (m, 2H), 6.87-6.98 (m, 3H), 7.29-7.33 (m, 1H), 10.17 (brs, 1H)
492
490






F-597


embedded image


(400 MHz, CDCl3) 0.78-0.89 (m, 12H), 1.16-1.30 (m, 1H), 1.46- 1.57 (m, 3H), 2.11-2.23 (m, 4H), 2.23-2.29 (m, 3H), 2.37-2.63 (m, 4H), 3.29-3.43 (m, 1H), 3.52- 3.75 (m, 4H), 4.13-4.31 (m, 2H), 4.47-4.60 (m, 4H), 4.80-4.90 (m, 1H), 6.85-6.97 (m, 3H), 7.28- 7.31 (m, 1H), 10.19 (brs, 1H), 12.22-12.44 (m, 1H)
478
476






F-598


embedded image


(400 MHz, DMSO-D6) 0.85 (d, J = 6.68 Hz, 6H), 1.06-1.35 (m, 12H), 1.35-1.58 (m, 2H), 1.77- 2.08 (m, 4H), 2.04 (s, 3H), 2.22 (s, 3H), 2.37-2.63 (m, 3H), 2.94- 4.00 (m, 5H), 6.92 (d, J = 8.00 Hz, 1H), 6.98 (s, 1H), 7.08 (d, J = 8.00 Hz, 1H), 9.49 (s, 1H)
467
465






F-599


embedded image


(400 MHz, DMSO-D6) 0.85 (d, J = 6.68 Hz, 6H), 1.06-1.35 (m, 12H), 1.38-1.58 (m, 2H), 1.77- 2.08 (m, 4H), 2.04 (s, 3H), 2.22 (s, 3H), 2.37-2.63 (m, 3H), 2.94- 4.00 (m, 5H), 6.92 (d, J = 8.00 Hz, 1H), 6.98 (s, 1H), 7.08 (d, J = 8.00 Hz, 1H), 9.49 (s, 1H)
467
465




















TABLE 310











Infor-





MS
mation












Ex-


M +
M −
of


ample
Chemical structure
NMR
H
H
structure





F-600


embedded image


(400 MHz, DMSO-D6) 0.85 (d, J = 6.80 Hz, 6H), 1.08-1.23 (m, 4H), 1.31 (t, J = 7.19 Hz, 2H), 1.42- 1.55 (m, 2H), 1.97-2.07 (m, 4H), 2.13-2.15 (m, 3H), 2.41-2.54 (m, 3H), 3.24-4.20 (m, 10H), 6.95- 7.01 (m, 1H), 7.08 (dd, J = 9.62, 2.90 Hz, 1H), 7.28-7.34 (m, 1H), 9.74 (d, J = 12.29 Hz, 1H)
482
480






F-601


embedded image


(400 MHz, DMSO-D6) 0.84 (dt, J = 16.47, 6.29 Hz, 8H), 0.92 (dd, J = 9.04, 5.95 Hz, 6H), 1.02 (dd, J = 7.50, 4.63 Hz, 1H), 1.17-1.25 (m, 3H), 1.32 (t, J = 7.06 Hz, 3H), 1.42-1.70 (m, 3H), 1.93-1.96 (m, 1H), 2.06 (s, 3H), 2.21 (s, 3H), 2.45-2.53 (m, 2H), 2.95 (ddd, J = 27.35, 15.77, 7.28 Hz, 2H), 3.31- 3.38 (brm, 2H), 3.76 (t, J = 8.27 Hz, 2H), 6.92 (d, J = 8.16 Hz, 1H), 6.99 (d, J = 11.91 Hz, 1H), 7.10 (d, J = 7.94 Hz, 1H), 9.44 (s, 1H)
451
449






F-602


embedded image


(400 MHz, CDCl3) 0.84-0.91 (m, 10H), 1.09-1.18 (m, 2H), 1.21- 1.30 (m, 4H), 1.41-1.57 (m, 2H), 1.56-1.68 (m, 2H), 2.05-2.18 (m, 7H), 2.18-2.33 (m, 6H), 2.91- 3.05 (m, 1H), 3.18-3.35 (m, 2H), 3.58-3.66 (m, 1H), 3.73-3.89 (m, 1H), 3.97-4.24 (m, 2H), 6.88- 6.98 (m, 2H), 7.19-7.25 (m, 1H), 8.50-8.64 (m, 1H)
479
477




















TABLE 311











Infor-





MS
mation












Ex-


M +
M −
of


ample
Chemical structure
NMR
H
H
structure





F-603


embedded image


(400 MHz, DMSO-D6) 0.85 (d, J = 6.80 Hz, 6H), 1.05-1.23 (m, 4H), 1.30 (t, J = 6.84 Hz, 2H), 1.49- 1.55 (m, 2H), 1.97-2.07 (m, 4H), 2.14-2.15 (m, 3H), 2.41-2.55 (m, 3H), 3.20-4.17 (m, 9H), 7.21 (dd, J = 8.46, 2.67 Hz, 1H), 7.29 (s, 1H), 7.40 (dd, J = 13.33, 8.46 Hz, 1H), 9.74 (d, J = 10.44 Hz, 1H)
498
496






F-604


embedded image


(400 MHz, DMSO-D6) 0.84 (d, J = 6.40 Hz, 6H), 1.04-1.17 (m, 4H), 1.29 (t, J = 6.72 Hz, 2H), 1.48- 1.55 (m, 2H), 1.97-1.99 (m, 4H), 2.32-2.50 (m, 3H), 3.17-4.17 (m, 9H), 7.25 (d, J = 8.58 Hz, 1H), 7.47- 7.51 (m, 1H), 7.66-7.94 (m, 1H), 10.21 (d, J = 16.70 Hz, 1H)
502
500






F-605


embedded image


(400 MHz, DMSO-D6) 0.66 (t, J = 5.29 Hz, 1H), 0.95 (d, J = 6.62 Hz, 6H), 1.09-1.19 (m, 5H), 1.98 (s, 3H), 2.06 (td, J = 13.56, 6.84 Hz, 2H), 2.20 (d, J = 4.85 Hz, 3H), 2.76 (d, J = 7.06 Hz, 2H), 2.89 (tt, J = 22.39, 8.34 Hz, 3H), 3.14 (dd, J = 15.77, 9.37 Hz, 1H), 3.39 (dt, J = 12.28, 4.52 Hz, 1H), 4.03 (q, J = 7.13 Hz, 1H), 6.91 (d, J = 8.16 Hz, 1H), 6.96 (s, 1H), 7.08 (d, J = 7.94 Hz, 1H), 9.44 (s, 1H)
490
488






F-606


embedded image


(400 MHz, CDCl3) 0.98-1.05 (m, 14H), 1.42 (s, 2H), 1.68-1.70 (m, 3H), 2.10 (q, J = 6.73 Hz, 1H), 2.25 (s, 3H), 2.75 (d, J = 7.06 Hz, 2H), 3.19 (d, J = 10.00 Hz, 1H), 3.48 (s, 1H), 4.15 (s, 2H), 6.60 (s, 1H), 7.06 (d, J = 8.60 Hz, 1H), 7.11 (d, J = 2.43 Hz, 1H), 7.43 (d, J = 8.60 Hz, 1H), 8.92 (s, 1H)
484
482




















TABLE 312











Infor-





MS
mation












Ex-


M +
M −
of


ample
Chemical structure
NMR
H
H
structure





F-607


embedded image


(400 MHz, CDCl3) 0.92-1.01 (m, 14H), 1.43 (t, J = 3.20 Hz, 2H), 1.69- 1.78 (m, 3H), 2.07-2.14 (m, 1H), 2.24 (s, 3H), 2.75 (d, J = 7.06 Hz, 2H), 3.18 (d, J = 7.00 Hz, 1H), 3.50 (s, 1H), 4.17-4.19 (m, 2H), 6.61 (s, 1H), 6.76-6.85 (m, 2H), 7.35- 7.37 (m, 1H), 8.94 (s, 1H)
468
466






F-608


embedded image


(400 MHz, CDCl3) 0.92-1.05 (m, 1H), 1.02 (s, 9H), 1.32-1.49 (m, 2H), 1.55-1.65 (m, 1H), 2.15- 2.34 (m, 2H), 2.26 (s, 3H), 2.75 (s, 2H), 3.03-3.14 (m, 1H), 3.55- 3.66 (m, 1H), 3.76-3.91 (m, 2H), 4.13-4.25 (m, 1H), 4.27-4.39 (m, 1H), 6.61 (s, 1H), 7.08 (d, J = 8.68, 2.44 Hz, 1H), 7.13 (d, J = 2.20 Hz, 1H), 7.48 (d, J = 8.68 Hz, 1H), 8.61 (s, 1H)
486
484






F-609


embedded image


(400 MHz, CDCl3) 0.86 (d, J = 6.62 Hz, 6H), 1.20-1.46 (m, 6H), 1.50-1.57 (m, 1H), 2.19- 2.36 (m, 2H), 2.21 (s, 3H), 2.24 (s, 3H), 2.41-2.54 (m, 1H), 2.54- 2.67 (m, 2H), 3.37-3.47 (m, 2H), 3.58-3.68 (m, 1H), 3.93-4.03 (m, 1H), 4.06-4.16 (m, 2H), 5.72- 5.78 (m, 1H), 6.88-6.96 (m, 2H), 7.24-7.29 (m, 1H), 8.88 (brs, 1H)
493
491




















TABLE 313











Infor-





MS
mation












Ex-


M +
M −
of


ample
Chemical structure
NMR
H
H
structure





F-610


embedded image


(400 MHz, CDCl3) 1.00-1.09 (m, 2H), 1.12-1.23 (m, 2H), 1.57- 1.68 (m, 2H), 1.73-1.84 (m, 4H), 1.88-1.96 (m, 2H), 1.97-2.03 (m, 3H), 2.13-2.18 (m, 3H), 2.18- 2.25 (m, 1H), 2.27-2.36 (m, 2H), 3.15-3.23 (m, 2H), 3.59-3.93 (m, 4H), 3.96-4.10 (m, 2H), 4.10- 4.20 (m, 1H), 7.17-7.24 (m, 1H), 7.31 (brs, 1H), 7.37-7.46 (m, 1H), 9.69-9.77 (m, 1H)
546
544






F-611


embedded image


(400 MHz, DMSO-D6) 1.08-1.32 (m, 11H), 1.77 (dd, J = 20.29, 5.07 Hz, 2H), 1.94-2.05 (m, 4H), 2.13-2.22 (m, 6H), 2.57-2.59 (brm, 1H), 3.27 (brs, 1H), 3.48 (dd, J = 19.41, 9.26 Hz, 1H), 3.94 (ttt, J = 83.81, 28.56, 9.03 Hz, 8H), 7.22 (dd, J = 8.49, 2.32 Hz, 1H), 7.30 (s, 1H), 7.40 (dd, J = 13.01, 8.60 Hz, 1H), 9.81 (d, J = 13.89 Hz, 1H)
516
514






F-612


embedded image


(400 MHz, CDCl3) 0.82 (s, 1H), 1.00 (s, 9H), 1.15-1.21 (m, 3H) 2.11-2.19 (m, 8H), 2.70 (s, 2H), 2.99 (dd, J = 7.28, 3.64 Hz, 1H), 3.18 (dd, J = 12.13, 6.06 Hz, 1H), 3.34 (s, 2H), 3.71-3.73 (m, 2H), 4.12 (s, 1H), 6.48 (s, 1H), 6.91- 6.93 (m, 2H), 7.32 (d, J = 7.72 Hz, 1H), 8.12 (s, 1H)
466
464




















TABLE 314











Infor-





MS
mation












Ex-


M +
M −
of


ample
Chemical structure
NMR
H
H
structure





F-613


embedded image


(400 MHz, DMSO-D6) 0.80-0.89 (m, 1H), 0.95 (d, J = 6.80 Hz, 6H), 1.07-1.16 (m, 2H), 1.99-2.13 (m, 8H), 2.76 (d, J = 7.06 Hz, 2H), 3.37- 4.22 (m, 8H), 6.77 (d, J = 1.20 Hz, 1H), 7.20-7.22 (m, 1H), 7.29 (d, J = 2.21 Hz, 1H), 7.42 (dd, J = 11.80, 8.71 Hz, 1H), 9.72 (d, J = 8.16 Hz, 1H)
511
509






F-614


embedded image


(400 MHz, CDCl3) 1.01 (d, J = 6.84 Hz, 6H), 1.04-1.13 (m, 1H), 1.22-1.29 (m, 6H), 1.41- 1.53 (m, 3H), 2.05-2.18 (m, 1H), 2.29 (s, 3H), 2.76 (d, J = 7.06 Hz, 2H), 3.37 (dd, J = 14.89, 4.52 Hz, 1H), 3.51-3.66 (m, 1H), 3.96- 4.02 (m, 1H), 4.18-4.28 (m, 1H), 5.73 (dd, J = 9.92, 4.63 Hz, 1H), 6.70 (s, 1H), 7.05-7.10 (m, 1H), 7.11-7.15 (m, 1H), 7.51 (d, J = 8.60 Hz, 1H), 9.04 (s, 1H)
486
484






F-615


embedded image


(400 MHz, CDCl3) 0.98-1.04 (m, 7H), 1.33-1.36 (m, 2H), 1.58- 1.63 (m, 4H), 2.20-2.31 (m, 8H), 2.83-2.89 (m, 2H), 3.17 (d, J = 11 47 Hz, 1H), 3.69-3.79 (m, 3H), 3.93-3.96 (m, 1H), 4.27 (s, 1H), 6.60 (s, 1H), 6.90-6.92 (m, 2H), 7.24 (d, J = 8.38 Hz, 1H), 8.69 (s, 1H)
466
464






F-616


embedded image


(400 MHz, CDCl3) 0.97-1.01 (m, 7H), 1.36 (dd, J = 13.23, 6.84 Hz, 2H), 1.54-1.65 (m, 4H), 2.20- 2.23 (m, 5H), 2.84 (t, J = 7.61 Hz, 2H), 3.25 (d, J = 16.10 Hz, 1H), 3.75- 3.88 (m, 4H), 4.25 (s, 1H), 6.58 (s, 1H), 7.05-7.08 (m, 2H), 7.36 (d, J = 8.38 Hz, 1H), 9.01 (s, 1H)
486
484




















TABLE 315










MS
Information of












Example
Chemical structure
NMR
M + H
M − H
structure





F-617


embedded image


(400 MHz, CDCl3) 0.84 (d, J = 6.68 Hz, 6H), 0.91-1.02 (m, 1H), 1.08-1.30 (m, 5H), 1.43- 1.58 (m, 1H), 1.87-2.11 (m, 2H), 2.01 (s, 3H), 2.24 (s, 3H), 2.31- 2.57 (m, 3H), 2.99-3.10 (m, 1H), 3.15-3.27 (m, 1H), 3.37-3.57 (m, 2H), 3.83-3.99 (m, 2H), 4.48- 4.63 (m, 1H), 4.63-4.75 (m, 1H), 6.89-6.98 (m, 2H), 7.21 (d, J = 8.00 Hz, 1H), 7.88-8.02 (m, 1H)
475
473
Racemic form





F-618


embedded image


(400 MHz, CDCl3) 0.77-0.89 (m, 2H), 0.89-1.00 (m, 8H), 1.02- 1.17 (m, 2H), 1.99-2.10 (m, 2H), 2.10-2.13 (m, 3H), 2.22-2.27 (m, 3H), 2.74-2.80 (m, 1H), 2.97- 3.03 (m, 1H), 3.33-3.44 (m, 1H), 3.55-3.59 (m, 3H), 3.86-4.00 (m, 2H), 3.99-4.20 (m, 1H), 4.23- 4.48 (m, 1H), 6.77-6.81 (m, 1H), 6.94-7.01 (m, 1H), 7.01-7.04 (m, 1H), 7.23-7.30 (m, 1H)
463
461






F-619


embedded image


(400 MHz, CDCl3) 1.03-1.29 (m, 4H), 1.55-1.67 (m, 2H), 1.73- 1.85 (m, 4H), 1.83-1.98 (m, 4H), 2.00-2.06 (m, 3H), 2.07-2.19 (m, 2H), 2.18-2.24 (m, 3H), 2.27- 2.37 (m, 2H), 2.87-3.03 (m, 2H), 3.11-3.25 (m, 1H), 3.28-3.54 (m, 4H), 3.80-3.93 (m, 2H), 6.87- 6.95 (m, 1H), 6.97 (brs, 1H), 7.07- 7.13 (m, 1H), 9.41 (brs, 1H)
487
485




















TABLE 316










MS
Information of












Example
Chemical structure
NMR
M + H
M − H
structure





F-620


embedded image


(400 MHz, CDCl3) 0.69-1.02 (m, 2H), 1.15-1.23 (m, 2H), 1.69- 1.97 (m, 8H), 2.13-2.16 (m, 6H), 2.23-2.35 (m, 5H), 2.88-2.97 (m, 2H), 3.25-3.36 (m, 1H), 3.55- 3.63 (m, 1H), 3.64-3.74 (m, 1H), 3.86-3.95 (m, 1H), 4.17-4.27 (m, 3H), 4.40-4.47 (m, 1H), 6.90- 6.99 (m, 2H), 7.71-7.76 (m, 1H), 8.89 (brs, 1H)
526
524






F-621


embedded image


(400 MHz, CDCl3) 0.85 (d, J = 6.40 Hz, 6H), 0.99-1.08 (m, 1H), 1.23-1.43 (m, 4H), 1.47- 1.57 (m, 2H), 2.01-2.26 (m, 5H), 2.14 (s, 3H), 2.24 (s, 3H), 2.40- 2.49 (m, 1H), 2.50-2.62 (m, 2H), 3.16 (d, J = 15.66 Hz, 1H), 3.32- 3.43 (brm, 1H), 3.60 (t, J = 9.15 Hz, 1H), 3.72-3.88 (brm, 1H), 4.18- 4.32 (brm, 2H), 6.89-6.96 (m, 2H), 7.15-7.21 (m, 1H), 8.66 (s, 1H)
507
505
Single isomer (Stereochemistry of Hydroxyl group: Undetermined) (Diastereomer of F-622)





F-622


embedded image


(400 MHz, CDCl3) 0.83-0.87 (m, 6H), 1.05-2.37 (m, 13H), 2.12 (s, 3H), 2.25 (s, 3H), 2.37-2.67 (m, 3H), 2.91 (d, J = 11.69 Hz, 1H), 3.22- 3.32 (brm, 1H), 3.62-3.73 (brm, 1H), 4.16-4.32 (brm, 1H), 4.51- 4.67 (brm, 1H), 6.91-7.00 (m, 2H), 7.32 (d, J = 7.94 Hz, 1H)
507
505
Single isomer (Stereochemistry of Hydroxyl group: Undetermined) (Diastereomer of F-621)




















TABLE 317










MS
Information of












Example
Chemical structure
NMR
M + H
M − H
structure





F-623


embedded image


(400 MHz, DMSO-D6) 0.85 (d, J = 6.62 Hz, 6H), 1.06-1.29 (m, 4H), 1.31 (t, J = 6.95 Hz, 2H), 1.45- 1.58 (m, 1H), 1.85-2.06 (m, 4H), 1.97 (s, 3H), 2.12 (d, J = 1.98 Hz, 3H), 2.39-2.61 (m, 3H), 2.92- 3.08 (m, 2H), 3.20-3.29 (m, 1H), 3.39-3.54 (m, 2H), 3.71-3.91 (m, 2H), 6.93 (t, J = 8.71 Hz, 1H), 6.99 (dd, J = 8.71, 5.62 Hz, 1H), 9.63 (brs, 1H)
457
455






F-624


embedded image


(400 MHz, CDCl3) 1.01-1.31 (m, 4H), 1.56-1.66 (m, 1H), 1.73- 1.85 (m, 2H), 1.87-2.00 (m, 2H), 2.09 (s, 3H), 2.11-2.23 (m, 1H), 2.27-2.37 (m, 2H), 2.93-3.08 (m, 2H), 3.15-3.26 (m, 1H), 3.33- 3.53 (m, 9H), 3.79-3.92 (m, 2H), 7.13-7.20 (m, 1H), 7.26-7.34 (m, 2H), 9.53 (brs, 1H)
507
505






F-625


embedded image


(400 MHz, CDCl3) 0.80-0.92 (m, 1H), 0.96-1.07 (m, 15H), 1.32- 1.46 (m, 2H), 1.60-1.77 (m, 3H), 1.81-1.93 (m, 1H), 2.19 (s, 3H), 2.24 (s, 3H), 2.75 (s, 2H), 3.00 (dd, J = 15.16, 4.44 Hz, 1H), 3.38-3.47 (m, 1H), 3.92-4.08 (m, 1H), 4.08- 4.22 (m, 1H), 6.60 (s, 1H), 6.92 (d, J = 8.04 Hz, 1H), 6.94 (s, 1H), 7.36 (d, J = 8.28 Hz, 1H), 8.26 (s, 1H)
478
476




















TABLE 318










MS
Information of












Example
Chemical structure
NMR
M + H
M − H
structure





F-626


embedded image


(400 MHz, CDCl3) 0.78-0.96 (m, 1H), 0.97-1.10 (m, 15H), 1.36- 1.50 (m, 2H), 1.61-1.82 (m, 3H), 1.82-1.96 (m, 1H), 2.27 (s, 3H), 2.76 (s, 2H), 2.99-3.12 (m, 1H), 3.41-3.51 (m, 1H), 4.12-4.27 (m, 2H), 6.60 (s, 1H), 7.07 (dd, J = 8.72, 2.48 Hz, 1H), 7.12 (d, J = 2.20 Hz, 1H), 7.50 (d, J = 8.72 Hz, 1H), 8.64 (s, 1H)
498
496






F-627


embedded image


(400 MHz, CDCl3) 0.79-1.08 (m, 13H), 1.31-1.46 (m, 2H), 1.60- 1.80 (m, 6H), 1.81-1.94 (m, 1H), 2.19 (s, 3H), 2.24 (s, 3H), 2.80- 2.92 (m, 2H), 3.01 (dd, J = 14.92, 4.44 Hz, 1H), 3.36-3.49 (m, 1H), 3.96-4.25 (m, 2H), 6.58 (s, 1H), 6.91 (d, J = 8.00, 1H), 6.94 (s, 1H), 7.34 (d, J = 8.00 Hz, 1H), 8.32 (s, 1H)
478
476






F-628


embedded image


(400 MHz, CDCl3) 0.80-1.09 (m, 13H), 1.35-1.49 (m, 2H), 1.57- 1.79 (m, 6H), 1.82-1.95 (m, 1H), 2.26 (s, 3H), 2.81-2.92 (m, 2H), 2.98-3.11 (m, 1H), 3.40-3.50 (m, 1H), 4.06-4.22 (m, 2H), 6.58 (s, 1H), 7.07 (dd, J = 8.72, 2.44, 1H), 7.12 (d, J = 2.44 Hz, 1H), 7.49 (d, J = 8.72 Hz, 1H), 8.61 (s, 1H)
498
496




















TABLE 319










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-629


embedded image


(400 MHz, CDCl3) 1.01-1.11 (m, 1H), 1.02 (d, J = 6.72 Hz, 6H), 1.17- 1.28 (m, 1H), 1.39 (d, J = 7.42 Hz, 2H), 2.09-2.16 (m, 1H), 2.23 (s, 3H), 2.26 (s, 3H), 2.76 (d, J = 6.96 Hz, 2H), 3.29-3.38 (m, 1H), 3.50-3.58 (m, 1H), 3.95- 4.06 (m, 1H), 4.06-4.18 (m, 2H), 5.74-5.80 (m, 1H), 6.73 (s, 1H), 6.94-7.00 (m, 2H), 7.45 (d, J = 7.88 Hz, 1H), 8.19 (brs, 1H)
506
504






F-630


embedded image


(400 MHz, CDCl3) 1.02 (d, J = 6.49 Hz, 6H), 1.03-1.10 (m, 1H), 1.13-1.20 (m, 1H), 1.35- 1.43 (m, 2H), 2.09-2.16 (m, 1H), 2.27 (s, 3H), 2.76 (d, J = 6.96 Hz, 2H), 3.32-3.41 (brm, 1H), 3.48- 3.58 (brm, 1H), 3.86-4.00 (brm, 1H), 4.04-4.17 (m, 2H), 5.69- 5.71 (brm, 1H), 6.69 (s, 1H), 7.10- 7.17 (m, 2H), 7.63 (d, J = 10.00 Hz, 1H), 8.46 (brs, 1H)
526
524






F-631


embedded image


(400 MHz, CDCl3) 1.01 (s, 9H), 1.20-1.36 (m, 3H), 2.12 (s, 3H), 2.19 (s, 3H), 2.25 (s, 3H), 2.74 (s, 2H), 3.50-4.60 (m, 8H), 6.70 (s, 1H), 6.93-6.95 (m, 2H), 7.49 (d, J = 7.94 Hz, 1H), 9.25 (s, 1H)
505
503






F-632


embedded image


(400 MHz, CDCl3) 0.96 (s, 6H), 1.21-1.32 (m, 3H), 1.63-1.65 (m, 2H), 2.12 (s, 3H), 2.18 (s, 3H), 2.25 (s, 3H), 2.84 (t, J = 7.50 Hz, 2H), 3.52-3.72 (m, 3H), 3.95- 4.55 (m, 6H), 6.69 (s, 1H), 6.93- 6.95 (m, 2H), 7.50 (d, J = 7.72 Hz, 1H), 9.21 (s, 1H)
505
503




















TABLE 320










MS
Information of












Example
Chemical structure
NMR
M + H
M − H
structure





F-633


embedded image


(400 MHz, CDCl3) 1.01 (d, J = 6.18 Hz, 6H), 1.07-1.14 (m, 1H), 1.19-1.28 (m, 1H), 1.38- 1.47 (m, 2H), 2.09-2.16 (m, 1H), 2.20 (s, 3H), 2.76 (d, J = 6.84 Hz, 2H), 3.35-3.44 (brm, 1H), 3.52- 3.63 (brm, 1H), 4.07-4.19 (brm, 3H), 5.74-5.82 (brm, 1H), 6.74 (brs, 1H), 6.89-7.00 (m, 1H), 7.23- 7.32 (m, 1H), 8.73 (brs, 1H)
528
526






F-634


embedded image


(400 MHz, CDCl3) 1.02 (d, J = 6.72 Hz, 6H), 1.08-1.16 (m, 1H), 1.24-1.31 (m, 1H), 1.40- 1.47 (m, 2H), 2.09-2.18 (m, 1H), 2.14 (s, 3H), 2.16 (d, J = 1.86 Hz, 3H), 2.77 (d, J = 7.19 Hz, 2H), 3.36- 3.43 (m, 1H), 3.54-3.61 (m, 1H), 4.09-4.15 (m, 3H), 5.82 (dd, J = 10.20, 4.64 Hz, 1H), 6.77 (s, 1H), 6.83 (t, J = 8.81 Hz, 1H), 7.20 (dd, J = 8.70, 5.68 Hz, 1H), 8.49 (brs, 1H)
524
522






F-635


embedded image


(400 MHz, CDCl3) 0.51-0.59 (m, 1H), 0.74 -0.82 (m, 1H), 0.95- 1.02 (m, 2H), 0.98 (d, J = 5.29 Hz, 6H), 1.00 (d, J = 6.84 Hz, 6H), 1.55- 1.77 (m, 4H), 2.04-2.16 (m, 1H), 2.08 (s, 3H), 2.25 (s, 3H), 2.71 (d, J = 7.06 Hz, 2H), 2.79 (dd, J = 13.89, 4.85 Hz, 1H), 2.93 (dd, J = 13.89, 10.14 Hz, 1H), 3.69-3.79 (m, 1H), 6.39 (s, 1H), 6.94 (s, 1H), 6.95 (d, J = 7.94 Hz, 1H), 7.18 (brs, 1H), 7.49 (d, J = 7.94 Hz, 1H)
464
462




















TABLE 321










MS
Information of












Example
Chemical structure
NMR
M + H
M − H
structure





F-636


embedded image


(400 MHz, CDCl3) 0.32-0.52 (m, 4H), 0.82-0.92 (m, 6H), 1.32- 1.45 (m, 2H), 1.49-1.61 (m, 1H), 1.80-2.04 (m, 3H), 2.04-2.14 (m, 3H), 2.18-2.30 (m, 3H), 2.31- 2.42 (m, 4H), 2.41-2.49 (m, 2H), 2.72-2.81 (m, 1H), 2.90-3.01 (m, 1H), 3.25 (s, 3H), 3.44-3.57 (m, 1H), 3.57-3.68 (m, 1H), 6.92- 7.01 (m, 2H), 7.41-7.49 (m, 1H), 7.67 (brs, 1H)
544
542






F-637


embedded image


(400 MHz, DMSO-D6) 0.42-0.55 (m, 2H), 0.73-0.91 (m, 2H), 0.85 (d, J = 6.80 Hz, 6H), 1.26-1.35 (m, 2H), 1.39-1.57 (m, 2H), 1.74- 1.88 (m, 2H), 2.06 (s, 3H), 2.27- 2.44 (m, 3H), 2.59-2.73 (m, 2H), 2.73-2.85 (m, 2H), 3.14 (s, 3H), 3.48-3.60 (m, 1H), 3.77-3.87 (m, 1H), 6.96 (dt, J = 8.80, 2.80 Hz, 1H), 7.04 (dd, J = 9.60, 2.80 Hz, 1H), 7.26 (dd, J = 8.80, 5.60 Hz, 1H), 9.34 (s, 1H), 11.79 (s, 1H)
534
532






F-638


embedded image


(400 MHz, CDCl3) 0.45-0.51 (m, 2H), 0.88 (s, 9H), 1.36-1.43 (m, 3H), 1.55-1.60 (m, 1H), 1.98- 2.02 (m, 2H), 2.12 (s, 3H), 2.28 (s, 3H), 2.36-2.38 (m, 2H), 2.87- 2.92 (m, 3H), 3.11 (dd, J = 10.32, 5.16 Hz, 1H), 3.53 (s, 1H), 3.93 (s, 1H), 6.99 (s, 2H), 7.19 (d, J = 6.03 Hz, 1H), 7.48 (d, J = 8.58 Hz, 1H)
434
432




















TABLE 322










MS
Information of












Example
Chemical structure
NMR
M + H
M − H
structure





F-639


embedded image


(400 MHz, CDCl3) 0.47 (d, J = 5.33 Hz, 2H), 0.88-0.89 (m, 8H), 1.34-1.41 (m, 12H), 1.52- 1.59 (m, 1H), 1.97 (d, J = 9.74 Hz, 2H), 2.16 (s, 3H), 2.28 (s, 3H), 2.38 (t, J = 6.84 Hz, 3H), 2.57-2.65 (m, 2H), 2.85-2.92 (m, 2H), 3.50- 3.52 (m, 1H), 3.86-3.87 (m, 1H), 5.92 (s, 1H), 6.98 (q, J = 6.03 Hz, 2H), 7.59 (d, J = 8.58 Hz, 1H), 8.03 (s, 1H)
508
506






F-640


embedded image


(400 MHz, CDCl3) 0.46-0.47 (m, 2H), 0.87-0.94 (m, 8H), 1.37 (dd, J = 13.45, 6.40 Hz, 3H), 1.52-1.59 (m, 1H), 1.96-1.99 (m, 2H), 2.18 (s, 3H), 2.28 (s, 3H), 2.37-2.40 (m, 3H), 2.90-2.93 (m, 3H), 3.21- 3.25 (m, 1H), 3.53 (t, J = 8.82 Hz, 1H), 3.82 (t, J = 6.40 Hz, 1H), 6.99- 7.00 (m, 2H), 7.51 (d, J = 8.82 Hz, 1H), 7.97 (s, 1H)
493
491






F-641


embedded image


(400 MHz, CDCl3) 0.46 (s, 2H), 0.87-0.94 (m, 8H), 1.34-1.44 (m, 3H), 1.52-1.59 (m, 1H), 1.94- 1.99 (m, 2H), 2.19 (s, 3H), 2.28 (s, 3H), 2.40 (s, 3H), 2.79 (dd, J = 14.11, 7.06 Hz, 1H), 2.94 (dd, J = 14.22, 4.96 Hz, 1H), 3.25 (dd, J = 14.67, 8.71 Hz, 1H), 3.53 (t, J = 8.82 Hz, 1H), 3.74 (dd, J = 14.78, 4.85 Hz, 1H), 3.84 (s, 1H), 6.98- 7.00 (m, 2H), 7.53 (d, J = 8.38 Hz,
477
475





1H), 8.36 (s, 1H)




















TABLE 323










MS
Information of












Example
Chemical structure
NMR
M + H
M − H
structure





F-642


embedded image


(400 MHz, CDCl3) 0.48 (s, 2H), 0.87-0.88 (m, 8H), 1.34-1.42 (m, 3H), 1.57 (d, J = 6.84 Hz, 1H), 1.96 (t, J = 10.26 Hz, 2H), 2.15 (s, 3H), 2.27 (s, 3H), 2.33-2.40 (m, 3H), 2.72-2.80 (m, 2H), 2.92 (d, J = 7.28 Hz, 2H), 3.49-3.51 (m, 1H), 3.89 (t, J = 6.73 Hz, 1H), 5.45 (s, 1H), 6.28 (s, 1H), 6.97 (s, 2H), 7.57 (d, J = 8.60 Hz, 1H), 7.87 (s, 1H)
452
450






F-643


embedded image


(400 MHz, DMSO-D6) 0.33-0.44 (m, 1H), 0.44-0.53 (m, 1H), 0.74- 0.83 (m, 1H), 0.83-0.88 (m, 7H), 1.27-1.34 (m, 2H), 1.36-1.47 (m, 1H), 1.47-1.57 (m, 1H), 1.76- 1.91 (m, 2H), 1.97-2.06 (m, 6H), 2.22 (s, 4H), 2.29-2.42 (m, 4H), 2.65-2.83 (m, 2H), 3.41-3.60 (m, 1H), 6.89-6.94 (m, 1H), 6.97 (br s, 1H), 7.12 (d, J = 8.40 Hz, 1H), 9.24 (brs, 1H), 12.11 (brs, 1H)
507
505






F-644


embedded image


(400 MHz, DMSO-D6) 0.25-0.43 (m, 1H), 0.43-0.51 (m, 1H), 0.70- 0.83 (m, 2H), 0.83-0.89 (m, 7H), 1.26-1.35 (m, 2H), 1.35-1.45 (m, 1H), 1.47-1.57 (m, 1H), 1.75- 1.94 (m, 2H), 1.97-2.02 (m, 4H), 2.10-2.20 (m, 2H), 2.22 (s, 3H), 2.31-2.44 (m, 2H), 2.69-2.91 (m, 4H), 3.40-3.60 (m, 1H), 6.89- 6.94 (m, 1H), 6.97 (brs, 1H), 7.11 (d, J = 8.40 Hz, 1H), 9.26 (brs, 1H)
491
489




















TABLE 324










MS
Information of












Example
Chemical structure
NMR
M + H
M − H
structure





F-645


embedded image


(400 MHz, CDCl3) 0.88 (d, J = 6.72 Hz, 6H), 1.32-1.39 (m, 5H), 1.51-1.58 (m, 1H), 1.98- 2.09 (m, 2H), 2.21 (s, 3H), 2.29 (s, 3H), 2.40-2.54 (m, 3H), 2.94 (t, J = 6.96 Hz, 2H), 3.18 (t, J = 6.84 Hz, 2H), 3.58 (dd, J = 17.04, 8.93 Hz, 1H), 4.25 (q, J = 7.11 Hz, 2H), 6.13 (d, J = 16.46 Hz, 1H), 6.98-7.03 (m, 2H), 7.36 (brs, 1H), 7.44 (d,
453
451





J = 16.23 Hz, 1H), 7.64 (d,







J = 8.12 Hz, 1H)








F-646


embedded image


(400 MHz, DMSO-D6) 0.83-0.86 (m, 1H), 0.84 (d, J = 6.49 Hz, 6H), 1.31 (t, J = 6.84 Hz, 2H), 1.44-1.55 (m, 1H), 1.87 (dd, J = 16.46, 7.42 Hz, 2H), 2.11 (s, 3H), 2.23 (s, 3H), 2.36-2.53 (m, 2H), 2.75 (t, J = 7.30 Hz, 2H), 3.02 (t, J = 7.19 Hz, 2H), 3.69-3.79 (m, 1H), 6.10 (d, J = 16.23 Hz, 1H), 6.93 (d, J = 7.88 Hz, 1H), 6.99 (s, 1H), 7.21
425
423





(d, J = 7.88 Hz, 1H), 7.36 (d,







J = 16.23 Hz, 1H), 9.27 (s, 1H),







12.48 (brs, 1H)




















TABLE 325










MS
Information of












Example
Chemical structure
NMR
M + H
M − H
structure





F-647


embedded image


(400 MHz, DMSO-D6) 0.37-0.42 (m, 1H), 0.48-0.53 (m, 1H), 0.76- 0.81 (m, 2H), 0.84 (d, J = 6.96 Hz, 6H), 1.27-1.32 (m, 2H), 1.39- 1.46 (m, 1H), 1.48-1.56 (m, 1H), 1.76-1.89 (m, 2H), 1.96 (s, 3H), 2.21 (s, 3H), 2.31-2.39 (m, 3H), 2.64-2.71 (m, 1H), 2.77 (dd, J = 14.73, 9.62 Hz, 1H), 3.29-3.46 (m, 2H), 3.49-3.60 (m, 2H), 3.62 (s, 2H), 6.90 (d, J = 8.12 Hz, 1H), 6.95 (s, 1H), 7.07 (d, J = 8.58 Hz,
491
489





1H), 8.38 (t, J = 5.80 Hz, 1H), 9.24







(s, 1H)








F-648


embedded image


(400 MHz, DMSO-D6) 0.86 (s, 9H), 1.04-1.24 (m, 4H), 1.36 (d, J = 6.26 Hz, 2H), 2.01-2.16 (m, 2H), 2.10 (s, 1.5H), 2.11 (s, 1.5H), 2.23 (s, 3H), 2.43-2.61 (m, 4H), 2.83 (s, 3H), 2.84 (s, 3H), 3.21- 3.31 (m, 1H), 3.55-4.32 (m, 9H), 6.95 (d, J = 8.58 Hz, 1H), 7.01 (s, 1H), 7.15-7.21 (m, 1H), 9.79 (s, 0.5H), 9.82-9.96 (m, 1H), 9.88 (s, 0.5H)
535
533






F-649


embedded image


(400 MHz, DMSO-D6) 0.86 (s, 9H), 0.99-1.19 (m, 4H), 1.07 (t, J = 6.96 Hz, 3H), 1.16 (t, J = 6.96 Hz, 3H), 1.36 (d, J = 6.26 Hz, 2H), 2.01- 2.26 (m, 2H), 2.09 (s, 3H), 2.23 (s, 3H), 2.42-2.60 (m, 3H), 3.11-3.19 (m, 1H), 3.25 (q, J = 6.96 Hz, 2H), 3.30-3.40 (m, 2H), 3.36-4.46 (m, 8H), 4.56 (s, 2H), 6.95 (d, J = 8.12 Hz, 1H), 7.01 (s, 1H), 7.13- 7.26 (m, 1H), 9.89 (s, 0.5H), 9.95 (s, 0.5H), 10.53-10.73 (m, 1H)
563
561




















TABLE 326










MS
Information of












Example
Chemical structure
NMR
M + H
M − H
structure





F-650


embedded image


(400 MHz, DMSO-D6) 0.86 (s, 9H), 1.03-1.28 (m, 10H), 1.36 (d, J = 6.26 Hz, 2H), 2.03-2.20 (m, 2H), 2.10 (s, 1.5H), 2.12 (s, 1.5H), 2.23 (s, 3H), 2.43-2.75 (m, 4H), 3.09-3.24 (m, 4H), 3.24-3.36 (m, 1H), 3.57-4.32 (m, 9H), 6.95 (d, J = 8.12 Hz, 1H), 7.01 (s, 1H), 7.12- 7.22 (m, 1H), 9.39-9.58 (m, 1H), 9.84 (s, 0.5H), 9.93 (s, 0.5H)
563
561






F-651


embedded image


(400 MHz, DMSO-D6) 0.86 (s, 9H), 0.99-1.27 (m, 4H), 1.35 (d, J = 6.26 Hz, 2H), 1.99-2.16 (m, 2H), 2.08 (s, 3H), 2.22 (s, 3H), 2.42-2.60 (m, 4H), 2.75 (d, J = 4.17 Hz, 3H), 2.87-3.09 (m, 2H), 3.13-3.30 (m, 3H), 3.31- 3.41 (m, 2H), 3.54-3.69 (m, 2H), 3.69-3.85 (m, 4H), 3.86-3.98 (m, 2H), 4.03-4.13 (m, 1H), 6.93 (d, J = 8.12 Hz, 1H), 7.00 (s, 1H), 7.18
576
574





(d, J = 8.12 Hz, 1H), 9.67 (s, 1H),







10.94-11.11 (m, 1H)








F-652


embedded image


(400 MHz, DMSO-D6) 0.86 (s, 9H), 0.98-1.21 (m, 4H), 1.35 (d, J = 6.26 Hz, 2H), 2.01-2.16 (m, 2H), 2.10 (s, 3H), 2.23 (s, 3H), 2.43-2.61 (m, 4H), 2.90 (s, 3H), 2.94 (s, 3H), 3.12-3.20 (m, 1H), 3.43-4.46 (m, 7H), 4.54 (s, 2H), 6.95 (d, J = 8.12 Hz, 1H), 7.01 (s, 1H), 7.15-7.25 (m, 1H), 9.84- 10.02 (m, 1H), 10.51-10.84 (m, 1H)
535
533




















TABLE 327










MS
Information of












Example
Chemical structure
NMR
M + H
M − H
structure





F-653


embedded image


(400 MHz, DMSO-D6) 0.85 (d, J = 6.49 Hz, 6H), 0.97-1.19 (m, 4H), 1.07 (t, J = 6.96 Hz, 3H), 1.16 (t, J = 6.96 Hz, 3H), 1.32 (t, J = 6.96 Hz, 2H), 1.40-1.59 (m, 1H), 1.99-2.15 (m, 2H), 2.10 (s, 3H), 2.23 (s, 3H), 2.36-2.59 (m, 3H), 3.11-3.21 (m, 1H), 3.26 (q, J = 7.19 Hz, 2H), 3.30-3.42 (m, 2H), 3.46-4.46 (m, 8H), 4.57 (s, 2H), 6.96 (d, J = 8.12 Hz, 1H), 7.01 (s, 1H), 7.13-7.26 (m, 1H), 9.89 (s, 0.5H), 9.95 (s, 0.5H), 10.53- 10.76 (m, 1H)
549
547






F-654


embedded image


(400 MHz, DMSO-D6) 0.85 (d, J = 6.26 Hz, 6H), 1.03-1.28 (m, 10H), 1.32 (t, J = 6.96 Hz, 2H), 1.41- 1.59 (m, 1H), 2.00-2.17 (m, 2H), 2.10 (s, 1.5H), 2.11 (s, 1.5H), 2.23 (s, 3H), 2.36-2.63 (m, 4H), 3.07- 3.35 (m, 5H), 3.55- 4.30 (m, 8H), 6.95 (d, J = 8.12 Hz, 1H), 7.01 (s, 1H), 7.15-7.22 (m, 1H), 9.35- 9.55 (m, 1H), 9.81 (s, 0.5H), 9.90 (s, 0.5H)
549
547




















TABLE 328










MS
Information of












Example
Chemical structure
NMR
M + H
M − H
structure





F-655


embedded image


(400 MHz, DMSO-D6) 0.85 (d, J = 6.26 Hz, 6H), 0.99-1.25 (m, 4H), 1.31 (t, J = 7.19 Hz, 2H), 1.41- 1.59 (m, 1H), 1.94-2.16 (m, 2H), 2.07 (s, 3H), 2.22 (s, 3H), 2.35- 2.59 (m, 4H), 2.75 (d, J = 4.64 Hz, 3H), 2.88-3.08 (m, 2H), 3.11- 3.30 (m, 3H), 3.31-3.40 (m, 2H), 3.54-3.69 (m, 2H), 3.69-3.85 (m, 4H), 3.86-3.95 (m, 2H), 4.03-
562
560





4.12 (m, 1H), 6.94 (d, J = 7.88 Hz,







1H), 7.00 (s, 1H), 7.18 (d,







J = 7.88 Hz, 1H), 9.65 (s, 1H),







10.77-11.00 (m, 1H)








F-656


embedded image


(400 MHz, DMSO-D6) 0.85 (d, J = 6.26 Hz, 6H), 0.97-1.20 (m, 4H), 1.32 (t, J = 6.96 Hz, 2H), 1.40- 1.58 (m, 1H), 1.97-2.15 (m, 2H), 2.09 (s, 3H), 2.23 (s, 3H), 2.36- 2.59 (m, 4H), 2.90 (s, 3H), 2.94 (s, 3H), 3.10-3.21 (m, 1H), 3.45- 4.46 (m, 7H), 4.53 (s, 2H), 6.95 (d, J = 8.15 Hz, 1H), 7.01 (s, 1H), 7.15- 7.25 (m, 1H), 9.82-10.00 (m, 1H), 10.52 -10.91 (m, 1H)
521
519






F-657


embedded image


(400 MHz, DMSO-D6) 0.85 (d, J = 6.49 Hz, 6H), 1.02-1.28 (m, 4H), 1.32 (d, J = 6.96 Hz, 2H), 1.40- 1.60 (m, 1H), 1.96-2.17 (m, 2H), 2.10 (s, 1.5H), 2.11 (s, 1.5H), 2.23 (s, 3H), 2.37-2.59 (m, 4H), 2.84 (brs, 6H), 3.19-3.31 (m, 1H), 3.56- 4.34 (m, 9H), 6.95 (d, J = 8.12 Hz, 1H), 7.01 (s, 1H), 7.14-7.23 (m, 1H), 9.79 (s, 0.5H), 9.82-9.99 (m, 1H), 9.88 (s, 0.5H)
521
519




















TABLE 329










MS
Information of












Example
Chemical structure
NMR
M + H
M − H
structure





F-658


embedded image


(400 MHz, DMSO-D6) 0.85 (d, J = 6.26 Hz, 6H), 0.99-1.25 (m, 4H), 1.26-1.36 (m, 7H), 1.40- 1.60 (m, 1H), 1.92-2.18 (m, 2H), 2.08 (s, 1.5H), 2.09 (s, 1.5H), 2.23 (s, 3H), 2.37-2.59 (m, 4H), 3.16- 3.29 (m, 1H), 3.45-4.20 (m, 7H), 4.44 - 4.59 (m, 2H), 6.94 (d, J = 8.35 Hz, 1H), 7.01 (s, 1H), 7.13- 7.23 (m, 1H), 9.63 (s, 0.5H), 9.65 (s, 0.5H)
522
520






F-659


embedded image


(400 MHz, DMSO-D6) 0.74-0.76 (brm, 1H), 0.84-0.87 (brm, 1H), 0.91-0.97 (m, 8H), 1.05-1.08 (br m, 2H), 1.23 (brs, 2H), 1.99 (s, 3H), 2.20 (s, 3H), 2.74-2.76 (br m, 1H), 3.36 (brs, 3H), 3.47 (brs, 2H), 3.89 (s, 12H), 6.73-6.75 (br m, 1H), 6.89 (d, J = 8.58 Hz, 1H), 6.94- 6.96 (brm, 1H), 7.09 (d, J = 7.19 Hz, 1H), 9.32 (brs, 1H)
452
450






F-660


embedded image


(400 MHz, DMSO-D6) 0.69-0.80 (m, 1H), 0.84-0.87 (m, 2H), 0.94 (d, J = 6.72 Hz, 8H), 1.06-1.09 (m, 4H), 1.23-1.26 (brm, 3H), 1.90 (s, 3H), 2.05 (s, 6H), 2.63-2.70 (m, 2H), 2.74-2.76 (m, 2H), 2.93- 3.07 (m, 1H), 3.35-3.38 (m, 2H), 3.82-3.91 (m, 2H), 6.74 (s, 1H), 7.09-7.19 (m, 1H), 7.23-7.26 (m, 1H), 7.28-7.30 (m, 1H), 7.30- 7.33 (m, 1H), 9.46 (s, 1H)
472
470




















TABLE 330










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-661


embedded image


(400 MHz, DMSO-D6) 0.75-0.77 (brm, 1H), 0.84-0.87 (brm, 3H), 0.94-0.95 (m, 6H), 1.06-1.08 (brm, 2H), 1.23-1.25 (brm, 3H), 1.91 (s, 3H), 2.09 (s, 3H), 2.75 (d, J = 6.26 Hz, 2H), 2.80-2.92 (brm, 2H), 2.98-3.00 (brm, 2H), 3.35- 3.38 (brm, 3H), 3.46-3.49 (brm, 2H), 3.85-3.88 (brm, 2H), 6.74- 6.76 (m, 1H), 6.91-6.95 (m, 2H), 9.51 (brs, 1H)
470
468






F-662


embedded image


(400 MHz, DMSO-D6) 0.76-0.78 (brm, 2H), 0.84-0.87 (brm, 2H), 0.94-0.95 (m, 6H), 1.06-1.09 (brm, 4H), 1.23-1.25 (brm, 3H), 1.79-1.99 (m, 6H), 2.05 (s, 2H), 2.69-2.78 (m, 3H), 2.82-2.94 (m, 2H), 2.96-3.07 (m, 2H), 3.20- 3.42 (m, 3H), 3.42-3.57 (m, 2H), 3.82-3.94 (m, 3H), 6.75 (s, 1H), 7.04-7.07 (m, 1H), 7.16-7.19 (m, 2H), 9.64 (s, 1H)
474
472






F-663


embedded image


(400 MHz, CDCl3) 0.86-0.91 (m, 1H), 0.87 (d, J = 6.72 Hz, 6H), 1.20- 1.29 (m, 3H), 1.36 (t, J = 6.72 Hz, 2H), 1.52-1.58 (m, 1H), 1.95- 2.02 (m, 2H), 2.17 (s, 3H), 2.28 (s, 3H), 2.35-2.45 (m, 4H), 2.63 (t, J = 7.65 Hz, 2H), 2.91 (t, J = 6.61 Hz, 2H), 3.01 (t, J = 6.72 Hz, 2H), 3.37- 3.46 (m, 1H), 4.09-4.14 (m, 2H), 6.97-7.02 (m, 2H), 7.44-7.51 (m,
455
453





1H), 7.63 (d, J = 7.65 Hz, 1H)




















TABLE 331










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-664


embedded image


(400 MHz, CDCl3) 0.86-0.91 (m, 1H), 0.87 (d, J = 6.72 Hz, 6H), 1.35 (t, J = 6.84 Hz, 2H), 1.51-1.58 (m, 1H), 1.93-2.04 (m, 2H), 2.14 (s, 3H), 2.28 (s, 3H), 2.33-2.41 (m, 2H), 2.48 (t, J = 7.19 Hz, 2H), 2.64 (t, J = 7.42 Hz, 2H), 2.91 (t, J = 6.38 Hz, 2H), 3.01 (t, J = 6.38 Hz, 2H), 3.35-3.46 (m, 1H), 6.96- 7.01 (m, 2H), 7.49 (brs, 1H), 7.53 (d, J = 8.58 Hz, 1H)
427
425






F-665


embedded image


(400 MHz, CDCl3) 0.42 (d, J = 4.19 Hz, 2H), 0.82-0.89 (m, 8H), 1.34-1.35 (m, 3H), 1.51- 1.58 (m, 1H), 1.98 (t, J = 8.82 Hz, 2H), 2.15 (s, 3H), 2.27 (s, 3H), 2.35-2.38 (m, 3H), 2.89 (t, J = 6.95 Hz, 2H), 3.07 (t, J = 6.95 Hz, 2H), 3.48-3.50 (m, 1H), 6.97-
395
393





6.99 (m, 2H), 7.53 (s, 1H), 7.63 (d,







J = 7.94 Hz, 1H)








F-666


embedded image


(400 MHz, CDCl3) 0.36-0.42 (m, 2H), 0.80-0.89 (m, 8H), 1.28- 1.36 (m, 3H), 1.51-1.57 (m, 1H), 1.95 (t, J = 9.92 Hz, 2H), 2.05 (s, 3H), 2.21 (s, 3H), 2.39 (brs, 3H), 2.72 (dd, J = 16.76, 4.19 Hz, 1H), 2.86-2.95 (m, 2H), 3.12 (dd, J = 16.10, 9.70 Hz, 1H), 3.46-3.53 (m, 2H), 6.92-6.93 (m, 2H), 7.48
453
451

custom-character





d, J = 8.60 Hz, 1H), 8.07 (s, 1H)




















TABLE 332










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-667


embedded image


(400 Mz, DMSO-D6) 0.47 (td, J = 5.62, 3.86 Hz, 2H), 0.78-0.85 (m, 8H), 1.26 (dd, J = 16.23, 9.28 Hz, 2H), 1.40-1.53 (m, 2H), 1.76-1.84 (m, 2H), 2.29-2.37 (m, 3H), 2.37 (s, 3H), 2.54-2.81 (m, 4H), 3.47-3.54 (1H, m), 3.74-3.82 (m, 1H), 7.16 (d, J = 8.35 Hz, 1H),
440
438





7.85 (dd, J = 8.46, 2.67 Hz, 1H),







8.53 (d, J = 2.32 Hz, 1H), 10.07 (s,







1H), 12.16 (brs, 1H)








F-668


embedded image


(400 MHz, CDCl3) 0.36-0.42 (m, 2H), 0.81-0.88 (m, 8H), 1.28- 1.36 (m, 3H), 1.51-1.57 (m, 1H), 1.93-2.06 (m, 5H), 2.24 (s, 3H), 2.36 (t, J = 16.54 Hz, 3H), 2.71 (dd, J = 16.87, 4.30 Hz, 1H), 2.85-2.96 (m, 2H), 3.12 (dd, J = 15.99, 9.59 Hz, 1H), 3.46-3.52 (m, 2H), 6.90-6.92 (m, 2H), 7.46 (d,
453
451





J = 8.82 Hz, 1H), 8.07 (s, 1H)








F-669


embedded image


(400 Mz, DMSO-D6) 0.44-0.49 (m, 2H), 0.78-0.85 (m, 8H), 1.29 (t, J = 6.84 Hz, 2H), 1.39-1.56 (m, 2H), 1.82 (m, 2H), 2.05 (s, 3H), 2.29-2.37 (m, 3H), 2.54-2.82 (m, 4H), 3.45 (s, 3H), 3.49-3.58 (m, 1H), 3.71-3.78 (m, 1H), 5.89 (s, 1H), 9.89 (s, 1H), 12.24 (brs, 1H)
443
441




















TABLE 333










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-670


embedded image


(400 Mz, DMSO-D6) 0.46-0.47 (m, 2H), 0.78-0.85 (m, 8H), 1.28 (t, J = 6.84 Hz, 2H), 1.40-1.56 (m, 2H), 1.78-1.84 (m, 2H), 2.32- 2.35 (m, 6H), 2.51-2.57 (m, 1H), 2.66-2.70 (m, 2H), 2.81 (dd, J = 15.65, 7.77 Hz, 1H), 3.48-3.54 (m, 1H), 3.74 (dd, J = 14.49, 7.30 Hz, 1H), 6.57 (s, 1H), 10.92 (s,
430
428





1H), 12.25 (brs, 1H)








F-671


embedded image


(400 MHz, CDCl3) 0.31-0.33 (m, 1H), 0.49-0.50 (m, 1H), 0.83- 0.86 (m, 8H), 1.32-1.34 (m, 3H), 1.52 (dd, J = 13.45, 6.62 Hz, 1H), 1.95-1.98 (m, 6H), 2.20-2.24 (m, 4H), 2.36 (s, 3H), 2.49 (s, 1H), 2.59 (s, 1H), 2.74 (dd, J = 15.44, 3.97 Hz, 1H), 3.20 (dd, J = 15.33, 11.36 Hz, 1H), 3.34 (s, 1H), 3.46- 3.49 (m, 1H), 6.89-6.90 (m, 2H),
467
465





7.32 (d, J = 8.60 Hz, 1H), 8.49 (s,







1H)








F-672


embedded image


(400 MHz, CDCl3) 0.34-0.52 (m, 2H), 0.77-0.93 (m, 2H), 0.87 (s, 9H), 1.31-1.42 (m, 1H), 1.38 (d, J = 5.84 Hz, 2H), 1.44-1.70 (m, 3H), 1.76-2.13 (m, 4H), 2.27 (s, 3H), 2.30-2.46 (m, 3H), 2.65- 2.79 (m, 1H), 2.91-3.07 (m, 1H), 3.42-3.71 (m, 4H), 7.02 (d, J = 8.40 Hz, 1H), 7.14 (s, 1H), 7.75 (s, 1H), 8.11 (d, J = 8.40 Hz, 1H)
487
485




















TABLE 334










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-673


embedded image


(400 MHz, DMSO-D6) 0.34-0.52 (m, 2H), 0.75-0.87 (m, 2H), 0.84 (s, 9H), 1.32 (d, J = 6.00 Hz, 2H), 1.36-1.45 (m, 1H), 1.77-1.98 (m, 4H), 2.12-2.25 (m, 2H), 2.31- 2.43 (m, 3H), 2.48 (s, 3H), 2.63 (s, 3H), 2.80 (dd, J = 15.20, 6.80 Hz, 1H), 2.88 (dd, J = 15.20, 8.40 Hz, 1H), 3.23-3.68 (m, 2H), 7.60 (d,
482
480





J = 8.00 Hz, 1H), 8.27 (d, J = 8.00 Hz,







1H), 10.10 (s, 1H)








F-674


embedded image


(400 MHz, DMSO-D6) 0.32-0.53 (m, 2H), 0.73-0.88 (m, 2H), 0.85 (s, 9H), 1.33 (d, J = 6.00 Hz, 2H), 1.36-1.45 (m, 1H), 1.77-1.99 (m, 4H), 2.10-2.23 (m, 2H), 2.27 (s, 3H), 2.31-2.44 (m, 3H), 2.55 (s, 3H), 2.76 (dd, J = 14.80, 6.80 Hz, 1H), 2.83 (dd, J = 14.80, 8.40 Hz, 1H), 3.41-3.59 (m, 2H), 8.58 (s, 1H), 9.82 (s, 1H)
483
481






F-675


embedded image


(400 MHz, DMSO-D6) 0.34-0.52 (m, 2H), 0.73-0.89 (m, 2H), 0.84 (s, 9H), 1.32 (d, J = 5.60 Hz, 2H), 1.36-1.46 (m, 1H), 1.77-1.98 (m, 4H), 2.11-2.25 (m, 2H), 2.29- 2.45 (m, 3H), 2.32 (s, 3H), 2.59 (s, 3H), 2.82 (dd, J = 15.20, 6.80 Hz, 1H), 2.91 (dd, J = 15.20, 8.40 Hz, 1H), 3.26-3.71 (m, 2H), 7.70 (s, 1H), 8.74 (s, 1H), 9.95 (s, 1H)
482
480




















TABLE 335










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-676


embedded image


(400 MHz, DMSO-D6) 0.83 (s, 9H), 1.31 (d, J = 6.75 Hz, 2H), 1.75- 1.80 (m, 3H), 1.90 (t, J = 5.35 Hz, 1H), 2.14 (t, J = 7.56 Hz, 2H), 2.27 (d, J = 13.49 Hz, 3H), 2.34-2.43 (m, 3H), 2.68 (t, J = 5.70 Hz, 2H), 3.24- 3.28 (m, 2H), 3.38-3.47 (m, 1H), 6.21 (s, 1H), 7.08 (d, J = 8.14 Hz, 1H), 7.42 (d, J = 8.14 Hz, 1H), 9.41 (s, 1H), 12.06 (s, 1H)
461
459






F-677


embedded image


(400 MHz, CDCl3) 0.36-0.39 (m, 2H), 0.80-0.84 (m, 2H), 0.87 (s, 9H), 1.28-1.35 (m, 1H), 1.38 (d, J = 5.95 Hz, 2H), 1.96-2.06 (m, 2H), 2.28 (s, 3H), 2.34-2.44 (m, 3H), 2.76 (dd, J = 17.09, 4.08 Hz, 1H), 2.89 (dd, J = 15.99, 5.84 Hz, 1H), 2.97 (dd, J = 16.98, 9.04 Hz, 1H), 3.11 (dd, J = 16.10, 8.82 Hz,
487
485





1H), 3.45-3.58 (m, 2H), 7.02 (dd,







J = 8.38, 1.54 Hz, 1H), 7.14 (d,







J = 1.32 Hz, 1H), 8.08 (d, J = 8.38 Hz,







1H), 8.31 (s, 1H)








F-678


embedded image


(400 MHz, CDCl3) 0.36-0.39 (m, 2H), 0.80-0.84 (m, 2H), 0.87 (s, 9H), 1.28-1.35 (m, 1H), 1.39 (d, J = 5.95 Hz, 2H), 1.99-2.05 (m, 2H), 2.28 (s, 3H), 2.34-2.43 (m, 3H), 2.79 (dd, J = 16.76, 3.97 Hz, 1H), 2.90 (dd, J = 15.55, 5.18 Hz, 1H), 2.96 (dd, J = 16.87, 8.71 Hz, 1H), 3.11 (dd, J = 15.99, 8.93 Hz,
487
485





1H), 3.45-3.59 (m, 2H), 7.03 (d,







J = 6.84 Hz, 1H), 7.15 (s, 1H), 8.09







(d, J = 8.38 Hz, 1H), 8.36 (s, 1H)




















TABLE 336










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-679


embedded image


(400 MHz, DMSO-D6) 0.32-0.43 (m, 1H), 0.45-0.56 (m, 1H), 0.74- 0.95 (m, 2H), 0.86 (s, 9H), 1.29- 1.46 (m, 1H), 1.34 (d, J = 6.00 Hz, 2H), 1.65 (s, 3H), 1.77-1.97 (m, 4H), 2.06-2.24 (m, 2H), 2.11 (s, 3H), 2.31-2.46 (m, 3H), 2.64- 2.85 (m, 2H), 3.21-3.61 (m, 2H), 10.50 (s, 1H), 12.14 (brs, 1H)
472
470






F-680


embedded image


(400 MHz, DMSO-D6) 0.36-0.45 (m, 1H), 0.45-0.55 (m, 1H), 0.74- 0.90 (m, 2H), 0.85 (s, 9H), 1.33 (d, J = 6.00 Hz, 2H), 1.37-1.48 (m, 1H), 1.77-1.95 (m, 4H), 2.09- 2.25 (m, 2H), 2.19 (s, 3H), 2.30- 2.46 (m, 3H), 2.37 (s, 3H), 2.75 (dd, J = 15.60, 6.80 Hz, 1H), 2.83 (dd, J = 15.60, 7.60 Hz, 1H), 3.40- 3.59 (m, 2H), 7.54 (d, J = 8.00 Hz, 1H), 7.73 (d, J = 8.00 Hz, 1H), 10.52
482
480





(s, 1H)








F-681


embedded image


(400 MHz, DMSO-D6) 0.34-0.57 (m, 2H), 0.76-0.92 (m, 2H), 0.86 (s, 9H), 1.34 (d, J = 6.00 Hz, 2H), 1.38-1.49 (m, 1H), 1.78-2.01 (m, 4H), 2.13-2.26 (m, 2H), 2.17 (s, 3H), 2.27-2.46 (m, 3H), 2.31 (s, 3H), 2.88 (dd, J = 15.60, 6.80 Hz, 1H), 3.00 (dd, J = 15.60, 8.40 Hz, 1H), 3.44-3.61 (m, 2H), 7.92 (s, 1H), 8.16 (s, 1H), 10.56 (brs, 1H)
482
480




















TABLE 337










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-682


embedded image


(400 MHz, CDCl3) 0.55-0.55 (m, 1H), 0.71-0.72 (m, 1H), 0.87 (s, 9H), 0.96-1.00 (m, 2H), 1.29 (d, J = 5.73 Hz, 2H), 1.61 (t, J = 4.19 Hz, 1H), 1.85 (d, J = 9.92 Hz, 1H), 2.00 (dd, J = 18.75, 9.92 Hz, 1H), 2.30- 2.41 (m, 10H), 3.05 (dd, J = 14.56, 4.63 Hz, 1H), 3.29-3.37 (m, 2H), 5.28 (s, 1H), 6.98 (d, J = 8.16 Hz, 1H), 7.11 (s, 1H), 7.77 (d, J = 8.38 Hz, 1H), 7.92 (s, 1H)
501
499






F-683


embedded image


(400 MHz, CDCl3) 0.33-0.37 (m, 1H), 0.40-0.45 (m, 1H), 0.79- 0.83 (m, 2H), 0.86 (s, 9H), 1.29- 1.35 (m, 1H), 1.37 (d, J = 5.73 Hz, 2H), 1.95-2.05 (m, 3H), 2.13- 2.23 (m, 1H), 2.26 (s, 3H), 2.31- 2.42 (m, 3H), 2.47-2.61 (m, 2H), 2.79 (dd, J = 15.44, 4.63 Hz, 1H), 3.13 (dd, J = 15.55, 10.03 Hz, 1H), 3.27-3.34 (m, 1H), 3.43-3.52 (m, 1H), 7.00 (d, J = 8.16 Hz, 1H), 7.11
501
499





(s, 1H), 7.95 (d, J = 8.38 Hz, 1H),







8.32 (s, 1H)








F-684


embedded image


(400 MHz, CDCl3) 0.33-0.37 (m, 1H), 0.40-0.45 (m, 1H), 0.79- 0.84 (m, 2H), 0.86 (s, 9H), 1.29- 1.35 (m, 1H), 1.37 (d, J = 5.95 Hz, 2H), 1.95-2.05 (m, 3H), 2.14- 2.23 (m, 1H), 2.26 (s, 3H), 2.31- 2.42 (m, 3H), 2.47-2.61 (m, 2H), 2.79 (dd, J = 15.55, 4.74 Hz, 1H), 3.14 (dd, J = 15.55, 10.03 Hz, 1H), 3.27-3.34 (m, 1H), 3.43-3.52 (m, 1H), 7.00 (dd, J = 8.31, 1.32 Hz,
501
499





1H), 7.11 (d, J = 1.32 Hz, 1H), 7.95







(d, J = 8.16 Hz, 1H), 8.32 (s, 1H)




















TABLE 338










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-685


embedded image


(400 MHz, CDCl3) 0.31-0.36 (m, 1H), 0.46-0.50 (m, 1H), 0.80- 0.85 (m, 2H), 0.87 (s, 9H), 1.31- 1.37 (m, 1H), 1.37 (d, J = 5.95 Hz, 2H), 1.93-2.01 (m, 3H), 2.01 (s, 3H), 2.14-2.22 (m, 1H), 2.24 (s, 3H), 2.32-2.43 (m, 3H), 2.46- 2.54 (m, 1H), 2.57-2.64 (m, 1H), 2.74 (dd, J = 15.44, 3.97 Hz, 1H), 3.19 (dd, J = 15.22, 11.25 Hz, 1H),
481
479





3.30-3.38 (m, 1H), 3.45-3.54 (m,







1H), 6.90-6.94 (m, 2H), 7.34 (d,







J = 8.60 Hz, 1H), 8.43 (s, 1H)








F-686


embedded image


(400 MHz, CDCl3) 0.33-0.48 (m, 2H), 0.77-0.94 (m, 11H), 1.20- 1.45 (m, 3H), 1.93-2.15 (m, 5H), 2.28 (s, 3H), 2.34-2.49 (m, 3H), 3.24-3.35 (m, 0.7H), 3.46-3.59 (m, 1.3H), 3.59-3.74 (m, 1H), 3.84- 4.03 (m, 2H), 4.07-4.23 (m, 1.3H), 4.37-4.47 (m, 0.7H), 7.01- 7.08 (m, 1H), 7.11-7.18 (m, 1H), 8.06-8.16 (m, 1.3H), 8.59 (s,
512
510





0.7H)








F-687


embedded image


(400 MHz, DMSO-D6) 0.35-0.48 (m, 2H), 0.73-0.91 (m, 2H), 0.86 (s, 9H), 1.30-1.43 (m, 1H), 1.35 (d, J = 5.60 Hz, 2H), 1.82-1.96 (m, 2H), 2.28 (s, 3H), 2.34-2.53 (m, 3H), 3.15-4.14 (m, 7H), 4.28 (s, 2H), 7.14 (d, J = 8.00 Hz, 1H), 7.32 (s, 1H), 7.50 (d, J = 8.00 Hz, 1H), 9.88 (s, 1H)
528
526




















TABLE 339










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-688


embedded image


(400 MHz, DMSO-D6) 0.35-0.51 (m, 2H), 0.74-0.92 (m, 2H), 0.86 (s, 9H), 1.28-1.49 (m, 1H), 1.34 (d, J = 5.60 Hz, 2H), 1.81-1.97 (m, 2H), 2.23-2.57 (m, 5H), 2.27 (s, 3H), 3.04-4.16 (m, 9H), 7.12 (d, J = 8.00 Hz, 1H), 7.31 (s, 1H), 7.50 (dd, J = 12.80, 8.00 Hz, 1H), 9.67 (d, J = 4.80 Hz, 1H)
570
568






F-689


embedded image


(400 MHz, DMSO-D6) 0.33-055 (m, 2H), 0.73-0.91 (m, 2H), 0.86 (s, 9H), 1.29-1.47 (m, 5H), 1.63- 1.76 (m, 2H), 1.78-1.94 (m, 2H), 2.31-2.46 (m, 3H), 2.52 (s, 3H), 2.66 (s, 3H), 2.81 (dd, J = 15.12, 6.76 Hz, 1H), 2.92 (dd, J = 15.36, 8.60 Hz, 1H), 3.30-3.62 (m, 4H), 7.62 (d, J = 8.60 Hz, 1H), 8.30 (d, J = 8.36 Hz, 1H), 10.14 (s, 1H)
468
466






F-690


embedded image


(400 MHz, CDCl3) 0.88 (d, J = 6.62 Hz, 6H), 1.14 (d, J = 6.62 Hz, 3H), 1.33-1.52 (m, 6H), 1.80- 1.88 (m, 4H), 2.08 (s, 1H), 2.26- 2.34 (m, 5H), 2.68-2.76 (m, 3H), 3.06 (t, J = 11.80 Hz, 1H), 3.51 (s, 1H), 6.97 (d, J = 7.72 Hz, 1H), 7.11 (s, 1H), 8.04 (d, J = 8.16 Hz, 1H), 8.16 (s, 1H)
475
473
Single isomer (Stereo- chemistry of Cyclo- hexene ring: Undeter- mined)





F-691


embedded image


(400 MHz, CDCl3) 0.85-0.88 (m, 6H), 1.12 (d, J = 8.38 Hz, 3H), 1.29- 1.36 (m, 3H), 1.54-1.56 (m, 3H), 1.75-1.81 (m, 3H), 1.99-2.07 (m, 2H), 2.29-2.38 (m, 5H), 2.67- 2.73 (m, 3H), 3.07 (t, J = 11.69 Hz, 1H), 3.47 (brs, 1H), 6.97 (d, J = 8.16 Hz, 1H), 7.10 (s, 1H), 7.81- 7.99 (m, 2H)
475
473
Mixture of three stereoi- somers (Mixture of F-693 to F-695)




















TABLE 340










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-692


embedded image


(400 MHz, DMSO-D6) 0.32-0.44 (m, 1H), 0.44-0.53 (m, 1H), 0.72- 0.84 (m, 10H), 1.12-1.24 (m, 2H), 1.28-1.35 (m, 1H), 1.36-1.46 (m, 1H), 1.77-1.98 (m, 4H), 2.11- 2.27 (m, 5H), 2.28-2.42 (m, 5H), 2.65-2.84 (m, 2H), 3.40-3.62 (m, 2H), 6.91-7.20 (m, 1H), 7.44- 7.70 (m, 1H), 9.37-9.61 (m, 1H), 11.93-12.15 (m, 1H)
496
494






F-693


embedded image


(400 MHz, CDCl3) 0.88 (d, J = 11.03 Hz, 6H), 1.18 (d, J = 6.84 Hz, 3H), 1.21-1.51 (m, 6H), 1.66-1.93 (m, 3H), 2.11 (t, J = 7.17 Hz, 1H), 2.26-2.28 (m, 4H), 2.43-2.51 (m, 2H), 2.72- 2.80 (m, 4H), 3.53 (t, J = 5.95 Hz, 1H), 7.02 (d, J = 8.38 Hz, 1H), 7.12 (s, 1H), 7.56 (s, 1H), 8.05 (d, J = 8.38 Hz, 1H)
475
473
Single isomer (Stereo- chemistry of Cyclo- hexene ring Undeter- mined)





F-694


embedded image


(400 MHz, CDCl3) 0.88 (d, J = 19.19 Hz, 6H), 1.14 (t, J = 7.50 Hz, 3H), 1.33-1.41 (m, 3H), 1.55- 1.59 (m, 4H), 1.79-1.89 (m, 2H), 2.10 (dd, J = 8.60, 5.51 Hz, 1H), 2.27 (s, 4H), 2.46-2.48 (m, 2H), 2.61 (s, 1H), 2.76-2.87 (m, 3H), 3.47 (t, J = 8.49 Hz, 1H), 7.02 (d, J = 8.16 Hz, 1H), 7.13 (s, 1H), 7.59 (s, 19), 8.03 (d, J = 8.16 Hz, 1H)
475
473
Single isomer (Stereo- chemistry of Cyclo- hexene ring: Undeter- mined)




















TABLE 341










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-695


embedded image


(400 MHz, CDCl3) 0.89 (d, J = 6.62 Hz, 6H), 1.13 (d, J = 6.84 Hz, 3H), 1.32-1.38 (m, 3H), 1.55- 1.58 (m, 3H), 1.80 (t, J = 18.42 Hz, 3H), 2.04-2.10 (m, 2H), 2.27 (s, 3H), 2.36-2.40 (m, 2H), 2.69- 2.76 (m, 3H), 3.10 (dd, J = 11.69, 5.84 Hz, 1H), 3.50 (s, 1H), 7.01 (d, J = 8.38 Hz, 1H), 7.13 (s, 1H), 8.02- 8.05 (m, 2H)
475
473
Single isomer (Stereo- chemistry of Cyclo- hexene ring: Undeter- mined)





F-696


embedded image


(400 MHz, CDCl3) 0.32-0.54 (m, 2H), 0.75-0.93 (m, 2H), 0.87 (s, 9H), 1.30-1.44 (m, 3H), 1.48- 1.72 (m, 3H), 1.74-2.10 (m, 4H), 2.00 (s, 3H), 2.23 (s, 3H), 2.32- 2.46 (m, 3H), 2.72 (dd, J = 13.72, 4.88 Hz, 1H), 2.96 (dd, J = 13.96, 10.40 Hz, 1H), 3.44-3.74 (m, 4H), 3.66 (s, 3H), 6.96 (d, J = 8.04 Hz, 1H), 7.28 (d, J = 8.40 Hz, 1H), 7.38 (s, 1H)
497
495






F-697


embedded image


(400 MHz, DMSO-D6) 0.72-0.83 (m, 9H), 1.11-1.22 (m, 2H), 1.28- 1.36 (m, 1H), 1.85-2.04 (m, 4H), 2.15-2.27 (m, 6H), 2.35-2.39 (m, 4H), 2.40-2.47 (m, 2H), 2.73- 2.86 (m, 2H), 3.41-3.51 (m, 1H), 3.60-3.77 (m, 1H), 7.02 (d, J = 7.60 Hz, 1H), 7.53 (d, J = 8.40 Hz, 1H), 9.51 (s, 1H), 12.13 (brs, 1H)
524
522




















TABLE 342










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-698


embedded image


(400 MHz, CDCl3) 0.89 (d, J = 6.56 Hz, 6H), 1.25-1.57 (m, 6H), 1.79-2.09 (m, 5H), 2.27 (s, 3H), 2.37-2 41 (m, 4H), 2.75- 2.76 (m, 2H), 2.96-2.98 (m, 1H), 3.41-3.43 (m, 1H), 7.02 (d, J = 8.38 Hz, 1H), 7.13 (s, 1H), 7.89 (d, J = 5.29 Hz, 1H), 8.04 (d, J = 8.38 Hz, 1H)
461
459
Mixture of two stereo- isomers (Stereo- chemistry of Isopentyl group: Undeter- mined)





F-699


embedded image


(400 MHz, CDCl3) 0.32-0.53 (m, 2H), 0.76-0.93 (m, 2H), 0.87 (s, 9H), 1.23-1.42 (m, 3H), 1.44- 1.70 (m, 3H), 1.75-2.11 (m, 4H), 1.95 (s, 3H), 2.18 (s, 3H), 2.32- 2.47 (m, 3H), 2.72 (dd, J = 13.76, 4.92 Hz, 1H), 2.94 (dd, J = 13.76, 10.40 Hz, 1H), 3.45-3.72 (m, 4H), 4.74 (s, 1H), 6.89 (d, J = 8.16 Hz, 1H), 6.99 (d, J = 8.16 Hz, 1H), 7.35 (s, 1H)
483
481






F-700


embedded image


(400 MHz, DMSO-D6) 0.34-0.44 (m, 1H), 0.44-0.53 (m, 1H), 0.73- 0.83 (m, 2H), 1.36-1.48 (m, 1H), 1.65-1.76 (m, 2H), 1.80-1.99 (m, 4H), 2.12-2.22 (m, 3H), 2.28 (s, 3H), 2.32-2.42 (m, 2H), 2.63- 2.87 (m, 2H), 3.39-3.59 (m, 2H), 7.05-7.12 (m, 1H), 7.13-7.21 (m, 3H), 7.23-7.30 (m, 3H), 7.42 (d, J = 8.40 Hz, 1H), 9.43 (s, 1H), 12.02
535
533





(brs, 1H)




















TABLE 343










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-701


embedded image


(400 MHz, CDCl3) 0.29-0.40 (m, 1H), 0.61-0.70 (m, 1H), 0.74- 0.92 (m, 2H), 1.07-1.22 (m, 2H), 1.47-1.73 (m, 7H), 1.75-1.87 (m, 3H), 2.11-2.31 (m, 2H), 2.26 (s, 3H), 2.33-2.49 (m, 2H), 2.69 (t, J = 8.00 Hz, 2H), 2.85 (dd, J = 14.00, 4.80 Hz, 1H), 3.12 (dd, J = 14.00, 10.00 Hz, 1H), 3.59-3.68 (m, 1H), 7.00 (d, J = 8.40 Hz, 1H), 7.11 (s,
549
547





1H), 7.29 (d, J = 8.40 Hz, 2H), 7.37







(d, J = 8.40 Hz, 2H), 7.76 (s, 1H),







7.97 (d, J = 8.40 Hz, 1H)








F-702


embedded image


(400 MHz, CDCl3) 0.49-0.59 (m, 1H), 0.65-0.74 (m, 1H), 0.91- 1.04 (m, 2H), 0.97 (d, J = 6.88 Hz, 6H), 1.57-1.73 (m, 3H), 1.82- 2.02 (m, 3H), 2.28 (s, 3H), 2.59 (d, J = 7.24 Hz, 2H), 2.79 (dd, J = 14.52, 5.64 Hz, 1H), 3.03 (dd, J = 14.52, 8.88 Hz, 1H), 3.60-3.78 (m, 3H), 6.52 (s, 1H), 6.80-6 90 (m, 2H), 7.65 (s, 1H), 7.97-8.04 (m, 1H)
469
467






F-703


embedded image


(400 MHz, CDCl3) 0.54 (brs, 1H), 0.74 (brs, 1H), 0.82 (s, 9H), 0.99 (d, J = 8.16 Hz, 2H), 1.27 (d, J = 5.73 Hz, 2H), 1.64 (s, 1H), 1.85- 1.97 (m, 2H), 2.31-2.41 (m, 10H), 3.08 (dd, J = 9.92, 4.96 Hz, 1H), 3.33-3.36 (m, 2H), 5.29 (s, 1H), 6.81-6.83 (m, 2H), 7.67 (t, J = 8.27 Hz, 1H), 8.07 (s, 1H)
485
483




















TABLE 344










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-704


embedded image


(400 MHz, CDCl3) 0.86 (s, 9H), 1.38 (d, J = 5.95 Hz, 2H), 2.00-2.09 (m, 2H), 2.26 (s, 3H), 2.35-2.45 (m, 3H), 2.88-2.91 (m, 2H), 3.07- 3.10 (m, 2H), 3.39-3.48 (m, 1H), 4.04 (brs, 2H), 4.34 (brs, 2H), 7.00 (d, J = 7.28 Hz, 1H), 7.13 (s, 1H), 7.77 (s, 1H), 8.06 (d, J = 8.16 Hz, 1H)
477
475






F-705


embedded image


(400 MHz, CDCl3) 0.24-0.34 (m, 1H), 0.42-0.52 (m, 1H), 0.78- 0.96 (m, 2H), 0.96-1.02 (m, 9H), 1.50-1.54 (m, 1H), 1.59-1.71 (m, 2H), 1.80-2.00 (m, 5H), 2.29 (s, 3H), 2.73-2.84 (m, 1H), 2.93- 3.05 (m, 1H), 3.64-3.75 (m, 3H), 4.20-4.28 (m, 2H), 6.81-6.93 (m, 2H), 7.50-7.56 (m, 1H), 7.75 (brs, 1H), 7.97-8.05 (m, 1H)
565
563






F-706


embedded image


(400 MHz, CDCl3) 0.45-0.54 (m, 1H), 0.74-0.79 (m, 6H), 0.79- 0.83 (m, 6H), 0.93-1.02 (m, 3H), 1.40-1.48 (m, 4H), 2.04-2.17 (m, 4H), 2.21-2.26 (m, 4H), 2.27- 2.36 (m, 3H), 2.36-2.48 (m, 1H), 2.52-2.68 (m, 2H), 2.71-2.81 (m, 1H), 2.92-3.02 (m, 1H), 3.44- 3.60 (m, 1H), 4.66-4.81 (m, 1H), 6.74-6.86 (m, 2H), 7.67 (brs, 1H), 7.79-7.87(m, 1H)
513
511




















TABLE 345










MS
Information of












Example
Chemical structure
NMR
M + H
M − H
structure





F-707


embedded image


(400 MHz, CDCl3) 0.76 (s, 6H), 0.79-0.84 (m, 6H), 1.36-1.48 (m, 2H), 2.05-2.17 (m, 3H), 2.20- 2.33 (m, 7H), 2.33-2.51 (m, 2H), 2.57-2.73 (m, 2H), 2.75-2.86 (m, 1H), 2.98-3.09 (m, 1H), 3.58- 3.73 (m, 1H), 4.66-4.78 (m, 1H), 6.80-6.88 (m, 2H), 7.42 (brs, 1H), 7.93-7.99 (m, 1H)
541
539






F-708


embedded image


(400 MHz, DMSO-D6) 0.73-0.78 (m, 7H), 0.78-0.82 (m, 6H), 0.99- 1.12 (m, 4H), 1.29-1.36 (m, 2H), 1.38-1.48 (m, 1H), 1.87-2.01 (m, 2H), 2.15-2.22 (m, 1H), 2.24- 2.27 (m, 3H), 2.31-2.43 (m, 2H), 2.62-2.80 (m, 2H), 2.87-3.01 (m, 3H), 3.42-3.53 (m, 1H), 3.55- 3.65 (m, 1H), 7.05-7.10 (m, 1H), 7.26 (brs, 1H), 7.37-7.42 (m, 1H), 9.47 (brs, 1H), 11.86-12.34 (m, 1H)
529
527






F-709


embedded image


(400 MHz, CDCl3) 0.45-0.53 (m, 1H), 0.72-0.79 (m, 8H), 0.79- 0.84 (m, 6H), 0.95-1.01 (m, 2H), 1.37-1.50 (m, 4H), 1.52-1.63 (m, 2H), 1.72-1.92 (m, 2H), 2.17- 2.24 (m, 1H), 2.24-2.27 (m, 3H), 2.27-2.35 (m, 1H), 2.35-2.47 (m, 1H), 2.51-2.68 (m, 2H), 2.70- 2.77 (m, 1H), 2.89-2.99 (m, 1H), 3.37-3.45 (m, 1H), 3.57-3.62 (m, 2H), 4.70-4.80 (m, 1H), 6.77- 6.86 (m, 2H), 7.53 (brs, 1H), 7.89
499
497





(t, J = 8.00 Hz, 1H)




















TABLE 346










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-710


embedded image


(400 MHz, CDCl3) 0.79 (s, 6H), 0.83 (d, J = 6.80 Hz, 6H), 1.45-1.49 (m, 4H), 1.78-1.91 (m, 2H), 2.20- 2.27 (m, 2H), 2.29 (s, 3H), 2.36- 2.52 (m, 2H), 2.60-2.75 (m, 2H), 2.77-2.87 (m, 1H), 2.97-3.08 (m, 1H), 3.56-3.67 (m, 4H), 4.68- 4.81 (m, 1H), 6.81-6.91 (m, 2H), 7.45 (brs, 1H), 7.96-8.04 (m, 1H)
527
525






F-711


embedded image


(400 MHz, CDCl3) 0.34-0.39 (m, 1H), 0.43-0.48 (m, 1H), 0.81 (dt, J = 8.26, 4.30 Hz, 2H), 0.85 (s, 9H), 1.31-1.36 (m, 1H), 1.37 (d, J = 5.58 Hz, 2H), 1.52-1.66 (m, 3H), 1.76 (dd, J = 18.72, 9.65 Hz, 1H), 1.96-2.18 (m, 5H), 2.21- 2.29 (m, 1H), 2.33-2.40 (m, 5H), 2.53 (dd, J = 13.84, 6.16 Hz, 1H), 2.60 (dd, J = 13.96, 9.77 Hz, 1H), 3.45-3.60 (m, 2H), 4.25 (q, J = 7.68 Hz, 1H), 6.06 (brd,
431
429





J = 7.91 Hz, 1H)








F-712


embedded image


(400 MHz, CDCl3) 0.34-0.39 (m, 1H), 0.43-0.48 (m, 1H), 0.80- 0.85 (m, 2H), 0.86 (s, 9H), 1.22- 1.39 (m, 4H), 1.94-2.14 (m, 4H), 1.97 (s, 6H), 2.32-2.42 (m, 5H), 2.47 (dd, J = 14.07, 6.40 Hz, 1H), 2.56 (dd, J = 14.19, 8.37 Hz, 1H), 3.47-3.55 (m, 2H), 6.09 (brs, 1H)
443
441




















TABLE 347










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-713


embedded image


(400 MHz, DMSO-D6) 0.45-0.53 (m, 1H), 0.75-0.84 (m, 14H), 0.89- 0.96 (m, 2H), 1.39-1.45 (m, 2H), 1.53-1.60 (m, 1H), 1.84-1.96 (m, 2H), 2.03-2.11 (m, 2H), 2.22- 2.27 (m, 4H), 2.58-2.70 (m, 4H), 2.70-2.83 (m, 1H), 4.79-4.94 (m, 1H), 7.04-7.10 (m, 1H), 7.25 (brs, 1H), 7.36 (d, J = 8.40 Hz, 1H), 9.30- 9.37 (m, 1H), 11.99 (brs, 1H)
529
527






F-714


embedded image


(400 MHz, CDCl3) 0.69-0.78 (m, 6H), 0.78-0.85 (m, 6H), 1.19- 1.30 (m, 1H), 1.30-1.46 (m, 3H), 1.91-2.21 (m, 4H), 2.21-2.29 (m, 3H), 2.33-2.56 (m, 4H), 2.77- 2.97 (m, 2H), 2.99-3.14 (m, 1H), 3.15-3.42 (m, 2H), 3.54-3.76 (m, 3H), 6.89-7.03 (m, 1H), 7.08- 7.14 (m, 1H), 7.58-7.80 (m, 1H), 8.07-8.25 (m, 1H)
565
563
Racemic form (Stereo- chemistry of asym- metric point on Cyclo- propane Mixture of R-isomer and S-iso- mer)





E-77


embedded image


(400 MHz, DMSO-D6) 0.45-0.58 (m, 1H), 0.63-0.75 (m, 1H), 0.90- 1.02 (m, 2H), 1.08 (s, 9H), 1.71- 1.82 (m, 1H), 1.90-2.05 (m, 2H), 2.18-2.33 (m, 2H), 2.87 (dd, J = 15.60, 6.40 Hz, 1H), 2.97 (dd, J = 15.60, 8.80 Hz, 1H), 3.55-3.67 (m, 1H), 7.17-7.23 (m, 1H), 7.39 (s, 1H), 7.43 (dd, J = 10.80, 2.40 Hz, 1H), 7.83 (dd, J = 8.80, 8.00 Hz, 1H), 9.92 (s, 1H), 12.16 (brs, 1H)
554
552




















TABLE 348










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





E-78


embedded image


(400 MHz, DMSO-D6) 0.42-0.54 (m, 1H), 0.60-0.71 (m, 1H), 0.86- 1.02 (m, 2H), 0.95 (s, 9H), 1.67- 1.77 (m, 1H), 1.98 (dd, J = 14.40, 7.60 Hz, 2H), 2.16-2.33 (m, 2H), 2.76 (s, 2H), 2.85 (dd, J = 15.60, 6.40 Hz, 1H), 2.95 (dd, J = 15.60, 8.80 Hz, 1H), 3.52-3.64 (m, 1H), 6.74 (s, 1H), 7.36 (dd, J = 8.80, 2.00 Hz, 1H), 7.60 (d, J = 2.00 Hz, 1H), 7.63 (d, J = 8.80 Hz, 1H), 9.68 (s, 1H), 12.30 (brs, 1H)
534
532






E-79


embedded image


(400 MHz, CDCl3) 0.57-0.62 (m, 1H), 0.72-0.77 (m, 1H), 0.97- 1.06 (m, 2H), 1.01 (s, 9H), 1.65- 1.72 (m, 1H), 2.11-2.26 (m, 2H), 2.43-2.48 (m, 2H), 2.72 (s, 2H), 2.84 (dd, J = 14.78, 5.29 Hz, 1H) 3.10 (dd, J = 14.78, 9.70 Hz, 1H), 3.75-3.82 (m, 1H), 6.41 (s, 1H), 7.19 (dd, J = 8.82, 2.43 Hz, 1H), 7.33 (d, J = 2.43 Hz, 1H), 7.82 (s, 1H), 8.21 (d, J = 9.04 Hz, 1H)
534
532






E-80


embedded image


(400 MHz, CDCl3) 0.60-0.65 (m, 1H), 0.77-0.83 (m, 1H), 1.03- 1.08 (m, 2H), 1.14 (s, 9H), 1.68- 1.75 (m, 1H), 2.09-2.26 (m, 2H), 2.44-2.48 (m, 2H), 2.83 (dd, J = 15.11, 5.18 Hz, 1H), 3.07 (dd, J = 15.11, 9.59 Hz, 1H), 3.77-3.84 (m, 1H), 6.88 (s, 1H), 7.06-7.10 (m, 2H), 7.60 (s, 1H), 8.16 (t, J = 8.82 Hz, 1H)
554
552




















TABLE 349










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-715


embedded image


(400 MHz, CDCl3) 0.29-0.37 (m, 1H), 0.54-0.63 (m, 1H), 0.75- 0.83 (m, 2H), 0.85 (s, 9H), 1.22- 1.37 (m, 3H), 1.79-1.91 (m, 1H), 1.93-2.03 (m, 1H), 2.04-2.13 (m, 2H), 2.23-2.34 (m, 5H), 2.36- 2.53 (m, 3H), 2.69-2.89 (m, 2H), 3.26-3.37 (m, 1H), 3.67-3.78 (m, 1H), 7.02 (d, J = 8.38 Hz, 1H), 7.14 (s, 1H), 7.45 (brs, 1H), 8.03 (d, J = 8.38 Hz, 1H)
500
498






F-716


embedded image


(400 MHz, DMSO-D6) 0.33-0.54 (m, 2H), 0.71-0.83 (m, 8H), 1.30- 1.49 (m, 3H), 1.78-2.00 (m, 4H), 2.06-2.44 (m, 8H), 2.65-2.89 (m, 2H), 3.06 (s, 2H), 3.38-3.60 (m, 2H), 4.42 (brs, 1H), 7.09 (d, J = 7.86 Hz, 1H), 7.28 (s, 1H), 7.42 (d, J = 8.32 Hz, 1H), 9.46 (s, 1H)
517
515






F-717


embedded image


(400 MHz, CDCl3) 0.25-0.39 (m, 1H), 0.55-0.68 (m, 1H), 0.79- 0.82 (m, 2H), 0.84 (s, 9H), 1.24- 1.37 (m, 3H), 1.78-1.88 (m, 1H), 1.88-2.00 (m, 1H), 2.00-2.13 (m, 2H), 2.23-2.34 (m, 2H), 2.34- 2.55 (m, 3H), 2.72-2.91 (m, 2H), 3.25-3.38 (m, 1H), 3.74 (dd, J = 10.81, 3.97 Hz, 1H), 7.00-7.11 (m, 2H), 7.56 (brs, 1H), 8.07 (t, J = 8.71 Hz, 1H)
505
503




















TABLE 350










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-718


embedded image


(400 MHz, CDCl3) 0.26-0.37 (m, 1H), 0.53-0.63 (m, 1H), 0.80 (ddd, J = 11.03, 5.07, 2.98 Hz, 2H), 0.85 (s, 9H), 1.22-1.38 (m, 3H), 1.77- 1.88 (m, 1H), 1.91-2.02 (m, 1H), 2.03-2.14 (m, 2H), 2.30 (t, J = 7.39 Hz, 2H), 2.36-2.52 (m, 3H), 2.76 (dd, J = 14.56, 5.95 Hz, 1H), 2.85 (dd, J = 14.56, 9.04 Hz, 1H), 3.27-3.37 (m, 1H), 3.66- 3.78 (m, 1H), 7.20 (dd, J = 9.04,
521
519





2.21 Hz, 1H), 7.34 (d, J = 2.21 Hz,







1H), 7.50 (brs, 1H), 8.18 (d,







J = 9.04 Hz, 1H)








F-719


embedded image


(400 MHz, CDCl3) 0.43 (tdd, J = 5.60, 4.12, 0.12 Hz, 2H), 0.83 (ddd, J = 9.36, 5.09, 3.47 Hz, 2H), 0.87 (s, 9H), 1.33-1.49 (m, 3H), 1.98-2.07 (m, 2H), 2.29 (s, 3H), 2.33-2.44 (m, 3H), 2.92 (t, J = 7.28 Hz, 2H), 3.07 (t, J = 7.17 Hz, 2H), 3.51 (ddd, J = 19.25, 8.73,
429
427





6.53 Hz, 1H), 7.05 (d, J = 8.79 Hz,







1H), 7.17 (d, J = 0.92 Hz, 1H), 7.85







(brs, 1H), 8.20 (d, J = 8.55 Hz, 1H)








F-720


embedded image


(400 MHz, CDCl3) 0.43 (td, J = 5.43, 4.62 Hz, 2H), 0.84 (ddd, J = 9.42, 5.03, 3.29 Hz, 2H), 0.87 (s, 9H), 1.33-1.41 (m, 3H), 1.98- 2.07 (m, 2H), 2.36-2.43 (m, 3H), 2.94 (t, J = 6.94 Hz, 2H), 3.07 (t, J = 6.94 Hz, 2H), 3.51 (tt, J = 10.17, 4.16 Hz, 1H), 7.23 (dd, J = 8.90,
449
447





2.43 Hz, 1H), 7.36 (d, J = 2.31 Hz,







1H), 8.00 (brs, 1H), 8.34 (d,







J = 9.02 Hz, 1H)




















TABLE 351










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-721


embedded image


(400 MHz, CDCl3) 0.42 (td, J = 5.72, 4.16 Hz, 2H), 0.83 (ddd, J = 9.13, 4.62, 3.01 Hz, 2H), 0.87 (s, 9H), 1.32-1.40 (m, 3H), 1.99- 2.05 (m, 2H), 2.16 (s, 3H), 2.27 (s, 3H), 2.37-2.43 (m, 3H), 2.90 (t, J = 7.05 Hz, 2H), 3.07 (t, J = 7.05 Hz, 2H), 3.51 (ddd, J = 19.30, 8.90,
409
407





6.70 Hz, 1H), 6.97 (s, 1H), 6.99 (d,







J = 8.79 Hz, 1H), 7.50 (brs, 1H),







7.64 (d, J = 7.86 Hz, 1H)








F-722


embedded image


(400 MHz, CDCl3) 0.43-0.44 (m, 1H), 0.51-0.54 (m, 1H), 0.86- 0.88 (m, 10H), 0.97-1.01 (m, 2H), 1.28-1.35 (m, 5H), 2.03-2.09 (m, 5H), 2.37-2.40 (m, 5H), 2.74- 2.78 (m, 1H), 2.84-2.93 (m, 2H), 3.50-3.53 (m, 1H), 3.64-3.67 (m, 1H)
481
479






F-723


embedded image


(400 MHz, CDCl3) 0.30 (d, J = 3.97 Hz, 2H), 0.76-0.80 (m, 2H), 0.88 (s, 9H), 1.25 (dd, J = 10.92, 5.62 Hz, 1H), 1.39 (d J = 5.95 Hz, 2H), 1.93-2.05 (m, 4H), 2.30-2.40 (m, 5H), 2.66 (dd, J = 14.89, 5.62 Hz, 1H), 2.82 (dd, J = 14.89, 9.59 Hz, 1H), 3.47-3.50 (m, 2H), 7.46 (t, J = 7.72 Hz, 2H), 7.57 (t, J = 7.50 Hz, 1H), 7.95 (d, J = 4.30 Hz, 2H)
517
515




















TABLE 352










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-724


embedded image


(400 MHz, DMSO-D6) 0.34-0.54 (m, 2H), 0.73-0.91 (m, 8H), 1.32- 1.46 (m, 3H), 1.77-2.00 (m, 4H), 2.10-2.28 (m, 2H), 2.30-2.45 (m, 3H), 2.66-2.87 (m, 2H), 2.97 (s, 2H), 3.23 (s, 3H), 3.40-3.58 (m, 2H), 4.45 (s, 2H), 5.27 (brs, 1H), 7.21 (d, J = 8.55 Hz, 1H), 7.38 (s, 1H), 7.51 (d, J = 8.09 Hz, 1H), 9.50 (s, 1H), 12.08 (brs, 1H)
547
545






F-725


embedded image


(400 MHz, DMSO-D6) 0.32-0.54 (m, 2H), 0.72-0.85 (m, 8H), 1.33- 1.45 (m, 3H), 1.79-1.99 (m, 4H), 2.09-2.24 (m, 2H), 2.26 (s, 3H), 2.30-2.45 (m, 3H), 2.65-2.85 (m, 2H), 2.97 (s, 2H), 3.23 (s, 3H), 3.38-3.59 (m, 2H), 7.09 (d, J = 7.17 Hz, 1H), 7.28 (s, 1H), 7.42 (d, J = 8.32 Hz, 1H), 9.46 (1H, s), 12.08 (1H, s)
531
529






F-726


embedded image


(400 MHz, DMSO-D6) 0.31-0.56 (m, 2H), 0.69-0.90 (m, 8H), 0.88 (s, 4H), 1.32-1.50 (m, 3H), 1.78- 1.98 (m, 4H), 2.04-2.26 (m, 2H), 2.29-2.45 (m, 3H), 2.63-2.89 (m, 2H), 3.05 (s, 2H), 3.40-3.61 (m, 2H), 4.36-4.52 (m, 3H), 5.27 (brs, 1H), 7.21 (d, J = 7.40 Hz, 1H), 7.38 (s, 1H), 7.51 (d, J = 8.09 Hz, 1H), 9.51 (s, 1H)
533
531




















TABLE 353










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-727


embedded image


(400 MHz, DMSO-D6) 0.34-0.53 (m, 2H), 0.75-0.84 (m, 2H), 1.07 (s, 6H), 1.37-1.46 (m, 1H), 1.60- 1.67 (m, 2H), 1.82-1.99 (m, 4H), 2.11-2.24 (m, 2H), 2.27 (s, 3H), 2.29-2.41 (m, 3H), 2.65-2.85 (m, 2H), 3.27-3.31 (m, 1H), 3.38- 3.58 (m, 2H), 7.09 (d, J = 7.86 Hz, 1H), 7.28 (s, 1H ), 7.42 (d,
531
529





J = 8.32 Hz, 1H), 9.46 (s, 1H), 12.07







(s, 1H)








F-728


embedded image


(400 MHz, DMSO-D6) 0.34-0.53 (m, 2H), 0.74-0.83 (m, 2H), 1.03 (s, 6H), 1.35-1.45 (m, 1H), 1.56- 1.63 (m, 2H), 1.77-1.98 (m, 4H), 2.09-2.36 (m, 8H), 2.47-2.57 (m, 3H), 2.65-2.86 (m, 2H), 3.39- 3.55 (m, 2H), 7.09 (d, J = 8.09 Hz, 1H), 7.28 (s, 1H), 7.36-7.46 (m, 2H), 9.45 (s, 1H), 12.07 (brs, 1H)
544
542






F-729


embedded image


(400 MHz, CDCl3) 0.43-0.49 (m, 2H), 0.80-0.90 (m, 11H), 1.24 (ddd, J = 14.81, 8.16, 4.73 Hz, 2H), 1.40 (dq, J = 11.89, 3.16 Hz, 1H), 1.59-1.68 (m, 2H), 2.29 (s, 3H), 2.68 (t, J = 7.66 Hz, 2H), 2.94 (t, J = 7.25 Hz, 2H), 3.09 (t, J = 7.25 Hz, 2H), 7.05 (dd, J = 8.46, 2.01 Hz,
403
401





1H), 7.17 (d, J = 1.21 Hz, 1H), 7.88







(s, 1H), 8.20 (d, J = 8.46 Hz, 1H)




















TABLE 354










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-730


embedded image


(400 MHz, CDCl3) 0.53-0.60 (m, 2H), 0.81-0.90 (m, 2H), 0.84 (s, 3.6H), 0.85 (s, 5.4H), 1.35 (d, J = 6.70 Hz, 1.2H), 1.37 (d, J = 7.17 Hz, 0.8H), 1.42-1.55 (m, 2H), 1.93 (ddd, J = 10.87, 8.21, 1.73 Hz, 0.8H), 2.16 (ddd, J = 10.40, 7.98, 1.50 Hz, 1.2H), 2.29 (s, 3H),
459
457
Mixture of two stereoi- somers (Stereo- chemistry, on Cyclobu- tane ring:




2.36-2.49 (m, 2H), 2.77-2.83 (m,


Mixture of




1H), 2.91-2.98 (m, 2H), 3.08 (t,


Cis-isomer




J = 7.05 Hz, 1.2H), 3.11 (t,


and Trans-




J = 7.17 Hz, 0.8H), 3.77 (s, 0.8H),


isomer)




3.95 (s, 1.2H), 7.06 (dd, J = 8.55,







1.85 Hz, 1H), 7.17 (s, 1H), 7.87







(brs, 0.6H), 7.89 (brs, 0.4H), 8.21







(d, J = 8.32 Hz, 1H)








F-731


embedded image


(400 MHz, DMSO-D6) 0.35-0.55 (m, 2H), 0.72-0.84 (m, 8H), 1.33 (d, J = 5.55 Hz, 2H), 1.37-1.47 (m, 1H), 1.78-1.99 (m, 4H), 2.12- 2.26 (m, 2H), 2.30-2.44 (m, 3H), 2.77-3.00 (m, 2H), 3.01-3.10 (m, 2H), 3.42-3.59 (m, 2H), 4.39- 4.46 (m, 1H), 7.84 (dd, J = 8.55, 1.85 Hz, 1H), 7.89-7.96 (m, 2H), 9.66 (s, 1H)
547
545




















TABLE 355










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-732


embedded image


(400 MHz, CDCl3) 0.59 (td, J = 5.61, 3.70 Hz, 0.4H), 0.66 (td, J = 5.66, 4.16 Hz, 1.6H), 0.86 (s, 7.2H), 0.87 (s, 1.8H), 0.84-0.93 (m, 2H), 1.38 (d, J = 6.94 Hz, 0.4H), 1.43 (d, J = 5.78 Hz, 1.6H), 1.51- 1.55 (m, 1H), 2.00-2.06 (m, 2.4H), 2.29 (s, 24H), 2.26-2.36 (m,
445
443
Mixture of two stereoi- somers (Stereo- chemistry on Cyclobu- tane ring:




1.4H), 2.36 (s, 0.6H), 2.44-2.52


Mixture of




(m, 0.4H), 2.73-2.83 (m, 0.2H),


Cis-isomer




2.94-3.00 (m, 3.6H), 3.08-3.14


and Trans-




(m, 2H), 7.06 (d, J = 8.55 Hz, 1H),


isomer)




7.18 (s, 1H), 7.81 (brs, 0.2H), 7.84







(brs, 0.8H), 8.21 (d, J = 8.32 Hz, 1H)








F-733


embedded image


(400 MHz, CDCl3) 0.86 (s, 9H), 1.35 (d, J = 6.70 Hz, 2H), 1.86 (ddd, J = 19.07, 9.13, 2.89 Hz, 2H), 2.29 (s, 3H), 2.34-2.42 (m, 1H), 2.48 (ddd, J = 15.72, 8.09, 2.77 Hz, 2H), 2.84 (t, J = 7.17 Hz, 2H), 3.06 (t,
389
387





J = 7.28 Hz, 2H), 3.35-3.44 (m,







1H), 5.85 (s, 1H), 7.06 (dd, J = 8.55,







1.39 Hz, 1H), 7.17 (brs, 1H), 7.70







(s, 1H), 8.20 (d, J = 8.32 Hz, 1H)








F-734


embedded image


(400 MHz, CDCl3) 0.60-0.62 (m, 2H), 0.92-0.95 (m, 2H), 1.47- 1.51 (m, 1H), 1.78 (t, J = 3.09 Hz, 6H), 2.07 (s, 3H), 2.13 (d, J = 3.09 Hz, 6H), 2.28 (s, 3H), 2.92 (t, J = 7.17 Hz, 2H), 3.08 (t, J = 7.06 Hz, 2H), 7.05 (d, J = 8.38 Hz, 1H), 7.16 (s, 1H), 7.92 (s, 1H), 8.20 (d, J = 8.38 Hz, 1H)
439
437




















TABLE 356










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-735


embedded image


(400 MHz, CDCl3) 0.58-0.61 (m, 2H), 0.90-0.92 (m, 2H), 1.43- 1.47 (m, 1H), 1.78 (d, J = 2.87 Hz, 6H), 2.06 (s, 3H), 2.11 (d, J = 2.87 Hz, 6H), 2.34 (s, 3H), 2.64 (t, J = 7.50 Hz, 2H), 2.98 (t, J = 7.50 Hz, 2H), 3.83 (d, J = 5.29 Hz, 3H), 4.39 (d, J = 5.73 Hz, 2H), 6.20 (s, 1H), 6.69-6.71 (m, 2H), 7.11 (d, J = 7.50 Hz, 1H)
449
447






F-736


embedded image


(400 MHz, CDCl3) 0.36 (dd, J = 9.02, 3.70 Hz, 1H), 0.47 (dd, J = 11.21, 5.90 Hz, 1H), 0.81-0.85 (m, 11H), 1.11-1.18 (m, 2H), 1.32- 1.37 (m, 4H), 1.54-1.57 (m, 1H), 1.95-2.09 (m, 5H), 2.35-2.41 (m, 5H), 2.59 (dd, J = 13.76. 5.20 Hz, H), 2.70 (dd, J = 13.87, 10.17 Hz, 1H), 2.89-2.96 (m, 1H), 3.10- 3.17 (m, 1H), 3.23-3.27 (m, 2H), 3.50-3.56 (m, 2H), 3.87-3.88 (m, 2H), 6.39 (t, J = 6.01 Hz, 1H)
475
473






F-737


embedded image


(400 MHz, CDCl3) 0.49 (td, J = 5.61, 4.16 Hz, 2H), 0.82-0.86 (m, 2H), 0.85 (s, 9H), 1.34 (d, J = 6.94 Hz, 2H), 1.39-1.44 (m, 1H), 1.93 (s, 3H), 2.18-2.24 (m, 2H), 2.29 (s, 3H), 2.29-2.33 (m, 2H), 2.38 (td, J = 9.02, 2.54 Hz, 2H), 2.45-2.58 (m, 1H), 2.89-2.96 (m, 2H), 3.06 (t, J = 7.28 Hz, 2H), 3.98 (t, J = 7.05 Hz, 2H), 7.06 (d,
515
513
Mixture of two stereoi- somers (Stereo- chemistry on Cyclobu- tane ring: Mixture of Cis-isomer




J = 8.32 Hz, 1H), 7.17 (s, 1H), 7.87


and Trans-




(brs, 1H), 8.21 (d, J = 8.09 Hz, 1H)


isomer)




















TABLE 357











Informa-


Exam-


MS
tion of












ple
Chemical structure
NMR
M + H
M − H
structure





F-738


embedded image


(400 MHz, CDCl3) 0.47 (td, J = 5.64, 4.16 Hz, 2H), 0.89 (ddt, J = 19.54, 10.95, 4.33 Hz, 2H), 1.20- 1.48 (m, 3H), 1.68 (dt, J = 16.39, 6.95 Hz, 2H), 2.08 (dt, J = 14.64, 4.63 Hz, 2H), 2.72 (t, J = 7.66 Hz,
365
363





2H), 2.87 (t, J = 7.05 Hz, 2H), 3.09







(t, J = 7.05 Hz, 2H), 4.98 (dtt,







J = 19.79, 8.03, 2.69 Hz, 2H), 5.25







(d, J = 10.88 Hz, 1H), 5.78 (ddt,







J = 21.83, 12.29, 4.48 Hz, 2H), 6.68







(dd, J = 17.73, 10.88 Hz, 1H), 7.14







(d, J = 7.66 Hz, 1H), 7.25-7.27 (m,







1H), 7.38 (d, J = 8.06 Hz, 1H), 7.60







(s, 1H), 7.82 (s, 1H)








F-739


embedded image


(400 MHz, DMSO-D6) 0.34-0.53 (m, 2H), 0.74-0.83 (m, 2H), 1.07 (s, 6H), 1.35-1.47 (m, 1H), 1.59- 1.68 (m, 2H), 1.80-1.98 (m, 4H), 2.12-2.24 (m, 2H), 2.24-2.41 (m, 3H), 2.69-2.87 (m, 2H), 3.40- 3.60 (m, 2H), 4.45 (s, 2H), 5.28 (brs, 1H), 7.21 (d, J = 8.09 Hz, 1H), 7.38 (s, 1H), 7.51 (d, J = 8.32 Hz,
547
545





1H), 9.51 (s, 1H), 12.07 (brs, 1H)








F-740


embedded image


(400 MHz, CDCl3) 0.66-0.67 (m, 2H), 0.89-0.94 (m, 2H), 1.36 (s, 9H), 1.56 (s, 1H), 2.29 (s, 3H), 2.96 (t, J = 7.06 Hz, 2H), 3.16 (t, J = 7.28 Hz, 2H), 6.56 (d, J = 1.10 Hz, 1H), 7.06 (d, J = 8.38 Hz, 1H), 7.18 (s, 1H), 7.74 (s, 1H), 8.18 (d, J = 8.38 Hz, 1H)
478
476




















TABLE 358










MS
Information












Example
Chemical structure
NMR
M + H
M − H
of structure





F-741


embedded image


(400 MHz, CDCl3) 0.60-0.63 (m, 2H), 0.87-0.89 (m, 2H), 1.36 (s, 9H), 1.48-1.51 (m, 1H), 2.34 (s, 3H), 2.67 (t, J = 7.50 Hz, 2H), 3.06 (t, J = 7.50 Hz, 2H), 3.83 (s, 3H), 4.39 (d, J = 5.73 Hz, 2H), 6.11 (s, 1H), 6.55 (d, J = 1.10 Hz, 1H), 6.70- 6.72 (m, 2H), 7.12 (d, J = 7.50 Hz, 1H)
488
486






F-742


embedded image


(400 MHz, CDCl3) 0.49 (td, J = 5.72, 4.16 Hz, 2H), 0.82-0.86 (m, 2H), 0.85 (s, 9H), 1.20-1.45 (m, 2H), 1.33 (d, J = 7.40 Hz, 2H), 2.20 (td, J = 11.10, 2.70 Hz, 2H), 2.23 (t, J = 7.17 Hz, 2H), 2.29 (s, 3H), 2.40 (td, J = 8.84, 2.77 Hz, 1H), 2.54 (t, J = 8.21 Hz, 1H), 2.92 (t,
473
471
Mixture of two stereoi- somers (Stereo- chemistry on Cyclobu- tane ring:




J = 6.82 Hz, 3H), 3.06 (t, J = 7.28 Hz,


Mixture of




2H), 3.56 (dd, J = 12.37, 7.05 Hz,


Cis-isomer




2H), 7.06 (d, J = 7.86 Hz, 1H), 7.17


and Trans-




(s, 1H), 7.88 (brs, 1H), 8.21 (d,


isomer)




J = 7.86 Hz, 1H)








F-743


embedded image


(400 MHz, DMSO-D6) 0.49 (dd, J = 9.48, 5.55 Hz, 2H), 0.78-0.83 (m, 2H), 0.84 (s, 9H), 1.32 (d, J = 6.70 Hz, 2H), 1.45-1.52 (m, 1H), 2.15 (t, J = 10.63 Hz, 2H), 2.28 (s, 3H), 2.42 (t, J = 10.17 Hz, 2H), 2.51-2.60 (m, 1H), 2.77 (t, J = 7.63 Hz, 2H), 2.88 (dd, J = 13.52,
487
485
Mixture of two stereoi- somers (Stereo- chemistry, on Cyclobu- tane ring:




5.20 Hz, 2H), 2.96 (s, 2H), 7.12 (d,


Mixture of




J = 8.32 Hz, 1H), 7.31 (s, 1H), 7.55


Cis-isomer




(d, J = 8.09 Hz, 1H), 9.48 (s, 1H),


and Trans-




12.03 (brs, 1H)


isomer)




















TABLE 359











Informa-





MS
tion of












Example
Chemical structure
NMR
M + H
M − H
structure





F-744


embedded image


(400 MHz, CDCl3) 0.52-0.65 (m, 2H), 0.83-0.93 (m, 2H), 1.28 (s, 9H), 1.42-1.51 (m, 1H), 2.28 (s, 3H), 2.93 (t, J = 7.17 Hz, 2H), 3.09- 3.14 (m, 2H), 3.73 (brs, 1H), 6.13 (d, J = 5.29 Hz, 1H), 6.26 (s, 1H), 7.03-7.08 (m, 1H), 7.16 (s, 1H), 7.82 (s, 1H), 8.14 (d, J = 8.38 Hz,
458
456
Racemic form




1H)








F-745


embedded image


(400 MHz, CDCl3) 0.65-0.66 (m, 2H), 0.87-0.92 (m, 2H), 1.36 (d, J = 0.69 Hz, 9H), 1.52-1.57 (m, 2H), 2.28 (s, 3H), 2.95 (t, J = 7.28 Hz, 2H), 3.14 (t, J = 7.28 Hz, 2H), 6.23 (s, 1H), 7.05 (d, J = 8.55 Hz, 1H), 7.16 (s, 1H), 7.73 (s, 1H), 8.17 (d, J = 8.55 Hz, 1H)
478
476






F-746


embedded image


(400 MHz, DMSO-D6) 0.31-0.54 (m, 2H), 0.74-0.83 (m, 2H), 1.01- 1.10 (m, 6H), 1.33-1.46 (m, 1H), 1.57-1.68 (m, 2H), 1.80-1.98 (m, 4H), 2.11-2.39 (m, 5H), 2.74- 2.94 (m, 2H), 3.15-3.58 (m, 3H), 7.68-7.82 (m, 2H), 7.88 (s, 1H), 9.54 (s, 1H)
561
559









Formulation examples of the present invention include for example the following, but which should not be construed as limitative.


Formulation Example 1
Preparation of Capsule

















(1)
Compound of Example E-01
30
mg


(2)
Microcrystalline cellulose
10
mg


(3)
Lactose
19
mg


(4)
Magnesium stearate
1
mg










(1), (2), (3) and (4) are mixed and filled in a gelatin capsule


Formulation Example 2
Preparation of Tablet
















(1)
Compound of Example E-01
10 g


(2)
Lactose
50 g


(3)
Corn starch
15 g


(4)
Carmellose calcium
44 g


(5)
Magnesium stearate
 1 g









The entire amounts of (1), (2) and (3) and 30 g of (4) are mixed with water and dried in vacuo and then granulated. The granulated powder is mixed with 14 g of (4) and 1 g of (5) and tableted by a tableting machine. In this way, 1000 tablets can be obtained, each of which contains 10 mg of Compound of Example E-01.


Formulation examples of the present invention include for example the following, but which should not be construed as limitative.


Formulation Example 3
Preparation of Capsule

















(1)
Compound of Example F-499
30
mg


(2)
Microcrystalline cellulose
10
mg


(3)
Lactose
19
mg


(4)
Magnesium stearate
1
mg










(1), (2), (3) and (4) are mixed and filled in a gelatin capsule.


Formulation Example 4
Preparation of Tablet

















(1)
Compound of Example F-499
10
g


(2)
Lactose
50
g


(3)
Corn starch
15
g


(4)
Carmellose calcium
44
g


(5)
Magnesium stearate
1
g









The entire amounts of (1), (2) and (3) and 30 g of (4) are mixed with water and dried in vacuo and then granulated. The granulated powder is mixed with 14 g of (4) and 1 g of (5) and tableted by a tableting machine. In this way, 1000 tablets can be obtained, each of which contains 10 mg of Compound of Example F-499.


Biological Assay1

Pharmacological effects of the typical compounds of the present invention were observed.


In vitro assay of inhibitory effect against RORγ transcriptional activity


Inhibitory effect of test article on transcriptional activity of RORγ was measured by means of the following luciferase reporter gene assay.


A cDNA encoding human and mouse RORγ ligand binding domain (LBD) were obtained based on the reported sequences (Genebank accession number and sequence: human, NM_005060.3 and from Ser253 to Lys518; mouse, NM_011281.2 and from Ile251 to Lys516).


The cDNA of human RORγ or mouse RORγ was inserted into pFA-CMV vector (Strategene), which expresses GAL4-DNA binding domain fusion protein.


The resulting plasmids are hereinafter referred to as GAL4-hRORγ plasmid and GAL4-mRORγ plasmid, respectively.


Human or mouse GAL4-RORγ plasmid was transiently co-transfected into Chinese hamster ovary cells (CHO cells) with pGL5-Luc plasmid, a reporter plasmid expressing firefly luciferase depending on GAL4.


TransIT CHO transfection reagent (Mirus) was used to co-transfect human or mouse GAL4-RORγ plasmid into CHO cells with pG5-Luc plasmid.


One day before the assay, CHO cells were suspended in HAM F-12 Nutrient medium containing 10 v/v % fetal bovine serum and seeded at 6×106 cells per 175 cm2 cell culture flask.


Fifty four micro litters of Transit-CHO reagent was added into a 15 ml tube containing 1.16 ml of HAM F-12 Nutrient medium without fetal bovine serum and incubated at room temperature for 10 min.


A total 36 uL plasmid solution containing the GAL4-hRORγ plasmid (400 ng), pG5-Luc plasmid (9000 ng) and pcDNA3 plasmid (8600 ng) were added into the tube and mixed gently.


In case of mouse assay, the GAL4-mRORγ plasmid (250 ng), pG5-Luc plasmid (9000 ng) and pcDNA3 plasmid (8750 ng) were added.


The mixture was incubated at room temperature for 10 min.


Nine micro litters of CHO Mojo Reagent was then added into each tube and mixed gently. The mixture was incubated at room temperature for 10 min.


The resultant transfection reagent was applied to the cell culture.


After incubation at 37° C., 5% CO2 for 4 hr, the transfected CHO cells were harvested by a trypsin treatment.


The collected cells were resuspended in HAM F-12 Nutrient medium supplemented with 10 v/v % fetal bovine serum and plated into a 384-well-white plate at 8,000 cells/50 uL/well.


The plate was incubated at room temperature for 1 hour and then further incubated at 37° C., 5% CO2 for 3 hours.


The test articles were dissolved in dimethylsulfoxide (DMSO) to obtain a concentration of 10 mmol/L. The resulting solution was diluted with the medium just before use and added to the cells in the plate to prepare 8 different concentrations of the test article.


The final concentration of DMSO was 0.1 v/v % After the addition of the test articles, the cells were incubated at 37° C., 5% CO2 for 2 days.


Cell viability was tested by a fluorescence method using Resazurin (invitrogen).


Two days after the addition of the test article, Resazurin was diluted with culture medium to make the 20 umol/L resazurin solution.


10 uL of the diluted resazurin solution was added into the 384-well-plate.


Then, the fluorescence was measured immediately at 615 nm with the excitation wavelength of 570 nm (0 hr reading). After incubation at 37° C., 5% CO2 for 2 hr, the fluorescence was measured at 615 nm with the excitation wavelength of 570 nm again (2 hr reading).


The fluorescence counts (2 hr-0 hr) were calculated by subtracting the 0 hr readings from the 2 hr readings.


The luminescence count in the cells treated with 0.1% DMSO alone was defined as 100%, and the cell viability in the test article was calculated as a percentage (%-of-control) based on the value of 0.1% DMSO alone.


When the cell viability is 70% or less, it was judged that the test article has cytotoxicity.


RORγ transcriptional activity was detected as the intracellular luciferase activity using SteadyLite HTS Reporter Gene Assay System (Perkin Elmer).


StedyLite Reagent was diluted five-fold into a solution containing 10 mM Tricine, 0.2% w/v BSA, 0.02% v/v Tween-20 to obtain the luciferase substrate solution.


After the measurement of the cell viability using Resazurin, the culture media in the 384 well-plate were removed. Then the Luc substrate solution was added into each well.


After the incubation at room temperature for 10 minutes, luminescence of each well was measured by a microplate reader.


The luciferase activity derived from the luminescence count in the vehicle-control well treated with 0.1% DMSO alone was defined as 100%, and the luciferase activity in the test article was calculated as a percentage (%-of-control) based on the value of the vehicle-control.


EC50 value of test article was calculated by curve fitting with GraphPad Prism.


The luminescence counts at the concentration of the test article where the cytotoxicity was observed were excluded from the data analysis.


The results are shown in Tables 360-385.


In the tables, “+” means EC50≧3 μM, and “++” means EC50<3 μM.












TABLE 360









LUC EC50 (μM)












Example
hRORg
mRORg







E-01
++
++



E-02
++
++



E-03
++
++



E-04
++
++



E-05
++
++



E-06
++
++



E-07
+
+



E-08
+
+



E-09
++
++



E-10
++
++



E-11
++
++



E-12
+
++



E-13
+
++



E-14
++
++



E-15
++
++



E-16
++
++



E-17
++
++



E-18
++
++



E-19
+
+



E-20
++
++



E-21
++
++



E-22
++
++



E-23
++
++



E-24
++
++



E-25
+
++



E-26
++
++



E-27
++
++



E-28
++
++



E-29
++
++



E-30
++
++



E-31
++
++



E-32
++
++



E-33
++
++




















TABLE 361









LUC EC50 (μM)












Example
hRORg
mRORg







E-34
++
++



E-35
++
++



E-36
+
++



E-37
++
++



E-38
++
++



E-39
++
++



E-40
++
++



E-41
++
++



E-42
++
++



E-43
++
++



E-44
++
++



E-45
++
++



E-46
++
++



E-47
++
++



E-48
++
++



E-49
++
++



E-50
++
++



E-51
++
++



E-52
++
++



E-53
++
++



E-54
++
++



E-55
++
++



E-56
++
++



E-57
++
++



E-58
++
++



E-59
++
++



E-60
++
++



E-61
++
++



E-62
++
++



E-63
++
++



E-64
++
++



E-65
++
++



E-66
++
++




















TABLE 362









LUC EC50 (μM)












Example
hRORg
mRORg







E-67
++
++



E-68
++
++



E-69
++
++



E-70
++
++



E-71
++
++



E-72
++
++



E-73
++
++



E-74
++
++



E-75
++
++



E-76
++
++




















TABLE 363









LUC EC50 (μM)












Example
hRORg
mRORg







F-1
++
++



F-2
++
++



F-3
+
++



F-4
++
++



F-5
+
+



F-6
+
+



F-7
+
++



F-8
+
++



F-9
+
+



F-10
+
+



F-11
+
+



F-12
++
++



F-13
++
++



F-14
++
++



F-15
+
+



F-16
+
++



F-17
+
++



F-18
++
++



F-19
+
++



F-20
+
+



F-21
+
+



F-22
+
+



F-23
+
+



F-24
+
+



F-25
+
++



F-26
+
+



F-27
+
++



F-28
+
+



F-29
+
+



F-30
+
++



F-31
+
+



F-32
++
++



F-33
++
++




















TABLE 364









LUC EC50 (μM)












Example
hRORg
mRORg







F-34
+
+



F-35
++
++



F-36
+
+



F-37
+
++



F-38
++
+



F-39
++
++



F-40
++
++



F-41
++
++



F-42
+
+



F-43
+
+



F-44
++
++



F-45
+
+



F-46
+
+



F-47
+
++



F-48
+
++



F-49
+
+



F-50
+
+



F-51
+
+



F-52
+
++



F-53
+
++



F-54
++
++



F-55
+
++



F-56
+
+



F-57
+
+



F-58
+
+



F-59
+
+



F-60
+
+



F-61
+
+



F-62
+
+



F-63
+
+



F-64
+
+



F-65
+
+



F-66
+
+




















TABLE 365









LUC EC50 (μM)












Example
hRORg
mRORg







F-67
+
+



F-68
+
+



F-69
+
++



F-70
+
+



F-71
+
+



F-72
+
+



F-73
+
+



F-74
+
+



F-75
+
+



F-76
+
+



F-77
+
+



F-78
+
++



F-79
+
+



F-80
+
+



F-81
++
++



F-82
+
+



F-83
+
+



F-84
++
++



F-85
+
+



F-86
+
+



F-87
+
+



F-88
+
+



F-89
+
+



F-90
+
+



F-91
+
+



F-92
+
+



F-93
+
+



F-94
++
++



F-95
++
++



F-96
+
+



F-97
+
+



F-98
+
++



F-99
+
++




















TABLE 366









LUC EC50 (μM)












Example
hRORg
mRORg







F-100
+
+



F-101
+
+



F-102
+
+



F-103
+
+



F-104
+
+



F-105
+
+



F-106
+
+



F-107
+
+



F-108
+
+



F-109
+
+



F-110
+
+



F-111
+
+



F-112
+
++



F-113
+
+



F-114
+
+



F-115
+
+



F-116
+
+



F-117
+
++



F-118
+
+



F-119
++
++



F-120
++
++



F-121
+
+



F-122
+
+



F-123
+
+



F-124
+
+



F-125
+
+



F-126
+
+



F-127
+
+



F-128
+
+



F-129
+
+



F-130
+
+



F-131
+
+



F-132
+
+




















TABLE 367









LUC EC50 (μM)












Example
hRORg
mRORg







F-133
+
+



F-134
+
+



F-135
+
++



F-136
+
+



F-137
+
++



F-138
+
++



F-139
+
+



F-140
+
+



F-141
+
++



F-142
++
++



F-143
+
+



F-144
++
++



F-145
++
++



F-146
+
++



F-147
+
++



F-148
++
++



F-149
+
+



F-150
+
+



F-151
+
+



F-152
+
+



F-153
+
+



F-154
+
+



F-155
++
++



F-156
+
++



F-157
+
+



F-158
+
++



F-159
+
+



F-160
++
++



F-161
+
+



F-162
+
++



F-163
++
++



F-164
+
++



F-165
+
++




















TABLE 368









LUC EC50 (μM)












Example
hRORg
mRORg







F-166
+
++



F-167
++
++



F-168
+
++



F-169
+
+



F-170
+
+



F-171
+
+



F-172
+
+



F-173
++
++



F-174
+
+



F-175
++
++



F-176
+
+



F-177
++
++



F-178
++
++



F-179
+
+



F-180
+
++



F-181
++
++



F-182
+
++



F-183
+
+



F-184
+
+



F-185
+
+



F-186
++
++



F-187
+
+



F-188
++
++



F-189
+
+



F-190
+
+



F-191
++
++



F-192
+
+



F-193
++
++



F-194
++
++



F-195
++
++



F-196
++
++



F-197
++
++



F-198
++
++




















TABLE 369









LUC EC50 (μM)












Example
hRORg
mRORg







F-199
++
++



F-200
++
++



F-201
++
++



F-202
++
++



F-203
+
+



F-204
+
+



F-205
+
+



F-206
++
++



F-207
++
++



F-208
+
+



F-209
+
+



F-210
++
++



F-211
++
++



F-212
++
++



F-213
+
+



F-214
++
++



F-215
++
++



F-216
++
++



F-217
++
++



F-218
+
++



F-219
++
++



F-220
++
++



F-221
+
+



F-222
+
++



F-223
++
++



F-224
++
++



F-225
+
+



F-226
+
+



F-227
++
++



F-228
++
++



F-229
+
+



F-230
++
++



F-231
+
+




















TABLE 370









LUC EC50 (μM)












Example
hRORg
mRORg







F-232
+
+



F-233
+
+



F-234
+
++



F-235
++
++



F-236
+
++



F-237
+
+



F-238
+
+



F-239
+
+



F-240
+
++



F-241
++
++



F-242
+
++



F-243
++
+



F-244
++
++



F-245
++
++



F-246
++
++



F-247
++
++



F-248
++
++



F-249
++
++



F-250
+
+



F-251
++
++



F-252
+
+



F-253
+
+



F-254
++
++



F-255
+
+



F-256
++
++



F-257
++
++



F-258
+
+



F-259
+
+



F-260
+
+



F-261
+
++



F-262
+
+



F-263
++
++



F-264
+
+




















TABLE 371










LUC EC50 (μM)











Example
hRORg
mRORg







F-265
+
++



F-266
++
++



F-267
++
++



F-268
++
++



F-269
++
++



F-270
++
++



F-271
++
++



F-272
++
++



F-273
+
+



F-274
+
+



F-275
+
+



F-276
+
+



F-277
+
++



F-278
+
++



F-279
++
++



F-280
++
++



F-281
++
++



F-282
+
+



F-283
+
+



F-284
+
+



F-285
+
++



F-286
++
++



F-287
+
+



F-288
+
+



F-289
++
++



F-290
+
+



F-291
++
++



F-292
+
++



F-293
++
++



F-294
+
+



F-295
++
++



F-296
++
++



F-297
++
++




















TABLE 372










LUC EC50 (μM)











Example
hRORg
mRORg







F-298
++
++



F-299
++
++



F-300
++
++



F-301
++
++



F-302
++
++



F-303
++
++



F-304
++
++



F-305
++
++



F-306
++
++



F-307
++
++



F-308
++
++



F-309
++
++



F-310
++
++



F-311
++
++



F-312
+
+



F-313
+
+



F-314
++
++



F-315
++
++



F-316
+
+



F-317
++
++



F-318
+
+



F-319
++
++



F-320
++
++



F-321
++
++



F-322
++
++



F-323
++
++



F-324
++
++



F-325
++
++



F-326
+
+



F-327
++
++



F-328
++
++



F-329
+
+



F-330
+
+




















TABLE 373










LUC EC50 (μM)











Example
hRORg
mRORg







F-331
++
++



F-332
++
++



F-333
++
++



F-334
++
++



F-335
+
+



F-336
+
+



F-337
+
+



F-338
++
++



F-339
+
+



F-340
+
++



F-341
++
++



F-342
+
+



F-343
++
++



F-344
++
++



F-345
++
++



F-346
++
++



F-347
++
++



F-348
+
+



F-349
+
+



F-350
++
++



F-351
++
++



F-352
+
+



F-353
++
++



F-354
++
++



F-355
++
++



F-356
++
++



F-357
++
++



F-358
++
++



F-359
++
++



F-360
+
+



F-361
++
++



F-362
+
+



F-363
++
++




















TABLE 374










LUC EC50 (μM)











Example
hRORg
mRORg







F-364
++
++



F-365
+
++



F-366
++
++



F-367
+
++



F-368
+
+



F-369
++
++



F-370
++
++



F-371
++
++



F-372
+
+



F-373
++
++



F-374
++
++



F-375
+
+



F-376
++
++



F-377
undetermined
undetermined



F-378
undetermined
undetermined



F-379
+
++



F-380
++
++



F-381
+
++



F-382
++
++



F-383
++
++



F-384
+
+



F-385
++
++



F-386
+
+



F-387
++
++



F-388
++
++



F-389
++
++



F-390
+
+



F-391
++
++



F-392
++
++



F-393
+
+



F-394
++
++



F-395
++
++



F-396
++
++




















TABLE 375










LUC EC50 (μM)











Example
hRORg
mRORg







F-397
++
++



F-398
++
++



F-399
++
++



F-400
++
++



F-401
++
++



F-402
++
++



F-403
++
++



F-404
++
++



F-405
++
++



F-406
++
++



F-407
+
+



F-408
++
++



F-409
+
+



F-410
++
++



F-411
++
++



F-412
++
++



F-413
++
++



F-414
++
++



F-415
+
++



F-416
+
+



F-417
+
+



F-418
+
+



F-419
+
+



F-420
++
++



F-421
++
++



F-422
++
++



F-423
++
++



F-424
++
++



F-425
++
++



F-426
++
++



F-427
+
++



F-428
++
++



F-429
++
++




















TABLE 376










LUC EC50 (μM)











Example
hRORg
mRORg







F-430
++
++



F-431
++
++



F-432
++
++



F-433
++
++



F-434
++
++



F-435
++
++



F-436
++
++



F-437
++
++



F-438
++
++



F-439
++
++



F-440
++
++



F-441
+
++



F-442
+
+



F-443
++
++



F-444
++
++



F-445
++
++



F-446
++
++



F-447
++
++



F-448
++
++



F-449
+
+



F-450
++
++



F-451
++
++



F-452
++
++



F-453
++
++



F-454
++
++



F-455
+
++



F-456
++
++



F-457
++
+



F-458
+
+



F-459
++
++



F-460
+
+



F-461
++
++



F-462
++
++




















TABLE 377










LUC EC50 (μM)











Example
hRORg
mRORg







F-463
+
++



F-464
+
++



F-465
++
++



F-466
++
++



F-467
+
+



F-468
+
+



F-469
+
+



F-470
++
++



F-471
+
+



F-472
++
++



F-473
++
++



F-474
+
++



F-475
++
++



F-476
++
++



F-477
++
++



F-478
+
++



F-479
++
++



F-480
++
++



F-481
+
+



F-482
++
++



F-483
++
++



F-484
++
++



F-485
++
++



F-486
++
++



F-487
++
++



F-488
+
++



F-489
+
++



F-490
+
+



F-491
+
++



F-492
+
+



F-493
++
++



F-494
++
++



F-495
++
++




















TABLE 378










LUC EC50 (μM)











Example
hRORg
mRORg







F-496
++
++



F-497
++
++



F-498
++
++



F-499
+
++



F-500
++
++



F-501
++
++



F-502
+
+



F-503
+
+



F-504
++
++



F-505
++
+



F-506
++
++



F-507
+
+



F-508
+
+



F-509
++
++



F-510
+
+



F-511
++
++



F-512
++
++



F-513
++
++



F-514
+
+



F-515
++
++



F-516
++
++



F-517
++
++



F-518
++
++



F-519
++
++



F-520
++
++



F-521
++
++



F-522
+
+



F-523
++
++



F-524
++
++



F-525
++
++



F-526
++
++



F-527
++
++



F-528
++
++




















TABLE 379










LUC EC50 (μM)











Example
hRORg
mRORg







F-529
++
++



F-530
++
++



F-531
++
++



F-532
+
+



F-533
++
++



F-534
++
++



F-535
++
++



F-536
++
++



F-537
++
++



F-538
++
++



F-539
+
++



F-540
++
++



F-541
++
++



F-542
++
++



F-543
++
++



F-544
++
++



F-545
++
++



F-546
++
++



F-547
++
++



F-548
++
++



F-549
++
++



F-550
++
++



F-551
++
++



F-552
++
++



F-553
++
++



F-554
++
++



F-555
+
+



F-556
++
++



F-557
+
+



F-558
++
++



F-559
++
++



F-560
++
++



F-561
++
++




















TABLE 380










LUC EC50 (μM)











Example
hRORg
mRORg







F-562
++
++



F-563
++
++



F-564
++
++



F-565
++
++



F-566
++
++



F-567
++
++



F-568
++
++



F-569
++
++



F-570
++
+



F-571
++
++



F-572
++
++



F-573
++
++



F-574
++
++



F-575
++
++



F-576
++
++



F-577
++
++



F-578
++
++



F-579
++
++



F-580
++
++



F-581
++
++



F-582
++
++



F-583
++
++



F-584
+
++



F-585
++
++



F-586
++
++



F-587
++
++



F-588
+
++



F-589
+
+



F-590
++
++



F-591
++
++



F-592
++
++



F-593
+
++



F-594
++
++




















TABLE 381










LUC EC50 (μM)











Example
hRORg
mRORg







F-595
++
++



F-596
++
++



F-597
++
++



F-598
+
+



F-599
++
++



F-600
++
++



F-601
++
++



F-602
++
++



F-603
++
++



F-604
++
++



F-605
++
++



F-606
++
++



F-607
++
++



F-608
++
++



F-609
++
++



F-610
++
++



F-611
++
++



F-612
++
++



F-613
++
++



F-614
++
++



F-615
++
++



F-616
++
++



F-617
++
++



F-618
++
++



F-619
++
++



F-620
++
++



F-621
++
++



F-622
++
++



F-623
++
++



F-624
++
++



F-625
++
++



F-626
++
++



F-627
++
++




















TABLE 382










LUC EC50 (μM)











Example
hRORg
mRORg







F-628
++
++



F-629
++
++



F-630
++
++



F-631
++
++



F-632
++
++



F-633
++
++



F-634
++
++



F-635
++
++



F-636
++
++



F-637
++
++



F-638
++
++



F-639
++
++



F-640
++
++



F-641
++
++



F-642
++
++



F-643
++
++



F-644
++
++



F-645
+
+



F-646
+
+



F-647
++
++



F-648
++
++



F-649
++
++



F-650
++
++



F-651
++
++



F-652
++
++



F-653
++
++



F-654
+
++



F-655
++
++



F-656
++
++



F-657
+
++



F-658
++
++



F-659
++
++



F-660
++
++




















TABLE 383










LUC EC50 (μM)











Example
hRORg
mRORg







F-661
++
++



F-662
++
++



F-663
+
+



F-664
+
+



F-665
++
++



F-666
+
++



F-667
+
++



F-668
+
++



F-669
+
++



F-670
+
++



F-671
++
++



F-672
++
++



F-673
++
++



F-674
++
++



F-675
++
++



F-676
++
++



F-677
++
++



F-678
++
undetermined



F-679
++
++



F-680
++
++



F-681
++
++



F-682
++
++



F-683
++
++



F-684
++
++



F-685
++
++



F-686
++
++



F-687
++
++



F-688
++
++



F-689
++
++



F-690
+
++



F-691
++
++



F-692
++
++



F-693
++
++




















TABLE 384










LUC EC50 (μM)











Example
hRORg
mRORg







F-694
++
++



F-695
+
++



F-696
++
++



F-697
++
++



F-698
++
++



F-699
++
++



F-700
++
++



F-701
++
++



F-702
++
++



F-703
++
++



F-704
+
+



F-705
+
+



F-706
++
++



F-707
++
++



F-708
++
++



F-709
++
++



F-710
++
++



F-711
+
+



F-712
+
+



F-713
++
++



F-714
++
++



E-77
++
++



E-78
++
++



E-79
++
++



E-80
++
++



F-715
++
++



F-716
++
++



F-717
++
++



F-718
++
++



F-719
++
++



F-720
++
++



F-721
++
++



F-722
+
+




















TABLE 385










LUC EC50 (μM)












custom-character

hRORg
mRORg







F-723
+
+



F-724
++
++



F-725
++
++



F-726
+
+



F-727
+
+



F-728
++
++



F-729
++
++



F-730
++
++



F-731
+
+



F-732
++
++



F-733
++
++



F-734
++
++



F-735
++
++



F-736
+
+



F-737
+
+



F-738
+
+



F-739
+
+



F-740
++
++



F-741
++
++



F-742
+
+



F-743
+
+



F-744
+
++



F-745
++
++



F-746
+
+









Claims
  • 1. A compound represented by Formula [I]:
  • 2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein
  • 3. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is represented by Formula [II-A]:
  • 4. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is represented by Formula [II-B]:
  • 5. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is represented by Formula [II-C]:
  • 6. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is represented by Formula [II-D]:
  • 7. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is represented by Formula [II-E]:
  • 8. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is represented by Formula [II-F]:
  • 9. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is represented by Formula [II-G]:
  • 10. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Rc is hydrogen atom.
  • 11. A pharmaceutical composition comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable carrier.
  • 12. A method of inhibiting RORγ in a mammal, comprising administering to the mammal a therapeutically effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.
  • 13. A method for treating or preventing a autoimmune disease, allergic disease, dry eye, fibrosis, or metabolic disease in a mammal, comprising administering to the mammal a therapeutically effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.
  • 14. The method according to claim 13, wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, ankylosing spondylitis, uveitis, polymyalgia rheumatica and type I diabetes.
  • 15. The method according to claim 13, wherein the metabolic disease is diabetes.
  • 16. A compound represented by the following formulas:
  • 17. A compound represented by the following formulas:
  • 18. A compound represented by the following formulas:
  • 19. A compound represented by the following formulas:
  • 20. A compound represented by the following formulas:
  • 21. A compound represented by the following formulas:
  • 22. A compound represented by the following formula:
  • 23. A compound represented by the following formula:
  • 24. A compound represented by the following formula:
  • 25. A compound represented by the following formula:
  • 26. A compound represented by the following formula:
Priority Claims (1)
Number Date Country Kind
2012-236162 Oct 2012 JP national
PCT Information
Filing Document Filing Date Country Kind
PCT/JP2013/079016 10/25/2013 WO 00
Provisional Applications (1)
Number Date Country
61719097 Oct 2012 US